<SEC-DOCUMENT>0001010549-13-000144.txt : 20130314
<SEC-HEADER>0001010549-13-000144.hdr.sgml : 20130314
<ACCEPTANCE-DATETIME>20130314163259
ACCESSION NUMBER:		0001010549-13-000144
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		22
CONFORMED PERIOD OF REPORT:	20121231
FILED AS OF DATE:		20130314
DATE AS OF CHANGE:		20130314

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHINA PHARMA HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001106644
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				731564807
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34471
		FILM NUMBER:		13690862

	BUSINESS ADDRESS:	
		STREET 1:		2ND FLOOR, NO. 17, JINPAN ROAD
		STREET 2:		HAIKOU
		CITY:			HAINAN PROVINCE
		STATE:			F4
		ZIP:			570216
		BUSINESS PHONE:		8689866811730

	MAIL ADDRESS:	
		STREET 1:		2ND FLOOR, NO. 17, JINPAN ROAD
		STREET 2:		HAIKOU
		CITY:			HAINAN PROVINCE
		STATE:			F4
		ZIP:			570216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TS ELECTRONICS INC
		DATE OF NAME CHANGE:	20030818

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SOFTSTONE INC
		DATE OF NAME CHANGE:	20030128

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SOFTSTONE INC /DE/
		DATE OF NAME CHANGE:	20010808
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>cphi10k123112.htm
<DESCRIPTION>CHINA PHARMA HOLDINGS, INC.
<TEXT>
<html>
<head>
    <title>cphi10k123112.htm</title>
    <!--Licensed to: Securities Transfer Corp-->
    <!--Document Created using EDGARizerAgent 5.4.4.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<div>&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div>&#160;</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Washington, DC&#160;&#160;20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">FORM 10-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline;" face="Wingdings">x</font> ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OF THE SECURITIES EXCHANGE ACT OF 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the fiscal year ended December 31, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">or</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font> TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">THE SECURITIES EXCHANGE ACT OF 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the transition period from _________ to _____________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Commission file number: 001-34471</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 20pt; FONT-WEIGHT: bold">China Pharma Holdings, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Exact name of registrant as specified in its charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="43%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Nevada</font></div>
</td>
<td valign="top" width="43%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">73-1564807</font></div>
</td>
</tr><tr>
<td valign="top" width="43%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or other jurisdiction of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">incorporation or organization)</font></div>
</td>
<td valign="top" width="43%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(IRS Employer Identification No.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Second Floor, No. 17, Jinpan Road</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Haikou, Hainan Province, China 570216</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Address of Principal Executive Offices) (Zip Code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Registrant&#8217;s telephone number:<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;&#160;(011) 86 898-6681-1730</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Securities registered pursuant to Section 12(b) of the Act:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="42%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Title of each class</font></div>
</td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="42%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Name of each exchange on which registered</font></div>
</td>
</tr><tr>
<td valign="top" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="42%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="42%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common Stock, $0.001 Par Value Per Share</font></div>
</td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="42%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">NYSE MKT</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Securities registered pursuant to Section 12(g) of the Act:&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold"> None.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font><br>
&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&#160;&#160; <font style="DISPLAY: inline;" face="Wingdings">&#168;</font> &#160;&#160;&#160;&#160;&#160;No&#160;&#160; <font style="DISPLAY: inline; FONT-WEIGHT: bold" face="Wingdings">x</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.&#160;&#160;Yes&#160;&#160; <font style="DISPLAY: inline;" face="Wingdings">&#168;</font> &#160;&#160;&#160;&#160;&#160;No&#160; <font style="DISPLAY: inline; FONT-WEIGHT: bold" face="Wingdings">x</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such report(s)), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;Yes <font style="DISPLAY: inline; FONT-WEIGHT: bold" face="Wingdings">x</font> &#160;&#160;&#160;&#160;&#160;No&#160;&#160; <font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;&#160;&#160;Yes <font style="DISPLAY: inline; FONT-WEIGHT: bold" face="Wingdings">x</font> &#160;&#160;&#160;&#160;&#160;No&#160;&#160; <font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of Registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.&#160;&#160; <font style="DISPLAY: inline; FONT-WEIGHT: bold" face="Wingdings">x</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.&#160; See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font><br>
&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="42%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Large accelerated filer <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td valign="bottom" width="45%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accelerated filer <font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
</tr><tr>
<td valign="bottom" width="42%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non-accelerated filer&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Do not check if a smaller reporting company</font></div>
</td>
<td valign="top" width="45%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Smaller reporting company <font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;&#160; <font style="DISPLAY: inline;" face="Wingdings">&#168;</font> &#160;&#160;&#160;&#160;&#160; No &#160; <font style="DISPLAY: inline; FONT-WEIGHT: bold" face="Wingdings">x</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and ask price of such common equity, as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter:&#160;&#160;$8,233,748 as of June 29, 2012, based on the closing price of $0.34 of the Company&#8217;s common stock on such date.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The number of outstanding shares of the registrant&#8217;s common stock on March 11, 2013&#160;was 43,579,557.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Documents Incorporated by Reference:&#160;&#160;None.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FORM 10-K ANNUAL REPORT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FISCAL YEAR ENDED DECEMBER 31, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">TABLE OF CONTENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">PAGE</font></div>
</td>
</tr><tr>
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">PART&#160;I</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;1.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Business.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 4</font></td>
</tr><tr bgcolor="white">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;1A.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Risk Factors.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 18</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;1B.&#160;</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Unresolved Staff Comments.&#160;</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 35</font></td>
</tr><tr bgcolor="white">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;2.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Properties.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 36</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;3.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Legal Proceedings.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 36</font></td>
</tr><tr bgcolor="white">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 4.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Mine Safety Disclosures.&#160;</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 36</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">PART&#160;II&#160;</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;5.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.&#160;</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 36</font></td>
</tr><tr bgcolor="white">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 6.&#160;</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Selected Financial Data&#160;</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 37</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;7.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of&#160;Operations.&#160;</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 38</font></td>
</tr><tr bgcolor="white">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 7A.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Quantitative and Qualitative Disclosures about Market Risk.&#160;</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 47</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;8.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Financial Statements and Supplementary Data.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 47</font></td>
</tr><tr bgcolor="white">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;9.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 47</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;9A.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Controls and Procedures.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 47</font></td>
</tr><tr bgcolor="white">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item 9B.&#160;</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other Information.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 48</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">PART&#160;III</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;10.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Directors, Executive Officers and Corporate Governance.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 48</font></td>
</tr><tr bgcolor="white">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;11.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Executive Compensation.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 50</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;12.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 54</font></td>
</tr><tr bgcolor="white">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;13.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certain Relationships and Related Transactions, and Director Independence.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 55</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;14.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Principal Accountant Fees and Services.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 55</font></td>
</tr><tr bgcolor="white">
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">PART&#160;IV</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Item&#160;15.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exhibits, Financial Statement Schedules.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 55</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td colspan="3" valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">SIGNATURES</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 57</font></td>
</tr><tr bgcolor="aliceblue">
<td colspan="3" valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">EXHIBIT INDEX</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 58</font></td>
</tr><tr bgcolor="white">
<td colspan="3" valign="top" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">FINANCIAL STATEMENTS</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; F 1 - F 20</font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FORWARD-LOOKING STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The statements contained in this report with respect to our financial condition, results of operations and business that are not historical facts are &#8220;forward-looking statements&#8221;. Forward-looking statements can be identified by the use of forward-looking terminology, such as&#160;&#160;"anticipate", "believe", "expect", "plan", "intend", "seek", "estimate", "project", "could", "may" or the negative thereof or other variations thereon, or by discussions of strategy that involve risks and uncertainties. Management wishes to caution the reader of the forward-looking statements that any such statements that are contained in this report reflect our current beliefs with respect to future events and involve known and unknown risks, uncertainties and other factors, including, but not limited to, economic, competitive, regulatory, technological, key employees, and general business factors affecting our operations, markets, growth, services, products, licenses and other factors, some of which are described in this report including in &#8220;Risk Factors&#8221; in Item 1A and some of which are discussed in our other filings with the SEC. These forward-looking statements are only estimates or predictions. No assurances can be given regarding the achievement of future results, as actual results may differ materially as a result of risks facing our company, and actual events may differ from the assumptions underlying the statements that have been made regarding anticipated events.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">These risk factors should be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue. All written and oral forward looking statements made in connection with this report that are attributable to our company or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given these uncertainties, we caution investors not to unduly rely on our forward-looking statements. We do not undertake any obligation to review or confirm analysts&#8217; expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Notwithstanding the above, Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) expressly state that the safe harbor for forward-looking statements does not apply to companies that issue penny stock.&#160;&#160;If we are ever considered to be an issuer of penny stock, the safe harbor for forward-looking statements may not apply to us at certain times.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART I</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;BUSINESS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Overview</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions in the People&#8217;s Republic of China (the &#8220;PRC&#8221;).&#160;&#160;All of our operations are conducted in the PRC, where our manufacturing facilities are located.&#160;&#160;We manufacture pharmaceutical products in the form of dry powder injectibles, liquid injectibles, tablets, capsules, oral solutions and granules.&#160;&#160;All of our pharmaceutical products are sold on&#160;a prescription basis and have been approved for at least one or more therapeutic indications by the Chinese State Food and Drug Administration (the &#8220;SFDA&#8221;) based upon demonstrated safety and efficacy.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;At December 31, 2012, we manufactured 20 pharmaceutical products for a wide variety of diseases and medical indications,<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>each of which may be classified into one of three general categories:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">o&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a basic generic drug, which is a common drug in the PRC marketplace for which there is a very large market;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">o&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a first-to-market generic drug, which is a generic Western drug that is new to the PRC marketplace; or</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">o&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a&#160;modern Traditional Chinese Medicine, which generally is a non-synthetic, plant-based medicinal compound of the type that has been widely used in the PRC for thousands of years, to which we apply modern production techniques to produce a pharmaceutical product in different formulations, such as tablets, capsules or powders.</font></div>
</td>
</tr></table>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In selecting generic drugs to develop and manufacture, we consider several factors, including the number of other manufacturers currently producing the particular drug, the size of the market, the proposed or required method of distribution, the existing and expected pricing for the particular drug in the marketplace, the costs of manufacturing that drug, and the costs of acquiring or developing the formula for that drug.&#160;&#160;We believe we have historically selected generic drugs to manufacture that have large addressable markets and higher profit margins relative to other drugs being manufactured and distributed in the PRC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In 2002, we built, and we currently own and operate an approximately 8,000-square-meter manufacturing facility in Haikou, Hainan Province that supports eight modern, scalable production lines.&#160;&#160;We implement quality control procedures in compliance with China&#8217;s Good Manufacturing Practice, or GMP standards, and applicable SFDA regulations to ensure consistent quality in our products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We market and sell our products through 16 sales offices covering all major cities and provinces in the PRC.&#160;&#160;To comply with applicable Chinese law relating to sales of prescription drugs to certain hospitals and clinics, we also use a distribution system comprised of approximately 1,220 independent regional distributors.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Corporate History</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are a holding company and conduct substantially all of our production, marketing, finance,&#160;&#160;development and administrative activities through our wholly-owned subsidiary located in the PRC. We were incorporated in the state of Delaware under the name &#8220;Softstone, Inc.&#8221; on January 28, 1999. From mid-2003 to October 19, 2005, we did not generate any significant revenue and we accumulated no significant assets as we explored business opportunities as a publicly-held &#8220;shell&#8221; corporation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We entered into our current line of business on October 19, 2005 by acquiring Onny Investment Limited, a holding company formed in the British Virgin Islands (&#8220;Onny&#8221;), and its operating subsidiary located in the PRC, Hainan Helpson Medical &amp; Biotechnology Co., Ltd. (&#8220;Helpson&#8221;).&#160;&#160;On March 16, 2006, we changed our corporate name to China Pharma Holdings, Inc. On December 31, 2012, we reincorporated from the State of Delaware to the State of Nevada.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Helpson was established in Haikou, Hainan Province, PRC as a foreign-invested enterprise on February 25, 1993. The company was originally an &#8220;equity joint venture,&#8221; as defined by China&#8217;s laws on foreign invested enterprises, between Haikou Biomedical Engineering Co., Ltd., a PRC company, and Hong Kong Fudao Development Co., Ltd., a Hong Kong company (&#8220;Fudao&#8221;).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On June 16, 2001, Fudao entered into an Equity Interest Transfer Agreement with Hainan Kaidi Science and Technology Co., Ltd., a PRC company (&#8220;Kaidi&#8221;), pursuant to which Fudao transferred all of its ownership interest in Helpson to Kaidi.&#160;&#160;As a result of such transfer,&#160;&#160;Helpson became a PRC domestic company, rather than a foreign-invested company.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Onny was incorporated on January 12, 2005 under the laws of the British Virgin Islands.&#160;&#160;On May 25, 2005, the then-existing three shareholders of Helpson entered into an equity interest transfer agreement with Onny, as a result of which, effective as of June 21, 2005, Helpson became a wholly foreign-owned&#160;enterprise (WFOE) and Onny became the sole stockholder of Helpson.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">O</font>n&#160;October 19, 2005, we acquired all of the issued and outstanding shares of Onny in exchange for 27,499,940&#160;&#160;shares of our common stock and became Onny&#8217;s sole stockholder. In connection with such share exchange, all of our officers and directors at that time resigned as officers and directors of our company, and new directors and executive officers were appointed.&#160;&#160;In addition, as a result of such share exchange, which is commonly referred to as a &#8220;reverse acquisition,&#8221; Helpson became our indirect wholly-owned subsidiary.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our corporate organizational chart as of December 31, 2012 is set forth below.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><img src="chart.jpg" alt=""></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Industry Background and Market Opportunities</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Chinese pharmaceutical industry has been a key contributor to the PRC&#8217;s economic growth. According to the research report <font style="FONT-STYLE: italic; DISPLAY: inline">China Pharma Sector</font> issued by CITI on January 13, 2013, they estimated that the Chinese prescription market reached a size of approximately RMB548 billion (approximately 88 billion USD) in 2012 and forecast that the pharma market could grow approximately 17% in 2013.&#160;&#160;We believe the growth of Chinese pharmaceutical industry will continue.&#160;&#160;According to the State Food and Drug Administration (SFDA) information center, the Chinese pharmaceutical market size has grown from RMB157.2 billion in 2000 to RMB619.4 billion in 2009. Furthermore, according to a report from IMS Health, a leading consulting firm focusing on healthcare and pharmaceutical areas, <font style="FONT-STYLE: italic; DISPLAY: inline">Asian, Australian and Chinese Pharmaceutical Market 2010-2014 Forecast</font> released on September 2010, the pharmaceutical market in China was expected to grow by a CAGR of 23.2%, and to reach US$ 90 billion in 2014. According to the report, this projected growth is supported by the strong growth in the Chinese economy, the aging population, increasing rate of chronic disease in the PRC, the recent health care reform, and improvements in intellectual property right protection in the PRC.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Chinese pharmaceutical market is highly fragmented with over 4,900 pharmaceutical manufacturers (including Active Pharmaceutical Ingredient (API) manufacturers) comprised of a number of larger state-owned enterprises and a large number of small enterprises. We believe this fragmentation provides opportunities for better managed and more financially sound companies to gain market share by using comparatively strong technical, manufacturing and marketing abilities.&#160;&#160;In addition, regulatory agencies in the PRC have introduced a series of new regulations to control the standards and quality of manufacturing and distribution in the pharmaceutical industry.&#160;&#160;These new regulations require companies to obtain government-recognized manufacturing and distribution licenses, and good manufacturing practice (GMP) and good sales practice certificates, and have resulted in the elimination of many small or poorly-managed companies.&#160;&#160;We believe this new regulation will precipitate consolidation opportunities in the pharmaceutical industry and a generally more favorable competitive environment for our company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;According to the State Food and Drug Administration (SFDA) information center, the total sales from hospital pharmacies reached RMB 442.8 billion in 2010, which represented an increase of 20% compared to the previous year. Due to the impact of health care reform in China, the medicine prices overall in hospital pharmacies have fallen, and the growth rate of the sales in hospital pharmacies has slowed. Instead, the rural area has become a fast growing segment for pharmaceutical products as the healthcare reform continues to expand government subsidies for the rural population.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We expect China&#8217;s healthcare spending to rise significantly in relation to its rapidly-growing GDP and to become more aligned with international standards.&#160;&#160;Growth drivers, such as the rapidly growing economy, increased income levels and rising living standards, increasing health consciousness, an aging population and life style-related diseases are expected to positively affect China&#8217;s healthcare spending. We believe the increased healthcare spending by the Chinese government to reform the healthcare system has already greatly improved the accessibility of and desire for medical care. We also believe the Chinese government&#8217;s increased spending on the rural market will be another driving force for our future growth.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">National Medical Insurance Program</font>. The National Medical Insurance Program (the &#8220;NMIP&#8221;), introduced in 1999, is the largest medical insurance program in the PRC.&#160;&#160;According to. <font style="FONT-STYLE: italic; DISPLAY: inline">The Notice of Key Healthcare Works in 2013</font> released by Ministry of Health of PRC on January 22, 2013, the government is determined to maintain the coverage rate of NMIP above 95%; increase the average level of participant&#8217;s contribution to RMB340, and increase the government subsidy; optimize overall planning and reimbursement methods, increase the reimbursement rate to 75%, try to increase the real reimbursement rate by 5% to the previous year; increase the maximum reimbursement amount over RMB80,000 per person; increase the reimbursement level of outpatient expenses; and gradually reduce the percentage of participant&#8217;s out-of-pocket expenses to such participant&#8217;s total expenses.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The NMIP is funded primarily by central and provincial governments and, to a lesser degree, by program participants and their employers. The program has two types of accounts: individual accounts and social pool accounts. Each participant has an individual account that holds all contributions from the participant and 30% of the contributions from his or her employer. The amounts of the employer&#8217;s and the participant&#8217;s contributions are determined as fixed percentages of the participant&#8217;s salary. An increase in the participant&#8217;s salary will increase the size of both contributions to the participant&#8217;s individual account, subject to a fixed monthly cap that varies from city to city and may be adjusted from year to year. A participant may claim reimbursement from his or her individual account for prescription medicines, OTC medicines and other out-patient and in-patient medical expenses. The maximum amount available for reimbursement for an individual program participant is capped at a level equal to the balance in that individual&#8217;s account. In addition to individual accounts, the NMIP in each province also includes a social pool account, which holds the contributions from the provincial government as well as the remaining 70% of employer contributions. The social medical expense pool is used to pay for hospitalization costs and in-patient related charges incurred by the participants, subject to certain co-payments, exclusions and limitations. Other than in the relatively more affluent eastern provinces in China, many provincial governments have not fully funded the provincial social medical expense pools, which results in delay or failure in reimbursing the hospitalization costs and other in-patient related expenses of the NMIP participants.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The SFDA promulgated <font style="FONT-STYLE: italic; DISPLAY: inline">Good Manufacturing Practices for Pharmaceutical Products (2010 revised version) </font>(the &#8220;new GMP&#8221;) on February 12, 2011, which became effective on March 1, 2011.&#160;&#160;The new GMP standards outline the basic principles and standards for the manufacturing of pharmaceutical products and the management of quality controls in the manufacturing process in the PRC. Since it was first enacted in 1988, GMP has over two decades of history in China, and went through two revisions in 1992 and 1998. As of June 30, 2004, manufacturing of all active pharmaceutical ingredients (API) and finished dosage must be in compliance with the GMP standards. The new GMP standards that became effective on March 1, 2011 include improvements based upon foreign manufacturing advancements, and has taken into consideration of local conditions in China. Based on the principle of &#8220;equal importance between hardware and software&#8221;, strictly implementing the idea of risk control during the manufacturing process of pharmaceutical products, and more focus on scientific guidance and operability, the new GMP standards are consistent with the World Health Organization (WHO) standards.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The four main characteristics of the new GMP standards are: (1) strengthening the establishment of the quality control system during the manufacturing process of pharmaceutical products by significantly increasing the requirements on quality control software; (2) improving the requirements on the quality of practitioners; (3) refining operation procedures, rules on document management, including manufacturing records, improving guidance and operability; (4) further improvement related to measures to ensure the safety of pharmaceutical products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The new GMP standards became effective on March 1, 2011 and existing pharmaceutical manufacturers (except manufacturers of injectables, blood products, or vaccines, which have a three-year grace period) have a five-year grace period to upgrade existing facilities to comply with the revisions.&#160; Per those mandatory requirements, the upgrading of our two injectable product lines must be accomplished by the end of 2013. We have completed the planning, design and an environment contamination evaluation, and commenced construction relative to certain required facilities and equipment. We continue to evaluate and implement the additional requirements of the standards.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Healthcare Reform</font>.&#160;&#160;In September 2008, the State Council of China published a draft plan to ease the difficulties and minimize the costs for Chinese citizens to obtain proper healthcare treatment.&#160;&#160;On March 17, 2009, the PRC government issued an Opinion on &#8220;Deepening the Healthcare System Reform&#8221;. The State Council subsequently released the Notice on Important Implementing Plans for the Healthcare System Reform 2009-2011. The goal of the healthcare reform plan is to establish a basic, universal healthcare framework to provide safe, efficient, convenient and affordable healthcare to urban and rural residents.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The five major goals in the RMB 850 billion healthcare reform plan for 2009 -2011 (which has recognized a record-high investment of RMB 1.5 trillion according to a statement made by&#160;&#160;the Health Minister, Mr. Chen Zhu in July 2012) included: i) expanding basic medical insurance coverage, ii) establishing a national essential drug list (EDL) system, iii) improving grassroots medical infrastructure, iv) providing more equitable access to basic healthcare services, and v) carrying out public hospital pilot reforms. Approximately 45% of the government&#8217;s RMB850 billion has been spent on expanding the public medical insurance system (especially to cover the previously uncovered rural population), while about a quarter of the amount has been spent on upgrading and constructing medical institutions&#8211; especially country-level hospitals and rural clinics. Although the timeframe for implementing the three-year healthcare reform has been concluded, the government&#8217;s commitment to invest heavily in healthcare is expected to remain in place during the 12<font style="DISPLAY: inline; FONT-SIZE: 10pt">th</font> Five-Year Plan and beyond.&#160;&#160;Over time, the PRC government is committed to bringing down the amount of out-of-pocket expenses for individuals to less than 30% of the total cost during the 12<font style="DISPLAY: inline; FONT-SIZE: 10pt">th</font> Five-Year Plan period and aims to provide universal access to a range of a healthcare services by 2020.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our Strategy</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;We believe we are well positioned in a rapidly-growing industry in one of the fastest-growing economies in the world. We currently manufacture a number of off-patent branded generic drugs that were among the first to market in the PRC. We expect to continue to gain additional competitive advantages through the growing pipeline of new pharmaceutical products we are developing for specific target patient groups. Our diverse portfolio of products and our new product pipeline include products for high-incidence and high-mortality conditions in China, including cardiovascular, central nervous system (CNS), infectious and digestive diseases.&#160;&#160;Furthermore, the Healthcare Reform initiated by the State Council in 2008 in China has significantly expanded the landscape of healthcare industry in China. For example, the total number of healthcare institutions has increased to 956,000 as of the end of May 2012, with a breaking-down of 22,000 hospitals, 919,000 basic level healthcare institutions and 14,000 other institutions; which represented an increase of 14,183 in total number, an increase of 1,136 hospitals, and an increase of 13,007 basic level healthcare institutions to the situation as of the end of May 2011 according to the statistic center of MOH. The increase in demand from these sources should allow us to continue to grow organically. In addition, the new production approval we received from the SFDA on Candesartan, an angiotensin II receptor antagonist serving as a first-line treatment for hypertension in November 2012 and new products from our pipeline of products under development (such as the generic version of Crestor and novel anti-drug-resistant combination antibiotics) would offer us significant growth opportunities if these products were approved for manufacture and sale in the PRC. Finally, the Healthcare Reform has started to change the landscape of the Chinese pharmaceutical industry, which we believe will create many attractive acquisition opportunities. We plan to explore these opportunities in an effort to add synergistic products that can help us continue to grow at rates that are commensurate with our historical rate of growth.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our objective is to become a market leader in the PRC for the development, manufacture and commercialization of pharmaceutical products. We intend to achieve this objective by:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Promoting Our Existing Brands to Increase Our National Recognition</font>. We intend to support and grow the existing recognition and reputation of our brands and to maintain our branded pricing strategy through continued sales and marketing efforts. To achieve this goal, we plan to promote the efficacy and safety profile of our established prescription pharmaceutical products to physicians at hospitals and clinics in all provinces in the PRC through the efforts of our sales force and our independent distributors and through educational physician conferences and seminars.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Developing and Introducing Additional Products to Expand or Strengthen Our Existing Product Portfolio</font>. We plan to focus our development capabilities towards expanding our existing portfolio of approved products. We have a number of products in various stages of the SFDA approval process. In addition, we intend to conduct clinical trials for new generic or&#160;modernized products and product line extensions for our existing products. We plan to introduce new generic or modernized products to leverage our branded market leadership position, particularly in the therapeutic areas in which we already have a strong presence.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Expanding Our Distribution Network For Further Market Penetration</font>. We intend to expand our reach beyond our current 16 offices in the PRC to drive additional growth of our existing and future products. We currently contract with around 1,220 distributors in the PRC and plan to expand upon these relationships to target new markets. In addition, we plan to continue to broaden our marketing efforts outside of major cities in the PRC and increase our market penetration in cities and rural areas in which we already have a presence.&#160;&#160;Over the long term, we also intend to expand our presence beyond the PRC to international markets by working with international pharmaceutical companies in cross selling our products.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Acquiring Complementary Products Lines, Technologies, Distribution Networks and Companies</font>. We intend to selectively pursue strategic acquisition opportunities that we believe will grow our customer base, expand our product lines and distribution network, enhance our manufacturing and technical expertise or otherwise complement our business or further our strategic goals. Pursuing strategic acquisitions is a significant component of our growth strategy.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Products</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;We currently have a product portfolio of 20 pharmaceutical products that address a wide variety of diseases and medical indications.&#160;&#160;All of our pharmaceutical products have demonstrated safety and efficacy in clinical trials sufficient to obtain approval by the SFDA and are sold on a&#160;prescription basis. The following table summarizes the approved indications for our marketed pharmaceutical products and the year in which each of such products was first marketed to our customers.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">Product</font></font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">Indication</font></font></div>
</td>
<td colspan="2" valign="top" width="29%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Commercial</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">Launch</font></font></div>
</td>
</tr><tr>
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td colspan="3" valign="top" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Central Nervous System (CNS) and </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cerebral-Cardiovascular Diseases</font></div>
</td>
<td colspan="2" valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cerebroprotein Hydroloysate </font></div>

<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Injection</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Memory decline and attention deficit disorder caused by the sequela of craniocerebral trauma and cerebrovascular diseases.</font></div>
</div>
</td>
<td colspan="2" valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1996</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Buflomedil Hydrochloride</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Peripheral blood vessel diseases, including intermission claudication, Renaud syndrome and blood vessel convulsion.</font></div>
</div>
</td>
<td colspan="2" valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2002</font></div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gastrodin Injection</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tiredness, loss of concentration, poor sleep (the &#8220;declined spirit&#8221; syndrome), and for traumatic syndromes of the brain, including vertigo, neuralgia and headaches.</font></div>
</div>
</td>
<td colspan="2" valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2005</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Propylgallate for Injection</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cerebral thrombosis, coronary heart disease and complication after surgery-thrombus deep phlebitis.</font></div>
</div>
</td>
<td colspan="2" valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2006</font></div>
</div>
</td>
</tr><tr bgcolor="white">
<td colspan="2" valign="top" width="23%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Ozagrel Sodium for Injection</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cerebral thrombosis, coronary heart disease and complication after the surgery-thrombus deep phlebitis.</font></div>
</div>
</td>
<td colspan="2" valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2006</font></div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="22%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Alginic Sodium Diester </font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Injection</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Ischemic heart disease, cerebrovascular diseases (cerebral thrombosis, cerebral embolism and coronary heart disease) and high lipoprotein blood disease.</font></div>
</div>
</td>
<td colspan="2" valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2006</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Bumetanide for Injection</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Various edema diseases (including those associated with heart failure, hepatic cirrhosis, nephropathy, and pulmonary edema), hypertension, acute renal failure, hyperkalemia, hypercalcemia and for the rescue of acute drug poisoning.</font></div>
</div>
</td>
<td colspan="2" valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2007</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
</tr></table>

<div>&#160;</div>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">8</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="white">
<td colspan="3" valign="top" width="71%"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td colspan="3" valign="top" width="71%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Anti-infection&#160;and Respiratory Diseases</font></div>
</div>
</td>
<td colspan="2" valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Roxithromycin Dispersible </font></div>

<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tablets</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pharyngitis and tonsillitis caused by Streptococcus pyogenes; sinusitis, tympanitis, acute and chronic bronchitis caused by acute bacteria, Mycoplasma pneumonia and Chlamydia pneumoniae; urethritis and cervical infection caused by chlamydia trachomatis; skin soft tissue infection caused by sensitive bacteria.</font></div>
</div>
</td>
<td colspan="2" valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1995</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cefaclor Dispersible </font></div>

<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tablets</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tympanitis, lower respiratory tract infection, urinary tract infections and skin/skin tissue infection.</font></div>
</div>
</td>
<td colspan="2" valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2002</font></div>
</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="aliceblue">
<td valign="top" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cefalexin Capsules</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Acute tonsillitis caused by sensitive fungi, airway infections, such as pharyngitis, otitis media, nasal sinusitis and bronchitis; pneumonia, respiratory tract infection, urinary tract infections and skin soft tissue infections.</font></div>
</div>
</td>
<td valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="22%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Anhydrondrographolide</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Ischemic heart disease, cerebrovascular diseases (cerebral thrombosis, cerebral embolism and coronary heart disease) and high lipoprotein blood disease.</font></div>
</div>
</td>
<td valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2003</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Clarithromycin Granules </font></div>

<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">and Capsules</font></div>

<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nasopharynx infection, lower respiratory tract infection, skin tissue infection, acute tympanitis and mycoplasma pneumonia caused by clarithromycin susceptible organisms; urethritis and cervical infection caused by chlamydia trachomatis; and the treatment of legionella infection, mycobacterium avium complex (MAC) infection and helicobacter pylori infection.</font></div>
</div>
</td>
<td valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2004</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">9</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div>&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="white">
<td valign="top" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Product</font></font></div>
</td>
<td valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="48%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Indication</font></font></div>
</td>
<td valign="top" width="29%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Year of</font> </font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Commercial</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Launch</font></font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Naproxen Sodium and </font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pseudophedrine Hydrochlorida </font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sustained Release Tablets</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Relieve cold, sinus and flu symptoms, blocked nose caused by anaphylaxis rhinitis, runny nose, fever, sore throat, symptoms of myalgia in the limbs and pain around the joints.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
<td valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2005</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gull Wood Extract Syrup</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Detoxicating, anti-inflammatory, quickly reducing swelling, for the indication of acute tonsillitis, acute pharyngitis, acute conjunctivitis, and upper respiratory tract infection.</font></div>
</div>
</td>
<td valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
</tr><tr bgcolor="white">
<td colspan="2" valign="top" width="23%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td colspan="2" valign="top" width="23%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Digestive Diseases</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Hepatocyte Growth-promoting </font></div>

<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Factor for Injection</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Serious viral hepatitis symptoms caused by various viral hepatitis types (acute, subnormal temperature, chronic serious disease early or middle period of hepatitis).</font></div>
</div>
</td>
<td valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2005</font></div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tiopronin</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Acute and chronic Hepatitis B, and for the relief of drug-induced liver injury.</font></div>
</div>
</td>
<td valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2009</font></div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Compound Ammonium </font></div>

<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Glycyrrhetate S for Injection</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Liver dysfunction caused by acute and chronic hepatitis; supplemental treatment to toxic/trauma hepatitis, liver cancer; also for the indication of food/drug poisoning, and drug allergy.</font></div>
</div>
</td>
<td valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2009</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Omeparzole</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gastroesophageal reflux disease, and other conditions caused by excess acidic formulations in the stomach, including gastric ulcers, recurrent duodenal ulcers and Zollinger-Ellison Syndrome.</font></div>
</div>
</td>
<td valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2009</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
</tr><tr bgcolor="white">
<td colspan="2" valign="top" width="23%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Others</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Vitamin B6 for Injection</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Vitamin supplement.</font></div>
</div>
</td>
<td valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2005</font></div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="22%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granisetron Hydrochloride </font></div>

<div style="TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Injection</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors.</font></div>
</div>
</td>
<td valign="top" width="29%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2006</font></div>
</div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition to our pharmaceutical products, we also manufacture Recombined Human Fibroblast Growth Factor (rhaFGF), which is used by other companies in the manufacture of products for the repair of wounded skin cells.&#160;&#160;We sell this product only to distributors for resale to other manufacturers as an active pharmaceutical ingredient, for the production of cosmetics.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table sets forth the aggregate amount and percentage of our revenues attributed to our product portfolio by indication group in the years ended December 31, 2012 and 2011.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="27%" style="BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 2px; BORDER-TOP: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Product Category</font></div>
</td>
<td colspan="2" valign="top" width="28%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1.5pt solid; BORDER-TOP: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fiscal Years Ended December 31</font></div>
</td>
<td valign="top" width="11%" style="BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 2px; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net Change</font></div>
</td>
<td valign="top" width="10%" style="PADDING-BOTTOM: 2px; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">% Change</font></div>
</td>
</tr><tr>
<td valign="top" width="27%" style="BORDER-BOTTOM: black 4px double; BORDER-LEFT: black 1.5pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="15%" style="BORDER-BOTTOM: black 4px double; BORDER-LEFT: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td valign="top" width="13%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 4px double; BORDER-LEFT: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 4px double; BORDER-RIGHT: black 1.5pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="27%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CNS Cerebral &amp; Cardio Vascular</font></div>
</td>
<td valign="top" width="15%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$15.2</font></div>
</td>
<td valign="top" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$25.8</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-$10.6</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-41%</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="27%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Anti-Viro/ Infection &amp; Respiratory</font></div>
</td>
<td valign="top" width="15%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$24.5</font></div>
</td>
<td valign="top" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$32.0</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-$7.5</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-24%</font></div>
</td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="27%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Digestive Diseases</font></div>
</td>
<td valign="top" width="15%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$7.0</font></div>
</td>
<td valign="top" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$12.4</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-$5.4</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-44%</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="27%" style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other</font></div>
</td>
<td valign="top" width="15%" style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$7.8</font></div>
</td>
<td valign="top" width="13%" style="BORDER-BOTTOM: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$11.0</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-$3.2</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-29%</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Due to the nature of the pharmaceutical industry, we continually strive to change our product portfolio to respond to changes in market demand.&#160;&#160;Based on the foundation established by a number of our widely-recognized prescription products, such as Cefaclor, Roxithromycin and Buflomedil, we have launched and will continue to launch a variety of medicines.&#160;&#160;The core criteria for our selection of potential pipeline products are strong market demand, proven efficacy and safety. In an effort to gain an advantage in the marketplace, we often seek to improve the production process of the new generic products we elect to manufacture or to strengthen the quality of a proposed product to increase its efficacy.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We also adjust the delivery system and marketing for each of our products based on the product&#8217;s target patient group. We believe that maintaining a variety of delivery systems (e.g. tablet, capsule, granule, injectable and dry powder ) for certain of our products targeted at different groups enhances our competitive position in the marketplace. As a result, our sales and marketing personnel work closely with management and our research and development personnel to determine which of our products can successfully be marketed in more than one delivery system and which generics in the marketplace may be a good candidate for us to try to manufacture and distribute in the marketplace using a different delivery system.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Product Development</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our product portfolio includes both branded and generic drugs that we either developed or were developed by us in joint research efforts with our academic institutional partners or, to a lesser extent, acquired from third parties. We develop new products in-house as well as through relationships with several research institutes, including the Chinese Academy of Sciences, China University of Pharmaceuticals, Sichuan University, Chongqing Medical Industry Institute and the Military Medical Academy Basic Medical Science Institute. We only pay these institutes for their research efforts and expenses if the research goals are accomplished, including certification of an applicable drug candidate and approval of drug production by the SFDA. Following our receipt of such certification and approval, the rights to the applicable drug candidate are transferred to us. Following any such payment and transfer, we are the sole owner the drug certifications and/or approvals and any related research and we have no further payment or other obligations to the research institute from which we acquired such assets.&#160;&#160;For example, we obtained certificates and approvals of drug production for our Naproxen Sodium and Pseudophedrine Hydroclorida sustained release tablets through our cooperative relationship with the Chongqing Medical Industry Institute, and obtained certificates and approvals of drug production for our Cefalcor dispersible tablets through our cooperative relationship with the China University of Pharmaceuticals, both of which drugs we are now manufacturing and selling. We expect to continue to develop additional new drugs under this method. We also intend to continue purchase or license drug products from third parties on a limited basis, as we regard this as an important and effective means for us to develop our business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;As of December 31, 2012, the product candidates that we are developing at different stages include the following:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">11</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="30%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Indication of Product Candidate</font></div>
</td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="46%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SFDA Status</font></div>
</td>
</tr><tr>
<td valign="bottom" width="30%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="46%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Anti Infection</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In Phase II Clinical Study</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cholesterol Control Drug</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Clinical Trial Completed. Waiting for Production Approval</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Alzheimer's Disease Drug</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In SFDA Technical Review</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="middle" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Coronary Heart Disease Drug<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
<td valign="middle" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In Phase III Clinical Study</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">New Medicine Delivery Technology</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In Technical Transfer; may or may not need clinical trial</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Hepatitis Drug</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Received Clinical Approval, preparing for Clinical</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Central Nervous System Drug</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Received Clinical Approval, preparing for Clinical</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cerebral Vascular Drug</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="46%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In Technical Transfer; may or may not need clinical trial</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our drug formula development and acquisition expenditures&#160;&#160;were&#160;&#160;$3.2 million and $5.3 million in the years ended December 31,&#160;2012&#160;and 2011, respectively, which represented 6% and 7% of our revenues for such years, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We believe the first products to market from our product candidates will be Rosuvastatin, which is a generic form of Crestor&#174; used in the treatment of hyperlipidemia, or high cholesterol.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Anti-Drug-Resistant Cephalosporin (anti-infection drug)</font>.&#160;&#160;Cephalosporin continues to be the most widely prescribed class of antibiotics in China.&#160;&#160;According to the SFDA, approximately 50% of antibiotic sales are derived from cephalosporin. According to Chinese industry publications, sales of cephalosporin antibiotics in China were estimated by the SFDA to be over $17.4 billion in 2015.&#160;&#160;Due to broad usage of antibiotics, including cephalosporin, drug resistance has become a significant issue in China.&#160;&#160;We believe our new combination antibiotic possesses substantial competitive advantages in this environment.&#160;The SFDA will designate our combination antibiotic as a Class 1 drug, which carries a five-year exclusivity when the SFDA approval is obtained.&#160;&#160;The clinical trials for our cephalosporin product candidate commenced in November 2008, and we are currently in phase II of clinical trials. </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Distribution and Customers</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We believe we have a well-developed sales network.&#160;&#160;As our current pharmaceutical product portfolio is comprised mainly prescription drugs, our major sales targets are hospitals. To comply with applicable Chinese law relating to sales of prescription drugs to certain hospitals and clinics, we use a distribution system comprised of approximately 1,220 independent regional distributors.&#160;&#160;At December 31, 2012, we also had 16 sales offices covering all major provinces of China, and 141 sales representatives who assist in managing many of our relationships with hospitals, doctors and local drug distributors. Overall, our distribution model is rather flat, with relatively few intermediaries compared to many other pharmaceutical companies in China<font style="DISPLAY: inline; FONT-WEIGHT: bold">.&#160;</font> Due to this advantage, we believe we are able to keep our selling cost down than the industry average.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Due to the nature of our products and current governmental regulations, all of our customers are located in the PRC.&#160;&#160;We have established long-standing relationships with most of our key customers as our operating subsidiary, Helpson, was formed in 1993.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Production Facilities</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We manufacture and package our products at our manufacturing facility in the Haikou Free Trade Zone in Haikou, Hainan Province. Our manufacturing facility, which was built in 2002, is approximately 8,000 square meters and has eight production lines for different forms including: tablets, capsule, granule, dried power, liquid injectable, Cephalosporins (specifically designated), chemical API, and biological API.&#160;&#160;This facility is in compliance with GMP standards in China and has five GMP certificates that remain valid until May 7, 2013, August 10, 2013, September 20, 2014, February 9, 2015 and December 31, 2015, respectively. In order to meet the new GMP standards that became effective in March 2011, we are preparing to upgrade our production facilities and bring them in line with the new GMP standards before the end of the three-year grace period for injectables and five-year grace period for all other products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Each of our eight production lines meets GMP guidelines promulgated in 1998.&#160;&#160;Two of our production lines are used only for the production of active pharmaceutical ingredients, or API, that are used in the production of certain of our products.&#160;&#160;The following table sets forth the capacity utilization rates for our eight pharmaceutical production lines for the years ended December 31, 2012 and 2011.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">12</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="50%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="30%" style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Capacity Utilization Rate %</font></div>
</td>
</tr><tr>
<td valign="top" width="70%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">Production Line</font></font></div>
</td>
<td valign="top" width="15%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td valign="top" width="15%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">2012</font></font></div>
</td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tablet</font></div>
</td>
<td valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">75</font></div>
</td>
<td valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">85</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Capsule</font></div>
</td>
<td valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">55</font></div>
</td>
<td valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">70</font></div>
</td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granule</font></div>
</td>
<td valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">100</font></div>
</td>
<td valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">100</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Injectable</font></div>
</td>
<td valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">84</font></div>
</td>
<td valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">95</font></div>
</td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dry Powder</font></div>
</td>
<td valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">82</font></div>
</td>
<td valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">100</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cephalosporins</font></div>
</td>
<td valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">100</font></div>
</td>
<td valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">100</font></div>
</td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chemical API</font></div>
</td>
<td valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">65</font></div>
</td>
<td valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">65</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Biological API</font></div>
</td>
<td valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">53</font></div>
</td>
<td valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">60</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Raw Materials</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We require a supply of a wide variety of raw materials to manufacture our products.&#160;&#160;We employ purchasing staff with extensive knowledge of our products who work with our product development, and formulations and quality control personnel to source raw materials for our products.&#160;&#160;Currently, we rely on numerous suppliers in the PRC and overseas to deliver our required raw materials and believe we have at least three principal suppliers for each of our most critical raw materials.&#160;&#160;In certain cases, we enter into arrangements with suppliers to hedge against the risk of shortages of supply, and have the capability and warehouse capacity to store such materials if we anticipate a shortage of such materials.&#160;&#160;Historically, we have not had difficulty obtaining raw materials from suppliers. For the year ended December 31, 2011, purchases from one supplier accounted for approximately 20.8% of raw material purchases.&#160;&#160;For the year ended December 31, 2012, purchases from two suppliers accounted for 12.1% and 10.3% of raw material purchases, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Competition</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We believe we have established a commercially competitive position in the highly-fragmented pharmaceutical industry in China through our core competitive advantages, as described below:</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have a highly-efficient commercialization process for new products, including significant experience with the SFDA registration process.</font></font></div>
</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have over 19 years of product-development experience during which time we have implemented processes to efficiently introduce and market new and existing products to the Chinese market. We have successfully obtained the final production approval from the SFDA for many pharmaceutical products, including fifteen new products in the past ten years.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have a market-oriented product portfolio and product lines.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our product focus is on developing and manufacturing medicines that help large patient groups, such as the infectious disease and cardio vascular disease patient groups. Our diversified GMP-certified manufacturing facility includes eight production lines targeting a variety of delivery mechanisms, such as tablets, capsules, granules,&#160;liquid-injectables and dried-powder-injectables, and enables us to effectively manufacture a broad range of new drugs.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have product diversification to target specific sub-markets.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We attempt to differentiate our products from those of our competitors by changing, and, in many cases, improving, and certain physical aspects of our products to address different market segments.&#160;&#160;For example, to make our Cefaclor product more patient friendly to children and patients with swallowing problems, we added an enteric coating to make our tablets easier to swallow.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">13</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have a national sales network and a highly-trained marketing team.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our experienced sales team has the industry knowledge and know-how to synergistically combine our strong market insight with a successful commercialization platform.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have developed high-quality relationships with leading hospital and clinic administrators and physicians.</font></font></div>
</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">While sales of our pharmaceutical products to hospitals are made through our distributors, we believe our long-term relationships with leading hospitals and healthcare clinics throughout China resulting from our long-term promotional efforts and periodic physician seminars improve the perception of our products in the marketplace and help us identify and select high-volume drugs to develop into new generic products relatively early in the process.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We cooperate effectively with a number of leading academic research institutions.</font></font></div>
</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Through our cooperative efforts with our research partners we are able to develop new product candidates in a cost-effective manner and currently have a number of significant projects in active development in our pipeline.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Notwithstanding such favorable positioning, we are subject to intense competition. There are both local and overseas pharmaceutical enterprises that are engaged in the manufacture and sale of potential substitute or similar pharmaceutical products for sale in the PRC. These competitors may have more capital and better research and development resources, and manufacturing and marketing capability and experience than we do.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our profitability may be adversely affected if</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the number of our competitors increases;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">competitors engage in increased price competition; or</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">competitors develop new products or product substitutes having comparable medicinal applications or therapeutic effects that are more effective, less costly and/or have more perceived benefits than those produced by us.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, competition from imported products and China's admission as a member of the World Trade Organization (&#8220;WTO&#8221;) creates increased competition. The PRC became a member of the WTO in December 2001. As a result of the admission of the PRC into the WTO, competition in the pharmaceutical industry in the PRC intensify generally in two respects. With lower import tariffs, imported pharmaceutical products manufactured overseas may become increasingly competitive with domestically produced products in terms of pricing. We also believe that well-established foreign pharmaceutical manufacturers may set up production facilities in the PRC and compete with domestic manufacturers directly. With the expected increased supply of competitively-priced pharmaceutical products in the PRC, we may face increased competition from foreign pharmaceutical products, especially in terms of high-end pharmaceutical products, including certain types of products manufactured by U.S. manufacturers.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Intellectual Property</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We regard our packaging designs, trademarks, trade secrets, patent and similar intellectual property as part of our core competence that is critical to our success. We rely on patent, trademark and trade secret law, as well as confidentiality agreements with certain of our employees, distributors and others to protect our intellectual property rights.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In November 2008, we purchased the patented medical formula for a cerebral/cardio-vascular indication and the manufacturing processes for that product candidate from a third party laboratory.&#160;&#160;In connection with that acquisition, we obtained the title of the patent.&#160;&#160;This patent expires in 2025.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In 2012, we acquired another patent related to a medical formula for the treatment of cerebral/cardio-vascular diseases. This patent expires in 2029.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At December 31, 2012, we owned 17 registered trademarks, including marks for nine of the 20&#160;&#160;pharmaceutical products we manufacture, including the tradenames Funalin, Fukexing, Beisha, Shiduotai, Xinuo, Pusenlitai, Pusenouke, Shuchang and Shenkaineng, as well as marks for our AFGF logo, our HPS logo, our two HELPSON logos and four other logos. The registration numbers of the 17 registered trademarks are as follows: No.1280259, No.1500459, No.1511770, No.1535416, No.1537828, No.1535420, No.1272792, No.1272759, No.1272760, No.1330294, No.1327731, No.1330295, No.1476339 and No.3993785, No. 4074317, No.4074321 and No. 4315247.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">14</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Environmental Matters</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We comply with the Environmental Protection Law of China as well as applicable local regulations. In addition to statutory and regulatory compliance, we actively ensure the environmental sustainability of our operations. Penalties may be levied upon us if we fail to adhere to and maintain certain standards. Such failure has not occurred in the past, and we generally do not anticipate that it will occur in the future, but no assurance can be given in this regard.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Regulations</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Regulations Relating to Pharmaceutical Industry</font>.&#160;The pharmaceutical industry in China is highly regulated. The primary regulatory authority is the SFDA, including its provincial and local branches. As a developer and producer of medicinal products, we are subject to regulation and oversight by the SFDA and its provincial and local branches. The Law of the PRC on the Administration of Pharmaceuticals provides the basic legal framework for the administration of the production and sale of pharmaceuticals in China and covers the manufacturing, distribution, packaging, pricing and advertising of pharmaceutical products. Its implementing regulations set forth detailed rules with respect to the administration of pharmaceuticals in China. We are also subject to other PRC laws and regulations that are applicable to business operators, manufacturers and distributors in general.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Registration and Approval of Medicine</font>.&#160;&#160;Pursuant to the PRC Provisions for Drug Registration, a medicine must be registered and approved by the SFDA before it can be manufactured and sold. The registration and approval process requires the manufacturer to submit to the SFDA a registration application containing detailed information concerning the efficacy and quality of the medicine and the manufacturing process and the production facilities the manufacturer expects to use. This process generally takes two to five years and could be longer, depending on the nature of the medicine under review, the quality of the data provided and the workload of the SFDA. If a manufacturer chooses to manufacture a pre-clinical medicine, it is also required to conduct pre-clinical trials, apply to the SFDA for permission to conduct clinical trials and go through the clinical trials. If a manufacturer chooses to manufacture a post-clinical medicine, it only needs to go through the clinical trials. In both cases, a manufacturer needs to file clinical data with the SFDA for approval for manufacturing after clinical trials are completed.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">New Medicine</font>. If a medicine is approved by the SFDA as a new medicine, the SFDA will issue a new medicine certificate to the manufacturer and impose a monitoring period of one to five years. During the monitoring period, the SFDA will monitor the safety of the new medicine, and will neither accept new medicine certificate applications for an identical medicine by another pharmaceutical company, nor approve the production or import of an identical medicine by other pharmaceutical companies. As a result of these regulations, the holder of a new medicine certificate effectively has the exclusive right to manufacture the new medicine during the monitoring period. We currently have new medicine certificates for our Buflomedil Hydrochloride (API, tablet, liquid injectable, dried power injectable), Pusenouke, Cefaclor dispersible tablets, Roxithromycin dispersible tablets and Bumetanide for injection products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">National Production Standard and Provisional Standard</font>. In connection with the SFDA&#8217;s approval of a new medicine, the SFDA will normally direct the manufacturer to produce the medicine according to a provisional national production standard, or a provisional standard. A provisional standard is valid for two years, during which time the SFDA closely monitors the production process and quality consistency of the medicine to develop a national final production standard for the medicine, or a final standard. Three months before the expiration of the two-year period, the manufacturer is required to apply to the SFDA to convert the provisional standard to a final standard. Upon approval, the SFDA will publish the final standard for the production of this medicine. There is no statutory timeline for the SFDA to complete its review and grant approval for the conversion. In practice, the approval for conversion to a final standard is time-consuming and could take a number of years. However, during the SFDA&#8217;s review period, the manufacturer may continue to produce the medicine according to the provisional standard.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Transitional Period</font>. Prior to the latter of (1) the expiration of a new medicine&#8217;s monitoring period or (2) the date when the SFDA grants a final standard for a new medicine after the expiration of the provisional standard, the SFDA will not accept applications for an identical medicine nor will it approve the production of an identical medicine by other pharmaceutical companies. Accordingly, the manufacturer will continue to have an exclusive production right for the new medicine during this transitional period.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">15</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Continuing SFDA Regulation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pharmaceutical manufacturers in China are subject to continuing regulation by the SFDA. If an approved medicine, its labeling or its manufacturing process is significantly modified, a new pre-market approval or pre-market approval supplement will be required by the SFDA. A pharmaceutical manufacturer is subject to periodic inspection and safety monitoring by the SFDA to determine compliance with regulatory requirements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The SFDA has a variety of enforcement actions available to enforce its regulations and rules, including fines and injunctions, recall or seizure of products, the imposition of operating restrictions, partial suspension or complete shutdown of production and criminal prosecution.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pharmaceutical Product Manufacturing</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Permits and Licenses for Pharmaceutical Manufacturers</font>. A pharmaceutical manufacturer must obtain a pharmaceutical manufacturing permit from the SFDA&#8217;s relevant provincial branch. This permit is valid for five years and is renewable for an additional five-year period upon its expiration. Our current pharmaceutical manufacturing permit, issued by the SFDA, will expire on December 31, 2015.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Good Manufacturing Practice.</font> A pharmaceutical manufacturer must meet the Good Manufacturing Practice standards, or GMP standards, for each of its production facilities in China in respect of each form of pharmaceutical product it produces.&#160;&#160;GMP standards include staff qualifications, production premises and facilities, equipment, raw materials, environmental hygiene, production management, quality control and customer complaint administration. If a manufacturer meets the GMP standards, the SFDA will issue to the manufacturer a Good Manufacturing Practice certificate, or a GMP certificate, with a five-year validity period.&#160;&#160;However, for a newly-established pharmaceutical manufacturer that meets the GMP standards, the SFDA will issue a GMP certificate with only a one-year validity period. The new GMP standards became effective on March 1, 2011and&#160;&#160;pharmaceutical manufacturers(except manufacturers of injectables, blood products or vaccines, which have a three-year grace period) have a five-year grace period to upgrade existing facilities to comply with the revisions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We obtained GMP certificates for our manufacturing facility in respect of every form of pharmaceutical product we produce, one on May 8, 2008 (tablets), one on August 11, 2008 (small volume parenteral solutions), one on September&#160;21, 2009 (capsules, granules), one on February 10, 2010 (lyophilized powder for injection) and one on February 18, 2011&#160;&#160;(tables, capsule - cephalosprins).&#160;&#160;All of our GMP certificates are valid for five years.&#160;&#160;While we are required to implement certain upgrades to our manufacturing facilities to comply with the new GMP standards, we do not currently anticipate any difficulty in renewing these certificates when they expire.&#160;&#160;We will be required to obtain a GMP certificate for each new production line we construct for the production of our new product candidates, including our planned production line for our new cholesterol-lowering statin product that we expect to begin manufacturing and to launch into the marketplace in the near future.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Product Liability and Consumers Protection</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Product liability claims may arise if any pharmaceutical products sold have a harmful effect on the consumers. The injured party may claim for damages or compensation. The General Principles of the Civil Law of the PRC, which became effective in January&#160;1987, state that manufacturers and sellers of defective products causing property damage or injury shall incur civil liabilities for such damage or injuries.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Product Quality Law of the PRC was enacted in 1993 and amended in 2000 to strengthen the quality control of products and protect consumers&#8217; rights and interests. Under this law, manufacturers and distributors who produce or sell defective products may be subject to confiscation of earnings from such sales, revocation of business licenses and imposition of fines, and in severe circumstances, may be subject to criminal liability.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Law of the PRC on the Protection of the Rights and Interests of Consumers was promulgated on October&#160;31, 1993 and became effective on January&#160;1, 1994 to protect consumers when they purchase or use goods or services. All business operators must comply with this law when they manufacture or sell goods and/or provide services to customers. In extreme situations, pharmaceutical product manufacturers and distributors may be subject to criminal liability if their goods or services lead to the death or injuries of customers or other third parties.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Price Controls</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The retail prices of some pharmaceutical products sold in China, primarily those included in the Essential Drug and Reimbursement Lists and those pharmaceutical products for which production or distribution are deemed to constitute monopolies, are subject to price controls in the form of retail price ceilings. In particular, manufacturers or distributors cannot freely set or change the retail price for any price-controlled product above the applicable price ceiling or deviate from the applicable fixed price imposed by the PRC government. The prices of medicines that are not subject to price controls are determined freely at the discretion of the respective pharmaceutical companies, subject to notification to the provincial pricing authorities. The National Development and Reform Commission (NDRC), may grant premium pricing status to certain pharmaceutical products that are subject to price controls, and may set the price-ceiling of pharmaceutical products that have obtained such status.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">16</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Only the manufacturer of a medicine may apply for an increase in the retail price of the medicine, and it must either apply to the provincial price control authorities in the province in which it is incorporated, if the medicine is provincially regulated, or to the NDRC, if the medicine is regulated by the NDRC. For a provincially regulated medicine, in cases where provincial price control authorities approve an application, manufacturers must file the newly-approved price with the NDRC for record and thereafter the newly-approved price will become binding and enforceable across China.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We currently have two products listed in the National Essential Drug List (EDL).&#160;&#160;Periodic reductions in the consumer prices of those products due to price changes implemented by the PRC government have had only a minimal impact on our revenues.&#160;&#160;The government announced two rounds of retail drug price cuts in 2011, first in March when the NDRC cut the maximum prices of certain antibiotics and circulatory system drugs by an average of 21%, and in August when prices for 32 types of endocrine and neurological drugs were cut by an average of 14%.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Reimbursement under the National Medical Insurance Program</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">By the end of 2012, approximately 1.3billion people had been enrolled into the NMIP. The Ministry of Labor and Social Security, together with other government authorities, determines which medicines are to be included in or removed from the national medicine catalog for the National Medical Insurance Program, and under which tier a medicine should fall, both of which affect the amounts reimbursable to program participants for their purchases of those medicines. These determinations are based on a number of factors, including price and efficacy. A National Medical Insurance Program participant can be reimbursed for the full cost of a Tier 1 medicine and 80-90% of the cost of a Tier 2 medicine.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Although it is designated as a national program, the implementation of the NMIP is delegated to various provincial governments, each of which has established its own medicine catalog. A provincial government must include all Tier 1 medicines listed in the national medicine catalog in its provincial medicine catalog, but may use its discretion based on its own selection criteria to add other medicines to, or exclude Tier 2 medicines listed in the national medicine catalog from, its provincial medicine catalog, so long as the combined numbers of the medicines added and excluded do not exceed 15% of the number of the Tier 2 medicines listed in the national catalog. In addition, provincial governments may use their discretion to upgrade a nationally classified Tier 2 medicine to Tier 1 in their provincial medicine catalogs, but may not downgrade a nationally classified Tier 1 medicine to Tier 2.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The total amount of reimbursement for the cost of prescription and OTC medicines, in addition to other medical expenses, for an individual program participant in a calendar year is capped at the amount in that participant&#8217;s individual account. The amount in a participant&#8217;s account varies, depending upon the amount of contributions from the participant and his or her employer. Generally, on average, program participants who are from relatively wealthier eastern parts of China and relatively wealthier metropolitan centers have greater amounts in their individual accounts than those from less developed provinces.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Currently, all of our pharmaceutical products are listed on the National Insurance Catalogue (NIC), and only two of our products -Vitamin B6 and Cefalexin - are listed on the EDL. However, some of our non-EDL drugs have been selected to enter the provincial EDL, which varies from province to province. We believe these drugs will experience an increase in sales volume due to the government-initiated promotion of those drugs, while remaining free from the pricing pressures often experienced by drugs listed on the EDL.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Other Regulations</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition to the regulations relating to pharmaceutical industry in China, we are also subject to the regulations applicable to a foreign invested enterprise in China.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Foreign Currency Exchange.&#160;&#160;</font>Pursuant to the Foreign Currency Administration Rules promulgated in 1996 and amended in 1997 and various regulations issued by State Administration of Foreign Exchange, or the SAFE, and other relevant PRC government authorities, Renminbi is freely convertible only to the extent of current account items, such as trade-related receipts and payments, interests and dividends. Capital account items, such as direct equity investments, loans and repatriation of investment, require the prior approval from the SAFE or its local counterpart for conversion of Renminbi into a foreign currency, such as U.S. dollars, and remittance of the foreign currency outside the PRC.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">17</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Payments for transactions that take place within the PRC must be made in Renminbi. Unless otherwise approved, PRC companies other than foreign investment enterprises (FIEs) must convert foreign currency payments they receive from abroad into Renminbi. On the other hand, FIEs may retain foreign exchange in accounts with designated foreign exchange banks, subject to a cap set by the SAFE or its local counterpart.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Dividend Distribution.&#160;&#160;</font>Under the PRC&#160;&#160;regulations governing dividend distributions by wholly foreign-owned enterprises and Sino-foreign equity joint ventures, wholly foreign-owned enterprises and Sino-foreign equity joint ventures in the PRC may pay dividends only out of their accumulated profits, if any, determined in accordance with PRC accounting standards and regulations. Additionally, these foreign-invested enterprises are required to set aside certain amounts of their accumulated profits each year, if any, to fund certain reserve funds. These reserves are not distributable as cash dividends.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Employees</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As of December 31, 2012, we had 443 employees, among which 401 employees were full-time employees and 42 employees were&#160;temporary employees.&#160;&#160;&#160;None of our employees is represented by a labor union and, in general, we consider our relationship with our employees to be good.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As required by applicable Chinese law, we have entered into employment contracts with substantially all of our officers, managers and employees. We are working towards entering into employment contracts with those employees who do not currently have employment contracts with us. The PRC enacted a new Labor Contract Law, which became effective on January 1, 2008. We have updated our employment contracts and employee handbook and are in compliance with such law. We will work with our employees to insure that our employees obtain the full benefit of the law.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 1A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;RISK FACTORS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risks Related to our Business and our Industry</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The commercial success of our products depends upon the degree of their market acceptance among the medical community.&#160;&#160;If our products do not attain market acceptance among the medical community, our operations and profitability would be adversely affected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The commercial success of our products depends upon the degree of market acceptance they achieve among the medical community, particularly among physicians and hospital administrators. Physicians may not prescribe or recommend our products to patients and procurement departments of hospitals may not purchase our products if physicians or hospital pharmacists do not find our products attractive. The acceptance and use of our products among the medical community will depend upon a number of factors, including:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">perceptions by physicians, patients and others in the medical community about the safety and effectiveness of our products;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the prevalence and severity of any side effects;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the pharmacological benefit of our products relative to competing products and products under development;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the efficacy and potential advantages of our products relative to competing products and products under development;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the relative convenience and ease of administration of our products;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the methods by which our pharmaceutical products may be delivered to patients;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the effectiveness of our education, marketing and distribution efforts and those of our distributors;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">publicity concerning our products or competing products and treatments;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the price of our products and competing products; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">18</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the continued inclusion of our products in the National Medical Insurance Program and competitive products being added to the National Medical Insurance Program.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If our products fail to achieve or maintain market acceptance, or if new products are introduced by others that are more favorably received than our products, are more cost effective or otherwise render our products obsolete, we may experience a decline in the demand for our products. If we are unable to market and sell our products successfully, our business, financial condition, results of operation and future growth would be adversely affected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our success is highly dependent on our continually developing new and advanced products, technologies and processes and our failure to do so may cause us to lose our competitiveness in the pharmaceutical industry and may cause our profits to decline.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To remain competitive in the pharmaceutical industry, it is important to continually develop new and advanced products, technologies and processes. There is no assurance that our competitors&#8217; new products, technologies and processes will not render our existing products obsolete or non-competitive. Our competitiveness in the pharmaceutical market therefore relies upon our ability to enhance our current products, introduce new products, and develop and implement new technologies and processes. Our failure to technologically evolve and/or develop new or enhanced products may cause us to lose our competitiveness in the pharmaceutical industry and may cause our profits to decline.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may not be able to obtain manufacturing or marketing approvals or pass on-site inspections for our current and future products, including re-registration certification and re-evaluation process of our products, or for our production facilities and failure to obtain the necessary approvals or pass as referenced above could materially harm our business prospects.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All medicines must be approved by the SFDA before they can be manufactured, marketed or sold in the PRC. The SFDA requires a pharmaceutical manufacturer to successfully complete clinical trials of a new medicine and demonstrate its manufacturing capability before approval to manufacture that new medicine is granted. Clinical trials are expensive and their results are uncertain. It usually takes two to five years for a manufacturer to obtain a typical application for an SFDA production approval.&#160;&#160;However, the SFDA may not strictly addict to such general time line due to its alteration of review procedure that is out of the applicant&#8217;s expectation and therefore delayed our launch of new products. Furthermore, the SFDA and other regulatory authorities may apply new standards for safety, manufacturing, labeling, marketing and distribution of future products.&#160;&#160;Complying with these standards may be time-consuming and expensive.&#160;&#160;In addition, our future products may not be efficacious or may have undesirable or unintended side effects, toxicities or other characteristics that may preclude us from obtaining approval or may prevent or limit their commercial use.&#160;&#160;As a result, we may not be able to obtain SFDA or other governmental approvals for our future products on a timely basis or at all.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In particular, we expect to receive the SFDA production approval for Rosuvastatin, a drug for indication of high blood cholesterol level , in the near future, which will allow us to commence our marketing and sale of this product in the marketplace.&#160;&#160;Due to the uncertainty set forth above, we cannot assure you that we will be able to obtain this approval within that timeframe, or at all. Even if we do obtain these approvals, we cannot assure you that such approvals will not be modified or revoked. We will not be able to manufacture and market this new product as planned or at all if we do not obtain this governmental approval.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Furthermore, even after we obtain such approvals for a proposed product, we may not be able to pass the on-site inspections required prior to the launch of such proposed product.&#160;&#160;If we fail to pass the on-site inspection in connection with a production permit application, we will not be able to obtain the production permit and commence production.&#160;&#160;Failure to obtain or renew approvals or pass on-site inspections for our existing or future products could materially harm our business prospects.&#160;&#160;In addition, in connection with our manufacture of any new products that will require us to add to or expand our existing production lines or to construct new production lines, we will be required to obtain production permits. Failure to obtain such permits could render us unable to produce any new products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Failure to comply with applicable GMP standards could have a material adverse effect on our business, financial condition and results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are required to comply with applicable GMP regulations, which include requirements relating to personnel, premises and equipment, raw materials and products, qualification and validation, documents management, production management, quality control and quality assurance, and products distribution and recall. Manufacturing facilities must be approved by governmental authorities before we can use them to commercially manufacture our products and are subject to inspection by regulatory agencies. The SFDA have implemented the more stringent new GMP standards which are aimed at improving drug production management and controlling risks in the production process and introduce internationally-recognized quality control mechanisms. The latest update to the GMP standards have greatly raised the bar for quality control, documentation, and overall manufacturing processes, thus causing an increase of cost in manufacturing and decrease of profit margins.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A pharmaceutical manufacturer must meet the new GMP standards, which became effective on March 1, 2011 for each of its production facilities in China with respect to each form of pharmaceutical products it produces within a five-year grace period. Manufacturers of injectables, blood products, or vaccines have a three-year grace period to bring existing&#160;facilities in line with the revisions.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">19</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Although each of our eight production lines meets GMP guidelines promulgated in 1998 and we are in the process of upgrading our production facilities to bring them in line with the new GMP standards, we may not obtain clearance from the SFDA in the event that we are inspected.&#160;&#160;Any failure to comply with the new GMP standards may subject us to fines or other penalties, which may have a material and adverse impact on our business, financial condition and results of operations.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If we fail to develop new products with high profit margins and our high-profit-margin products are replaced by competitor&#8217;s products, then our gross and net profits margins will be adversely affected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In each of&#160;the years ended December 31, 2011 and 2010, our gross profit margin exceeded 35%.&#160;&#160;However, our gross profit margin decreased to 26% in the year ended December 31, 2012. The pharmaceutical market in the PRC is very competitive, and there may be pressure to reduce sale prices of products without a corresponding decrease in the price of raw materials. To the extent that we fail to develop new products with high profit margins and our high-profit-margin products are substituted by competitors&#8217; products, our gross profit margins and net profit margins will be adversely affected.&#160;&#160;In addition, in the event that our products are included in the EDL, which is subject to high level of governmental price control, our gross profit margin and net profit margins could be adversely affected notwithstanding any increase in our revenues that may result from the listing of such products on EDL.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our products face substantial competition. Other companies may discover, develop, acquire or commercialize products earlier or more successfully than we do.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We operate in a highly competitive environment. Our products compete with other products or treatments for diseases for which our products may be indicated.&#160;&#160;Many of our products may compete against products that have lower prices, superior performance, greater ease of administration or other advantages compared to our products. We would face enhanced competition if competitive products were added to the National Medical Insurance Program.&#160;&#160;Our inability to compete effectively could reduce sales or margins, which could have a material adverse effect on our results of our operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certain of our competitors market products or are actively engaged in research and development in areas in which we have products or in which we are developing product candidates or new indications for existing products.&#160;&#160;In the future, we expect that our products will compete with new drugs currently in development, drugs approved for other indications that may be approved for the same indications as those of our products and drugs approved for other indications that are used off-label. If alternatives to our products are dispensed or prescribed to patients, the volume of our competing products may decline or we may be required to lower the price of our competing products to remain competitive, either of which could&#160;&#160;negatively impact our sales. In addition, an increasing number of foreign pharmaceutical companies have introduced their pharmaceutical products into the Chinese market. Competitive products introduced by these companies can also negatively impact our sales and results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;Large Chinese state-owned and privately owned pharmaceutical companies and foreign-invested or foreign pharmaceutical companies may have greater clinical, research, regulatory, manufacturing, marketing, financial and human resources than we do.&#160;&#160;In addition, some of our competitors may have technical or competitive advantages over us with respect to the development of technologies and processes. These resources may make it difficult for us to compete with them to successfully discover, develop and market new products and for our current products to compete with new products or new product indications that these competitors may bring to market. There may also be significant consolidation in the pharmaceutical industry among our competitors.&#160;&#160;Alliances may develop among competitors, and these alliances may rapidly acquire significant market share.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Furthermore, in order to gain market share in China, competitors may significantly increase their advertising expenditures and promotional activities or engage in irrational or predatory pricing behavior. In addition, our competitors may engage in inappropriate competition or illegal acts, such as bribery. Third parties may actively engage in activities designed to undermine our brand name and product quality or to influence customer confidence in our products. Increased competition may result in price reductions, reduced margins and loss of market share, any of which could materially adversely affect our profit margins.&#160;&#160;We may not be able to compete effectively against current and future competitors.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Most of our products are off-patent branded generics that can be manufactured and sold by other pharmaceutical manufacturers in the PRC once the relevant protection or monitoring periods, if any, elapse.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Most of our products are off-patent branded generic pharmaceuticals and are not protected by intellectual property rights. As a result, other pharmaceutical companies may sell equivalent products at a lower cost, and this might result in a commensurate loss in sales of our branded generic products or require us to lower our prices to compete.&#160;&#160;Certain of our generic products are subject to protection during the SFDA&#8217;s monitoring period.&#160;&#160;During such period, the SFDA will not accept applications for new medicine certificates for the same product by other pharmaceutical companies or approve the production or import of the same product by other pharmaceutical companies. Once such monitoring period expires, other manufacturers may obtain relevant production approvals and will be entitled to sell generic pharmaceutical products with similar formulae or production methods in China. The maximum monitoring period currently granted by the SFDA is five years.&#160;&#160;As a result, we expect to face increased competition for our products following the expirations of their respective monitoring periods.&#160;&#160;If other pharmaceutical companies sell pharmaceutical products that are similar to our unprotected products or our protected products for which the relevant protection or monitoring period has expired, we may face additional competition and our business and profitability may be adversely affected.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">20</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our business depends in part on our well-known Helpson brand name, and if we are not able to maintain and enhance our brand recognition to maintain our competitive advantage, our reputation, business and operating results may be harmed.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We believe that market awareness of our Helpson brand has contributed significantly to the success of our business. We also believe that maintaining and enhancing the Helpson brand is critical to maintaining our competitive advantage. Although our sales and marketing staff will continue to further promote our brand to remain competitive, we may not be successful. If we are unable to further enhance our brand recognition and increase awareness of our products, or if we are compelled to incur excessive marketing and promotion expenses in order to maintain our brand awareness, our business and results of operations may be materially and adversely affected. Furthermore, our sales and results of operations could be adversely affected if the Helpson brand or our reputation is impaired by recalls or negative publicity for one of our branded products, and certain actions taken by our distributors, competitors, third-party marketing firms or relevant regulatory authorities.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pricing of our principal products is subject to government approval. Changes in government control on prices of our products may limit our profitability or cause us to stop manufacturing certain products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The prices of pharmaceutical products listed in the national medical insurance catalog and other medicines, the production or&#160;&#160;trading of which may constitute monopolies, are subject to the control of the NDRC of the PRC and the relevant provincial or local price control authorities, either in the form of fixed prices or price ceilings. From time to time, the NDRC publishes a list of medicines subject to price controls. The NDRC directly regulates retail prices of certain medicines on the list and authorizes provincial price control authorities to regulate retail prices of the remaining products on that list. Because of these price controls, which are in the form of price ceilings, it would be difficult for us to raise the wholesale prices of any products subject to such controls if their price ceilings are not raised by the NDRC.&#160;&#160;The limitation on our ability to raise the wholesale prices of our products may prevent us from absorbing or offsetting the effect resulting from any increase in the cost of raw materials or other costs, which would lower our margins. We are required to file the prices of our products with the provincial price control authorities. The prices of our products may be adjusted downward by the relevant governmental authorities in the future. Separately, the government implemented two rounds of retail drug price cuts in 2012, first in May when the NDRC cut the maximum prices of certain digestive diseases drugs by an average of 17%, and in October when prices for certain tumor, immune system and hematological system drugs were cut by an average of 17%. In addition, since the prices of all medicines are set by NDRC or relevant governmental authorities, if we are required to lower the wholesale prices to distributors of our principal products in the future as a result of any government-mandated reduction in the price ceilings of our products, our future revenue and profitability would be adversely affected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Reimbursement may not be available for our products, which could diminish our sales or affect our ability to sell our products profitably.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Market acceptance and sales of our products also depend to a large extent on the reimbursement policies of the PRC government. The Ministry of Labor and Social Security of the PRC or provincial or local labor and social security authorities, together with other government authorities, review the inclusion or removal of drugs from the national medical insurance catalog or provincial or local medical insurance catalogs for the National Medical Insurance Program every other year, and catalogs under which a drug will be classified affects the amounts reimbursable to program participants for their purchases of those medicines.&#160;&#160;These determinations are made based on a number of factors, including price and efficacy.&#160;&#160;Generally, there are two catalogs, the NIC and&#160;&#160;the EDL on which a product can be included. The products selected for the EDL generally are selected from the NIC. A consumer can be reimbursed for the full cost of a medicine on the EDL and can be reimbursed&#160;&#160;for 80% to 90% of the cost of a medicine listed on the NIC. Our Vitamin B6 and Cefalexin products are currently included in the EDL. If the relevant government authorities decide to remove our products from the medicine catalogs, such removal may reduce the affordability of our products and change the public perception regarding our products, which, in turn, would adversely affect the sales of these products and reduce our net revenue. Furthermore, if we are unable to obtain approval from the relevant government authorities to include our new products in the national, provincial or local medicine catalogs, sales of our new products maybe materially and adversely affected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The growth and success of our business depends on our ability to successfully market our principal products to hospitals and their selection in tender processes used by hospitals for medicine purchases.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our future growth and success significantly depend on our ability to successfully market our products to hospitals as prescription medicines. Approximately 90% of the end-customers&#160;of our products were hospitals. Hospitals may make bulk purchases of a medicine included in the national and provincial medicine catalogs only if that medicine is selected under a government-administered tender process. The interest of a hospital in a medicine is evidenced by:</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">21</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the inclusion of this medicine on the hospital&#8217;s formulary, which establishes the scope of medicines physicians at this hospital may prescribe to their patients, and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the willingness of physicians at the hospital to prescribe this medicine to their patients.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We believe effective marketing efforts are critical in making and keeping hospitals and physicians interested in purchasing our products.&#160;&#160;If our marketing efforts are not effective, hospital administrators may not want to include our products in their formularies or may remove them from their formularies, or physicians may not be interested in prescribing our products to their patients. As a result, we may find it difficult to maintain the existing level of sales of our products, and our revenues and profitability may decline.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our future research and development projects may not be successful.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The successful development of pharmaceutical products can be affected by many factors. Products that appear to be promising at their early phases of research and development may fail to be commercialized for various reasons, including the failure to obtain the necessary regulatory approvals.&#160;&#160;In addition, the research and development cycle for new products for which we may obtain an approval certificate is long. The process of conducting basic research and various stages of tests and trials of a new product before obtaining an approval certificate and commercializing the product may require ten years or longer. A few of our product candidates are in the early stages of pre-clinical study and clinical trial and we must conduct significant additional clinical trials before we can seek the regulatory approvals necessary to begin commercial production and sales of these products. There is no assurance that our future research and development projects will be successful or completed within the anticipated time frame or budget or that we will receive the necessary approvals from relevant authorities for the production of these newly developed products, or that these newly-developed products will achieve commercial success.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Others may obtain approval for a competitive product before the product we are developing is approved.&#160;&#160;In that case, we may be precluded from getting approval until the competitor&#8217;s monitoring period expires and realize little or no benefit from our research and development investment.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Even if such products can be successfully commercialized, they may not achieve the level of market acceptance that we expect. In addition, the pharmaceutical industry is characterized by rapid changes in technology, constant enhancement of industrial knowhow and frequent emergence of new products.&#160;&#160;Future technological improvements and continual product developments in the pharmaceutical market may render our existing products obsolete or affect their viability and competitiveness. Therefore, our future success will largely depend on our development capability, including our ability to improve our existing products, diversify our product range and develop new and competitively-priced products that can meet the requirements of the changing market. Should we fail to respond to these frequent technological advances by improving our existing products or developing new products in a timely manner or these products do not achieve a desirable level of market acceptance, our business and profitability will be materially and adversely affected.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">We rely on research institutions and universities in the PRC for the research and development of new products and any failure of such research institutions to meet our timing and quality standards or our failure to continue such collaborative arrangement or enter into such new arrangements could adversely affect our ability to develop new pharmaceuticals and our overall business prospects</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our business strategy includes collaborating with third parties for research and development of new products. We rely on long-term cooperative relationships with a number of research institutions and universities in the PRC, including Chinese Academy of Sciences, China University of Pharmaceuticals, the Military Medical Academy Basic Medical Science Institute, Chongqing Pharmaceutical Research Institute and Sichuan University.&#160;&#160;These research institutions and universities have collaborated with us in a number of research projects and certain of our products that have obtained approval certificates were developed by such research institutions.&#160;&#160;At present, several research institutions and universities are working with us on various research and development projects.&#160;&#160;Any failure of such research institutions to meet the required quality standards and timetables set in their research agreements with us, or our inability to enter into additional research agreements with these research institutions on terms acceptable to us in the future, may have an adverse effect on our ability to develop new medicines and on our business prospects.&#160;&#160;In addition, the growth of our business and development of new products may require that we seek additional research institutions.&#160;&#160;We cannot assure you that we will be able to enter into agreements with new parties on terms acceptable to us.&#160;&#160;Our inability to enter into such agreements or our failure to maintain such arrangements could limit the number of new products that we develop and ultimately decrease our sources of future revenue.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may not be able to obtain regulatory approval for any of the new products and failure to obtain these approvals could materially harm our business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All new medicines must be approved by the SFDA before they can be marketed and sold in the PRC. The SFDA requires successful completion of clinical trials and demonstrated manufacturing capability before it grants approval. It often takes a number of years before a medicine can be ultimately approved by the SFDA. In addition, the SFDA and other regulatory authorities may apply new standards for safety, manufacturing, packaging, and distribution of future product candidates. </font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">22</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Complying with such standards may be time-consuming and expensive and could result in delays in obtaining SFDA approval for our future product candidates, or possibly preclude us from obtaining SFDA approval altogether.&#160;&#160;Furthermore, our future products may not be effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude us from obtaining regulatory approval or prevent or limit commercial use.&#160;&#160;The SFDA and other regulatory authorities may not approve the products that we develop and even if we do obtain regulatory approvals, such regulatory approvals may be subject to limitations on the indicated uses for which we may market a product, which may limit the size of the market for such product.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">New product development in the pharmaceutical industry is time-consuming and costly and has a low rate of successful commercialization</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our success will depend in part on our ability to enhance our existing products and to develop new products. The development process for pharmaceutical products is complex and uncertain, as well as time-consuming and costly. Relatively few research and development programs produce a commercial product. A product candidate that appears promising in the early phases of development may fail to reach the market for a number of reasons, such as:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the failure to demonstrate safety and efficacy in preclinical and clinical trials;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the failure to obtain approvals for intended use from relevant regulatory bodies, such as the SFDA;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">our inability to manufacture and commercialize sufficient quantities of the product economically; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">proprietary rights, such as patent rights, held by others to our product candidates and their refusal to sell or license such rights to us on reasonable terms, or at all.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Delays in any part of the development process or our inability to obtain regulatory approval of our products could adversely affect our operating results by restricting or delaying our introduction of new products. Even if we successfully commercialize new products, these products may address markets that are currently being served by our mature products and may result in a reduction in the sales volume of our mature product or vice versa. Failure to develop, obtain necessary regulatory clearances or approvals for or successfully commercialize or market potential new products or technologies could have a material adverse effect on our financial condition and results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">We may not be able to successfully identify and acquire new products or businesses</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition to our own product development efforts, our growth strategy also relies on our acquisitions of new product candidates, products or businesses from third parties. Any future growth through acquisitions will be dependent upon the continued availability of suitable acquisition candidates at favorable prices and upon advantageous terms and conditions. Even if such opportunities are present, we may not be able to successfully identify them. Moreover, other companies, many of which may have substantially greater financial, marketing and sales resources, are competing with us for the right to acquire such product candidates, products or businesses.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">We depend on distributors for all of our revenues and failure to maintain relationships with our distributors or to otherwise expand our distribution network would materially and adversely affect our business</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We sell our products exclusively to pharmaceutical distributors in the PRC and depend on distributors for all of our revenues. We have business relationships with approximately 1,220 distributors in the PRC. Although for the year ended December 31, 2012, no customer accounted for more than 10% of sales or ending accounts receivable. For the years ended December 31, 2011 one distributor accounted for 20.4% of our revenues.&#160;In line with industry practices in the PRC, we enter into written sales agreements with our distributors. However, such sales agreements are not in substance equivalent to a typical distribution agreement in the United States.&#160;&#160;Each sales agreement is more in the form of a sales order and specifies one or several purchases of one or more products without any continuing obligation to purchase any additional amount of products.&#160;&#160;In the event certain distributors choose not to continue their relationship with us after completing their existing sales agreements, they can do so without breaching any contract or agreement and our financial results could be adversely affected if we cannot find the equivalent distributors in time under such circumstances. In addition, some of our distributors may sell products that compete with our products.&#160;&#160;We compete for desired distributors with other pharmaceutical manufacturers, many of which may have higher visibility, greater name recognition and financial resources, and broader product selection than we do. Consequently, maintaining relationships with existing distributors and replacing distributors may be difficult and time consuming. Any disruption of our distribution network, including our failure to renew our existing distribution agreements with our desired distributors, could negatively affect our ability to effectively sell our products and would materially and adversely affect our business, financial condition and results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">We rely on a limited number of distributors for the majority of sales of our products</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">23</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We rely on a limited number of distributors for most of our net revenue. Our top five distributors in the aggregate accounted for 33% and 46% of our net revenues in 2012 and 2011, respectively. We expect that a relatively small number of our distributors will continue to account for a major portion of our net revenue in the near future. Our dependence on a few distributors could expose us to the risk of substantial losses if a single large distributor stops purchasing our products, purchases fewer of our products or goes out of business and we cannot find substitute distributors on equivalent terms. If any of our significant distributors reduces the quantity of the products they purchase from us or stops purchasing from us, our net revenue would be materially and adversely affected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our operation may be affected if we could not obtain raw materials from our current&#160;&#160;key suppliers on acceptable terms.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We require a supply of a wide variety of raw materials to manufacture our products.&#160;&#160;Currently, we rely on numerous suppliers in the PRC and overseas to deliver our required raw materials and believe we have at least three principal suppliers for each of our most critical raw materials. For the year ended December 31, 2011, purchases from one supplier accounted for 20.8% of our raw material purchases.&#160;For the year ended December 31, 2012, purchases from two suppliers accounted for 12.1%&#160;&#160;and 10.3% of our raw material purchases, respectively.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Historically, we have not had difficulty obtaining raw materials from suppliers. However, we cannot predict the impact on our suppliers of the current economic environment and other developments in their respective businesses.&#160;&#160;Insolvency, financial difficulties or other factors may result in our suppliers not being able to fulfill the terms of their agreements with us.&#160;&#160;Furthermore, such factors may render suppliers unwilling to extend contracts that provide favorable terms to us or may force them to seek to renegotiate existing contracts.&#160;&#160;Although we believe we have alternative sources of supply for the raw materials used in our business, termination of our relationship with any of our key suppliers could have a material adverse effect on our business, financial condition or results of operations in the unlikely event that we are unable to obtain adequate raw materials from other sources in a timely manner or at all.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may not be able to effectively manage our employees and distribution network, and our reputation, business, prospects and brand may be materially and adversely affected by actions taken by our distributors and third party marketing firms.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have limited ability to manage the activities of our distributors and third-party marketing firms that we contract to promote our products and brand name, both of which are independent from us. Our distributors and third-party marketing firms could take one or more of the following actions, any of which could have a material adverse effect on our business, prospects and brand:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">sell our products outside their designated territory, possibly in violation of the exclusive distribution rights of other distributors;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">fail to adequately promote our products;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">promote competing products in lieu of our products; or</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">violate the anti-corruption laws of China, the United States or other countries.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, although our company policies prohibit our employees from making improper payments to hospitals or otherwise engaging in improper activities to influence the procurement decisions of hospitals, we may not be able to effectively manage our employees, as the compensation of our sales and marketing personnel is partially linked to their sales performance. As a result, we cannot assure you that our employees will not violate the anticorruption laws of the PRC, the United States and other countries. Such violations could have a material adverse effect on our reputation, business, prospects and brand.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;Failure to adequately manage our employees, distribution network or third-party marketing firms, or their non-compliance with employment, distribution or marketing agreements could harm our corporate image among hospitals and end users of our products and disrupt our sales, resulting in a failure to meet our sales goals. Furthermore, we could be liable for actions taken by our employees, distributors or third-party marketing firms, including any violations of applicable law in connection with the marketing or sale of our products, including China&#8217;s anticorruption laws and the Foreign Corrupt Practices Act of the United States, or the FCPA. In particular, if our employees, distributors or third-party marketing firms make any payments that are forbidden under the FCPA, we could be subject to civil and criminal penalties imposed by the U.S. government.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Recently, the PRC government has increased its anti-corruption measures. In the pharmaceutical industry, corrupt practices include, among others, acceptance of kickbacks, bribes or other illegal gains or benefits by the hospitals and medical practitioners from pharmaceutical manufacturers and distributors in connection with the prescription of certain pharmaceuticals. Our employees, affiliates, distributors or third-party marketing firms may violate these laws or otherwise engage in illegal practices with respect to their sales or marking of our products or other activities involving our products. If our employees, affiliates, distributors or third-party marketing firms violate these laws, we could be required to pay damages or fines, which could materially and adversely affect our financial condition and results of operations. In addition, PRC laws regarding what types of payments to promote or sell our products are impermissible are not always clear. As a result, we, our employees, affiliates, our distributors or third-party marketing firms could make certain payments in connection with the promotion or sale of our products or other activities involving our products which at the time are considered by us or them to be legal but are later deemed impermissible by the PRC government. Furthermore, our brand and reputation, our sales activities or the price of our common stock could be adversely affected if we become the target of any negative publicity as a result of actions taken by our employees, affiliates, distributors or third-party marketing firms.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">24</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We have limited insurance coverage and may incur losses resulting from product liability claims, business interruptions or claims that could be covered by D&amp;O Insurance.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The nature of our business exposes us to the risk of product liability claims that is inherent in the research and development, manufacturing and marketing of pharmaceutical products. Using product candidates in clinical trials also exposes us to product liability claims. These risks are greater for our products that receive regulatory approval for commercial sale. Even if a product were approved for commercial use by an appropriate governmental agency, there can be no assurance that users will not claim effects other than those intended resulted from the use of our products. While to date no material claim for personal injury resulting from allegedly defective products has been brought against us, a substantial claim or a substantial number of claims, if successful, could have a material adverse impact on our business, financial condition and results of operations. Such lawsuits may divert the attention of our management from our business strategies, may be costly to defend and may negatively impact our reputation and our Helpson brand&#8217;s reputation, and harm the sales of our other branded products. In addition, product liability insurance for pharmaceutical products is not available in the PRC. In the event of allegations that any of our products are harmful, we may experience reduced consumer demand for our products or our products may be recalled from the market. We may also be forced to defend lawsuits and, if unsuccessful, to pay a substantial amount in damages. In addition, business interruption insurance available in the PRC offers limited coverage compared to that offered in many other countries. We do not have any business interruption insurance. Any business disruption or natural disaster could result in substantial costs and diversion of resources.&#160;&#160;Lastly, we currently do not have directors and officers insurance. In the event we or any of our directors or officers are sued under any proceedings or actions that could be covered by a standard D&amp;O insurance, we may incur substantial costs and expenses to defend such case.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our future liquidity needs are uncertain and we may need to raise additional funds in the future.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;Based on our current operating plans, we expect our existing resources to be sufficient to fund our existing operations for at least 12 months. However, we may be required to raise additional funds to expand our operations, including the construction of a production line dedicated to the production of cephalosporin combination drug. In addition, we may,&#160;&#160;need to raise additional funds if our expenditures exceed our current expectations. This could occur for a number of reasons, including:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">we determine to devote significant amount of financial resources to the development of products that we believe to have significant commercialization potential;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">we determine to acquire or license rights to additional product candidates or new technologies;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">some or all of our product candidates fail in clinical trials or pre-clinical studies or prove to be not as commercially promising as we expect and we are forced to develop or acquire additional product candidates;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">our product candidates require more extensive clinical or pre-clinical testing or clinical trials of these product candidates take longer to complete than we currently expect; or</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">we determine or are required to conduct more high-throughput screening than expected against current or additional disease targets to develop additional product candidates.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our ability to raise additional funds in the future is subject to a variety of uncertainties, including:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">our future financial condition, results of operations and cash flows;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">general market conditions for capital-raising activities by pharmaceutical companies; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">economic, political and other conditions in China and elsewhere.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We cannot assure you that our revenues will be sufficient to meet our operational needs and capital requirements. If we need to obtain external financing, we cannot assure you that financing will be available in amounts or on terms acceptable to us, if at all. Our future liquidity needs and other business reasons could require us to sell additional equity or debt securities or obtain a credit facility.&#160;&#160;The sale of additional equity or equity-linked securities could result in additional dilution to our stockholders. The incurrence of additional indebtedness would result in increased debt service obligations and could result in operating and financing covenants that would restrict our operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may undertake acquisitions in the future, and any difficulties in integrating these acquisitions may damage our profitability.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">25</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the future, we may acquire additional businesses or products that complement our existing business and expand our business scale. The integration of new businesses and products may prove to be an expensive and time consuming procedure. We can offer no assurance that we will be able to successfully integrate the newly acquired businesses and products or operate the acquired business in a profitable manner. Failure to locate an appropriate acquisition target, failure to successfully integrate and operate acquired businesses and products, and failure to identify substantial liabilities associated with acquired businesses, may materially adversely impact our operations and profits.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The failure to manage growth effectively could have an adverse effect on our business, financial condition and results of our operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The rapid market growth of our pharmaceutical products may require us to expand our employee base for managerial, operational, financial and other purposes. As of December 31, 2012, we had 443employees.&#160;&#160;Our continued future growth will impose significant responsibilities upon the members of management to identify, recruit, maintain, integrate and motivate new employees. Aside from increased difficulties in the management of human resources, we may also encounter working capital issues, as we need increased liquidity to finance the purchases of raw materials and supplies, research and development and purchase of drug formulas for new products, acquisition of new businesses and technologies, and the hiring of additional employees. For effective growth management, we will be required to continue improving our operations, management, and financial systems and control. Our failure to manage growth effectively may lead to operational and financial inefficiencies that will have a negative effect on our profitability.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We depend upon key employees and consultants in a competitive market for skilled personnel. If we are unable to attract and retain key personnel, it could adversely affect our ability to develop and market our products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are highly dependent upon the principal members of our management team, especially Ms. Zhilin Li, our Chairman, President and Chief Executive Officer. The loss of the services of any of these persons would adversely affect our ability to develop and market our products.&#160;&#160;We also depend in part on the continued services of our key scientific personnel and our ability to identify, hire and retain additional personnel, including marketing and sales staff.&#160;&#160;We face intense competition for qualified personnel, and the existence of noncompetition agreements between prospective employees and their former employers may prevent us from hiring those individuals or subject us to suit from their former employers. While we attempt to provide competitive compensation packages to attract and retain key personnel, many of our competitors are likely to have greater resources and more experience than we have, making it difficult for us to compete successfully for key personnel.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certain of our employees and consultants were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors, or at universities or other research institutions. Although no claims against us are currently pending, we may be subject to claims that these employees or consultants have, inadvertently or otherwise, used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims.&#160;&#160;Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management.&#160;&#160;If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We are subject to environmental regulations and may be exposed to liability and potential costs for environmental compliance.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are subject to PRC laws and regulations concerning the discharge of waste water, gaseous waste and solid waste during our manufacturing processes.&#160;&#160;We are required to establish and maintain facilities to dispose of waste and report the volume of waste to the relevant government authorities, which conduct scheduled or unscheduled inspections of our facilities and treatment of such discharge.&#160;&#160;We may not at all times comply fully with environmental regulations.&#160;&#160;Any violation of these regulations may result in substantial fines, criminal sanctions, revocations of operating permits, shutdown of our facilities and obligation to take corrective measures.&#160;&#160;Our cost of complying with current and future environmental protection laws and regulations and our liabilities which may potentially arise from the discharge of effluent water and solid waste may materially adversely affect our business, financial condition and results of operations.&#160;&#160;The government may take steps towards the adoption of more stringent environmental regulations.&#160;&#160;Due to the possibility of unanticipated regulatory or other developments, the amount and timing of future environmental expenditures may vary substantially from those currently anticipated. If there is any unanticipated change in the environmental regulations, we may need to incur substantial capital expenditures to install, replace, upgrade or supplement our pollution control equipment or make operational changes to limit any adverse impact or potential adverse impact on the environment in order to comply with new environmental protection laws and regulations. If such costs become prohibitively expensive, we may be forced to cease certain aspects of our business operations.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Power shortages, natural disasters, terrorist acts or other calamities could disrupt our production and have a material adverse effect on our business, financial position and results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">26</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All of our products are produced at our manufacturing facility in Hainan, China.&#160;&#160;A significant disruption at that facility, even on a short-term basis, could impair our ability to timely produce and ship products, which could have a material adverse effect on our business, financial position and results of operations.&#160;&#160;Our manufacturing operations are vulnerable to interruption and damage from natural and other types of disasters, including earthquake, fire, floods, environmental accidents, power loss, communications failures and similar events. If any disaster were to occur, our ability to operate our business at our facilities would be seriously impaired. In addition, the nature of our production and research activities could cause significant delays in our programs and make it difficult for us to recover from a disaster.&#160;&#160;We do not maintain any insurance other than property insurance for some of our buildings and equipment.&#160;&#160;Accordingly, unexpected business interruptions resulting from disasters could disrupt our operations and thereby result in substantial costs and diversion of resources. In addition, our production process requires a continuous supply of electricity. We have encountered power shortages historically due to restricted power supply to industrial users during summers when the usage of electricity is high and supply is limited or as a result of damage to the electricity supply network.&#160;&#160;Because the duration of those power shortages was brief, they had no material impact on our operations. Interruptions of electricity supply could result in lengthy production shutdowns, increased costs associated with restarting production and the loss of production in progress.&#160;&#160;Any major suspension or termination of electricity or other unexpected business interruptions could have a material adverse impact on our business, financial condition and results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The discontinuation of any preferential tax treatments or other incentives currently available to us in the PRC could materially and adversely affect our business, financial condition and results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Prior to January 1, 2008, pursuant to the original Income Tax Law of the PRC for Enterprises with Foreign Investment and Foreign Enterprises and its implementation rules, a foreign invested enterprise as defined under PRC laws was required to pay a 30% corporate income tax and a 3% local income tax; an enterprise with foreign investment of a production nature scheduled to operate for a period of not less than ten years was, from the year of making profits, exempt from enterprise income tax in the first and second years and allowed a fifty percent reduction in the third to fifth years. Pursuant to the State Council&#8217;s Regulations on Encouraging Investment in and Development of Hainan Island promulgated in May 1988, the corporate income tax for all companies incorporated in Hainan Province is reduced to 15%. Pursuant to the Regulations on Foreign Investment in Hainan Special Economic Zone promulgated by Hainan Province in March 1991 (the &#8220;Regulation on Foreign Investment&#8221;), all foreign-invested enterprises incorporated in Hainan Province are exempt from the local income tax.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">However, on March 16, 2007, China&#8217;s national congress approved the Enterprise Income Tax Law of the PRC (&#8220;New Income Tax Law&#8221;), which took effect on January 1, 2008. The New Income Tax Law unified the enterprise income tax rate, cost deduction and tax incentive policies for both domestic and foreign invested enterprises. Under the New Income Tax Law, enterprises that were established and already enjoyed preferential tax rates or tax holidays before March 16, 2007 will (i) in the case of preferential tax rates, gradually increase to a 25% rate over a period of five years, (ii) in the case of tax holidays, continue to receive the benefit of such holidays until the expiration of such term.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As a result, we enjoyed a preferential tax rate of 9%, 10% and 11% in the years of 2008, 2009 and 2010. We obtained the High Tech Enterprise status from the government in 2010 and we enjoy a 15% income tax rate for a three-year period from 2011 to 2013. We expect to be subject to a standard income tax rate of 25% starting from 2014 unless we continue to receive preferential tax treatment as a High Tech Enterprise or we qualify for any other preferential tax treatment according to any regulations or policies applicable at that time. We intend to apply for continued High Tech Enterprise status in 2013, with its associated favorable tax rate, but can give no assurances that our application will be successful. The discontinuation of any of our existing special or preferential tax treatment or other incentives could have an adverse affect on our business, financial condition and results of operations.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We cannot guarantee the protection of our intellectual property rights, and if infringement or counterfeiting of our intellectual property rights occurs, then our reputation and business may be adversely affected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To protect the brand names of our products, we have registered and applied for registration of certain of our trademarks in the PRC. Currently nine of the 20 pharmaceutical products we manufacture are marketed under a brand is&#160;registered as a trademark in China. We also purchased from a third party for a pharmaceutical compound that we are seeking to develop into a further product. To date, we have not experienced any infringements of our trademarks for sales of pharmaceutical products or our exclusive patent license, and we are not aware of any infringement of our intellectual property rights. However, there is no assurance that there will not be any infringement of our brand name or other registered trademarks or counterfeiting of our products in the future. There is no assurance that there will not be any third-party infringement of our patent. Should any such infringement or counterfeiting occur, our reputation and business may be adversely affected. We may also incur significant expenses and substantial amounts of time and effort to protect our intellectual property rights in the future. Such diversion of our resources may adversely affect our existing business and future expansion plans.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risks Related to Doing Business in China</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Adverse changes in political and economic policies of the PRC government could have a material and adverse effect on the overall economic growth of China, which could reduce the demand for our services and materially and adversely affect our competitive position.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We conduct substantially all of our business and have historically derived all of our revenues in China.&#160;&#160;Accordingly, our business, financial condition, results of operations and prospects are affected significantly by economic, political and legal developments in China.&#160;&#160;The Chinese economy differs from the economies of most developed countries in many respects, including:</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">27</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the degree of government involvement;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the level of development;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the growth rate;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the control of foreign exchange;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">access to financing; and</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the allocation of resources.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">While the Chinese economy has experienced significant growth in the past 30 years, growth has been uneven, both geographically and among various sectors of the economy.&#160;&#160;The Chinese economy has also experienced certain adverse effects due to the recent global financial crisis.&#160;&#160;The Chinese government has implemented various measures to encourage economic growth and guide the allocation of resources. Some of these measures benefit the overall Chinese economy, but may also have a negative effect on us. For example, our operating results and financial condition may be adversely affected by government control over capital investments or changes in tax regulations that are applicable to us, and by government policies or guidance aimed at curtailing the perceived over-capacity of certain industry sectors, such as pharmaceutical companies.&#160;&#160;The Chinese government has implemented certain measures, including interest rate increases, to control the pace of economic growth. These measures may cause decreased economic activity in China, which could in turn reduce the demand for our products and materially and adversely affect our operating results and financial condition.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Chinese economy has been transitioning from a planned economy to a more market-oriented economy. Although in recent years the Chinese government has implemented measures emphasizing the utilization of market forces for economic reform, the reduction of state ownership of productive assets and the establishment of sound corporate governance in business enterprises, a substantial portion of the productive assets in China is still owned by the Chinese government.&#160;&#160;The continued control of these assets and other aspects of the national economy by the Chinese government could materially and adversely affect our business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Chinese government also exercises significant control over Chinese economic growth through the allocation of resources, controlling payment of foreign currency-denominated obligations, setting monetary policy and providing preferential treatment to particular industries or companies.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;Any adverse change in the economic conditions or government policies in China could have a material and adverse effect on overall economic growth and the level of investments in health industries in China, which in turn could lead to a reduction in demand for our products and consequently have a material and adverse effect on our business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The PRC legal system has inherent uncertainties that could limit the legal protections available to us.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The PRC legal system is a civil law system based on written statutes. Unlike common law systems, it is a system in which decided legal cases have little precedential value. In the late 1970s, the PRC government began to promulgate a comprehensive system of laws and regulations governing commercial matters. The overall effect of legislation enacted over the past 20 years has significantly enhanced the protections afforded to foreign-invested enterprises in China. However, these laws, regulations and legal requirements are relatively recent and are evolving rapidly, and their interpretation and enforcement involve uncertainties. These uncertainties could limit the legal protections available to foreign investors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The practical effect of the PRC legal system on our business operations in China can be viewed from two separate but intertwined considerations. First, as a matter of substantive law, the Foreign Invested Enterprise laws provide significant protection from government interference. In addition, these laws guarantee the full benefit of corporate articles and contracts to Foreign Invested Enterprise participants. These laws, however, do impose standards concerning corporate formation and governance that are not qualitatively different from the corporation laws found in the United States. Similarly, PRC accounting laws mandate accounting practices that may not be consistent with the U.S. generally accepted accounting principles.&#160;&#160;PRC accounting laws require that an annual &#8220;statutory audit&#8221; be performed in accordance with PRC accounting standards and that the account books of a foreign invested enterprise be maintained in accordance with PRC accounting laws.&#160;&#160;Article 14 of the PRC Wholly Foreign-Owned Enterprise Law requires a wholly foreign-owned enterprise to submit certain periodic fiscal reports and statements to designated financial and tax authorities. If a foreign-invested enterprise refuses to keep account books in China, the financial and tax authorities may impose a fine on it, and the industry and commerce administration authority may order it to suspend operations or may revoke its business license.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">28</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Second, while the enforcement of substantive rights may be less clear than United States procedures, foreign invested enterprises and wholly foreign-owned enterprises are PRC registered companies that enjoy the same status as other PRC registered companies in business-to-business dispute resolutions.&#160;&#160;The PRC legal infrastructure, however, is significantly different in operation from its United States counterpart, and may present a significant impediment to the operation of a foreign invested enterprise.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PRC economic reform policies or nationalization could result in a total investment loss in our common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Since 1979, the PRC government has reformed its economic policies. Because many reforms are unprecedented or experimental, they are expected to be refined and improved. Other political, economic and social factors, such as political changes, changes in the economic growth rates, unemployment or inflation, or in the disparities in per capita wealth between regions within China, could lead to further readjustment of the reform measures. This refining and readjustment process may negatively affect our operations.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Although the PRC government owns the majority of productive assets in China, in the past several years the government has implemented economic reform measures that emphasize decentralization and encourage private economic activity. Because these economic reform measures may be inconsistent or ineffectual, there are no assurances that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We will be able to capitalize on economic reforms;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Chinese government will continue its pursuit of economic reform policies;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The economic policies, even if pursued, will be successful;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Economic policies will not be significantly altered from time to time; or</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Business operations in China will not become subject to the risk of nationalization.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Over the last few years, China&#8217;s economy has registered high growth rates. Recently, there have been indications that rates of inflation have increased. In response, the Chinese government recently has taken measures to curb this excessively expansive economy. These measures have included restrictions on the availability of domestic credit, reducing the purchasing capability of some of its customers, and limited recentralization of the approval process for purchases of certain foreign products. These austere measures alone may not succeed in slowing down the economy&#8217;s excessive expansion or control inflation, and may result in severe dislocations in the Chinese economy. The PRC government may adopt additional measures to further combat inflation, including the establishment of freezes or restraints on certain projects or markets. These measures may adversely affect our operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There can be no assurance that the reforms to China&#8217;s economic system will continue or that we will not be adversely affected by changes in China&#8217;s political, economic, and social conditions and by changes in policies of the PRC government, such as changes in laws and regulations, measures which may be introduced to control inflation, changes in the rate or method of taxation, imposition of additional restrictions on currency conversion and remittance abroad, and reduction in tariff protection and other import restrictions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">You may experience difficulties in effecting service of legal process, enforcing foreign judgments or bringing original actions in the PRC against our company or our management based on U.S. or other foreign laws.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our operating subsidiary, Helpson, is incorporated under the laws of the PRC and substantially all of our assets are located in the PRC. In addition, substantially all of our directors, executive officers and managers reside within the PRC, and substantially all of the assets of these persons are located within the PRC.&#160;&#160;As a result, it may not be possible to effect service of process within the United States or elsewhere outside the PRC upon certain of our directors, executive officers or managers, including with respect to matters arising under U.S. federal securities laws or applicable state securities laws.&#160;&#160;Moreover, the PRC does not have treaties providing for the reciprocal recognition and enforcement of judgments of courts with the United States, the United Kingdom, Japan or many other countries.&#160;&#160;As a result, recognition and enforcement in the PRC of judgments of a court in the United States and any of the other jurisdictions mentioned above in relation to any matter may be difficult or impossible.&#160;&#160;Furthermore, an original action may be brought in the PRC against us, our directors, executive officers or managers only if the actions are not required to be arbitrated by PRC law and Helpson&#8217;s articles of association, and only if the facts alleged in the complaint give rise to a cause of action under PRC law.&#160;&#160;In connection with any such original action, a PRC court may impose civil liability, including monetary damages.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Because we receive substantially all of our revenue in Renminbi, which currently is not a freely convertible currency, and the PRC government controls the currency conversion and the fluctuation of the Remninbi, we are subject to changes in the PRC&#8217;s political and economic decisions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">29</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We receive substantially all of our revenues in Renminbi, which currently is not a freely-convertible currency.&#160;&#160;The PRC government may, at its discretion, restrict access in the future to foreign currencies for current account transactions.&#160;&#160;Any future restrictions on currency exchanges may limit our ability to use revenue generated in Renminbi to fund any future business activities outside China or to make dividend or other payments in U.S. dollars.&#160;&#160;Although the Chinese government introduced regulations in 1996 to allow greater convertibility of the Renminbi for current account transactions, significant restrictions still remain, including primarily the restriction that foreign-invested enterprises may only buy, sell or remit foreign currencies, after providing valid commercial documents, at those banks authorized to conduct foreign exchange business. In addition, conversion of Renminbi for capital account items, including direct investment and loans, is subject to governmental approval in China, and companies are required to open and maintain separate foreign exchange accounts for capital account items.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We cannot be certain that the Chinese regulatory authorities will not impose more stringent restrictions on the convertibility of the Renminbi, especially with respect to foreign exchange transactions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Fluctuation in the value of the Renminbi may have a material and adverse effect on your investment.&#160;&#160;The change in value of the Renminbi against the U.S. dollar is affected by, among other things, changes in PRC&#8217;s political and economic conditions.&#160;&#160;From 1995 until July 2005, the People&#8217;s Bank of China intervened in the foreign exchange market to maintain an exchange rate of approximately RMB8.3 per U.S. dollar.&#160;&#160;On July 21, 2005, the PRC government changed this policy and began allowing modest appreciation of the Renminbi versus the U.S. dollar.&#160;&#160;Under the new policy, the Renminbi was permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies.&#160;&#160;This change in policy caused the Renminbi to appreciate approximately 21.5% against the U.S. dollar over the following three years. &#160;As a consequence, the Renminbi has fluctuated sharply since July 2008 against other freely traded currencies, in tandem with the U.S. dollar. It is difficult to predict how long the current situation may last and when and how it may change again. There remains significant international pressure on the PRC government to adopt a substantial liberalization of its currency policy, which could result in a further and more significant appreciation in the value of the Renminbi against the U.S. dollar.&#160;&#160;Significant revaluation of the Renminbi may have a material and adverse effect on your investment.&#160;&#160;For example, to the extent that we need to convert U.S. dollars we receive from securities offering into Renminbi for our operations, appreciation of the Renminbi against the U.S. dollar would have an adverse effect on the Renminbi amount we would receive from the conversion. Conversely, if we decide to convert our Renminbi into U.S. dollars for the purpose of making payments for dividends on our common stock or for other business purposes, appreciation of the U.S. dollar against the Renminbi would have a negative effect on the U.S. dollar amount available to us.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, appreciation or depreciation in the value of the Renminbi relative to the U.S. dollar would affect our financial results reported in U.S. dollar terms without giving effect to any underlying change in our business or results of operations.&#160;&#160;The income statements of our operations are translated into U.S. dollars at the average exchange rates in each applicable period.&#160;&#160;To the extent the U.S. dollar strengthens against foreign currencies, the translation of these foreign currencies denominated transactions results in reduced revenue, operating expenses and net income for our international operations.&#160;&#160;Similarly, to the extent the U.S. dollar weakens against foreign currencies, the translation of these foreign currency denominated transactions results in increased revenue, operating expenses and net income for our international operations.&#160;&#160;We are also exposed to foreign exchange rate fluctuations as we convert the financial statements of our foreign subsidiaries into U.S. dollars in consolidation.&#160;&#160;If there is a change in foreign currency exchange rates, the conversion of the foreign subsidiaries&#8217; financial statements into U.S. dollars will lead to a translation gain or loss, which is recorded as a component of other comprehensive income.&#160;&#160;Very limited hedging transactions are available in China to reduce our exposure to exchange rate fluctuations.&#160;&#160;To date, we have not entered into any hedging transactions.&#160;&#160;While we may enter into hedging transactions in the future, the availability and effectiveness of these transactions may be limited, and we may not be able to successfully hedge our exposure at all.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We are subject to the environmental protection laws of the PRC that may be costly to comply with and may adversely affect our manufacturing operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our manufacturing process may produce by-products, such as effluent, gases and noise,&#160;&#160;that are harmful to the environment. We are subject to multiple laws governing environmental protection, such as &#8220;The Law on Environmental Protection in the PRC&#8221; and &#8220;The Law on Prevention of Effluent Pollution in the PRC,&#8221; as well as standards set by the relevant governmental bodies determining the classification of different wastes and proper disposal. We have properly attained a waste disposal permit for our manufacturing facility, which details the types and concentration of effluents and gases allowed for disposal. We are responsible for the renewal of the waste disposal permit. There is no assurance that we will obtain the renewal of the waste disposal permit when the current permit expires.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">China is experiencing substantial problems with environmental pollution. Accordingly, it is likely that the national, provincial and local governmental agencies will adopt stricter pollution controls. There can be no assurance that future changes in environmental laws and regulations will not impose costly compliance requirements on us or otherwise subject us to future liabilities. Our business&#8217;s profitability may be adversely affected if additional or modified environmental control regulations are imposed upon us.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We rely on dividends paid by our subsidiaries for our cash needs, and any limitation on the ability of our subsidiaries to make payments to us could have a material and adverse effect on our ability to conduct our business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">30</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We conduct all of our business through Helpson, our subsidiary established in China.&#160;&#160;We rely on dividends paid by this subsidiary for our cash needs, including the funds necessary to pay dividends and other cash distributions, if any, to our stockholders, to service any debt we may incur and to pay our operating expenses.&#160;&#160;The payment of dividends by entities established in China is subject to limitations. Regulations in China currently permit payment of dividends only out of accumulated profits as determined in accordance with accounting standards and regulations in China.&#160;&#160;Our PRC subsidiary is also required to set aside at least 10.0% of its after-tax profit based on PRC accounting standards each year to its general reserves or statutory capital reserve fund until the accumulative amount of such reserves reach 50.0% of its respective registered capital. Our restricted reserves are not distributable as cash dividends.&#160;&#160;In addition, if any of our PRC subsidiaries incurs debt on its own behalf in the future, the instruments governing the debt may restrict its ability to pay dividends or make other distributions to us.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Failure to comply with PRC regulations regarding the registration requirements for employee equity incentive plans may subject our PRC citizen employees or us to fines and other legal or administrative sanctions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 28, 2007, the SAFE promulgated the Application Procedure of Foreign Exchange Administration for Domestic Individuals Participating in Employee Stock Holding Plan or Share Option Plan of Overseas-Listed Company, which were superseded by Notice from SAFE regarding Issues related to Domestic Individual Participating Offshore Public Company Equity Incentive Plan&#160;&#160;promulgated on February 15, 2012 (&#8220;SAFE #7&#8221;) or the Share Option Rule.&#160;&#160;Under the Share Option Rule, PRC citizens who are granted share options or other employee equity incentive awards by an overseas publicly-listed company are required, through a PRC agent who may be a PRC subsidiary of such overseas publicly-listed company, to register with the SAFE and complete certain other procedures related to the share options or other employee equity incentive plans.&#160;&#160;We and our PRC citizen employees who are granted share options or other equity incentive awards under our 2010 Long-Term Incentive Plan, or PRC optionees, are subject to the Share Option Rule.&#160;&#160;If we or our PRC optionees fail to comply with these regulations, we or our PRC optionees may be subject to fines and legal sanctions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The enforcement of new labor contract law and its implementation rules and increase in labor costs in the PRC may adversely affect our business and our profitability.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">China adopted the PRC Employment Contract Law, or the new Labor Contract Law, effective January 1, 2008 and the implementation rules effective September 18, 2008.&#160;&#160;The new Labor Contract Law and its implementation rules impose more stringent obligations on employers for, among others, entering into written employment contracts, hiring temporary employees, dismissing employees, setting compensations for dismissal and protecting certain sick or disabled employees from dismissal and setting forth detailed requirements relating to the contents of the employment contracts.&#160;&#160;The implementation of the new Labor Contract Law may increase our operating expenses, in particular our personnel expenses, as the continued success of our business depends significantly on our ability to attract and retain qualified personnel. In the event that we decide to terminate some of our employees or otherwise change our employment or labor practices, the new Labor Contract Law may also limit our ability to effect those changes in a manner that we believe to be cost-effective or desirable, which could adversely affect our business and results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PRC regulation of loans and direct investment by offshore holding companies to PRC entities may delay or prevent us from using the proceeds we receive from a securities offering to make loans or additional capital contributions to our PRC operating subsidiary.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In utilizing the proceeds we receive from a securities offering, as an offshore holding company with a PRC subsidiary, we may make loans to our PRC subsidiary, or we may make additional capital contributions to our PRC subsidiary. Any loans to our PRC subsidiary are subject to PRC regulations and approvals. For example, loans to our PRC subsidiary Helpson, which is a foreign-invested enterprise, to finance its activities cannot exceed statutory limits and must be registered with the State Administration of Foreign Exchange in China, or SAFE, or its local counterpart. Loans by us to domestic PRC enterprises must be approved by the relevant government authorities and must also be registered with the SAFE or its local counterpart.&#160;&#160;Any capital contributions to our PRC subsidiary must be approved by the Ministry of Commerce in China or its local counterpart.&#160;&#160;On August 29, 2008, SAFE promulgated Circular 142, a notice regulating the conversion by a foreign-invested company of foreign currency into Renminbi by restricting how the converted Renminbi may be used. The notice requires that Renminbi converted from the foreign currency denominated capital of a foreign-invested company may only be used for purposes within the business scope approved by the applicable governmental authority and may not be used for equity investments within the PRC unless specifically provided for otherwise.&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, SAFE strengthened its oversight over the flow and use of Renminbi funds converted from the foreign currency-denominated capital of a foreign-invested company.&#160;&#160;The use of such Renminbi may not be changed without approval from SAFE, and may not be used to repay Renminbi loans if the proceeds of such loans have not yet been used. Violations of Circular 142 may result in severe penalties, including substantial fines as set forth in the Foreign Exchange Administration Rules.&#160;&#160;We cannot assure you that we will be able to obtain these government registrations or approvals on a timely basis, if at all, with respect to our future loans or capital contributions to our direct or indirect subsidiaries. If we fail to receive such registrations or approvals, our ability to use the proceeds from a securities offering and to capitalize our PRC operations may be negatively affected, which could materially and adversely affect our liquidity and ability to fund and expand our business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The 2006 M&amp;A Rule establishes more complex procedures for some acquisitions of Chinese companies by foreign investors, which could make it more difficult for us to pursue growth through acquisitions in China.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">31</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On August 8, 2006, six PRC regulatory agencies, namely, the Ministry of Commerce, the State Assets Supervision and Administration Commission, or SASAC, the State Administration for Taxation, the State Administration for Industry and Commerce, the CSRC and SAFE, jointly adopted the Regulations on Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, or the 2006 M&amp;A Rule, which became effective on September 8, 2006. The 2006 M&amp;A Rule establishes additional procedures and requirements that could make some acquisitions of PRC companies by foreign entities, such as our company, more time-consuming and complex, including requirements in some instances that the approval of the Ministry of Commerce shall be required for transactions involving the shares of an offshore listed company being used as the acquisition consideration by foreign entities, including Sino-foreign joint ventures. In the future, we may grow our business in part by acquiring complementary businesses.&#160;&#160;Complying with the requirements of the 2006 M&amp;A Rule to complete such transactions could be time-consuming, and any required approval processes, including obtaining approval from the Ministry of Commerce, may delay or inhibit our ability to complete such transactions, which could affect our ability to expand our business or maintain our market share.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our China-sourced income is subject to PRC withholding tax under the new Enterprise Income Tax Law of the PRC, and we may be subject to PRC enterprise income tax at the rate of 25% when more detailed rules or precedents are promulgated.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are a Nevada holding company with substantially all of our operations conducted through our operating subsidiary in China.&#160;&#160;Under the new PRC Enterprise Income Tax Law, or the new EIT Law, and its implementation rules, both of which became effective on January 1, 2008, China-sourced income of foreign enterprises, such as dividends paid by a PRC subsidiary to its overseas parent, is generally subject to a 10% withholding tax.&#160;&#160;The new EIT Law, however, also provides that enterprises established outside China whose &#8220;de facto management bodies&#8221; are located in China are considered &#8220;tax resident enterprises&#8221; and will generally be subject to the uniform 25% enterprise income tax rate as to their global income.&#160;&#160;Under the implementation rules, &#8220;de facto management bodies&#8221; are defined as the bodies that have, in substance, overall management control over such aspects as the production and business, personnel, accounts and properties of an enterprise.&#160;&#160;In April 2009, the PRC tax authority promulgated the Notice on Determination of Tax Resident Enterprises of Chinese-controlled Offshore Incorporated Enterprises in accordance with Their De Facto Management Bodies, or Circular 82, to clarify the criteria for determining whether the &#8220;de facto management bodies&#8221; are located within the PRC for enterprises incorporated overseas with controlling shareholders being PRC enterprises.&#160;&#160;As all of the our operational management is currently based in the PRC, and we expect them to continue to be located in China, our company may be deemed a PRC resident enterprise and therefore subject to the PRC enterprise income tax at a rate of 25% on our worldwide income, which excludes the dividends received directly from another PRC resident enterprise.&#160;&#160;Due to the lack of clear guidance on the criteria pursuant to which the PRC tax authorities will determine our tax residency under the new EIT Law, it remains unclear whether the PRC tax authorities will treat us as a PRC resident enterprise.&#160;&#160;Therefore, we are unable to confirm whether we are subject to the tax applicable to resident enterprises or non-resident enterprises under the new EIT Law.&#160;&#160;Furthermore, in connection with the new EIT Law and Tax Implementation Regulations, the Ministry of Finance and State Administration of Taxation jointly issued, on April 30, 2009, the Notice on Issues Concerning Process of Enterprise Income Tax in Enterprise Restructuring Business, or Circular 59, which became effective retrospectively on January 1, 2008. As Circular 59 has only recently been promulgated, it is uncertain to us as to how it will be implemented and the respective tax base and the tax exposure cannot be determined reliably at this stage.&#160;&#160;In case we are required to pay the income tax on capital gains by the relevant PRC tax authorities, our financial conditions and results of operations could be adversely affected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Dividends payable by us to our foreign investors and gain on the sale of our shares may become subject to taxes under PRC tax laws.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under the new EIT law and its implementation rules, to the extent that we are considered a &#8220;resident enterprise&#8221; which is &#8220;domiciled&#8221; in China, PRC income tax at the rate of 10% is applicable to dividends payable by us to investors that are &#8220;non-resident enterprises&#8221; so long as such &#8220;non-resident enterprise&#8221; investors do not have an establishment or place of business in China or, despite the existence of such establishment or place of business in China, the relevant income is not effectively connected with such establishment or place of business in China.&#160;&#160;Similarly, any gain realized on the transfer of our shares by such investors is also subject to a 10% PRC income tax if such gain is regarded as income derived from sources within China and we are considered a &#8220;resident enterprise&#8221; which is domiciled in China for tax purposes.&#160;&#160;Additionally, there is a possibility that the relevant PRC tax authorities may take the view that our purpose is that of a holding company, and the capital gain derived by our overseas stockholders would be deemed China-sourced income, in which case such capital gain may be subject to PRC withholding tax at the rate of up to 10%. If we are required under the new EIT law to withhold PRC income tax on our dividends payable to our foreign stockholders who are &#8220;non-resident enterprises&#8221;, or if you are required to pay PRC income tax on the transfer of our shares under the circumstances mentioned above, the value of your investment in our shares may be materially and adversely affected. It is unclear whether, if we are considered a PRC &#8220;resident enterprise,&#8221; holders of our shares would be able to claim the benefit of income tax treaties or agreements entered into between China and other countries or areas.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The strengthened scrutiny over acquisition transactions by the PRC tax authorities may have a negative impact on our acquisition strategy.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">32</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the new EIT Law, the Ministry of Finance and State Administration of Taxation jointly issued, on April 30, 2009, the Notice on Issues Concerning Process of Enterprise Income Tax in Enterprise Restructuring Business, or Circular 59.&#160;&#160;On December 10, 2009, the State Administration of Taxation issued the Notice on Strengthening the Management on Enterprise Income Tax for Non-resident Enterprises Equity Transfer, or Circular 698. Both Circular 59 and Circular 698 became effective retrospectively on January 1, 2008.&#160;&#160;By promulgating and implementing these circulars, the PRC tax authorities have strengthened their scrutiny over the direct or indirect transfer of equity interest in a PRC resident enterprise by a non-resident enterprise.&#160;&#160;For example, Circular 698 specifies that the PRC State Administration of Taxation is entitled to redefine the nature of an equity transfer where offshore vehicles are interposed by abusing corporate structures for tax-avoidance purposes and without reasonable commercial intention.&#160;&#160;We may pursue acquisitions as one of our growth strategies, and may conduct acquisitions involving complex corporate structures.&#160;&#160;We cannot be assured that the PRC tax authorities will not, at their discretion, adjust the capital gains thus causing us to incur additional acquisition costs.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Any future outbreak of H1N1 influenza, also known as swine flu, avian influenza or severe acute respiratory syndrome in China, or similar adverse public health developments, may severely disrupt our business and operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In May and June 2009, occurrences of H1N1 influenza were reported in Hong Kong and other parts of China. Since 2005, there have been reports on the occurrences of avian influenza in various parts of China, including a few confirmed human cases that resulted in fatalities.&#160;&#160;In addition, from December 2002 to June 2003, China and other countries experienced an outbreak of a new and highly contagious form of atypical pneumonia now known as severe acute respiratory syndrome, or SARS.&#160;&#160;On July 5, 2003, the World Health Organization declared that the SARS outbreak had been contained.&#160;&#160;Since September 2003, however, a number of isolated new cases of SARS have been reported, most recently in central China in April 2004.&#160;&#160;During May and June of 2003, many businesses in China were temporarily closed by the PRC government to prevent transmission of SARS. Any prolonged recurrence of H1N1 or avian influenza, SARS or other adverse public health developments in China could require the temporary closure of our facilities.&#160;&#160;Such closures could severely disrupt our production and business operations and materially and adversely affect our results of operations. We have not adopted any written preventive measures or contingency plans to combat any future outbreak of H1N1 influenza, avian influenza, SARS or any other epidemic.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risks Related to our Common Stock</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The market price for our common stock may be volatile which could results in a complete loss of your investment.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The market price for our common stock is likely to be highly volatile and subject to wide fluctuations in response to factors including the following:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">actual or anticipated fluctuations in our quarterly operating results;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">announcements of new products by us or our competitors;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">changes in financial estimates by securities analysts;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">conditions in the pharmaceutical market;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">changes in the economic performance or market valuations of other companies involved in pharmaceutical production;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">announcements by our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">economic, regulatory and political developments;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">additions or departures of key personnel, or&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#183;&#160;&#160;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">potential litigation.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, the securities markets have from time to time experienced significant price and volume fluctuations that are not related to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may issue additional shares of our capital stock to raise additional cash for working capital; if we issue additional shares of our capital stock, our stockholders will experience dilution in their respective percentage ownership in us the company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We may issue additional shares of our capital stock to raise additional cash for working capital. There is no anti-dilution protection or preemptive rights in connection with our common stock. Thus, the percentage ownership of existing holders of common stock may be diluted in their respective percentage ownership in us if we issue additional shares of our capital stock.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">33</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">A large portion of our common stock is controlled by a small number of stockholders and as a result, these stockholders are able to influence and ultimately control the outcome of stockholder votes on various matters.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A large portion of our common stock is held by a small number of stockholders. For instance, Heung Mei Tsui holds 21.4% and Zhilin Li holds 23.1% of our common stock, respectively, as of the date hereof. As a result, these two stockholders are able to significantly influence the outcome of stockholder votes on various matters, including the election of directors and other corporate transactions including business combinations. In addition, the occurrence of sales of a large number of shares of our common stock, or the perception that these sales could occur, may affect our stock price and could impair our ability to obtain capital through an offering of equity securities. Furthermore, the current ratios of ownership of our common stock reduce the public float and liquidity of our common stock which can in turn affect the market price of our common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We are likely to remain subject to &#8220;penny stock&#8221; regulations and as a consequence there are additional sales practice requirements and additional warnings issued by the SEC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If at any time we have net tangible assets of $5,000,000 or less and the trading price of our common stock is below $5.00 per share, the open-market trading of our common stock will be subject to the &#8220;penny stock&#8221; rules of the SEC. The &#8220;penny stock&#8221; rules impose additional sales practice requirements on broker-dealers who sell securities to persons other than established customers and accredited investors (generally those with assets in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 together with their spouse). For transactions covered by these rules, the broker-dealer must make a special suitability determination for the purchase of securities and have received the purchaser&#8217;s written consent to the transaction before the purchase. Additionally, for any transaction involving a penny stock, unless exempt, the broker-dealer must deliver, before the transaction, a disclosure schedule prescribed by the SEC relating to the penny stock market. The broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative and current quotations for the securities. Finally, monthly statements must be sent disclosing recent price information on the limited market in penny stocks. These additional burdens imposed on broker-dealers may restrict the ability of broker-dealers to sell the common stock and may affect a stockholder&#8217;s ability to resell the common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There can be no assurance that our common stock will qualify for exemption from the &#8220;penny stock&#8221; rules. In any event, even if our common stock is exempt from such rules, we would remain subject to Section 15(b)(6) of the Exchange Act, which gives the SEC the authority to restrict any person from participating in a distribution of a &#8220;penny stock&#8221; if the SEC finds that such a restriction would be in the public interest.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Stockholders should be aware that, according to SEC Release No. 34-29093, the market for penny stocks has suffered in recent years from patterns of fraud and abuse. Such patterns include (i) control of the market for the security by one or a few broker-dealers that are often related to the promoter or issuer; (ii) manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases; (iii) boiler room practices involving high-pressure sales tactics and unrealistic price projections by inexperienced sales persons; (iv) excessive and undisclosed bid-ask differential and markups by selling broker-dealers; and (v) the wholesale dumping of the same securities by promoters and broker-dealers after prices have been manipulated to a desired level, along with the resulting inevitable collapse of those prices and with consequent investor losses. Our management is aware of the abuses that have occurred historically in the penny stock market.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We are responsible for the indemnification of our officers and directors under certain circumstances which could result in substantial expenditures, which we may be unable to recoup.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our bylaws provide for the indemnification of our directors, officers, employees, and agents, under certain circumstances, against attorney&#8217;s fees and other expenses incurred by them in any litigation to which they become a party arising from their association with or activities on behalf of us. This indemnification policy could result in substantial expenditures, which we may be unable to recoup.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We have identified material weaknesses in our internal control over financial reporting, which could affect our ability to ensure timely and reliable financial reports, affect the ability of our auditors to attest to the effectiveness of our internal controls should we become an accelerated filer in the future, and weaken investor confidence in our financial reporting.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As directed by Section 404 of the Sarbanes-Oxley Act of 2002, the SEC adopted rules requiring public companies in their annual reports to include a report of management on the reporting company's disclosure controls and procedures and internal controls over financial reporting. We became subject to this requirement commencing with our fiscal year ended December 31, 2007 and a report of our management is included under Item 9A. &#8220;Controls and Procedures&#8221; of this Annual Report on Form 10-K. As set forth in such report, our management has concluded that our internal controls over financial reporting were not effective as of December 31, 2012 and there existed&#160;&#160;material weakness in our internal control over financial reporting as of December 31, 2012.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">34</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 27pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;Although the material weakness identified in Item 9A of this Annual Report was the result of our failure to appropriately classify inventory obsolescence and impairment of long-lived assets and&#160;&#160;we believe we are taking appropriate actions to remediate such material weakness, such measures may not be sufficient to address the material weaknesses identified or ensure that our controls and procedures are effective.&#160; We may also discover other material weaknesses in the future. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter in the implementation of such controls, could cause us to fail to meet our periodic reporting obligations or result in material misstatements in our financial statements and affect the ability of our auditors to attest to the effectiveness of our internal control over financing reporting to the extent we become an accelerated filer in the future. In addition, substantial costs and resources may be required to rectify any internal control deficiencies. If we cannot produce reliable financial reports, investors could lose confidence in our reported financial information, the market price of our common stock could decline significantly, and our business and financial condition could be adversely affected.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We do not anticipate paying cash dividends on our common stock.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">You should not rely on an investment our common stock to provide dividend income, as we have not paid any cash dividends on our common stock and do not plan to pay any in the foreseeable future. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any return on their investment.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Restrictions on the Use of Rule 144 by Shell Companies or Former Shell Companies.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Historically, the SEC has taken the position that Rule 144 under the Securities Act, as amended, is not available for the resale of securities initially issued by companies that are, or previously were, blank check companies like us, to their promoters or affiliates despite technical compliance with the requirements of Rule 144. The SEC has codified and expanded this position in its amendments effective on February 15, 2008 and apply to securities acquired both before and after that date by prohibiting the use of Rule 144 for resale of securities issued by shell companies (other than business transaction related shell companies) or issuers that have been at any time previously a shell company. The SEC has provided an important exception to this prohibition, however, if the following conditions are met: the issuer of the securities that was formerly a shell company has ceased to be a shell company; the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act; the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports; and at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company. As such, due to the fact that we had been a shell company prior to October 2005,&#160;&#160;holders of "restricted securities" within the meaning of Rule 144, when reselling their shares pursuant to Rule 144, shall be subject to the conditions set forth herein.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 1B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Smaller reporting companies are not required to provide the information required by this item.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; PROPERTIES.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There is no private ownership of land in China.&#160;&#160;All land is owned by the government of the PRC on behalf of all Chinese citizens or collectively owned by farmers. Land use rights can be allocated by the PRC State Land Administration Bureau or its authorized branches. Helpson was granted land use rights from the PRC government for approximately 22,936 square meters of land located on Plot C09-2 at Haikou Bonded Zone, Hainan Province, PRC in 2003. The land use rights will expire on September 10, 2063.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Helpson owns two production facilities in Haikou, Hainan Province, PRC, one of which has a construction area of 663.94 square meters located at the 6th floor of Standard Plant Building B, Jinpan Industrial Development Zone, and another factory, which is located on Plot C09-2 at Haikou Bonded Zone, has a production area of 6,593.20 square meters.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, Helpson rented the offices located at the second floor, Jiahai Building owned by Hainan Zhongfu Going-abroad Personnel Service Center (the &#8220;Center&#8221;) as its principal executive offices. The monthly rent was RMB5,580 (approximately $843). The term of the lease was 3 years, from December 1, 2010 to November 30, 2013.&#160;&#160;On December 31, 2011, the lease was superseded by the new lease Helpson entered into with the Center.&#160;&#160;The new lease is for a term of nine years for the office spaces on the second floor and the entire third floor at a monthly rent of RMB20,000 (approximately $2,941) with a 5% increment every two years from the fourth year until the end of the term. The aggregate spaces Helpson rented are 1,686 square meters, which is 16,812 square feet.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We believe that all our properties have been adequately maintained, are generally in good condition, and are suitable and adequate for our business. However, our expansion plans contemplate the need for additional space as we increase production.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Mortgaged Property</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Helpson entered into a loan agreement with Bank of China in October 2012. In order to secure the loan, Helpson mortgaged its land use rights and owned buildings as set forth in the table below:</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">35</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1.5pt solid; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Loan Amount</font></div>
</td>
<td valign="top" width="16%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Lending Institution</font></div>
</td>
<td valign="top" width="17%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contract Period</font></div>
</td>
<td valign="top" width="18%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Interest&#160;&#160;Rate</font></div>
</td>
<td valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Properties under</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Mortgage</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
</tr><tr>
<td align="left" valign="middle" width="17%" style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1.5pt solid; BORDER-RIGHT: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">RMB 30 million </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(approximately </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$4.75 million)</font></div>
</td>
<td align="left" valign="middle" width="16%" style="BORDER-BOTTOM: black 1.5pt solid; BORDER-RIGHT: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Bank of China</font></div>
</td>
<td align="left" valign="middle" width="17%" style="BORDER-BOTTOM: black 1.5pt solid; BORDER-RIGHT: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">October 29, 2012 </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">to October 28, 2013</font></div>
</td>
<td align="left" valign="middle" width="18%" style="BORDER-BOTTOM: black 1.5pt solid; BORDER-RIGHT: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The interest rate is a variable </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">rate&#160;&#160;equal to 115% of the</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;floating base interest for loans </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">of the&#160;&#160;same term promulgated </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">by the PRC&#8217;s central bank.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
<td align="left" valign="middle" width="20%" style="BORDER-BOTTOM: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Helpson&#8217;s land : 22,936 square </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">meters (Certificate #: Guo Yong </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">[2003] No. 005572)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Helpson&#8217;s buildings: 663.94 square </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">meters (Certificate #: HK008109) </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">and 6593.2 square meters&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Certificate #: HK122889)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 3.&#160;&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. However, we are currently not aware of any such legal proceedings or claims that we believe will have, individually or in the aggregate, a material adverse affect on our business, financial condition or operating results.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 4.&#160;&#160;&#160; MINE SAFETY DISCLOSURES.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Not applicable.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART II</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 5.&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Market Information</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our shares began trading on the NYSE MKT (Formerly known as NYSE Amex) on September 30, 2009 under the symbol &#8220;CPHI&#8221;. &#160;&#160;Prior to September 30, 2009, our shares traded on the OTC Bulletin Board under the symbol &#8220;CPHI.OB.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table, based upon yahoo finance, contains information about the range of high and low sales prices for our common stock for each full quarterly period during the period from January 1, 2011 to December 31, 2012.&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="75%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">High</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Low</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fiscal 2012</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">First Quarter</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.82</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.66</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Second Quarter</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.68</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.29</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Third Quarter</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.46</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.29</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fourth Quarter</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.37</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.19</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fiscal 2011</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">First Quarter</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.19</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.25</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Second Quarter</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.75</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.59</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Third Quarter</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.52</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.96</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fourth Quarter</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.05</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.62</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div align="center">&#160;</div>

<div align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">36</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Holders</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of March 11, 2013, there were approximately 142 shareholders of record of our common stock and an indeterminate number of beneficial holders who held our common stock in street name.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Transfer Agent and Registrar</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The transfer agent and registrar for our common stock is Securities Transfer Corporation, 2591 Dallas Parkway, Suite 102, Frisco, Texas 75034.&#160;&#160;Their telephone number is (469) 633-0101.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Dividend Policy</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.6pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have never paid or declared any dividend on our common stock and we do not anticipate paying cash dividends in the foreseeable future. As a result of our holding company structure, we would rely entirely on dividend payments from our subsidiaries, Onny Investment Ltd. and Hainan Helpson Medial &amp; Biotechnology Co., Ltd., for our cash flow to pay dividends on our common stock.&#160;&#160;The PRC government imposes controls on the conversion of Renminbi into foreign currencies and the remittance of currencies out of the PRC, which also may affect our ability to pay cash dividends in the future.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Securities Authorized for Issuance Under Equity Compensation Plans</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The disclosure contained in &#8220;Item 11. Executive Compensation &#8211; Discussion of Summary Compensation and Grants of Plan-based Awards Tables&#8221; is incorporated herein by reference.&#160;&#160;The following table summarizes the number of shares of our common stock authorized for issuance under our equity compensation plans as of December 31, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Plan Category</font></div>
</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(a)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Number of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Securities </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">to be</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Issued </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Upon</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exercise of </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Outstanding</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Options</font></div>
</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(b)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Weighted-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Average</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exercise </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Price</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">of </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Outstanding</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Options</font></div>
</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(c)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Number of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Securities</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Remaining</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Available</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">for Future</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Issuance </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Under</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Equity</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Compensation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Plans </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(excluding</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">securities </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">reflected</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">in column(a))</font></div>
</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Equity compensation plans approved by security holders</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;The 2009 Stock Option Plan <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(1)</font></font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;The 2010 Long-Term Incentive Plan</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,000</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.54</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,975,000<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(2)</font></font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Equity compensation plans not approved by security holders</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,000</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,975,000</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">__________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The 2009 Stock Option Plan ceased its effectiveness as of April 29, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Does not include the 125,000 shares of restricted stock granted under the 2010 Long-Term Incentive Plan.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 6.&#160;&#160;&#160;&#160;&#160;&#160;&#160; SELECTED FINANCIAL DATA</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As a "smaller" reporting company as defined in Item 10 of Regulation S-K, we are not required to provide the information required by this item.</font></div>
</div>

<div>&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">37</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 7.&#160;&#160;&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The statements contained in this report with respect to our financial condition, results of operations and business that are not historical facts are forward-looking statements. Forward-looking statements can be identified by the use of forward-looking terminology, such as "anticipate", "believe", "expect", "plan", "intend", "seek", "estimate", "project", "could", "may" or the negative thereof or other variations thereon, or by discussions of strategy that involve risks and uncertainties. Management wishes to caution the reader of the forward-looking statements that any such statements that are contained in this report reflect our current beliefs with respect to future events and involve known and unknown risks, uncertainties and other factors, including, but not limited to, economic, competitive, regulatory, technological, key employees, and general business factors affecting our operations, markets, growth, services, products, licenses and other factors, some of which are described in this report including in &#8220;Risk Factors&#8221; in Item 1A and some of which are discussed in our other filings with the Securities and Exchange Commission. These forward-looking statements are only estimates or predictions. No assurances can be given regarding the achievement of future results, as actual results may differ materially as a result of risks facing our company, and actual events may differ from the assumptions underlying the statements that have been made regarding anticipated events.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">These risk factors should be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue. All written and oral forward looking statements made in connection with this report that are attributable to our company or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given these uncertainties, we caution investors not to unduly rely on our forward-looking statements. We do not undertake any obligation to review or confirm analysts&#8217; expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Summary of the Fiscal Year Ended December 31, 2012</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The economic and pharmaceutical challenges and uncertainties had negatively impacted our business in 2012, which led to the overall decline in sales of our products. For the year ended December 31, 2012, we had a certain drop in financial performance. Revenue decreased by 33% to $54.5 million, as compared to $81.2 million in the year ended December 31, 2011. This decrease was primarily from our CNS Cerebral &amp; Cardio Vascular product category in terms of the decrease in dollar amount (approximately $10.6 million) and digestive disease product category in terms of percentage of decrease in revenues (approximately 44%).</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net income for the year ended December 31, 2012 was $4.6 million, a decrease of 76%, from $19.3 million in the year ended December 31, 2011. Our net income for the year ended December 31, 2012 included inventory obsolescence, while the net income for the year ended December 31, 2011included gains resulting from changes in the fair value of our derivative warrant liability. Due to the negative impact on sales of finished goods from price cutting, rising cost and policy adjustment, significant differences occurred between the sales estimates when raw materials were purchased compared to the sales performance realized for certain products. This lead to certain raw materials approached their expiration dates. Based on the evaluation the management made on December 31, 2012, we recognized a reserve of $1.77 million for inventory obsolescence. Without the effect of the inventory obsolescence and derivative warrant liability, management estimates that net income would have been approximately $6.1 million and $18.4 million in 2012 and 2011. The decrease in net income was mainly due to the decrease in revenue, gross profit margin, and the incurrence of inventory obsolescence in 2012.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">From a profitability perspective, our gross profit margin for the year ended December 31, 2012 was 26% compared to 36% in 2011. Without the effect of inventory obsolescence in 2012, management estimates that our gross profit would have been approximately 29% in 2012. The decrease in gross profit margin was mainly due to increases in costs and margin compression as a result of the Healthcare Reform. Pricing pressure is now quite a prominent feature in the overall pharmaceutical market in China.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">38</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cash flow from operations for the year ended December 31, 2012 was $3.64 million, compared to $5.24 million in 2011. The decrease is due primarily to the decrease in net income, partially offset by a decrease in accounts receivable.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Earnings per common share (basic and diluted) for the year ended December 31, 2012 was $0.11 per share compared to $0.44 per share for the year ended December 31, 2011.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Business Overview &amp; Recent Developments</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the year ended December 31, 2012, we continued to execute our business strategy of expanding revenues from our core portfolio of products while continuing the development process of new products. However the year was a challenging one as the implementation of the Healthcare Reform has resulted in increased pricing pressure and lower gross profit margins across the board for almost all pharmaceutical products.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The products in our pipe-line progressed slowly but steadily along the development process, and are getting closer to product launch. The SFDA is also revising its production approval criteria and processes, resulting in longer approval time for new production applications across all types of products. In some cases they are adding additional requirements for products already under review. In November, 2012, we received production approval from the SFDA for Candesartan, a front-line drug therapy we developed for the treatment of hypertension. We plan to launch this product during 2013. The clinical trial for Rosuvastatin, or the generic version of Crestor, was completed in December, 2010 and we are in the process of applying for the production approval for this product. In September 2010, we also completed Phase I of our clinical trial for our new antibiotic combination drug. We are currently moving ahead and are in Phase II of the trial for this drug.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -25.6pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following is a list of the current status of some of our pipeline products:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cadesartan. We received production approval from the SFDA for Candesartan, a front-line drug therapy we developed for the treatment of hypertension in November 2012. We plan to launch this product during 2013.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Antibiotic Combination. We completed the Phase I clinical trials of our novel cephalosporin-based combination antibiotic in the third quarter of 2010. We are currently in Phase II of the clinical trial which is progressing well.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Rosuvastatin. Rosuvastatin is a generic form of Crestor, a drug for indication of high blood cholesterol level. Clinical trials for this generic drug were completed in the fourth quarter of 2010 and we have submitted an application for production approval.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt" face="Symbol, serif">&#183;&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Heart Disease Drug. We are developing a liquid oral medicine for the treatment of coronary heart disease. This product comes with a patented Traditional Chinese Medicine (TCM) formula and we are currently conducting Phase III clinical trials for this drug. Due to the improved regulatory requests for clinical works, we adjusted our anticipated completion timeframe for the clinical trials work for this product to 2013.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">39</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Market Trends</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The growth of China&#8217;s pharmaceutical market is driven by China&#8217;s rapid economic growth. Increased healthcare spending by the Chinese government to reform the healthcare system has already greatly improved the accessibility of, and desire for, medical care. Important additional factors include, but are not limited to: the aging of the population and the resulting increase in age-related disorders; the urban migration of the population; and improved awareness of personal health care.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.1pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Healthcare Reform program announced by the Chinese government in late 2009 is having a significant impact on all healthcare related industries in China, including the pharmaceutical industry. Over all, the government plans to provide a basic, universal healthcare system to all citizens of China. We believe volume expansion will continue as government subsidies to rural communities expand further. While pricing is generally set at the central government level, provincial government intervention has added complexity to the pricing-volume interaction. In addition to EDL products, we have also seen pricing pressure on most of the drugs we sell. While these changes have more impact on pharmaceutical distribution companies, manufacturers of pharmaceutical products are also affected. We believe the general implication is that gross margins for pharmaceutical products will continue to be under pressure for some time. That being said, a pharmaceutical manufacturer with experienced management and the ability to react quickly to changes will not only survive but thrive in this environment.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Results of Operations for the Fiscal Year Ended December 31, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -25.6pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Revenu</font>e</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -25.6pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the year ended December 31, 2012, our sales revenue was $54.5 million, a decrease of 33%, compared to $81.2 million in 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -25.6pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Set forth below are our revenues by product category in millions USD for the years ended December 31, 2012 and 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -25.6pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -25.6pt" align="justify">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="27%" style="BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 2px; BORDER-TOP: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Product Category</font></div>
</td>
<td colspan="2" valign="top" width="28%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1.5pt solid; BORDER-TOP: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fiscal Years Ended December 31</font></div>
</td>
<td valign="top" width="11%" style="BORDER-LEFT: black 1.5pt solid; PADDING-BOTTOM: 2px; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net Change</font></div>
</td>
<td valign="top" width="10%" style="PADDING-BOTTOM: 2px; BORDER-TOP: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">% Change</font></div>
</td>
</tr><tr>
<td valign="top" width="27%" style="BORDER-BOTTOM: black 4px double; BORDER-LEFT: black 1.5pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="15%" style="BORDER-BOTTOM: black 4px double; BORDER-LEFT: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td valign="top" width="13%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 4px double; BORDER-LEFT: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 4px double; BORDER-RIGHT: black 1.5pt solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="27%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CNS Cerebral &amp; Cardio Vascular</font></div>
</td>
<td valign="top" width="15%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$15.2</font></div>
</td>
<td valign="top" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$25.8</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">($10.6)</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-41%</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="27%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Anti-Viro/ Infection &amp; Respiratory</font></div>
</td>
<td valign="top" width="15%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$24.5</font></div>
</td>
<td valign="top" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$32.0</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">($7.5)</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-24%</font></div>
</td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="27%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Digestive Diseases</font></div>
</td>
<td valign="top" width="15%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$7.0</font></div>
</td>
<td valign="top" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$12.4</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">($5.4)</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-44%</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="27%" style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other</font></div>
</td>
<td valign="top" width="15%" style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$7.8</font></div>
</td>
<td valign="top" width="13%" style="BORDER-BOTTOM: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$11.0</font></div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 1.5pt solid; BORDER-LEFT: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">($3.2)</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 1.5pt solid; BORDER-RIGHT: black 1.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-29%</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The most significant revenue decrease in terms of dollar amount was in our &#8220;CNS Cerebral &amp; Cardio Vascular&#8221; product category, which generated $15.2 million in sales revenue compared to $25.8 million a year ago, a decrease of $10.6 million, or 41%. This decrease was mainly due to sales of Bumetanide, a drug prescribed for treatments of various edema diseases, hypertension, acute renal failure, and Ozagrel, also a drug prescribed for treatments of cerebral thrombosis, coronary heart disease. Sales of the &#8220;Anti-Viro/Infection &amp; Respiratory&#8221; category decreased by $7.5 million to $24.5 million in 2012 compared to $32.0 million in 2011, which was mainly due to the decrease in sales of our Cefalexin Capsules, an EDL drug. Our &#8220;Digestive Diseases&#8221; category generated $7.0 million of sales in 2012, compared to $12.4 million in the previous year, or a decrease of $5.4 million.&#160;&#160;Our &#8220;Other&#8221; product category sales fell to $7.8 million from $11.0 million, a decrease of $3.2 million.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">40</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the year ended December 31, 2012, revenue breakdown by product category showed small changes. Sales of the &#8220;Anti-Viro &amp; Respiratory&#8221; products category represented 45% of total sales in the year ended on December 31, 2012, compared to 39% in 2011. The &#8220;CNS, Cerebral &amp; Cardio Vascular&#8221; category was steady, representing 28% of total revenue in 2012 and 32% 2011. The &#8220;Digestive Diseases&#8221; category represented 13% of total revenue in 2012 compared to 15% in 2011.&#160;&#160;The &#8220;Other&#8221; category represented 14% and 14% of revenues in 2012 and 2011, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cost of Revenue</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the year ended December 31, 2012, our cost of revenue was $38.7 million, or 71% of total revenue, which represented a decrease of $13.5 million from $52.2 million, or 64% of total revenue, in 2011, a decrease of 25.9%.&#160;&#160;The decrease in cost of revenue during 2012 was not proportional to the revenue decrease, primarily due to increases in our average unit costs for inventory.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gross Profit and Gross Margin</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Gross profit for the year ended December 31, 2012 was $14.1 million, a decrease of $15 million, or 51%, from $29.0 million in 2011.&#160;&#160;Our gross profit margin in 2012 was 26%, compared to 36% in 2011. Without the effect of inventory obsolescence in 2012, management estimates that our gross profit would have been approximately 29% in 2012. The Healthcare Reform instituted by the Chinese government since 2009 has resulted in margin compression in most pharmaceutical products on the markets today, especially in the generic space that many of our products are in. The decrease of sales and continuously increase of the purchase price of raw materials attributed to the decrease of gross profit. Going forward we expect to see continued pricing pressure on most products, but new products such as Candesartan and Rosuvastatin could help to support overall gross margin once they are launched.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Selling Expenses</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our selling expenses for the year ended December 31, 2012 were $3.54 million, an increase of approximately $0.1 million, compared to $3.44 million in 2011.&#160;&#160;Selling expenses accounted for 6.5% of the total revenue in 2012 compared to 4.2% in 2011.&#160;&#160;Due to many adjustments in our selling processes from healthcare reform policies, despite the decrease in sales, we required additional personnel and expenses to support the sales and collection of accounts receivable.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">General and Administrative Expenses</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our general and administrative expenses for the year ended December 31, 2012 were $3.31 million, a decrease of $0.41 million from $3.72 million in 2011.&#160;&#160;General and administrative expenses accounting for 6.1% and 4.6% of our total revenues in 2012 and 2011, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Bad Debt Expenses (Benefit)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In general, our normal credit or payment terms extended to customers are 90 days. This has not changed in recent years. Due to the peculiarity of the Chinese pharmaceutical market environment, deferred payments to pharmaceutical companies by state-owned hospitals and local medicine distributors are a normal phenomenon. Our customers are primarily pharmaceutical distributors who sell to mostly government-backed hospitals. Therefore the age of our receivables from our customers tends to be long. Although these customers typically pay after the due date of the receivables, since the majority of hospitals in China are backed by the government, management believes that the deferred payments from state-owned hospitals are secure and will eventually be collected. So far, we have always been able to collect our receivables and have not written-off any receivables in our 19-year history of doing business with hospitals.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">41</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The amount of accounts receivable that were past due (or the amount of accounts receivable that were more than 90 days old) was $62.1 million and $51.4 million as of December 31, 2012 and 2011, respectively. The following table illustrates our accounts receivable aging distribution in terms of percentage of total accounts receivable as of December 30, 2012 and 2011:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="60%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="16%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31,</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="16%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31,</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="16%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="16%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1 - 90 Days</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12.1%</font></div>
</div>
</td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">29.9%</font></div>
</div>
</td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">90 - 180 Days</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12.8%</font></div>
</div>
</td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21.8%</font></div>
</div>
</td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">180 - 360 Days</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32.4%</font></div>
</div>
</td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27.9%</font></div>
</div>
</td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">360 - 720 Days</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">42.7%</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20.4%</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">100%</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">100%</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Although we have not had to write off any receivables thus far in our history, we do set aside an allowance for doubtful accounts. Our bad debt allowance estimate is currently the sum of 3.5% of accounts receivable that are less than 365 days old, 10% of accounts receivable that are between 365 days and 720 days old and 100% of accounts receivable that are greater than 720 days old (although there were no accounts receivable over 720 days old at December 31, 2012 or 2011).</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To the extent that our current allowance for doubtful accounts is higher than that of the previous period, we recognize a bad debt expense for the difference during the current period, and when the current allowance is lower than that of the previous period, we recognize a bad debt benefit for the difference. The allowance for doubtful accounts was $4.43 million and $3.54 million as of December 31, 2012 and December 31, 2011 respectively. The changes in the allowance for doubtful accounts during the years ended December 31, 2012 and 2011 were as follows (there were no write-offs or recoveries):</font><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="60%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="64%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="6" valign="bottom" width="34%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">For the Fiscal Years Ended</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="6" valign="bottom" width="34%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31,</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="16%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="16%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance, Beginning of Year</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,536,405</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,317,017</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="64%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Bad debt expense (benefit)</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">871,612</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">108,085</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Foreign currency translation adjustment</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21,928</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">111,303</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance, End of Year</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,429,945</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></div>
</div>
</td>
<td valign="bottom" width="15%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,536,405</font></div>
</div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Impairment of intangible assets</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying values may not be recoverable. </font>As a result of the evaluations made in December 31, 2012, the Company determined that it is not likely that the carrying value of two medical formulas will be realized from future cash flows due to the failure to meet certain improved technical criteria for one formula and pricing pressures on the other one. As a result, impairment losses relating to those intangible assets were $593,095 during the year ended December 31, 2012.&#160;&#160;No impairment losses were recognized during the year ended December 31, 2011.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -27pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -27pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">42</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -27pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Income from Operations</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our operating income for the year ended December 31, 2012 was $5.9 million, compared to $22.0 million in 2011, a decrease of $16.1 million. The main reasons for the decrease were lower revenue, lower gross profits and higher bad debt expenses in 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -27pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Interest Income (Expense)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net interest expense for the year ended December 31, 2012 was $303,431, compared to $247,990 in 2011, an increase of $55,441.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -27pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Derivative Gains (Losses)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Changes to derivative warrant liability are recognized in the results of operations and resulted in a derivative gain of $934,260 during the year ended December 31, 2011. (Please see Note 9 to our consolidated financial statements contained in this report.) There was no derivative gain during the year ended December 31, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -27pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Income Tax Expense</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the years ended December 31, 2012 and 2011, we paid income tax at the rate of 15%. Income tax expense was $0.98 million and $3.44 million for the years ended December 31, 2012 and 2011 respectively. We obtained the "National High-Tech Enterprise" status ("National HT Status") from the PRC government in the fourth quarter of 2010. With this designation, we are entitled to a preferential tax rate of 15% for the years ending December 31, 2011, 2012 and 2013, which is notably lower than the statutory income tax rate of 25%.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -27pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Income</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net income for year ended December 31, 2012 was $4.6 million, a decrease of 76%, from $19.3 million in the year ended December 31, 2011.The decrease in net income was mainly due to the decrease in revenue, gross profit margin, increase in cost, and changes in derivative gain.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the year ended December 31, 2012, earnings per basic and diluted common share was $0.11 per share, compared to $0.44 per share in the year ended December 31, 2011.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The number of basic and diluted weighted average outstanding shares used to calculate earnings per share were 43,579,557 for 2012 and 43,479,899 for 2011.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">43</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liquidity and Capital Resources</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our principal sources of liquidity are cash generated from operations and short-term bank loans.&#160;&#160;Our cash and cash equivalents was $4.03 million, which represents 2.47% of our total assets as of December 31, 2012, was comparable to $4.05 million, which represents 2.59% of our total assets as of December 31, 2011. Of the $4.03 million of cash and cash equivalents at December 31, 2012, a total of $3.92 million is considered to be reinvested indefinitely in Helpson and is not expected to be available for payment of dividends, for other payments to our parent company or to its shareholders. As of December 31, 2012, we had a principal balance of $4.76 million in short-term bank loans. The cash flow generated from operating activities funded the new purchases of our intangible assets (drug formulas).</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During 2012, we continued our vigorous collection efforts from our customers and achieved good results. While we have made progress, improving our accounts receivable collection continues to be a focus of our management team and we expect to make further progress in the quarters to come.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At December 31, 2012, the Company was obligated to pay laboratories $6.47 million upon their completion of the various phases of contracts to provide SFDA production approval of more than 10 medical formulas. Those payments are expected to be made out of the Company&#8217;s cash flow from operations ratably over approximately the following 48 months, depending on the progress of the various contracts. A typical contract requires an upfront deposit and then two to three additional milestone payments plus a final payment when the SFDA approval is obtained. Since the payments are progress driven, it is difficult to calculate the timing of the payments with any precision; however, management expects that the payments will be somewhat even over the payment period given the number of contracts in progress. The funding obligation is not expected to have an undue negative impact on the liquidity of the Company given the Company&#8217;s historical cash flows and estimated future cash flows from operating activities.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Based on our current operating plan, management believes that our cash provided by operations as well as the anticipated capital expenditure project financing from a bank will be sufficient to meet our working capital needs and our anticipated capital expenditures, including expenditures for new formula acquisitions and new GMP upgrading related construction and equipment, for the next twelve months. However, if events or circumstances occur and we do not meet our operating plan as expected, we may be required to seek additional capital and/or to reduce certain discretionary spending, which could have a material adverse effect on our ability to achieve our business objectives. Notwithstanding the foregoing, we may seek additional financing as necessary for expansion purposes and when we believe market conditions are most advantageous, which may include debt and/or equity financing.&#160;&#160;There can be no assurance that any additional financing will be available on acceptable terms, if at all.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -25.6pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Operating Activities</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net cash provided by operating activities was $3.64 million in the twelve months period ended December 31, 2012 compared to $5.24 million for the same period in 2011. As a common business practice in China, Banker's Acceptances (BAs) are often used to settle payment instead of checks. During the year ended December 31, 2012, the Company collected accounts receivable with BAs with a maturity of more than 90 days, and such BAs are not treated as cash and cash equivalent under U.S. GAAP. If cash equivalent treatment were to be applied to BAs with more than 90 days maturity, $5.22 million would have been generated in operating activities in the year ended December 31, 2012. This was mainly because of the improved performance in collection of accounts receivable partially offset the decrease in net income in 2012.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">44</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At December 31, 2012, our accounts receivable was $66.2 million, a decrease of $3.5 million from $69.7 million at December 31, 2011. Our receivables decreased due to decreased sales and the improved performance of our collection in account receivables. For fiscal 2012, $1.1 million was generated from decreases in Account Receivables, compared to $11.4 million was used to fund increases in Accounts Receivable in the comparable period a year ago.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At December 31, 2012, total inventory was $36.4 million, an increase of $6.0 million from $30.4 million at December 31, 2011. In order to avoid any negative impact from our transition to our new production facility, new GMP upgrading and construction, we have gradually increased our inventory to a relatively high level. Cash used on Inventories for the year ended December 31, 2012 was $4.7 million as compared to $2.9 million in the comparable period for 2011.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the period ending December 31, 2012, the decrease in our accounts payable was responsible for a cash usage of $0.3 million in 2012, compared to a cash usage of $1.9 million in the same period in 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Investing Activities</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the year ended December 31, 2012, net cash used in investment activities was $4.99 million, a decrease of $0.64 million, compared to $5.63 million in 2011. As a common business practice in China, Banker's Acceptances (BAs) are often used to settle payment instead of checks. During the year ended December 31, 2012, the Company made payment with BAs with a maturity of more than 90 days, and such BAs are not treated as cash and cash equivalent under U.S. GAAP. If cash equivalent treatment were to be applied to BAs with more than 90 days maturity, $6.56 million would have been used in investment activities. The investment spending in 2012 was mainly for the new GMP upgrading related construction and equipment, as well as purchase of medical formulas.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Financing Activities</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the year ended December 31, 2012, net cash flow generated from financing activities was approximately $1.3 million compared to $0.6 million in the same period of 2011. The main source of the 2012 financing came from the increased size of the new credit line we got from a bank, as well as the loan from a related party.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">According to relevant PRC laws, companies registered in the PRC, including our PRC subsidiary, Helpson, are required to allocate at least ten percent (10%) of their after-tax net income, as determined under accounting standards and regulations in the PRC, to statutory surplus reserve accounts until the reserve account balances reach fifty percent (50%) of the companies&#8217; registered capital prior to their remittance of funds out of the PRC.&#160;&#160;Allocations to these reserves and funds can only be used for specific purposes and are not transferrable to the parent company in the form of loans, advances or cash dividends.&#160;&#160;As of December 31, 2012 and 2011, the net assets of Helpson were $142,597,000 and $135,748,004, respectively.&#160;&#160;Due to the restriction on dividend distribution to overseas shareholders, the amount of Helpson&#8217;s net assets that were designated for general and statutory capital reserves, and thus could not be transferred to our parent company as cash dividends, were $7,935,122 and $7,863,490 (50% of registered capital) for the fiscal years ended December 31, 2012 and 2011.&#160;&#160;Since the amount that Helpson must set aside for the statutory surplus fund only accounts for 5.6% and 5.8%, respectively, of its total net assets, this reserve does not have a major impact on our liquidity.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The PRC government also imposes controls on the conversion of RMB into foreign currencies and the remittance of currencies out of the PRC.&#160;&#160;Our businesses and assets are primarily denominated in RMB.&#160;&#160;All foreign exchange transactions take place either through the People&#8217;s Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the People&#8217;s Bank of China.&#160;&#160;Approval of foreign currency payments by the People&#8217;s Bank of China or other regulatory institutions requires submitting a payment application form together with applicable invoices and signed contracts.&#160;&#160;These currency exchange control procedures imposed by the PRC government authorities may restrict the ability of Helpson, our PRC subsidiary, to transfer its net assets to our parent company through loans, advances or cash dividends.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">45</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -25.6pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Off Balance Sheet Arrangements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -25.6pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 45.8pt"></font>As of December 31, 2012, we did not have any off-balance sheet arrangements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -25.6pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Commitments</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At December 31, 2012, we were obligated to pay laboratories and others approximately $6,476,000 over approximately the next 4 years upon completion of the various phases of contracts to provide SFDA production approval of medical formulas.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">We entered into purchase and construction agreements during the year ended December 31, 2012 in connection with the construction of a new facility and required manufacturing improvements.&#160;&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">F</font>uture minimum commitments under the <font style="DISPLAY: inline; FONT-SIZE: 10pt">agreements</font> are as follows:</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div align="left">
<table cellpadding="0" cellspacing="0" width="60%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="85%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">For the year ended December, 31</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="85%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2013</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,133,498</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="85%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2014</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">968,859</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="85%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,102,358</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Critical Accounting Policies</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Management's discussion and analysis of its financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles. Our financial statements reflect the selection and application of accounting policies which require management to make significant estimates and judgments. The discussion of our critical accounting policies contained in Note 1 to our consolidated financial statements, &#8220;Organization and Significant Accounting Policies&#8221;, is incorporated herein by reference.</font></div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">46</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: justify; TEXT-INDENT: 45pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 7A.&#160;&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Smaller reporting companies are not required to provide the information required by this item.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our consolidated balance sheets, as of December 31, 2012 and 2011, and the related consolidated statements of operations and comprehensive income, stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2012 and 2011, together with the related notes and the report of our independent registered public accounting firm, are set forth on the &#8220;F&#8221; pages of this report.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 9.&#160;&#160; CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">None.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM&#160;&#160;9A.&#160;&#160; CONTROLS AND PROCEDURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Management's Report on Internal Control over Financial Reporting</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) under the Exchange Act as a process designed by, or under the supervision of, a company&#8217;s principal executive and principal financial officers, or persons performing similar functions, and effected by a company&#8217;s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles and includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of a company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles and that receipts and expenditures of a company are being made only in accordance with authorizations of management and directors of a company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of a company&#8217;s assets that could have a material effect on the financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Any system of internal control, no matter how well designed, has inherent limitations, including the possibility that a control can be circumvented or overridden and misstatements due to error or fraud may occur and not be detected in a timely manner. Also, because of changes in conditions, internal control effectiveness may vary over time. Accordingly, even an effective system of internal control will provide only reasonable assurance with respect to financial statement preparation. In addition, the design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Therefore, any current evaluation of controls cannot and should not be projected to future periods.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Management assessed our internal control over financial reporting as of the year ended December 31, 2012. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in the report entitled "Internal Control-Integrated Framework." The COSO framework summarizes each of the components of a company&#8217;s internal control system, including (i) the control environment, (ii) risk assessment, (iii) control activities, (iv) information and communication, and (v) monitoring.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Based on management's assessment using the COSO criteria, management has concluded that our internal control over financial reporting was not effective as of December 31, 2012 to allow our management, employees and consultants, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely and reasonable basis and to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;).</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A material weakness is a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected. Our Chief Executive Officer and interim Chief Financial Officer has determined there existed a material weakness in our internal control over financial reporting as of December 31, 2012 with respect to our reporting for inventory obsolescence and impairment of long-lived assets.&#160;&#160;The material weakness occurred as a result of lack of accounting financial reporting personnel knowledgeable in U. S. GAAP. As of the date of this report, we are undertaking steps to correct the aforementioned material weakness by obtaining education and training for our personnel regarding the proper accounting under U.S. GAAP. Notwithstanding this material weakness, management has concluded that our consolidated financial statements included in this annual report are fairly stated in all material respects in accordance with U.S. GAAP for each period presented herein.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">47</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Because we are a smaller reporting company, this Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Changes in Internal Controls over Financial Reporting</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 9B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;OTHER INFORMATION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">None.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART III</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">General</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Listed below are the names and ages of all our directors and executive officers at March 12, 2013 along with their positions, offices and term:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="26%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Name</font></div>
</td>
<td valign="top" width="15%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Age</font></div>
</td>
<td valign="top" width="59%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Position</font></div>
</td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Zhilin Li</font></div>
</div>
</td>
<td valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">59</font></div>
</div>
</td>
<td valign="top" width="59%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chairman, President, Chief Executive Officer and interim Chief Financial Officer</font></div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Heung Mei Tsui</font></div>
</div>
</td>
<td valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">55</font></div>
</div>
</td>
<td valign="top" width="59%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></div>
</div>
</td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gene Michael Bennett</font></div>
</div>
</td>
<td valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">65</font></div>
</div>
</td>
<td valign="top" width="59%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Independent Director</font></div>
</div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Yingwen Zhang</font></div>
</div>
</td>
<td valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">67</font></div>
</div>
</td>
<td valign="top" width="59%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Independent Director</font></div>
</div>
</td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Baowen Dong</font></div>
</div>
</td>
<td valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">71</font></div>
</div>
</td>
<td valign="top" width="59%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Independent Director</font></div>
</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All of our directors hold offices until our next annual meeting of the stockholders, at which&#160;&#160;a successor will be duly elected and qualified or until his or her earlier resignation, removal from office, death or incapacity. Officers serve at the discretion of the board of directors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following sets forth biographical information regarding the above directors and executive officers.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Zhilin Li</font>, is the Chairman, President, Chief Executive Officer and interim Chief Financial Officer of our company. She has served as a director since 2006 and as the President and Chief Executive Officer since 2005. She was a founder of Helpson, and served as chairman and Chief Executive Officer of Helpson from 1993 to 2005. Ms. Li was formerly the president of Haikou Bio-Engineering Institute as well as the vice president of Sichuan Institute of Biology.&#160;&#160;She graduated from Sichuan University with a degree in biology.&#160;&#160;Her role as a one of the founders of our company and her extensive experience in bio-engineering make her well suited to serve as our Chairman.&#160;&#160;&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Heung Mei Tsui</font>,<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>has served as a director since April 28, 2009. Previously, Ms. Tsui served as a member of our board from October 2005 to February 2008. Ms. Tsui has been a self-employed businesswoman engaged in strategic investments and was previously engaged in the pharmaceutical chemical&#160;raw material import/export business. Ms. Tsui graduated from Hunan Financial &amp; Economic College in 1982. Her experience in the trading side of the business affords her unique insights into the pharmaceutical industry, and her presence on our board of directors benefits the company greatly in the areas of strategic planning and execution.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Gene Michael Bennett</font>, has served as our independent director since February 2008.&#160; Mr. Bennett also presently serves as Chief Executive Officer of the American General Business Association in Beijing, China, since 2009.&#160;&#160;Mr. Bennett was a partner of Nexis Investment Consulting Corporation based in Beijing from 2004-2009. He acted as a partner of ProCFO Company based in California which provided contract chief&#160;&#160;financial officer service for firms during 2000-2004. During 1998-2000, he was a basic law, accounting and tax professor at University of Hawaii, and an accounting, tax and audit professor at Chaminade of Honolulu. He also previously served as the chief financial officer and member of the board of directors of Argonaut Computers in Southern California. Mr. Bennett worked as an accounting and audit professor at Chapman University.&#160;&#160;Mr. Bennett also worked as an accounting, tax, and audit professor at California State University at Fullerton, and he acted as chief financial officer and a board member of the National Automobile Club. Mr. Bennett graduated from Michigan State University with an MBA in Finance and BA in Accounting. He currently is a DBA candidate in Corporate Governance at City University of Hong Kong. Mr. Bennett obtained his CPA license from the State of Colorado, but is currently inactive. Mr. Bennett&#8217;s extensive background in accounting, financial management and reporting, including SEC related reporting qualifies Mr. Bennett to serve as an independent director of our company and the chairman of our audit committee.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">48</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Yingwen Zhang</font>,&#160;has served as an independent director since February 2008. He also currently serves as the Vice-Chairman of the Board of Shanghai Reseat Medical Tech Co. Ltd., a medical device producer.&#160;&#160;Mr. Zhang is also a director and a member of the compensation committee of Chongqing Wanli Battery Holdings (Group) LLC (SHA:600847).&#160;&#160;He acted as Senior Consultant and Chairman of Safety Production Committee of Sinofert Holdings Limited (HKG: 0297) of Sinochem Group from October 2005 to June 2009. Additionally, Mr. Zhang was the representative of the 9th Nation People&#8217;s Congress of China. He was also appointed as the Commercial Counselor of the China Embassy in Malaysia from March 2000 through October 2005. Prior to that, Mr. Zhang was appointed as the Director-General to Sichuan Provincial Foreign Trade and Economic Cooperation Bureau (the Commercial Bureau of Sichuan Province, China) from 1988 to 2000. In his early career he was a chemical-engineer, and then became a senior manager for several chemical corporations in China. From 1983 to 1988, Mr. Zhang served as the Chief Executive Officer of a large nature gas-chemical state owned enterprise (SOE) in the PRC affiliated with the Sinopec Group.&#160;&#160;Mr. Zhang graduated from the Chemical Engineering Department of Tianjin University in 1967. Mr. Zhang&#8217;s extensive knowledge in areas of government regulation and policies, his experience as director of a China listed company, as well as his vast experience in senior management in SOE and the private sector, qualify him as an independent director of our company.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Baowen Dong</font>, has served as an independent director since February 2008. Mr. Dong participated on the expert team of the Sichuan University from 2003 to 2008, doing teaching evaluation and assessment work in Engineering and Medical Science faculty. In recent years, Mr. Dong has focused on the research of China's Health Care Reform. Previously, he concentrated on biomedical and medical information researches. Mr. Dong has had different roles in areas of teaching and research, including as a dean and a professor, at Sichuan University from 1974 to 2001. Additionally, Mr. Dong was engaged in the field of communication technology from 1966 to 1974. Mr. Dong graduated from Xi&#8217;an University of Science and Technology in 1966. His strong academic background in science and research brings value to our company in respect of research and development and qualifies him to serve as a director of our company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Family Relationships</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There are no family relationships among our directors or executive officers.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Director or Officer Involvement in Certain Legal Proceedings</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To our knowledge, our directors and executive officers were not involved in any legal proceedings as described in Item 401(f) of Regulation S-K in the past ten years.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Section&#160;16(a) Beneficial Ownership Reporting Compliance</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Section&#160;16(a) of the Securities Exchange Act of 1934, as amended, requires our directors, executive officers and persons who own more than 10% a registered class of our equity securities (&#8220;Reporting Persons&#8221;), to file reports of ownership and changes in ownership on Forms 3, 4 and 5 with the SEC.&#160;&#160;The Reporting Persons are also required by SEC rules to furnish us with copies of Section 16(a) forms they file. Based upon a review of the filings made on their behalf during the fiscal year ended December 31, 2011, as well as an examination of the SEC&#8217;s EDGAR system Form 3, 4, and 5 filings and our&#160;&#160;records, we believe that, during the year ended December 31, 2012, the Reporting Persons met all applicable Section 16(a) filing requirements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Code of Ethics</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On July 8, 2008, we adopted a code of business conduct and ethics for all directors and employees (including officers) within the meaning of the regulations adopted by the SEC under Section 406 of the Sarbanes-Oxley Act of 2002.&#160;&#160;The code has been designed to deter wrongdoing and promote (i) honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships, (ii) full, fair, accurate, timely, and understandable disclosure in reports and documents that we file with, or submit to, the SEC and in other public communications made by us, (iii) compliance with applicable governmental laws, rules and regulations, (iv) the prompt internal reporting of violations of the code to an appropriate person or persons, and (v) accountability for adherence to the code. The application of the code to the persons it applies to may only be waived by our Board of Directors in accordance with SEC regulations and the Sarbanes-Oxley Act of 2002. A copy of the code is available on our website at www.chinapharmaholdings.com or may be obtained by sending a written request to our corporate secretary at China Pharma Holdings, Inc., Second Floor, No. 17, Jinpan Road, Haikou, Hainan Province, China 570216.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Audit Committee</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">49</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On February 1, 2008, we established an audit committee, which currently consists of our three independent directors: Gene Michael Bennett, Yingwen Zhang and Baowen Dong.&#160;&#160;Mr. Bennett, the Chairman of the Audit Committee, is an &#8220;audit committee financial expert&#8221; as defined in Item 401(d)(5) of Regulation S-K promulgated under the Securities Act. The audit committee carries out its responsibilities in accordance with the terms of its Audit Committee Charter, a copy of which attached as Exhibit 99.1 to our Current Report on Form 10-K filed on March 17, 2009.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 11.&#160;&#160;&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Summary of Executive Compensation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table sets forth information concerning all cash and non-cash compensation awarded to, earned by or paid to our principal executive officer and principal financial officer during the last two fiscal years in all capacities to our company and our subsidiaries (collectively, the &#8220;Named Executive Officers&#8221;).&#160;&#160;No other executive officer received compensation in excess of $100,000 during the fiscal year ended December 31, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="10" valign="top" width="87%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SUMMARY COMPENSATION TABLE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
</tr><tr>
<td valign="bottom" width="16%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name and principal</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">position</font></div>
</td>
<td valign="bottom" width="6%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Year</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Ended</font></div>
</td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Salary</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">($)</font></div>
</td>
<td valign="bottom" width="4%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160; Bonus</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">($)</font></div>
</td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Awards</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">($)</font></div>
</td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Option</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Awards</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">($)</font></div>
</td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non-Equity</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Incentive Plan</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Compensation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">($)</font></div>
</td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nonqualified</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Compensation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Earnings ($)</font></div>
</td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">All Other</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Compensation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">($)</font></div>
</td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">($)</font></div>
</td>
</tr><tr>
<td valign="top" width="16%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="16%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Zhilin&#160;Li</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chairman, Chief</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Executive Officer,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">President and interim Chief Financial</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Officer</font></div>
</td>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;220,000</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;220,000</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">50,661<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(1)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">76,339<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(1)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,039<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(2)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,606<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(2)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
<td valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;16,000<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(3)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;16,000<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(3)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">293,700</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">322,945</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="16%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="16%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Frank Waung</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Former Chief Financial</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Officer</font></div>
</td>
<td valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; 61,857</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">160,000</font></div>
</td>
<td valign="top" width="4%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">76,646<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(4)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">42,854<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(4)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,374<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(5)</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">66,384<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(5)</font></font></div>
</td>
<td valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">145,877</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">269,238</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;_____________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amounts represent the vested portion of the fair value of 50,000 restricted shares at a price of $2.54 per share granted to Ms. Li on May 25, 2011 for which we recognized compensation expense of $50,661 and $76,339 in our financial statements for the years ended December 31, 2012 and 2011, respectively.&#160;The shares had a one-year vesting period and vested on May 25, 2012.&#160;The amounts do not reflect the actual amounts that may be realized by the named executive officer.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amounts represent vested portion of the fair value of a two-year option to purchase 25,000 shares of our common stock award granted on May 25, 2011 for which we recognized compensation expense of $7,039 and $10,606 in our financial statements for the years ended December 31, 2012 and 2011, respectively.&#160; The amounts do not reflect the actual amounts that may be realized by the named executive officer.&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Represents the amount payable to Ms. Li for serving as a director of our company.&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amounts represent the vested portion of the fair value of restricted stock awards recognized in our financial statements in 2012 and 2011.&#160;&#160;In 2012, we issued 100,000 restricted shares at a price of $0.56 per share which vested immediately. In 2011 we issued 25,000 shares at a price of $2.54 per share granted to Mr. Waung on May 25, 2011, for which recognized $20,646 and $42,844 in our financial statements for the years ended December 31, 2012 and 2011, respectively.&#160;The shares had a one-year vesting period.&#160;The amounts do not reflect the actual amounts that may be realized by the named executive officer.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(5)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amounts represent the fair value of stock option awards recognized in our financial statements in 2012 and 2011.&#160; On April 28, 2010, we issued a two-year option to purchase 150,000 shares of common stock at an exercise price of $3.47 per share vesting over a one year period.&#160;&#160;The fair value of the option on the date of grant was $169,921, of which $54,934 was recognized as compensation expense in 2011.&#160;&#160;On May 25, 2011, we issued a two-year option to purchase 25,000 shares of common stock at an exercise price of $2.54 per share vesting over a one year period.&#160;&#160;The fair value of the option on the date of grant was $19,050. A total of $7,599 and $11,451 was recognized for the years ended December 31, 2012 and 2011, respectively. The amounts do not reflect the actual amounts that may be realized by the named executive officer.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">50</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The fair value of the options described above were determined using the Black-Scholes Option Pricing Model. We apply the simplified method due to the lack of historical share option exercise data to provide a reasonable basis upon which to estimate expected term. A more detailed discussion of the assumptions used in calculating these value may be found in Note&#160;11 to the consolidated audited financial statements included in this Annual Report on Form 10-K.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Employment Agreements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Zhilin Li</font>.&#160;&#160;Hainan Helpson Medical &amp; Biotechnology Co., Ltd., our wholly-owned subsidiary and operating entity in the PRC (&#8220;Helpson&#8221;), entered into an employment agreement with Ms. Zhilin Li, our Chairman of the Board and Chief Executive Officer, which expired on June 30, 2010. Upon the expiration of the original agreement, Helpson renewed the agreement with Ms. Li on the same terms as the original agreement.&#160;&#160;Pursuant to the terms of the new employment agreement, Ms. Li agreed to continue to serve as Helpson&#8217;s chief executive officer for a term of five years at an annual salary of RMB800,000. Helpson may adjust Ms. Li's compensation based upon her production and operating achievement and her technical ability and working performance. Ms. Li&#8217;s total annual cash compensation for the fiscal year ended 2010, when aggregated with her compensation from our U.S. holding company level, was $200,000.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On May 25, 2011, Ms. Li&#8217;s annual base salary was increased to $220,000. In addition, pursuant to the 2010 Incentive Plan and the Restricted Share Award Agreement dated May 25, 2011 between the Company and Ms. Li, she was granted 75,000 shares of restricted stock, of which (i) 50,000 shares vested on May 25, 2012, and (ii) 25,000 shares were to vest on the six-month anniversary of the achievement of certain performance-based vesting criteria, which was forfeited as criteria was not achieved.&#160;&#160;Under the 2010 Incentive Plan and pursuant to the Non-qualified Stock Option Agreement dated May 25, 2011 between the Company and Ms. Li (&#8220;Li&#8217;s Stock Option Agreement&#8221;), she was also granted non-qualified stock options to purchase 50,000 shares of common stock at an exercise price of $2.54 per share, of which (i) 25,000 shares vested on May 25, 2012, and (ii) 25,000 shares were to vest on the three-month anniversary of the achievement of certain performance-based vesting criteria, which was forfeited as criteria were not achieved.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Frank Waung</font>. &#160;We entered into an employment agreement with Mr. Frank Waung on April 28, 2009, according to which Mr. Waung agreed to serve as our Chief Financial Officer for one year for an annual salary of $100,000. According to the agreement, Mr. Waung was granted an option to purchase 100,000 shares of our common stock, at the price of $1.70 per share, of which (i) 50,000 of the shares vested on April 28, 2010 and (ii) 50,000 of the shares vested on September 30, 2010. When our 2009 Stock Option Plan was implemented, on October 13, 2009 we issued Mr. Waung an option to purchase 100,000 shares at an exercise price of $2.75 per&#160;share and we subsequently agreed that the difference ($1.70 to $2.75) would be provided to Mr. Waung at the time of exercise of the options, subject to approval of the board of directors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Upon the expiration of the original agreement on April 28, 2010, we renewed the agreement with Mr. Waung on similar terms.&#160;&#160;Pursuant to the terms of the renewed agreement, Mr. Waung agreed to continue to serve as our Chief Financial Officer for one year at an annual salary of $150,000. Mr. Waung was also granted an additional option to purchase 200,000 shares of common stock, of which (i) options to purchase 150,000 of the shares will vest on April 28, 2011 and (ii) options to purchase 50,000 shares were to vest on April 28, 2011 if we consummated an equity offering with minimum gross proceeds of at least $10 million prior to December 31, 2010.&#160;&#160;Because we did not consummate such an offering prior to December 31, 2010, options to purchase 50,000 shares have failed to vest and were forfeited.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On April 28, 2011, we renewed the employment agreement with Mr. Waung, pursuant to which Mr. Waung agreed to continue to serve as our Chief Financial Officer for one year at an annual salary of $165,000.&#160;&#160;In addition, pursuant to the 2010 Incentive Plan and the Restricted Share Award Agreement dated May 25, 2011 between the Company and Mr. Waung, he was granted 50,000 shares of restricted stock, of which (i) 25,000 shares will vest on April 28, 2012, and (ii) 25,000 shares were to vest on the six-month anniversary of the achievement of certain performance-based vesting criteria.&#160;&#160;Under the 2010 Incentive Plan and pursuant to the Non-qualified Stock Option Agreement dated May 25, 2011 between the Company and Mr. Waung (&#8220;Waung&#8217;s Stock Option Agreement&#8221;), he was also granted non-qualified stock options to purchase 50,000 shares of common stock at an exercise price of $2.54 per share, of which (i) 25,000 shares vested on April 28, 2012, and (ii) 25,000 shares were to vest on the three-month anniversary of the achievement of certain performance-based vesting criteria, which was forfeited as criteria were not achieved.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Effective April 28, 2012, we entered into an Amendment Agreement to the Non-Qualified Stock Option Agreements to amend the terms of the equity award previously granted to Mr. Waung under the 2009 Option Plan and 2010 Incentive Plan in conjunction with the termination of his employment agreement effective April 29, 2012.&#160;&#160;The effect of the amendment was to terminate a total of 185,000 vested but unexercised options immediately on April 28, 2012 as opposed to 90 days after the employment termination date.&#160;&#160;&#160;Effective the same date, the Company granted 100,000 shares of common stock to Mr. Waung under the 2010 Incentive Plan<font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Payments upon Termination or Change-in-Control</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">51</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">PRC Law.&#160;&#160;</font>Under the applicable laws of the PRC, we must pay severance to all employees who are Chinese nationals and who are terminated with or without cause, or whose employment agreement with us expires and we choose not to continue their employment.&#160;&#160;The severance benefit required to be paid under the laws of the PRC equals the average monthly compensation paid to the terminated employee (including any bonuses or other payments made in the 12 months prior to the employee&#8217;s termination) multiplied by the number of years the employee has been employed with us, plus an additional month&#8217;s salary if 30 days&#8217; prior notice of such termination has not been given.&#160;&#160;However, if the average monthly compensation to be received by the terminated employee exceeds three times the average monthly salary of the employee&#8217;s local area, as determined and published by the local government, such average monthly compensation shall be capped at three times the average monthly salary of the employee&#8217;s local area.&#160;&#160;Except as described above, none of our executive officers have any other agreement or arrangement under which he or she may be entitled to severance payments upon termination of employment.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Outstanding Equity Awards at Fiscal Year-End</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table provides information on the outstanding restricted stock and stock option awards held by our named executive officers (including former named executive officer) as of December 31, 2012.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="13" valign="bottom" width="87%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END</font></div>
</td>
</tr><tr>
<td valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="7" valign="bottom" width="44%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="4" valign="bottom" width="29%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="7" valign="bottom" width="44%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Option&#160;Awards</font></div>
</td>
<td colspan="4" valign="bottom" width="29%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock&#160; Awards</font></div>
</td>
</tr><tr>
<td valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name</font></div>
</td>
<td valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number&#160;of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Securities</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Underlying</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Unexercised</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Options&#160;(#)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercisable</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number&#160;of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Securities</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Underlying</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Unexercised</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Options</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(#)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Unexercisable</font></div>
</td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Equity</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Incentive</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Plan</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Awards:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Securities</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Underlying</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Unexercised</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Unearned</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Options</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(#)</font></div>
</td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Option</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercise</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Price</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">($)</font></div>
</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Option</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expiration</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date</font></div>
</td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shares</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">or&#160;Units</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">That</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Have</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Not</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Vested</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(#)</font></div>
</td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Market</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Value</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shares</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">or</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Units</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">That</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Have</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Not</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Vested</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">($)</font></div>
</td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Equity</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Incentive</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Plan</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Awards:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Unearned</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shares,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Units&#160;or</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Rights</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">That</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Have&#160;Not</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Vested</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(#)</font></div>
</td>
<td valign="bottom" width="6%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Equity</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Incentive</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Plan</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Awards:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Market</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">or&#160;Payout</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Value&#160;of</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Unearned</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shares,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Units&#160;or</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Rights</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">That</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Have&#160;Not</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Vested</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">($)</font></div>
</td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Zhilin&#160;Li</font></div>
</td>
<td valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;25,000<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(1)</font></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;-&#160;</font></div>
</td>
<td valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;-&#160;</font></div>
</td>
<td valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.54</font></div>
</td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5/25/2013</font></div>
</td>
<td valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;-&#160;</font></div>
</td>
<td valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;-&#160;</font></div>
</td>
<td valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;</font></div>
</td>
<td valign="bottom" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;-&#160;</font></div>
</td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="14%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chairman,</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Executive</font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Officer,&#160;President </font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">and interim Chief </font></div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Financial</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Officer</font></div>
</td>
<td valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="14%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Frank Waung</font></div>
</td>
<td valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;-</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;-&#160;</font></div>
</td>
<td valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;-&#160;</font></div>
</td>
<td valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;-&#160;</font></div>
</td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;-&#160;</font></div>
</td>
<td valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;-&#160;</font></div>
</td>
<td valign="bottom" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;-&#160;</font></div>
</td>
<td valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;-&#160;</font></div>
</td>
<td valign="bottom" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;-</font></div>
</td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="14%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;Former Chief </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Financial Officer</font></div>
</td>
<td valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; ______________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;These options were granted under our 2010 Incentive Plan and became&#160;exercisable on May 25, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Discussion of Summary Compensation and Grants of Plan-based Awards Tables</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A summary of certain material terms of our existing compensation plans and arrangements is set forth below.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On November 12, 2010, our Board of Directors adopted, and on December 22, 2010 our stockholders approved, our 2010 Long-Term Incentive Plan (the &#8220;2010 Incentive Plan&#8221;), which gave us the ability to grant stock options, restricted stock, stock appreciation rights and performance units to employees, directors and consultants, or those who will become employees, directors and consultants of our company and/or our subsidiaries.&#160;&#160;The 2010 Incentive Plan currently allows for equity awards of up to 4,000,000 shares of common stock.&#160;&#160;As of March 11, 2013, 125,000 shares of restricted stock and options to purchase an aggregate of 100,000 shares of common stock had been granted under the 2010 Incentive Plan, among which, 50,000 shares of restricted stock and options to purchase 75,000 shares were forfeited or cancelled.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">52</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Director Compensation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table sets forth information concerning cash and non-cash compensation paid to our directors during the year ended December 31, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="8" valign="top" width="87%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DIRECTOR COMPENSATION</font></div>
</td>
</tr><tr>
<td valign="bottom" width="21%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fees</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Earned</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">or</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Paid in</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">($)</font></div>
</td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Awards</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">($)</font></div>
</td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Option</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Awards</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">($)</font></div>
</td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non-Equity</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Incentive</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Plan</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Compensation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">($)</font></div>
</td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non-Qualified</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Compensation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Earnings</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">($)</font></div>
</td>
<td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">All</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Compensation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">($)</font></div>
</td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">($)</font></div>
</td>
</tr><tr>
<td valign="bottom" width="21%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="8%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="21%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Heung Mei Tsui</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,000</font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="top" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="top" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="top" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,000</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="21%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gene Michael Bennett</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,000</font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="top" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="top" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="top" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,000</font></div>
</td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="21%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Yingwen Zhang</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,346</font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="top" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="top" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="top" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,346</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="21%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Baowen Dong</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,346</font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="top" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="top" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="top" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8212;</font></div>
</td>
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,346</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our directors will also be reimbursed for all of their out-of-pocket expenses in traveling to and attending meetings of our Board of Directors and committees on which they serve.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Ms. Zhilin Li, our Chairman, President and Chief Executive Officer, was also compensated for serving on our board of directors as set forth in the Summary Compensation Table appearing earlier in this Item 11.&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Engagement Letters</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 24, 2012, we renewed the engagement letters with each of our three independent directors.&#160;&#160;Pursuant to the renewed engagement letters on the same terms and conditions as the previous engagement, each of Mr. Zhang and Mr. Dong is entitled to receive annual compensation of RMB40,000 (approximately $6,346), payable quarterly and Mr. Bennett is entitled to receive annual compensation of $16,000, payable quarterly, and a warrant to purchase 5,000 shares of common stock at an exercise price of $3.32 per share.&#160;&#160;As of the date of this report, no warrants have been issued to Mr. Bennett.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 24, 2012, we also entered into a renewal engagement letter with Ms. Tsui, pursuant to which Ms. Tsui is entitled to annual compensation of $16,000 for serving as our director for a term of three years.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Compensation Committee Interlocks and Insider Participation</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The members of the Nominating and Compensation Committee of our Board of Directors during fiscal 2012 were Messrs. Gene Michael Bennett, Baowen Dong and Yingwen Zhang.&#160;&#160;During fiscal 2012:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#183;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;none of the members of the Nominating and Compensation Committee of our Board of Directors was an officer (or former officer) or employee of our company or any of its subsidiaries;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#183;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;none of the members of the Nominating and Compensation Committee had a direct or indirect material interest in any transaction in which we were a participant and the amount involved exceeded $120,000;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#183;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;none of our executive officers served on the compensation committee (or another board committee with similar functions or, if none, the entire Board of Directors) of another entity where one of that entity&#8217;s executive officers served on our Nominating and Compensation Committee;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#183;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;none of our executive officers was a director of another entity where one of that entity&#8217;s executive officers served on our Nominating and Compensation Committee; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#183;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;none of our executive officers served on the compensation committee (or another board committee with similar functions or, if none, the entire Board of Directors) of another entity where one of that entity&#8217;s executive officers served as a director on our Board of Directors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">53</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM&#160;12.&#160;&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND&#160;&#160;&#160;RELATED&#160;&#160;STOCKHOLDERS MATTERS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table sets forth certain information as of March 11, 2013 with respect to the beneficial ownership of our common stock, the sole outstanding class of our voting securities, by (i) any person or group owning more than 5% of each class of voting securities, (ii) each director, (iii) each executive officer and (iv) all executive officers and directors as a group.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of March 11, 2013, an aggregate of 43,579,557 shares of our common stock were outstanding.</font></div>

<div>
<div>&#160;</div>

<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="45%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Name and Address of Beneficial Owners<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(1)(2)</font></font></font></div>
</td>
<td align="right" valign="top" width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="top" width="16%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amount</font></font></div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">and Nature</font></font></div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">of Beneficial</font></font></div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Ownership</font></font></div>
</td>
<td align="right" valign="top" width="6%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="top" width="4%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Percent of Class<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(3)</font></font></font></div>
</td>
<td valign="top" width="4%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="45%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Directors and Executive Officers</font></font></div>
</td>
<td align="right" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="top" width="16%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="45%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="top" width="16%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="45%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Zhilin Li&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">President, Chief Executive Officer,</font></font></div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interim Chief Financial Officer</font></font></div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">and Chairman of the Board</font></font></div>

<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="top" width="16%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;10,075,000<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(4)</font></font></td>
<td align="right" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="top" width="12%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23.1%</font></font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="top" width="45%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Heung Mei Tsui&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="16%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,312,651</font></div>
</td>
<td align="right" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21.4%</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="45%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Yingwen Zhang&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="16%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0</font></div>
</td>
<td align="right" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="45%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gene Michael Bennett&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="16%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0</font></div>
</td>
<td align="right" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="45%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Baowen Dong&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></div>
</td>
<td align="right" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="16%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0</font></div>
</td>
<td align="right" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="45%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">All directors and executive officers as a&#160;group (5 persons)</font></div>
</td>
<td align="right" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="16%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,387,651</font></div>
</td>
<td align="right" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="12%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">44.5%</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="45%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="16%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="45%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Greater than 5% Stockholders</font></div>
</td>
<td align="right" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="16%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="45%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="16%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="45%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pope Asset Management, LLC</font></div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5100 Poplar Ave, Ste 805</font></div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Memphis, TN 38137</font></div>
</td>
<td align="right" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="16%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,224,831<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(5)</font></font></div>
</td>
<td align="right" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.1%</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="45%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="16%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="45%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Jian Yang&#160;</font></div>

<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="right" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="16%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,278,815&#160;</font></div>
</td>
<td align="right" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="12%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.2%</font></div>
</td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">__________________</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Represents less than 1%.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)&#160;&#160;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to Rule 13d-3 under the Exchange Act, a person has beneficial ownership of any securities as to which such person, directly or indirectly, through any contract, arrangement, undertaking, relationship or otherwise has or shares voting power and/or investment power or as to which such person has the right to acquire such voting and/or investment power within 60 days.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(2)&#160;&#160;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Unless otherwise stated, each beneficial owner has sole power to vote and dispose of the shares and the address of such person is c/o China Pharma Holdings, Inc., 2nd Floor, No. 17 Jinpan Road, Haikou, Hainan Province, People&#8217;s Republic of China 570216.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(3)&#160;&#160;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In determining the percentage of common stock owned by the beneficial owners, (a) the numerator is the number of shares of common stock beneficially owned by such owner, including shares the owner may&#160;&#160;acquire, within 60 days of March 11, 2013 upon the exercise of the options, if any, held by the owner; and (b) the denominator is the sum of (i) the total 43,579,557 shares of common stock outstanding as of March 11, 2013, and (ii) the number of shares underlying the options, which such owner has the right to acquire upon the exercise of the options within 60 days of March 11, 2013 (for those who have options).</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">54</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(4)&#160;&#160;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Include options to purchase 25,000 shares of common stock that vested on May 25, 2012 and presently exercisable within 60 days.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(5)&#160;&#160;</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pope Asset Management, LLC (&#8220;Pope Management&#8221;) is the investment adviser for Pope Investments II LLC (&#8220;Pope Investment&#8221;). Pope Investments owns 52,823 shares. Pope Management owns 2,172,008 shares on behalf of its clients.&#160;&#160;Therefore, Pope Management, as investment advisor to Pope Investments could be deemed to be beneficial owners of&#160;&#160;2,224,831 shares. &#160;&#160;Mr. William Wells is the sole manager of Pope Management and has dispositive and voting power over the shares held by Pope Investment.&#160;&#160;This information is derived from Schedule 13G filed by Pope Management, Pope Investment and Mr. William jointly on February 13, 2013.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">ITEM 13.</font>&#160;&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Related Party Transactions</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the years ended December 31, 2012 and December 31, 2011, Mr. Tsui, one of our directors, loaned $493,004 and $595,670 to the Company, respectively.&#160;&#160;The balance of such loans was $1,354,567 and $899,314 at December 31, 2012 and 2011, respectively.&#160; The loan bears interest at a rate of 1% per annum and principle and interest are payable on December 31, 2013, pursuant to a loan confirmation letter by and between the Company and Ms. Tsui.&#160;&#160;We recognized interest expense of $9,942 and $7,180 for the years ended December 31, 2012 and 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Independence of the Board of Directors</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The board of directors has determined that Messrs. Gene Michael Bennett, Baowen Dong and Yingwen Zhang are &#8220;independent directors&#8221; as defined in the listing standards of NYSE MKT.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 14.&#160;&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Audit Fees</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The aggregate fees billed by Hansen, Barnett &amp; Maxwell, P.C. for professional services rendered for the audit of our annual financial statements included in our Annual Reports on Form 10-K, for the reviews of the financial statements included in our Quarterly Reports on Form 10-Q, and for services in connection with statutory and regulatory filings or engagements were approximately $142,000 and $140,800&#160;for the fiscal years ended December 31, 2011 and 2012, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Audit-Related Fees</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The aggregate fees billed by our principal accountants for audit-related services were approximately $43,000 for the fiscal year ended December 31, 2011. The audit-related fees related to the review of responses to SEC comment letters. We did not incur any audit-related fees during the fiscal year ended December 31, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Tax Fees</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The aggregate fees billed by our principal accountants for tax or tax related services were $4,000 and $1,776 for the fiscal years ended December 31, 2011 and 2012, respectively.&#160;&#160;The tax services related to the preparation of U.S. Federal income tax returns.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">All Other Fees</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We did not engage our principal accountants to render services to us during the last two fiscal years, other than as reported above.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our Board of Directors has approved the tax and tax related services provided by our principal accountants.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART IV</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 15.&#160;&#160; EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">55</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160; The following documents are filed as part of this report:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Financial Statements</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following financial statements of China Pharma Holdings, Inc. and Reports of Independent Registered Public Accounting Firms are presented in the &#8220;F&#8221; pages of this report:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reports of Independent Registered Public Accounting Firms</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-2</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="78%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consolidated Balance Sheets - as of December 31, 2012 and 2011</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-3</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="78%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consolidated Statements of&#160;Income and Other Comprehensive Income&#160;- for the years ended December 31, 2012 and 2011</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-4</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="78%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consolidated Statements of Shareholders&#8217; Equity - for the years ended December 31, 2011 and 2012</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-5</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="78%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consolidated Statements of Cash Flows - for the years ended December 31, 2012 and 2011</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-6</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="78%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="78%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Notes to Consolidated Financial Statements</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-7 - F-20</font></div>
</div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)&#160;&#160;&#160;&#160;&#160; Exhibits</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">See the Exhibit Index following the signature page of this report, which Index is incorporated herein by reference.</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">56</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="43%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date: March 14, 2013&#160;&#160;&#160;</font></div>
</td>
<td valign="middle" width="43%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CHINA PHARMA HOLDINGS, INC.&#160;</font></div>
</td>
</tr><tr>
<td valign="middle" width="43%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="43%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="middle" width="43%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="43%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="middle" width="43%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="43%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By: <font style="DISPLAY: inline"><font style="TEXT-DECORATION: underline">/s/ Zhilin Li&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></font></div>
</td>
</tr><tr>
<td valign="middle" width="43%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="43%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name: Zhilin Li&#160;</font></div>
</td>
</tr><tr>
<td valign="middle" width="43%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="43%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title: Chief Executive Officer&#160;</font></div>
</td>
</tr><tr>
<td valign="middle" width="43%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="43%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(principal executive officer)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Signature</font></div>
</td>
<td valign="top" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title</font></div>
</td>
<td valign="top" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr><tr>
<td valign="top" width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">/<font style="TEXT-DECORATION: underline">s/ Zhilin Li</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Zhilin Li</font></div>
</td>
<td align="left" valign="top" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chairman of the Board, President, Chief Executive Officer </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(principal executive officer) and interim Chief Financial </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Officer (principal financial officer and principal accounting officer)</font></div>
</td>
<td valign="top" width="13%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 14, 2012</font></div>
</td>
</tr><tr>
<td valign="top" width="19%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="52%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">/<font style="TEXT-DECORATION: underline">s/ Heung Mei Tsui</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Heung Mei Tsui</font></div>
</td>
<td valign="top" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></div>
</td>
<td valign="top" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 14, 2012</font></div>
</td>
</tr><tr>
<td valign="top" width="19%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="52%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">/<font style="TEXT-DECORATION: underline">s/ Gene Michael Bennett</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gene Michael Bennett</font></div>
</td>
<td valign="top" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></div>
</td>
<td valign="top" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 14, 2012</font></div>
</td>
</tr><tr>
<td valign="top" width="19%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="52%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">/<font style="TEXT-DECORATION: underline">s/ Yingwen Zhang</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Yingwen Zhang</font></div>
</td>
<td valign="top" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></div>
</td>
<td valign="top" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 14, 2012</font></div>
</td>
</tr><tr>
<td valign="top" width="19%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="52%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">/<font style="TEXT-DECORATION: underline">s/ Baowen Dong</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Baowen Dong</font></div>
</td>
<td valign="top" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></div>
</td>
<td valign="top" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 14, 2012</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Supplemental Information to be Furnished With Reports Filed Pursuant to Section 15(d) of the Act by Registrants Which Have Not Registered Securities Pursuant to Section 12 of the Act.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of the date of filing of this Annual Report on Form 10-K, we have not provided any annual report with respect to our last fiscal year or any proxy materials to our shareholders.&#160;&#160;We intend to provide proxy materials to our shareholders with respect to our next annual meeting, and if we do so, we shall concurrently furnish such materials to the Securities and Exchange Commission.&#160;&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">57</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARMA HOLDINGS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit Index to Annual Report on Form 10-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Fiscal Year Ended December 31, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit No.</font></div>
</td>
<td colspan="4" valign="top" width="79%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.1</font></div>
</div>
</td>
<td colspan="4" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Articles of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on December 31, 2012).</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="4" valign="top" width="79%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.2</font></div>
</div>
</td>
<td colspan="4" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Bylaws of the Company (incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K filed on December 31, 2012).&#160;</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="73%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.1*</font></div>
</div>
</td>
<td colspan="5" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Engagement Letter dated December 24, 2012 by and between the Company and Ms. Heung Mei Tsui for Ms. Tsui serving as a director of the Company.</font></div>
</div>
</td>
<td colspan="2" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="5" valign="top" width="79%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.2*</font></div>
</div>
</td>
<td colspan="5" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Engagement Letter dated December 24, 2012 by and between the Company and Mr. Yingwen Zhang for Mr. Zhang serving as a director of the Company.</font></div>
</div>
</td>
<td colspan="2" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="5" valign="top" width="79%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.3*</font></div>
</div>
</td>
<td colspan="5" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Engagement Letter dated December 24, 2012 by and between the Company and Mr. Baowen Dong for Mr. Dong serving as a director of the Company.</font></div>
</div>
</td>
<td colspan="2" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="5" valign="top" width="79%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.4*</font></div>
</div>
</td>
<td colspan="5" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Engagement Letter dated December 24, 2012 by and between the Company and Mr. Gene Michael Bemmett for Mr. Bennett serving as a director of the Company.</font></div>
</div>
</td>
<td colspan="2" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="73%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.5</font></div>
</div>
</td>
<td colspan="5" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2009 Stock Option Plan of the Company (incorporated by reference to Appendix B of the Company&#8217;s Preliminary Information Statement on Schedule 14C filed on September 3, 2009).</font></div>
</div>
</td>
<td colspan="3" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="5" valign="top" width="79%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="3" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.6</font></div>
</div>
</td>
<td colspan="5" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Option Grant Agreement dated as of April 28, 2010 between the Company and Frank Waung&#160;&#160;(incorporated by reference to our Quarterly Report on Form 10-Q filed on August 9, 2010).</font></div>
</div>
</td>
<td colspan="3" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="5" valign="top" width="79%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="3" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.7</font></div>
</div>
</td>
<td colspan="5" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Employment Agreement dated July 1, 2010 between Hainan Helpson Medical &amp; Biotechnology Co., Ltd. and Zhilin Li. (incorporated by reference to our Quarterly Report on Form 10-Q filed on November 10, 2010).</font></div>
</div>
</td>
<td colspan="3" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="5" valign="top" width="79%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.8</font></div>
</div>
</td>
<td colspan="5" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Warrant, dated May 17, 2010, issued to FirsTrust Group Inc. (incorporated by reference to our Annual Report on Form 10-K filed on March 3, 2011).</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="5" valign="top" width="79%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.9*</font></div>
</div>
</td>
<td colspan="5" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loan Extension Agreement between the Company and Heung Mei Tsui.</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="5" valign="top" width="79%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.10</font></div>
</div>
</td>
<td colspan="5" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010 Long-Term Incentive Plan of the Company (incorporated by reference to the Definitive Proxy Statement on Schedule 14A filed on November 12, 2010).</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="5" valign="top" width="79%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.11</font></div>
</div>
</td>
<td colspan="5" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Employment Agreement dated May 31, 2011 between Hainan Helpson Medical &amp; Biotechnology Co., Ltd. and Frank Waung (incorporated by reference to our Current Report on Form 8-K filed on June 1, 2011).</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="73%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.12</font></div>
</div>
</td>
<td colspan="4" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Restricted Stock Grant Agreement between the Company and the grantees under 2010 Long-Term Incentive Plan of the Company (incorporated by reference to our Current Report on Form 8-K filed on June 1, 2011).</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="75%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.13</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>
</td>
<td colspan="4" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form of Non-Qualified Stock Option Grant Agreement between the Company and the grantees under 2010 Long-Term Incentive Plan of the Company (incorporated by reference to our Current Report on Form 8-K filed on June 1, 2011).</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="4" valign="top" width="79%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10.14</font></div>
</div>
</td>
<td colspan="4" valign="top" width="79%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amendment Agreement to Non-Qualified Stock Option Agreements dated as of April 28, 2012 by and between the Company and Mr. Waung&#160;&#160;(incorporated by reference to our Current Report on Form 8-K filed on April 30, 2012).</font></div>
</div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="75%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14.1</font></div>
</div>
</td>
<td colspan="2" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Code of Business Conduct and Ethics (incorporated by reference to the Registration Statement on Form S-1 filed on July 11, 2008).</font></div>
</div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="75%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21.1</font></div>
</div>
</td>
<td colspan="2" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Subsidiaries of the Company&#160;&#160;(incorporated by reference to our Annual Report on Form 10-K filed on March 3, 2011).</font></div>
</div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="75%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23.1*</font></div>
</div>
</td>
<td colspan="2" valign="top" width="75%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consent of Hansen, Barnett &amp; Maxwell, P.C.</font></div>
</div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">58</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="aliceblue">
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31.1*&#160;</font></div>
</div>
</td>
<td valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of Chief Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a) of the Exchange Act.</font></div>
</div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="89%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31.2*&#160;</font></div>
</div>
</td>
<td valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of Chief Financial Officer pursuant to Rule 13a-14 and Rule 15d-14(a) of the Exchange Act.</font></div>
</div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="89%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32.1*&#160;</font></div>
</div>
</td>
<td valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></div>
</div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="aliceblue">
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">32.2*&#160;</font></div>
</div>
</td>
<td valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></div>
</div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="89%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101**</font></div>
</div>
</td>
<td valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interactive data files pursuant to Rule 405 of Regulation S-T (furnished herewith).</font></div>
</div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">___________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">* filed herewith.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">** The interactive data files in Exhibit No. 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, and not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">59</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>
</div>
</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARMA HOLDINGS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INDEX TO FINANCIAL STATEMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="67%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">Page</font></font></div>
</td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="top" width="67%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Report of Independent Registered Public Accounting Firm</font></div>
</td>
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-2</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="67%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="top" width="67%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consolidated Balance Sheets as of December 31, 2012 and 2011</font></div>
</td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-3</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="67%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="top" width="67%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consolidated Statements of Operations and Comprehensive Income for the Years Ended December 31, 2012 and 2011</font></div>
</td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-4</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="67%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="top" width="67%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consolidated Statements of Stockholders&#8217; Equity for the Years Ended December 31, 2011 and 2012</font></div>
</td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-5</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="67%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="top" width="67%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consolidated Statements of Cash Flows for the Years Ended December 31, 2012 and 2011</font></div>
</td>
<td valign="bottom" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-6</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="67%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="top" width="67%">
<div style="TEXT-INDENT: -36pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0.8pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Notes to Consolidated Financial Statements</font></div>
</td>
<td valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0.8pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-7</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 1</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><img src="hbm.jpg" alt=""></font></div>

<br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To the Board of Directors and the Stockholders</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">China Pharma Holdings, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have audited the consolidated balance sheets of China Pharma Holdings, Inc. and subsidiaries as of December 31, 2012 and 2011, and the related consolidated statements of operations and comprehensive income, stockholders&#8217; equity, and cash flows for the years then ended. These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In our opinion the consolidated financial statements referred to above present fairly, in all material respects, the financial position of China Pharma Holdings, Inc. and subsidiaries as of December 31, 2012 and 2011, and the results of their operations and their cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="50%">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ <font style="DISPLAY: inline; FONT-WEIGHT: bold">HANSEN, BARNETT &amp; MAXWELL, P.C.</font></font></font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Salt Lake City, Utah</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">March 13, 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: center"><img src="footer.jpg" alt=""></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="8" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARMA HOLDINGS, INC.</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="8" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONSOLIDATED BALANCE SHEETS</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ASSETS</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Current Assets:</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,029,708</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,050,854</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Banker's acceptances</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101,570</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">83,512</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Trade accounts receivable, less allowance for doubtful</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">accounts of $4,429,945 and $3,536,405, respectively</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">66,175,570</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">69,695,556</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other receivables, less allowance for doubtful</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">accounts of $49,881 and $38,921, respectively</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">80,799</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">55,039</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Advances to suppliers</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,816,354</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,778,841</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Inventory</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">36,359,516</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,378,658</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred tax assets</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">967,671</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">566,226</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Current Assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">112,531,188</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">110,608,686</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Advances for purchases of property and equipment</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">170,323</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Advances for purchases of intangible assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">39,263,977</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">36,194,494</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Property and equipment</font>, net of accumulated depreciation of</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$4,273,373 and $3,391,124, respectively</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,031,894</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,334,817</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Intangible assets</font>, net of accumulated amortization of</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$2,944,726 and $3,041,804, respectively</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,412,854</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,082,671</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">TOTAL ASSETS</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">163,239,913</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">156,390,991</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">LIABILITIES AND STOCKHOLDERS' EQUITY</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Current Liabilities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Trade accounts payable</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,841,862</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,112,385</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">202,185</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">184,017</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued taxes payable</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,426,826</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,082,353</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other payables</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,094,886</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">822,448</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Advances from customers</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,945,984</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,784,474</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other payables - related parties</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,354,567</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">861,563</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Short-term notes payable</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,761,073</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,931,745</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Current Liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,627,383</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,778,985</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Long-term deferred tax liability</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">95,963</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">128,909</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,723,346</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,907,894</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stockholders' Equity:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Preferred stock, $0.001 par value; 5,000,000 shares authorized;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">no shares issued or outstanding</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock, $0.001 par value; 95,000,000 shares authorized;</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,579,557 shares and 43,529,557 shares outstanding, respectively</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,580</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,530</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Additional paid-in capital</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,590,204</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,448,534</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Retained earnings</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">108,904,325</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">104,286,666</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accumulated other comprehensive income</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,978,458</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,704,367</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Stockholders' Equity</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">148,516,567</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">142,483,097</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">163,239,913</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">156,390,991</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The accompanying notes are an integral part of these consolidated financial statements.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="8" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARMA HOLDINGS, INC.</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="8" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONSOLIDATED STATEMENTS OF OPERATIONS</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td colspan="8" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AND COMPREHENSIVE INCOME</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Years Ended</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenue</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">54,507,049</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">81,166,739</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cost of revenue</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">38,660,814</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52,178,680</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Inventory obsolescence</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,769,984</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gross profit</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,076,251</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28,988,059</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Operating expenses:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Selling expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,535,214</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,439,522</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General and administrative expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,313,306</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,716,397</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Bad debt expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">871,612</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">108,085</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Impairment of intangible assets</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">593,095</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total operating expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,313,227</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,264,004</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Government subsidy income</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">141,987</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">301,672</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Income from operations</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,905,011</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22,025,727</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other income (expense):</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest income</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,944</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,208</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(308,375</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(255,198</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Derivative gain</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">934,260</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net other income (expense)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(303,431</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">686,270</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Income before income taxes</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,601,580</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22,711,997</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Income tax expense</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(983,921</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,442,355</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net income</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,617,659</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,269,642</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" colspan="8" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other comprehensive income - foreign currency</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">translation adjustment</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,274,091</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,080,098</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Comprehensive income</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,891,750</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24,349,740</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Earnings per Share:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Basic</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.11</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.44</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Diluted</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.11</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.44</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The accompanying notes are an integral part of these consolidated financial statements.</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="24" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARMA HOLDINGS, INC.</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="24" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accumulated</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Additional</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Other</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Common Stock</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Paid-in</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Retained</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Comprehensive</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stockholders'</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Shares</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amount</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Capital</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Earnings</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Income</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Equity</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Balance, December 31, 2010</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,404,557</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,405</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,252,476</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">85,017,024</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,624,269</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">117,937,174</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance of options as compensation</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">76,991</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">76,991</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance of stock as compensation</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">125,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">125</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">119,067</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">119,192</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net income for the year</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,269,642</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,269,642</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Foreign currency translation adjustment</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,080,098</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,080,098</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Balance, December 31, 2011</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,529,557</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,530</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,448,534</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">104,286,666</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,704,367</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">142,483,097</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Share-based compensation</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">100,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">100</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">141,620</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">141,720</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Forfeiture of contingently vesting shares</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(50,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(50</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">50</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net income for the year</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,617,659</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,617,659</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Foreign currency translation adjustment</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,274,091</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,274,091</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="28%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Balance, December 31, 2012</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,579,557</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,580</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,590,204</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">108,904,325</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,978,458</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">148,516,567</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The accompanying notes are an integral part of these consolidated financial statements.</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="8" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARMA HOLDINGS, INC.</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td colspan="8" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Years Ended</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash Flows from Operating Activities:</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net income</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,617,659</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,269,642</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Depreciation and amortization</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,462,771</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,174,822</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock based compensation</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">141,721</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">196,183</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Derivative gain</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(934,260</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Bad debt expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">871,612</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">108,085</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Impairment of intangible assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">593,095</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Inventory obsolescence provision</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,769,984</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred income taxes</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(430,250</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">37,281</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Changes in assets and liabilities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Trade accounts and other receivables</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,098,322</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(11,392,154</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Advances to suppliers</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,014,760</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(251,171</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Inventory</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,702,575</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,925,143</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Trade accounts payable</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(306,040</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,928,259</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued expenses and other liabilities</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">246,817</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">758,783</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued taxes payable</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(683,357</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">591,470</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other payables</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">744</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,327</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Advances from customers</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">145,201</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">518,718</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Cash Provided by Operating Activities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,643,820</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,237,324</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash Flows from Investing Activities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net investment in banker's acceptances</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(82,149</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Advances for purchases of property and equipment</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,612,670</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Advances for purchases of intangible assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,218,035</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,191,385</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Purchase of property and equipment</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(156,878</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(352,362</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Cash Used in Investing Activities</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,987,583</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,625,896</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash Flows from Financing Activity:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from issuance of notes payable</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">793,223</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Borrowings from related party</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">493,004</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">595,670</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Cash Provided by Financing Activity</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,286,227</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">595,670</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Effect of Exchange Rate Changes on Cash</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">36,390</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">151,670</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Increase (Decrease) in Cash</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(21,146</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">358,768</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and Cash Equivalents at Beginning of Period</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,050,854</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,692,086</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash and Cash Equivalents at End of Period</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,029,708</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,050,854</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Supplemental Cash Flow Information:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash paid for interest</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">298,433</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">248,018</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash paid for income taxes</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,138,853</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,532,592</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Supplemental Noncash Investing and Financing Activities:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable for purchases of property and equipment</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">151,731</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">143,151</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts receivable collected with banker's acceptances</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,354,825</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,102,570</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Inventory purchased with banker's acceptances</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,768,805</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,102,570</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Advances for purchases of property and equipment paid with banker's acceptances</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,540,820</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Advances for purchases of intangibles paid with banker's acceptances</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,909</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The accompanying notes are an integral part of these consolidated financial statements.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARMA HOLDINGS, INC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 1 &#8211; ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Organization and Nature of Operations &#8211; </font>China Pharma Holdings, Inc., a Nevada corporation as of December 31, 2012, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, that in turn owns 100% of Hainan Helpson Medical &amp; Biotechnology Co., Ltd (Helpson), a company organized under the laws of the People's Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: #ffffff; DISPLAY: inline">On December 31, 2012, China Pharma Holdings, Inc consummated a reincorporation merger for the purpose of changing the state of incorporation from Delaware to Nevada pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012.&#160;&#160;The reincorporation merger was approved by stockholders holding the majority of the outstanding common shares on December 21, 2012.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Foreign Investment Industrial Catalogue<font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font>(the &#8220;Catalogue&#8221;) jointly issued by the China&#8217;s Ministry of Commerce and the National Development and Reform Commission (as the latest version is the year 2012 version, effective January 30, 2012) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the &#8220;FIE&#8221;) shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case of the Company&#8217;s business.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson&#8217;s business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson from Helpson&#8217;s three former shareholders on May 25, 2005 by entry into an Equity Transfer Agreement with such three parties on May 25, 2005. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has and continues to acquire well-accepted medical formulas to a diverse portfolio of Western and Chinese medicines.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Consolidation and Basis of Presentation </font>&#8211; The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Helpson&#8217;s functional currency is the Chinese Renminbi. Helpson&#8217;s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson&#8217;s financial statements are included in accumulated other comprehensive income, which is a component of stockholders&#8217; equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Reclassification</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"> - </font>The Company has made certain reclassifications to the consolidated balance sheet at December 31, 2011 to conform to the December 31, 2012 presentation. These reclassifications had no effect on the consolidated statements of operations or cash flows for any periods presented.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARMA HOLDINGS, INC.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011</font></font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Accounting Estimates </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">- </font>The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the management of the Company (&#8220;Management&#8221;) to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Cash and Cash Equivalents </font>&#8211; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker&#8217;s acceptances purchased with maturities of three months or less.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Trade Accounts Receivable and Allowance for Doubtful Accounts &#8211; </font>Trade accounts receivables are carried at original invoiced amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts and an estimation of the overall economic conditions affecting the Company's customer base. The Company reviews a customer's credit history before extending credit. If the financial condition of its customers were to deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable to the extent they are considered unlikely to be collected. It is common practice in the PRC for receivables to extend beyond one year. Customer balances outstanding for more than one year are allowed for at a greater rate when calculating the allowance for doubtful accounts. At December 31, 2012, trade accounts receivables included $30,134,909 from sales that occurred more than one year prior to December 31, 2012, that Management believes are collectable.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Advances to Suppliers and Advances from Customers</font> &#8211; Common practice in the PRC is to make advances to suppliers for materials and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances received from customers are applied against trade accounts receivable when finished products are sold.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Inventory</font> &#8211; Inventory is stated at the lower of cost or net realizable value, computed on an average cost basis. An allowance for inventory obsolescence is provided when the market value of inventory items is lower than its cost.&#160;&#160;The Company recognized an inventory obsolescence reserve of $1,769,984 and $0 for the years ended December 31, 2012 and 2011, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Valuation of Long-Lived Assets</font> &#8211; The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash flows estimated to be generated by the asset. The Company evaluated its long-lived assets at December 31, 2012 and determined that the value of certain of its intangible assets were impaired and recognized an impairment loss of $593,095 for the year ended December 31, 2012. No impairment was recognized during the year ended December 31, 2011.&#160;&#160;See Note 4.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Property and Equipment</font> &#8211; Property and equipment are stated at cost. Maintenance and repairs are charged to expense as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Revenue Recognition</font> &#8211; Revenue is considered earned when the Company has persuasive evidence of an arrangement with the customer, delivery of the products has occurred, the sales price is fixed or determinable, and collectability is reasonably assured. Delivery does not occur until products have been shipped to the customer, risk of loss has transferred to the customer and customer acceptance has been obtained, customer acceptance provisions have lapsed, or the Company has objective evidence that the criteria specified in the customer acceptance provisions have been satisfied. The sales price is not considered to be fixed or determinable until all contingencies related to the sale have been resolved.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 8</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARMA HOLDINGS, INC.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011</font></font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Cost of Revenues</font> &#8211; Cost of revenues includes wages, materials, handling charges, and other expenses associated with the manufacture and delivery of products.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Research and Development</font> &#8211; Research and development expenditures are recorded as expenses in the period in which they occur. Research and development costs were not material during the years ended December 31, 2012 and 2011.&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Retirement Benefit Plans</font> &#8211; The Company is required to make monthly contributions at prescribed rates to various employee retirement benefit plans organized by provincial governments. The governments benefit plans assume the retirement benefit obligations of all existing and future retired employees of the Company. The Company contributed $233,846 and $166,071 to retirement benefit plans for the years ended December 31, 2012 and 2011, respectively. Contributions to these plans are charged to expense as incurred.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Advertising Costs</font> &#8211; Advertising costs are expensed when incurred. The Company did not incur any advertising costs for the years ended December 31, 2012 and 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Basic and Diluted Earnings per Common Share </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">- </font>Basic earnings per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per share are calculated to give effect to potentially issuable dilutive common shares.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Potential common shares were not included in the computation of diluted earnings per share as their effect would have been anti-dilutive as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Years Ended</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Warrants with exercise prices of $3.00 to $3.80 per share</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">150,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">150,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Options with an exercise price of $2.54 to $3.47 per share</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">50,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">310,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">200,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">460,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div align="center">&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Credit Risk</font> &#8211; The carrying amounts of accounts receivable included in the balance sheet represent the Company's exposure to credit risk in relation to its financial assets. No other financial assets carry a significant exposure to credit risk. The Company performs ongoing credit evaluations of each customer's financial condition. It maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded Management's estimations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secure due to the state policy on protecting depositors&#8217; interests. The PRC promulgated a new Bankruptcy Law in August 2006, effective June&#160;1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. In the event that bankruptcy laws are enacted for banks in the PRC, the Company&#8217;s deposits may be at a higher risk of loss.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Interest Rate Risk</font> &#8211; The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and viability of securing future debt instruments within the PRC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 9</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARMA HOLDINGS, INC.</font></font></font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></font></font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011</font></font></font></font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Recently Announced Accounting Standards</font> &#8211; The Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2011-05, <font style="FONT-STYLE: italic; DISPLAY: inline">Presentation of Comprehensive Income</font>, which revises the manner in which comprehensive income is presented in an entity&#8217;s financial statements. This update requires the presentation of the components of comprehensive income in either a continuous statement of comprehensive income or in two separate but consecutive financial statements. The option to present comprehensive income in the statement of stockholders&#8217; equity has been eliminated. The provisions of this update were effective as of January 1, 2012, and the Company has included a continuous consolidated statement of comprehensive income as part of these consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ASU 2011-04, <font style="FONT-STYLE: italic; DISPLAY: inline">Fair Value Measurement &#8211; Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS</font>, provides converged guidance on how to measure fair value, which is largely consistent with existing U.S. GAAP. This update also requires additional fair value measurement disclosures. The provisions of this update were effective as of January 1, 2012. The effects of adoption were not significant to the accompanying consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ASU No. 2012-02, <font style="FONT-STYLE: italic; DISPLAY: inline">Testing Indefinite-Lived Intangible Assets for Impairment</font>, permits, but does not require, an entity to conduct an initial qualitative assessment to determine whether it is more likely than not that a non-goodwill indefinite-lived asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test currently required (i.e., comparing the asset's fair value with its carrying amount). This new standard was adopted by the Company on September 30, 2012 and had no significant effect on the accompanying consolidated financial statements.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ASU No. 2011-11, <font style="FONT-STYLE: italic; DISPLAY: inline">Disclosures about Offsetting Assets and Liabilities</font>, requires disclosures about assets and liabilities that are offset or have the potential to be offset. This new guidance will be effective for reporting periods beginning January 1, 2013, with retrospective application required. The adoption of this guidance is not expected to have a material impact on the Company&#8217;s results of operations or financial position.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 2 &#8211; INVENTORY</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Inventory consisted of the following:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Raw materials</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,198,816</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24,920,825</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Finished goods</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,930,684</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,457,833</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">38,129,500</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,378,658</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Allowance for obsolescence - raw materials</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,769,984</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total inventory</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">36,359,516</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,378,658</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 3 - PROPERTY AND EQUIPMENT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Property and equipment consisted of the following:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 10</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARMA HOLDINGS, INC.</font></font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011</font></font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="70%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Permit of land use</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">447,013</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">442,978</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Building</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,419,125</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,397,286</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Plant, machinery and equipment</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,381,209</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,184,254</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Motor vehicle</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">147,080</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">145,300</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Office equipment</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">222,273</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">204,552</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Construction in progress</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,688,567</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">351,571</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="70%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,305,267</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,725,941</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Less: accumulated depreciation</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,273,373</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,391,124</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Property and Equipment, net</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,031,894</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,334,817</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Construction in progress consisted of machinery, equipment, construction costs incurred in connection with the construction of a new facility and required manufacturing upgrades.&#160;&#160;Once the machinery is in production and the facility is in use, construction in progress is moved into plant, machinery and equipment and depreciated.&#160;&#160;Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows::</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="33%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Asset</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;Life - years</font></div>
</td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="top" width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Permit of land use</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">40 - 70</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Building</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20 - 35</font></div>
</td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="top" width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Plant, machinery and equipment</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Motor vehicle</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5 - 10</font></div>
</td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="top" width="33%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Office equipment</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3-5</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue. For the years ended December 31, 2012 and 2011, depreciation expense was $851,047 and $555,036, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 4 - INTANGIBLE ASSETS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Intangible assets represent the cost of medical formulas approved for production by the State Food and Drug Administration (the &#8220;SFDA&#8221;) in China. The Company did not obtain SFDA production approval for any medical formula during the year ended December 31, 2011 and no costs were reclassified from advances to intangible assets in 2011. During the year ended December 31, 2012, the Company received production approval from the SFDA for one medical formula and reclassified $507,174 from advances to intangible assets. The new medical formula is being amortized from the date SFDA approval was received over its estimated useful life of thirteen years and is not expected to have a residual value at the end of its useful life.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Approved medical formulas are amortized from the date SFDA approval is obtained over their individually identifiable estimated useful life, which are from ten to thirteen years.&#160;&#160;It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets was $611,724 and $596,525 for the years ended December 31, 2012 and 2011, respectively, and was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of their amortization period.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 11</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-STYLE: italic; DISPLAY: inline">&#160;</font></font> </font>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARMA HOLDINGS, INC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company evaluates each approved medical formula for impairment at the date of SFDA approval, when indications of impairment are present and at the date of each financial statement. The Company&#8217;s evaluation is based on an estimated undiscounted net cash flow model, considering currently available market data for the related drug and the Company&#8217;s estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. As a result of the evaluations, the Company determined that it is not likely that the carrying value of two medical formulas will be realized from future cash flows due to the failure to meet certain improved technical criteria for one formula and from pricing pressures on the other one. As a result, impairment losses relating to those intangible assets were $593,095 for the year ended December 31, 2012. No impairment losses were recognized during the year ended December 31, 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Intangible assets consisted solely of SFDA approved medical formulas as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Gross carrying amount</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,357,580</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,124,475</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accumulated amortization</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,944,726</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,041,804</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net carrying amount</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,412,854</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,082,671</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The estimated aggregate annual amortization expense for each of the next five years and thereafter is as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="left">
<div align="center">
<table cellpadding="0" cellspacing="0" width="35%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;Amount</font></div>
</td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2013</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;$&#160;&#160;&#160;&#160;521,980</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2014</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;505,653</font></div>
</td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2015</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;364,978</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2016</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;318,939</font></div>
</td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2017</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;272,386</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="8%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Thereafter</font></div>
</td>
<td valign="top" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;428,918</font></div>
</td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="8%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;$ 2,412,854</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 21.6pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 5 &#8211; ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In order to expand the number of medicines manufactured and marketed by the Company, it has entered into contracts with independent laboratories and others for the purchase of medical formulas. Although SFDA approval had not been obtained for these medical formulas at the dates of the contracts, the objective of the contracts is for the Company to obtain SFDA-approved medical formulas once the SFDA approval process is completed. The Company received the title to two patents that relate to medical formulas currently in the SFDA approval process at December 31, 2012. The related patents have not expired.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Prior to entering into the contracts, the laboratories typically have completed all required research and development to determine the medical formula for and the method of production of the generic medicine. The application to the SFDA for production approval must be made by the production facility that will produce the related product. As a result, a contract typically provides that the Company buys the medical formula from the laboratory and the laboratory is required to assist the Company in applying for and obtaining the production approval from the SFDA.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A typical SFDA approval process for the production of a generic medical product involves a number of steps that generally requires three to five years. If the medical formula is purchased at the point when the generic medical product receives the SFDA&#8217;s approval for a clinical study, which is very typical for the Company, the clinical study that follows will usually take from one and a half to three years to complete. After the clinical study is completed, the results are submitted to the SFDA and a production approval application is filed with the SFDA. In most cases, it will take between eight to eighteen months to prepare and submit the production approval application and obtain SFDA approval. Upon approving the generic medical product, the SFDA issues a production certificate and the Company can produce and sell the generic medical product. As a result of this process, SFDA approval is expected to be received in approximately two to five years from the dates of the medical formula contracts.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 12</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARMA HOLDINGS, INC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under the terms of the contracts, the laboratories are required to assist the Company in obtaining production approval for the medical formulas from the SFDA. Management monitors the status of each medical formula on a regular basis in order to assess whether the laboratories are performing adequately under the contracts. If a medical product is not approved by the SFDA, as evidenced by their issuance of a denial letter, or if the laboratory breaches the contract, the laboratory is required under the contract to provide a refund to the Company of the full amount of the payments made to the laboratory for that formula, or the Company can require the application of those payments to another medical formula with the same laboratory. As a result of the refund right, the Company is ultimately purchasing an approved medical product. Accordingly, payments made prior to the issuance of production approval by the SFDA are recorded as advances for purchases of intangible assets.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To date, no formula has failed to receive SFDA production approval nor has the Company been informed or become aware of any formula that may fail to receive such approval. However, there is no assurance that the medical products will receive production approval and if the Company does not receive such approval, it will enforce its contractual rights to receive the refund from the laboratory or have the payments applied to another medical formula with the same laboratory.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At December 31, 2012, the Company was obligated to pay laboratories and others approximately $6,476,000 upon completion of the various phases of contracts to provide SFDA production approval of medical formulas.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 6 &#8211; RELATED PARTY TRANSACTIONS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During the years ended December 31, 2012 and December 31, 2011, a member of the Company&#8217;s board of directors advanced the Company $493,004 and $595,670, respectively. The advances bear interest at a rate of 1.0% per year.&#160;&#160;Total interest expense of $9,942 and $7,180 was recognized for the years ended December 31, 2012 and 2011. Total advances owing to the board member were $1,354,567 and $861,563 as of December 31, 2012 and December 31, 2011, respectively, and are recorded as other payables &#8211; related parties on the accompanying consolidated balance sheets.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 7 &#8211; NOTES PAYABLE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On September 30, 2010, the Company entered into a revolving line of credit with a bank in the amount of RMB 25,000,000 (approximately $3.97 million). &#160;Advances on the line of credit were due one year from the date of the advance, with the note payable collateralized by certain land use rights and buildings. On October 26, 2011, the Company renewed the underlying note with the same bank.&#160;&#160;The note bears interest at a base rate equal to the PRC&#8217;s floating six-month to one year rate of 6.56% plus an additional 15% of the base rate, with a resulting rate of 7.54% at December 31, 2011. Advances on the line of credit were due one year from the date of the advance and collateralized by certain land use rights and buildings. The outstanding balance due under the revolving line of credit was RMB 25,000,000 ($3,931,745) at December 31, 2011. This amount was classified as a short-term notes payable in the accompanying consolidated balance sheet at December 31, 2011. On October 18, 2012, the Company fully paid the amount due under this line of credit and on October 26, 2012, it matured and was not renewed.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 13</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARMA HOLDINGS, INC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On October 30, 2012, the Company entered into a new revolving line of credit with another bank in the amount of RMB 30,000,000.&#160;The related note payable bears interest at an annual rate of 6.90% (based upon 115% of the PRC government&#8217;s current short term rate of 6.00%). Advances on the line of credit are due one year from the date of the advance and are collateralized by certain land use rights, buildings and accounts receivable. The outstanding balance due under the revolving line of credit was RMB30,000,000 ($4,761,073) as of December 31, 2012.&#160;&#160;The Company has no additional amounts available to it under the line of credit.&#160;&#160;This amount has been classified as short-term notes payable in the accompanying consolidated balance sheet at December 31, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Fair Value of</font> <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Notes Payable</font> &#8211; Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts of notes payable outstanding at December 31, 2012 and 2011 approximated their fair value because of the immediate or short-term maturity of these financial instruments or because the underlying instruments bear interest rates that approximated current market rates.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 8 - INCOME TAXES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax laws or rates is recognized in income in the period that includes the enactment date.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Undistributed earnings of Helpson, the Company&#8217;s foreign subsidiary, since its acquisition, amounted to approximately $113.4 million at December 31, 2012. Those earnings, as well as the investment in Helpson of approximately $23.3 million, are considered to be indefinitely reinvested and, accordingly, no U.S. federal or state income taxes have been provided thereon. Upon distribution of those earnings in the form of dividends or otherwise, the Company would be subject to U.S. federal and state income taxes (net of an adjustment for foreign tax credits) and withholding taxes payable to the PRC. Determination of the amount of unrecognized deferred U.S. income tax liability is not practical because of the complexities associated with its hypothetical calculation; however, unrecognized foreign tax credits may be available to reduce a portion of the U.S. tax liability.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Liabilities are established for uncertain tax positions expected to be taken in income tax returns when such positions are judged to meet the &#8220;more-likely-than-not&#8221; threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax penalties are included as a component of other expenses. Through December 31, 2012, the Company has not identified any uncertain tax positions that it had taken. U.S. income tax returns for the years ended December 31, 2009 through December 31, 2012 and the Chinese income tax return for the year ended December 31, 2012 are open for possible examination.</font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 16, 2007, the National People&#8217;s Congress of China passed the new Enterprise Income Tax Law (EIT Law) and on December 6, 2007, the State Council of China issued the Implementation Regulations for the EIT Law which took effect on January&#160;1, 2008. The EIT Law and Implementation Regulations impose a unified EIT of 25% on all domestic-invested enterprises and Foreign Invested Entities, or FIEs, unless they qualify under certain limited exceptions.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company is located in a special region, which had a 15% corporate income tax rate before the new EIT Law. The new EIT Law abolished the preferential corporate income tax rate in the special region. The Company has transitioned to the new 25% tax rate over a five year period which began on January 1, 2008. During 2010, the Company applied for and received a favorable tax rate of 15% for fiscal 2011 through 2013 due to its status in the PRC as a high technology enterprise. Under current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="center">
<table cellpadding="0" cellspacing="0" width="35%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="13%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Enterprise Income </font></div>
</td>
</tr><tr>
<td valign="top" width="13%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year</font></div>
</td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="15%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Tax Rate</font></font></td>
</tr><tr bgcolor="aliceblue">
<td valign="top" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2013</font></div>
</td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15%</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="13%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2014 and after</font></div>
</td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="15%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25%</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The provision for income taxes consisted of the following:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 14</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARMA HOLDINGS, INC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011</font></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Years Ended December 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Current</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,414,171</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,458,568</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(430,250</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(16,213</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total income tax expense</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">983,921</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,442,355</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Following is a reconciliation of income taxes calculated at the federal statutory rate to the provision for income taxes:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Years Ended December 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tax at statutory rate of 25%</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,400,395</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,677,999</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Non-deductible stock-based compensation from</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;current and prior years</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">149,644</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">261,122</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Effect of tax holiday</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(655,947</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,330,566</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other, primarily the effect of US tax rates</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(70,471</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in valuation allowance</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">160,300</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(166,200</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Income tax expense</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">983,921</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,442,355</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The effect of the tax holiday amounted to savings of $655,947 and $2,330,566 for the years ended December 31, 2012 and 2011, which was equivalent to basic and diluted earnings per share of $0.02 and $0.05 per share for the years ended December 31, 2012 and 2011, respectively. The temporary differences which give rise to the deferred income tax assets and liability are as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Deferred income tax assets:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Allowance for doubtful trade receivables</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">664,492</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">530,461</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Allowance for doubtful other receivables</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,482</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,838</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Inventory obsolescence reserve</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">265,498</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expenses not deductible in current year</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,200</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">29,927</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Share based compensation</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">45,777</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">172,911</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">U.S. net operating loss carry forwards</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">905,669</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">618,236</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total deferred income tax assets</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,919,118</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,357,373</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Valuation allowance</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(951,447</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(791,147</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net deferred income tax asset</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">967,671</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">566,226</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Deferred income tax liability:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intangible assets</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">95,963</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">128,909</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of December 31, 2012, the Company has net operating losses from continuing operations for United States federal income tax purposes of $2,663,731 which are available to offset future taxable income, if any, and expire, if not used, from 2029 through 2032.&#160;&#160;In assessing the realizability of deferred tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.&#160;&#160;The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized.&#160;&#160;Management considers projected future taxable income and tax planning strategies in making this assessment.&#160;&#160;Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, Management believes it is not likely the Company will realize all of the benefits of the deferred tax assets as of December 31, 2012 and 2011.&#160;&#160;Therefore, the Company has provided for a valuation allowance against its deferred tax assets of $951,447 and $791,147 as of December 31, 2012 and 2011, respectively.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 15</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARMA HOLDINGS, INC.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011</font></font></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.&#160;&#160;During 2012 and 2011, the Company received an incentive payment from the tax authority of the Hainan provincial government in the PRC totaling $141,987 and $301,672, respectively, which has been recorded as government subsidy income on the accompanying statements of operations and comprehensive income for the years ended December 31, 2012 and 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 9 &#8211; DERIVATIVE WARRANT LIABILITY</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On May 27, 2008 and on May 30, 2008, the Company issued warrants to purchase 1,250,000 shares of common stock at $2.80 per share and warrants to purchase 300,000 shares of common stock at $2.98 per share, respectively, exercisable for a period of three years. These warrants contained certain pricing reset provisions which caused the warrants to be treated as a derivative. These warrants were never exercised and expired on May 27, 2011. Changes to the warrant derivative liability were recognized in the results of operations and resulted in derivative gains of $0 and $934,260 for the years ended December 31, 2012 and 2011, respectively.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 10 &#8211; FAIR VALUE MEASUREMENTS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities. Level 2 &#8211; Observable inputs other than Level 1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable market data. Level 3 &#8211; Unobservable inputs supported by little or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company uses fair value to measure the derivative warrant liability on a recurring basis because fair value is the primary measure for accounting. The Company also uses fair value to measure the value of the banker&#8217;s acceptance notes it holds.&#160;&#160;The Company values its derivative warrants using a valuation method explained above.&#160;&#160;The banker&#8217;s acceptance notes are recorded at cost which approximates fair value.&#160;&#160;The Company held the following assets and liabilities recorded at fair value as of December 31, 2012 and 2011:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" width="34%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair Value Measurements at</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="3" valign="bottom" width="11%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" width="34%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Reporting Date Using</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="52%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2012</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level 1</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level 2</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level 3</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Banker's acceptance notes</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101,570</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101,570</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101,570</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">101,570</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" width="34%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair Value Measurements at</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="3" valign="bottom" width="11%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="10" valign="bottom" width="34%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Reporting Date Using</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="52%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2011</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level 1</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level 2</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level 3</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Banker's acceptance notes</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">83,512</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">83,512</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">83,512</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">83,512</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div align="center">&#160;</div>

<div align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 16</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARMA HOLDINGS, INC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011</font></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 11 - STOCKHOLDERS' EQUITY</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 31, 2012, the domicile of China Pharma Holdings, Inc. was changed from the State of Delaware to the State of Nevada through a merger of the Delaware corporation with and into its newly set-up Nevada subsidiary, with the Nevada subsidiary being the surviving corporation. Each common share, warrant and stock option outstanding on the merger date was automatically converted into a common share, warrant or stock option of the Nevada corporation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company is authorized to issue 95,000,000 shares of common shares, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Company&#8217;s board of directors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Warrants</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of December 31, 2012, the Company had warrants outstanding and exercisable to purchase an aggregate of 150,000 shares of Company's common stock at exercise prices ranging from $3.00 to $3.80 per share, which expire May 16, 2013. At December 31, 2012, the warrants had a weighted-average exercise price of $3.40 per share, a weighted-average remaining contractual life of 0.4 years and a total intrinsic value of $0.&#160;&#160;</font><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Employee Stock Options</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2010 Incentive Plan</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On November 12, 2010, the Company&#8217;s Board of Directors adopted, and on December 22, 2010 its stockholders approved the 2010 Long-Term Incentive Plan (the &#8220;2010 Incentive Plan&#8221;), which gave the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries. The 2010 Incentive Plan currently allows for equity awards of up to 4,000,000 shares of common stock.&#160;&#160;Through December 31, 2012, 125,000 shares of common stock and options to purchase an aggregate of 100,000 shares of stock options had been granted under the 2010 Incentive Plan.</font></font></div>

<br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On May 25, 2011 the Company issued two-year options to purchase a total of 100,000 shares of its common stock under the 2010 Incentive Plan to two of its executive officers as follows. The Company&#8217;s Chief Executive Officer was granted non-qualified stock options to purchase 50,000 shares of common stock at an exercise price of $2.54 per share, the closing price of the Company&#8217;s common stock on the day prior to the day of grant, expiring on May 25, 2013, of which 25,000 shares vested on May 25, 2012 and 25,000 shares were to vest on the three-month anniversary of the achievement of certain performance-based vesting criteria. The Company also granted its former Chief Financial Officer non-qualified stock options to purchase 50,000 shares of common stock at an exercise price of $2.54 per share, expiring on April 28, 2013, of which 25,000 shares vested on April 28, 2012 and 25,000 shares were to vest on the three-month anniversary of the achievement of certain performance-based vesting criteria.</font></font></div>

<br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The grant-date fair value of the options of $0.71 per share, or $70,580 in total, was based on the grant-date closing market price of $2.54 per share and on the following weighted-average assumptions: risk free interest rate of 0.54%, expected dividend yield of 0%, expected volatility of 70.4% and an expected life of 1.0 year. The share-based compensation expense relative to the fixed stock options was recognized over the period the options vested. Share-based compensation relative to the performance-based options will be recognized only if the performance criterion is met.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 17</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARMA HOLDINGS, INC.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011</font></font></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, on May 25, 2011 the Company granted 125,000 shares of common stock under the 2010 Incentive Plan to two of its executive officers valued at $317,500 based on the closing market price on the date of grant of $2.54 per share. Specifically, the Company granted 75,000 shares of restricted stock to its Chief Executive Officer, of which 50,000 shares vested on May 25, 2012, and 25,000 shares were to vest on the six-month anniversary of the achievement of certain performance-based vesting criteria, and the Company granted 50,000 shares of restricted stock to its former Chief Financial Officer, of which 25,000 shares vested on April 28, 2012 and 25,000 shares were to vest on the six-month anniversary of the achievement of certain performance-based vesting criteria. The performance criterion was not met and the performance-based shares were forfeited during the year ended December 31, 2012. The share-based compensation related to the fixed share awards was recognized over the period the shares vested.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Effective April 28, 2012, the Company and Frank Waung, its former Chief Financial Officer, entered into an Amendment Agreement to Non-Qualified Stock Option Agreements to amend the terms of the equity awards previously granted to Mr. Waung in conjunction with the termination of his employment agreement with the Company effective April 29, 2012.&#160;&#160;The effect of the amendment was to terminate a total of 185,000 vested but unexercised options immediately on April 28, 2012 as opposed to 90 days after the employment termination date. Effective the same date, the Company awarded 100,000 shares of common stock to Mr. Waung for his previous service to the Company<font style="DISPLAY: inline; FONT-WEIGHT: bold">.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Accordingly, the Company recorded a total of $55,775 of stock compensation expense based upon the excess of the fair value of the common stock issued in exchange for the options that were cancelled, i.e., 185,000 options with a fair value of $225 in exchange for 100,000 shares of common stock with a fair value of $56,000 based on the closing market price of the common stock of $0.56 per share on the date awarded. The fair value of the stock options was computed using the Black-Scholes Option Pricing Model, using the following assumptions: risk free interest rate of 0.14% to 0.19%, expected dividend yield of 0%, expected volatility of 66.7% and an expected life of 0.5 to 1.1 years.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On April 27 and 28, 2012 a total of 50,000 options to purchase common stock granted under the 2010 Incentive Plan with an exercise price of $2.54 per share were forfeited due to the failure to achieve the performance-based vesting criteria.</font></font></div>

<br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company recognized $141,720 and $196,183 of compensation expense during the years ended December 31, 2012 and 2011, respectively, as general and administrative expenses related to the awards of common shares and grants and modifications of stock options. The total income tax benefit recognized from the related stock-based compensation was $35,430 and $49,046 for the years ended December 31, 2012 and 2011, respectively. </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model using the assumptions noted in the preceding paragraphs. Expected volatility is based on the historical volatility of the Company&#8217;s common stock prices. The Company uses historical data to estimate employee termination rates. The expected term of options granted is determined by the simplified method, which is one-half of the original contractual term. The simplified method is used due to the lack of historical share option exercise data to provide a reasonable basis upon which to estimate expected term. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A summary of stock option activity as of December 31, 2012, and changes during the year then ended is presented below:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 18</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARMA HOLDINGS, INC.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011</font></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Weighted-</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Weighted-</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Average</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Average</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Remaining</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Aggregate</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exercise</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contractual</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Intrinsic</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Shares</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Price</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Term (Years)</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Value</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding at December 31, 2011</font></div>
</td>
<td align="right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">310,000</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.03</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Forfeited</font></div>
</td>
<td align="right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(50,000</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.54</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expired</font></div>
</td>
<td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(235,000</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="right" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.19</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Outstanding at December 31, 2012</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.54</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.40</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exercisable at December 31, 2012</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.54</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.40</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At December 31, 2012, there was no remaining unrecognized compensation expense related to the fixed stock options. The unrecognized performance-based compensation expense related to performance-based options was $17,645, but will only be recognized if the performance criterion is met. There was no remaining unrecognized compensation expense related to restrictive stock awards at December 31, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 12 &#8211; COMMITMENTS AND CONTINGENCIES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Economic environment </font><font style="DISPLAY: inline; FONT-WEIGHT: bold">- </font>Substantially all of the Company's operations are conducted in the PRC, and therefore the Company is subject to special considerations and significant risks not typically associated with companies operating in the United States of America. These risks include, among others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The Company's results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely affect the Company&#8217;s operations.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, all of the Company's revenue is denominated in the PRC's currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Contractual Commitments &#8211;</font> The Company entered into purchase and construction agreements during the year ended December 31, 2012 in connection with the construction of a new facility and required manufacturing improvements.&#160;&#160;Under these agreements, the Company made payments in the amount of $3,110,319 during the year ended December 31, 2012. These payments are classified as construction in progress on the accompanying balance sheet at December 31, 2012. Future minimum commitments under the agreements are as follows:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div align="center">
<table cellpadding="0" cellspacing="0" width="60%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="white">
<td align="left" valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Years Ending December 31:</font></div>
</td>
<td valign="top" width="19%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2013</font></div>
</td>
<td align="right" valign="top" width="19%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;$ 13,133,498</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="81%" style="PADDING-BOTTOM: 2px">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2014</font></div>
</td>
<td align="right" valign="top" width="19%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;968,860</font></div>
</td>
</tr><tr bgcolor="aliceblue">
<td align="left" valign="top" width="81%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td align="right" valign="top" width="19%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;$ 14,102,358</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 13 &#8211; CONCENTRATIONS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the year ended December 31, 2011, a customer accounted for 20.4% of sales and at December 31, 2011, one customer accounted for 10.2% of accounts receivable. For the year ended December 31, 2011, purchases from a supplier made up 20.8% of raw material purchases.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 19</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARMA HOLDINGS, INC.</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: normal; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR THE YEARS ENDED DECEMBER 31, 2012 AND 2011</font></font></font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the year ended December 31, 2012, no customer accounted for more than 10% of sales or ending accounts receivable. Two suppliers accounted for 12.1% and 10.3%, respectively, of the raw materials the Company purchased during the year ended December 31, 2012.</font></font></div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">F - 20</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>cphi10kex101123112.htm
<TEXT>
<html>
<head>
    <title>cphi10kex101123112.htm</title>
    <!--Licensed to: Securities Transfer Corp-->
    <!--Document Created using EDGARizerAgent 5.4.4.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>Exhibit 10.1</div>

<div>&#160;</div>

<div>&#160;</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">December 24, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dear Ms. Heung Mei Tsui</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On behalf of the Board of Directors and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc as a director. The compensation is $16,000 per year. I look forward to working with you. Your starting date will be the December 24, 2012, and the term will be three years.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If you agree to the terms and conditions stated above, please sign and date this letter below.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I look forward to working with you and sincerely hope that your service will be enjoyable and rewarding.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Sincerely</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chairman of the Board</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">China Pharma Holdings, Inc</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">By: <font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;/s/ Zhilin Li</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date<font style="DISPLAY: inline; TEXT-DECORATION: underline">:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Response:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This letter correctly sets forth the understanding of Ms. Heung Mei Tsui.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">By: <font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;/s/&#160;&#160;&#160;Heung Mei Tsui</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date<font style="DISPLAY: inline; TEXT-DECORATION: underline">:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>cphi10kex102123112.htm
<TEXT>
<html>
<head>
    <title>cphi10kex102123112.htm</title>
    <!--Licensed to: Securities Transfer Corp-->
    <!--Document Created using EDGARizerAgent 5.4.4.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>Exhibit 10.2</div>

<div>&#160;</div>

<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><img src="cphi.jpg" alt="">&#160;</font></td>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Re: Service about being independent director, Chairman of the Nominating and Compensation Committee, and member of the Audit Committee of China Pharma Holdings, Inc.</font></div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">December 24, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dear Mr. Yingwen Zhang,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On behalf of the Board of Directors and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an independent director, Chairman of the Nominating and Compensation Committee, and member of the Audit Committee. I look forward to working with you. Your starting date will be the date of the board approves your engagement and your engagement for this term will end on the date of the next annual shareholders meeting.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Your compensation will consist of the following:</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A retainer of RMB 40,000 per year, payable quarterly within 5 days of the end of the quarter;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If you agree to the terms and conditions stated above, please sign and date this letter below.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I look forward to working with you and sincerely hope that your service will be enjoyable and rewarding.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Sincerely</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chairman of the Board</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">China Pharma Holdings, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Response:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This letter correctly sets forth the understanding of Mr. Yingwen Zhang.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">By: <font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;/s/ Yingwen Zhang</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date<font style="DISPLAY: inline; TEXT-DECORATION: underline">:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><img src="cphi2.jpg" alt=""></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>cphi10kex103123112.htm
<TEXT>
<html>
<head>
    <title>cphi10kex103123112.htm</title>
    <!--Licensed to: Securities Transfer Corp-->
    <!--Document Created using EDGARizerAgent 5.4.4.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>Exhibit 10.3</div>

<div>&#160;</div>

<div><img src="cphi.jpg" alt=""></div>

<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal">Re: Service about being independent director, member of the Audit Committee, and member of the Nominating and Compensation Committee of China Pharma Holdings, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal">December 24, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dear Mr. Baowen Dong,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On behalf of the Board of Directors and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an independent director, member of the Audit Committee, and member of the Nominating and Compensation Committee. I look forward to working with you. Your starting date will be the date of the board approves your engagement and your engagement for this term will end on the date of the next annual shareholders meeting.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Your compensation will consist of the following:</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A retainer of RMB 40,000 per year, payable quarterly within 5 days of the end of the quarter;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If you agree to the terms and conditions stated above, please sign and date this letter below.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I look forward to working with you and sincerely hope that your service will be enjoyable and rewarding.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Sincerely</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chairman of the Board</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">China Pharma Holdings, Inc</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Response:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This letter correctly sets forth the understanding of Mr. Baowen Dong.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">By: <font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;/s/ Baowen Dong</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date<font style="DISPLAY: inline; TEXT-DECORATION: underline">:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><img src="cphi2.jpg" alt=""></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>cphi10kex104123112.htm
<TEXT>
<html>
<head>
    <title>cphi10kex104123112.htm</title>
    <!--Licensed to: Securities Transfer Corp-->
    <!--Document Created using EDGARizerAgent 5.4.4.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>Exhibit 10.4</div>

<div>&#160;</div>

<div><img src="cphi.jpg" alt="">

<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal">Re: Service about being independent director, chairman of the Audit Committee, and member of the Nominating and Compensation Committee of China Pharma Holdings, Inc.</font></div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal">December 24, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dear Mr. Gene Michael Bennett,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On behalf of the Board of Directors and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an independent director, chairman of the Audit Committee, and member of the Nominating and Compensation Committee. I look forward to working with you. Your starting date will be the date of the board approves your engagement and your engagement for this term will end on the date of the next annual shareholders meeting.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Your compensation will consist of the following:</font></div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A retainer of $16,000 per year, payable quarterly within 5 days of the end of the quarter;</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" id="list" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td align="right" style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2)&#160;&#160;</font></div>
</td>
<td>
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5,000 warrants of common stocks with an exercise price $3.32 per share which is determined by the average stock price of 15 days before December 19<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> 2007. The warrants will be vested on the anniversary date of the board resolution. The warrants issued will be subject to the warrants plan to be adopted by the Company.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If you agree to the terms and conditions stated above, please sign and date this letter below.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I look forward to working with you and sincerely hope that your service will be enjoyable and rewarding.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Sincerely</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chairman of the Board</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">China Pharma Holdings, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Response:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This letter correctly sets forth the understanding of Gene Michael Bennett.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">By: <font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;/s/ Gene Michael Bennett</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date<font style="DISPLAY: inline; TEXT-DECORATION: underline">:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><img src="cphi2.jpg" alt=""></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>6
<FILENAME>cphi10kex109123112.htm
<TEXT>
<html>
<head>
    <title>cphi10kex109123112.htm</title>
    <!--Licensed to: Securities Transfer Corp-->
    <!--Document Created using EDGARizerAgent 5.4.4.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>Exhibit 10.9</div>

<div>&#160;</div>

<div>&#160;</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Loans Extension Agreement</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">With respect to the loans from Ms. Heung Mei Tsui to China Pharma Holdings, Inc. (the Company), the principal and accumulated interest totaled USD $1,354,567 and $17,122 respectively as of December 31, 2012. Because the Company temporarily did not have enough balance in its oversea account to repay the loans, Ms. Tsui and the Company unanimously agreed to extend the loans to December 31, 2013. The Company shall repay the principal and accumulated interest on December 31, 2013.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Creditor</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#65306;</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Heung Mei Tsui</font></font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Debtor<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#65306;</font>China Pharma Holdings, Inc.</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;January 2, 2013</font></font></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>cphi10kex231123112.htm
<TEXT>
<html>
<head>
    <title>cphi10kex231123112.htm</title>
    <!--Licensed to: Securities Transfer Corp-->
    <!--Document Created using EDGARizerAgent 5.4.4.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>Exhibit 23.1</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: right"><img src="hbm.jpg" alt=""></div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We consent to the incorporation by reference in Registration Statement No. 333-141734 Post-Effective Amendment No. 1 to Form SB-2 on Form S-3 of our report dated March 13, 2013 relating to the consolidated financial statements of China Pharma Holdings, Inc. and subsidiaries appearing in this Annual Report on Form 10-K of China Pharma Holdings, Inc. for the year ended December 31, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="50%"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="50%"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> </font>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">/s/ HANSEN, BARNETT &amp; MAXWELL, P.C.</font></font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Salt Lake City, Utah</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">March 13, 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block"><img src="footer.jpg" alt=""></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>cphi10kex311123112.htm
<TEXT>
<html>
<head>
    <title>cphi10kex311123112.htm</title>
    <!--Licensed to: Securities Transfer Corp-->
    <!--Document Created using EDGARizerAgent 5.4.4.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>&#160;</div>

<div>&#160;</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 31.1</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATION OF</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PRINCIPAL EXECUTIVE OFFICER</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PURSUANT TO SECTION 302</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I, Zhilin Li certify that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.&#160;&#160;</font></div>
</td>
<td valign="top" width="72%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.&#160;&#160;</font></div>
</td>
<td valign="top" width="72%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.&#160;&#160;</font></div>
</td>
<td valign="top" width="72%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.&#160;&#160;</font></div>
</td>
<td valign="top" width="72%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.&#160;&#160;</font></div>
</td>
<td valign="top" width="72%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><a name="page_0_3_2"><!--EFPlaceholder--></a>a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date:&#160;&#160;March 14, 2013&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">/s/ Zhilin Li</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Name: Zhilin Li</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Title: Chief Executive Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(principal executive officer)</font></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>cphi10kex312123112.htm
<TEXT>
<html>
<head>
    <title>cphi10kex312123112.htm</title>
    <!--Licensed to: Securities Transfer Corp-->
    <!--Document Created using EDGARizerAgent 5.4.4.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td>
<div align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Exhibit 31.2</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATION OF</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PRINCIPAL FINANCIAL OFFICER</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PURSUANT TO SECTION 302</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I, Zhilin Li, certify that:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.&#160;&#160;</font></div>
</td>
<td align="left" valign="top" width="72%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.&#160;&#160;</font></div>
</td>
<td valign="top" width="72%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.&#160;&#160;</font></div>
</td>
<td valign="top" width="72%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.&#160;&#160;</font></div>
</td>
<td valign="top" width="72%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="right" valign="top" width="6%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.&#160;&#160;</font></div>
</td>
<td valign="top" width="72%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date: March 14, 2013&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">/s/ Zhilin Li</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Name: Zhilin Li</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Title: Interim Chief Financial Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(principal financial officer and principal accounting officer)</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>cphi10kex321123112.htm
<TEXT>
<html>
<head>
    <title>cphi10kex321123112.htm</title>
    <!--Licensed to: Securities Transfer Corp-->
    <!--Document Created using EDGARizerAgent 5.4.4.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 32.1</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATION PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">18 U.S.C. SECTION 1350,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AS ADOPTED PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>The undersigned hereby certifies, in her capacity as principal executive officer of China Pharma Holdings, Inc. (the &#8220;Company&#8221;), for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of her knowledge:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1) &#160;The Company&#8217;s&#160;Annual Report on Form 10-K for the fiscal year ended December 31, 2012 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(2) &#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dated:&#160;&#160;March 14, 2013&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">/s/ Zhilin Li</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Name: Zhilin Li</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">President and Chief Executive Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(principal executive officer)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This certification accompanies each Report pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of &#167;18 of the Securities Exchange Act of 1934, as amended.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>11
<FILENAME>cphi10kex322123112.htm
<TEXT>
<html>
<head>
    <title>cphi10kex322123112.htm</title>
    <!--Licensed to: Securities Transfer Corp-->
    <!--Document Created using EDGARizerAgent 5.4.4.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 32.2</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATION PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">18 U.S.C. SECTION 1350,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AS ADOPTED PURSUANT TO</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The undersigned hereby certifies, in her capacity as principal financial officer and principal accounting officer of China Pharma Holdings, Inc. (the &#8220;Company&#8221;), for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of her knowledge:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1) &#160;The Company&#8217;s&#160;Annual Report on Form 10-K for the fiscal year ended December 31, 2012 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(2) &#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dated:&#160;&#160;March 14, 2013&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">/s/ Zhilin Li</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Name: Zhilin Li</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Title: Interim Chief Financial Officer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(principal financial officer and principal accounting officer)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This certification accompanies each Report pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of &#167;18 of the Securities Exchange Act of 1934, as amended.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>12
<FILENAME>cphi-20121231.xml
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- NeoClarus - iFile Suite version 4.2311  -->
<xbrl xmlns:dei='http://xbrl.sec.gov/dei/2011-01-31' xmlns:fil='http://www.chinapharmaholdings.com/20121231' xmlns='http://www.xbrl.org/2003/instance' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xbrli='http://www.xbrl.org/2003/instance' xmlns:us-gaap='http://fasb.org/us-gaap/2011-01-31' xmlns:iso4217='http://www.xbrl.org/2003/iso4217' xmlns:num='http://www.xbrl.org/dtr/type/numeric' xmlns:nonnum='http://www.xbrl.org/dtr/type/non-numeric' xmlns:xbrldi='http://xbrl.org/2006/xbrldi'>
	<link:schemaRef xlink:type='simple' xlink:href='cphi-20121231.xsd' />
	<dei:DocumentType contextRef='Y12'>10-K</dei:DocumentType>
	<dei:DocumentPeriodEndDate contextRef='Y12'>2012-12-31</dei:DocumentPeriodEndDate>
	<dei:AmendmentFlag contextRef='Y12'>false</dei:AmendmentFlag>
	<dei:EntityRegistrantName contextRef='Y12'>CHINA PHARMA HOLDINGS, INC.</dei:EntityRegistrantName>
	<dei:EntityCentralIndexKey contextRef='Y12'>0001106644</dei:EntityCentralIndexKey>
	<dei:CurrentFiscalYearEndDate contextRef='Y12'>--12-31</dei:CurrentFiscalYearEndDate>
	<dei:EntityCommonStockSharesOutstanding unitRef='Shares' contextRef='I130314' decimals='INF'>43579557</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityFilerCategory contextRef='Y12'>Smaller Reporting Company</dei:EntityFilerCategory>
	<dei:EntityCurrentReportingStatus contextRef='Y12'>Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityVoluntaryFilers contextRef='Y12'>No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef='Y12'>No</dei:EntityWellKnownSeasonedIssuer>
	<dei:DocumentFiscalYearFocus contextRef='Y12'>2012</dei:DocumentFiscalYearFocus>
	<dei:DocumentFiscalPeriodFocus contextRef='Y12'>FY</dei:DocumentFiscalPeriodFocus>
	<us-gaap:Cash unitRef='USD' contextRef='E12' decimals='INF'>4029708</us-gaap:Cash>
	<us-gaap:Cash unitRef='USD' contextRef='E11' decimals='INF'>4050854</us-gaap:Cash>
	<us-gaap:CashEquivalentsAtCarryingValue unitRef='USD' contextRef='E12' decimals='INF'>101570</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue unitRef='USD' contextRef='E11' decimals='INF'>83512</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:ReceivablesNetCurrent unitRef='USD' contextRef='E12' decimals='INF'>66175570</us-gaap:ReceivablesNetCurrent>
	<us-gaap:ReceivablesNetCurrent unitRef='USD' contextRef='E11' decimals='INF'>69695556</us-gaap:ReceivablesNetCurrent>
	<us-gaap:OtherReceivablesNetCurrent unitRef='USD' contextRef='E12' decimals='INF'>80799</us-gaap:OtherReceivablesNetCurrent>
	<us-gaap:OtherReceivablesNetCurrent unitRef='USD' contextRef='E11' decimals='INF'>55039</us-gaap:OtherReceivablesNetCurrent>
	<fil:AdvancesToSuppliers unitRef='USD' contextRef='E12' decimals='INF'>4816354</fil:AdvancesToSuppliers>
	<fil:AdvancesToSuppliers unitRef='USD' contextRef='E11' decimals='INF'>5778841</fil:AdvancesToSuppliers>
	<us-gaap:InventoryDisclosureTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:&quot;&gt;&lt;b&gt;NOTE 2 &amp;#150; INVENTORY.&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Inventory consisted of the following:&lt;/p&gt; &lt;table width=&quot;445&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:333.7pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;88&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;11&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;83&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;94&quot; colspan=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:70.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;&amp;nbsp;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;11&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;89&quot; colspan=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:67pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;&amp;nbsp;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;88&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;11&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;83&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Raw materials&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;88&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp; 30,198,816 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;11&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;83&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp; 24,920,825 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Finished goods&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;88&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 7,930,684 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;11&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;83&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 5,457,833 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;88&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 38,129,500 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;11&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;83&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 30,378,658 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Allowance for obsolescence - raw materials&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;88&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; (1,769,984)&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;11&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;83&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&amp;nbsp; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Total inventory&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;88&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp; 36,359,516 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;11&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;83&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp; 30,378,658 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
	<us-gaap:DeferredTaxAssetsNetCurrent unitRef='USD' contextRef='E12' decimals='INF'>967671</us-gaap:DeferredTaxAssetsNetCurrent>
	<us-gaap:DeferredTaxAssetsNetCurrent unitRef='USD' contextRef='E11' decimals='INF'>566226</us-gaap:DeferredTaxAssetsNetCurrent>
	<us-gaap:AssetsCurrent unitRef='USD' contextRef='E12' decimals='INF'>112531188</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent unitRef='USD' contextRef='E11' decimals='INF'>110608686</us-gaap:AssetsCurrent>
	<fil:AdvancesForPurchasesOfPropertyAndEquipment unitRef='USD' contextRef='E12' decimals='INF'>0</fil:AdvancesForPurchasesOfPropertyAndEquipment>
	<fil:AdvancesForPurchasesOfPropertyAndEquipment unitRef='USD' contextRef='E11' decimals='INF'>170323</fil:AdvancesForPurchasesOfPropertyAndEquipment>
	<fil:AdvancesForPurchasesOfIntangibleAssetsTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:&quot;&gt;&lt;b&gt;NOTE 5 &amp;#150; ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS. &lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;In order to expand the number of medicines manufactured and marketed by the Company, it has entered into contracts with independent laboratories and others for the purchase of medical formulas. Although SFDA approval had not been obtained for these medical formulas at the dates of the contracts, the objective of the contracts is for the Company to obtain SFDA-approved medical formulas once the SFDA approval process is completed. The Company received the title to two patents that relate to medical formulas currently in the SFDA approval process at December 31, 2012. The related patents have not expired. &lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Prior to entering into the contracts, the laboratories typically have completed all required research and development to determine the medical formula for and the method of production of the generic medicine. The application to the SFDA for production approval must be made by the production facility that will produce the related product. As a result, a contract typically provides that the Company buys the medical formula from the laboratory and the laboratory is required to assist the Company in applying for and obtaining the production approval from the SFDA.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;A typical SFDA approval process for the production of a generic medical product involves a number of steps that generally requires three to five years. If the medical formula is purchased at the point when the generic medical product receives the SFDA&amp;#146;s approval for a clinical study, which is very typical for the Company, the clinical study that follows will usually take from one and a half to three years to complete. After the clinical study is completed, the results are submitted to the SFDA and a production approval application is filed with the SFDA. In most cases, it will take between eight to eighteen months to prepare and submit the production approval application and obtain SFDA approval. Upon approving the generic medical product, the SFDA issues a production certificate and the Company can produce and sell the generic medical product. As a result of this process, SFDA approval is expected to be received in approximately two to five years from the dates of the medical formula contracts.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Under the terms of the contracts, the laboratories are required to assist the Company in obtaining production approval for the medical formulas from the SFDA. Management monitors the status of each medical formula on a regular basis in order to assess whether the laboratories are performing adequately under the contracts. If a medical product is not approved by the SFDA, as evidenced by their issuance of a denial letter, or if the laboratory breaches the contract, the laboratory is required under the contract to provide a refund to the Company of the full amount of the payments made to the laboratory for that formula, or the Company can require the application of those payments to another medical formula with the same laboratory. As a result of the refund right, the Company is ultimately purchasing an approved medical product. Accordingly, payments made prior to the issuance of production approval by the SFDA are recorded as advances for purchases of intangible assets. &lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;To date, no formula has failed to receive SFDA production approval nor has the Company been informed or become aware of any formula that may fail to receive such approval. However, there is no assurance that the medical products will receive production approval and if the Company does not receive such approval, it will enforce its contractual rights to receive the refund from the laboratory or have the payments applied to another medical formula with the same laboratory.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;At December 31, 2012, the Company was obligated to pay laboratories and others approximately $6,476,000 upon completion of the various phases of contracts to provide SFDA production approval of medical formulas. &lt;/p&gt;</fil:AdvancesForPurchasesOfIntangibleAssetsTextBlock>
	<us-gaap:PropertyPlantAndEquipmentNet unitRef='USD' contextRef='E12' decimals='INF'>9031894</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet unitRef='USD' contextRef='E11' decimals='INF'>6334817</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill unitRef='USD' contextRef='E12' decimals='INF'>2412854</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill unitRef='USD' contextRef='E11' decimals='INF'>3082671</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:Assets unitRef='USD' contextRef='E12' decimals='INF'>163239913</us-gaap:Assets>
	<us-gaap:Assets unitRef='USD' contextRef='E11' decimals='INF'>156390991</us-gaap:Assets>
	<us-gaap:AccountsPayableTradeCurrent unitRef='USD' contextRef='E12' decimals='INF'>2841862</us-gaap:AccountsPayableTradeCurrent>
	<us-gaap:AccountsPayableTradeCurrent unitRef='USD' contextRef='E11' decimals='INF'>3112385</us-gaap:AccountsPayableTradeCurrent>
	<us-gaap:AccruedLiabilitiesCurrent unitRef='USD' contextRef='E12' decimals='INF'>202185</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent unitRef='USD' contextRef='E11' decimals='INF'>184017</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:TaxesPayableCurrent unitRef='USD' contextRef='E12' decimals='INF'>2426826</us-gaap:TaxesPayableCurrent>
	<us-gaap:TaxesPayableCurrent unitRef='USD' contextRef='E11' decimals='INF'>3082353</us-gaap:TaxesPayableCurrent>
	<us-gaap:AccountsPayableOtherCurrent unitRef='USD' contextRef='E12' decimals='INF'>1094886</us-gaap:AccountsPayableOtherCurrent>
	<us-gaap:AccountsPayableOtherCurrent unitRef='USD' contextRef='E11' decimals='INF'>822448</us-gaap:AccountsPayableOtherCurrent>
	<us-gaap:CustomerAdvancesCurrent unitRef='USD' contextRef='E12' decimals='INF'>1945984</us-gaap:CustomerAdvancesCurrent>
	<us-gaap:CustomerAdvancesCurrent unitRef='USD' contextRef='E11' decimals='INF'>1784474</us-gaap:CustomerAdvancesCurrent>
	<us-gaap:DueToRelatedPartiesCurrent unitRef='USD' contextRef='E12' decimals='INF'>1354567</us-gaap:DueToRelatedPartiesCurrent>
	<us-gaap:DueToRelatedPartiesCurrent unitRef='USD' contextRef='E11' decimals='INF'>861563</us-gaap:DueToRelatedPartiesCurrent>
	<us-gaap:NotesPayableCurrent unitRef='USD' contextRef='E12' decimals='INF'>4761073</us-gaap:NotesPayableCurrent>
	<us-gaap:NotesPayableCurrent unitRef='USD' contextRef='E11' decimals='INF'>3931745</us-gaap:NotesPayableCurrent>
	<us-gaap:LiabilitiesCurrent unitRef='USD' contextRef='E12' decimals='INF'>14627383</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent unitRef='USD' contextRef='E11' decimals='INF'>13778985</us-gaap:LiabilitiesCurrent>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent unitRef='USD' contextRef='E12' decimals='INF'>95963</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent unitRef='USD' contextRef='E11' decimals='INF'>128909</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:Liabilities unitRef='USD' contextRef='E12' decimals='INF'>14723346</us-gaap:Liabilities>
	<us-gaap:Liabilities unitRef='USD' contextRef='E11' decimals='INF'>13907894</us-gaap:Liabilities>
	<us-gaap:PreferredStockValue unitRef='USD' contextRef='E12' decimals='INF'>0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue unitRef='USD' contextRef='E11' decimals='INF'>0</us-gaap:PreferredStockValue>
	<us-gaap:CommonStockValue unitRef='USD' contextRef='E12' decimals='INF'>43580</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue unitRef='USD' contextRef='E11' decimals='INF'>43530</us-gaap:CommonStockValue>
	<us-gaap:AdditionalPaidInCapital unitRef='USD' contextRef='E12' decimals='INF'>23590204</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital unitRef='USD' contextRef='E11' decimals='INF'>23448534</us-gaap:AdditionalPaidInCapital>
	<us-gaap:RetainedEarningsAccumulatedDeficit unitRef='USD' contextRef='E12' decimals='INF'>108904325</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit unitRef='USD' contextRef='E11' decimals='INF'>104286666</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax unitRef='USD' contextRef='E12' decimals='INF'>15978458</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax unitRef='USD' contextRef='E11' decimals='INF'>14704367</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:StockholdersEquity unitRef='USD' contextRef='E12' decimals='INF'>148516567</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity unitRef='USD' contextRef='E11' decimals='INF'>142483097</us-gaap:StockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity unitRef='USD' contextRef='E12' decimals='INF'>163239913</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity unitRef='USD' contextRef='E11' decimals='INF'>156390991</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent unitRef='USD' contextRef='E12' decimals='INF'>4429945</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
	<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent unitRef='USD' contextRef='E11' decimals='INF'>3536405</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
	<fil:AllowanceForDoubtfulAccountsOnOtherReceivables unitRef='USD' contextRef='E12' decimals='INF'>49881</fil:AllowanceForDoubtfulAccountsOnOtherReceivables>
	<fil:AllowanceForDoubtfulAccountsOnOtherReceivables unitRef='USD' contextRef='E11' decimals='INF'>38921</fil:AllowanceForDoubtfulAccountsOnOtherReceivables>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment unitRef='USD' contextRef='E12' decimals='INF'>4273373</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment unitRef='USD' contextRef='E11' decimals='INF'>3391124</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization unitRef='USD' contextRef='E12' decimals='INF'>2944726</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization unitRef='USD' contextRef='E11' decimals='INF'>3041804</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:PreferredStockParOrStatedValuePerShare unitRef='UsdPerShare' contextRef='E12' decimals='INF'>0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare unitRef='UsdPerShare' contextRef='E11' decimals='INF'>0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized unitRef='Shares' contextRef='E12' decimals='INF'>5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized unitRef='Shares' contextRef='E11' decimals='INF'>5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued unitRef='Shares' contextRef='E12' decimals='INF'>0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued unitRef='Shares' contextRef='E11' decimals='INF'>0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding unitRef='Shares' contextRef='E12' decimals='INF'>0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding unitRef='Shares' contextRef='E11' decimals='INF'>0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:CommonStockParOrStatedValuePerShare unitRef='UsdPerShare' contextRef='E12' decimals='INF'>0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare unitRef='UsdPerShare' contextRef='E11' decimals='INF'>0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized unitRef='Shares' contextRef='E12' decimals='INF'>95000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized unitRef='Shares' contextRef='E11' decimals='INF'>95000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued unitRef='Shares' contextRef='E12' decimals='INF'>43579557</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued unitRef='Shares' contextRef='E11' decimals='INF'>43529557</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding unitRef='Shares' contextRef='E12' decimals='INF'>43579557</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding unitRef='Shares' contextRef='E11' decimals='INF'>43529557</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:Revenues unitRef='USD' contextRef='Y12' decimals='INF'>54507049</us-gaap:Revenues>
	<us-gaap:Revenues unitRef='USD' contextRef='Y11' decimals='INF'>81166739</us-gaap:Revenues>
	<us-gaap:CostOfRevenue unitRef='USD' contextRef='Y12' decimals='INF'>38660814</us-gaap:CostOfRevenue>
	<us-gaap:CostOfRevenue unitRef='USD' contextRef='Y11' decimals='INF'>52178680</us-gaap:CostOfRevenue>
	<us-gaap:InventoryWriteDown unitRef='USD' contextRef='Y12' decimals='INF'>1769984</us-gaap:InventoryWriteDown>
	<us-gaap:InventoryWriteDown unitRef='USD' contextRef='Y11' decimals='INF'>0</us-gaap:InventoryWriteDown>
	<us-gaap:GrossProfit unitRef='USD' contextRef='Y12' decimals='INF'>14076251</us-gaap:GrossProfit>
	<us-gaap:GrossProfit unitRef='USD' contextRef='Y11' decimals='INF'>28988059</us-gaap:GrossProfit>
	<us-gaap:SellingExpense unitRef='USD' contextRef='Y12' decimals='INF'>3535214</us-gaap:SellingExpense>
	<us-gaap:SellingExpense unitRef='USD' contextRef='Y11' decimals='INF'>3439522</us-gaap:SellingExpense>
	<us-gaap:GeneralAndAdministrativeExpense unitRef='USD' contextRef='Y12' decimals='INF'>3313306</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense unitRef='USD' contextRef='Y11' decimals='INF'>3716397</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:ProvisionForDoubtfulAccounts unitRef='USD' contextRef='Y12' decimals='INF'>871612</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:ProvisionForDoubtfulAccounts unitRef='USD' contextRef='Y11' decimals='INF'>108085</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:GoodwillAndIntangibleAssetImpairment unitRef='USD' contextRef='Y12' decimals='INF'>593095</us-gaap:GoodwillAndIntangibleAssetImpairment>
	<us-gaap:GoodwillAndIntangibleAssetImpairment unitRef='USD' contextRef='Y11' decimals='INF'>0</us-gaap:GoodwillAndIntangibleAssetImpairment>
	<us-gaap:OperatingExpenses unitRef='USD' contextRef='Y12' decimals='INF'>8313227</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses unitRef='USD' contextRef='Y11' decimals='INF'>7264004</us-gaap:OperatingExpenses>
	<fil:GovernmentSubsidyIncome unitRef='USD' contextRef='Y12' decimals='INF'>141987</fil:GovernmentSubsidyIncome>
	<fil:GovernmentSubsidyIncome unitRef='USD' contextRef='Y11' decimals='INF'>301672</fil:GovernmentSubsidyIncome>
	<us-gaap:OperatingIncomeLoss unitRef='USD' contextRef='Y12' decimals='INF'>5905011</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss unitRef='USD' contextRef='Y11' decimals='INF'>22025727</us-gaap:OperatingIncomeLoss>
	<us-gaap:InvestmentIncomeInterest unitRef='USD' contextRef='Y12' decimals='INF'>4944</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest unitRef='USD' contextRef='Y11' decimals='INF'>7208</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InterestExpense unitRef='USD' contextRef='Y12' decimals='INF'>-308375</us-gaap:InterestExpense>
	<us-gaap:InterestExpense unitRef='USD' contextRef='Y11' decimals='INF'>-255198</us-gaap:InterestExpense>
	<us-gaap:GainLossOnSaleOfDerivatives unitRef='USD' contextRef='Y12' decimals='INF'>0</us-gaap:GainLossOnSaleOfDerivatives>
	<us-gaap:GainLossOnSaleOfDerivatives unitRef='USD' contextRef='Y11' decimals='INF'>934260</us-gaap:GainLossOnSaleOfDerivatives>
	<us-gaap:NonoperatingIncomeExpense unitRef='USD' contextRef='Y12' decimals='INF'>-303431</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense unitRef='USD' contextRef='Y11' decimals='INF'>686270</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest unitRef='USD' contextRef='Y12' decimals='INF'>5601580</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest unitRef='USD' contextRef='Y11' decimals='INF'>22711997</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeTaxExpenseBenefit unitRef='USD' contextRef='Y12' decimals='INF'>-983921</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit unitRef='USD' contextRef='Y11' decimals='INF'>-3442355</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:ProfitLoss unitRef='USD' contextRef='Y12' decimals='INF'>4617659</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss unitRef='USD' contextRef='Y11' decimals='INF'>19269642</us-gaap:ProfitLoss>
	<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease unitRef='USD' contextRef='Y12' decimals='INF'>1274091</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
	<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease unitRef='USD' contextRef='Y11' decimals='INF'>5080098</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease>
	<us-gaap:ComprehensiveIncomeNetOfTax unitRef='USD' contextRef='Y12' decimals='INF'>5891750</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax unitRef='USD' contextRef='Y11' decimals='INF'>24349740</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:EarningsPerShareBasic unitRef='UsdPerShare' contextRef='Y12' decimals='INF'>0.11</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic unitRef='UsdPerShare' contextRef='Y11' decimals='INF'>0.44</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareDiluted unitRef='UsdPerShare' contextRef='Y12' decimals='INF'>0.11</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted unitRef='UsdPerShare' contextRef='Y11' decimals='INF'>0.44</us-gaap:EarningsPerShareDiluted>
	<us-gaap:SharesOutstanding unitRef='Shares' contextRef='E10_capitalunits' decimals='INF'>43404557</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding unitRef='Shares' contextRef='E10_commonstock' decimals='INF'>43405</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding unitRef='Shares' contextRef='E10_additionalpaidincapital' decimals='INF'>23252476</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding unitRef='Shares' contextRef='E10_retainedearnings' decimals='INF'>85017024</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding unitRef='Shares' contextRef='E10_accumulatedothercomprehensiveincome' decimals='INF'>9624269</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding unitRef='Shares' contextRef='E10_parent' decimals='INF'>117937174</us-gaap:SharesOutstanding>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef='Shares' contextRef='Y11_capitalunits' decimals='INF'>0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef='Shares' contextRef='Y11_commonstock' decimals='INF'>0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef='Shares' contextRef='Y11_additionalpaidincapital' decimals='INF'>76991</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef='Shares' contextRef='Y11_retainedearnings' decimals='INF'>0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef='Shares' contextRef='Y11_accumulatedothercomprehensiveincome' decimals='INF'>0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef='Shares' contextRef='Y11_parent' decimals='INF'>76991</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<fil:IssuanceOfStockAsCompensation unitRef='Shares' contextRef='Y11_capitalunits' decimals='INF'>125000</fil:IssuanceOfStockAsCompensation>
	<fil:IssuanceOfStockAsCompensation unitRef='Shares' contextRef='Y11_commonstock' decimals='INF'>125</fil:IssuanceOfStockAsCompensation>
	<fil:IssuanceOfStockAsCompensation unitRef='Shares' contextRef='Y11_additionalpaidincapital' decimals='INF'>119067</fil:IssuanceOfStockAsCompensation>
	<fil:IssuanceOfStockAsCompensation unitRef='Shares' contextRef='Y11_retainedearnings' decimals='INF'>0</fil:IssuanceOfStockAsCompensation>
	<fil:IssuanceOfStockAsCompensation unitRef='Shares' contextRef='Y11_accumulatedothercomprehensiveincome' decimals='INF'>0</fil:IssuanceOfStockAsCompensation>
	<fil:IssuanceOfStockAsCompensation unitRef='Shares' contextRef='Y11_parent' decimals='INF'>119192</fil:IssuanceOfStockAsCompensation>
	<fil:NetIncomeForTheYear2011 unitRef='USD' contextRef='Y11_capitalunits' decimals='INF'>0</fil:NetIncomeForTheYear2011>
	<fil:NetIncomeForTheYear2011 unitRef='USD' contextRef='Y11_commonstock' decimals='INF'>0</fil:NetIncomeForTheYear2011>
	<fil:NetIncomeForTheYear2011 unitRef='USD' contextRef='Y11_additionalpaidincapital' decimals='INF'>0</fil:NetIncomeForTheYear2011>
	<fil:NetIncomeForTheYear2011 unitRef='USD' contextRef='Y11_retainedearnings' decimals='INF'>19269642</fil:NetIncomeForTheYear2011>
	<fil:NetIncomeForTheYear2011 unitRef='USD' contextRef='Y11_accumulatedothercomprehensiveincome' decimals='INF'>0</fil:NetIncomeForTheYear2011>
	<fil:NetIncomeForTheYear2011 unitRef='USD' contextRef='Y11_parent' decimals='INF'>19269642</fil:NetIncomeForTheYear2011>
	<fil:ForeignCurrencyTranslationAdjustment unitRef='USD' contextRef='Y11_capitalunits' decimals='INF'>0</fil:ForeignCurrencyTranslationAdjustment>
	<fil:ForeignCurrencyTranslationAdjustment unitRef='USD' contextRef='Y11_commonstock' decimals='INF'>0</fil:ForeignCurrencyTranslationAdjustment>
	<fil:ForeignCurrencyTranslationAdjustment unitRef='USD' contextRef='Y11_additionalpaidincapital' decimals='INF'>0</fil:ForeignCurrencyTranslationAdjustment>
	<fil:ForeignCurrencyTranslationAdjustment unitRef='USD' contextRef='Y11_retainedearnings' decimals='INF'>0</fil:ForeignCurrencyTranslationAdjustment>
	<fil:ForeignCurrencyTranslationAdjustment unitRef='USD' contextRef='Y11_accumulatedothercomprehensiveincome' decimals='INF'>5080098</fil:ForeignCurrencyTranslationAdjustment>
	<fil:ForeignCurrencyTranslationAdjustment unitRef='USD' contextRef='Y11_parent' decimals='INF'>5080098</fil:ForeignCurrencyTranslationAdjustment>
	<us-gaap:SharesOutstanding unitRef='Shares' contextRef='E11_capitalunits' decimals='INF'>43529557</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding unitRef='Shares' contextRef='E11_commonstock' decimals='INF'>43530</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding unitRef='Shares' contextRef='E11_additionalpaidincapital' decimals='INF'>23448534</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding unitRef='Shares' contextRef='E11_retainedearnings' decimals='INF'>104286666</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding unitRef='Shares' contextRef='E11_accumulatedothercomprehensiveincome' decimals='INF'>14704367</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding unitRef='Shares' contextRef='E11_parent' decimals='INF'>142483097</us-gaap:SharesOutstanding>
	<us-gaap:ShareBasedCompensation unitRef='USD' contextRef='Y12_capitalunits' decimals='INF'>100000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation unitRef='USD' contextRef='Y12_commonstock' decimals='INF'>100</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation unitRef='USD' contextRef='Y12_additionalpaidincapital' decimals='INF'>141620</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation unitRef='USD' contextRef='Y12_retainedearnings' decimals='INF'>0</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation unitRef='USD' contextRef='Y12_accumulatedothercomprehensiveincome' decimals='INF'>0</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation unitRef='USD' contextRef='Y12_parent' decimals='INF'>141720</us-gaap:ShareBasedCompensation>
	<fil:ForfeitureOfContingentlyVestingShares unitRef='Shares' contextRef='Y12_capitalunits' decimals='INF'>-50000</fil:ForfeitureOfContingentlyVestingShares>
	<fil:ForfeitureOfContingentlyVestingShares unitRef='Shares' contextRef='Y12_commonstock' decimals='INF'>-50</fil:ForfeitureOfContingentlyVestingShares>
	<fil:ForfeitureOfContingentlyVestingShares unitRef='Shares' contextRef='Y12_additionalpaidincapital' decimals='INF'>50</fil:ForfeitureOfContingentlyVestingShares>
	<fil:ForfeitureOfContingentlyVestingShares unitRef='Shares' contextRef='Y12_retainedearnings' decimals='INF'>0</fil:ForfeitureOfContingentlyVestingShares>
	<fil:ForfeitureOfContingentlyVestingShares unitRef='Shares' contextRef='Y12_accumulatedothercomprehensiveincome' decimals='INF'>0</fil:ForfeitureOfContingentlyVestingShares>
	<fil:ForfeitureOfContingentlyVestingShares unitRef='Shares' contextRef='Y12_parent' decimals='INF'>0</fil:ForfeitureOfContingentlyVestingShares>
	<fil:NetIncomeForTheYear2012 unitRef='USD' contextRef='Y12_capitalunits' decimals='INF'>0</fil:NetIncomeForTheYear2012>
	<fil:NetIncomeForTheYear2012 unitRef='USD' contextRef='Y12_commonstock' decimals='INF'>0</fil:NetIncomeForTheYear2012>
	<fil:NetIncomeForTheYear2012 unitRef='USD' contextRef='Y12_additionalpaidincapital' decimals='INF'>0</fil:NetIncomeForTheYear2012>
	<fil:NetIncomeForTheYear2012 unitRef='USD' contextRef='Y12_retainedearnings' decimals='INF'>4617659</fil:NetIncomeForTheYear2012>
	<fil:NetIncomeForTheYear2012 unitRef='USD' contextRef='Y12_accumulatedothercomprehensiveincome' decimals='INF'>0</fil:NetIncomeForTheYear2012>
	<fil:NetIncomeForTheYear2012 unitRef='USD' contextRef='Y12_parent' decimals='INF'>4617659</fil:NetIncomeForTheYear2012>
	<fil:ForeignCurrencyTranslationAdjustment1 unitRef='USD' contextRef='Y12_capitalunits' decimals='INF'>0</fil:ForeignCurrencyTranslationAdjustment1>
	<fil:ForeignCurrencyTranslationAdjustment1 unitRef='USD' contextRef='Y12_commonstock' decimals='INF'>0</fil:ForeignCurrencyTranslationAdjustment1>
	<fil:ForeignCurrencyTranslationAdjustment1 unitRef='USD' contextRef='Y12_additionalpaidincapital' decimals='INF'>0</fil:ForeignCurrencyTranslationAdjustment1>
	<fil:ForeignCurrencyTranslationAdjustment1 unitRef='USD' contextRef='Y12_retainedearnings' decimals='INF'>0</fil:ForeignCurrencyTranslationAdjustment1>
	<fil:ForeignCurrencyTranslationAdjustment1 unitRef='USD' contextRef='Y12_accumulatedothercomprehensiveincome' decimals='INF'>1274091</fil:ForeignCurrencyTranslationAdjustment1>
	<fil:ForeignCurrencyTranslationAdjustment1 unitRef='USD' contextRef='Y12_parent' decimals='INF'>1274091</fil:ForeignCurrencyTranslationAdjustment1>
	<us-gaap:SharesOutstanding unitRef='Shares' contextRef='E12_capitalunits' decimals='INF'>43579557</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding unitRef='Shares' contextRef='E12_commonstock' decimals='INF'>43580</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding unitRef='Shares' contextRef='E12_additionalpaidincapital' decimals='INF'>23590204</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding unitRef='Shares' contextRef='E12_retainedearnings' decimals='INF'>108904325</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding unitRef='Shares' contextRef='E12_accumulatedothercomprehensiveincome' decimals='INF'>15978458</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding unitRef='Shares' contextRef='E12_parent' decimals='INF'>148516567</us-gaap:SharesOutstanding>
	<dei:EntityPublicFloat unitRef='USD' contextRef='E12' decimals='INF'>0</dei:EntityPublicFloat>
	<us-gaap:InventoryNet unitRef='USD' contextRef='E12' decimals='INF'>36359516</us-gaap:InventoryNet>
	<us-gaap:InventoryNet unitRef='USD' contextRef='E11' decimals='INF'>30378658</us-gaap:InventoryNet>
	<fil:AdvancesForPurchasesOfIntangibleAssets unitRef='USD' contextRef='E12' decimals='INF'>39263977</fil:AdvancesForPurchasesOfIntangibleAssets>
	<fil:AdvancesForPurchasesOfIntangibleAssets unitRef='USD' contextRef='E11' decimals='INF'>36194494</fil:AdvancesForPurchasesOfIntangibleAssets>
	<us-gaap:NetIncomeLoss unitRef='USD' contextRef='Y12' decimals='INF'>4617659</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss unitRef='USD' contextRef='Y11' decimals='INF'>19269642</us-gaap:NetIncomeLoss>
	<us-gaap:DepreciationAndAmortization unitRef='USD' contextRef='Y12' decimals='INF'>1462771</us-gaap:DepreciationAndAmortization>
	<us-gaap:DepreciationAndAmortization unitRef='USD' contextRef='Y11' decimals='INF'>1174822</us-gaap:DepreciationAndAmortization>
	<fil:StockBasedCompensation unitRef='USD' contextRef='Y12' decimals='INF'>141720</fil:StockBasedCompensation>
	<fil:StockBasedCompensation unitRef='USD' contextRef='Y11' decimals='INF'>196183</fil:StockBasedCompensation>
	<fil:DerivativeGain unitRef='USD' contextRef='Y12' decimals='INF'>0</fil:DerivativeGain>
	<fil:DerivativeGain unitRef='USD' contextRef='Y11' decimals='INF'>-934260</fil:DerivativeGain>
	<fil:BadDebtExpenseBenefit unitRef='USD' contextRef='Y12' decimals='INF'>871613</fil:BadDebtExpenseBenefit>
	<fil:BadDebtExpenseBenefit unitRef='USD' contextRef='Y11' decimals='INF'>108085</fil:BadDebtExpenseBenefit>
	<us-gaap:ImpairmentOfIntangibleAssetsFinitelived unitRef='USD' contextRef='Y12' decimals='INF'>1769984</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
	<us-gaap:ImpairmentOfIntangibleAssetsFinitelived unitRef='USD' contextRef='Y11' decimals='INF'>0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
	<us-gaap:DeferredIncomeTaxExpenseBenefit unitRef='USD' contextRef='Y12' decimals='INF'>-430250</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit unitRef='USD' contextRef='Y11' decimals='INF'>37281</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables unitRef='USD' contextRef='Y12' decimals='INF'>-1098322</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
	<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables unitRef='USD' contextRef='Y11' decimals='INF'>-11392154</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
	<us-gaap:IncreaseDecreaseInInventories unitRef='USD' contextRef='Y12' decimals='INF'>-4702575</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories unitRef='USD' contextRef='Y11' decimals='INF'>-2925143</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInAccountsPayableTrade unitRef='USD' contextRef='Y12' decimals='INF'>-306040</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
	<us-gaap:IncreaseDecreaseInAccountsPayableTrade unitRef='USD' contextRef='Y11' decimals='INF'>-1928259</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities unitRef='USD' contextRef='Y12' decimals='INF'>246817</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities unitRef='USD' contextRef='Y11' decimals='INF'>758783</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedTaxesPayable unitRef='USD' contextRef='Y12' decimals='INF'>-683357</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedTaxesPayable unitRef='USD' contextRef='Y11' decimals='INF'>591470</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
	<us-gaap:IncreaseDecreaseInOtherAccountsPayable unitRef='USD' contextRef='Y12' decimals='INF'>744</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
	<us-gaap:IncreaseDecreaseInOtherAccountsPayable unitRef='USD' contextRef='Y11' decimals='INF'>13327</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
	<us-gaap:IncreaseDecreaseInCustomerAdvances unitRef='USD' contextRef='Y12' decimals='INF'>145201</us-gaap:IncreaseDecreaseInCustomerAdvances>
	<us-gaap:IncreaseDecreaseInCustomerAdvances unitRef='USD' contextRef='Y11' decimals='INF'>518718</us-gaap:IncreaseDecreaseInCustomerAdvances>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef='USD' contextRef='Y12' decimals='INF'>3643820</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef='USD' contextRef='Y11' decimals='INF'>5237324</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<fil:NetInvestmentInBankerSAcceptances unitRef='USD' contextRef='Y12' decimals='INF'>0</fil:NetInvestmentInBankerSAcceptances>
	<fil:NetInvestmentInBankerSAcceptances unitRef='USD' contextRef='Y11' decimals='INF'>-82149</fil:NetInvestmentInBankerSAcceptances>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment unitRef='USD' contextRef='Y12' decimals='INF'>-156878</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment unitRef='USD' contextRef='Y11' decimals='INF'>-352362</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef='USD' contextRef='Y12' decimals='INF'>-4987583</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef='USD' contextRef='Y11' decimals='INF'>-5625896</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:ProceedsFromNotesPayable unitRef='USD' contextRef='Y12' decimals='INF'>793223</us-gaap:ProceedsFromNotesPayable>
	<us-gaap:ProceedsFromNotesPayable unitRef='USD' contextRef='Y11' decimals='INF'>0</us-gaap:ProceedsFromNotesPayable>
	<us-gaap:ProceedsFromRelatedPartyDebt unitRef='USD' contextRef='Y12' decimals='INF'>493004</us-gaap:ProceedsFromRelatedPartyDebt>
	<us-gaap:ProceedsFromRelatedPartyDebt unitRef='USD' contextRef='Y11' decimals='INF'>595670</us-gaap:ProceedsFromRelatedPartyDebt>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef='USD' contextRef='Y12' decimals='INF'>1286227</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef='USD' contextRef='Y11' decimals='INF'>595670</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents unitRef='USD' contextRef='Y12' decimals='INF'>36390</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents unitRef='USD' contextRef='Y11' decimals='INF'>151670</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease unitRef='USD' contextRef='Y12' decimals='INF'>-21146</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease unitRef='USD' contextRef='Y11' decimals='INF'>358768</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef='USD' contextRef='E11' decimals='INF'>4050854</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef='USD' contextRef='E10' decimals='INF'>3692086</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef='USD' contextRef='E12' decimals='INF'>4029708</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:InterestPaid unitRef='USD' contextRef='Y12' decimals='INF'>298433</us-gaap:InterestPaid>
	<us-gaap:InterestPaid unitRef='USD' contextRef='Y11' decimals='INF'>248018</us-gaap:InterestPaid>
	<us-gaap:IncomeTaxesPaidNet unitRef='USD' contextRef='Y12' decimals='INF'>2138853</us-gaap:IncomeTaxesPaidNet>
	<us-gaap:IncomeTaxesPaidNet unitRef='USD' contextRef='Y11' decimals='INF'>4532592</us-gaap:IncomeTaxesPaidNet>
	<fil:AccountsPayableForPurchasesOfPropertyAndEquipment unitRef='USD' contextRef='Y12' decimals='INF'>151731</fil:AccountsPayableForPurchasesOfPropertyAndEquipment>
	<fil:AccountsPayableForPurchasesOfPropertyAndEquipment unitRef='USD' contextRef='Y11' decimals='INF'>143151</fil:AccountsPayableForPurchasesOfPropertyAndEquipment>
	<fil:AccountsReceivableCollectedWithBankerSAcceptances unitRef='USD' contextRef='Y12' decimals='INF'>4354825</fil:AccountsReceivableCollectedWithBankerSAcceptances>
	<fil:AccountsReceivableCollectedWithBankerSAcceptances unitRef='USD' contextRef='Y11' decimals='INF'>6102570</fil:AccountsReceivableCollectedWithBankerSAcceptances>
	<fil:InventoryPurchasedWithBankerSAcceptances unitRef='USD' contextRef='Y12' decimals='INF'>2768805</fil:InventoryPurchasedWithBankerSAcceptances>
	<fil:InventoryPurchasedWithBankerSAcceptances unitRef='USD' contextRef='Y11' decimals='INF'>6102570</fil:InventoryPurchasedWithBankerSAcceptances>
	<fil:AdvancesForPurchasesOfPropertyAndEquipmentPaidWithBankerSAcceptances unitRef='USD' contextRef='Y12' decimals='INF'>1540820</fil:AdvancesForPurchasesOfPropertyAndEquipmentPaidWithBankerSAcceptances>
	<fil:AdvancesForPurchasesOfPropertyAndEquipmentPaidWithBankerSAcceptances unitRef='USD' contextRef='Y11' decimals='INF'>0</fil:AdvancesForPurchasesOfPropertyAndEquipmentPaidWithBankerSAcceptances>
	<fil:AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances unitRef='USD' contextRef='Y12' decimals='INF'>27909</fil:AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances>
	<fil:AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances unitRef='USD' contextRef='Y11' decimals='INF'>0</fil:AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances>
	<fil:ChangesInAdvancesToSuppliers unitRef='USD' contextRef='Y12' decimals='INF'>1014760</fil:ChangesInAdvancesToSuppliers>
	<fil:ChangesInAdvancesToSuppliers unitRef='USD' contextRef='Y11' decimals='INF'>-251171</fil:ChangesInAdvancesToSuppliers>
	<fil:AdvancesForPaymentOfPurchasesOfPropertyAndEquipment unitRef='USD' contextRef='Y12' decimals='INF'>-1612670</fil:AdvancesForPaymentOfPurchasesOfPropertyAndEquipment>
	<fil:AdvancesForPaymentOfPurchasesOfPropertyAndEquipment unitRef='USD' contextRef='Y11' decimals='INF'>0</fil:AdvancesForPaymentOfPurchasesOfPropertyAndEquipment>
	<fil:AdvancesForPaymentOfPurchasesOfIntangibleAssets unitRef='USD' contextRef='Y12' decimals='INF'>-3218035</fil:AdvancesForPaymentOfPurchasesOfIntangibleAssets>
	<fil:AdvancesForPaymentOfPurchasesOfIntangibleAssets unitRef='USD' contextRef='Y11' decimals='INF'>-5191385</fil:AdvancesForPaymentOfPurchasesOfIntangibleAssets>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill unitRef='USD' contextRef='Y12' decimals='INF'>593095</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill unitRef='USD' contextRef='Y11' decimals='INF'>0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:&quot;&gt;&lt;b&gt;NOTE 1 &amp;#150; ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Organization and Nature of Operations&lt;/b&gt; &amp;#150; China Pharma Holdings, Inc., a Nevada corporation as of December 31, 2012, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, that in turn owns 100% of Hainan Helpson Medical &amp;amp; Biotechnology Co., Ltd (Helpson), a company organized under the laws of the People&apos;s Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.&amp;nbsp; &lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;On December 31, 2012, China Pharma Holdings, Inc consummated a reincorporation merger for the purpose of changing the state of incorporation from Delaware to Nevada pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012.&amp;nbsp; The reincorporation merger was approved by stockholders holding the majority of the outstanding common shares on December 21, 2012.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;The Foreign Investment Industrial Catalogue&amp;nbsp;(the &amp;#147;Catalogue&amp;#148;) jointly issued by the China&amp;#146;s Ministry of Commerce and the National Development and Reform Commission (as the latest version is the year 2012 version, effective January 30, 2012) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the &amp;#147;FIE&amp;#148;) shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case of the Company&amp;#146;s business.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson&amp;#146;s business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson from Helpson&amp;#146;s three former shareholders on May 25, 2005 by entry into an Equity Transfer Agreement with such three parties on May 25, 2005. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;The Company has and continues to acquire well-accepted medical formulas to a diverse portfolio of Western and Chinese medicines.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Consolidation and Basis of Presentation&lt;/b&gt; &amp;#150; The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Helpson&amp;#146;s functional currency is the Chinese Renminbi. Helpson&amp;#146;s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson&amp;#146;s financial statements are included in accumulated other comprehensive income, which is a component of stockholders&amp;#146; equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Reclassification &lt;/b&gt;- The Company has made certain reclassifications to the consolidated balance sheet at December 31, 2011 to conform to the December 31, 2012 presentation. These reclassifications had no effect on the consolidated statements of operations or cash flows for any periods presented.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Accounting Estimates&lt;/b&gt; - The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the management of the Company (&amp;#147;Management&amp;#148;) to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt; &amp;#150; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker&amp;#146;s acceptances purchased with maturities of three months or less. &lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Trade Accounts Receivable and Allowance for Doubtful Accounts&lt;/b&gt; &amp;#150; Trade accounts receivables are carried at original invoiced amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts and an estimation of the overall economic conditions affecting the Company&apos;s customer base. The Company reviews a customer&apos;s credit history before extending credit. If the financial condition of its customers were to deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable to the extent they are considered unlikely to be collected. It is common practice in the PRC for receivables to extend beyond one year. Customer balances outstanding for more than one year are allowed for at a greater rate when calculating the allowance for doubtful accounts. At December 31, 2012, trade accounts receivables included $30,134,909 from sales that occurred more than one year prior to December 31, 2012, that Management believes are collectable.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Advances to Suppliers and Advances from Customers&lt;/b&gt; &amp;#150; Common practice in the PRC is to make advances to suppliers for materials and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances received from customers are applied against trade accounts receivable when finished products are sold.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Inventory &lt;/b&gt;&amp;#150; Inventory is stated at the lower of cost or net realizable value, computed on an average cost basis. An allowance for inventory obsolescence is provided when the market value of inventory items is lower than its cost.&amp;nbsp; The Company recognized an inventory obsolescence reserve of $1,769,984 and $0 for the years ended December 31, 2012 and 2011, respectively.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Valuation of Long-Lived Assets&lt;/b&gt; &amp;#150; The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash flows estimated to be generated by the asset. The Company evaluated its long-lived assets at December 31, 2012 and determined that the value of certain of its intangible assets were impaired and recognized an impairment loss of $593,095 for the year ended December 31, 2012. No impairment was recognized during the year ended December 31, 2011.&amp;nbsp; See Note 4.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Property and Equipment&lt;/b&gt; &amp;#150; Property and equipment are stated at cost. Maintenance and repairs are charged to expense as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt; &amp;#150; Revenue is considered earned when the Company has persuasive evidence of an arrangement with the customer, delivery of the products has occurred, the sales price is fixed or determinable, and collectability is reasonably assured. Delivery does not occur until products have been shipped to the customer, risk of loss has transferred to the customer and customer acceptance has been obtained, customer acceptance provisions have lapsed, or the Company has objective evidence that the criteria specified in the customer acceptance provisions have been satisfied. The sales price is not considered to be fixed or determinable until all contingencies related to the sale have been resolved.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Cost of Revenues&lt;/b&gt; &amp;#150; Cost of revenues includes wages, materials, handling charges, and other expenses associated with the manufacture and delivery of products.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Research and Development&lt;/b&gt; &amp;#150; Research and development expenditures are recorded as expenses in the period in which they occur. Research and development costs were not material during the years ended December 31, 2012 and 2011.&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Retirement Benefit Plans&lt;/b&gt; &amp;#150; The Company is required to make monthly contributions at prescribed rates to various employee retirement benefit plans organized by provincial governments. The governments benefit plans assume the retirement benefit obligations of all existing and future retired employees of the Company. The Company contributed $233,846 and $166,071 to retirement benefit plans for the years ended December 31, 2012 and 2011, respectively. Contributions to these plans are charged to expense as incurred.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Advertising Costs&lt;/b&gt; &amp;#150; Advertising costs are expensed when incurred. The Company did not incur any advertising costs for the years ended December 31, 2012 and 2011.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Basic and Diluted Earnings per Common Share&lt;/b&gt; - Basic earnings per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per share are calculated to give effect to potentially issuable dilutive common shares.&lt;/p&gt; &lt;table width=&quot;493&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:370pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;152&quot; colspan=&quot;3&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:114pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;For the Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt;&lt;/td&gt; &lt;td width=&quot;152&quot; colspan=&quot;3&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:114pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Net income&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$ 4,617,659 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$ 19,269,642 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Basic weighted-average common shares outstanding&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;43,579,557 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;43,479,899 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Effect of dilutive securities:&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt&quot;&gt;Warrants&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&amp;nbsp; &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt&quot;&gt;Options&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&amp;nbsp; &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:19.5pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:19.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Diluted weighted-average common shares outstanding&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:19.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;43,579,557 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:19.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:19.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;43,479,899 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:0.25in&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Basic earnings per share&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 0.11 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 0.44 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:0.25in&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Diluted earnings per share&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 0.11 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;0.44 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Potential common shares were not included in the computation of diluted earnings per share as their effect would have been anti-dilutive as follows:&lt;/p&gt; &lt;table width=&quot;493&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:370pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;152&quot; colspan=&quot;3&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:114pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;For the Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;152&quot; colspan=&quot;3&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:114pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Warrants with exercise prices of $3.00 to $3.80 per share&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 150,000 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 150,000 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Options with an exercise price of $2.54 to $3.47 per share&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 50,000 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 310,000 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.5pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt&quot;&gt;Total&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 200,000 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 460,000 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Credit Risk &lt;/b&gt;&amp;#150; The carrying amounts of accounts receivable included in the balance sheet represent the Company&apos;s exposure to credit risk in relation to its financial assets. No other financial assets carry a significant exposure to credit risk. The Company performs ongoing credit evaluations of each customer&apos;s financial condition. It maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded Management&apos;s estimations.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secure due to the state policy on protecting depositors&amp;#146; interests. The PRC promulgated a new Bankruptcy Law in August 2006, effective June&amp;nbsp;1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. In the event that bankruptcy laws are enacted for banks in the PRC, the Company&amp;#146;s deposits may be at a higher risk of loss.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Interest Rate Risk&lt;/b&gt; &amp;#150; The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and viability of securing future debt instruments within the PRC.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Recently Announced Accounting Standards&lt;/b&gt; &amp;#150; The Financial Accounting Standards Board (&amp;#147;FASB&amp;#148;) issued Accounting Standards Update (&amp;#147;ASU&amp;#148;) 2011-05, Presentation of Comprehensive Income, which revises the manner in which comprehensive income is presented in an entity&amp;#146;s financial statements. This update requires the presentation of the components of comprehensive income in either a continuous statement of comprehensive income or in two separate but consecutive financial statements. The option to present comprehensive income in the statement of stockholders&amp;#146; equity has been eliminated. The provisions of this update were effective as of January 1, 2012, and the Company has included a continuous consolidated statement of comprehensive income as part of these consolidated financial statements.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;ASU 2011-04, Fair Value Measurement &amp;#150; Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS, provides converged guidance on how to measure fair value, which is largely consistent with existing U.S. GAAP. This update also requires additional fair value measurement disclosures. The provisions of this update were effective as of January 1, 2012. The effects of adoption were not significant to the accompanying consolidated financial statements.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;ASU No. 2012-02, Testing Indefinite-Lived Intangible Assets for Impairment, permits, but does not require, an entity to conduct an initial qualitative assessment to determine whether it is more likely than not that a non-goodwill indefinite-lived asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test currently required (i.e., comparing the asset&apos;s fair value with its carrying amount). This new standard was adopted by the Company on September 30, 2012 and had no significant effect on the accompanying consolidated financial statements.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;ASU No. 2011-11, Disclosures about Offsetting Assets and Liabilities, requires disclosures about assets and liabilities that are offset or have the potential to be offset. This new guidance will be effective for reporting periods beginning January 1, 2013, with retrospective application required. The adoption of this guidance is not expected to have a material impact on the Company&amp;#146;s results of operations or financial position. &lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:&quot;&gt;&lt;b&gt;NOTE 3 - PROPERTY AND EQUIPMENT&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Property and equipment consisted of the following:&lt;/p&gt; &lt;table width=&quot;430&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:322.4pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;&amp;nbsp;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;&amp;nbsp;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Permit of land use&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 447,013 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 442,978 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Building&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 2,419,125 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 2,397,286 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Plant, machinery and equipment&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 6,381,209 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 6,184,254 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Motor vehicle&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 147,080 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 145,300 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Office equipment&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 222,273 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 204,552 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Construction in progress&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 3,688,567 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 351,571 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; TEXT-INDENT:10.05pt; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; 13,305,267 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 9,725,941 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; (4,273,373)&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; (3,391,124)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Property and Equipment, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp; 9,031,894 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp; 6,334,817 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Construction in progress consisted of machinery, equipment, construction costs incurred in connection with the construction of a new facility and required manufacturing upgrades.&amp;nbsp; Once the machinery is in production and the the facility is in use, construction in progress is moved into plant, machinery and equipment and depreciated.&amp;nbsp; Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:&lt;/p&gt; &lt;table width=&quot;337&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:253pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;Asset&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;75&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:56pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&amp;nbsp;Life - years &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Permit of land use&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;75&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:56pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;40 - 70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Building&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;75&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:56pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;20 - 35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Plant, machinery and equipment&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;75&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:56pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Motor vehicle&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;75&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:56pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;5 - 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Office equipment&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;75&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:56pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;3-5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue. For the years ended December 31, 2012 and 2011, depreciation expense was $851,047 and $555,036, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:IntangibleAssetsDisclosureTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:&quot;&gt;&lt;b&gt;NOTE 4 - INTANGIBLE ASSETS&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Intangible assets represent the cost of medical formulas approved for production by the State Food and Drug Administration (the &amp;#147;SFDA&amp;#148;) in China. The Company did not obtain SFDA production approval for any medical formula during the year ended December 31, 2011 and no costs were reclassified from advances to intangible assets in 2011. During the year ended December 31, 2012, the Company received production approval from the SFDA for one medical formula and reclassified $507,174 from advances to intangible assets. The new medical formula is being amortized from the date SFDA approval was received over its estimated useful life of thirteen years and is not expected to have a residual value at the end of its useful life.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Approved medical formulas are amortized from the date SFDA approval is obtained over their individually identifiable estimated useful life, which are from ten to thirteen years.&amp;nbsp; It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets was $611,724 and $596,525 for the years ended December 31, 2012 and 2011, respectively, and was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of their amortization period. &lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;The Company evaluates each approved medical formula for impairment at the date of SFDA approval, when indications of impairment are present and at the date of each financial statement. The Company&amp;#146;s evaluation is based on an estimated undiscounted net cash flow model, considering currently available market data for the related drug and the Company&amp;#146;s estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. As a result of the evaluations, the Company determined that it is not likely that the carrying value of two medical formulas will be realized from future cash flows due to the failure to meet certain improved technical criteria for one formula and from pricing pressures on the other one. As a result, impairment losses relating to those intangible assets were $593,095 for the year ended December 31, 2012. No impairment losses were recognized during the year ended December 31, 2011.&amp;nbsp; &lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Intangible assets consisted solely of SFDA approved medical formulas as follows:&lt;/p&gt; &lt;table width=&quot;357&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:267.4pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;187&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:140pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;16&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;187&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:140pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;16&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;154&quot; colspan=&quot;3&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:115.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;187&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:140pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;16&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:17.1pt&quot;&gt; &lt;td width=&quot;187&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:140pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Gross carrying amount&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;16&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$ 5,357,580 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$ 6,124,475 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;187&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:140pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;16&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp; (2,944,726)&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp; (3,041,804)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:0.25in&quot;&gt; &lt;td width=&quot;187&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:140pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Net carrying amount&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;16&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$ 2,412,854 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$ 3,082,671 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;The estimated aggregate annual amortization expense for each of the next five years and thereafter is as follows:&lt;/p&gt; &lt;table width=&quot;144&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:1.5in; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;63&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;69&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;&amp;nbsp;Amount &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;63&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;2013&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;69&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp; 521,980 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;63&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;2014&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;69&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 505,653 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;63&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;2015&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;69&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 364,978 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;63&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;2016&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;69&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 318,939 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;63&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;2017&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;69&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 272,386 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;63&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;Thereafter&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;69&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 428,918 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;63&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;69&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;$ 2,412,854 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:&quot;&gt;&lt;b&gt;NOTE 6 &amp;#150; RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;During the years ended December 31, 2012 and December 31, 2011, a member of the Company&amp;#146;s board of directors advanced the Company $493,004 and $595,670, respectively. The advances bear interest at a rate of 1.0% per year.&amp;nbsp; Total interest expense of $9,942 and $7,180 was recognized for the years ended December 31, 2012 and 2011. Total advances owing to the board member were $1,354,567 and $861,563 as of December 31, 2012 and December 31, 2011, respectively, and are recorded as other payables &amp;#150; related parties on the accompanying consolidated balance sheets. &lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<fil:NotesPayableTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:&quot;&gt;&lt;b&gt;NOTE 7 &amp;#150; NOTES PAYABLE&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;On September 30, 2010, the Company entered into a revolving line of credit with a bank in the amount of RMB 25,000,000 (approximately $3.97 million). Advances on the line of credit were due one year from the date of the advance, with the note payable collateralized by certain land use rights and buildings. On October 26, 2011, the Company renewed the underlying note with the same bank.&amp;nbsp; The note bears interest at a base rate equal to the PRC&amp;#146;s floating six-month to one year rate of 6.56% plus an additional 15% of the base rate, with a resulting rate of 7.54% at December 31, 2011. Advances on the line of credit were due one year from the date of the advance and collateralized by certain land use rights and buildings. The outstanding balance due under the revolving line of credit was RMB 25,000,000 ($3,931,745) at December 31, 2011. This amount was classified as a short-term notes payable in the accompanying consolidated balance sheet at December 31, 2011. On October 18, 2012, the Company fully paid the amount due under this line of credit and on October 26, 2012, it matured and was not renewed. &lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;On October 30, 2012, the Company entered into a new revolving line of credit with another bank in the amount of RMB 30,000,000.&amp;nbsp;The related note payable bears interest at an annual rate of 6.90% (based upon 115% of the PRC government&amp;#146;s current short term rate of 6.00%). Advances on the line of credit are due one year from the date of the advance and are collateralized by certain land use rights, buildings and accounts receivable. The outstanding balance due under the revolving line of credit was RMB30,000,000 ($4,761,073) as of December 31, 2012.&amp;nbsp; The Company has no additional amounts available to it under the line of credit.&amp;nbsp; This amount has been classified as short-term notes payable in the accompanying consolidated balance sheet at December 31, 2012.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Fair Value of Notes Payable &amp;#150; Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts of notes payable outstanding at December 31, 2012 and 2011 approximated their fair value because of the immediate or short-term maturity of these financial instruments or because the underlying instruments bear interest rates that approximated current market rates.&lt;/p&gt;</fil:NotesPayableTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:&quot;&gt;&lt;b&gt;NOTE 8 - INCOME TAXES&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax laws or rates is recognized in income in the period that includes the enactment date.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Undistributed earnings of Helpson, the Company&amp;#146;s foreign subsidiary, since its acquisition, amounted to approximately $113.4 million at December 31, 2012. Those earnings, as well as the investment in Helpson of approximately $23.3 million, are considered to be indefinitely reinvested and, accordingly, no U.S. federal or state income taxes have been provided thereon. Upon distribution of those earnings in the form of dividends or otherwise, the Company would be subject to U.S. federal and state income taxes (net of an adjustment for foreign tax credits) and withholding taxes payable to the PRC. Determination of the amount of unrecognized deferred U.S. income tax liability is not practical because of the complexities associated with its hypothetical calculation; however, unrecognized foreign tax credits may be available to reduce a portion of the U.S. tax liability.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Liabilities are established for uncertain tax positions expected to be taken in income tax returns when such positions are judged to meet the &amp;#147;more-likely-than-not&amp;#148; threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax penalties are included as a component of other expenses. Through December 31, 2012, the Company has not identified any uncertain tax positions that it had taken. U.S. income tax returns for the years ended December 31, 2009 through December 31, 2012 and the Chinese income tax return for the year ended December 31, 2012 are open for possible examination. &lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;On March 16, 2007, the National People&amp;#146;s Congress of China passed the new Enterprise Income Tax Law (EIT Law) and on December 6, 2007, the State Council of China issued the Implementation Regulations for the EIT Law which took effect on January&amp;nbsp;1, 2008. The EIT Law and Implementation Regulations impose a unified EIT of 25% on all domestic-invested enterprises and Foreign Invested Entities, or FIEs, unless they qualify under certain limited exceptions.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;The Company is located in a special region, which had a 15% corporate income tax rate before the new EIT Law. The new EIT Law abolished the preferential corporate income tax rate in the special region. The Company has transitioned to the new 25% tax rate over a five year period which began on January 1, 2008. During 2010, the Company applied for and received a favorable tax rate of 15% for fiscal 2011 through 2013 due to its status in the PRC as a high technology enterprise. Under current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:&lt;/p&gt; &lt;table width=&quot;240&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:2.5in; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;96&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1in; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;25&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:19pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;119&quot; style=&quot;BORDER-BOTTOM:black 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:89pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; rowspan=&quot;2&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Enterprise Income Tax Rate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;96&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1in; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;25&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:19pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;96&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1in; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;2013&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;25&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:19pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;119&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:89pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;15%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;96&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1in; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;2014 and after&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;25&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:19pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;119&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:89pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;25%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;The provision for income taxes consisted of the following:&lt;/p&gt; &lt;table width=&quot;483&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:362pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;167&quot; colspan=&quot;3&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:125pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.55pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Current&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.55pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp; 1,414,171&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp; 3,458,568&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Deferred&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.55pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;(430,250)&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;(16,213)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Total income tax expense&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.55pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 983,921&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp; 3,442,355&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Following is a reconciliation of income taxes calculated at the federal statutory rate to the provision for income taxes:&lt;/p&gt; &lt;table width=&quot;490&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:367.4pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:18.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:18.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:18.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:18.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:18.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:18.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;174&quot; colspan=&quot;3&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:130.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;2012&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;2011&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Tax at statutory rate of 25%&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp; 1,400,395&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp; 5,677,999&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Non-deductible stock-based compensation from&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;current and prior years&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;149,644&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;261,122&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Effect of tax holiday&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;(655,947)&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;(2,330,566)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Other, primarily the effect of US tax rates&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;(70,471)&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;160,300&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;(166,200)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Income tax expense&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 983,921&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp; 3,442,355&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;The effect of the tax holiday amounted to savings of $655,947 and $2,330,566 for the years ended December 31, 2012 and 2011, which was equivalent to basic and diluted earnings per share of $0.02 and $0.05 per share for the years ended December 31, 2012 and 2011, respectively. The temporary differences which give rise to the deferred income tax assets and liability are as follows:&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table width=&quot;483&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:362.05pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;167&quot; colspan=&quot;3&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:125.05pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Deferred income tax assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Allowance for doubtful trade receivables&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 664,492 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 530,461 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Allowance for doubtful other receivables&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 7,482 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 5,838 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Inventory obsolescence reserve&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 265,498 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&amp;nbsp; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Expenses not deductible in current year&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 30,200 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 29,927 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Share based compensation&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 45,777 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 172,911 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;U.S. net operating loss carry forwards&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 905,669 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 618,236 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Total deferred income tax assets&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 1,919,118 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 1,357,373 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; (951,447)&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; (791,147)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt&quot;&gt;Net deferred income tax asset&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 967,671 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 566,226 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Deferred income tax liability:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Intangible assets&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 95,963 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 128,909 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;As of December 31, 2012, the Company has net operating losses from continuing operations for United States federal income tax purposes of $2,663,731 which are available to offset future taxable income, if any, and expire, if not used, from 2029 through 2032.&amp;nbsp; In assessing the realizability of deferred tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.&amp;nbsp; The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized.&amp;nbsp; Management considers projected future taxable income and tax planning strategies in making this assessment.&amp;nbsp; Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, Management believes it is not likely the Company will realize all of the benefits of the deferred tax assets as of December 31, 2012 and 2011.&amp;nbsp; Therefore, the Company has provided for a valuation allowance against its deferred tax assets of $951,447 and $791,147 as of December 31, 2012 and 2011, respectively.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;The Company has also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.&amp;nbsp; During 2012 and 2011, the Company received an incentive payment from the tax authority of the Hainan provincial government in the PRC totaling $141,987 and $301,672, respectively, which has been recorded as government subsidy income on the accompanying statements of operations and comprehensive income for the years ended December 31, 2012 and 2011.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:DerivativesAndFairValueTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:&quot;&gt;&lt;b&gt;NOTE 9 &amp;#150; DERIVATIVE WARRANT LIABILITY&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;On May 27, 2008 and on May 30, 2008, the Company issued warrants to purchase 1,250,000 shares of common stock at $2.80 per share and warrants to purchase 300,000 shares of common stock at $2.98 per share, respectively, exercisable for a period of three years. These warrants contained certain pricing reset provisions which caused the warrants to be treated as a derivative. These warrants were never exercised and expired on May 27, 2011. Changes to the warrant derivative liability were recognized in the results of operations and resulted in derivative gains of $0 and $934,260 for the years ended December 31, 2012 and 2011, respectively. &lt;/p&gt;</us-gaap:DerivativesAndFairValueTextBlock>
	<us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:&quot;&gt;&lt;b&gt;NOTE 10 &amp;#150; FAIR VALUE MEASUREMENTS&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 &amp;#150; Quoted prices in active markets for identical assets or liabilities. Level 2 &amp;#150; Observable inputs other than Level 1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable market data. Level 3 &amp;#150; Unobservable inputs supported by little or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. &lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;The Company uses fair value to measure the derivative warrant liability on a recurring basis because fair value is the primary measure for accounting. The Company also uses fair value to measure the value of the banker&amp;#146;s acceptance notes it holds.&amp;nbsp;&amp;nbsp;The Company values its derivative warrants using a valuation method explained above.&amp;nbsp;&amp;nbsp;The banker&amp;#146;s acceptance notes are recorded at cost which approximates fair value.&amp;nbsp;&amp;nbsp;The Company held the following assets and liabilities recorded at fair value as of December 31, 2012 and 2011: &lt;/p&gt; &lt;table width=&quot;489&quot; style=&quot;WIDTH:366.6pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;219&quot; colspan=&quot;5&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:164pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Fair Value Measurements at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;219&quot; colspan=&quot;5&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:164pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Reporting Date Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Banker&apos;s acceptance notes&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 101,570&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp; 101,570&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.5pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Total&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 101,570&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp; 101,570&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;table width=&quot;489&quot; style=&quot;WIDTH:366.6pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;219&quot; colspan=&quot;5&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:164pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Fair Value Measurements at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;219&quot; colspan=&quot;5&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:164pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Reporting Date Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Banker&apos;s acceptance notes&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 83,512 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&amp;nbsp; &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp; 83,512 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&amp;nbsp; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.5pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Total&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 83,512 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&amp;nbsp; &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp; 83,512 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&amp;nbsp; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:&quot;&gt;&lt;b&gt;NOTE 11 - STOCKHOLDERS&apos; EQUITY&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;On December 31, 2012, the domicile of China Pharma Holdings, Inc. was changed from the State of Delaware to the State of Nevada through a merger of the Delaware corporation with and into its newly set-up Nevada subsidiary, with the Nevada subsidiary being the surviving corporation. Each common share, warrant and stock option outstanding on the merger date was automatically converted into a common share, warrant or stock option of the Nevada corporation. &lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;The Company is authorized to issue 95,000,000 shares of common shares, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Company&amp;#146;s board of directors.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Warrants&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;As of December 31, 2012, the Company had warrants outstanding and exercisable to purchase an aggregate of 150,000 shares of Company&apos;s common stock at exercise prices ranging from $3.00 to $3.80 per share, which expire May 16, 2013. At December 31, 2012, the warrants had a weighted-average exercise price of $3.40 per share, a weighted-average remaining contractual life of 0.4 years and a total intrinsic value of $0.&amp;nbsp;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Employee Stock Options&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;2010 Incentive Plan&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;On November 12, 2010, the Company&amp;#146;s Board of Directors adopted, and on December 22, 2010 its stockholders approved the 2010 Long-Term Incentive Plan (the &amp;#147;2010 Incentive Plan&amp;#148;), which gave the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries. The 2010 Incentive Plan currently allows for equity awards of up to 4,000,000 shares of common stock.&amp;nbsp; Through December 31, 2012, 125,000 shares of common stock and options to purchase an aggregate of 100,000 shares of stock options had been granted under the 2010 Incentive Plan.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;On May 25, 2011 the Company issued two-year options to purchase a total of 100,000 shares of its common stock under the 2010 Incentive Plan to two of its executive officers as follows. The Company&amp;#146;s Chief Executive Officer was granted non-qualified stock options to purchase 50,000 shares of common stock at an exercise price of $2.54 per share, the closing price of the Company&amp;#146;s common stock on the day prior to the day of grant, expiring on May 25, 2013, of which 25,000 shares vested on May 25, 2012 and 25,000 shares were to vest on the three-month anniversary of the achievement of certain performance-based vesting criteria. The Company also granted its former Chief Financial Officer non-qualified stock options to purchase 50,000 shares of common stock at an exercise price of $2.54 per share, expiring on April 28, 2013, of which 25,000 shares vested on April 28, 2012 and 25,000 shares were to vest on the three-month anniversary of the achievement of certain performance-based vesting criteria.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;The grant-date fair value of the options of $0.71 per share, or $70,580 in total, was based on the grant-date closing market price of $2.54 per share and on the following weighted-average assumptions: risk free interest rate of 0.54%, expected dividend yield of 0%, expected volatility of 70.4% and an expected life of 1.0 year. The share-based compensation expense relative to the fixed stock options was recognized over the period the options vested. Share-based compensation relative to the performance-based options will be recognized only if the performance criterion is met. &lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;In addition, on May 25, 2011 the Company granted 125,000 shares of common stock under the 2010 Incentive Plan to two of its executive officers valued at $317,500 based on the closing market price on the date of grant of $2.54 per share. Specifically, the Company granted 75,000 shares of restricted stock to its Chief Executive Officer, of which 50,000 shares vested on May 25, 2012, and 25,000 shares were to vest on the six-month anniversary of the achievement of certain performance-based vesting criteria, and the Company granted 50,000 shares of restricted stock to its former Chief Financial Officer, of which 25,000 shares vested on April 28, 2012 and 25,000 shares were to vest on the six-month anniversary of the achievement of certain performance-based vesting criteria. The performance criterion was not met and the performance-based shares were forfeited during the year ended December 31, 2012. The share-based compensation related to the fixed share awards was recognized over the period the shares vested.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Effective April 28, 2012, the Company and Frank Waung, its former Chief Financial Officer, entered into an Amendment Agreement to Non-Qualified Stock Option Agreements to amend the terms of the equity awards previously granted to Mr. Waung in conjunction with the termination of his employment agreement with the Company effective April 29, 2012.&amp;nbsp;&amp;nbsp;The effect of the amendment was to terminate a total of 185,000 vested but unexercised options immediately on April 28, 2012 as opposed to 90 days after the employment termination date. Effective the same date, the Company awarded 100,000 shares of common stock to Mr. Waung for his previous service to the Company.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Accordingly, the Company recorded a total of $55,775 of stock compensation expense based upon the excess of the fair value of the common stock issued in exchange for the options that were cancelled, i.e., 185,000 options with a fair value of $225 in exchange for 100,000 shares of common stock with a fair value of $56,000 based on the closing market price of the common stock of $0.56 per share on the date awarded. The fair value of the stock options was computed using the Black-Scholes Option Pricing Model, using the following assumptions: risk free interest rate of 0.14% to 0.19%, expected dividend yield of 0%, expected volatility of 66.7% and an expected life of 0.5 to 1.1 years. &lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;On April 27 and 28, 2012 a total of 50,000 options to purchase common stock granted under the 2010 Incentive Plan with an exercise price of $2.54 per share were forfeited due to the failure to achieve the performance-based vesting criteria. &lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;The Company recognized $141,720 and $196,183 of compensation expense during the years ended December 31, 2012 and 2011, respectively, as general and administrative expenses related to the awards of common shares and grants and modifications of stock options. The total income tax benefit recognized from the related stock-based compensation was $35,430 and $49,046 for the years ended December 31, 2012 and 2011, respectively. &amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model using the assumptions noted in the preceding paragraphs. Expected volatility is based on the historical volatility of the Company&amp;#146;s common stock prices. The Company uses historical data to estimate employee termination rates. The expected term of options granted is determined by the simplified method, which is one-half of the original contractual term. The simplified method is used due to the lack of historical share option exercise data to provide a reasonable basis upon which to estimate expected term. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. &lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;A summary of stock option activity as of December 31, 2012, and changes during the year then ended is presented below:&lt;/p&gt; &lt;table width=&quot;542&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:406.2pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;227&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;68&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;64&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;227&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;68&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;64&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;227&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;68&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;64&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;227&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;68&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;64&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Contractual &lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;227&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;68&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;64&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Term (Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td width=&quot;227&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Outstanding at December 31, 2011&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;68&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 310,000 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;64&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 3.03 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td width=&quot;227&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt&quot;&gt;Forfeited&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;68&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; (50,000)&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;64&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 2.54 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td width=&quot;227&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt&quot;&gt;Expired&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;68&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; (235,000)&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;64&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 3.19 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td width=&quot;227&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Outstanding at December 31, 2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;68&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 25,000 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;64&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 2.54 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 0.40 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&amp;nbsp; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td width=&quot;227&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Exercisable at December 31, 2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;68&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 25,000 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;64&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 2.54 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 0.40 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&amp;nbsp; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;At December 31, 2012, there was no remaining unrecognized compensation expense related to the fixed stock options. The unrecognized performance-based compensation expense related to performance-based options was $17,645, but will only be recognized if the performance criterion is met. There was no remaining unrecognized compensation expense related to restrictive stock awards at December 31, 2012.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:&quot;&gt;&lt;b&gt;NOTE 12 &amp;#150; COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Economic environment - Substantially all of the Company&apos;s operations are conducted in the PRC, and therefore the Company is subject to special considerations and significant risks not typically associated with companies operating in the United States of America. These risks include, among others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The Company&apos;s results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely affect the Company&amp;#146;s operations.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;In addition, all of the Company&apos;s revenue is denominated in the PRC&apos;s currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Contractual Commitments &amp;#150; The Company entered into purchase and construction agreements during the year ended December 31, 2012 in connection with the construction of a new facility and required manufacturing improvements. &amp;nbsp;Under these agreements, the Company made payments in the amount of $3,110,319 during the year ended December 31, 2012. These payments are classified as construction in progress on the accompanying balance sheet at December 31, 2012. Future minimum commitments under the agreements are as follows:&lt;/p&gt; &lt;table width=&quot;341&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:256pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td width=&quot;255&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:191pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;For the Years Ending December 31:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;87&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td width=&quot;255&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:191pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; TEXT-INDENT:11pt; MARGIN:0in 0in 0pt&quot;&gt;2013&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;87&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$ 13,133,498 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td width=&quot;255&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:191pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; TEXT-INDENT:11pt; MARGIN:0in 0in 0pt&quot;&gt;2014&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;87&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 968,860 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td width=&quot;255&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:191pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; TEXT-INDENT:11pt; MARGIN:0in 0in 0pt&quot;&gt;Total&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;87&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$ 14,102,358 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td width=&quot;255&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:191pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;87&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ConcentrationRiskDisclosureTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:&quot;&gt;&lt;b&gt;NOTE 13 &amp;#150; CONCENTRATIONS&lt;/b&gt;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;For the year ended December 31, 2011, a customer accounted for 20.4% of sales and at December 31, 2011, one customer accounted for 10.2% of accounts receivable. For the year ended December 31, 2011, purchases from a supplier made up 20.8% of raw material purchases. &lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:&quot;&gt;&lt;font style=&quot;LINE-HEIGHT:115%&quot;&gt;For the year ended December 31, 2012, no customer accounted for more than 10% of sales or ending accounts receivable. Two suppliers accounted for 12.1% and 10.3%, respectively, of the raw materials &amp;nbsp;the Company purchased during the year ended December 31, 2012.&lt;/font&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
	<us-gaap:NatureOfOperations contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Organization and Nature of Operations&lt;/b&gt; &amp;#150; China Pharma Holdings, Inc., a Nevada corporation as of December 31, 2012, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, that in turn owns 100% of Hainan Helpson Medical &amp;amp; Biotechnology Co., Ltd (Helpson), a company organized under the laws of the People&apos;s Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.&amp;nbsp; &lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;On December 31, 2012, China Pharma Holdings, Inc consummated a reincorporation merger for the purpose of changing the state of incorporation from Delaware to Nevada pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012.&amp;nbsp; The reincorporation merger was approved by stockholders holding the majority of the outstanding common shares on December 21, 2012.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;The Foreign Investment Industrial Catalogue&amp;nbsp;(the &amp;#147;Catalogue&amp;#148;) jointly issued by the China&amp;#146;s Ministry of Commerce and the National Development and Reform Commission (as the latest version is the year 2012 version, effective January 30, 2012) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the &amp;#147;FIE&amp;#148;) shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case of the Company&amp;#146;s business.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson&amp;#146;s business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson from Helpson&amp;#146;s three former shareholders on May 25, 2005 by entry into an Equity Transfer Agreement with such three parties on May 25, 2005. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;The Company has and continues to acquire well-accepted medical formulas to a diverse portfolio of Western and Chinese medicines.&lt;/p&gt;</us-gaap:NatureOfOperations>
	<us-gaap:ConsolidationPolicyTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Consolidation and Basis of Presentation&lt;/b&gt; &amp;#150; The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Helpson&amp;#146;s functional currency is the Chinese Renminbi. Helpson&amp;#146;s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson&amp;#146;s financial statements are included in accumulated other comprehensive income, which is a component of stockholders&amp;#146; equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:Reclassifications contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Reclassification &lt;/b&gt;- The Company has made certain reclassifications to the consolidated balance sheet at December 31, 2011 to conform to the December 31, 2012 presentation. These reclassifications had no effect on the consolidated statements of operations or cash flows for any periods presented.&lt;/p&gt;</us-gaap:Reclassifications>
	<us-gaap:UseOfEstimates contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Accounting Estimates&lt;/b&gt; - The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the management of the Company (&amp;#147;Management&amp;#148;) to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt; &amp;#150; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker&amp;#146;s acceptances purchased with maturities of three months or less. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:ReceivablesPolicyTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Trade Accounts Receivable and Allowance for Doubtful Accounts&lt;/b&gt; &amp;#150; Trade accounts receivables are carried at original invoiced amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts and an estimation of the overall economic conditions affecting the Company&apos;s customer base. The Company reviews a customer&apos;s credit history before extending credit. If the financial condition of its customers were to deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable to the extent they are considered unlikely to be collected. It is common practice in the PRC for receivables to extend beyond one year. Customer balances outstanding for more than one year are allowed for at a greater rate when calculating the allowance for doubtful accounts. At December 31, 2012, trade accounts receivables included $30,134,909 from sales that occurred more than one year prior to December 31, 2012, that Management believes are collectable.&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
	<us-gaap:SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Advances to Suppliers and Advances from Customers&lt;/b&gt; &amp;#150; Common practice in the PRC is to make advances to suppliers for materials and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances received from customers are applied against trade accounts receivable when finished products are sold.&lt;/p&gt;</us-gaap:SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock>
	<us-gaap:InventoryPolicyTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Inventory &lt;/b&gt;&amp;#150; Inventory is stated at the lower of cost or net realizable value, computed on an average cost basis. An allowance for inventory obsolescence is provided when the market value of inventory items is lower than its cost.&amp;nbsp; The Company recognized an inventory obsolescence reserve of $1,769,984 and $0 for the years ended December 31, 2012 and 2011, respectively.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
	<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Valuation of Long-Lived Assets&lt;/b&gt; &amp;#150; The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash flows estimated to be generated by the asset. The Company evaluated its long-lived assets at December 31, 2012 and determined that the value of certain of its intangible assets were impaired and recognized an impairment loss of $593,095 for the year ended December 31, 2012. No impairment was recognized during the year ended December 31, 2011.&amp;nbsp; See Note 4.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Property and Equipment&lt;/b&gt; &amp;#150; Property and equipment are stated at cost. Maintenance and repairs are charged to expense as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt; &amp;#150; Revenue is considered earned when the Company has persuasive evidence of an arrangement with the customer, delivery of the products has occurred, the sales price is fixed or determinable, and collectability is reasonably assured. Delivery does not occur until products have been shipped to the customer, risk of loss has transferred to the customer and customer acceptance has been obtained, customer acceptance provisions have lapsed, or the Company has objective evidence that the criteria specified in the customer acceptance provisions have been satisfied. The sales price is not considered to be fixed or determinable until all contingencies related to the sale have been resolved.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:CostOfSalesPolicyTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Cost of Revenues&lt;/b&gt; &amp;#150; Cost of revenues includes wages, materials, handling charges, and other expenses associated with the manufacture and delivery of products.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Research and Development&lt;/b&gt; &amp;#150; Research and development expenditures are recorded as expenses in the period in which they occur. Research and development costs were not material during the years ended December 31, 2012 and 2011.&amp;nbsp;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Retirement Benefit Plans&lt;/b&gt; &amp;#150; The Company is required to make monthly contributions at prescribed rates to various employee retirement benefit plans organized by provincial governments. The governments benefit plans assume the retirement benefit obligations of all existing and future retired employees of the Company. The Company contributed $233,846 and $166,071 to retirement benefit plans for the years ended December 31, 2012 and 2011, respectively. Contributions to these plans are charged to expense as incurred.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
	<us-gaap:AdvertisingCostsPolicyTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Advertising Costs&lt;/b&gt; &amp;#150; Advertising costs are expensed when incurred. The Company did not incur any advertising costs for the years ended December 31, 2012 and 2011.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Basic and Diluted Earnings per Common Share&lt;/b&gt; - Basic earnings per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per share are calculated to give effect to potentially issuable dilutive common shares.&lt;/p&gt; &lt;table width=&quot;493&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:370pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;152&quot; colspan=&quot;3&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:114pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;For the Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt;&lt;/td&gt; &lt;td width=&quot;152&quot; colspan=&quot;3&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:114pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Net income&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$ 4,617,659 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$ 19,269,642 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Basic weighted-average common shares outstanding&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;43,579,557 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;43,479,899 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Effect of dilutive securities:&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt&quot;&gt;Warrants&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&amp;nbsp; &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt&quot;&gt;Options&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&amp;nbsp; &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:19.5pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:19.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Diluted weighted-average common shares outstanding&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:19.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;43,579,557 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:19.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:19.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;43,479,899 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:0.25in&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Basic earnings per share&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 0.11 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 0.44 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:0.25in&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Diluted earnings per share&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 0.11 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;0.44 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Potential common shares were not included in the computation of diluted earnings per share as their effect would have been anti-dilutive as follows:&lt;/p&gt; &lt;table width=&quot;493&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:370pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;152&quot; colspan=&quot;3&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:114pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;For the Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;152&quot; colspan=&quot;3&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:114pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Warrants with exercise prices of $3.00 to $3.80 per share&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 150,000 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 150,000 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Options with an exercise price of $2.54 to $3.47 per share&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 50,000 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 310,000 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.5pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt&quot;&gt;Total&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 200,000 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 460,000 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:ScheduleOfCreditLossesRelatedToFinancingReceivablesCurrentAndNoncurrentTableTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Credit Risk &lt;/b&gt;&amp;#150; The carrying amounts of accounts receivable included in the balance sheet represent the Company&apos;s exposure to credit risk in relation to its financial assets. No other financial assets carry a significant exposure to credit risk. The Company performs ongoing credit evaluations of each customer&apos;s financial condition. It maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded Management&apos;s estimations.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secure due to the state policy on protecting depositors&amp;#146; interests. The PRC promulgated a new Bankruptcy Law in August 2006, effective June&amp;nbsp;1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. In the event that bankruptcy laws are enacted for banks in the PRC, the Company&amp;#146;s deposits may be at a higher risk of loss.&lt;/p&gt;</us-gaap:ScheduleOfCreditLossesRelatedToFinancingReceivablesCurrentAndNoncurrentTableTextBlock>
	<us-gaap:FinancingReceivableCreditQualityIndicatorsTableTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Interest Rate Risk&lt;/b&gt; &amp;#150; The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and viability of securing future debt instruments within the PRC.&lt;/p&gt;</us-gaap:FinancingReceivableCreditQualityIndicatorsTableTextBlock>
	<us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Recently Announced Accounting Standards&lt;/b&gt; &amp;#150; The Financial Accounting Standards Board (&amp;#147;FASB&amp;#148;) issued Accounting Standards Update (&amp;#147;ASU&amp;#148;) 2011-05, Presentation of Comprehensive Income, which revises the manner in which comprehensive income is presented in an entity&amp;#146;s financial statements. This update requires the presentation of the components of comprehensive income in either a continuous statement of comprehensive income or in two separate but consecutive financial statements. The option to present comprehensive income in the statement of stockholders&amp;#146; equity has been eliminated. The provisions of this update were effective as of January 1, 2012, and the Company has included a continuous consolidated statement of comprehensive income as part of these consolidated financial statements.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;ASU 2011-04, Fair Value Measurement &amp;#150; Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS, provides converged guidance on how to measure fair value, which is largely consistent with existing U.S. GAAP. This update also requires additional fair value measurement disclosures. The provisions of this update were effective as of January 1, 2012. The effects of adoption were not significant to the accompanying consolidated financial statements.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;ASU No. 2012-02, Testing Indefinite-Lived Intangible Assets for Impairment, permits, but does not require, an entity to conduct an initial qualitative assessment to determine whether it is more likely than not that a non-goodwill indefinite-lived asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test currently required (i.e., comparing the asset&apos;s fair value with its carrying amount). This new standard was adopted by the Company on September 30, 2012 and had no significant effect on the accompanying consolidated financial statements.&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;ASU No. 2011-11, Disclosures about Offsetting Assets and Liabilities, requires disclosures about assets and liabilities that are offset or have the potential to be offset. This new guidance will be effective for reporting periods beginning January 1, 2013, with retrospective application required. The adoption of this guidance is not expected to have a material impact on the Company&amp;#146;s results of operations or financial position. &lt;/p&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Diluted earnings per share are calculated to give effect to potentially issuable dilutive common shares.&lt;/p&gt; &lt;table width=&quot;493&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:370pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;152&quot; colspan=&quot;3&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:114pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;For the Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt;&lt;/td&gt; &lt;td width=&quot;152&quot; colspan=&quot;3&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:114pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Net income&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$ 4,617,659 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$ 19,269,642 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Basic weighted-average common shares outstanding&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;43,579,557 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;43,479,899 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Effect of dilutive securities:&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt&quot;&gt;Warrants&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&amp;nbsp; &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt&quot;&gt;Options&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&amp;nbsp; &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;top&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:19.5pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:19.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Diluted weighted-average common shares outstanding&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:19.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;43,579,557 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:19.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:19.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;43,479,899 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:0.25in&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Basic earnings per share&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 0.11 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 0.44 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:0.25in&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Diluted earnings per share&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 0.11 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 0.44 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<fil:PotentialCommonSharesWereNotIncludedInTheComputationOfDilutedEarningsPerShareTableTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Potential common shares were not included in the computation of diluted earnings per share as their effect would have been anti-dilutive as follows:&lt;/p&gt; &lt;table width=&quot;493&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:370pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;152&quot; colspan=&quot;3&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:114pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;For the Years Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;152&quot; colspan=&quot;3&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:114pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Warrants with exercise prices of $3.00 to $3.80 per share&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 150,000 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 150,000 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Options with an exercise price of $2.54 to $3.47 per share&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 50,000 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 310,000 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.5pt&quot;&gt; &lt;td width=&quot;341&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt&quot;&gt;Total&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 200,000 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 460,000 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fil:PotentialCommonSharesWereNotIncludedInTheComputationOfDilutedEarningsPerShareTableTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Inventory consisted of the following:&lt;/p&gt; &lt;table width=&quot;445&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:333.7pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;88&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;11&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;83&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;94&quot; colspan=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:70.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;&amp;nbsp;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;11&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;89&quot; colspan=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:67pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;&amp;nbsp;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;88&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;11&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;83&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Raw materials&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;88&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp; 30,198,816 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;11&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;83&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp; 24,920,825 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Finished goods&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;88&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 7,930,684 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;11&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;83&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 5,457,833 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;88&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 38,129,500 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;11&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;83&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp; &amp;nbsp;&amp;nbsp;&amp;nbsp;30,378,658 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Allowance for obsolescence - raw materials&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;88&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; (1,769,984)&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;11&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;83&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&amp;nbsp; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Total inventory&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;88&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp; 36,359,516 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;11&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;7&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;83&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp; 30,378,658 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Property and equipment consisted of the following:&lt;/p&gt; &lt;table width=&quot;430&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:322.4pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;&amp;nbsp;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;&amp;nbsp;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Permit of land use&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 447,013 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 442,978 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Building&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 2,419,125 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 2,397,286 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Plant, machinery and equipment&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 6,381,209 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 6,184,254 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Motor vehicle&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 147,080 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 145,300 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Office equipment&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 222,273 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 204,552 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Construction in progress&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 3,688,567 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 351,571 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; TEXT-INDENT:10.05pt; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; 13,305,267 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 9,725,941 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; (4,273,373)&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; (3,391,124)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Property and Equipment, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp; 9,031,894 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;78&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp; 6,334,817 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<fil:UsefulLivesOfTheAssetsTableTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:&lt;/p&gt; &lt;table width=&quot;337&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:253pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;Asset&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;75&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:56pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&amp;nbsp;Life - years &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Permit of land use&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;75&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:56pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;40 - 70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Building&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;75&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:56pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;20 - 35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Plant, machinery and equipment&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;75&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:56pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Motor vehicle&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;75&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:56pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;5 - 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;251&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Office equipment&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;75&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:56pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;3-5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fil:UsefulLivesOfTheAssetsTableTextBlock>
	<fil:IntangibleAssetsMedicalFormulasTablesTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Intangible assets consisted solely of SFDA approved medical formulas as follows:&lt;/p&gt; &lt;table width=&quot;357&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:267.4pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;187&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:140pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;16&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;187&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:140pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;16&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;154&quot; colspan=&quot;3&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:115.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;187&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:140pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;16&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:17.1pt&quot;&gt; &lt;td width=&quot;187&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:140pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Gross carrying amount&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;16&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$ 5,357,580 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$ 6,124,475 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;187&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:140pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;16&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp; (2,944,726)&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp; (3,041,804)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:0.25in&quot;&gt; &lt;td width=&quot;187&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:140pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Net carrying amount&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;16&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$ 2,412,854 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;71&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$ 3,082,671 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fil:IntangibleAssetsMedicalFormulasTablesTextBlock>
	<fil:IntangibleAssetsAmortizationExpense contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;The estimated aggregate annual amortization expense for each of the next five years and thereafter is as follows:&lt;/p&gt; &lt;table width=&quot;144&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:1.5in; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;63&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;69&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;&amp;nbsp;Amount &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;63&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;2013&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;69&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp; 521,980 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;63&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;2014&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;69&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 505,653 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;63&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;2015&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;69&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 364,978 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;63&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;2016&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;69&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 318,939 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;63&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;2017&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;69&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 272,386 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;63&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;Thereafter&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;69&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 428,918 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;63&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;69&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;$ 2,412,854 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;</fil:IntangibleAssetsAmortizationExpense>
	<fil:IncomeTaxesTableTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Under current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:&lt;/p&gt; &lt;table width=&quot;240&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:2.5in; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;96&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1in; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;25&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:19pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;119&quot; style=&quot;BORDER-BOTTOM:black 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:89pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; rowspan=&quot;2&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Enterprise Income Tax Rate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;96&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1in; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;25&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:19pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;96&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1in; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;2013&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;25&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:19pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;119&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:89pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;15%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;96&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1in; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;2014 and after&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;25&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:19pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;119&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:89pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;25%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;</fil:IncomeTaxesTableTextBlock>
	<fil:ProvisionForIncomeTaxesTableTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;The provision for income taxes consisted of the following:&lt;/p&gt; &lt;table width=&quot;483&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:362pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;167&quot; colspan=&quot;3&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:125pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Years Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.55pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Current&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.55pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp; 1,414,171&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp; 3,458,568&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Deferred&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.55pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;(430,250)&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;(16,213)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Total income tax expense&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.55pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 983,921&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp; 3,442,355&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fil:ProvisionForIncomeTaxesTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Following is a reconciliation of income taxes calculated at the federal statutory rate to the provision for income taxes:&lt;/p&gt; &lt;table width=&quot;490&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:367.4pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:18.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:18.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:18.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:18.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:18.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:18.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;174&quot; colspan=&quot;3&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:130.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;2012&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;2011&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Tax at statutory rate of 25%&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp; 1,400,395&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp; 5,677,999&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Non-deductible stock-based compensation from&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;current and prior years&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;149,644&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;261,122&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Effect of tax holiday&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;(655,947)&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;(2,330,566)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Other, primarily the effect of US tax rates&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;(70,471)&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;160,300&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;(166,200)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Income tax expense&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 983,921&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;81&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp; 3,442,355&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;The temporary differences which give rise to the deferred income tax assets and liability are as follows:&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table width=&quot;483&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:362.05pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;167&quot; colspan=&quot;3&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:125.05pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Deferred income tax assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Allowance for doubtful trade receivables&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 664,492 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 530,461 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Allowance for doubtful other receivables&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 7,482 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 5,838 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Inventory obsolescence reserve&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 265,498 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&amp;nbsp; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Expenses not deductible in current year&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 30,200 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 29,927 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Share based compensation&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 45,777 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 172,911 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;U.S. net operating loss carry forwards&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 905,669 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 618,236 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Total deferred income tax assets&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 1,919,118 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 1,357,373 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; (951,447)&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; (791,147)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt&quot;&gt;Net deferred income tax asset&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 967,671 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 566,226 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Deferred income tax liability:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.9pt&quot;&gt; &lt;td width=&quot;304&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Intangible assets&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 95,963 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;2&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;right&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 128,909 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<fil:AssetsFairValuesTablETextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;The Company held the following assets and liabilities recorded at fair value as of December 31, 2012 and 2011: &lt;/p&gt; &lt;table width=&quot;489&quot; style=&quot;WIDTH:366.6pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;219&quot; colspan=&quot;5&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:164pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Fair Value Measurements at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;219&quot; colspan=&quot;5&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:164pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Reporting Date Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Banker&apos;s acceptance notes&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 101,570&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp; 101,570&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.5pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Total&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 101,570&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp; 101,570&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt; &lt;table width=&quot;489&quot; style=&quot;WIDTH:366.6pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;219&quot; colspan=&quot;5&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:164pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Fair Value Measurements at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;219&quot; colspan=&quot;5&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:164pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Reporting Date Using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Banker&apos;s acceptance notes&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 83,512 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&amp;nbsp; &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp; 83,512 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&amp;nbsp; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:13.5pt&quot;&gt; &lt;td width=&quot;161&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Total&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;85&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 83,512 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&amp;nbsp; &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp; 83,512 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;13&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&amp;nbsp; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fil:AssetsFairValuesTablETextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;A summary of stock option activity as of December 31, 2012, and changes during the year then ended is presented below:&lt;/p&gt; &lt;table width=&quot;542&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:406.2pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;227&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;68&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;64&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;227&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;68&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;64&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;227&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;68&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;64&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;227&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;68&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;64&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Contractual &lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:12.75pt&quot;&gt; &lt;td width=&quot;227&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;68&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;64&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Term (Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot; align=&quot;center&quot;&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td width=&quot;227&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Outstanding at December 31, 2011&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;68&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 310,000 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;64&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 3.03 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td width=&quot;227&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt&quot;&gt;Forfeited&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;68&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; (50,000)&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;64&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 2.54 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td width=&quot;227&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt&quot;&gt;Expired&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;68&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp; (235,000)&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;64&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 3.19 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td width=&quot;227&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Outstanding at December 31, 2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;68&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 25,000 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;64&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 2.54 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 0.40 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp;&amp;nbsp;-&amp;nbsp;&amp;nbsp; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td width=&quot;227&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;Exercisable at December 31, 2012&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;68&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 25,000 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;64&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 2.54 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;82&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 0.40 &lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;12&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;65&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; -&amp;nbsp;&amp;nbsp; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock contextRef='Y12'>&lt;!--egx--&gt;&lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;Future minimum commitments under the agreements are as follows:&lt;/p&gt; &lt;table width=&quot;341&quot; style=&quot;MARGIN:auto auto auto -0.75pt; WIDTH:256pt; BORDER-COLLAPSE:collapse&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td width=&quot;255&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:191pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot; valign=&quot;bottom&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&lt;b&gt;For the Years Ending December 31:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;87&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td width=&quot;255&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:191pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; TEXT-INDENT:11pt; MARGIN:0in 0in 0pt&quot;&gt;2013&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;87&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$ 13,133,498 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15pt&quot;&gt; &lt;td width=&quot;255&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:191pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; TEXT-INDENT:11pt; MARGIN:0in 0in 0pt&quot;&gt;2014&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;87&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 968,860 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style=&quot;HEIGHT:15.75pt&quot;&gt; &lt;td width=&quot;255&quot; style=&quot;BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:191pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; TEXT-INDENT:11pt; MARGIN:0in 0in 0pt&quot;&gt;Total&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;87&quot; style=&quot;BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in&quot;&gt; &lt;p style=&quot;LINE-HEIGHT:normal; MARGIN:0in 0in 0pt&quot;&gt;&amp;nbsp;$ 14,102,358 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock>
	<fil:PercentageOfShareOwned unitRef='Pure' contextRef='E12' decimals='INF'>1.0000</fil:PercentageOfShareOwned>
	<fil:PercentageOfShareOwnedofHelpsonMedicalAmpBiotechnologyCoLtd unitRef='Pure' contextRef='E12' decimals='INF'>1.0000</fil:PercentageOfShareOwnedofHelpsonMedicalAmpBiotechnologyCoLtd>
	<fil:PercetageOfAcquiredByOnnyInHelpson unitRef='Pure' contextRef='E12' decimals='INF'>1.0000</fil:PercetageOfAcquiredByOnnyInHelpson>
	<fil:NetIncome unitRef='USD' contextRef='Y12' decimals='INF'>4617659</fil:NetIncome>
	<fil:NetIncome unitRef='USD' contextRef='Y11' decimals='INF'>19269642</fil:NetIncome>
	<us-gaap:WeightedAverageNumberOfSharesIssuedBasic unitRef='Shares' contextRef='Y12' decimals='INF'>43579557</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
	<us-gaap:WeightedAverageNumberOfSharesIssuedBasic unitRef='Shares' contextRef='Y11' decimals='INF'>43479899</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
	<fil:Warrants unitRef='USD' contextRef='Y12' decimals='INF'>0</fil:Warrants>
	<fil:Warrants unitRef='USD' contextRef='Y11' decimals='INF'>0</fil:Warrants>
	<fil:Options unitRef='USD' contextRef='Y12' decimals='INF'>0</fil:Options>
	<fil:Options unitRef='USD' contextRef='Y11' decimals='INF'>0</fil:Options>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding unitRef='Shares' contextRef='Y12' decimals='INF'>43579557</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding unitRef='Shares' contextRef='Y11' decimals='INF'>43479899</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<fil:BasicEarningsPerShare unitRef='UsdPerShare' contextRef='Y12' decimals='INF'>0.11</fil:BasicEarningsPerShare>
	<fil:BasicEarningsPerShare unitRef='UsdPerShare' contextRef='Y11' decimals='INF'>0.44</fil:BasicEarningsPerShare>
	<fil:DilutedEarningsPerShare unitRef='UsdPerShare' contextRef='Y12' decimals='INF'>0.11</fil:DilutedEarningsPerShare>
	<fil:DilutedEarningsPerShare unitRef='UsdPerShare' contextRef='Y11' decimals='INF'>0.44</fil:DilutedEarningsPerShare>
	<fil:WarrantsWithExercisePrice unitRef='Shares' contextRef='Y12' decimals='INF'>150000</fil:WarrantsWithExercisePrice>
	<fil:WarrantsWithExercisePrice unitRef='Shares' contextRef='Y11' decimals='INF'>150000</fil:WarrantsWithExercisePrice>
	<fil:OptionsWithAnExercisePrice unitRef='Shares' contextRef='Y12' decimals='INF'>50000</fil:OptionsWithAnExercisePrice>
	<fil:OptionsWithAnExercisePrice unitRef='Shares' contextRef='Y11' decimals='INF'>310000</fil:OptionsWithAnExercisePrice>
	<fil:TotalWarrantsAndOptions unitRef='Shares' contextRef='Y12' decimals='INF'>200000</fil:TotalWarrantsAndOptions>
	<fil:TotalWarrantsAndOptions unitRef='Shares' contextRef='Y11' decimals='INF'>460000</fil:TotalWarrantsAndOptions>
	<fil:RecognizedAnImpairmentLossOfItsIntangibleAssets unitRef='USD' contextRef='Y12' decimals='INF'>593095</fil:RecognizedAnImpairmentLossOfItsIntangibleAssets>
	<fil:RecognizedAnImpairmentLossOfItsIntangibleAssets unitRef='USD' contextRef='Y11' decimals='INF'>0</fil:RecognizedAnImpairmentLossOfItsIntangibleAssets>
	<fil:CompanyContributionToRetirementBenefitPlans unitRef='USD' contextRef='Y12' decimals='INF'>233846</fil:CompanyContributionToRetirementBenefitPlans>
	<fil:CompanyContributionToRetirementBenefitPlans unitRef='USD' contextRef='Y11' decimals='INF'>166071</fil:CompanyContributionToRetirementBenefitPlans>
	<us-gaap:InventoryRawMaterials unitRef='USD' contextRef='E12' decimals='INF'>30198816</us-gaap:InventoryRawMaterials>
	<us-gaap:InventoryRawMaterials unitRef='USD' contextRef='E11' decimals='INF'>24920825</us-gaap:InventoryRawMaterials>
	<us-gaap:InventoryFinishedGoods unitRef='USD' contextRef='E12' decimals='INF'>7930684</us-gaap:InventoryFinishedGoods>
	<us-gaap:InventoryFinishedGoods unitRef='USD' contextRef='E11' decimals='INF'>5457833</us-gaap:InventoryFinishedGoods>
	<us-gaap:InventoryGross unitRef='USD' contextRef='E12' decimals='INF'>38129500</us-gaap:InventoryGross>
	<us-gaap:InventoryGross unitRef='USD' contextRef='E11' decimals='INF'>30378658</us-gaap:InventoryGross>
	<fil:AllowanceForObsolescenceRawMaterials unitRef='USD' contextRef='E12' decimals='INF'>-1769984</fil:AllowanceForObsolescenceRawMaterials>
	<fil:TotalInventoryNet unitRef='USD' contextRef='E12' decimals='INF'>36359516</fil:TotalInventoryNet>
	<fil:TotalInventoryNet unitRef='USD' contextRef='E11' decimals='INF'>30378658</fil:TotalInventoryNet>
	<fil:PermitOfLandUse unitRef='USD' contextRef='E12' decimals='INF'>447013</fil:PermitOfLandUse>
	<fil:PermitOfLandUse unitRef='USD' contextRef='E11' decimals='INF'>442978</fil:PermitOfLandUse>
	<us-gaap:BuildingsAndImprovementsGross unitRef='USD' contextRef='E12' decimals='INF'>2419125</us-gaap:BuildingsAndImprovementsGross>
	<us-gaap:BuildingsAndImprovementsGross unitRef='USD' contextRef='E11' decimals='INF'>2397286</us-gaap:BuildingsAndImprovementsGross>
	<fil:PlantMachineryAndEquipmentGross unitRef='USD' contextRef='E12' decimals='INF'>6381209</fil:PlantMachineryAndEquipmentGross>
	<fil:PlantMachineryAndEquipmentGross unitRef='USD' contextRef='E11' decimals='INF'>6184254</fil:PlantMachineryAndEquipmentGross>
	<fil:MotorVehicleGross unitRef='USD' contextRef='E12' decimals='INF'>147080</fil:MotorVehicleGross>
	<fil:MotorVehicleGross unitRef='USD' contextRef='E11' decimals='INF'>145300</fil:MotorVehicleGross>
	<us-gaap:FurnitureAndFixturesGross unitRef='USD' contextRef='E12' decimals='INF'>222273</us-gaap:FurnitureAndFixturesGross>
	<us-gaap:FurnitureAndFixturesGross unitRef='USD' contextRef='E11' decimals='INF'>204552</us-gaap:FurnitureAndFixturesGross>
	<us-gaap:ConstructionInProgressGross unitRef='USD' contextRef='E12' decimals='INF'>3688567</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionInProgressGross unitRef='USD' contextRef='E11' decimals='INF'>351571</us-gaap:ConstructionInProgressGross>
	<fil:TotalPropertyAndEquipment unitRef='USD' contextRef='E12' decimals='INF'>13305267</fil:TotalPropertyAndEquipment>
	<fil:TotalPropertyAndEquipment unitRef='USD' contextRef='E11' decimals='INF'>9725941</fil:TotalPropertyAndEquipment>
	<fil:LessAccumulatedDepreciationDetails unitRef='USD' contextRef='E12' decimals='INF'>-4273373</fil:LessAccumulatedDepreciationDetails>
	<fil:LessAccumulatedDepreciationDetails unitRef='USD' contextRef='E11' decimals='INF'>-3391124</fil:LessAccumulatedDepreciationDetails>
	<fil:PropertyAndEquipmentNet unitRef='USD' contextRef='E12' decimals='INF'>9031894</fil:PropertyAndEquipmentNet>
	<fil:PropertyAndEquipmentNet unitRef='USD' contextRef='E11' decimals='INF'>6334817</fil:PropertyAndEquipmentNet>
	<fil:PermitOfLandUseMinimumLife unitRef='Pure' contextRef='E12' decimals='INF'>40</fil:PermitOfLandUseMinimumLife>
	<fil:PermitOfLandUseMaximumLife unitRef='Pure' contextRef='E12' decimals='INF'>70</fil:PermitOfLandUseMaximumLife>
	<fil:BuildingMinimumLife unitRef='Pure' contextRef='E12' decimals='INF'>20</fil:BuildingMinimumLife>
	<fil:BuildingMaximumLife unitRef='Pure' contextRef='E12' decimals='INF'>35</fil:BuildingMaximumLife>
	<fil:PlantMachineryAndEquipmentLife unitRef='Pure' contextRef='E12' decimals='INF'>10</fil:PlantMachineryAndEquipmentLife>
	<fil:MotorVehicleMinimumLife unitRef='Pure' contextRef='E12' decimals='INF'>5</fil:MotorVehicleMinimumLife>
	<fil:MotorVehicleMaximumLife unitRef='Pure' contextRef='E12' decimals='INF'>10</fil:MotorVehicleMaximumLife>
	<fil:OfficeEquipmentMinimumLife unitRef='Pure' contextRef='E12' decimals='INF'>3</fil:OfficeEquipmentMinimumLife>
	<fil:OfficeEquipmentMaximumLife unitRef='Pure' contextRef='E12' decimals='INF'>5</fil:OfficeEquipmentMaximumLife>
	<fil:DepreciationExpensePropertyAndEquipment unitRef='USD' contextRef='Y12' decimals='INF'>851047</fil:DepreciationExpensePropertyAndEquipment>
	<fil:DepreciationExpensePropertyAndEquipment unitRef='USD' contextRef='Y11' decimals='INF'>555036</fil:DepreciationExpensePropertyAndEquipment>
	<fil:AmortizationExpenseIntangibleAssets unitRef='USD' contextRef='Y12' decimals='INF'>611724</fil:AmortizationExpenseIntangibleAssets>
	<fil:AmortizationExpenseIntangibleAssets unitRef='USD' contextRef='Y11' decimals='INF'>596525</fil:AmortizationExpenseIntangibleAssets>
	<fil:GrossCarryingAmount unitRef='USD' contextRef='E12' decimals='INF'>5357580</fil:GrossCarryingAmount>
	<fil:GrossCarryingAmount unitRef='USD' contextRef='E11' decimals='INF'>6124475</fil:GrossCarryingAmount>
	<fil:NetCarryingAmount unitRef='USD' contextRef='E12' decimals='INF'>2412854</fil:NetCarryingAmount>
	<fil:NetCarryingAmount unitRef='USD' contextRef='E11' decimals='INF'>3082671</fil:NetCarryingAmount>
	<fil:AnnualAmortization2013 unitRef='USD' contextRef='E12' decimals='INF'>521980</fil:AnnualAmortization2013>
	<fil:AnnualAmortization2014 unitRef='USD' contextRef='E12' decimals='INF'>505653</fil:AnnualAmortization2014>
	<fil:AnnualAmortization2015 unitRef='USD' contextRef='E12' decimals='INF'>364978</fil:AnnualAmortization2015>
	<fil:AnnualAmortization2016 unitRef='USD' contextRef='E12' decimals='INF'>318939</fil:AnnualAmortization2016>
	<fil:AnnualAmortization2017 unitRef='USD' contextRef='E12' decimals='INF'>272386</fil:AnnualAmortization2017>
	<fil:AnnualAmortizationThereafter unitRef='USD' contextRef='E12' decimals='INF'>428918</fil:AnnualAmortizationThereafter>
	<fil:AnnualAmortizationTotal unitRef='USD' contextRef='E12' decimals='INF'>2412854</fil:AnnualAmortizationTotal>
	<fil:CompanyObligationToPayLaboratoriesAndOthers unitRef='USD' contextRef='E12' decimals='INF'>6476000</fil:CompanyObligationToPayLaboratoriesAndOthers>
	<fil:AmountAdvancedByMemberOfBODToTheCompany unitRef='USD' contextRef='Y12' decimals='INF'>493004</fil:AmountAdvancedByMemberOfBODToTheCompany>
	<fil:AmountAdvancedByMemberOfBODToTheCompany unitRef='USD' contextRef='Y11' decimals='INF'>595670</fil:AmountAdvancedByMemberOfBODToTheCompany>
	<fil:InterestRateOnAdvancesFromMemberOfBOD unitRef='Pure' contextRef='Y12' decimals='INF'>0.0100</fil:InterestRateOnAdvancesFromMemberOfBOD>
	<fil:InterestRateOnAdvancesFromMemberOfBOD unitRef='Pure' contextRef='Y11' decimals='INF'>0.0100</fil:InterestRateOnAdvancesFromMemberOfBOD>
	<fil:AccumulatedAmortizationIntangibleAssetsSFDAApprovedMedicalFormulas unitRef='USD' contextRef='E12' decimals='INF'>-2944726</fil:AccumulatedAmortizationIntangibleAssetsSFDAApprovedMedicalFormulas>
	<fil:AccumulatedAmortizationIntangibleAssetsSFDAApprovedMedicalFormulas unitRef='USD' contextRef='E11' decimals='INF'>-3041804</fil:AccumulatedAmortizationIntangibleAssetsSFDAApprovedMedicalFormulas>
	<fil:AdavanceOwingToBoardmember unitRef='USD' contextRef='E12' decimals='INF'>1354567</fil:AdavanceOwingToBoardmember>
	<fil:AdavanceOwingToBoardmember unitRef='USD' contextRef='E11' decimals='INF'>861563</fil:AdavanceOwingToBoardmember>
	<fil:RevolvingLineOfCreditWithABankRMD25000000 unitRef='USD' contextRef='I111026' decimals='INF'>3970000</fil:RevolvingLineOfCreditWithABankRMD25000000>
	<fil:RevolvingLineOfCreditWithABankRMD25000000 unitRef='USD' contextRef='E12' decimals='INF'>0</fil:RevolvingLineOfCreditWithABankRMD25000000>
	<fil:AnnualInterestRate unitRef='Pure' contextRef='I111026' decimals='INF'>0.0754</fil:AnnualInterestRate>
	<fil:AnnualInterestRate unitRef='Pure' contextRef='E12' decimals='INF'>0.0000</fil:AnnualInterestRate>
	<fil:OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000 unitRef='USD' contextRef='I111026' decimals='INF'>0</fil:OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000>
	<fil:OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000 unitRef='USD' contextRef='E12' decimals='INF'>4761073</fil:OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000>
	<fil:UndistributedEarningsOfHelpson unitRef='USD' contextRef='E12' decimals='INF'>113400000</fil:UndistributedEarningsOfHelpson>
	<fil:InvestmentInHelpsonAForeignSubsidiaryForTheCompany unitRef='USD' contextRef='E12' decimals='INF'>23300000</fil:InvestmentInHelpsonAForeignSubsidiaryForTheCompany>
	<fil:EnterpriseIncomeTaxRatesForTheYear2012 unitRef='Pure' contextRef='E12' decimals='INF'>0.1500</fil:EnterpriseIncomeTaxRatesForTheYear2012>
	<fil:EnterpriseIncomeTaxRatesForTheYear2013 unitRef='Pure' contextRef='E12' decimals='INF'>0.1500</fil:EnterpriseIncomeTaxRatesForTheYear2013>
	<fil:EnterpriseIncomeTaxRatesForTheYear2014AndAfter unitRef='Pure' contextRef='E12' decimals='INF'>0.2500</fil:EnterpriseIncomeTaxRatesForTheYear2014AndAfter>
	<us-gaap:CurrentIncomeTaxExpenseBenefit unitRef='USD' contextRef='Y12' decimals='INF'>1414171</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit unitRef='USD' contextRef='Y11' decimals='INF'>3458568</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<fil:TotalIncomeTaxExpense unitRef='USD' contextRef='Y12' decimals='INF'>983921</fil:TotalIncomeTaxExpense>
	<fil:TotalIncomeTaxExpense unitRef='USD' contextRef='Y11' decimals='INF'>3442355</fil:TotalIncomeTaxExpense>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit unitRef='USD' contextRef='Y12' decimals='INF'>-430250</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit unitRef='USD' contextRef='Y11' decimals='INF'>-16213</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxReconciliationTaxCredits unitRef='USD' contextRef='Y12' decimals='INF'>1400395</us-gaap:IncomeTaxReconciliationTaxCredits>
	<us-gaap:IncomeTaxReconciliationTaxCredits unitRef='USD' contextRef='Y11' decimals='INF'>5677999</us-gaap:IncomeTaxReconciliationTaxCredits>
	<fil:CurrentAndPriorYears unitRef='USD' contextRef='Y12' decimals='INF'>149644</fil:CurrentAndPriorYears>
	<fil:CurrentAndPriorYears unitRef='USD' contextRef='Y11' decimals='INF'>261122</fil:CurrentAndPriorYears>
	<fil:EffectOfTaxHoliday unitRef='USD' contextRef='Y12' decimals='INF'>-655947</fil:EffectOfTaxHoliday>
	<fil:EffectOfTaxHoliday unitRef='USD' contextRef='Y11' decimals='INF'>-2330566</fil:EffectOfTaxHoliday>
	<fil:OtherPrimarilyTheEffectOfUSTaxRates unitRef='USD' contextRef='Y12' decimals='INF'>-70471</fil:OtherPrimarilyTheEffectOfUSTaxRates>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance unitRef='USD' contextRef='Y12' decimals='INF'>160300</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance unitRef='USD' contextRef='Y11' decimals='INF'>-166200</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate unitRef='USD' contextRef='Y12' decimals='INF'>983921</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate unitRef='USD' contextRef='Y11' decimals='INF'>3442355</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<fil:InventoryObsolescenceReserve unitRef='USD' contextRef='Y12' decimals='INF'>265498</fil:InventoryObsolescenceReserve>
	<fil:ExpensesNotDeductibleInCurrentYear unitRef='USD' contextRef='Y12' decimals='INF'>30200</fil:ExpensesNotDeductibleInCurrentYear>
	<fil:ExpensesNotDeductibleInCurrentYear unitRef='USD' contextRef='Y11' decimals='INF'>29927</fil:ExpensesNotDeductibleInCurrentYear>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost unitRef='USD' contextRef='E12' decimals='INF'>45777</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost unitRef='USD' contextRef='E11' decimals='INF'>172911</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards unitRef='USD' contextRef='E12' decimals='INF'>905669</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards unitRef='USD' contextRef='E11' decimals='INF'>618236</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<fil:TotalDeferredIncomeTaxAssets unitRef='USD' contextRef='Y12' decimals='INF'>1919118</fil:TotalDeferredIncomeTaxAssets>
	<fil:TotalDeferredIncomeTaxAssets unitRef='USD' contextRef='Y11' decimals='INF'>1357373</fil:TotalDeferredIncomeTaxAssets>
	<us-gaap:DeferredTaxAssetsValuationAllowance unitRef='USD' contextRef='E12' decimals='INF'>-951447</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance unitRef='USD' contextRef='E11' decimals='INF'>-791147</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxLiabilities unitRef='USD' contextRef='E12' decimals='INF'>95963</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilities unitRef='USD' contextRef='E11' decimals='INF'>128909</us-gaap:DeferredTaxLiabilities>
	<fil:AllowanceForDoubtfulTradeReceivablesDeferredTax unitRef='USD' contextRef='Y12' decimals='INF'>664492</fil:AllowanceForDoubtfulTradeReceivablesDeferredTax>
	<fil:AllowanceForDoubtfulTradeReceivablesDeferredTax unitRef='USD' contextRef='Y11' decimals='INF'>530461</fil:AllowanceForDoubtfulTradeReceivablesDeferredTax>
	<fil:AllowanceForDoubtfulOtherReceivablesDeferredTax unitRef='USD' contextRef='Y12' decimals='INF'>7482</fil:AllowanceForDoubtfulOtherReceivablesDeferredTax>
	<fil:AllowanceForDoubtfulOtherReceivablesDeferredTax unitRef='USD' contextRef='Y11' decimals='INF'>5838</fil:AllowanceForDoubtfulOtherReceivablesDeferredTax>
	<fil:NetDeferredIncomeTaxAsset unitRef='USD' contextRef='Y12' decimals='INF'>967671</fil:NetDeferredIncomeTaxAsset>
	<fil:NetDeferredIncomeTaxAsset unitRef='USD' contextRef='Y11' decimals='INF'>566226</fil:NetDeferredIncomeTaxAsset>
	<fil:DerivativeGainsRecognized unitRef='USD' contextRef='Y12' decimals='INF'>0</fil:DerivativeGainsRecognized>
	<fil:DerivativeGainsRecognized unitRef='USD' contextRef='Y11' decimals='INF'>934260</fil:DerivativeGainsRecognized>
	<fil:BankersAcceptanceNotes unitRef='USD' contextRef='E12' decimals='INF'>101570</fil:BankersAcceptanceNotes>
	<fil:BankersAcceptanceNotes unitRef='USD' contextRef='E11' decimals='INF'>83512</fil:BankersAcceptanceNotes>
	<fil:Total1 unitRef='USD' contextRef='E12' decimals='INF'>101570</fil:Total1>
	<fil:Total1 unitRef='USD' contextRef='E11' decimals='INF'>83512</fil:Total1>
	<fil:BankersAcceptanceNotesLevel1 unitRef='USD' contextRef='E12' decimals='INF'>0</fil:BankersAcceptanceNotesLevel1>
	<fil:BankersAcceptanceNotesLevel1 unitRef='USD' contextRef='E11' decimals='INF'>0</fil:BankersAcceptanceNotesLevel1>
	<fil:TotalLevel1 unitRef='USD' contextRef='E12' decimals='INF'>0</fil:TotalLevel1>
	<fil:TotalLevel1 unitRef='USD' contextRef='E11' decimals='INF'>0</fil:TotalLevel1>
	<fil:BankersAcceptanceNotesLevel2 unitRef='USD' contextRef='E12' decimals='INF'>101570</fil:BankersAcceptanceNotesLevel2>
	<fil:BankersAcceptanceNotesLevel2 unitRef='USD' contextRef='E11' decimals='INF'>83512</fil:BankersAcceptanceNotesLevel2>
	<fil:TotalLevel2 unitRef='USD' contextRef='E12' decimals='INF'>101570</fil:TotalLevel2>
	<fil:TotalLevel2 unitRef='USD' contextRef='E11' decimals='INF'>83512</fil:TotalLevel2>
	<fil:BankersAcceptanceNotesLevel3 unitRef='USD' contextRef='E12' decimals='INF'>0</fil:BankersAcceptanceNotesLevel3>
	<fil:BankersAcceptanceNotesLevel3 unitRef='USD' contextRef='E11' decimals='INF'>0</fil:BankersAcceptanceNotesLevel3>
	<fil:TotalLevel3 unitRef='USD' contextRef='E12' decimals='INF'>0</fil:TotalLevel3>
	<fil:TotalLevel3 unitRef='USD' contextRef='E11' decimals='INF'>0</fil:TotalLevel3>
	<fil:CommonSharesAuthorized unitRef='Shares' contextRef='E12' decimals='INF'>95000000</fil:CommonSharesAuthorized>
	<fil:PreferredSharesAuthorized unitRef='Shares' contextRef='E12' decimals='INF'>5000000</fil:PreferredSharesAuthorized>
	<fil:NumberOfCommonStockSharesToPurchaseByWarrantsOutstaningAndExercisable unitRef='Shares' contextRef='E12' decimals='INF'>150000</fil:NumberOfCommonStockSharesToPurchaseByWarrantsOutstaningAndExercisable>
	<fil:WarrantsStartRangeExercisePrice unitRef='UsdPerShare' contextRef='E12' decimals='INF'>3.00</fil:WarrantsStartRangeExercisePrice>
	<fil:WarrantsEndRangeExercisePrice unitRef='UsdPerShare' contextRef='E12' decimals='INF'>3.80</fil:WarrantsEndRangeExercisePrice>
	<fil:WarrantsWeightedAverageExercisePrice unitRef='UsdPerShare' contextRef='E12' decimals='INF'>3.40</fil:WarrantsWeightedAverageExercisePrice>
	<fil:WarrantsWeightedAverageContractualLife unitRef='Pure' contextRef='E12' decimals='INF'>0.4</fil:WarrantsWeightedAverageContractualLife>
	<fil:TotalIntrinsicValue unitRef='USD' contextRef='E12' decimals='INF'>0</fil:TotalIntrinsicValue>
	<fil:NumberOfCommonShares unitRef='Shares' contextRef='E12' decimals='INF'>0</fil:NumberOfCommonShares>
	<fil:NumberOfCommonSharesPurchasedByOptions unitRef='Shares' contextRef='I101112' decimals='INF'>0</fil:NumberOfCommonSharesPurchasedByOptions>
	<fil:NumberOfCommonSharesPurchasedByOptions unitRef='Shares' contextRef='E12' decimals='INF'>125000</fil:NumberOfCommonSharesPurchasedByOptions>
	<fil:StockOptionsGranted unitRef='Shares' contextRef='I101112' decimals='INF'>0</fil:StockOptionsGranted>
	<fil:StockOptionsGranted unitRef='Shares' contextRef='E12' decimals='INF'>100000</fil:StockOptionsGranted>
	<fil:NumberOfCommonShares unitRef='Shares' contextRef='I101112' decimals='INF'>4000000</fil:NumberOfCommonShares>
	<fil:VestedAndUnexercisedOptions unitRef='Shares' contextRef='I120428' decimals='INF'>185000</fil:VestedAndUnexercisedOptions>
	<fil:NumberOfDaysOpposedAfterTheEmploymentTerminationDate unitRef='Pure' contextRef='I120428' decimals='INF'>90</fil:NumberOfDaysOpposedAfterTheEmploymentTerminationDate>
	<fil:CommonSharesGranted unitRef='Shares' contextRef='I120428' decimals='INF'>100000</fil:CommonSharesGranted>
	<fil:RecordedCompensationExpense unitRef='USD' contextRef='I120428' decimals='INF'>55775</fil:RecordedCompensationExpense>
	<fil:FairValueOf185000OptionsCancelled unitRef='USD' contextRef='I120428' decimals='INF'>225</fil:FairValueOf185000OptionsCancelled>
	<fil:FairValueOf100000CommonSharesExchanged unitRef='USD' contextRef='I120428' decimals='INF'>56000</fil:FairValueOf100000CommonSharesExchanged>
	<fil:ClosingMarketPriceOfCommonStock unitRef='UsdPerShare' contextRef='I120428' decimals='INF'>0.56</fil:ClosingMarketPriceOfCommonStock>
	<fil:StartingRiskFreeInterestRate unitRef='Pure' contextRef='I120428' decimals='INF'>0.0014</fil:StartingRiskFreeInterestRate>
	<fil:ClosingRiskFreeInterestRate unitRef='Pure' contextRef='I120428' decimals='INF'>0.0019</fil:ClosingRiskFreeInterestRate>
	<fil:ExpectedDividendYield unitRef='Pure' contextRef='I120428' decimals='INF'>0.0000</fil:ExpectedDividendYield>
	<fil:ExpectedVolatility unitRef='Pure' contextRef='I120428' decimals='INF'>0.6670</fil:ExpectedVolatility>
	<fil:MinimumExpectedLife unitRef='Pure' contextRef='I120428' decimals='INF'>0.5</fil:MinimumExpectedLife>
	<fil:MaximumExpectedLife unitRef='Pure' contextRef='I120428' decimals='INF'>1.1</fil:MaximumExpectedLife>
	<fil:NumberOfOptionsToPurchaseCommonStockGranted unitRef='Shares' contextRef='I120428' decimals='INF'>50000</fil:NumberOfOptionsToPurchaseCommonStockGranted>
	<fil:OptionsExercisePrice unitRef='UsdPerShare' contextRef='I120428' decimals='INF'>2.54</fil:OptionsExercisePrice>
	<fil:CommonStockSharesGranted unitRef='UsdPerShare' contextRef='I120428' decimals='INF'>50000</fil:CommonStockSharesGranted>
	<fil:RecognizedCompensationExpenses unitRef='USD' contextRef='Y12' decimals='INF'>141720</fil:RecognizedCompensationExpenses>
	<fil:RecognizedCompensationExpenses unitRef='USD' contextRef='Y11' decimals='INF'>196183</fil:RecognizedCompensationExpenses>
	<fil:IncomeTaxBenefitRecognizedFromStockBasedCompensation unitRef='USD' contextRef='Y12' decimals='INF'>35430</fil:IncomeTaxBenefitRecognizedFromStockBasedCompensation>
	<fil:IncomeTaxBenefitRecognizedFromStockBasedCompensation unitRef='USD' contextRef='Y11' decimals='INF'>49046</fil:IncomeTaxBenefitRecognizedFromStockBasedCompensation>
	<fil:UnrecognizedCompensationExpenseRelatedToPerformanceBasedStockOptions unitRef='USD' contextRef='E12' decimals='INF'>17645</fil:UnrecognizedCompensationExpenseRelatedToPerformanceBasedStockOptions>
	<fil:UnrecognizedCompensationExpenseRelatedToFixedStockOptions unitRef='USD' contextRef='E12' decimals='INF'>0</fil:UnrecognizedCompensationExpenseRelatedToFixedStockOptions>
	<fil:TotalRemainingUnrecognizedCompensationExpenseRelatedToRestrictiveStockGrants unitRef='USD' contextRef='E12' decimals='INF'>0</fil:TotalRemainingUnrecognizedCompensationExpenseRelatedToRestrictiveStockGrants>
	<fil:NumberOfCommonSharesIssuedToTwoExecutiveOfficers unitRef='Shares' contextRef='I110525' decimals='INF'>100000</fil:NumberOfCommonSharesIssuedToTwoExecutiveOfficers>
	<fil:NumberOfNonQualifiedStockOptionsToPurchaseCommonStock unitRef='Shares' contextRef='I110525' decimals='INF'>50000</fil:NumberOfNonQualifiedStockOptionsToPurchaseCommonStock>
	<fil:ExercisePrice unitRef='UsdPerShare' contextRef='I110525' decimals='INF'>2.54</fil:ExercisePrice>
	<fil:OptionsExpiringOnMay252013 unitRef='Shares' contextRef='I110525' decimals='INF'>25000</fil:OptionsExpiringOnMay252013>
	<fil:OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria unitRef='Shares' contextRef='I110525' decimals='INF'>25000</fil:OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria>
	<fil:QualifiedStockOptionsGrantedToFormerCFONonQualifiedOptionsToPurchaseCommonStock unitRef='Shares' contextRef='I110525' decimals='INF'>50000</fil:QualifiedStockOptionsGrantedToFormerCFONonQualifiedOptionsToPurchaseCommonStock>
	<fil:ExercisePrice1 unitRef='UsdPerShare' contextRef='I110525' decimals='INF'>2.54</fil:ExercisePrice1>
	<fil:OptionsVestedOnApril282013 unitRef='Shares' contextRef='I110525' decimals='INF'>25000</fil:OptionsVestedOnApril282013>
	<fil:OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria1 unitRef='Shares' contextRef='I110525' decimals='INF'>25000</fil:OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria1>
	<fil:GrantedDateFairValueOfTheOptionsPerShare unitRef='UsdPerShare' contextRef='I110525' decimals='INF'>0.71</fil:GrantedDateFairValueOfTheOptionsPerShare>
	<fil:GrantedDateFairValueOfTheOptionsTotalValue unitRef='USD' contextRef='I110525' decimals='INF'>70580</fil:GrantedDateFairValueOfTheOptionsTotalValue>
	<fil:GrantedDateClosingMarketPrice unitRef='UsdPerShare' contextRef='I110525' decimals='INF'>2.54</fil:GrantedDateClosingMarketPrice>
	<fil:RiskFreeInterestRate unitRef='Pure' contextRef='I110525' decimals='INF'>0.0054</fil:RiskFreeInterestRate>
	<fil:DividendYield unitRef='Pure' contextRef='I110525' decimals='INF'>0.0000</fil:DividendYield>
	<fil:ExpectedVolatality unitRef='Pure' contextRef='I110525' decimals='INF'>0.7040</fil:ExpectedVolatality>
	<fil:ExpectedPeriodOfLife unitRef='Pure' contextRef='I110525' decimals='INF'>1</fil:ExpectedPeriodOfLife>
	<fil:NumberOfCommonSharesIssuedToExecutiveOfficers unitRef='Shares' contextRef='I110525' decimals='INF'>125000</fil:NumberOfCommonSharesIssuedToExecutiveOfficers>
	<fil:ValueOfTheOptionsGranted unitRef='USD' contextRef='I110525' decimals='INF'>317500</fil:ValueOfTheOptionsGranted>
	<fil:ExercisePriceForOptionsGranted unitRef='UsdPerShare' contextRef='I110525' decimals='INF'>2.54</fil:ExercisePriceForOptionsGranted>
	<fil:RestrictedStockGrantedToCEO unitRef='Shares' contextRef='I110525' decimals='INF'>75000</fil:RestrictedStockGrantedToCEO>
	<fil:OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria unitRef='Shares' contextRef='I110525' decimals='INF'>25000</fil:OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria>
	<fil:OptionsVestedOnMay252012 unitRef='Shares' contextRef='I110525' decimals='INF'>50000</fil:OptionsVestedOnMay252012>
	<fil:RestrictedStockOptionsGrantedToFormerCFO unitRef='Shares' contextRef='I110525' decimals='INF'>25000</fil:RestrictedStockOptionsGrantedToFormerCFO>
	<fil:OptionsVestedOnApril282012 unitRef='Shares' contextRef='I110525' decimals='INF'>25000</fil:OptionsVestedOnApril282012>
	<fil:OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria1 unitRef='Shares' contextRef='I110525' decimals='INF'>25000</fil:OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria1>
	<fil:SharesForfeitedDueToNonAchievementOfPerformanceCriteria unitRef='Shares' contextRef='I110525' decimals='INF'>50000</fil:SharesForfeitedDueToNonAchievementOfPerformanceCriteria>
	<fil:ShareBasedCompensationRelatedToTheFixedShareAwardsWasRecognizedOverThePeriodTheSharesVested unitRef='USD' contextRef='I110525' decimals='INF'>50000</fil:ShareBasedCompensationRelatedToTheFixedShareAwardsWasRecognizedOverThePeriodTheSharesVested>
	<fil:OutstandingOptions unitRef='Shares' contextRef='E11_noofshares' decimals='INF'>310000</fil:OutstandingOptions>
	<fil:OutstandingOptions unitRef='Shares' contextRef='E11_weightedaverageexerciseprice' decimals='INF'>3.03</fil:OutstandingOptions>
	<fil:Forfeited unitRef='Shares' contextRef='Y12_noofshares' decimals='INF'>-50000</fil:Forfeited>
	<fil:Forfeited unitRef='Shares' contextRef='Y12_weightedaverageexerciseprice' decimals='INF'>2.54</fil:Forfeited>
	<fil:Expired unitRef='Shares' contextRef='Y12_noofshares' decimals='INF'>-235000</fil:Expired>
	<fil:Expired unitRef='Shares' contextRef='Y12_weightedaverageexerciseprice' decimals='INF'>3.19</fil:Expired>
	<fil:OutstandingOptions1 unitRef='Shares' contextRef='E12_noofshares' decimals='INF'>25000</fil:OutstandingOptions1>
	<fil:OutstandingOptions1 unitRef='Shares' contextRef='E12_weightedaverageexerciseprice' decimals='INF'>2.54</fil:OutstandingOptions1>
	<fil:OutstandingOptions1 unitRef='Shares' contextRef='E12_weightedaverageremainingcontractualtermyears' decimals='INF'>0.4</fil:OutstandingOptions1>
	<fil:OutstandingOptions1 unitRef='Shares' contextRef='E12_aggregateintrinsicvalue' decimals='INF'>0</fil:OutstandingOptions1>
	<fil:ExercisableAtDecember312012 unitRef='Shares' contextRef='E12_noofshares' decimals='INF'>25000</fil:ExercisableAtDecember312012>
	<fil:ExercisableAtDecember312012 unitRef='Shares' contextRef='E12_weightedaverageexerciseprice' decimals='INF'>2.54</fil:ExercisableAtDecember312012>
	<fil:ExercisableAtDecember312012 unitRef='Shares' contextRef='E12_weightedaverageremainingcontractualtermyears' decimals='INF'>0.4</fil:ExercisableAtDecember312012>
	<fil:ExercisableAtDecember312012 unitRef='Shares' contextRef='E12_aggregateintrinsicvalue' decimals='INF'>0</fil:ExercisableAtDecember312012>
	<fil:PaymentsMadeForConstructionInProgress unitRef='USD' contextRef='E12' decimals='INF'>3110319</fil:PaymentsMadeForConstructionInProgress>
	<fil:ForTheYear2013 unitRef='USD' contextRef='E12' decimals='INF'>13133498</fil:ForTheYear2013>
	<fil:ForTheYear2014 unitRef='USD' contextRef='E12' decimals='INF'>968860</fil:ForTheYear2014>
	<fil:TotalAmount unitRef='USD' contextRef='E12' decimals='INF'>14102358</fil:TotalAmount>
	<fil:PercentageOfNoCustomerAccountedForMoreThanSales unitRef='Pure' contextRef='Y12' decimals='INF'>0.2040</fil:PercentageOfNoCustomerAccountedForMoreThanSales>
	<fil:PercentageOfNoCustomerAccountedForMoreThanSales unitRef='Pure' contextRef='Y11' decimals='INF'>0.1020</fil:PercentageOfNoCustomerAccountedForMoreThanSales>
	<fil:PercentageOfOneCustomerAccountedForMoreThanSales unitRef='Pure' contextRef='Y12' decimals='INF'>0.0000</fil:PercentageOfOneCustomerAccountedForMoreThanSales>
	<fil:PercentageOfOneCustomerAccountedForMoreThanSales unitRef='Pure' contextRef='Y11' decimals='INF'>0.0000</fil:PercentageOfOneCustomerAccountedForMoreThanSales>
	<fil:PercentageOfPurchasesFromOneSupplierOfRawMaterials unitRef='Pure' contextRef='Y12' decimals='INF'>0.0000</fil:PercentageOfPurchasesFromOneSupplierOfRawMaterials>
	<fil:PercentageOfPurchasesFromOneSupplierOfRawMaterials unitRef='Pure' contextRef='Y11' decimals='INF'>0.2080</fil:PercentageOfPurchasesFromOneSupplierOfRawMaterials>
	<fil:PercentageOfOneCustomerAccountedForAccountsReceivables unitRef='Pure' contextRef='Y12' decimals='INF'>0.0000</fil:PercentageOfOneCustomerAccountedForAccountsReceivables>
	<fil:PercentageOfOneCustomerAccountedForAccountsReceivables unitRef='Pure' contextRef='Y11' decimals='INF'>0.0000</fil:PercentageOfOneCustomerAccountedForAccountsReceivables>
	<fil:PercentageOfAccountsPayableToTwoSuppliersForPurchaseOfRawMaterials unitRef='Pure' contextRef='E12' decimals='INF'>0.1210</fil:PercentageOfAccountsPayableToTwoSuppliersForPurchaseOfRawMaterials>
	<fil:PercentageOfAccountsPayableToTwoSuppliersForPurchaseOfRawMaterials unitRef='Pure' contextRef='E11' decimals='INF'>0.1030</fil:PercentageOfAccountsPayableToTwoSuppliersForPurchaseOfRawMaterials>
	<fil:IssueOfWarrantsForPurchaseOfCommonStockTreatedAsDerivatives unitRef='Shares' contextRef='I080527' decimals='INF'>1250000</fil:IssueOfWarrantsForPurchaseOfCommonStockTreatedAsDerivatives>
	<fil:IssueOfWarrantsForPurchaseOfCommonStockTreatedAsDerivatives unitRef='Shares' contextRef='I080530' decimals='INF'>300000</fil:IssueOfWarrantsForPurchaseOfCommonStockTreatedAsDerivatives>
	<fil:ValuePerShare unitRef='UsdPerShare' contextRef='I080527' decimals='INF'>2.80</fil:ValuePerShare>
	<fil:ValuePerShare unitRef='UsdPerShare' contextRef='I080530' decimals='INF'>2.98</fil:ValuePerShare>
	<context id='Y12'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<startDate>2012-01-01</startDate>
			<endDate>2012-12-31</endDate>
		</period>
	</context>
	<context id='I130314'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2013-03-14</instant>
		</period>
	</context>
	<context id='E12'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2012-12-31</instant>
		</period>
	</context>
	<context id='E11'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2011-12-31</instant>
		</period>
	</context>
	<context id='Y11'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<startDate>2011-01-01</startDate>
			<endDate>2011-12-31</endDate>
		</period>
	</context>
	<context id='E10_capitalunits'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CapitalUnitsMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2010-12-31</instant>
		</period>
	</context>
	<context id='E10_commonstock'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2010-12-31</instant>
		</period>
	</context>
	<context id='E10_additionalpaidincapital'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2010-12-31</instant>
		</period>
	</context>
	<context id='E10_retainedearnings'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2010-12-31</instant>
		</period>
	</context>
	<context id='E10_accumulatedothercomprehensiveincome'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2010-12-31</instant>
		</period>
	</context>
	<context id='E10_parent'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ParentMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2010-12-31</instant>
		</period>
	</context>
	<context id='Y11_capitalunits'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CapitalUnitsMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<startDate>2011-01-01</startDate>
			<endDate>2011-12-31</endDate>
		</period>
	</context>
	<context id='Y11_commonstock'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<startDate>2011-01-01</startDate>
			<endDate>2011-12-31</endDate>
		</period>
	</context>
	<context id='Y11_additionalpaidincapital'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<startDate>2011-01-01</startDate>
			<endDate>2011-12-31</endDate>
		</period>
	</context>
	<context id='Y11_retainedearnings'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<startDate>2011-01-01</startDate>
			<endDate>2011-12-31</endDate>
		</period>
	</context>
	<context id='Y11_accumulatedothercomprehensiveincome'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<startDate>2011-01-01</startDate>
			<endDate>2011-12-31</endDate>
		</period>
	</context>
	<context id='Y11_parent'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ParentMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<startDate>2011-01-01</startDate>
			<endDate>2011-12-31</endDate>
		</period>
	</context>
	<context id='E11_capitalunits'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CapitalUnitsMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2011-12-31</instant>
		</period>
	</context>
	<context id='E11_commonstock'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2011-12-31</instant>
		</period>
	</context>
	<context id='E11_additionalpaidincapital'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2011-12-31</instant>
		</period>
	</context>
	<context id='E11_retainedearnings'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2011-12-31</instant>
		</period>
	</context>
	<context id='E11_accumulatedothercomprehensiveincome'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2011-12-31</instant>
		</period>
	</context>
	<context id='E11_parent'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ParentMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2011-12-31</instant>
		</period>
	</context>
	<context id='Y12_capitalunits'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CapitalUnitsMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<startDate>2012-01-01</startDate>
			<endDate>2012-12-31</endDate>
		</period>
	</context>
	<context id='Y12_commonstock'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<startDate>2012-01-01</startDate>
			<endDate>2012-12-31</endDate>
		</period>
	</context>
	<context id='Y12_additionalpaidincapital'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<startDate>2012-01-01</startDate>
			<endDate>2012-12-31</endDate>
		</period>
	</context>
	<context id='Y12_retainedearnings'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<startDate>2012-01-01</startDate>
			<endDate>2012-12-31</endDate>
		</period>
	</context>
	<context id='Y12_accumulatedothercomprehensiveincome'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<startDate>2012-01-01</startDate>
			<endDate>2012-12-31</endDate>
		</period>
	</context>
	<context id='Y12_parent'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ParentMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<startDate>2012-01-01</startDate>
			<endDate>2012-12-31</endDate>
		</period>
	</context>
	<context id='E12_capitalunits'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CapitalUnitsMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2012-12-31</instant>
		</period>
	</context>
	<context id='E12_commonstock'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2012-12-31</instant>
		</period>
	</context>
	<context id='E12_additionalpaidincapital'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2012-12-31</instant>
		</period>
	</context>
	<context id='E12_retainedearnings'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2012-12-31</instant>
		</period>
	</context>
	<context id='E12_accumulatedothercomprehensiveincome'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2012-12-31</instant>
		</period>
	</context>
	<context id='E12_parent'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>us-gaap:ParentMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2012-12-31</instant>
		</period>
	</context>
	<context id='E10'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2010-12-31</instant>
		</period>
	</context>
	<context id='I111026'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2011-10-26</instant>
		</period>
	</context>
	<context id='I101112'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2010-11-12</instant>
		</period>
	</context>
	<context id='I120428'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2012-04-28</instant>
		</period>
	</context>
	<context id='I110525'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2011-05-25</instant>
		</period>
	</context>
	<context id='E11_noofshares'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>fil:NoOfSharesMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2011-12-31</instant>
		</period>
	</context>
	<context id='E11_weightedaverageexerciseprice'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>fil:WeightedAverageExercisePriceMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2011-12-31</instant>
		</period>
	</context>
	<context id='Y12_noofshares'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>fil:NoOfSharesMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<startDate>2012-01-01</startDate>
			<endDate>2012-12-31</endDate>
		</period>
	</context>
	<context id='Y12_weightedaverageexerciseprice'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>fil:WeightedAverageExercisePriceMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<startDate>2012-01-01</startDate>
			<endDate>2012-12-31</endDate>
		</period>
	</context>
	<context id='E12_noofshares'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>fil:NoOfSharesMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2012-12-31</instant>
		</period>
	</context>
	<context id='E12_weightedaverageexerciseprice'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>fil:WeightedAverageExercisePriceMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2012-12-31</instant>
		</period>
	</context>
	<context id='E12_weightedaverageremainingcontractualtermyears'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>fil:WeightedAverageRemainingContractualTermYearsMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2012-12-31</instant>
		</period>
	</context>
	<context id='E12_aggregateintrinsicvalue'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
			<segment><xbrldi:explicitMember dimension='us-gaap:StatementEquityComponentsAxis'>fil:AggregateIntrinsicValueMember</xbrldi:explicitMember></segment>
		</entity>
		<period>
			<instant>2012-12-31</instant>
		</period>
	</context>
	<context id='I080527'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2008-05-27</instant>
		</period>
	</context>
	<context id='I080530'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2008-05-30</instant>
		</period>
	</context>
	<unit id='Shares'>
		<measure>shares</measure>
	</unit>
	<unit id='USD'>
		<measure>iso4217:USD</measure>
	</unit>
	<unit id='UsdPerShare'>
		<divide>
			<unitNumerator>
				<measure>iso4217:USD</measure>
			</unitNumerator>
			<unitDenominator>
				<measure>shares</measure>
			</unitDenominator>
		</divide>
	</unit>
	<unit id='Pure'>
		<measure>pure</measure>
	</unit>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>cphi-20121231.xsd
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- NeoClarus - iFile Suite version 4.2311  -->
<schema xmlns:dei='http://xbrl.sec.gov/dei/2011-01-31' xmlns:fil='http://www.chinapharmaholdings.com/20121231' attributeFormDefault='unqualified' elementFormDefault='qualified' targetNamespace='http://www.chinapharmaholdings.com/20121231' xmlns='http://www.w3.org/2001/XMLSchema' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xbrli='http://www.xbrl.org/2003/instance' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' xmlns:us-gaap='http://fasb.org/us-gaap/2011-01-31' xmlns:num='http://www.xbrl.org/dtr/type/numeric' xmlns:nonnum='http://www.xbrl.org/dtr/type/non-numeric'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="cphi-20121231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="cphi-20121231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="cphi-20121231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="cphi-20121231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosurePROPERTYANDEQUIPMENTTables" id="idr_DisclosurePROPERTYANDEQUIPMENTTables">
				<link:definition>000230 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINTANGIBLEASSETS" id="idr_DisclosureINTANGIBLEASSETS">
				<link:definition>000100 - Disclosure - INTANGIBLE ASSETS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_COMMITMENTSANDCONTINGENCIESDETAILS" id="idr_COMMITMENTSANDCONTINGENCIESDETAILS">
				<link:definition>000540 - Statement - COMMITMENTS AND CONTINGENCIES (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureNOTESPAYABLE" id="idr_DisclosureNOTESPAYABLE">
				<link:definition>000130 - Disclosure - NOTES PAYABLE</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" id="idr_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
				<link:definition>000050 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_PROPERTYANDEQUIPMENTDetails" id="idr_PROPERTYANDEQUIPMENTDetails">
				<link:definition>000330 - Statement - PROPERTY AND EQUIPMENT (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_INTANGIBLEASSETSSFDAApprovedMedicalFormulasDetails" id="idr_INTANGIBLEASSETSSFDAApprovedMedicalFormulasDetails">
				<link:definition>000360 - Statement - INTANGIBLE ASSETS SFDA Approved Medical Formulas (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_INVENTORYDetails" id="idr_INVENTORYDetails">
				<link:definition>000320 - Statement - INVENTORY. (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINCOMETAXES" id="idr_DisclosureINCOMETAXES">
				<link:definition>000140 - Disclosure - INCOME TAXES</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINVENTORYTables" id="idr_DisclosureINVENTORYTables">
				<link:definition>000220 - Disclosure - INVENTORY(Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS" id="idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS">
				<link:definition>000110 - Disclosure - ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureFAIRVALUEMEASUREMENTSTables" id="idr_DisclosureFAIRVALUEMEASUREMENTSTables">
				<link:definition>000260 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureCONCENTRATIONS" id="idr_DisclosureCONCENTRATIONS">
				<link:definition>000190 - Disclosure - CONCENTRATIONS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWS" id="idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
				<link:definition>000060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureAccountingPoliciesPolicies" id="idr_DisclosureAccountingPoliciesPolicies">
				<link:definition>000200 - Disclosure - Accounting Policies (Policies)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DERIVATIVEWARRANTGAINSDetails" id="idr_DERIVATIVEWARRANTGAINSDetails">
				<link:definition>000440 - Statement - DERIVATIVE WARRANT GAINS (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" id="idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME">
				<link:definition>000040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_StockOptionPlanDetails" id="idr_StockOptionPlanDetails">
				<link:definition>000470 - Statement - 2010 Stock Option Plan (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureFUTUREMINIMUMCOMMITMENTSTables" id="idr_DisclosureFUTUREMINIMUMCOMMITMENTSTables">
				<link:definition>000280 - Disclosure - FUTURE MINIMUM COMMITMENTS (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CONCENTRATIONSAccountsPayableDetails" id="idr_CONCENTRATIONSAccountsPayableDetails">
				<link:definition>000560 - Statement - CONCENTRATIONS Accounts Payable (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_RELATEDPARTYTRANSACTIONSMemberOfBODDetails" id="idr_RELATEDPARTYTRANSACTIONSMemberOfBODDetails">
				<link:definition>000370 - Statement - RELATED PARTY TRANSACTIONS Member Of BOD (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DERIVATIVEWARRANTLIABILITYDetails" id="idr_DERIVATIVEWARRANTLIABILITYDetails">
				<link:definition>000435 - Statement - DERIVATIVE WARRANT LIABILITY (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_PROPERTYANDEQUIPMENTAssetsLifeDetails" id="idr_PROPERTYANDEQUIPMENTAssetsLifeDetails">
				<link:definition>000340 - Statement - PROPERTY AND EQUIPMENT Assets Life (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_BASISOFPRESENTATIONDetails" id="idr_BASISOFPRESENTATIONDetails">
				<link:definition>000290 - Statement - BASIS OF PRESENTATION (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINCOMETAXESTables" id="idr_DisclosureINCOMETAXESTables">
				<link:definition>000250 - Disclosure - INCOME TAXES (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINVENTORY" id="idr_DisclosureINVENTORY">
				<link:definition>000080 - Disclosure - INVENTORY.</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureFAIRVALUEMEASUREMENTS" id="idr_DisclosureFAIRVALUEMEASUREMENTS">
				<link:definition>000160 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_OFFICERS2010StockOptionPlanDetails" id="idr_OFFICERS2010StockOptionPlanDetails">
				<link:definition>000520 - Statement - OFFICERS 2010 Stock Option Plan (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_FAIRVALUEMEASUREMENTSAtReportingDateUsingDetails" id="idr_FAIRVALUEMEASUREMENTSAtReportingDateUsingDetails">
				<link:definition>000450 - Statement - FAIR VALUE MEASUREMENTS At Reporting Date Using (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureDERIVATIVEWARRANTLIABILITY" id="idr_DisclosureDERIVATIVEWARRANTLIABILITY">
				<link:definition>000150 - Disclosure - DERIVATIVE WARRANT LIABILITY</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDBALANCESHEETS" id="idr_CONSOLIDATEDBALANCESHEETS">
				<link:definition>000020 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_BASISOFPRESENTATIONPOLICIESDetails" id="idr_BASISOFPRESENTATIONPOLICIESDetails">
				<link:definition>000310 - Statement - BASIS OF PRESENTATION POLICIES (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosurePROPERTYANDEQUIPMENT" id="idr_DisclosurePROPERTYANDEQUIPMENT">
				<link:definition>000090 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureSTOCKHOLDERSEQUITY" id="idr_DisclosureSTOCKHOLDERSEQUITY">
				<link:definition>000170 - Disclosure - STOCKHOLDERS&apos; EQUITY</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS" id="idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS">
				<link:definition>000030 - Statement - CONSOLIDATED BALANCE SHEETS PARENTHETICALS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_RELATEDPARTYTRANSACTIONSOwingsDetails" id="idr_RELATEDPARTYTRANSACTIONSOwingsDetails">
				<link:definition>000380 - Statement - RELATED PARTY TRANSACTIONS Owings (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_BASISOFPRESENTATIONBasicAndDilutedEarningsPerCommonShareDetails" id="idr_BASISOFPRESENTATIONBasicAndDilutedEarningsPerCommonShareDetails">
				<link:definition>000300 - Statement - BASIS OF PRESENTATION Basic and Diluted Earnings per Common Share (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureBASISOFPRESENTATIONTables" id="idr_DisclosureBASISOFPRESENTATIONTables">
				<link:definition>000210 - Disclosure - BASIS OF PRESENTATION (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_EXECUTIVEOFFICERS2010StockOptionPlanDetails" id="idr_EXECUTIVEOFFICERS2010StockOptionPlanDetails">
				<link:definition>000510 - Statement - EXECUTIVE OFFICERS 2010 Stock Option Plan (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES" id="idr_DisclosureCOMMITMENTSANDCONTINGENCIES">
				<link:definition>000180 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_StockOptionPlanFrankWaungDetails" id="idr_StockOptionPlanFrankWaungDetails">
				<link:definition>000480 - Statement - 2010 Stock Option Plan Frank Waung (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CompensationExpenseDetails" id="idr_CompensationExpenseDetails">
				<link:definition>000490 - Statement - Compensation Expense (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_ASSETSDepreciationDetails" id="idr_ASSETSDepreciationDetails">
				<link:definition>000350 - Statement - ASSETS Depreciation (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINTANGIBLEASSETSTables" id="idr_DisclosureINTANGIBLEASSETSTables">
				<link:definition>000240 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureRELATEDPARTYTRANSACTIONS" id="idr_DisclosureRELATEDPARTYTRANSACTIONS">
				<link:definition>000120 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_ChangesOfDeferredIncomeTaxAssetsAndLiabilityDetails" id="idr_ChangesOfDeferredIncomeTaxAssetsAndLiabilityDetails">
				<link:definition>000430 - Statement - Changes of deferred income tax assets and liability (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_UnrecognizedCompensationExpenseDetails" id="idr_UnrecognizedCompensationExpenseDetails">
				<link:definition>000500 - Statement - Unrecognized Compensation Expense (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_NOTESPAYABLESDetails" id="idr_NOTESPAYABLESDetails">
				<link:definition>000390 - Statement - NOTES PAYABLES. (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" id="idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES">
				<link:definition>000070 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureSTOCKOPTIONACTIVITYTables" id="idr_DisclosureSTOCKOPTIONACTIVITYTables">
				<link:definition>000270 - Disclosure - STOCK OPTION ACTIVITY (Tables)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_ReconciliationOfIncomeTaxesDetails" id="idr_ReconciliationOfIncomeTaxesDetails">
				<link:definition>000420 - Statement - Reconciliation of income taxes (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CONCENTRATIONSSalesAndPurchasesDetails" id="idr_CONCENTRATIONSSalesAndPurchasesDetails">
				<link:definition>000550 - Statement - CONCENTRATIONS Sales And Purchases (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_PreferredCommonStockAndWarrantsDetails" id="idr_PreferredCommonStockAndWarrantsDetails">
				<link:definition>000460 - Statement - Preferred Common Stock And Warrants (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_SummaryOfStockOptionActivityDetailsStockholdersEquity" id="idr_SummaryOfStockOptionActivityDetailsStockholdersEquity">
				<link:definition>000530 - Statement - Summary of stock option activity (Details) {Stockholders Equity}</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_INCOMETAXESProvisionDetails" id="idr_INCOMETAXESProvisionDetails">
				<link:definition>000410 - Statement - INCOME TAXES Provision (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_INCOMETAXESUndistributedEarningsAndIncomeTaxRatesDetails" id="idr_INCOMETAXESUndistributedEarningsAndIncomeTaxRatesDetails">
				<link:definition>000400 - Statement - INCOME TAXES Undistributed Earnings And Income Tax Rates (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd' namespace='http://www.xbrl.org/dtr/type/numeric'/>
	<import schemaLocation='http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd' namespace='http://www.xbrl.org/dtr/type/non-numeric'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import schemaLocation='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd' namespace='http://fasb.org/us-gaap/2011-01-31' />
	<import schemaLocation='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd' namespace='http://xbrl.sec.gov/dei/2011-01-31' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' abstract='true' id='fil_DocumentAndEntityInformationAbstract' substitutionGroup='xbrli:item' name='DocumentAndEntityInformationAbstract' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_AdvancesToSuppliers' substitutionGroup='xbrli:item' name='AdvancesToSuppliers' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_AdvancesForPurchasesOfPropertyAndEquipment' substitutionGroup='xbrli:item' name='AdvancesForPurchasesOfPropertyAndEquipment' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_AllowanceForDoubtfulAccountsOnOtherReceivables' substitutionGroup='xbrli:item' name='AllowanceForDoubtfulAccountsOnOtherReceivables' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_GovernmentSubsidyIncome' substitutionGroup='xbrli:item' name='GovernmentSubsidyIncome' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_InventoryPurchasedWithBankerSAcceptances' substitutionGroup='xbrli:item' name='InventoryPurchasedWithBankerSAcceptances' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_AccountsReceivableCollectedWithBankerSAcceptances' substitutionGroup='xbrli:item' name='AccountsReceivableCollectedWithBankerSAcceptances' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_AccountsPayableForPurchasesOfPropertyAndEquipment' substitutionGroup='xbrli:item' name='AccountsPayableForPurchasesOfPropertyAndEquipment' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_DerivativeGain' substitutionGroup='xbrli:item' name='DerivativeGain' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_BadDebtExpenseBenefit' substitutionGroup='xbrli:item' name='BadDebtExpenseBenefit' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_AdvancesForPurchasesOfIntangibleAssetsAbstract' abstract='true' name='AdvancesForPurchasesOfIntangibleAssetsAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='nonnum:textBlockItemType' id='fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' name='AdvancesForPurchasesOfIntangibleAssetsTextBlock' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' abstract='true' id='fil_NotesPayable1Abstract' substitutionGroup='xbrli:item' name='NotesPayable1Abstract' />
	<element nillable='true' xbrli:periodType='duration' type='nonnum:textBlockItemType' id='fil_NotesPayableTextBlock' substitutionGroup='xbrli:item' name='NotesPayableTextBlock' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_NetInvestmentInBankerSAcceptances' name='NetInvestmentInBankerSAcceptances' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='nonnum:textBlockItemType' id='fil_PotentialCommonSharesWereNotIncludedInTheComputationOfDilutedEarningsPerShareTableTextBlock' substitutionGroup='xbrli:item' name='PotentialCommonSharesWereNotIncludedInTheComputationOfDilutedEarningsPerShareTableTextBlock' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' abstract='true' id='fil_InventoryTablesAbstract' substitutionGroup='xbrli:item' name='InventoryTablesAbstract' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' abstract='true' id='fil_BasisOfPresentationTablesAbstract' substitutionGroup='xbrli:item' name='BasisOfPresentationTablesAbstract' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_PropertyAndEquipmentTablesAbstract' abstract='true' name='PropertyAndEquipmentTablesAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='nonnum:textBlockItemType' id='fil_UsefulLivesOfTheAssetsTableTextBlock' name='UsefulLivesOfTheAssetsTableTextBlock' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_IntangibleAssetsTablesAbstract' abstract='true' name='IntangibleAssetsTablesAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='nonnum:textBlockItemType' id='fil_IntangibleAssetsMedicalFormulasTablesTextBlock' name='IntangibleAssetsMedicalFormulasTablesTextBlock' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_IncomeTaxesTablesAbstract' abstract='true' name='IncomeTaxesTablesAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='nonnum:textBlockItemType' id='fil_IncomeTaxesTableTextBlock' name='IncomeTaxesTableTextBlock' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='nonnum:textBlockItemType' id='fil_ProvisionForIncomeTaxesTableTextBlock' name='ProvisionForIncomeTaxesTableTextBlock' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_FairValueMeasurementsTablesAbstract' abstract='true' name='FairValueMeasurementsTablesAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='nonnum:textBlockItemType' id='fil_AssetsFairValuesTablETextBlock' name='AssetsFairValuesTablETextBlock' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='num:percentItemType' id='fil_PercentageOfShareOwned' substitutionGroup='xbrli:item' name='PercentageOfShareOwned' />
	<element nillable='true' xbrli:periodType='instant' type='num:percentItemType' id='fil_PercetageOfAcquiredByOnnyInHelpson' substitutionGroup='xbrli:item' name='PercetageOfAcquiredByOnnyInHelpson' />
	<element nillable='true' xbrli:periodType='instant' type='num:percentItemType' id='fil_PercentageOfShareOwnedofHelpsonMedicalAmpBiotechnologyCoLtd' substitutionGroup='xbrli:item' name='PercentageOfShareOwnedofHelpsonMedicalAmpBiotechnologyCoLtd' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' abstract='true' id='fil_BASISOFPRESENTATIONBasicAndDilutedEarningsPerCommonShareDetailsAbstract' substitutionGroup='xbrli:item' name='BASISOFPRESENTATIONBasicAndDilutedEarningsPerCommonShareDetailsAbstract' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_NetIncome' substitutionGroup='xbrli:item' name='NetIncome' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_Warrants' substitutionGroup='xbrli:item' name='Warrants' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_Options' substitutionGroup='xbrli:item' name='Options' />
	<element nillable='true' xbrli:periodType='duration' type='num:perShareItemType' id='fil_BasicEarningsPerShare' substitutionGroup='xbrli:item' name='BasicEarningsPerShare' />
	<element nillable='true' xbrli:periodType='duration' type='num:perShareItemType' id='fil_DilutedEarningsPerShare' substitutionGroup='xbrli:item' name='DilutedEarningsPerShare' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:sharesItemType' id='fil_WarrantsWithExercisePrice' substitutionGroup='xbrli:item' name='WarrantsWithExercisePrice' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:sharesItemType' id='fil_OptionsWithAnExercisePrice' substitutionGroup='xbrli:item' name='OptionsWithAnExercisePrice' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:sharesItemType' id='fil_TotalWarrantsAndOptions' substitutionGroup='xbrli:item' name='TotalWarrantsAndOptions' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' abstract='true' id='fil_PROPERTYANDEQUIPMENTAbstract' substitutionGroup='xbrli:item' name='PROPERTYANDEQUIPMENTAbstract' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_PermitOfLandUse' substitutionGroup='xbrli:item' name='PermitOfLandUse' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_PlantMachineryAndEquipmentGross' substitutionGroup='xbrli:item' name='PlantMachineryAndEquipmentGross' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_MotorVehicleGross' substitutionGroup='xbrli:item' name='MotorVehicleGross' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_PropertyAndEquipmentNet' substitutionGroup='xbrli:item' name='PropertyAndEquipmentNet' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:pureItemType' id='fil_OfficeEquipmentMaximumLife' substitutionGroup='xbrli:item' name='OfficeEquipmentMaximumLife' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:pureItemType' id='fil_MotorVehicleMaximumLife' substitutionGroup='xbrli:item' name='MotorVehicleMaximumLife' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:pureItemType' id='fil_BuildingMaximumLife' substitutionGroup='xbrli:item' name='BuildingMaximumLife' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:pureItemType' id='fil_PermitOfLandUseMaximumLife' substitutionGroup='xbrli:item' name='PermitOfLandUseMaximumLife' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' abstract='true' id='fil_PROPERTYANDEQUIPMENTAssetsLifeAbstract' substitutionGroup='xbrli:item' name='PROPERTYANDEQUIPMENTAssetsLifeAbstract' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:pureItemType' id='fil_OfficeEquipmentMinimumLife' substitutionGroup='xbrli:item' name='OfficeEquipmentMinimumLife' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:pureItemType' id='fil_MotorVehicleMinimumLife' substitutionGroup='xbrli:item' name='MotorVehicleMinimumLife' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:pureItemType' id='fil_BuildingMinimumLife' substitutionGroup='xbrli:item' name='BuildingMinimumLife' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:pureItemType' id='fil_PermitOfLandUseMinimumLife' substitutionGroup='xbrli:item' name='PermitOfLandUseMinimumLife' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:pureItemType' id='fil_PlantMachineryAndEquipmentLife' substitutionGroup='xbrli:item' name='PlantMachineryAndEquipmentLife' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' abstract='true' id='fil_INTANGIBLEASSETSSFDAApprovedMedicalFormulasAbstract' substitutionGroup='xbrli:item' name='INTANGIBLEASSETSSFDAApprovedMedicalFormulasAbstract' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_GrossCarryingAmount' substitutionGroup='xbrli:item' name='GrossCarryingAmount' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_NetCarryingAmount' substitutionGroup='xbrli:item' name='NetCarryingAmount' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_RELATEDPARTYTRANSACTIONSMemberOfBODAbstract' abstract='true' name='RELATEDPARTYTRANSACTIONSMemberOfBODAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_AmountAdvancedByMemberOfBODToTheCompany' name='AmountAdvancedByMemberOfBODToTheCompany' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_RevolvingLineOfCreditWithABankRMD25000000' name='RevolvingLineOfCreditWithABankRMD25000000' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='num:percentItemType' id='fil_AnnualInterestRate' name='AnnualInterestRate' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_INCOMETAXESUndistributedEarningsAbstract' abstract='true' name='INCOMETAXESUndistributedEarningsAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_UndistributedEarningsOfHelpson' name='UndistributedEarningsOfHelpson' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany' name='InvestmentInHelpsonAForeignSubsidiaryForTheCompany' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_INCOMETAXESEnterpriseIncomeTaxRatesAbstract' abstract='true' name='INCOMETAXESEnterpriseIncomeTaxRatesAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='num:percentItemType' id='fil_EnterpriseIncomeTaxRatesForTheYear2012' name='EnterpriseIncomeTaxRatesForTheYear2012' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='num:percentItemType' id='fil_EnterpriseIncomeTaxRatesForTheYear2013' name='EnterpriseIncomeTaxRatesForTheYear2013' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='num:percentItemType' id='fil_EnterpriseIncomeTaxRatesForTheYear2014AndAfter' name='EnterpriseIncomeTaxRatesForTheYear2014AndAfter' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_TotalIncomeTaxExpense' name='TotalIncomeTaxExpense' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_INCOMETAXESProvisionAbstract' abstract='true' name='INCOMETAXESProvisionAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' abstract='true' id='fil_RelatedPartyTransactionMemberOwingsAbstract' substitutionGroup='xbrli:item' name='RelatedPartyTransactionMemberOwingsAbstract' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_AdavanceOwingToBoardmember' substitutionGroup='xbrli:item' name='AdavanceOwingToBoardmember' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_STOCKHOLDERSEQUITYPreferredCommonStockAndWarrantsAbstract' abstract='true' name='STOCKHOLDERSEQUITYPreferredCommonStockAndWarrantsAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_CommonSharesAuthorized' name='CommonSharesAuthorized' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_PreferredSharesAuthorized' name='PreferredSharesAuthorized' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_NumberOfCommonStockSharesToPurchaseByWarrantsOutstaningAndExercisable' name='NumberOfCommonStockSharesToPurchaseByWarrantsOutstaningAndExercisable' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='num:perShareItemType' id='fil_WarrantsStartRangeExercisePrice' name='WarrantsStartRangeExercisePrice' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='num:perShareItemType' id='fil_WarrantsEndRangeExercisePrice' name='WarrantsEndRangeExercisePrice' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='num:perShareItemType' id='fil_WarrantsWeightedAverageExercisePrice' name='WarrantsWeightedAverageExercisePrice' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:pureItemType' id='fil_WarrantsWeightedAverageContractualLife' name='WarrantsWeightedAverageContractualLife' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_TotalIntrinsicValue' name='TotalIntrinsicValue' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_NumberOfCommonSharesPurchasedByOptions' name='NumberOfCommonSharesPurchasedByOptions' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_STOCKHOLDERSEQUITY2010StockOptionPlanAbstract' abstract='true' name='STOCKHOLDERSEQUITY2010StockOptionPlanAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_NumberOfCommonShares' name='NumberOfCommonShares' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_StockOptionsGranted' name='StockOptionsGranted' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_STOCKHOLDERSEQUITY2010StockOptionPlanFrankWaungAbstract' abstract='true' name='STOCKHOLDERSEQUITY2010StockOptionPlanFrankWaungAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_VestedAndUnexercisedOptions' name='VestedAndUnexercisedOptions' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:pureItemType' id='fil_NumberOfDaysOpposedAfterTheEmploymentTerminationDate' name='NumberOfDaysOpposedAfterTheEmploymentTerminationDate' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_CommonSharesGranted' name='CommonSharesGranted' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_RecordedCompensationExpense' name='RecordedCompensationExpense' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_FairValueOf185000OptionsCancelled' name='FairValueOf185000OptionsCancelled' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_FairValueOf100000CommonSharesExchanged' name='FairValueOf100000CommonSharesExchanged' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='num:perShareItemType' id='fil_ClosingMarketPriceOfCommonStock' name='ClosingMarketPriceOfCommonStock' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='num:percentItemType' id='fil_StartingRiskFreeInterestRate' name='StartingRiskFreeInterestRate' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='num:percentItemType' id='fil_ClosingRiskFreeInterestRate' name='ClosingRiskFreeInterestRate' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='num:percentItemType' id='fil_ExpectedDividendYield' name='ExpectedDividendYield' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='num:percentItemType' id='fil_ExpectedVolatility' name='ExpectedVolatility' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:pureItemType' id='fil_MinimumExpectedLife' name='MinimumExpectedLife' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:pureItemType' id='fil_MaximumExpectedLife' name='MaximumExpectedLife' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_NumberOfOptionsToPurchaseCommonStockGranted' name='NumberOfOptionsToPurchaseCommonStockGranted' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='num:perShareItemType' id='fil_OptionsExercisePrice' name='OptionsExercisePrice' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='num:perShareItemType' id='fil_CommonStockSharesGranted' name='CommonStockSharesGranted' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_STOCKHOLDERSEQUITYCompensationExpenseAbstract' abstract='true' name='STOCKHOLDERSEQUITYCompensationExpenseAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_RecognizedCompensationExpenses' name='RecognizedCompensationExpenses' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_STOCKHOLDERSEQUITYUnrecognizedCompensationExpenseAbstract' abstract='true' name='STOCKHOLDERSEQUITYUnrecognizedCompensationExpenseAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_TotalRemainingUnrecognizedCompensationExpenseRelatedToRestrictiveStockGrants' name='TotalRemainingUnrecognizedCompensationExpenseRelatedToRestrictiveStockGrants' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' abstract='true' id='fil_CONCENTRATIONSSalesAndPurchasesAbstract' substitutionGroup='xbrli:item' name='CONCENTRATIONSSalesAndPurchasesAbstract' />
	<element nillable='true' xbrli:periodType='duration' type='num:percentItemType' id='fil_PercentageOfNoCustomerAccountedForMoreThanSales' substitutionGroup='xbrli:item' name='PercentageOfNoCustomerAccountedForMoreThanSales' />
	<element nillable='true' xbrli:periodType='duration' type='num:percentItemType' id='fil_PercentageOfOneCustomerAccountedForMoreThanSales' substitutionGroup='xbrli:item' name='PercentageOfOneCustomerAccountedForMoreThanSales' />
	<element nillable='true' xbrli:periodType='duration' type='num:percentItemType' id='fil_PercentageOfPurchasesFromOneSupplierOfRawMaterials' substitutionGroup='xbrli:item' name='PercentageOfPurchasesFromOneSupplierOfRawMaterials' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' abstract='true' id='fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract' substitutionGroup='xbrli:item' name='FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_BankersAcceptanceNotes' substitutionGroup='xbrli:item' name='BankersAcceptanceNotes' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_BankersAcceptanceNotesLevel1' substitutionGroup='xbrli:item' name='BankersAcceptanceNotesLevel1' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_TotalLevel1' substitutionGroup='xbrli:item' name='TotalLevel1' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_BankersAcceptanceNotesLevel2' substitutionGroup='xbrli:item' name='BankersAcceptanceNotesLevel2' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_TotalLevel2' substitutionGroup='xbrli:item' name='TotalLevel2' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_BankersAcceptanceNotesLevel3' substitutionGroup='xbrli:item' name='BankersAcceptanceNotesLevel3' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_TotalLevel3' substitutionGroup='xbrli:item' name='TotalLevel3' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_ChangesInStockholderSEquityAbstract' abstract='true' name='ChangesInStockholderSEquityAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:sharesItemType' id='fil_IssuanceOfStockAsCompensation' name='IssuanceOfStockAsCompensation' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_ForeignCurrencyTranslationAdjustment' name='ForeignCurrencyTranslationAdjustment' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_ForeignCurrencyTranslationAdjustment1' name='ForeignCurrencyTranslationAdjustment1' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:sharesItemType' id='fil_ForfeitureOfContingentlyVestingShares' name='ForfeitureOfContingentlyVestingShares' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_NetIncomeForTheYear2011' name='NetIncomeForTheYear2011' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_NetIncomeForTheYear2012' name='NetIncomeForTheYear2012' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_AdvancesForPurchasesOfIntangibleAssets' substitutionGroup='xbrli:item' name='AdvancesForPurchasesOfIntangibleAssets' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_StockBasedCompensation' substitutionGroup='xbrli:item' name='StockBasedCompensation' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_AdvancesForPurchasesOfPropertyAndEquipmentPaidWithBankerSAcceptances' substitutionGroup='xbrli:item' name='AdvancesForPurchasesOfPropertyAndEquipmentPaidWithBankerSAcceptances' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances' substitutionGroup='xbrli:item' name='AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_ChangesInAdvancesToSuppliers' substitutionGroup='xbrli:item' name='ChangesInAdvancesToSuppliers' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_AdvancesForPaymentOfPurchasesOfPropertyAndEquipment' substitutionGroup='xbrli:item' name='AdvancesForPaymentOfPurchasesOfPropertyAndEquipment' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_AdvancesForPaymentOfPurchasesOfIntangibleAssets' substitutionGroup='xbrli:item' name='AdvancesForPaymentOfPurchasesOfIntangibleAssets' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' abstract='true' id='fil_DerivativeInstrumentsAndHedgingActivitiesAbstract' substitutionGroup='xbrli:item' name='DerivativeInstrumentsAndHedgingActivitiesAbstract' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' abstract='true' id='fil_CommitmentAndContingenciesAbstract' substitutionGroup='xbrli:item' name='CommitmentAndContingenciesAbstract' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' abstract='true' id='fil_AccountingPoliciesPoliciesAbstract' substitutionGroup='xbrli:item' name='AccountingPoliciesPoliciesAbstract' />
	<element nillable='true' xbrli:periodType='duration' type='nonnum:textBlockItemType' id='fil_IntangibleAssetsAmortizationExpense' name='IntangibleAssetsAmortizationExpense' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' abstract='true' id='fil_CompensationRelatedCostsShareBasedPaymentsAbstract' substitutionGroup='xbrli:item' name='CompensationRelatedCostsShareBasedPaymentsAbstract' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' abstract='true' id='fil_Leases1Abstract' substitutionGroup='xbrli:item' name='Leases1Abstract' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_OrganizationAndOperationsAbstract' abstract='true' name='OrganizationAndOperationsAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_BASISOFPRESENTATIONPOLICIESAbstract' abstract='true' name='BASISOFPRESENTATIONPOLICIESAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_RecognizedAnImpairmentLossOfItsIntangibleAssets' name='RecognizedAnImpairmentLossOfItsIntangibleAssets' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_CompanyContributionToRetirementBenefitPlans' name='CompanyContributionToRetirementBenefitPlans' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_INVENTORYABSTRACTAbstract' abstract='true' name='INVENTORYABSTRACTAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_AllowanceForObsolescenceRawMaterials' name='AllowanceForObsolescenceRawMaterials' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_TotalInventoryNet' name='TotalInventoryNet' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_TotalPropertyAndEquipment' name='TotalPropertyAndEquipment' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_LessAccumulatedDepreciationDetails' name='LessAccumulatedDepreciationDetails' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_AssetsDepreciationAbstract' abstract='true' name='AssetsDepreciationAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_DepreciationExpensePropertyAndEquipment' name='DepreciationExpensePropertyAndEquipment' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_AmortizationExpenseIntangibleAssets' name='AmortizationExpenseIntangibleAssets' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_AnnualAmortization2013' name='AnnualAmortization2013' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_AnnualAmortization2014' name='AnnualAmortization2014' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_AnnualAmortization2015' name='AnnualAmortization2015' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_AnnualAmortization2016' name='AnnualAmortization2016' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_AnnualAmortization2017' name='AnnualAmortization2017' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_AnnualAmortizationThereafter' name='AnnualAmortizationThereafter' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_AnnualAmortizationTotal' name='AnnualAmortizationTotal' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_CompanyObligationToPayLaboratoriesAndOthers' name='CompanyObligationToPayLaboratoriesAndOthers' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='num:percentItemType' id='fil_InterestRateOnAdvancesFromMemberOfBOD' name='InterestRateOnAdvancesFromMemberOfBOD' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_AccumulatedAmortizationIntangibleAssetsSFDAApprovedMedicalFormulas' name='AccumulatedAmortizationIntangibleAssetsSFDAApprovedMedicalFormulas' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' name='OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_ReconciliationOfIncomeTaxesAbstract' abstract='true' name='ReconciliationOfIncomeTaxesAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_NonDeductibleStockBasedCompensationFromAbstract' abstract='true' name='NonDeductibleStockBasedCompensationFromAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_CurrentAndPriorYears' name='CurrentAndPriorYears' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_EffectOfTaxHoliday' name='EffectOfTaxHoliday' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_OtherPrimarilyTheEffectOfUSTaxRates' name='OtherPrimarilyTheEffectOfUSTaxRates' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_DeferredIncomeTaxAssetsAbstract' abstract='true' name='DeferredIncomeTaxAssetsAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_InventoryObsolescenceReserve' name='InventoryObsolescenceReserve' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_ExpensesNotDeductibleInCurrentYear' name='ExpensesNotDeductibleInCurrentYear' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_DeferredIncomeTaxLiabilityAbstract' abstract='true' name='DeferredIncomeTaxLiabilityAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_TotalDeferredIncomeTaxAssets' name='TotalDeferredIncomeTaxAssets' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_AllowanceForDoubtfulTradeReceivablesDeferredTax' name='AllowanceForDoubtfulTradeReceivablesDeferredTax' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_AllowanceForDoubtfulOtherReceivablesDeferredTax' name='AllowanceForDoubtfulOtherReceivablesDeferredTax' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_NetDeferredIncomeTaxAsset' name='NetDeferredIncomeTaxAsset' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_DerivativeWarrantGainsAbstract' abstract='true' name='DerivativeWarrantGainsAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_DerivativeGainsRecognized' name='DerivativeGainsRecognized' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_Total1' substitutionGroup='xbrli:item' name='Total1' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='duration' type='xbrli:monetaryItemType' id='fil_IncomeTaxBenefitRecognizedFromStockBasedCompensation' substitutionGroup='xbrli:item' name='IncomeTaxBenefitRecognizedFromStockBasedCompensation' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_UnrecognizedCompensationExpenseRelatedToPerformanceBasedStockOptions' substitutionGroup='xbrli:item' name='UnrecognizedCompensationExpenseRelatedToPerformanceBasedStockOptions' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_UnrecognizedCompensationExpenseRelatedToFixedStockOptions' substitutionGroup='xbrli:item' name='UnrecognizedCompensationExpenseRelatedToFixedStockOptions' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' abstract='true' id='fil_STOCKHOLDERSEQUITYTOEXECUTIVEOFFICERS2010StockOptionPlanAbstract' substitutionGroup='xbrli:item' name='STOCKHOLDERSEQUITYTOEXECUTIVEOFFICERS2010StockOptionPlanAbstract' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_NumberOfCommonSharesIssuedToTwoExecutiveOfficers' substitutionGroup='xbrli:item' name='NumberOfCommonSharesIssuedToTwoExecutiveOfficers' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_NumberOfNonQualifiedStockOptionsToPurchaseCommonStock' substitutionGroup='xbrli:item' name='NumberOfNonQualifiedStockOptionsToPurchaseCommonStock' />
	<element nillable='true' xbrli:periodType='instant' type='num:perShareItemType' id='fil_ExercisePrice' substitutionGroup='xbrli:item' name='ExercisePrice' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_OptionsExpiringOnMay252013' substitutionGroup='xbrli:item' name='OptionsExpiringOnMay252013' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria' substitutionGroup='xbrli:item' name='OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_QualifiedStockOptionsGrantedToFormerCFONonQualifiedOptionsToPurchaseCommonStock' substitutionGroup='xbrli:item' name='QualifiedStockOptionsGrantedToFormerCFONonQualifiedOptionsToPurchaseCommonStock' />
	<element nillable='true' xbrli:periodType='instant' type='num:perShareItemType' id='fil_ExercisePrice1' substitutionGroup='xbrli:item' name='ExercisePrice1' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_OptionsVestedOnApril282013' substitutionGroup='xbrli:item' name='OptionsVestedOnApril282013' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria1' substitutionGroup='xbrli:item' name='OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria1' />
	<element nillable='true' xbrli:periodType='instant' type='num:perShareItemType' id='fil_GrantedDateFairValueOfTheOptionsPerShare' substitutionGroup='xbrli:item' name='GrantedDateFairValueOfTheOptionsPerShare' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_GrantedDateFairValueOfTheOptionsTotalValue' substitutionGroup='xbrli:item' name='GrantedDateFairValueOfTheOptionsTotalValue' />
	<element nillable='true' xbrli:periodType='instant' type='num:perShareItemType' id='fil_GrantedDateClosingMarketPrice' substitutionGroup='xbrli:item' name='GrantedDateClosingMarketPrice' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' abstract='true' id='fil_WeightedAverageAssumptionsAbstract' substitutionGroup='xbrli:item' name='WeightedAverageAssumptionsAbstract' />
	<element nillable='true' xbrli:periodType='instant' type='num:percentItemType' id='fil_RiskFreeInterestRate' substitutionGroup='xbrli:item' name='RiskFreeInterestRate' />
	<element nillable='true' xbrli:periodType='instant' type='num:percentItemType' id='fil_DividendYield' name='DividendYield' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='num:percentItemType' id='fil_ExpectedVolatality' name='ExpectedVolatality' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:pureItemType' id='fil_ExpectedPeriodOfLife' substitutionGroup='xbrli:item' name='ExpectedPeriodOfLife' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_STOCKHOLDERSEQUITYTOOFFICERS2010StockOptionPlanAbstract' abstract='true' name='STOCKHOLDERSEQUITYTOOFFICERS2010StockOptionPlanAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_NumberOfCommonSharesIssuedToExecutiveOfficers' name='NumberOfCommonSharesIssuedToExecutiveOfficers' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='credit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_ValueOfTheOptionsGranted' name='ValueOfTheOptionsGranted' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='num:perShareItemType' id='fil_ExercisePriceForOptionsGranted' name='ExercisePriceForOptionsGranted' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_RestrictedStockGrantedToCEO' name='RestrictedStockGrantedToCEO' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria' name='OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_OptionsVestedOnMay252012' name='OptionsVestedOnMay252012' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_RestrictedStockOptionsGrantedToFormerCFO' name='RestrictedStockOptionsGrantedToFormerCFO' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_OptionsVestedOnApril282012' name='OptionsVestedOnApril282012' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria1' name='OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria1' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_SharesForfeitedDueToNonAchievementOfPerformanceCriteria' name='SharesForfeitedDueToNonAchievementOfPerformanceCriteria' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_ShareBasedCompensationRelatedToTheFixedShareAwardsWasRecognizedOverThePeriodTheSharesVested' name='ShareBasedCompensationRelatedToTheFixedShareAwardsWasRecognizedOverThePeriodTheSharesVested' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='nonnum:domainItemType' id='fil_AggregateIntrinsicValueMember' name='AggregateIntrinsicValueMember' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='nonnum:domainItemType' id='fil_WeightedAverageRemainingContractualTermYearsMember' name='WeightedAverageRemainingContractualTermYearsMember' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='nonnum:domainItemType' id='fil_WeightedAverageExercisePriceMember' name='WeightedAverageExercisePriceMember' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='nonnum:domainItemType' id='fil_NoOfSharesMember' name='NoOfSharesMember' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' id='fil_SummaryOfStockOptionActivityAbstract' abstract='true' name='SummaryOfStockOptionActivityAbstract' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_OutstandingOptions' name='OutstandingOptions' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_OutstandingOptions1' name='OutstandingOptions1' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_ExercisableAtDecember312012' name='ExercisableAtDecember312012' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:sharesItemType' id='fil_Forfeited' name='Forfeited' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:sharesItemType' id='fil_Expired' name='Expired' substitutionGroup='xbrli:item' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_PaymentsMadeForConstructionInProgress' substitutionGroup='xbrli:item' name='PaymentsMadeForConstructionInProgress' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' abstract='true' id='fil_FutureMinimumPaymentsAsPerPurchaseAndConstructionAgreementsAbstract' substitutionGroup='xbrli:item' name='FutureMinimumPaymentsAsPerPurchaseAndConstructionAgreementsAbstract' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_ForTheYear2013' substitutionGroup='xbrli:item' name='ForTheYear2013' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_ForTheYear2014' substitutionGroup='xbrli:item' name='ForTheYear2014' />
	<element nillable='true' xbrli:balance='debit' xbrli:periodType='instant' type='xbrli:monetaryItemType' id='fil_TotalAmount' substitutionGroup='xbrli:item' name='TotalAmount' />
	<element nillable='true' xbrli:periodType='duration' type='num:percentItemType' id='fil_PercentageOfOneCustomerAccountedForAccountsReceivables' substitutionGroup='xbrli:item' name='PercentageOfOneCustomerAccountedForAccountsReceivables' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' abstract='true' id='fil_CONCENTRATIONSAccountsPayableAbstract' substitutionGroup='xbrli:item' name='CONCENTRATIONSAccountsPayableAbstract' />
	<element nillable='true' xbrli:periodType='instant' type='num:percentItemType' id='fil_PercentageOfAccountsPayableToTwoSuppliersForPurchaseOfRawMaterials' substitutionGroup='xbrli:item' name='PercentageOfAccountsPayableToTwoSuppliersForPurchaseOfRawMaterials' />
	<element nillable='true' xbrli:periodType='duration' type='xbrli:stringItemType' abstract='true' id='fil_DERIVATIVEWARRANTLIABILITYAbstract' substitutionGroup='xbrli:item' name='DERIVATIVEWARRANTLIABILITYAbstract' />
	<element nillable='true' xbrli:periodType='instant' type='xbrli:sharesItemType' id='fil_IssueOfWarrantsForPurchaseOfCommonStockTreatedAsDerivatives' substitutionGroup='xbrli:item' name='IssueOfWarrantsForPurchaseOfCommonStockTreatedAsDerivatives' />
	<element nillable='true' xbrli:periodType='instant' type='num:perShareItemType' id='fil_ValuePerShare' substitutionGroup='xbrli:item' name='ValuePerShare' />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>cphi-20121231_cal.xml
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- NeoClarus - iFile Suite version 4.2311  -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.chinapharmaholdings.com/20121231"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_CONSOLIDATEDBALANCESHEETS"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDBALANCESHEETS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesToSuppliers' xlink:label='fil_AdvancesToSuppliers'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='fil_AdvancesToSuppliers' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashEquivalentsAtCarryingValue'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_CashEquivalentsAtCarryingValue' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash' xlink:label='us-gaap_Cash'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_Cash' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent' xlink:label='us-gaap_DeferredTaxAssetsNetCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_DeferredTaxAssetsNetCurrent' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_InventoryNet' use='optional' order='5.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherReceivablesNetCurrent' xlink:label='us-gaap_OtherReceivablesNetCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_OtherReceivablesNetCurrent' use='optional' order='6.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ReceivablesNetCurrent' xlink:label='us-gaap_ReceivablesNetCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_AssetsCurrent' xlink:to='us-gaap_ReceivablesNetCurrent' use='optional' order='7.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesForPurchasesOfIntangibleAssets' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='fil_AdvancesForPurchasesOfIntangibleAssets' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesForPurchasesOfPropertyAndEquipment' xlink:label='fil_AdvancesForPurchasesOfPropertyAndEquipment'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='fil_AdvancesForPurchasesOfPropertyAndEquipment' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='4.0' weight='1.0'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_AssetsCurrent' use='optional' order='5.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_AccruedLiabilitiesCurrent' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TaxesPayableCurrent' xlink:label='us-gaap_TaxesPayableCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_TaxesPayableCurrent' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CustomerAdvancesCurrent' xlink:label='us-gaap_CustomerAdvancesCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_CustomerAdvancesCurrent' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableOtherCurrent' xlink:label='us-gaap_AccountsPayableOtherCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_AccountsPayableOtherCurrent' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent' xlink:label='us-gaap_DueToRelatedPartiesCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_DueToRelatedPartiesCurrent' use='optional' order='5.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesPayableCurrent' xlink:label='us-gaap_NotesPayableCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_NotesPayableCurrent' use='optional' order='6.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableTradeCurrent' xlink:label='us-gaap_AccountsPayableTradeCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='us-gaap_AccountsPayableTradeCurrent' use='optional' order='7.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent' xlink:label='us-gaap_DeferredTaxLiabilitiesNoncurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_DeferredTaxLiabilitiesNoncurrent' use='optional' order='1.0' weight='1.0'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Liabilities' xlink:to='us-gaap_LiabilitiesCurrent' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='us-gaap_Liabilities' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='us-gaap_StockholdersEquity' use='optional' order='2.0' weight='1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues' xlink:label='us-gaap_Revenues'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_Revenues' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfRevenue' xlink:label='us-gaap_CostOfRevenue'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_CostOfRevenue' use='optional' order='2.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryWriteDown' xlink:label='us-gaap_InventoryWriteDown'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_InventoryWriteDown' use='optional' order='3.0' weight='-1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense' xlink:label='us-gaap_GeneralAndAdministrativeExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_GeneralAndAdministrativeExpense' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment' xlink:label='us-gaap_GoodwillAndIntangibleAssetImpairment'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_GoodwillAndIntangibleAssetImpairment' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingExpense' xlink:label='us-gaap_SellingExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_SellingExpense' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_GovernmentSubsidyIncome' xlink:label='fil_GovernmentSubsidyIncome'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='fil_GovernmentSubsidyIncome' use='optional' order='1.0' weight='1.0'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='us-gaap_GrossProfit' use='optional' order='2.0' weight='1.0'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='us-gaap_OperatingExpenses' use='optional' order='3.0' weight='-1.0'/>
	</link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>cphi-20121231_def.xml
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- NeoClarus - iFile Suite version 4.2311  -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.chinapharmaholdings.com/20121231"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DocumentDocumentAndEntityInformation">
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_CONSOLIDATEDBALANCESHEETS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDBALANCESHEETS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_AssetsAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_AssetsAbstract' xlink:to='us-gaap_AssetsCurrentAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash' xlink:label='us-gaap_Cash'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_Cash' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashEquivalentsAtCarryingValue'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_CashEquivalentsAtCarryingValue' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ReceivablesNetCurrent' xlink:label='us-gaap_ReceivablesNetCurrent'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_ReceivablesNetCurrent' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherReceivablesNetCurrent' xlink:label='us-gaap_OtherReceivablesNetCurrent'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_OtherReceivablesNetCurrent' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesToSuppliers' xlink:label='fil_AdvancesToSuppliers'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='fil_AdvancesToSuppliers' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_InventoryNet' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent' xlink:label='us-gaap_DeferredTaxAssetsNetCurrent'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_DeferredTaxAssetsNetCurrent' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_AssetsCurrent' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesForPurchasesOfPropertyAndEquipment' xlink:label='fil_AdvancesForPurchasesOfPropertyAndEquipment'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_AssetsAbstract' xlink:to='fil_AdvancesForPurchasesOfPropertyAndEquipment' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesForPurchasesOfIntangibleAssets' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssets'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_AssetsAbstract' xlink:to='fil_AdvancesForPurchasesOfIntangibleAssets' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_AssetsAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_AssetsAbstract' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_AssetsAbstract' xlink:to='us-gaap_Assets' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_LiabilitiesAndStockholdersEquityAbstract' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_LiabilitiesCurrentAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableTradeCurrent' xlink:label='us-gaap_AccountsPayableTradeCurrent'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_AccountsPayableTradeCurrent' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_AccruedLiabilitiesCurrent' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TaxesPayableCurrent' xlink:label='us-gaap_TaxesPayableCurrent'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_TaxesPayableCurrent' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableOtherCurrent' xlink:label='us-gaap_AccountsPayableOtherCurrent'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_AccountsPayableOtherCurrent' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CustomerAdvancesCurrent' xlink:label='us-gaap_CustomerAdvancesCurrent'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_CustomerAdvancesCurrent' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent' xlink:label='us-gaap_DueToRelatedPartiesCurrent'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_DueToRelatedPartiesCurrent' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesPayableCurrent' xlink:label='us-gaap_NotesPayableCurrent'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_NotesPayableCurrent' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_LiabilitiesCurrent' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent' xlink:label='us-gaap_DeferredTaxLiabilitiesNoncurrent'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_DeferredTaxLiabilitiesNoncurrent' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_Liabilities' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_StockholdersEquityAbstract' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue' xlink:label='us-gaap_PreferredStockValue'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_PreferredStockValue' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_CommonStockValue' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital' xlink:label='us-gaap_AdditionalPaidInCapital'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_AdditionalPaidInCapital' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_RetainedEarningsAccumulatedDeficit' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_StockholdersEquity' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquity' use='optional' order='5.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent' xlink:label='us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AllowanceForDoubtfulAccountsOnOtherReceivables' xlink:label='fil_AllowanceForDoubtfulAccountsOnOtherReceivables'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AllowanceForDoubtfulAccountsOnOtherReceivables' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment' xlink:label='us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare' xlink:label='us-gaap_PreferredStockParOrStatedValuePerShare'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_PreferredStockParOrStatedValuePerShare' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized' xlink:label='us-gaap_PreferredStockSharesAuthorized'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_PreferredStockSharesAuthorized' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued' xlink:label='us-gaap_PreferredStockSharesIssued'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_PreferredStockSharesIssued' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding' xlink:label='us-gaap_PreferredStockSharesOutstanding'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_PreferredStockSharesOutstanding' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_CommonStockParOrStatedValuePerShare' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_CommonStockSharesAuthorized' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_CommonStockSharesIssued' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_CommonStockSharesOutstanding' use='optional' order='12.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues' xlink:label='us-gaap_Revenues'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_Revenues' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfRevenue' xlink:label='us-gaap_CostOfRevenue'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_CostOfRevenue' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryWriteDown' xlink:label='us-gaap_InventoryWriteDown'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_InventoryWriteDown' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_GrossProfit' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OperatingExpensesAbstract' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingExpense' xlink:label='us-gaap_SellingExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_SellingExpense' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense' xlink:label='us-gaap_GeneralAndAdministrativeExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_GeneralAndAdministrativeExpense' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment' xlink:label='us-gaap_GoodwillAndIntangibleAssetImpairment'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_GoodwillAndIntangibleAssetImpairment' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_OperatingExpenses' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_GovernmentSubsidyIncome' xlink:label='fil_GovernmentSubsidyIncome'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_GovernmentSubsidyIncome' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract' xlink:label='us-gaap_NonoperatingIncomeExpenseAbstract'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_NonoperatingIncomeExpenseAbstract' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest' xlink:label='us-gaap_InvestmentIncomeInterest'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_NonoperatingIncomeExpenseAbstract' xlink:to='us-gaap_InvestmentIncomeInterest' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense' xlink:label='us-gaap_InterestExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_NonoperatingIncomeExpenseAbstract' xlink:to='us-gaap_InterestExpense' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives' xlink:label='us-gaap_GainLossOnSaleOfDerivatives'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_NonoperatingIncomeExpenseAbstract' xlink:to='us-gaap_GainLossOnSaleOfDerivatives' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense' xlink:label='us-gaap_NonoperatingIncomeExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_NonoperatingIncomeExpenseAbstract' xlink:to='us-gaap_NonoperatingIncomeExpense' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease' xlink:label='us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ComprehensiveIncomeNetOfTax' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareAbstract' xlink:label='us-gaap_EarningsPerShareAbstract'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_EarningsPerShareAbstract' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EarningsPerShareAbstract' xlink:to='us-gaap_EarningsPerShareBasic' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EarningsPerShareAbstract' xlink:to='us-gaap_EarningsPerShareDiluted' use='optional' order='2.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementEquityComponentsAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalUnitsMember' xlink:label='us-gaap_CapitalUnitsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_CapitalUnitsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_CommonStockMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_AdditionalPaidInCapitalMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_RetainedEarningsMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeMember' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ParentMember' xlink:label='us-gaap_ParentMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_ParentMember' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NoOfSharesMember' xlink:label='fil_NoOfSharesMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='fil_NoOfSharesMember' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WeightedAverageExercisePriceMember' xlink:label='fil_WeightedAverageExercisePriceMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='fil_WeightedAverageExercisePriceMember' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WeightedAverageRemainingContractualTermYearsMember' xlink:label='fil_WeightedAverageRemainingContractualTermYearsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='fil_WeightedAverageRemainingContractualTermYearsMember' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AggregateIntrinsicValueMember' xlink:label='fil_AggregateIntrinsicValueMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='fil_AggregateIntrinsicValueMember' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues' xlink:label='us-gaap_StockIssuedDuringPeriodSharesNewIssues'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodSharesNewIssues' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_IssuanceOfStockAsCompensation' xlink:label='fil_IssuanceOfStockAsCompensation'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_IssuanceOfStockAsCompensation' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NetIncomeForTheYear2011' xlink:label='fil_NetIncomeForTheYear2011'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NetIncomeForTheYear2011' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ForeignCurrencyTranslationAdjustment' xlink:label='fil_ForeignCurrencyTranslationAdjustment'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ForeignCurrencyTranslationAdjustment' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ShareBasedCompensation' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ForfeitureOfContingentlyVestingShares' xlink:label='fil_ForfeitureOfContingentlyVestingShares'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ForfeitureOfContingentlyVestingShares' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NetIncomeForTheYear2012' xlink:label='fil_NetIncomeForTheYear2012'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NetIncomeForTheYear2012' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ForeignCurrencyTranslationAdjustment1' xlink:label='fil_ForeignCurrencyTranslationAdjustment1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ForeignCurrencyTranslationAdjustment1' use='optional' order='9.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss' xlink:label='us-gaap_NetIncomeLoss'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_NetIncomeLoss' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationAndAmortization' xlink:label='us-gaap_DepreciationAndAmortization'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_DepreciationAndAmortization' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_StockBasedCompensation' xlink:label='fil_StockBasedCompensation'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='fil_StockBasedCompensation' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DerivativeGain' xlink:label='fil_DerivativeGain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='fil_DerivativeGain' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BadDebtExpenseBenefit' xlink:label='fil_BadDebtExpenseBenefit'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='fil_BadDebtExpenseBenefit' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill' xlink:label='us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived' xlink:label='us-gaap_ImpairmentOfIntangibleAssetsFinitelived'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_ImpairmentOfIntangibleAssetsFinitelived' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_DeferredIncomeTaxExpenseBenefit' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:label='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables' xlink:label='us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ChangesInAdvancesToSuppliers' xlink:label='fil_ChangesInAdvancesToSuppliers'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='fil_ChangesInAdvancesToSuppliers' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInInventories' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayableTrade'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsPayableTrade' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccruedLiabilities' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable' xlink:label='us-gaap_IncreaseDecreaseInAccruedTaxesPayable'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccruedTaxesPayable' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInOtherAccountsPayable'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInOtherAccountsPayable' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInCustomerAdvances' xlink:label='us-gaap_IncreaseDecreaseInCustomerAdvances'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInCustomerAdvances' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivities' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NetInvestmentInBankerSAcceptances' xlink:label='fil_NetInvestmentInBankerSAcceptances'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='fil_NetInvestmentInBankerSAcceptances' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesForPaymentOfPurchasesOfPropertyAndEquipment' xlink:label='fil_AdvancesForPaymentOfPurchasesOfPropertyAndEquipment'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='fil_AdvancesForPaymentOfPurchasesOfPropertyAndEquipment' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesForPaymentOfPurchasesOfIntangibleAssets' xlink:label='fil_AdvancesForPaymentOfPurchasesOfIntangibleAssets'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='fil_AdvancesForPaymentOfPurchasesOfIntangibleAssets' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivities' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromNotesPayable' xlink:label='us-gaap_ProceedsFromNotesPayable'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_ProceedsFromNotesPayable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt' xlink:label='us-gaap_ProceedsFromRelatedPartyDebt'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_ProceedsFromRelatedPartyDebt' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivities' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease' xlink:label='us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract' xlink:label='us-gaap_SupplementalCashFlowInformationAbstract'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SupplementalCashFlowInformationAbstract' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid' xlink:label='us-gaap_InterestPaid'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_SupplementalCashFlowInformationAbstract' xlink:to='us-gaap_InterestPaid' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaidNet' xlink:label='us-gaap_IncomeTaxesPaidNet'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_SupplementalCashFlowInformationAbstract' xlink:to='us-gaap_IncomeTaxesPaidNet' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:label='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AccountsPayableForPurchasesOfPropertyAndEquipment' xlink:label='fil_AccountsPayableForPurchasesOfPropertyAndEquipment'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:to='fil_AccountsPayableForPurchasesOfPropertyAndEquipment' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AccountsReceivableCollectedWithBankerSAcceptances' xlink:label='fil_AccountsReceivableCollectedWithBankerSAcceptances'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:to='fil_AccountsReceivableCollectedWithBankerSAcceptances' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_InventoryPurchasedWithBankerSAcceptances' xlink:label='fil_InventoryPurchasedWithBankerSAcceptances'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:to='fil_InventoryPurchasedWithBankerSAcceptances' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesForPurchasesOfPropertyAndEquipmentPaidWithBankerSAcceptances' xlink:label='fil_AdvancesForPurchasesOfPropertyAndEquipmentPaidWithBankerSAcceptances'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:to='fil_AdvancesForPurchasesOfPropertyAndEquipmentPaidWithBankerSAcceptances' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances' xlink:label='fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:to='fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances' use='optional' order='5.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES">
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINVENTORY" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureINVENTORY"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINVENTORY">
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosurePROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosurePROPERTYANDEQUIPMENT"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosurePROPERTYANDEQUIPMENT">
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINTANGIBLEASSETS" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureINTANGIBLEASSETS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINTANGIBLEASSETS">
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS">
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureRELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureRELATEDPARTYTRANSACTIONS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureRELATEDPARTYTRANSACTIONS">
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureNOTESPAYABLE" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureNOTESPAYABLE"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureNOTESPAYABLE">
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINCOMETAXES" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureINCOMETAXES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINCOMETAXES">
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureDERIVATIVEWARRANTLIABILITY" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureDERIVATIVEWARRANTLIABILITY"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureDERIVATIVEWARRANTLIABILITY">
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureFAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureFAIRVALUEMEASUREMENTS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureFAIRVALUEMEASUREMENTS">
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureSTOCKHOLDERSEQUITY"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureSTOCKHOLDERSEQUITY">
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureCOMMITMENTSANDCONTINGENCIES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES">
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureCONCENTRATIONS" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureCONCENTRATIONS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureCONCENTRATIONS">
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureAccountingPoliciesPolicies"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureAccountingPoliciesPolicies">
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureBASISOFPRESENTATIONTables" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureBASISOFPRESENTATIONTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureBASISOFPRESENTATIONTables">
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINVENTORYTables" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureINVENTORYTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINVENTORYTables">
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosurePROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosurePROPERTYANDEQUIPMENTTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosurePROPERTYANDEQUIPMENTTables">
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINTANGIBLEASSETSTables" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureINTANGIBLEASSETSTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINTANGIBLEASSETSTables">
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINCOMETAXESTables" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureINCOMETAXESTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINCOMETAXESTables">
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureFAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureFAIRVALUEMEASUREMENTSTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureFAIRVALUEMEASUREMENTSTables">
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureSTOCKOPTIONACTIVITYTables" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureSTOCKOPTIONACTIVITYTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureSTOCKOPTIONACTIVITYTables">
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureFUTUREMINIMUMCOMMITMENTSTables" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureFUTUREMINIMUMCOMMITMENTSTables"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureFUTUREMINIMUMCOMMITMENTSTables">
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_BASISOFPRESENTATIONDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_BASISOFPRESENTATIONDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_BASISOFPRESENTATIONDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PercentageOfShareOwned' xlink:label='fil_PercentageOfShareOwned'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PercentageOfShareOwned' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PercentageOfShareOwnedofHelpsonMedicalAmpBiotechnologyCoLtd' xlink:label='fil_PercentageOfShareOwnedofHelpsonMedicalAmpBiotechnologyCoLtd'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PercentageOfShareOwnedofHelpsonMedicalAmpBiotechnologyCoLtd' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PercetageOfAcquiredByOnnyInHelpson' xlink:label='fil_PercetageOfAcquiredByOnnyInHelpson'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PercetageOfAcquiredByOnnyInHelpson' use='optional' order='3.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_BASISOFPRESENTATIONBasicAndDilutedEarningsPerCommonShareDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_BASISOFPRESENTATIONBasicAndDilutedEarningsPerCommonShareDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_BASISOFPRESENTATIONBasicAndDilutedEarningsPerCommonShareDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NetIncome' xlink:label='fil_NetIncome'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NetIncome' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesIssuedBasic'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_WeightedAverageNumberOfSharesIssuedBasic' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract' xlink:label='us-gaap_DilutiveSecuritiesAbstract'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DilutiveSecuritiesAbstract' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_Warrants' xlink:label='fil_Warrants'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_Warrants' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_Options' xlink:label='fil_Options'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_Options' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BasicEarningsPerShare' xlink:label='fil_BasicEarningsPerShare'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_BasicEarningsPerShare' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DilutedEarningsPerShare' xlink:label='fil_DilutedEarningsPerShare'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_DilutedEarningsPerShare' use='optional' order='8.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_BASISOFPRESENTATIONPOLICIESDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_BASISOFPRESENTATIONPOLICIESDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_BASISOFPRESENTATIONPOLICIESDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WarrantsWithExercisePrice' xlink:label='fil_WarrantsWithExercisePrice'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_WarrantsWithExercisePrice' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsWithAnExercisePrice' xlink:label='fil_OptionsWithAnExercisePrice'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OptionsWithAnExercisePrice' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalWarrantsAndOptions' xlink:label='fil_TotalWarrantsAndOptions'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_TotalWarrantsAndOptions' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RecognizedAnImpairmentLossOfItsIntangibleAssets' xlink:label='fil_RecognizedAnImpairmentLossOfItsIntangibleAssets'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RecognizedAnImpairmentLossOfItsIntangibleAssets' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CompanyContributionToRetirementBenefitPlans' xlink:label='fil_CompanyContributionToRetirementBenefitPlans'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CompanyContributionToRetirementBenefitPlans' use='optional' order='5.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_INVENTORYDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_INVENTORYDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_INVENTORYDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_InventoryRawMaterials' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryFinishedGoods' xlink:label='us-gaap_InventoryFinishedGoods'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_InventoryFinishedGoods' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryGross' xlink:label='us-gaap_InventoryGross'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_InventoryGross' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AllowanceForObsolescenceRawMaterials' xlink:label='fil_AllowanceForObsolescenceRawMaterials'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AllowanceForObsolescenceRawMaterials' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalInventoryNet' xlink:label='fil_TotalInventoryNet'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_TotalInventoryNet' use='optional' order='5.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_PROPERTYANDEQUIPMENTDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_PROPERTYANDEQUIPMENTDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_PROPERTYANDEQUIPMENTDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PermitOfLandUse' xlink:label='fil_PermitOfLandUse'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PermitOfLandUse' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BuildingsAndImprovementsGross' xlink:label='us-gaap_BuildingsAndImprovementsGross'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_BuildingsAndImprovementsGross' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PlantMachineryAndEquipmentGross' xlink:label='fil_PlantMachineryAndEquipmentGross'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PlantMachineryAndEquipmentGross' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_MotorVehicleGross' xlink:label='fil_MotorVehicleGross'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_MotorVehicleGross' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FurnitureAndFixturesGross' xlink:label='us-gaap_FurnitureAndFixturesGross'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_FurnitureAndFixturesGross' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConstructionInProgressGross' xlink:label='us-gaap_ConstructionInProgressGross'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ConstructionInProgressGross' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalPropertyAndEquipment' xlink:label='fil_TotalPropertyAndEquipment'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_TotalPropertyAndEquipment' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_LessAccumulatedDepreciationDetails' xlink:label='fil_LessAccumulatedDepreciationDetails'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_LessAccumulatedDepreciationDetails' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PropertyAndEquipmentNet' xlink:label='fil_PropertyAndEquipmentNet'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PropertyAndEquipmentNet' use='optional' order='9.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_PROPERTYANDEQUIPMENTAssetsLifeDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_PROPERTYANDEQUIPMENTAssetsLifeDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_PROPERTYANDEQUIPMENTAssetsLifeDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PermitOfLandUseMinimumLife' xlink:label='fil_PermitOfLandUseMinimumLife'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PermitOfLandUseMinimumLife' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PermitOfLandUseMaximumLife' xlink:label='fil_PermitOfLandUseMaximumLife'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PermitOfLandUseMaximumLife' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BuildingMinimumLife' xlink:label='fil_BuildingMinimumLife'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_BuildingMinimumLife' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BuildingMaximumLife' xlink:label='fil_BuildingMaximumLife'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_BuildingMaximumLife' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PlantMachineryAndEquipmentLife' xlink:label='fil_PlantMachineryAndEquipmentLife'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PlantMachineryAndEquipmentLife' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_MotorVehicleMinimumLife' xlink:label='fil_MotorVehicleMinimumLife'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_MotorVehicleMinimumLife' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_MotorVehicleMaximumLife' xlink:label='fil_MotorVehicleMaximumLife'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_MotorVehicleMaximumLife' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OfficeEquipmentMinimumLife' xlink:label='fil_OfficeEquipmentMinimumLife'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OfficeEquipmentMinimumLife' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OfficeEquipmentMaximumLife' xlink:label='fil_OfficeEquipmentMaximumLife'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OfficeEquipmentMaximumLife' use='optional' order='9.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_ASSETSDepreciationDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_ASSETSDepreciationDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_ASSETSDepreciationDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DepreciationExpensePropertyAndEquipment' xlink:label='fil_DepreciationExpensePropertyAndEquipment'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_DepreciationExpensePropertyAndEquipment' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AmortizationExpenseIntangibleAssets' xlink:label='fil_AmortizationExpenseIntangibleAssets'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AmortizationExpenseIntangibleAssets' use='optional' order='2.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_INTANGIBLEASSETSSFDAApprovedMedicalFormulasDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_INTANGIBLEASSETSSFDAApprovedMedicalFormulasDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_INTANGIBLEASSETSSFDAApprovedMedicalFormulasDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_GrossCarryingAmount' xlink:label='fil_GrossCarryingAmount'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_GrossCarryingAmount' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AccumulatedAmortizationIntangibleAssetsSFDAApprovedMedicalFormulas' xlink:label='fil_AccumulatedAmortizationIntangibleAssetsSFDAApprovedMedicalFormulas'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AccumulatedAmortizationIntangibleAssetsSFDAApprovedMedicalFormulas' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NetCarryingAmount' xlink:label='fil_NetCarryingAmount'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NetCarryingAmount' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AnnualAmortization2013' xlink:label='fil_AnnualAmortization2013'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AnnualAmortization2013' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AnnualAmortization2014' xlink:label='fil_AnnualAmortization2014'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AnnualAmortization2014' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AnnualAmortization2015' xlink:label='fil_AnnualAmortization2015'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AnnualAmortization2015' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AnnualAmortization2016' xlink:label='fil_AnnualAmortization2016'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AnnualAmortization2016' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AnnualAmortization2017' xlink:label='fil_AnnualAmortization2017'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AnnualAmortization2017' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AnnualAmortizationThereafter' xlink:label='fil_AnnualAmortizationThereafter'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AnnualAmortizationThereafter' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AnnualAmortizationTotal' xlink:label='fil_AnnualAmortizationTotal'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AnnualAmortizationTotal' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CompanyObligationToPayLaboratoriesAndOthers' xlink:label='fil_CompanyObligationToPayLaboratoriesAndOthers'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CompanyObligationToPayLaboratoriesAndOthers' use='optional' order='11.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_RELATEDPARTYTRANSACTIONSMemberOfBODDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_RELATEDPARTYTRANSACTIONSMemberOfBODDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_RELATEDPARTYTRANSACTIONSMemberOfBODDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AmountAdvancedByMemberOfBODToTheCompany' xlink:label='fil_AmountAdvancedByMemberOfBODToTheCompany'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AmountAdvancedByMemberOfBODToTheCompany' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_InterestRateOnAdvancesFromMemberOfBOD' xlink:label='fil_InterestRateOnAdvancesFromMemberOfBOD'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_InterestRateOnAdvancesFromMemberOfBOD' use='optional' order='2.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_RELATEDPARTYTRANSACTIONSOwingsDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_RELATEDPARTYTRANSACTIONSOwingsDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_RELATEDPARTYTRANSACTIONSOwingsDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdavanceOwingToBoardmember' xlink:label='fil_AdavanceOwingToBoardmember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AdavanceOwingToBoardmember' use='optional' order='1.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_NOTESPAYABLESDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_NOTESPAYABLESDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_NOTESPAYABLESDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RevolvingLineOfCreditWithABankRMD25000000' xlink:label='fil_RevolvingLineOfCreditWithABankRMD25000000'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RevolvingLineOfCreditWithABankRMD25000000' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AnnualInterestRate' xlink:label='fil_AnnualInterestRate'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AnnualInterestRate' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' xlink:label='fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' use='optional' order='3.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_INCOMETAXESUndistributedEarningsAndIncomeTaxRatesDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_INCOMETAXESUndistributedEarningsAndIncomeTaxRatesDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_INCOMETAXESUndistributedEarningsAndIncomeTaxRatesDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_UndistributedEarningsOfHelpson' xlink:label='fil_UndistributedEarningsOfHelpson'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_UndistributedEarningsOfHelpson' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany' xlink:label='fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_INCOMETAXESEnterpriseIncomeTaxRatesAbstract' xlink:label='fil_INCOMETAXESEnterpriseIncomeTaxRatesAbstract'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_INCOMETAXESEnterpriseIncomeTaxRatesAbstract' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_EnterpriseIncomeTaxRatesForTheYear2012' xlink:label='fil_EnterpriseIncomeTaxRatesForTheYear2012'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_EnterpriseIncomeTaxRatesForTheYear2012' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_EnterpriseIncomeTaxRatesForTheYear2013' xlink:label='fil_EnterpriseIncomeTaxRatesForTheYear2013'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_EnterpriseIncomeTaxRatesForTheYear2013' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_EnterpriseIncomeTaxRatesForTheYear2014AndAfter' xlink:label='fil_EnterpriseIncomeTaxRatesForTheYear2014AndAfter'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_EnterpriseIncomeTaxRatesForTheYear2014AndAfter' use='optional' order='6.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_INCOMETAXESProvisionDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_INCOMETAXESProvisionDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_INCOMETAXESProvisionDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit' xlink:label='us-gaap_CurrentIncomeTaxExpenseBenefit'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_CurrentIncomeTaxExpenseBenefit' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredFederalIncomeTaxExpenseBenefit'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DeferredFederalIncomeTaxExpenseBenefit' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalIncomeTaxExpense' xlink:label='fil_TotalIncomeTaxExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_TotalIncomeTaxExpense' use='optional' order='3.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_ReconciliationOfIncomeTaxesDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_ReconciliationOfIncomeTaxesDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_ReconciliationOfIncomeTaxesDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits' xlink:label='us-gaap_IncomeTaxReconciliationTaxCredits'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_IncomeTaxReconciliationTaxCredits' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NonDeductibleStockBasedCompensationFromAbstract' xlink:label='fil_NonDeductibleStockBasedCompensationFromAbstract'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NonDeductibleStockBasedCompensationFromAbstract' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CurrentAndPriorYears' xlink:label='fil_CurrentAndPriorYears'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CurrentAndPriorYears' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_EffectOfTaxHoliday' xlink:label='fil_EffectOfTaxHoliday'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_EffectOfTaxHoliday' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OtherPrimarilyTheEffectOfUSTaxRates' xlink:label='fil_OtherPrimarilyTheEffectOfUSTaxRates'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OtherPrimarilyTheEffectOfUSTaxRates' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance' xlink:label='us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate' xlink:label='us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate' use='optional' order='7.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_ChangesOfDeferredIncomeTaxAssetsAndLiabilityDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_ChangesOfDeferredIncomeTaxAssetsAndLiabilityDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_ChangesOfDeferredIncomeTaxAssetsAndLiabilityDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AllowanceForDoubtfulTradeReceivablesDeferredTax' xlink:label='fil_AllowanceForDoubtfulTradeReceivablesDeferredTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AllowanceForDoubtfulTradeReceivablesDeferredTax' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AllowanceForDoubtfulOtherReceivablesDeferredTax' xlink:label='fil_AllowanceForDoubtfulOtherReceivablesDeferredTax'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AllowanceForDoubtfulOtherReceivablesDeferredTax' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_InventoryObsolescenceReserve' xlink:label='fil_InventoryObsolescenceReserve'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_InventoryObsolescenceReserve' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExpensesNotDeductibleInCurrentYear' xlink:label='fil_ExpensesNotDeductibleInCurrentYear'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ExpensesNotDeductibleInCurrentYear' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost' xlink:label='us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards' xlink:label='us-gaap_DeferredTaxAssetsOperatingLossCarryforwards'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DeferredTaxAssetsOperatingLossCarryforwards' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalDeferredIncomeTaxAssets' xlink:label='fil_TotalDeferredIncomeTaxAssets'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_TotalDeferredIncomeTaxAssets' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance' xlink:label='us-gaap_DeferredTaxAssetsValuationAllowance'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DeferredTaxAssetsValuationAllowance' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NetDeferredIncomeTaxAsset' xlink:label='fil_NetDeferredIncomeTaxAsset'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NetDeferredIncomeTaxAsset' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DeferredIncomeTaxLiabilityAbstract' xlink:label='fil_DeferredIncomeTaxLiabilityAbstract'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_DeferredIncomeTaxLiabilityAbstract' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxLiabilities' xlink:label='us-gaap_DeferredTaxLiabilities'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DeferredTaxLiabilities' use='optional' order='11.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DERIVATIVEWARRANTLIABILITYDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DERIVATIVEWARRANTLIABILITYDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DERIVATIVEWARRANTLIABILITYDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_IssueOfWarrantsForPurchaseOfCommonStockTreatedAsDerivatives' xlink:label='fil_IssueOfWarrantsForPurchaseOfCommonStockTreatedAsDerivatives'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_IssueOfWarrantsForPurchaseOfCommonStockTreatedAsDerivatives' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ValuePerShare' xlink:label='fil_ValuePerShare'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ValuePerShare' use='optional' order='2.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DERIVATIVEWARRANTGAINSDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DERIVATIVEWARRANTGAINSDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DERIVATIVEWARRANTGAINSDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DerivativeGainsRecognized' xlink:label='fil_DerivativeGainsRecognized'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_DerivativeGainsRecognized' use='optional' order='1.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_FAIRVALUEMEASUREMENTSAtReportingDateUsingDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_FAIRVALUEMEASUREMENTSAtReportingDateUsingDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_FAIRVALUEMEASUREMENTSAtReportingDateUsingDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BankersAcceptanceNotes' xlink:label='fil_BankersAcceptanceNotes'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_BankersAcceptanceNotes' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_Total1' xlink:label='fil_Total1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_Total1' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BankersAcceptanceNotesLevel1' xlink:label='fil_BankersAcceptanceNotesLevel1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_BankersAcceptanceNotesLevel1' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalLevel1' xlink:label='fil_TotalLevel1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_TotalLevel1' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BankersAcceptanceNotesLevel2' xlink:label='fil_BankersAcceptanceNotesLevel2'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_BankersAcceptanceNotesLevel2' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalLevel2' xlink:label='fil_TotalLevel2'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_TotalLevel2' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BankersAcceptanceNotesLevel3' xlink:label='fil_BankersAcceptanceNotesLevel3'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_BankersAcceptanceNotesLevel3' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalLevel3' xlink:label='fil_TotalLevel3'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_TotalLevel3' use='optional' order='8.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_PreferredCommonStockAndWarrantsDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_PreferredCommonStockAndWarrantsDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_PreferredCommonStockAndWarrantsDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CommonSharesAuthorized' xlink:label='fil_CommonSharesAuthorized'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonSharesAuthorized' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PreferredSharesAuthorized' xlink:label='fil_PreferredSharesAuthorized'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PreferredSharesAuthorized' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NumberOfCommonStockSharesToPurchaseByWarrantsOutstaningAndExercisable' xlink:label='fil_NumberOfCommonStockSharesToPurchaseByWarrantsOutstaningAndExercisable'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NumberOfCommonStockSharesToPurchaseByWarrantsOutstaningAndExercisable' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WarrantsStartRangeExercisePrice' xlink:label='fil_WarrantsStartRangeExercisePrice'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_WarrantsStartRangeExercisePrice' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WarrantsEndRangeExercisePrice' xlink:label='fil_WarrantsEndRangeExercisePrice'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_WarrantsEndRangeExercisePrice' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WarrantsWeightedAverageExercisePrice' xlink:label='fil_WarrantsWeightedAverageExercisePrice'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_WarrantsWeightedAverageExercisePrice' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WarrantsWeightedAverageContractualLife' xlink:label='fil_WarrantsWeightedAverageContractualLife'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_WarrantsWeightedAverageContractualLife' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalIntrinsicValue' xlink:label='fil_TotalIntrinsicValue'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_TotalIntrinsicValue' use='optional' order='8.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_StockOptionPlanDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_StockOptionPlanDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_StockOptionPlanDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NumberOfCommonShares' xlink:label='fil_NumberOfCommonShares'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NumberOfCommonShares' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NumberOfCommonSharesPurchasedByOptions' xlink:label='fil_NumberOfCommonSharesPurchasedByOptions'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NumberOfCommonSharesPurchasedByOptions' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_StockOptionsGranted' xlink:label='fil_StockOptionsGranted'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_StockOptionsGranted' use='optional' order='3.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_StockOptionPlanFrankWaungDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_StockOptionPlanFrankWaungDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_StockOptionPlanFrankWaungDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_VestedAndUnexercisedOptions' xlink:label='fil_VestedAndUnexercisedOptions'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_VestedAndUnexercisedOptions' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NumberOfDaysOpposedAfterTheEmploymentTerminationDate' xlink:label='fil_NumberOfDaysOpposedAfterTheEmploymentTerminationDate'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NumberOfDaysOpposedAfterTheEmploymentTerminationDate' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CommonSharesGranted' xlink:label='fil_CommonSharesGranted'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonSharesGranted' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RecordedCompensationExpense' xlink:label='fil_RecordedCompensationExpense'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RecordedCompensationExpense' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_FairValueOf185000OptionsCancelled' xlink:label='fil_FairValueOf185000OptionsCancelled'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_FairValueOf185000OptionsCancelled' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_FairValueOf100000CommonSharesExchanged' xlink:label='fil_FairValueOf100000CommonSharesExchanged'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_FairValueOf100000CommonSharesExchanged' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ClosingMarketPriceOfCommonStock' xlink:label='fil_ClosingMarketPriceOfCommonStock'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ClosingMarketPriceOfCommonStock' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_StartingRiskFreeInterestRate' xlink:label='fil_StartingRiskFreeInterestRate'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_StartingRiskFreeInterestRate' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ClosingRiskFreeInterestRate' xlink:label='fil_ClosingRiskFreeInterestRate'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ClosingRiskFreeInterestRate' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExpectedDividendYield' xlink:label='fil_ExpectedDividendYield'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ExpectedDividendYield' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExpectedVolatility' xlink:label='fil_ExpectedVolatility'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ExpectedVolatility' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_MinimumExpectedLife' xlink:label='fil_MinimumExpectedLife'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_MinimumExpectedLife' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_MaximumExpectedLife' xlink:label='fil_MaximumExpectedLife'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_MaximumExpectedLife' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NumberOfOptionsToPurchaseCommonStockGranted' xlink:label='fil_NumberOfOptionsToPurchaseCommonStockGranted'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NumberOfOptionsToPurchaseCommonStockGranted' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsExercisePrice' xlink:label='fil_OptionsExercisePrice'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OptionsExercisePrice' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CommonStockSharesGranted' xlink:label='fil_CommonStockSharesGranted'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockSharesGranted' use='optional' order='16.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CompensationExpenseDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_CompensationExpenseDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_CompensationExpenseDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RecognizedCompensationExpenses' xlink:label='fil_RecognizedCompensationExpenses'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RecognizedCompensationExpenses' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_IncomeTaxBenefitRecognizedFromStockBasedCompensation' xlink:label='fil_IncomeTaxBenefitRecognizedFromStockBasedCompensation'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_IncomeTaxBenefitRecognizedFromStockBasedCompensation' use='optional' order='2.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_UnrecognizedCompensationExpenseDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_UnrecognizedCompensationExpenseDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_UnrecognizedCompensationExpenseDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_UnrecognizedCompensationExpenseRelatedToPerformanceBasedStockOptions' xlink:label='fil_UnrecognizedCompensationExpenseRelatedToPerformanceBasedStockOptions'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_UnrecognizedCompensationExpenseRelatedToPerformanceBasedStockOptions' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_UnrecognizedCompensationExpenseRelatedToFixedStockOptions' xlink:label='fil_UnrecognizedCompensationExpenseRelatedToFixedStockOptions'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_UnrecognizedCompensationExpenseRelatedToFixedStockOptions' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalRemainingUnrecognizedCompensationExpenseRelatedToRestrictiveStockGrants' xlink:label='fil_TotalRemainingUnrecognizedCompensationExpenseRelatedToRestrictiveStockGrants'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_TotalRemainingUnrecognizedCompensationExpenseRelatedToRestrictiveStockGrants' use='optional' order='3.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_EXECUTIVEOFFICERS2010StockOptionPlanDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_EXECUTIVEOFFICERS2010StockOptionPlanDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_EXECUTIVEOFFICERS2010StockOptionPlanDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NumberOfCommonSharesIssuedToTwoExecutiveOfficers' xlink:label='fil_NumberOfCommonSharesIssuedToTwoExecutiveOfficers'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NumberOfCommonSharesIssuedToTwoExecutiveOfficers' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NumberOfNonQualifiedStockOptionsToPurchaseCommonStock' xlink:label='fil_NumberOfNonQualifiedStockOptionsToPurchaseCommonStock'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NumberOfNonQualifiedStockOptionsToPurchaseCommonStock' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExercisePrice' xlink:label='fil_ExercisePrice'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ExercisePrice' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsExpiringOnMay252013' xlink:label='fil_OptionsExpiringOnMay252013'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OptionsExpiringOnMay252013' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria' xlink:label='fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_QualifiedStockOptionsGrantedToFormerCFONonQualifiedOptionsToPurchaseCommonStock' xlink:label='fil_QualifiedStockOptionsGrantedToFormerCFONonQualifiedOptionsToPurchaseCommonStock'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_QualifiedStockOptionsGrantedToFormerCFONonQualifiedOptionsToPurchaseCommonStock' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExercisePrice1' xlink:label='fil_ExercisePrice1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ExercisePrice1' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsVestedOnApril282013' xlink:label='fil_OptionsVestedOnApril282013'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OptionsVestedOnApril282013' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria1' xlink:label='fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria1' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_GrantedDateFairValueOfTheOptionsPerShare' xlink:label='fil_GrantedDateFairValueOfTheOptionsPerShare'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_GrantedDateFairValueOfTheOptionsPerShare' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_GrantedDateFairValueOfTheOptionsTotalValue' xlink:label='fil_GrantedDateFairValueOfTheOptionsTotalValue'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_GrantedDateFairValueOfTheOptionsTotalValue' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_GrantedDateClosingMarketPrice' xlink:label='fil_GrantedDateClosingMarketPrice'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_GrantedDateClosingMarketPrice' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WeightedAverageAssumptionsAbstract' xlink:label='fil_WeightedAverageAssumptionsAbstract'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_WeightedAverageAssumptionsAbstract' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RiskFreeInterestRate' xlink:label='fil_RiskFreeInterestRate'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RiskFreeInterestRate' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DividendYield' xlink:label='fil_DividendYield'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_DividendYield' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExpectedVolatality' xlink:label='fil_ExpectedVolatality'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ExpectedVolatality' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExpectedPeriodOfLife' xlink:label='fil_ExpectedPeriodOfLife'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ExpectedPeriodOfLife' use='optional' order='17.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_OFFICERS2010StockOptionPlanDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_OFFICERS2010StockOptionPlanDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_OFFICERS2010StockOptionPlanDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NumberOfCommonSharesIssuedToExecutiveOfficers' xlink:label='fil_NumberOfCommonSharesIssuedToExecutiveOfficers'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NumberOfCommonSharesIssuedToExecutiveOfficers' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ValueOfTheOptionsGranted' xlink:label='fil_ValueOfTheOptionsGranted'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ValueOfTheOptionsGranted' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExercisePriceForOptionsGranted' xlink:label='fil_ExercisePriceForOptionsGranted'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ExercisePriceForOptionsGranted' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RestrictedStockGrantedToCEO' xlink:label='fil_RestrictedStockGrantedToCEO'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RestrictedStockGrantedToCEO' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria' xlink:label='fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsVestedOnMay252012' xlink:label='fil_OptionsVestedOnMay252012'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OptionsVestedOnMay252012' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RestrictedStockOptionsGrantedToFormerCFO' xlink:label='fil_RestrictedStockOptionsGrantedToFormerCFO'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RestrictedStockOptionsGrantedToFormerCFO' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsVestedOnApril282012' xlink:label='fil_OptionsVestedOnApril282012'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OptionsVestedOnApril282012' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria1' xlink:label='fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria1' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_SharesForfeitedDueToNonAchievementOfPerformanceCriteria' xlink:label='fil_SharesForfeitedDueToNonAchievementOfPerformanceCriteria'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_SharesForfeitedDueToNonAchievementOfPerformanceCriteria' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ShareBasedCompensationRelatedToTheFixedShareAwardsWasRecognizedOverThePeriodTheSharesVested' xlink:label='fil_ShareBasedCompensationRelatedToTheFixedShareAwardsWasRecognizedOverThePeriodTheSharesVested'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ShareBasedCompensationRelatedToTheFixedShareAwardsWasRecognizedOverThePeriodTheSharesVested' use='optional' order='11.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_SummaryOfStockOptionActivityDetailsStockholdersEquity" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_SummaryOfStockOptionActivityDetailsStockholdersEquity"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_SummaryOfStockOptionActivityDetailsStockholdersEquity">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/hypercube-dimension' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementEquityComponentsAxis' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-domain' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain' xlink:label='us-gaap_EquityComponentDomain_1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/dimension-default' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_EquityComponentDomain_1' use='optional' order='1.0' xbrldt:contextElement='segment'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalUnitsMember' xlink:label='us-gaap_CapitalUnitsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_CapitalUnitsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_CommonStockMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_AdditionalPaidInCapitalMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_RetainedEarningsMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeMember' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ParentMember' xlink:label='us-gaap_ParentMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='us-gaap_ParentMember' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NoOfSharesMember' xlink:label='fil_NoOfSharesMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='fil_NoOfSharesMember' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WeightedAverageExercisePriceMember' xlink:label='fil_WeightedAverageExercisePriceMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='fil_WeightedAverageExercisePriceMember' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WeightedAverageRemainingContractualTermYearsMember' xlink:label='fil_WeightedAverageRemainingContractualTermYearsMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='fil_WeightedAverageRemainingContractualTermYearsMember' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AggregateIntrinsicValueMember' xlink:label='fil_AggregateIntrinsicValueMember'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_EquityComponentDomain' xlink:to='fil_AggregateIntrinsicValueMember' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OutstandingOptions' xlink:label='fil_OutstandingOptions'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OutstandingOptions' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_Forfeited' xlink:label='fil_Forfeited'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_Forfeited' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_Expired' xlink:label='fil_Expired'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_Expired' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OutstandingOptions1' xlink:label='fil_OutstandingOptions1'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OutstandingOptions1' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExercisableAtDecember312012' xlink:label='fil_ExercisableAtDecember312012'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ExercisableAtDecember312012' use='optional' order='5.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_COMMITMENTSANDCONTINGENCIESDETAILS" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_COMMITMENTSANDCONTINGENCIESDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_COMMITMENTSANDCONTINGENCIESDETAILS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PaymentsMadeForConstructionInProgress' xlink:label='fil_PaymentsMadeForConstructionInProgress'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PaymentsMadeForConstructionInProgress' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_FutureMinimumPaymentsAsPerPurchaseAndConstructionAgreementsAbstract' xlink:label='fil_FutureMinimumPaymentsAsPerPurchaseAndConstructionAgreementsAbstract'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_FutureMinimumPaymentsAsPerPurchaseAndConstructionAgreementsAbstract' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ForTheYear2013' xlink:label='fil_ForTheYear2013'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ForTheYear2013' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ForTheYear2014' xlink:label='fil_ForTheYear2014'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ForTheYear2014' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalAmount' xlink:label='fil_TotalAmount'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_TotalAmount' use='optional' order='5.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CONCENTRATIONSSalesAndPurchasesDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_CONCENTRATIONSSalesAndPurchasesDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_CONCENTRATIONSSalesAndPurchasesDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PercentageOfNoCustomerAccountedForMoreThanSales' xlink:label='fil_PercentageOfNoCustomerAccountedForMoreThanSales'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PercentageOfNoCustomerAccountedForMoreThanSales' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PercentageOfOneCustomerAccountedForMoreThanSales' xlink:label='fil_PercentageOfOneCustomerAccountedForMoreThanSales'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PercentageOfOneCustomerAccountedForMoreThanSales' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PercentageOfPurchasesFromOneSupplierOfRawMaterials' xlink:label='fil_PercentageOfPurchasesFromOneSupplierOfRawMaterials'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PercentageOfPurchasesFromOneSupplierOfRawMaterials' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PercentageOfOneCustomerAccountedForAccountsReceivables' xlink:label='fil_PercentageOfOneCustomerAccountedForAccountsReceivables'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PercentageOfOneCustomerAccountedForAccountsReceivables' use='optional' order='4.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CONCENTRATIONSAccountsPayableDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_CONCENTRATIONSAccountsPayableDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_CONCENTRATIONSAccountsPayableDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PercentageOfAccountsPayableToTwoSuppliersForPurchaseOfRawMaterials' xlink:label='fil_PercentageOfAccountsPayableToTwoSuppliersForPurchaseOfRawMaterials'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/domain-member' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PercentageOfAccountsPayableToTwoSuppliersForPurchaseOfRawMaterials' use='optional' order='1.0'/>
		<link:definitionArc xlink:type='arc' xlink:arcrole='http://xbrl.org/int/dim/arcrole/all' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StatementTable' order='0.5' xbrldt:contextElement='segment' use='optional'/>
	</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>cphi-20121231_lab.xml
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- NeoClarus - iFile Suite version 4.2311  -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.chinapharmaholdings.com/20121231"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PercentageOfOneCustomerAccountedForMoreThanSales' xlink:label='fil_PercentageOfOneCustomerAccountedForMoreThanSales'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfOneCustomerAccountedForMoreThanSales' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Percentage of one customer accounted for more than sales</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfOneCustomerAccountedForMoreThanSales' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Percentage of one customer accounted for more than sales</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PercentageOfOneCustomerAccountedForMoreThanSales' xlink:to='lab_fil_PercentageOfOneCustomerAccountedForMoreThanSales'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NoOfSharesMember' xlink:label='fil_NoOfSharesMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NoOfSharesMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>No. Of shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NoOfSharesMember' xlink:to='lab_fil_NoOfSharesMember'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NumberOfCommonSharesIssuedToExecutiveOfficers' xlink:label='fil_NumberOfCommonSharesIssuedToExecutiveOfficers'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NumberOfCommonSharesIssuedToExecutiveOfficers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of common shares issued to executive officers</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NumberOfCommonSharesIssuedToExecutiveOfficers' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Number of common shares issued to executive officers</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NumberOfCommonSharesIssuedToExecutiveOfficers' xlink:to='lab_fil_NumberOfCommonSharesIssuedToExecutiveOfficers'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NumberOfNonQualifiedStockOptionsToPurchaseCommonStock' xlink:label='fil_NumberOfNonQualifiedStockOptionsToPurchaseCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NumberOfNonQualifiedStockOptionsToPurchaseCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of non-qualified stock options to purchase common stock</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NumberOfNonQualifiedStockOptionsToPurchaseCommonStock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Number of non-qualified stock options to purchase common stock</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NumberOfNonQualifiedStockOptionsToPurchaseCommonStock' xlink:to='lab_fil_NumberOfNonQualifiedStockOptionsToPurchaseCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WarrantsWeightedAverageContractualLife' xlink:label='fil_WarrantsWeightedAverageContractualLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_WarrantsWeightedAverageContractualLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Warrants weighted average contractual life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_WarrantsWeightedAverageContractualLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Warrants weighted average contractual life</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_WarrantsWeightedAverageContractualLife' xlink:to='lab_fil_WarrantsWeightedAverageContractualLife'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost' xlink:label='us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Share based compensation deferred tax</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost' xlink:to='lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_InventoryObsolescenceReserve' xlink:label='fil_InventoryObsolescenceReserve'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InventoryObsolescenceReserve' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory obsolescence reserve</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_InventoryObsolescenceReserve' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Inventory obsolescence reserve</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InventoryObsolescenceReserve' xlink:to='lab_fil_InventoryObsolescenceReserve'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AnnualAmortization2013' xlink:label='fil_AnnualAmortization2013'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AnnualAmortization2013' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Annual amortization 2013</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AnnualAmortization2013' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Annual amortization 2013</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AnnualAmortization2013' xlink:to='lab_fil_AnnualAmortization2013'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_INTANGIBLEASSETSSFDAApprovedMedicalFormulasAbstract' xlink:label='fil_INTANGIBLEASSETSSFDAApprovedMedicalFormulasAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_INTANGIBLEASSETSSFDAApprovedMedicalFormulasAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INTANGIBLE ASSETS SFDA Approved Medical Formulas</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_INTANGIBLEASSETSSFDAApprovedMedicalFormulasAbstract' xlink:to='lab_fil_INTANGIBLEASSETSSFDAApprovedMedicalFormulasAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WarrantsWithExercisePrice' xlink:label='fil_WarrantsWithExercisePrice'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_WarrantsWithExercisePrice' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Warrants with exercise prices of $3.00 to $3.80 per share</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_WarrantsWithExercisePrice' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Warrants with exercise prices of $3.00 to $3.80 per share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_WarrantsWithExercisePrice' xlink:to='lab_fil_WarrantsWithExercisePrice'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OrganizationAndOperationsAbstract' xlink:label='fil_OrganizationAndOperationsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OrganizationAndOperationsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Organization and operations</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OrganizationAndOperationsAbstract' xlink:to='lab_fil_OrganizationAndOperationsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_IncomeTaxesTablesAbstract' xlink:label='fil_IncomeTaxesTablesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IncomeTaxesTablesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INCOME TAXES (Tables)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IncomeTaxesTablesAbstract' xlink:to='lab_fil_IncomeTaxesTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock' xlink:label='us-gaap_EarningsPerSharePolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerSharePolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Basic and Diluted Earnings per Common Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerSharePolicyTextBlock' xlink:to='lab_us-gaap_EarningsPerSharePolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock' xlink:label='us-gaap_CompensationRelatedCostsPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CompensationRelatedCostsPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retirement Benefit Plans</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CompensationRelatedCostsPolicyTextBlock' xlink:to='lab_us-gaap_CompensationRelatedCostsPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_InventoryPurchasedWithBankerSAcceptances' xlink:label='fil_InventoryPurchasedWithBankerSAcceptances'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InventoryPurchasedWithBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory purchased with banker&apos;s acceptances</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_InventoryPurchasedWithBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Inventory purchased with banker&apos;s acceptances</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InventoryPurchasedWithBankerSAcceptances' xlink:to='lab_fil_InventoryPurchasedWithBankerSAcceptances'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net Cash Provided by Financing Activity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInInventories' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInInventories' xlink:to='lab_us-gaap_IncreaseDecreaseInInventories'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue' xlink:label='us-gaap_PreferredStockValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockValue' xlink:to='lab_us-gaap_PreferredStockValue'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent' xlink:label='us-gaap_DueToRelatedPartiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DueToRelatedPartiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other payables - related parties</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DueToRelatedPartiesCurrent' xlink:to='lab_us-gaap_DueToRelatedPartiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>LIABILITIES AND STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryNet' xlink:to='lab_us-gaap_InventoryNet'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DocumentAndEntityInformationAbstract' xlink:label='fil_DocumentAndEntityInformationAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DocumentAndEntityInformationAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document and Entity Information</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='lab_fil_DocumentAndEntityInformationAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OutstandingOptions1' xlink:label='fil_OutstandingOptions1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutstandingOptions1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Outstanding options.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutstandingOptions1' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Outstanding options.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutstandingOptions1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Outstanding options ending balance</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OutstandingOptions1' xlink:to='lab_fil_OutstandingOptions1'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria' xlink:label='fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Options to vest on six month anniversary performance based vesting criteria</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Options to vest on six month anniversary performance based vesting criteria</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria' xlink:to='lab_fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_QualifiedStockOptionsGrantedToFormerCFONonQualifiedOptionsToPurchaseCommonStock' xlink:label='fil_QualifiedStockOptionsGrantedToFormerCFONonQualifiedOptionsToPurchaseCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_QualifiedStockOptionsGrantedToFormerCFONonQualifiedOptionsToPurchaseCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Qualified stock options granted to former CFO non qualified options to purchase common stock</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_QualifiedStockOptionsGrantedToFormerCFONonQualifiedOptionsToPurchaseCommonStock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Qualified stock options granted to former CFO non qualified options to purchase common stock</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_QualifiedStockOptionsGrantedToFormerCFONonQualifiedOptionsToPurchaseCommonStock' xlink:to='lab_fil_QualifiedStockOptionsGrantedToFormerCFONonQualifiedOptionsToPurchaseCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExpectedDividendYield' xlink:label='fil_ExpectedDividendYield'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ExpectedDividendYield' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Expected dividend yield</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ExpectedDividendYield' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Expected dividend yield</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ExpectedDividendYield' xlink:to='lab_fil_ExpectedDividendYield'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BankersAcceptanceNotesLevel1' xlink:label='fil_BankersAcceptanceNotesLevel1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotesLevel1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bankers acceptance notes Level 1</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotesLevel1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Bankers acceptance notes Level 1</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BankersAcceptanceNotesLevel1' xlink:to='lab_fil_BankersAcceptanceNotesLevel1'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AllowanceForDoubtfulTradeReceivablesDeferredTax' xlink:label='fil_AllowanceForDoubtfulTradeReceivablesDeferredTax'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AllowanceForDoubtfulTradeReceivablesDeferredTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Allowance for doubtful trade receivables deferred tax</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AllowanceForDoubtfulTradeReceivablesDeferredTax' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Allowance for doubtful trade receivables deferred tax</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AllowanceForDoubtfulTradeReceivablesDeferredTax' xlink:to='lab_fil_AllowanceForDoubtfulTradeReceivablesDeferredTax'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AnnualAmortization2017' xlink:label='fil_AnnualAmortization2017'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AnnualAmortization2017' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Annual amortization 2017</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AnnualAmortization2017' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Annual amortization 2017</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AnnualAmortization2017' xlink:to='lab_fil_AnnualAmortization2017'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BuildingsAndImprovementsGross' xlink:label='us-gaap_BuildingsAndImprovementsGross'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_BuildingsAndImprovementsGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Building</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_BuildingsAndImprovementsGross' xlink:to='lab_us-gaap_BuildingsAndImprovementsGross'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PermitOfLandUse' xlink:label='fil_PermitOfLandUse'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PermitOfLandUse' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Permit of land use</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PermitOfLandUse' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The amount of permit of land use as on the date.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PermitOfLandUse' xlink:to='lab_fil_PermitOfLandUse'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_FairValueMeasurementsTablesAbstract' xlink:label='fil_FairValueMeasurementsTablesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_FairValueMeasurementsTablesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>FAIR VALUE MEASUREMENTS (Tables)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_FairValueMeasurementsTablesAbstract' xlink:to='lab_fil_FairValueMeasurementsTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment consists</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentTextBlock' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory consists</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueRecognitionPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Revenue Recognition</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueRecognitionPolicyTextBlock' xlink:to='lab_us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaidNet' xlink:label='us-gaap_IncomeTaxesPaidNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxesPaidNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash paid for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxesPaidNet' xlink:to='lab_us-gaap_IncomeTaxesPaidNet'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net Cash Provided by Operating Activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable' xlink:label='us-gaap_IncreaseDecreaseInAccruedTaxesPayable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued taxes payable.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccruedTaxesPayable' xlink:to='lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables' xlink:label='us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trade accounts and other receivables.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DerivativeGain' xlink:label='fil_DerivativeGain'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DerivativeGain' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Derivative gain.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DerivativeGain' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DerivativeGain' xlink:to='lab_fil_DerivativeGain'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NetIncomeForTheYear2012' xlink:label='fil_NetIncomeForTheYear2012'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetIncomeForTheYear2012' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net income for the year 2012</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetIncomeForTheYear2012' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NetIncomeForTheYear2012' xlink:to='lab_fil_NetIncomeForTheYear2012'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues' xlink:label='us-gaap_StockIssuedDuringPeriodSharesNewIssues'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Issuance of options as compensation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockIssuedDuringPeriodSharesNewIssues' xlink:to='lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, shares authorized</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesAuthorized' xlink:to='lab_us-gaap_CommonStockSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract' xlink:label='us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stockholders equity number of shares par value and other disclosures</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract' xlink:to='lab_us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent' xlink:label='us-gaap_DeferredTaxAssetsNetCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxAssetsNetCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred tax assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxAssetsNetCurrent' xlink:to='lab_us-gaap_DeferredTaxAssetsNetCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Common Stock, Shares Outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PaymentsMadeForConstructionInProgress' xlink:label='fil_PaymentsMadeForConstructionInProgress'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PaymentsMadeForConstructionInProgress' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Payments made for Construction in Progress</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PaymentsMadeForConstructionInProgress' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Payments made for Construction in Progress</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PaymentsMadeForConstructionInProgress' xlink:to='lab_fil_PaymentsMadeForConstructionInProgress'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsVestedOnApril282012' xlink:label='fil_OptionsVestedOnApril282012'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OptionsVestedOnApril282012' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Options vested on April 28, 2012</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OptionsVestedOnApril282012' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Options vested on April 28, 2012</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OptionsVestedOnApril282012' xlink:to='lab_fil_OptionsVestedOnApril282012'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_GrantedDateFairValueOfTheOptionsPerShare' xlink:label='fil_GrantedDateFairValueOfTheOptionsPerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_GrantedDateFairValueOfTheOptionsPerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Granted date fair value of the options per share</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_GrantedDateFairValueOfTheOptionsPerShare' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Granted date fair value of the options per share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_GrantedDateFairValueOfTheOptionsPerShare' xlink:to='lab_fil_GrantedDateFairValueOfTheOptionsPerShare'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NumberOfOptionsToPurchaseCommonStockGranted' xlink:label='fil_NumberOfOptionsToPurchaseCommonStockGranted'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NumberOfOptionsToPurchaseCommonStockGranted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of options to purchase common stock granted</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NumberOfOptionsToPurchaseCommonStockGranted' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Number of options to purchase common stock granted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NumberOfOptionsToPurchaseCommonStockGranted' xlink:to='lab_fil_NumberOfOptionsToPurchaseCommonStockGranted'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_STOCKHOLDERSEQUITY2010StockOptionPlanFrankWaungAbstract' xlink:label='fil_STOCKHOLDERSEQUITY2010StockOptionPlanFrankWaungAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_STOCKHOLDERSEQUITY2010StockOptionPlanFrankWaungAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>STOCKHOLDERS EQUITY 2010 Stock Option Plan Frank Waung</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_STOCKHOLDERSEQUITY2010StockOptionPlanFrankWaungAbstract' xlink:to='lab_fil_STOCKHOLDERSEQUITY2010StockOptionPlanFrankWaungAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BankersAcceptanceNotesLevel3' xlink:label='fil_BankersAcceptanceNotesLevel3'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotesLevel3' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bankers acceptance notes Level 3</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotesLevel3' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Bankers acceptance notes Level 3</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BankersAcceptanceNotesLevel3' xlink:to='lab_fil_BankersAcceptanceNotesLevel3'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DerivativeGainsRecognized' xlink:label='fil_DerivativeGainsRecognized'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DerivativeGainsRecognized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Derivative gains recognized</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DerivativeGainsRecognized' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Derivative gains recognized</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DerivativeGainsRecognized' xlink:to='lab_fil_DerivativeGainsRecognized'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DERIVATIVEWARRANTLIABILITYAbstract' xlink:label='fil_DERIVATIVEWARRANTLIABILITYAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DERIVATIVEWARRANTLIABILITYAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>DERIVATIVE WARRANT LIABILITY {2}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DERIVATIVEWARRANTLIABILITYAbstract' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>DERIVATIVE WARRANT LIABILITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DERIVATIVEWARRANTLIABILITYAbstract' xlink:to='lab_fil_DERIVATIVEWARRANTLIABILITYAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RelatedPartyTransactionMemberOwingsAbstract' xlink:label='fil_RelatedPartyTransactionMemberOwingsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RelatedPartyTransactionMemberOwingsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>RELATED PARTY TRANSACTIONS Owings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RelatedPartyTransactionMemberOwingsAbstract' xlink:to='lab_fil_RelatedPartyTransactionMemberOwingsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OfficeEquipmentMaximumLife' xlink:label='fil_OfficeEquipmentMaximumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OfficeEquipmentMaximumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Office equipment maximum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OfficeEquipmentMaximumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OfficeEquipmentMaximumLife' xlink:to='lab_fil_OfficeEquipmentMaximumLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalInventoryNet' xlink:label='fil_TotalInventoryNet'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalInventoryNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Inventory net</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalInventoryNet' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalInventoryNet' xlink:to='lab_fil_TotalInventoryNet'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PercentageOfShareOwnedofHelpsonMedicalAmpBiotechnologyCoLtd' xlink:label='fil_PercentageOfShareOwnedofHelpsonMedicalAmpBiotechnologyCoLtd'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfShareOwnedofHelpsonMedicalAmpBiotechnologyCoLtd' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Percentage of share owned by China Pharma Holdings Inc of Helpson Medical &amp; Biotechnology Co., Ltd</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfShareOwnedofHelpsonMedicalAmpBiotechnologyCoLtd' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Percentage of share owned by China Pharma Holdings Inc of Helpson Medical &amp;amp; Biotechnology Co., Ltd</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PercentageOfShareOwnedofHelpsonMedicalAmpBiotechnologyCoLtd' xlink:to='lab_fil_PercentageOfShareOwnedofHelpsonMedicalAmpBiotechnologyCoLtd'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock' xlink:label='us-gaap_ReceivablesPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ReceivablesPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trade Accounts Receivable and Allowance for Doubtful Accounts</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ReceivablesPolicyTextBlock' xlink:to='lab_us-gaap_ReceivablesPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativesAndFairValueTextBlock' xlink:label='us-gaap_DerivativesAndFairValueTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DerivativesAndFairValueTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>DERIVATIVE WARRANT LIABILITY {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DerivativesAndFairValueTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>DERIVATIVE WARRANT LIABILITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DerivativesAndFairValueTextBlock' xlink:to='lab_us-gaap_DerivativesAndFairValueTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NotesPayable1Abstract' xlink:label='fil_NotesPayable1Abstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NotesPayable1Abstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>NOTES PAYABLE</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NotesPayable1Abstract' xlink:to='lab_fil_NotesPayable1Abstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesForPurchasesOfPropertyAndEquipmentPaidWithBankerSAcceptances' xlink:label='fil_AdvancesForPurchasesOfPropertyAndEquipmentPaidWithBankerSAcceptances'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfPropertyAndEquipmentPaidWithBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances for purchases of property and equipment paid with banker&apos;s acceptances</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfPropertyAndEquipmentPaidWithBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Advances for purchases of property and equipment paid with banker&apos;s acceptances</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesForPurchasesOfPropertyAndEquipmentPaidWithBankerSAcceptances' xlink:to='lab_fil_AdvancesForPurchasesOfPropertyAndEquipmentPaidWithBankerSAcceptances'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease' xlink:label='us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net Increase (Decrease) in Cash</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease' xlink:to='lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived' xlink:label='us-gaap_ImpairmentOfIntangibleAssetsFinitelived'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory obsolescence provision</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ImpairmentOfIntangibleAssetsFinitelived' xlink:to='lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock, $0.001 par value; 95,000,000 shares authorized; 43,579,557 shares and 43,529,557 shares outstanding, respectively</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockValue' xlink:to='lab_us-gaap_CommonStockValue'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible assets, net of accumulated amortization of $2,944,726 and $3,041,804, respectively</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalPeriodFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Period Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalPeriodFocus' xlink:to='lab_dei_DocumentFiscalPeriodFocus'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ForTheYear2014' xlink:label='fil_ForTheYear2014'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ForTheYear2014' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>For the year 2014</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ForTheYear2014' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>For the year 2014</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ForTheYear2014' xlink:to='lab_fil_ForTheYear2014'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AggregateIntrinsicValueMember' xlink:label='fil_AggregateIntrinsicValueMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AggregateIntrinsicValueMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Aggregate Intrinsic value</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AggregateIntrinsicValueMember' xlink:to='lab_fil_AggregateIntrinsicValueMember'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_GrantedDateClosingMarketPrice' xlink:label='fil_GrantedDateClosingMarketPrice'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_GrantedDateClosingMarketPrice' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Granted date closing market price</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_GrantedDateClosingMarketPrice' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Granted date closing market price</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_GrantedDateClosingMarketPrice' xlink:to='lab_fil_GrantedDateClosingMarketPrice'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_UnrecognizedCompensationExpenseRelatedToFixedStockOptions' xlink:label='fil_UnrecognizedCompensationExpenseRelatedToFixedStockOptions'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_UnrecognizedCompensationExpenseRelatedToFixedStockOptions' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Unrecognized compensation expense related to fixed stock options</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_UnrecognizedCompensationExpenseRelatedToFixedStockOptions' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Unrecognized compensation expense related to fixed stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_UnrecognizedCompensationExpenseRelatedToFixedStockOptions' xlink:to='lab_fil_UnrecognizedCompensationExpenseRelatedToFixedStockOptions'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_STOCKHOLDERSEQUITYCompensationExpenseAbstract' xlink:label='fil_STOCKHOLDERSEQUITYCompensationExpenseAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_STOCKHOLDERSEQUITYCompensationExpenseAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>STOCKHOLDERS EQUITY Compensation Expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_STOCKHOLDERSEQUITYCompensationExpenseAbstract' xlink:to='lab_fil_STOCKHOLDERSEQUITYCompensationExpenseAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RecordedCompensationExpense' xlink:label='fil_RecordedCompensationExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RecordedCompensationExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Recorded compensation expense</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_RecordedCompensationExpense' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Recorded compensation expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RecordedCompensationExpense' xlink:to='lab_fil_RecordedCompensationExpense'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CommonSharesAuthorized' xlink:label='fil_CommonSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common shares authorized</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum number of common shares permitted to be issued by an entity&apos;s charter and bylaws.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonSharesAuthorized' xlink:to='lab_fil_CommonSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_UndistributedEarningsOfHelpson' xlink:label='fil_UndistributedEarningsOfHelpson'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_UndistributedEarningsOfHelpson' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Undistributed earnings of Helpson</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_UndistributedEarningsOfHelpson' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Undistributed earnings of Helpson</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_UndistributedEarningsOfHelpson' xlink:to='lab_fil_UndistributedEarningsOfHelpson'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' xlink:label='fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Outstanding balance due under revolving line of credit (RMB 30,000,000)</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Outstanding balance due under revolving line of credit (RMB 30,000,000)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' xlink:to='lab_fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DepreciationExpensePropertyAndEquipment' xlink:label='fil_DepreciationExpensePropertyAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DepreciationExpensePropertyAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Depreciation Expense property and equipment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DepreciationExpensePropertyAndEquipment' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Depreciation Expense property and equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DepreciationExpensePropertyAndEquipment' xlink:to='lab_fil_DepreciationExpensePropertyAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PROPERTYANDEQUIPMENTAssetsLifeAbstract' xlink:label='fil_PROPERTYANDEQUIPMENTAssetsLifeAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PROPERTYANDEQUIPMENTAssetsLifeAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>PROPERTY AND EQUIPMENT Assets Life</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PROPERTYANDEQUIPMENTAssetsLifeAbstract' xlink:to='lab_fil_PROPERTYANDEQUIPMENTAssetsLifeAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_Options' xlink:label='fil_Options'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_Options' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Options</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_Options' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The amount of options.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_Options' xlink:to='lab_fil_Options'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_InventoryTablesAbstract' xlink:label='fil_InventoryTablesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InventoryTablesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INVENTORY (Tables)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InventoryTablesAbstract' xlink:to='lab_fil_InventoryTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:label='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Presentation of the numerators and denominators used in the calculation of basic and diluted earnings per share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:label='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Supplemental Noncash Investing and Financing Activities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:to='lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash and Cash Equivalents at Beginning of Period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Cash and Cash Equivalents at Beginning of Period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Cash and Cash Equivalents at End of Period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:to='lab_us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesForPaymentOfPurchasesOfIntangibleAssets' xlink:label='fil_AdvancesForPaymentOfPurchasesOfIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPaymentOfPurchasesOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances for payment of purchases of intangible assets.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPaymentOfPurchasesOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Advances for payment of purchases of intangible assets.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesForPaymentOfPurchasesOfIntangibleAssets' xlink:to='lab_fil_AdvancesForPaymentOfPurchasesOfIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ForeignCurrencyTranslationAdjustment' xlink:label='fil_ForeignCurrencyTranslationAdjustment'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ForeignCurrencyTranslationAdjustment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Foreign currency translation adjustment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ForeignCurrencyTranslationAdjustment' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency of the reporting entity, net of tax.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ForeignCurrencyTranslationAdjustment' xlink:to='lab_fil_ForeignCurrencyTranslationAdjustment'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ParentMember' xlink:label='us-gaap_ParentMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ParentMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Stockholders&apos; Equity {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ParentMember' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Total Stockholders&apos; Equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ParentMember' xlink:to='lab_us-gaap_ParentMember'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock Amount</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockMember' xlink:to='lab_us-gaap_CommonStockMember'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalUnitsMember' xlink:label='us-gaap_CapitalUnitsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CapitalUnitsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock Shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CapitalUnitsMember' xlink:to='lab_us-gaap_CapitalUnitsMember'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract' xlink:label='us-gaap_NonoperatingIncomeExpenseAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NonoperatingIncomeExpenseAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other income (expense):</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NonoperatingIncomeExpenseAbstract' xlink:to='lab_us-gaap_NonoperatingIncomeExpenseAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues' xlink:label='us-gaap_Revenues'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Revenues' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Revenue</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Revenues' xlink:to='lab_us-gaap_Revenues'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized' xlink:label='us-gaap_PreferredStockSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred Stock, shares authorized</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockSharesAuthorized' xlink:to='lab_us-gaap_PreferredStockSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated amortization on intangible assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CONCENTRATIONSSalesAndPurchasesAbstract' xlink:label='fil_CONCENTRATIONSSalesAndPurchasesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CONCENTRATIONSSalesAndPurchasesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CONCENTRATIONS Sales And Purchases</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CONCENTRATIONSSalesAndPurchasesAbstract' xlink:to='lab_fil_CONCENTRATIONSSalesAndPurchasesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_SummaryOfStockOptionActivityAbstract' xlink:label='fil_SummaryOfStockOptionActivityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_SummaryOfStockOptionActivityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Summary of stock option activity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_SummaryOfStockOptionActivityAbstract' xlink:to='lab_fil_SummaryOfStockOptionActivityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExpectedVolatality' xlink:label='fil_ExpectedVolatality'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ExpectedVolatality' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Expected volatality</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ExpectedVolatality' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Expected volatality</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ExpectedVolatality' xlink:to='lab_fil_ExpectedVolatality'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExercisePrice' xlink:label='fil_ExercisePrice'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ExercisePrice' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Exercise Price</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ExercisePrice' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Exercise Price</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ExercisePrice' xlink:to='lab_fil_ExercisePrice'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ClosingMarketPriceOfCommonStock' xlink:label='fil_ClosingMarketPriceOfCommonStock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ClosingMarketPriceOfCommonStock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Closing market price of common stock</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ClosingMarketPriceOfCommonStock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Closing market price of common stock</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ClosingMarketPriceOfCommonStock' xlink:to='lab_fil_ClosingMarketPriceOfCommonStock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WarrantsEndRangeExercisePrice' xlink:label='fil_WarrantsEndRangeExercisePrice'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_WarrantsEndRangeExercisePrice' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Warrants end range exercise price</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_WarrantsEndRangeExercisePrice' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Warrants start range exercise price.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_WarrantsEndRangeExercisePrice' xlink:to='lab_fil_WarrantsEndRangeExercisePrice'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards' xlink:label='us-gaap_DeferredTaxAssetsOperatingLossCarryforwards'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>U.S. net operating loss carry forwards</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxAssetsOperatingLossCarryforwards' xlink:to='lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_EffectOfTaxHoliday' xlink:label='fil_EffectOfTaxHoliday'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EffectOfTaxHoliday' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Effect of tax holiday</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_EffectOfTaxHoliday' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>A tax &quot;holiday&quot; refers to the tax benefit derived from a jurisdiction that provides an exemption from income taxes for some defined period of time as an incentive to attract business.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EffectOfTaxHoliday' xlink:to='lab_fil_EffectOfTaxHoliday'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_EnterpriseIncomeTaxRatesForTheYear2012' xlink:label='fil_EnterpriseIncomeTaxRatesForTheYear2012'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRatesForTheYear2012' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Enterprise Income Tax Rates for the year 2012</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRatesForTheYear2012' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Enterprise Income Tax Rates for the year 2012</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EnterpriseIncomeTaxRatesForTheYear2012' xlink:to='lab_fil_EnterpriseIncomeTaxRatesForTheYear2012'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AnnualAmortization2014' xlink:label='fil_AnnualAmortization2014'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AnnualAmortization2014' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Annual amortization 2014</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AnnualAmortization2014' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Annual amortization 2014</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AnnualAmortization2014' xlink:to='lab_fil_AnnualAmortization2014'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BuildingMinimumLife' xlink:label='fil_BuildingMinimumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BuildingMinimumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Building minimum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BuildingMinimumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BuildingMinimumLife' xlink:to='lab_fil_BuildingMinimumLife'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FurnitureAndFixturesGross' xlink:label='us-gaap_FurnitureAndFixturesGross'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FurnitureAndFixturesGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Office equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FurnitureAndFixturesGross' xlink:to='lab_us-gaap_FurnitureAndFixturesGross'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsWithAnExercisePrice' xlink:label='fil_OptionsWithAnExercisePrice'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OptionsWithAnExercisePrice' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Options with an exercise price of $2.54 to $3.47 per share</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OptionsWithAnExercisePrice' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Options with an exercise price of $2.54 to $3.47 per share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OptionsWithAnExercisePrice' xlink:to='lab_fil_OptionsWithAnExercisePrice'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock' xlink:label='us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred Tax Assets and Liabilities.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_IntangibleAssetsAmortizationExpense' xlink:label='fil_IntangibleAssetsAmortizationExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssetsAmortizationExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible Assets Amortization Expense</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssetsAmortizationExpense' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Table text block that refers to Intangible Assets Amortization Expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IntangibleAssetsAmortizationExpense' xlink:to='lab_fil_IntangibleAssetsAmortizationExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash Flows from Financing Activity:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Purchase of property and equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:to='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ForfeitureOfContingentlyVestingShares' xlink:label='fil_ForfeitureOfContingentlyVestingShares'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ForfeitureOfContingentlyVestingShares' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Forfeiture of contingently vesting shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ForfeitureOfContingentlyVestingShares' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Forfeiture of contingently vesting shares</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ForfeitureOfContingentlyVestingShares' xlink:to='lab_fil_ForfeitureOfContingentlyVestingShares'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense' xlink:label='us-gaap_GeneralAndAdministrativeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GeneralAndAdministrativeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>General and administrative expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GeneralAndAdministrativeExpense' xlink:to='lab_us-gaap_GeneralAndAdministrativeExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Current Liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='lab_us-gaap_LiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesPayableCurrent' xlink:label='us-gaap_NotesPayableCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NotesPayableCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Short-term notes payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NotesPayableCurrent' xlink:to='lab_us-gaap_NotesPayableCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current Assets:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='lab_us-gaap_AssetsCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PercentageOfPurchasesFromOneSupplierOfRawMaterials' xlink:label='fil_PercentageOfPurchasesFromOneSupplierOfRawMaterials'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfPurchasesFromOneSupplierOfRawMaterials' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Percentage of purchases from one supplier of raw materials</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfPurchasesFromOneSupplierOfRawMaterials' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Percentage of purchases from one supplier of raw materials</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PercentageOfPurchasesFromOneSupplierOfRawMaterials' xlink:to='lab_fil_PercentageOfPurchasesFromOneSupplierOfRawMaterials'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExercisableAtDecember312012' xlink:label='fil_ExercisableAtDecember312012'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ExercisableAtDecember312012' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Exercisable at December 31, 2012</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ExercisableAtDecember312012' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Exercisable at December 31, 2012</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ExercisableAtDecember312012' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Exercisable at December 31, 2012</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ExercisableAtDecember312012' xlink:to='lab_fil_ExercisableAtDecember312012'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ValueOfTheOptionsGranted' xlink:label='fil_ValueOfTheOptionsGranted'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ValueOfTheOptionsGranted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Value of the options granted</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ValueOfTheOptionsGranted' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Value of the options granted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ValueOfTheOptionsGranted' xlink:to='lab_fil_ValueOfTheOptionsGranted'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExercisePrice1' xlink:label='fil_ExercisePrice1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ExercisePrice1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Exercise Price.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ExercisePrice1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Exercise Price.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ExercisePrice1' xlink:to='lab_fil_ExercisePrice1'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExpectedVolatility' xlink:label='fil_ExpectedVolatility'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ExpectedVolatility' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Expected volatility</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ExpectedVolatility' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Expected volatility</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ExpectedVolatility' xlink:to='lab_fil_ExpectedVolatility'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExpensesNotDeductibleInCurrentYear' xlink:label='fil_ExpensesNotDeductibleInCurrentYear'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ExpensesNotDeductibleInCurrentYear' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Expenses not deductible in current year</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ExpensesNotDeductibleInCurrentYear' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Expenses not deductible in current year</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ExpensesNotDeductibleInCurrentYear' xlink:to='lab_fil_ExpensesNotDeductibleInCurrentYear'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_EnterpriseIncomeTaxRatesForTheYear2014AndAfter' xlink:label='fil_EnterpriseIncomeTaxRatesForTheYear2014AndAfter'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRatesForTheYear2014AndAfter' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Enterprise Income Tax Rates for the year 2014 and after</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRatesForTheYear2014AndAfter' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Enterprise Income Tax Rates for the year 2014 and after</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EnterpriseIncomeTaxRatesForTheYear2014AndAfter' xlink:to='lab_fil_EnterpriseIncomeTaxRatesForTheYear2014AndAfter'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AnnualAmortizationThereafter' xlink:label='fil_AnnualAmortizationThereafter'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AnnualAmortizationThereafter' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Annual amortization Thereafter</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AnnualAmortizationThereafter' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Annual amortization Thereafter</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AnnualAmortizationThereafter' xlink:to='lab_fil_AnnualAmortizationThereafter'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_GrossCarryingAmount' xlink:label='fil_GrossCarryingAmount'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_GrossCarryingAmount' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gross carrying amount</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_GrossCarryingAmount' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Gross carrying amount</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_GrossCarryingAmount' xlink:to='lab_fil_GrossCarryingAmount'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PlantMachineryAndEquipmentGross' xlink:label='fil_PlantMachineryAndEquipmentGross'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PlantMachineryAndEquipmentGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Plant, machinery and equipment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PlantMachineryAndEquipmentGross' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The amount of plant machinery and equipment gross as on the date.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PlantMachineryAndEquipmentGross' xlink:to='lab_fil_PlantMachineryAndEquipmentGross'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BASISOFPRESENTATIONPOLICIESAbstract' xlink:label='fil_BASISOFPRESENTATIONPOLICIESAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BASISOFPRESENTATIONPOLICIESAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>BASIS OF PRESENTATION POLICIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BASISOFPRESENTATIONPOLICIESAbstract' xlink:to='lab_fil_BASISOFPRESENTATIONPOLICIESAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_IncomeTaxesTableTextBlock' xlink:label='fil_IncomeTaxesTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IncomeTaxesTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current Taxes</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_IncomeTaxesTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Tabluar disclosure of Provision For Income Taxes.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IncomeTaxesTableTextBlock' xlink:to='lab_fil_IncomeTaxesTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract' xlink:label='us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INTANGIBLE ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract' xlink:to='lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract' xlink:label='us-gaap_SupplementalCashFlowInformationAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SupplementalCashFlowInformationAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Supplemental Cash Flow Information:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SupplementalCashFlowInformationAbstract' xlink:to='lab_us-gaap_SupplementalCashFlowInformationAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BadDebtExpenseBenefit' xlink:label='fil_BadDebtExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BadDebtExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bad debt expense (benefit).</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BadDebtExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected).</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BadDebtExpenseBenefit' xlink:to='lab_fil_BadDebtExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash Flows from Operating Activities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareBasic' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Basic</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareBasic' xlink:to='lab_us-gaap_EarningsPerShareBasic'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stockholders&apos; Equity:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='lab_us-gaap_StockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesForPurchasesOfIntangibleAssets' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances for purchases of intangible assets:</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Advances for purchases of intangible assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesForPurchasesOfIntangibleAssets' xlink:to='lab_fil_AdvancesForPurchasesOfIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherReceivablesNetCurrent' xlink:label='us-gaap_OtherReceivablesNetCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherReceivablesNetCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other receivables, less allowance for doubtful accounts of $49,881 and $38,921, respectively</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherReceivablesNetCurrent' xlink:to='lab_us-gaap_OtherReceivablesNetCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Type</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsVestedOnMay252012' xlink:label='fil_OptionsVestedOnMay252012'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OptionsVestedOnMay252012' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Options vested on May 25, 2012</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OptionsVestedOnMay252012' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Options vested on May 25, 2012</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OptionsVestedOnMay252012' xlink:to='lab_fil_OptionsVestedOnMay252012'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_STOCKHOLDERSEQUITY2010StockOptionPlanAbstract' xlink:label='fil_STOCKHOLDERSEQUITY2010StockOptionPlanAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_STOCKHOLDERSEQUITY2010StockOptionPlanAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>STOCKHOLDERS EQUITY 2010 Stock Option Plan</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_STOCKHOLDERSEQUITY2010StockOptionPlanAbstract' xlink:to='lab_fil_STOCKHOLDERSEQUITY2010StockOptionPlanAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalLevel1' xlink:label='fil_TotalLevel1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalLevel1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Level 1</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalLevel1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Bankers acceptance notes total Level 1</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalLevel1' xlink:to='lab_fil_TotalLevel1'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AllowanceForDoubtfulOtherReceivablesDeferredTax' xlink:label='fil_AllowanceForDoubtfulOtherReceivablesDeferredTax'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AllowanceForDoubtfulOtherReceivablesDeferredTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Allowance for doubtful other receivables deferred tax</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AllowanceForDoubtfulOtherReceivablesDeferredTax' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Allowance for doubtful other receivables deferred tax</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AllowanceForDoubtfulOtherReceivablesDeferredTax' xlink:to='lab_fil_AllowanceForDoubtfulOtherReceivablesDeferredTax'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance' xlink:label='us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Change in valuation allowance Reconciliation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance' xlink:to='lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_InterestRateOnAdvancesFromMemberOfBOD' xlink:label='fil_InterestRateOnAdvancesFromMemberOfBOD'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InterestRateOnAdvancesFromMemberOfBOD' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interest rate on advances from Member of BOD</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_InterestRateOnAdvancesFromMemberOfBOD' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Interest rate on advances from Member of BOD</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InterestRateOnAdvancesFromMemberOfBOD' xlink:to='lab_fil_InterestRateOnAdvancesFromMemberOfBOD'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AmountAdvancedByMemberOfBODToTheCompany' xlink:label='fil_AmountAdvancedByMemberOfBODToTheCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AmountAdvancedByMemberOfBODToTheCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amount advanced by Member of BOD to the Company</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AmountAdvancedByMemberOfBODToTheCompany' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Advance from member of board of director.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AmountAdvancedByMemberOfBODToTheCompany' xlink:to='lab_fil_AmountAdvancedByMemberOfBODToTheCompany'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_MotorVehicleMaximumLife' xlink:label='fil_MotorVehicleMaximumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_MotorVehicleMaximumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Motor vehicle maximum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_MotorVehicleMaximumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_MotorVehicleMaximumLife' xlink:to='lab_fil_MotorVehicleMaximumLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_INVENTORYABSTRACTAbstract' xlink:label='fil_INVENTORYABSTRACTAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_INVENTORYABSTRACTAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INVENTORY ABSTRACT</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_INVENTORYABSTRACTAbstract' xlink:to='lab_fil_INVENTORYABSTRACTAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AssetsFairValuesTablETextBlock' xlink:label='fil_AssetsFairValuesTablETextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AssetsFairValuesTablETextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Assets Fair Value</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AssetsFairValuesTablETextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Tabular disclosure of assets vair value.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AssetsFairValuesTablETextBlock' xlink:to='lab_fil_AssetsFairValuesTablETextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock' xlink:label='us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interest Rate Risk</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock' xlink:to='lab_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy' xlink:label='us-gaap_ResearchAndDevelopmentExpensePolicy'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ResearchAndDevelopmentExpensePolicy' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Research and Development.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ResearchAndDevelopmentExpensePolicy' xlink:to='lab_us-gaap_ResearchAndDevelopmentExpensePolicy'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and Equipment Policy</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NotesPayableTextBlock' xlink:label='fil_NotesPayableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NotesPayableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>NOTES PAYABLE {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NotesPayableTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>NOTES PAYABLE</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NotesPayableTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The entire disclosure of notes payable.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NotesPayableTextBlock' xlink:to='lab_fil_NotesPayableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances' xlink:label='fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances for purchases of intangibles paid with banker&apos;s acceptances</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Advances for purchases of intangibles paid with banker&apos;s acceptances</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances' xlink:to='lab_fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromNotesPayable' xlink:label='us-gaap_ProceedsFromNotesPayable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProceedsFromNotesPayable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Proceeds from issuance of notes payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProceedsFromNotesPayable' xlink:to='lab_us-gaap_ProceedsFromNotesPayable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayableTrade'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trade accounts payables.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsPayableTrade' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss' xlink:label='us-gaap_NetIncomeLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net income for the period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetIncomeLoss' xlink:to='lab_us-gaap_NetIncomeLoss'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesIssued' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, shares issued</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesIssued' xlink:to='lab_us-gaap_CommonStockSharesIssued'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent' xlink:label='us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Allowance for doubtful accounts on trade accounts receivables</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent' xlink:to='lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>TOTAL ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Assets' xlink:to='lab_us-gaap_Assets'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalAmount' xlink:label='fil_TotalAmount'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalAmount' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Amount</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalAmount' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Total Amount</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalAmount' xlink:to='lab_fil_TotalAmount'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria1' xlink:label='fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Options to vest on six month anniversary performance based vesting criteria.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Options to vest on six month anniversary performance based vesting criteria.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria1' xlink:to='lab_fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria1'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WeightedAverageAssumptionsAbstract' xlink:label='fil_WeightedAverageAssumptionsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_WeightedAverageAssumptionsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Weighted Average Assumptions</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_WeightedAverageAssumptionsAbstract' xlink:to='lab_fil_WeightedAverageAssumptionsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RecognizedCompensationExpenses' xlink:label='fil_RecognizedCompensationExpenses'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RecognizedCompensationExpenses' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Recognized compensation expenses</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_RecognizedCompensationExpenses' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Recognized compensation expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RecognizedCompensationExpenses' xlink:to='lab_fil_RecognizedCompensationExpenses'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_VestedAndUnexercisedOptions' xlink:label='fil_VestedAndUnexercisedOptions'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_VestedAndUnexercisedOptions' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Vested and unexercised options</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_VestedAndUnexercisedOptions' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Vested and unexercised options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_VestedAndUnexercisedOptions' xlink:to='lab_fil_VestedAndUnexercisedOptions'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PreferredSharesAuthorized' xlink:label='fil_PreferredSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PreferredSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred shares authorized</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PreferredSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity&apos;s charter and bylaws.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PreferredSharesAuthorized' xlink:to='lab_fil_PreferredSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalLevel3' xlink:label='fil_TotalLevel3'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalLevel3' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Level 3</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalLevel3' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Bankers acceptance notes Level 3 total.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalLevel3' xlink:to='lab_fil_TotalLevel3'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_Total1' xlink:label='fil_Total1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_Total1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_Total1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Total bankers acceptance notes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_Total1' xlink:to='lab_fil_Total1'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ReconciliationOfIncomeTaxesAbstract' xlink:label='fil_ReconciliationOfIncomeTaxesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ReconciliationOfIncomeTaxesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Reconciliation of income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ReconciliationOfIncomeTaxesAbstract' xlink:to='lab_fil_ReconciliationOfIncomeTaxesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AnnualInterestRate' xlink:label='fil_AnnualInterestRate'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AnnualInterestRate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Annual interest rate</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AnnualInterestRate' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Annual interest rate</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AnnualInterestRate' xlink:to='lab_fil_AnnualInterestRate'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalPropertyAndEquipment' xlink:label='fil_TotalPropertyAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalPropertyAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Property and Equipment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalPropertyAndEquipment' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Total Property and Equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalPropertyAndEquipment' xlink:to='lab_fil_TotalPropertyAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryRawMaterials' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Raw materials</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryRawMaterials' xlink:to='lab_us-gaap_InventoryRawMaterials'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BASISOFPRESENTATIONBasicAndDilutedEarningsPerCommonShareDetailsAbstract' xlink:label='fil_BASISOFPRESENTATIONBasicAndDilutedEarningsPerCommonShareDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BASISOFPRESENTATIONBasicAndDilutedEarningsPerCommonShareDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>BASIS OF PRESENTATION Basic and Diluted Earnings per Common Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BASISOFPRESENTATIONBasicAndDilutedEarningsPerCommonShareDetailsAbstract' xlink:to='lab_fil_BASISOFPRESENTATIONBasicAndDilutedEarningsPerCommonShareDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BasisOfPresentationTablesAbstract' xlink:label='fil_BasisOfPresentationTablesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BasisOfPresentationTablesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>BASIS OF PRESENTATION (Tables)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BasisOfPresentationTablesAbstract' xlink:to='lab_fil_BasisOfPresentationTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:label='us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Recently Announced Accounting Standards</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:to='lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScheduleOfCreditLossesRelatedToFinancingReceivablesCurrentAndNoncurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfCreditLossesRelatedToFinancingReceivablesCurrentAndNoncurrentTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfCreditLossesRelatedToFinancingReceivablesCurrentAndNoncurrentTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Credit Risk</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfCreditLossesRelatedToFinancingReceivablesCurrentAndNoncurrentTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfCreditLossesRelatedToFinancingReceivablesCurrentAndNoncurrentTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock' xlink:label='us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances to Suppliers and Advances from Customers</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock' xlink:to='lab_us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DerivativeInstrumentsAndHedgingActivitiesAbstract' xlink:label='fil_DerivativeInstrumentsAndHedgingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DerivativeInstrumentsAndHedgingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>DERIVATIVE WARRANT LIABILITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DerivativeInstrumentsAndHedgingActivitiesAbstract' xlink:to='lab_fil_DerivativeInstrumentsAndHedgingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>PROPERTY AND EQUIPMENT {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>PROPERTY AND EQUIPMENT</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid' xlink:label='us-gaap_InterestPaid'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InterestPaid' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash paid for interest</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InterestPaid' xlink:to='lab_us-gaap_InterestPaid'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementEquityComponentsAxis' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statement, Equity Components [Axis]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='lab_us-gaap_StatementEquityComponentsAxis'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareAbstract' xlink:label='us-gaap_EarningsPerShareAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Earnings per Share:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareAbstract' xlink:to='lab_us-gaap_EarningsPerShareAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital' xlink:label='us-gaap_AdditionalPaidInCapital'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapital' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional paid-in capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapital' xlink:to='lab_us-gaap_AdditionalPaidInCapital'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CustomerAdvancesCurrent' xlink:label='us-gaap_CustomerAdvancesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CustomerAdvancesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances from customers</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CustomerAdvancesCurrent' xlink:to='lab_us-gaap_CustomerAdvancesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsAbstract' xlink:to='lab_us-gaap_AssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Voluntary Filers</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PercentageOfAccountsPayableToTwoSuppliersForPurchaseOfRawMaterials' xlink:label='fil_PercentageOfAccountsPayableToTwoSuppliersForPurchaseOfRawMaterials'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfAccountsPayableToTwoSuppliersForPurchaseOfRawMaterials' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Percentage of accounts payable to two suppliers for purchase of raw materials</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfAccountsPayableToTwoSuppliersForPurchaseOfRawMaterials' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Percentage of accounts payable to two suppliers for purchase of raw materials</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PercentageOfAccountsPayableToTwoSuppliersForPurchaseOfRawMaterials' xlink:to='lab_fil_PercentageOfAccountsPayableToTwoSuppliersForPurchaseOfRawMaterials'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WeightedAverageRemainingContractualTermYearsMember' xlink:label='fil_WeightedAverageRemainingContractualTermYearsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_WeightedAverageRemainingContractualTermYearsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Weighted-Average Remaining Contractual term (Years)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_WeightedAverageRemainingContractualTermYearsMember' xlink:to='lab_fil_WeightedAverageRemainingContractualTermYearsMember'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExpectedPeriodOfLife' xlink:label='fil_ExpectedPeriodOfLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ExpectedPeriodOfLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Expected period of life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ExpectedPeriodOfLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Expected period of life</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ExpectedPeriodOfLife' xlink:to='lab_fil_ExpectedPeriodOfLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_STOCKHOLDERSEQUITYTOEXECUTIVEOFFICERS2010StockOptionPlanAbstract' xlink:label='fil_STOCKHOLDERSEQUITYTOEXECUTIVEOFFICERS2010StockOptionPlanAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_STOCKHOLDERSEQUITYTOEXECUTIVEOFFICERS2010StockOptionPlanAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>STOCKHOLDERS EQUITY TO EXECUTIVE OFFICERS 2010 Stock Option Plan</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_STOCKHOLDERSEQUITYTOEXECUTIVEOFFICERS2010StockOptionPlanAbstract' xlink:to='lab_fil_STOCKHOLDERSEQUITYTOEXECUTIVEOFFICERS2010StockOptionPlanAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_FairValueOf185000OptionsCancelled' xlink:label='fil_FairValueOf185000OptionsCancelled'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_FairValueOf185000OptionsCancelled' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Fair value of 185000 options cancelled</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_FairValueOf185000OptionsCancelled' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Fair value of 185000 options cancelled</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_FairValueOf185000OptionsCancelled' xlink:to='lab_fil_FairValueOf185000OptionsCancelled'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WarrantsWeightedAverageExercisePrice' xlink:label='fil_WarrantsWeightedAverageExercisePrice'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_WarrantsWeightedAverageExercisePrice' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Warrants weighted average exercise price</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_WarrantsWeightedAverageExercisePrice' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Warrants weighted average exercise price</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_WarrantsWeightedAverageExercisePrice' xlink:to='lab_fil_WarrantsWeightedAverageExercisePrice'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ValuePerShare' xlink:label='fil_ValuePerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ValuePerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Value per share</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ValuePerShare' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Value per share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ValuePerShare' xlink:to='lab_fil_ValuePerShare'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OtherPrimarilyTheEffectOfUSTaxRates' xlink:label='fil_OtherPrimarilyTheEffectOfUSTaxRates'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OtherPrimarilyTheEffectOfUSTaxRates' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other, primarily the effect of US tax rates</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OtherPrimarilyTheEffectOfUSTaxRates' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Other, primarily the effect of US tax rates</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OtherPrimarilyTheEffectOfUSTaxRates' xlink:to='lab_fil_OtherPrimarilyTheEffectOfUSTaxRates'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit' xlink:label='us-gaap_CurrentIncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CurrentIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current tax provision.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CurrentIncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_CurrentIncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany' xlink:label='fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Investment in Helpson, a foreign subsidiary for the company</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Investment in Helpson, a foreign subsidiary for the company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany' xlink:to='lab_fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PermitOfLandUseMinimumLife' xlink:label='fil_PermitOfLandUseMinimumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PermitOfLandUseMinimumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Permit of land use minimum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PermitOfLandUseMinimumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PermitOfLandUseMinimumLife' xlink:to='lab_fil_PermitOfLandUseMinimumLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BasicEarningsPerShare' xlink:label='fil_BasicEarningsPerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BasicEarningsPerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Basic earnings per share</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BasicEarningsPerShare' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BasicEarningsPerShare' xlink:to='lab_fil_BasicEarningsPerShare'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CompensationRelatedCostsShareBasedPaymentsAbstract' xlink:label='fil_CompensationRelatedCostsShareBasedPaymentsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompensationRelatedCostsShareBasedPaymentsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock option activity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CompensationRelatedCostsShareBasedPaymentsAbstract' xlink:to='lab_fil_CompensationRelatedCostsShareBasedPaymentsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_IntangibleAssetsTablesAbstract' xlink:label='fil_IntangibleAssetsTablesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssetsTablesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible Assets (Tables)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IntangibleAssetsTablesAbstract' xlink:to='lab_fil_IntangibleAssetsTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock' xlink:label='us-gaap_CostOfSalesPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CostOfSalesPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cost of Revenues</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CostOfSalesPolicyTextBlock' xlink:to='lab_us-gaap_CostOfSalesPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' xlink:label='us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Valuation of Long-Lived Assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' xlink:to='lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated Other Comprehensive Income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccumulatedOtherComprehensiveIncomeMember' xlink:to='lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense' xlink:label='us-gaap_InterestExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InterestExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interest expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InterestExpense' xlink:to='lab_us-gaap_InterestExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued' xlink:label='us-gaap_PreferredStockSharesIssued'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockSharesIssued' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred Stock, shares issued</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockSharesIssued' xlink:to='lab_us-gaap_PreferredStockSharesIssued'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AllowanceForDoubtfulAccountsOnOtherReceivables' xlink:label='fil_AllowanceForDoubtfulAccountsOnOtherReceivables'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AllowanceForDoubtfulAccountsOnOtherReceivables' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Allowance for doubtful accounts on other receivables</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AllowanceForDoubtfulAccountsOnOtherReceivables' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>A valuation allowance for other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AllowanceForDoubtfulAccountsOnOtherReceivables' xlink:to='lab_fil_AllowanceForDoubtfulAccountsOnOtherReceivables'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>TOTAL LIABILITIES AND STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TaxesPayableCurrent' xlink:label='us-gaap_TaxesPayableCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TaxesPayableCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued taxes payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TaxesPayableCurrent' xlink:to='lab_us-gaap_TaxesPayableCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExercisePriceForOptionsGranted' xlink:label='fil_ExercisePriceForOptionsGranted'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ExercisePriceForOptionsGranted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Exercise Price for options granted</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ExercisePriceForOptionsGranted' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Exercise Price for options granted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ExercisePriceForOptionsGranted' xlink:to='lab_fil_ExercisePriceForOptionsGranted'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsExpiringOnMay252013' xlink:label='fil_OptionsExpiringOnMay252013'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OptionsExpiringOnMay252013' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Options expiring on May 25, 2013</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OptionsExpiringOnMay252013' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Options expiring on May 25, 2013</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OptionsExpiringOnMay252013' xlink:to='lab_fil_OptionsExpiringOnMay252013'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_StartingRiskFreeInterestRate' xlink:label='fil_StartingRiskFreeInterestRate'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_StartingRiskFreeInterestRate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Starting risk free interest rate</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_StartingRiskFreeInterestRate' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Starting risk free interest rate</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_StartingRiskFreeInterestRate' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Starting risk free interest rate</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_StartingRiskFreeInterestRate' xlink:to='lab_fil_StartingRiskFreeInterestRate'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalIntrinsicValue' xlink:label='fil_TotalIntrinsicValue'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalIntrinsicValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total intrinsic value</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalIntrinsicValue' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Total intrinsic value</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalIntrinsicValue' xlink:to='lab_fil_TotalIntrinsicValue'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract' xlink:label='fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>FAIR VALUE MEASUREMENTS At Reporting Date Using</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract' xlink:to='lab_fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DeferredIncomeTaxLiabilityAbstract' xlink:label='fil_DeferredIncomeTaxLiabilityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DeferredIncomeTaxLiabilityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income tax liability:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DeferredIncomeTaxLiabilityAbstract' xlink:to='lab_fil_DeferredIncomeTaxLiabilityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance' xlink:label='us-gaap_DeferredTaxAssetsValuationAllowance'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxAssetsValuationAllowance' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Valuation allowance deferred tax assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxAssetsValuationAllowance' xlink:to='lab_us-gaap_DeferredTaxAssetsValuationAllowance'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AnnualAmortization2015' xlink:label='fil_AnnualAmortization2015'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AnnualAmortization2015' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Annual amortization 2015</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AnnualAmortization2015' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Annual amortization 2015</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AnnualAmortization2015' xlink:to='lab_fil_AnnualAmortization2015'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NetCarryingAmount' xlink:label='fil_NetCarryingAmount'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetCarryingAmount' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net carrying amount</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetCarryingAmount' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Net carrying amount</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NetCarryingAmount' xlink:to='lab_fil_NetCarryingAmount'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RecognizedAnImpairmentLossOfItsIntangibleAssets' xlink:label='fil_RecognizedAnImpairmentLossOfItsIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RecognizedAnImpairmentLossOfItsIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Recognized an impairment loss of its intangible assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_RecognizedAnImpairmentLossOfItsIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Recognized an impairment loss of its intangible assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RecognizedAnImpairmentLossOfItsIntangibleAssets' xlink:to='lab_fil_RecognizedAnImpairmentLossOfItsIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalWarrantsAndOptions' xlink:label='fil_TotalWarrantsAndOptions'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalWarrantsAndOptions' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Warrants And Options</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalWarrantsAndOptions' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Total Warrants And Options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalWarrantsAndOptions' xlink:to='lab_fil_TotalWarrantsAndOptions'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ProvisionForIncomeTaxesTableTextBlock' xlink:label='fil_ProvisionForIncomeTaxesTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ProvisionForIncomeTaxesTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Provision For Income Taxes</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ProvisionForIncomeTaxesTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Tabluar disclosure of Provision For Income Taxes.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ProvisionForIncomeTaxesTableTextBlock' xlink:to='lab_fil_ProvisionForIncomeTaxesTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock' xlink:label='us-gaap_ConsolidationPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ConsolidationPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Consolidation and Basis of Presentation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ConsolidationPolicyTextBlock' xlink:to='lab_us-gaap_ConsolidationPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations' xlink:label='us-gaap_NatureOfOperations'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NatureOfOperations' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Organization and Nature of Operations</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NatureOfOperations' xlink:to='lab_us-gaap_NatureOfOperations'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresAbstract' xlink:label='us-gaap_FairValueDisclosuresAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FairValueDisclosuresAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>FAIR VALUE MEASUREMENTS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FairValueDisclosuresAbstract' xlink:to='lab_us-gaap_FairValueDisclosuresAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AccountsReceivableCollectedWithBankerSAcceptances' xlink:label='fil_AccountsReceivableCollectedWithBankerSAcceptances'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccountsReceivableCollectedWithBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts receivable collected with banker&apos;s acceptances</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccountsReceivableCollectedWithBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Accounts receivable collected with banker&apos;s acceptances</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AccountsReceivableCollectedWithBankerSAcceptances' xlink:to='lab_fil_AccountsReceivableCollectedWithBankerSAcceptances'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net Cash Used in Investing Activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:label='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Changes in assets and liabilities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationAndAmortization' xlink:label='us-gaap_DepreciationAndAmortization'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DepreciationAndAmortization' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Depreciation and amortization</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DepreciationAndAmortization' xlink:to='lab_us-gaap_DepreciationAndAmortization'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment' xlink:label='us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated depreciation on property and equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment' xlink:to='lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent' xlink:label='us-gaap_DeferredTaxLiabilitiesNoncurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxLiabilitiesNoncurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Long-term deferred tax liability</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxLiabilitiesNoncurrent' xlink:to='lab_us-gaap_DeferredTaxLiabilitiesNoncurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current Liabilities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='lab_us-gaap_LiabilitiesCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Period End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_Forfeited' xlink:label='fil_Forfeited'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_Forfeited' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Forfeited</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_Forfeited' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Forfeited</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_Forfeited' xlink:to='lab_fil_Forfeited'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RestrictedStockOptionsGrantedToFormerCFO' xlink:label='fil_RestrictedStockOptionsGrantedToFormerCFO'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RestrictedStockOptionsGrantedToFormerCFO' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Restricted stock options granted to former CFO</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_RestrictedStockOptionsGrantedToFormerCFO' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Restricted stock options granted to former CFO</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RestrictedStockOptionsGrantedToFormerCFO' xlink:to='lab_fil_RestrictedStockOptionsGrantedToFormerCFO'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsVestedOnApril282013' xlink:label='fil_OptionsVestedOnApril282013'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OptionsVestedOnApril282013' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Options vested on April 28, 2013</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OptionsVestedOnApril282013' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Options vested on April 28, 2013</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OptionsVestedOnApril282013' xlink:to='lab_fil_OptionsVestedOnApril282013'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_MinimumExpectedLife' xlink:label='fil_MinimumExpectedLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_MinimumExpectedLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Minimum expected life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_MinimumExpectedLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Minimum expected life</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_MinimumExpectedLife' xlink:to='lab_fil_MinimumExpectedLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NumberOfCommonShares' xlink:label='fil_NumberOfCommonShares'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NumberOfCommonShares' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of common shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NumberOfCommonShares' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum number of common shares permitted to be issued by an entity&apos;s charter and bylaws.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NumberOfCommonShares' xlink:to='lab_fil_NumberOfCommonShares'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BankersAcceptanceNotesLevel2' xlink:label='fil_BankersAcceptanceNotesLevel2'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotesLevel2' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bankers acceptance notes Level 2</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotesLevel2' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Bankers acceptance notes Level 2</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BankersAcceptanceNotesLevel2' xlink:to='lab_fil_BankersAcceptanceNotesLevel2'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxLiabilities' xlink:label='us-gaap_DeferredTaxLiabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxLiabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible assets income tax liability</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxLiabilities' xlink:to='lab_us-gaap_DeferredTaxLiabilities'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NetDeferredIncomeTaxAsset' xlink:label='fil_NetDeferredIncomeTaxAsset'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetDeferredIncomeTaxAsset' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net deferred income tax asset.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetDeferredIncomeTaxAsset' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Net deferred income tax asset.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NetDeferredIncomeTaxAsset' xlink:to='lab_fil_NetDeferredIncomeTaxAsset'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate' xlink:label='us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Income tax expense Reconciliation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate' xlink:to='lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalIncomeTaxExpense' xlink:label='fil_TotalIncomeTaxExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalIncomeTaxExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total income tax expense</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalIncomeTaxExpense' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalIncomeTaxExpense' xlink:to='lab_fil_TotalIncomeTaxExpense'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AnnualAmortizationTotal' xlink:label='fil_AnnualAmortizationTotal'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AnnualAmortizationTotal' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Annual amortization Total</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AnnualAmortizationTotal' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Annual amortization Total</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AnnualAmortizationTotal' xlink:to='lab_fil_AnnualAmortizationTotal'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_MotorVehicleGross' xlink:label='fil_MotorVehicleGross'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_MotorVehicleGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Motor vehicle</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_MotorVehicleGross' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The amount of motor vehicle gross as on the date.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_MotorVehicleGross' xlink:to='lab_fil_MotorVehicleGross'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AllowanceForObsolescenceRawMaterials' xlink:label='fil_AllowanceForObsolescenceRawMaterials'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AllowanceForObsolescenceRawMaterials' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Allowance for obsolescence - raw materials</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AllowanceForObsolescenceRawMaterials' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Allowance for obsolescence - raw materials</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AllowanceForObsolescenceRawMaterials' xlink:to='lab_fil_AllowanceForObsolescenceRawMaterials'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract' xlink:label='us-gaap_DilutiveSecuritiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DilutiveSecuritiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Effect of dilutive securities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DilutiveSecuritiesAbstract' xlink:to='lab_us-gaap_DilutiveSecuritiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PercentageOfShareOwned' xlink:label='fil_PercentageOfShareOwned'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfShareOwned' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Percentage of share owned by China Pharma Holdings Inc of Onny Investment Limited</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfShareOwned' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Percentage of share owned by China Pharma Holdings Inc of Onny Investment Limited</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PercentageOfShareOwned' xlink:to='lab_fil_PercentageOfShareOwned'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Reclassifications' xlink:label='us-gaap_Reclassifications'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Reclassifications' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Reclassification</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Reclassifications' xlink:to='lab_us-gaap_Reclassifications'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock' xlink:label='us-gaap_RelatedPartyTransactionsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>RELATED PARTY TRANSACTIONS {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>RELATED PARTY TRANSACTIONS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RelatedPartyTransactionsDisclosureTextBlock' xlink:to='lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract' xlink:label='us-gaap_RelatedPartyTransactionsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RelatedPartyTransactionsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>RELATED PARTY TRANSACTIONS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RelatedPartyTransactionsAbstract' xlink:to='lab_us-gaap_RelatedPartyTransactionsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesForPurchasesOfIntangibleAssetsAbstract' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssetsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangibleAssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesForPurchasesOfIntangibleAssetsAbstract' xlink:to='lab_fil_AdvancesForPurchasesOfIntangibleAssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:to='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Effect of Exchange Rate Changes on Cash</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents' xlink:to='lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInCustomerAdvances' xlink:label='us-gaap_IncreaseDecreaseInCustomerAdvances'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInCustomerAdvances' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances from customers.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInCustomerAdvances' xlink:to='lab_us-gaap_IncreaseDecreaseInCustomerAdvances'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProfitLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProfitLoss' xlink:to='lab_us-gaap_ProfitLoss'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives' xlink:label='us-gaap_GainLossOnSaleOfDerivatives'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GainLossOnSaleOfDerivatives' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Derivative gain</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GainLossOnSaleOfDerivatives' xlink:to='lab_us-gaap_GainLossOnSaleOfDerivatives'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpensesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating expenses:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='lab_us-gaap_OperatingExpensesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesOutstanding' xlink:to='lab_us-gaap_CommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockParOrStatedValuePerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common Stock, par or stated value</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockParOrStatedValuePerShare' xlink:to='lab_us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare' xlink:label='us-gaap_PreferredStockParOrStatedValuePerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockParOrStatedValuePerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred Stock, par or stated value</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockParOrStatedValuePerShare' xlink:to='lab_us-gaap_PreferredStockParOrStatedValuePerShare'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsAccumulatedDeficit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retained earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsAccumulatedDeficit' xlink:to='lab_us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment, net of accumulated depreciation of $4,273,373 and $3,391,124, respectively</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentNet' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ReceivablesNetCurrent' xlink:label='us-gaap_ReceivablesNetCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ReceivablesNetCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trade accounts receivable, less allowance for doubtful accounts of $4,429,945 and $3,536,405, respectively</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ReceivablesNetCurrent' xlink:to='lab_us-gaap_ReceivablesNetCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementTable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statement [Table]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementTable' xlink:to='lab_us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_FutureMinimumPaymentsAsPerPurchaseAndConstructionAgreementsAbstract' xlink:label='fil_FutureMinimumPaymentsAsPerPurchaseAndConstructionAgreementsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_FutureMinimumPaymentsAsPerPurchaseAndConstructionAgreementsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Future Minimum payments as per purchase and construction agreements</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_FutureMinimumPaymentsAsPerPurchaseAndConstructionAgreementsAbstract' xlink:to='lab_fil_FutureMinimumPaymentsAsPerPurchaseAndConstructionAgreementsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_SharesForfeitedDueToNonAchievementOfPerformanceCriteria' xlink:label='fil_SharesForfeitedDueToNonAchievementOfPerformanceCriteria'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_SharesForfeitedDueToNonAchievementOfPerformanceCriteria' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shares forfeited due to non achievement of performance criteria</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_SharesForfeitedDueToNonAchievementOfPerformanceCriteria' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Shares forfeited due to non achievement of performance criteria</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_SharesForfeitedDueToNonAchievementOfPerformanceCriteria' xlink:to='lab_fil_SharesForfeitedDueToNonAchievementOfPerformanceCriteria'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_GrantedDateFairValueOfTheOptionsTotalValue' xlink:label='fil_GrantedDateFairValueOfTheOptionsTotalValue'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_GrantedDateFairValueOfTheOptionsTotalValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Granted date fair value of the options total value</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_GrantedDateFairValueOfTheOptionsTotalValue' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Granted date fair value of the options total value</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_GrantedDateFairValueOfTheOptionsTotalValue' xlink:to='lab_fil_GrantedDateFairValueOfTheOptionsTotalValue'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_IncomeTaxBenefitRecognizedFromStockBasedCompensation' xlink:label='fil_IncomeTaxBenefitRecognizedFromStockBasedCompensation'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IncomeTaxBenefitRecognizedFromStockBasedCompensation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Income Tax benefit recognized from stock based compensation</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_IncomeTaxBenefitRecognizedFromStockBasedCompensation' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Income Tax benefit recognized from stock based compensation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IncomeTaxBenefitRecognizedFromStockBasedCompensation' xlink:to='lab_fil_IncomeTaxBenefitRecognizedFromStockBasedCompensation'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsExercisePrice' xlink:label='fil_OptionsExercisePrice'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OptionsExercisePrice' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Options exercise price</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OptionsExercisePrice' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Options exercise price</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OptionsExercisePrice' xlink:to='lab_fil_OptionsExercisePrice'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NumberOfDaysOpposedAfterTheEmploymentTerminationDate' xlink:label='fil_NumberOfDaysOpposedAfterTheEmploymentTerminationDate'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NumberOfDaysOpposedAfterTheEmploymentTerminationDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of days opposed after the employment termination date</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NumberOfDaysOpposedAfterTheEmploymentTerminationDate' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Number of days opposed after the employment termination date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NumberOfDaysOpposedAfterTheEmploymentTerminationDate' xlink:to='lab_fil_NumberOfDaysOpposedAfterTheEmploymentTerminationDate'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredFederalIncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred tax provision.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredFederalIncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_INCOMETAXESUndistributedEarningsAbstract' xlink:label='fil_INCOMETAXESUndistributedEarningsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_INCOMETAXESUndistributedEarningsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INCOME TAXES Undistributed Earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_INCOMETAXESUndistributedEarningsAbstract' xlink:to='lab_fil_INCOMETAXESUndistributedEarningsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesPayableAbstract' xlink:label='us-gaap_NotesPayableAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NotesPayableAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>NOTES PAYABLES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NotesPayableAbstract' xlink:to='lab_us-gaap_NotesPayableAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdavanceOwingToBoardmember' xlink:label='fil_AdavanceOwingToBoardmember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdavanceOwingToBoardmember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Adavances owing to board member</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdavanceOwingToBoardmember' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Adavance owing to boardmember</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdavanceOwingToBoardmember' xlink:to='lab_fil_AdavanceOwingToBoardmember'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BuildingMaximumLife' xlink:label='fil_BuildingMaximumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BuildingMaximumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Building maximum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BuildingMaximumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BuildingMaximumLife' xlink:to='lab_fil_BuildingMaximumLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_LessAccumulatedDepreciationDetails' xlink:label='fil_LessAccumulatedDepreciationDetails'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_LessAccumulatedDepreciationDetails' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Less: accumulated depreciation details</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_LessAccumulatedDepreciationDetails' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_LessAccumulatedDepreciationDetails' xlink:to='lab_fil_LessAccumulatedDepreciationDetails'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConstructionInProgressGross' xlink:label='us-gaap_ConstructionInProgressGross'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ConstructionInProgressGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Construction in progress</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ConstructionInProgressGross' xlink:to='lab_us-gaap_ConstructionInProgressGross'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NetIncome' xlink:label='fil_NetIncome'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetIncome' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net income {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetIncome' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Net income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetIncome' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NetIncome' xlink:to='lab_fil_NetIncome'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:label='us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INTANGIBLE ASSETS {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>INTANGIBLE ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:to='lab_us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryDisclosureAbstract' xlink:label='us-gaap_InventoryDisclosureAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INVENTORY.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryDisclosureAbstract' xlink:to='lab_us-gaap_InventoryDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract' xlink:to='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NetInvestmentInBankerSAcceptances' xlink:label='fil_NetInvestmentInBankerSAcceptances'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetInvestmentInBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net investment in banker&apos;s acceptances</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetInvestmentInBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The cash outflow for the net investment in bankers acceptances.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NetInvestmentInBankerSAcceptances' xlink:to='lab_fil_NetInvestmentInBankerSAcceptances'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ChangesInAdvancesToSuppliers' xlink:label='fil_ChangesInAdvancesToSuppliers'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ChangesInAdvancesToSuppliers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Changes in Advances to suppliers.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ChangesInAdvancesToSuppliers' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Changes in Advances to suppliers.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ChangesInAdvancesToSuppliers' xlink:to='lab_fil_ChangesInAdvancesToSuppliers'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ShareBasedCompensation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Share-based compensation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ShareBasedCompensation' xlink:to='lab_us-gaap_ShareBasedCompensation'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ChangesInStockholderSEquityAbstract' xlink:label='fil_ChangesInStockholderSEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ChangesInStockholderSEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Changes in Stockholder&apos;s equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ChangesInStockholderSEquityAbstract' xlink:to='lab_fil_ChangesInStockholderSEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Income from operations</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='lab_us-gaap_OperatingIncomeLoss'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GrossProfit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gross profit</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GrossProfit' xlink:to='lab_us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryWriteDown' xlink:label='us-gaap_InventoryWriteDown'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryWriteDown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory obsolescence</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryWriteDown' xlink:to='lab_us-gaap_InventoryWriteDown'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableTradeCurrent' xlink:label='us-gaap_AccountsPayableTradeCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsPayableTradeCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trade accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsPayableTradeCurrent' xlink:to='lab_us-gaap_AccountsPayableTradeCurrent'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesToSuppliers' xlink:label='fil_AdvancesToSuppliers'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesToSuppliers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances to suppliers</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesToSuppliers' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Carrying amount as of the balance sheet date of advances to suppliers.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesToSuppliers' xlink:to='lab_fil_AdvancesToSuppliers'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current Fiscal Year End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PercentageOfOneCustomerAccountedForAccountsReceivables' xlink:label='fil_PercentageOfOneCustomerAccountedForAccountsReceivables'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfOneCustomerAccountedForAccountsReceivables' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Percentage of one customer accounted for accounts receivables</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfOneCustomerAccountedForAccountsReceivables' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Percentage of one customer accounted for accounts receivables</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PercentageOfOneCustomerAccountedForAccountsReceivables' xlink:to='lab_fil_PercentageOfOneCustomerAccountedForAccountsReceivables'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WeightedAverageExercisePriceMember' xlink:label='fil_WeightedAverageExercisePriceMember'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_WeightedAverageExercisePriceMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Weighted-Average exercise price</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_WeightedAverageExercisePriceMember' xlink:to='lab_fil_WeightedAverageExercisePriceMember'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RiskFreeInterestRate' xlink:label='fil_RiskFreeInterestRate'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RiskFreeInterestRate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Risk free interest rate</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_RiskFreeInterestRate' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Risk free interest rate</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RiskFreeInterestRate' xlink:to='lab_fil_RiskFreeInterestRate'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NumberOfCommonSharesIssuedToTwoExecutiveOfficers' xlink:label='fil_NumberOfCommonSharesIssuedToTwoExecutiveOfficers'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NumberOfCommonSharesIssuedToTwoExecutiveOfficers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of common shares issued to two executive officers</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NumberOfCommonSharesIssuedToTwoExecutiveOfficers' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Number of common shares issued to two executive officers</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NumberOfCommonSharesIssuedToTwoExecutiveOfficers' xlink:to='lab_fil_NumberOfCommonSharesIssuedToTwoExecutiveOfficers'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_STOCKHOLDERSEQUITYUnrecognizedCompensationExpenseAbstract' xlink:label='fil_STOCKHOLDERSEQUITYUnrecognizedCompensationExpenseAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_STOCKHOLDERSEQUITYUnrecognizedCompensationExpenseAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>STOCKHOLDERS EQUITY Unrecognized Compensation Expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_STOCKHOLDERSEQUITYUnrecognizedCompensationExpenseAbstract' xlink:to='lab_fil_STOCKHOLDERSEQUITYUnrecognizedCompensationExpenseAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_FairValueOf100000CommonSharesExchanged' xlink:label='fil_FairValueOf100000CommonSharesExchanged'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_FairValueOf100000CommonSharesExchanged' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Fair value of 100000 common shares exchanged</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_FairValueOf100000CommonSharesExchanged' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Fair value of 100000 common shares exchanged</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_FairValueOf100000CommonSharesExchanged' xlink:to='lab_fil_FairValueOf100000CommonSharesExchanged'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NumberOfCommonStockSharesToPurchaseByWarrantsOutstaningAndExercisable' xlink:label='fil_NumberOfCommonStockSharesToPurchaseByWarrantsOutstaningAndExercisable'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NumberOfCommonStockSharesToPurchaseByWarrantsOutstaningAndExercisable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of common stock shares to purchase by warrants outstaning and exercisable</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NumberOfCommonStockSharesToPurchaseByWarrantsOutstaningAndExercisable' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Number of common stock shares to purchase by warrants outstaning and exercisable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NumberOfCommonStockSharesToPurchaseByWarrantsOutstaningAndExercisable' xlink:to='lab_fil_NumberOfCommonStockSharesToPurchaseByWarrantsOutstaningAndExercisable'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NonDeductibleStockBasedCompensationFromAbstract' xlink:label='fil_NonDeductibleStockBasedCompensationFromAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NonDeductibleStockBasedCompensationFromAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Non-deductible stock-based compensation from</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NonDeductibleStockBasedCompensationFromAbstract' xlink:to='lab_fil_NonDeductibleStockBasedCompensationFromAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_INCOMETAXESEnterpriseIncomeTaxRatesAbstract' xlink:label='fil_INCOMETAXESEnterpriseIncomeTaxRatesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_INCOMETAXESEnterpriseIncomeTaxRatesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INCOME TAXES Enterprise Income Tax Rates</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_INCOMETAXESEnterpriseIncomeTaxRatesAbstract' xlink:to='lab_fil_INCOMETAXESEnterpriseIncomeTaxRatesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AmortizationExpenseIntangibleAssets' xlink:label='fil_AmortizationExpenseIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AmortizationExpenseIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amortization Expense Intangible assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AmortizationExpenseIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amortization Expense Intangible assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AmortizationExpenseIntangibleAssets' xlink:to='lab_fil_AmortizationExpenseIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OfficeEquipmentMinimumLife' xlink:label='fil_OfficeEquipmentMinimumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OfficeEquipmentMinimumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Office equipment minimum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OfficeEquipmentMinimumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OfficeEquipmentMinimumLife' xlink:to='lab_fil_OfficeEquipmentMinimumLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DilutedEarningsPerShare' xlink:label='fil_DilutedEarningsPerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DilutedEarningsPerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Diluted earnings per share</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DilutedEarningsPerShare' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DilutedEarningsPerShare' xlink:to='lab_fil_DilutedEarningsPerShare'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesIssuedBasic'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Basic weighted-average common shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfSharesIssuedBasic' xlink:to='lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock' xlink:label='us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>FUTURE MINIMUM COMMITMENTS {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>FUTURE MINIMUM COMMITMENTS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock' xlink:label='us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock option activity {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Stock option activity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PropertyAndEquipmentTablesAbstract' xlink:label='fil_PropertyAndEquipmentTablesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PropertyAndEquipmentTablesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>PROPERTY AND EQUIPMENT (Tables)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PropertyAndEquipmentTablesAbstract' xlink:to='lab_fil_PropertyAndEquipmentTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CommitmentAndContingenciesAbstract' xlink:label='fil_CommitmentAndContingenciesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommitmentAndContingenciesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>COMMITMENTS AND CONTINGENCIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommitmentAndContingenciesAbstract' xlink:to='lab_fil_CommitmentAndContingenciesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock' xlink:label='us-gaap_StockholdersEquityNoteDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>STOCKHOLDERS&apos; EQUITY {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityNoteDisclosureTextBlock' xlink:to='lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityAbstract' xlink:label='us-gaap_EquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EquityAbstract' xlink:to='lab_us-gaap_EquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock' xlink:label='us-gaap_IncomeTaxDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INCOME TAXES {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>INCOME TAXES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxDisclosureTextBlock' xlink:to='lab_us-gaap_IncomeTaxDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ForeignCurrencyTranslationAdjustment1' xlink:label='fil_ForeignCurrencyTranslationAdjustment1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ForeignCurrencyTranslationAdjustment1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Foreign currency translation adjustment.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ForeignCurrencyTranslationAdjustment1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency of the reporting entity, net of tax.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ForeignCurrencyTranslationAdjustment1' xlink:to='lab_fil_ForeignCurrencyTranslationAdjustment1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapitalMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional Paid-in Capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapitalMember' xlink:to='lab_us-gaap_AdditionalPaidInCapitalMember'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease' xlink:label='us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other comprehensive income - foreign currency translation adjustment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease' xlink:to='lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest' xlink:label='us-gaap_InvestmentIncomeInterest'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InvestmentIncomeInterest' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interest income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InvestmentIncomeInterest' xlink:to='lab_us-gaap_InvestmentIncomeInterest'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_GovernmentSubsidyIncome' xlink:label='fil_GovernmentSubsidyIncome'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_GovernmentSubsidyIncome' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Government subsidy income</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_GovernmentSubsidyIncome' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of Government subsidy income.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_GovernmentSubsidyIncome' xlink:to='lab_fil_GovernmentSubsidyIncome'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment' xlink:label='us-gaap_GoodwillAndIntangibleAssetImpairment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GoodwillAndIntangibleAssetImpairment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Impairment of intangible assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GoodwillAndIntangibleAssetImpairment' xlink:to='lab_us-gaap_GoodwillAndIntangibleAssetImpairment'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProvisionForDoubtfulAccounts' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bad debt expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProvisionForDoubtfulAccounts' xlink:to='lab_us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding' xlink:label='us-gaap_PreferredStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred Stock, shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockSharesOutstanding' xlink:to='lab_us-gaap_PreferredStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated other comprehensive income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax' xlink:to='lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Liabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Liabilities' xlink:to='lab_us-gaap_Liabilities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StatementLineItems' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Statement [Line Items]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StatementLineItems' xlink:to='lab_us-gaap_StatementLineItems'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Current Reporting Status</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PercentageOfNoCustomerAccountedForMoreThanSales' xlink:label='fil_PercentageOfNoCustomerAccountedForMoreThanSales'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfNoCustomerAccountedForMoreThanSales' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Percentage of no customer accounted for more than sales</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfNoCustomerAccountedForMoreThanSales' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Percentage of no customer accounted for more than sales</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PercentageOfNoCustomerAccountedForMoreThanSales' xlink:to='lab_fil_PercentageOfNoCustomerAccountedForMoreThanSales'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OutstandingOptions' xlink:label='fil_OutstandingOptions'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutstandingOptions' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Outstanding options</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutstandingOptions' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Outstanding options</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutstandingOptions' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Outstanding options</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutstandingOptions' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Outstanding options begining balance</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OutstandingOptions' xlink:to='lab_fil_OutstandingOptions'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_STOCKHOLDERSEQUITYTOOFFICERS2010StockOptionPlanAbstract' xlink:label='fil_STOCKHOLDERSEQUITYTOOFFICERS2010StockOptionPlanAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_STOCKHOLDERSEQUITYTOOFFICERS2010StockOptionPlanAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>STOCKHOLDERS EQUITY TO OFFICERS 2010 Stock Option Plan</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_STOCKHOLDERSEQUITYTOOFFICERS2010StockOptionPlanAbstract' xlink:to='lab_fil_STOCKHOLDERSEQUITYTOOFFICERS2010StockOptionPlanAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria' xlink:label='fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Options to vest on three month anniversary performance based vesting criteria</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Options to vest on three month anniversary performance based vesting criteria</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria' xlink:to='lab_fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ClosingRiskFreeInterestRate' xlink:label='fil_ClosingRiskFreeInterestRate'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ClosingRiskFreeInterestRate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Closing risk free interest rate</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ClosingRiskFreeInterestRate' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Closing risk free interest rate</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ClosingRiskFreeInterestRate' xlink:to='lab_fil_ClosingRiskFreeInterestRate'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DeferredIncomeTaxAssetsAbstract' xlink:label='fil_DeferredIncomeTaxAssetsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DeferredIncomeTaxAssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income tax assets:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DeferredIncomeTaxAssetsAbstract' xlink:to='lab_fil_DeferredIncomeTaxAssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits' xlink:label='us-gaap_IncomeTaxReconciliationTaxCredits'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxReconciliationTaxCredits' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tax at statutory rate of 25%</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxReconciliationTaxCredits' xlink:to='lab_us-gaap_IncomeTaxReconciliationTaxCredits'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_EnterpriseIncomeTaxRatesForTheYear2013' xlink:label='fil_EnterpriseIncomeTaxRatesForTheYear2013'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRatesForTheYear2013' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Enterprise Income Tax Rates for the year 2013</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRatesForTheYear2013' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Enterprise Income Tax Rates for the year 2013</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EnterpriseIncomeTaxRatesForTheYear2013' xlink:to='lab_fil_EnterpriseIncomeTaxRatesForTheYear2013'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AnnualAmortization2016' xlink:label='fil_AnnualAmortization2016'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AnnualAmortization2016' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Annual amortization 2016</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AnnualAmortization2016' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Annual amortization 2016</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AnnualAmortization2016' xlink:to='lab_fil_AnnualAmortization2016'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PlantMachineryAndEquipmentLife' xlink:label='fil_PlantMachineryAndEquipmentLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PlantMachineryAndEquipmentLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Plant, machinery and equipment life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PlantMachineryAndEquipmentLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Plant, machinery and equipment life</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PlantMachineryAndEquipmentLife' xlink:to='lab_fil_PlantMachineryAndEquipmentLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PROPERTYANDEQUIPMENTAbstract' xlink:label='fil_PROPERTYANDEQUIPMENTAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PROPERTYANDEQUIPMENTAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>PROPERTY AND EQUIPMENT {2}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PROPERTYANDEQUIPMENTAbstract' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>PROPERTY AND EQUIPMENT</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PROPERTYANDEQUIPMENTAbstract' xlink:to='lab_fil_PROPERTYANDEQUIPMENTAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryGross' xlink:label='us-gaap_InventoryGross'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory Gross</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryGross' xlink:to='lab_us-gaap_InventoryGross'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_Leases1Abstract' xlink:label='fil_Leases1Abstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_Leases1Abstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>FUTURE MINIMUM COMMITMENTS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_Leases1Abstract' xlink:to='lab_fil_Leases1Abstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock' xlink:label='us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Effective Income Tax Rate Reconciliation.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_IntangibleAssetsMedicalFormulasTablesTextBlock' xlink:label='fil_IntangibleAssetsMedicalFormulasTablesTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssetsMedicalFormulasTablesTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible Assets Medical Formulas</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssetsMedicalFormulasTablesTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Tabluar disclosure of Intangible Assets Medical Formulas</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IntangibleAssetsMedicalFormulasTablesTextBlock' xlink:to='lab_fil_IntangibleAssetsMedicalFormulasTablesTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract' xlink:label='us-gaap_RisksAndUncertaintiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RisksAndUncertaintiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CONCENTRATIONS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RisksAndUncertaintiesAbstract' xlink:to='lab_us-gaap_RisksAndUncertaintiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract' xlink:label='us-gaap_IncomeTaxDisclosureAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxDisclosureAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INCOME TAXES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxDisclosureAbstract' xlink:to='lab_us-gaap_IncomeTaxDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INVENTORY. {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>INVENTORY.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryDisclosureTextBlock' xlink:to='lab_us-gaap_InventoryDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AccountsPayableForPurchasesOfPropertyAndEquipment' xlink:label='fil_AccountsPayableForPurchasesOfPropertyAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccountsPayableForPurchasesOfPropertyAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts payable for purchases of property and equipment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccountsPayableForPurchasesOfPropertyAndEquipment' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Accounts receivable collected with banker&apos;s acceptances</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AccountsPayableForPurchasesOfPropertyAndEquipment' xlink:to='lab_fil_AccountsPayableForPurchasesOfPropertyAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash Flows from Investing Activities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInOtherAccountsPayable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other payables.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInOtherAccountsPayable' xlink:to='lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NetIncomeForTheYear2011' xlink:label='fil_NetIncomeForTheYear2011'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetIncomeForTheYear2011' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net income for the year 2011</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetIncomeForTheYear2011' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NetIncomeForTheYear2011' xlink:to='lab_fil_NetIncomeForTheYear2011'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ComprehensiveIncomeNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Comprehensive income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ComprehensiveIncomeNetOfTax' xlink:to='lab_us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccruedLiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccruedLiabilitiesCurrent' xlink:to='lab_us-gaap_AccruedLiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Central Index Key</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_Expired' xlink:label='fil_Expired'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_Expired' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Expired</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_Expired' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Expired</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_Expired' xlink:to='lab_fil_Expired'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RestrictedStockGrantedToCEO' xlink:label='fil_RestrictedStockGrantedToCEO'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RestrictedStockGrantedToCEO' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Restricted stock granted to CEO</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_RestrictedStockGrantedToCEO' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Restricted stock granted to CEO</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RestrictedStockGrantedToCEO' xlink:to='lab_fil_RestrictedStockGrantedToCEO'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria1' xlink:label='fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Options to vest on three month anniversary performance based vesting criteria.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Options to vest on three month anniversary performance based vesting criteria.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria1' xlink:to='lab_fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria1'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_MaximumExpectedLife' xlink:label='fil_MaximumExpectedLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_MaximumExpectedLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Maximum expected life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_MaximumExpectedLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Maximum expected life</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_MaximumExpectedLife' xlink:to='lab_fil_MaximumExpectedLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NumberOfCommonSharesPurchasedByOptions' xlink:label='fil_NumberOfCommonSharesPurchasedByOptions'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NumberOfCommonSharesPurchasedByOptions' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of common shares purchased by options</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NumberOfCommonSharesPurchasedByOptions' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Number of common shares purchased by options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NumberOfCommonSharesPurchasedByOptions' xlink:to='lab_fil_NumberOfCommonSharesPurchasedByOptions'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BankersAcceptanceNotes' xlink:label='fil_BankersAcceptanceNotes'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotes' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bankers acceptance notes</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotes' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Bankers acceptance notes,</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BankersAcceptanceNotes' xlink:to='lab_fil_BankersAcceptanceNotes'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_IssueOfWarrantsForPurchaseOfCommonStockTreatedAsDerivatives' xlink:label='fil_IssueOfWarrantsForPurchaseOfCommonStockTreatedAsDerivatives'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IssueOfWarrantsForPurchaseOfCommonStockTreatedAsDerivatives' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Issue of warrants for purchase of common stock treated as derivatives</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_IssueOfWarrantsForPurchaseOfCommonStockTreatedAsDerivatives' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Issue of warrants for purchase of common stock treated as derivatives</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IssueOfWarrantsForPurchaseOfCommonStockTreatedAsDerivatives' xlink:to='lab_fil_IssueOfWarrantsForPurchaseOfCommonStockTreatedAsDerivatives'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalDeferredIncomeTaxAssets' xlink:label='fil_TotalDeferredIncomeTaxAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalDeferredIncomeTaxAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total deferred income tax assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalDeferredIncomeTaxAssets' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Total deferred income tax assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalDeferredIncomeTaxAssets' xlink:to='lab_fil_TotalDeferredIncomeTaxAssets'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_INCOMETAXESProvisionAbstract' xlink:label='fil_INCOMETAXESProvisionAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_INCOMETAXESProvisionAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INCOME TAXES Provision</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_INCOMETAXESProvisionAbstract' xlink:to='lab_fil_INCOMETAXESProvisionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RELATEDPARTYTRANSACTIONSMemberOfBODAbstract' xlink:label='fil_RELATEDPARTYTRANSACTIONSMemberOfBODAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RELATEDPARTYTRANSACTIONSMemberOfBODAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>RELATED PARTY TRANSACTIONS Member Of BOD</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RELATEDPARTYTRANSACTIONSMemberOfBODAbstract' xlink:to='lab_fil_RELATEDPARTYTRANSACTIONSMemberOfBODAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CompanyObligationToPayLaboratoriesAndOthers' xlink:label='fil_CompanyObligationToPayLaboratoriesAndOthers'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyObligationToPayLaboratoriesAndOthers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Company obligation to pay laboratories and others</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyObligationToPayLaboratoriesAndOthers' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Company obligation to pay laboratories and others</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CompanyObligationToPayLaboratoriesAndOthers' xlink:to='lab_fil_CompanyObligationToPayLaboratoriesAndOthers'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PropertyAndEquipmentNet' xlink:label='fil_PropertyAndEquipmentNet'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PropertyAndEquipmentNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and Equipment, net</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PropertyAndEquipmentNet' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PropertyAndEquipmentNet' xlink:to='lab_fil_PropertyAndEquipmentNet'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CompanyContributionToRetirementBenefitPlans' xlink:label='fil_CompanyContributionToRetirementBenefitPlans'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyContributionToRetirementBenefitPlans' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Company contribution to retirement benefit plans</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyContributionToRetirementBenefitPlans' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Company contribution to retirement benefit plans</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CompanyContributionToRetirementBenefitPlans' xlink:to='lab_fil_CompanyContributionToRetirementBenefitPlans'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Diluted weighted-average common shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:to='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' xlink:label='us-gaap_CommitmentsAndContingenciesDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>COMMITMENTS AND CONTINGENCIES {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>COMMITMENTS AND CONTINGENCIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' xlink:to='lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS. {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The entire disclosure of advances for purchases of intangible assets.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' xlink:to='lab_fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract' xlink:label='us-gaap_PropertyPlantAndEquipmentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>PROPERTY AND EQUIPMENT</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentAbstract' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt' xlink:label='us-gaap_ProceedsFromRelatedPartyDebt'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProceedsFromRelatedPartyDebt' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Borrowings from related party</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProceedsFromRelatedPartyDebt' xlink:to='lab_us-gaap_ProceedsFromRelatedPartyDebt'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued expenses and other liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:to='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_StockBasedCompensation' xlink:label='fil_StockBasedCompensation'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_StockBasedCompensation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock based compensation.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_StockBasedCompensation' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers&apos; compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_StockBasedCompensation' xlink:to='lab_fil_StockBasedCompensation'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Balance</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Balance</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/periodEndLabel' xml:lang='en-US'>Balance</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SharesOutstanding' xlink:to='lab_us-gaap_SharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareDiluted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Diluted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareDiluted' xlink:to='lab_us-gaap_EarningsPerShareDiluted'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableOtherCurrent' xlink:label='us-gaap_AccountsPayableOtherCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsPayableOtherCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other payables</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsPayableOtherCurrent' xlink:to='lab_us-gaap_AccountsPayableOtherCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalYearFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Year Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalYearFocus' xlink:to='lab_dei_DocumentFiscalYearFocus'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ForTheYear2013' xlink:label='fil_ForTheYear2013'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ForTheYear2013' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>For the year 2013</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ForTheYear2013' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>For the year 2013</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ForTheYear2013' xlink:to='lab_fil_ForTheYear2013'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CommonStockSharesGranted' xlink:label='fil_CommonStockSharesGranted'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockSharesGranted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock shares granted</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonStockSharesGranted' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Common stock shares granted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonStockSharesGranted' xlink:to='lab_fil_CommonStockSharesGranted'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_StockOptionsGranted' xlink:label='fil_StockOptionsGranted'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_StockOptionsGranted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stock options granted</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_StockOptionsGranted' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Stock options granted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_StockOptionsGranted' xlink:to='lab_fil_StockOptionsGranted'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_STOCKHOLDERSEQUITYPreferredCommonStockAndWarrantsAbstract' xlink:label='fil_STOCKHOLDERSEQUITYPreferredCommonStockAndWarrantsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_STOCKHOLDERSEQUITYPreferredCommonStockAndWarrantsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred Common Stock And Warrants</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_STOCKHOLDERSEQUITYPreferredCommonStockAndWarrantsAbstract' xlink:to='lab_fil_STOCKHOLDERSEQUITYPreferredCommonStockAndWarrantsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalLevel2' xlink:label='fil_TotalLevel2'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalLevel2' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Level 2</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalLevel2' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Bankers acceptance notes Level 2 total</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalLevel2' xlink:to='lab_fil_TotalLevel2'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DerivativeWarrantGainsAbstract' xlink:label='fil_DerivativeWarrantGainsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DerivativeWarrantGainsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Derivative warrant gains</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DerivativeWarrantGainsAbstract' xlink:to='lab_fil_DerivativeWarrantGainsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RevolvingLineOfCreditWithABankRMD25000000' xlink:label='fil_RevolvingLineOfCreditWithABankRMD25000000'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RevolvingLineOfCreditWithABankRMD25000000' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Revolving line of credit with a bank ( RMD 25,000,000)</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_RevolvingLineOfCreditWithABankRMD25000000' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Revolving line of credit with a bank ( RMD 25000000)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RevolvingLineOfCreditWithABankRMD25000000' xlink:to='lab_fil_RevolvingLineOfCreditWithABankRMD25000000'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AccumulatedAmortizationIntangibleAssetsSFDAApprovedMedicalFormulas' xlink:label='fil_AccumulatedAmortizationIntangibleAssetsSFDAApprovedMedicalFormulas'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccumulatedAmortizationIntangibleAssetsSFDAApprovedMedicalFormulas' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated amortization Intangible assets SFDA Approved Medical Formulas</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccumulatedAmortizationIntangibleAssetsSFDAApprovedMedicalFormulas' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Accumulated amortization Intangible assets SFDA Approved Medical Formulas</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AccumulatedAmortizationIntangibleAssetsSFDAApprovedMedicalFormulas' xlink:to='lab_fil_AccumulatedAmortizationIntangibleAssetsSFDAApprovedMedicalFormulas'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PermitOfLandUseMaximumLife' xlink:label='fil_PermitOfLandUseMaximumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PermitOfLandUseMaximumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Permit of land use maximum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PermitOfLandUseMaximumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PermitOfLandUseMaximumLife' xlink:to='lab_fil_PermitOfLandUseMaximumLife'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryFinishedGoods' xlink:label='us-gaap_InventoryFinishedGoods'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryFinishedGoods' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Finished goods</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryFinishedGoods' xlink:to='lab_us-gaap_InventoryFinishedGoods'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PercetageOfAcquiredByOnnyInHelpson' xlink:label='fil_PercetageOfAcquiredByOnnyInHelpson'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercetageOfAcquiredByOnnyInHelpson' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Percetage of acquired by Onny in Helpson</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercetageOfAcquiredByOnnyInHelpson' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Percetage of acquired by Onny in Helpson</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PercetageOfAcquiredByOnnyInHelpson' xlink:to='lab_fil_PercetageOfAcquiredByOnnyInHelpson'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PotentialCommonSharesWereNotIncludedInTheComputationOfDilutedEarningsPerShareTableTextBlock' xlink:label='fil_PotentialCommonSharesWereNotIncludedInTheComputationOfDilutedEarningsPerShareTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PotentialCommonSharesWereNotIncludedInTheComputationOfDilutedEarningsPerShareTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Potential common shares were not included in the computation of diluted earnings per share</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PotentialCommonSharesWereNotIncludedInTheComputationOfDilutedEarningsPerShareTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Tabular disclosure of common shares not included in earnings per share.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PotentialCommonSharesWereNotIncludedInTheComputationOfDilutedEarningsPerShareTableTextBlock' xlink:to='lab_fil_PotentialCommonSharesWereNotIncludedInTheComputationOfDilutedEarningsPerShareTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock' xlink:label='us-gaap_AdvertisingCostsPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdvertisingCostsPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advertising Costs</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdvertisingCostsPolicyTextBlock' xlink:to='lab_us-gaap_AdvertisingCostsPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryPolicyTextBlock' xlink:label='us-gaap_InventoryPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory.Policy</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryPolicyTextBlock' xlink:to='lab_us-gaap_InventoryPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_UseOfEstimates' xlink:label='us-gaap_UseOfEstimates'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_UseOfEstimates' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounting Estimates</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_UseOfEstimates' xlink:to='lab_us-gaap_UseOfEstimates'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock' xlink:label='us-gaap_FairValueMeasurementInputsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>FAIR VALUE MEASUREMENTS {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>FAIR VALUE MEASUREMENTS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FairValueMeasurementInputsDisclosureTextBlock' xlink:to='lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesForPaymentOfPurchasesOfPropertyAndEquipment' xlink:label='fil_AdvancesForPaymentOfPurchasesOfPropertyAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPaymentOfPurchasesOfPropertyAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances for payment of purchases of property and equipment.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPaymentOfPurchasesOfPropertyAndEquipment' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Advances for payment of purchases of property and equipment.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesForPaymentOfPurchasesOfPropertyAndEquipment' xlink:to='lab_fil_AdvancesForPaymentOfPurchasesOfPropertyAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Income before income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpenses' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total operating expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpenses' xlink:to='lab_us-gaap_OperatingExpenses'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Stockholders&apos; Equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquity' xlink:to='lab_us-gaap_StockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashEquivalentsAtCarryingValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashEquivalentsAtCarryingValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Banker&apos;s acceptances</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashEquivalentsAtCarryingValue' xlink:to='lab_us-gaap_CashEquivalentsAtCarryingValue'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash' xlink:label='us-gaap_Cash'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Cash' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash and cash equivalents</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Cash' xlink:to='lab_us-gaap_Cash'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CONCENTRATIONSAccountsPayableAbstract' xlink:label='fil_CONCENTRATIONSAccountsPayableAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CONCENTRATIONSAccountsPayableAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CONCENTRATIONS Accounts Payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CONCENTRATIONSAccountsPayableAbstract' xlink:to='lab_fil_CONCENTRATIONSAccountsPayableAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ShareBasedCompensationRelatedToTheFixedShareAwardsWasRecognizedOverThePeriodTheSharesVested' xlink:label='fil_ShareBasedCompensationRelatedToTheFixedShareAwardsWasRecognizedOverThePeriodTheSharesVested'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ShareBasedCompensationRelatedToTheFixedShareAwardsWasRecognizedOverThePeriodTheSharesVested' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>share-based compensation related to the fixed share awards was recognized over the period the shares vested.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ShareBasedCompensationRelatedToTheFixedShareAwardsWasRecognizedOverThePeriodTheSharesVested' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>share-based compensation related to the fixed share awards was recognized over the period the shares vested.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ShareBasedCompensationRelatedToTheFixedShareAwardsWasRecognizedOverThePeriodTheSharesVested' xlink:to='lab_fil_ShareBasedCompensationRelatedToTheFixedShareAwardsWasRecognizedOverThePeriodTheSharesVested'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DividendYield' xlink:label='fil_DividendYield'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DividendYield' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Dividend Yield</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DividendYield' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Dividend Yield</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DividendYield' xlink:to='lab_fil_DividendYield'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalRemainingUnrecognizedCompensationExpenseRelatedToRestrictiveStockGrants' xlink:label='fil_TotalRemainingUnrecognizedCompensationExpenseRelatedToRestrictiveStockGrants'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalRemainingUnrecognizedCompensationExpenseRelatedToRestrictiveStockGrants' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total remaining unrecognized compensation expense related to restrictive stock grants</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalRemainingUnrecognizedCompensationExpenseRelatedToRestrictiveStockGrants' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Intrinsic value of outstanding stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalRemainingUnrecognizedCompensationExpenseRelatedToRestrictiveStockGrants' xlink:to='lab_fil_TotalRemainingUnrecognizedCompensationExpenseRelatedToRestrictiveStockGrants'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_UnrecognizedCompensationExpenseRelatedToPerformanceBasedStockOptions' xlink:label='fil_UnrecognizedCompensationExpenseRelatedToPerformanceBasedStockOptions'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_UnrecognizedCompensationExpenseRelatedToPerformanceBasedStockOptions' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Unrecognized compensation expense related to performance based stock options</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_UnrecognizedCompensationExpenseRelatedToPerformanceBasedStockOptions' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Unrecognized compensation expense related to performance based stock options</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_UnrecognizedCompensationExpenseRelatedToPerformanceBasedStockOptions' xlink:to='lab_fil_UnrecognizedCompensationExpenseRelatedToPerformanceBasedStockOptions'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CommonSharesGranted' xlink:label='fil_CommonSharesGranted'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonSharesGranted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common shares granted</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonSharesGranted' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Common shares granted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonSharesGranted' xlink:to='lab_fil_CommonSharesGranted'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WarrantsStartRangeExercisePrice' xlink:label='fil_WarrantsStartRangeExercisePrice'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_WarrantsStartRangeExercisePrice' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Warrants start range exercise price</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_WarrantsStartRangeExercisePrice' xlink:role='http://www.xbrl.org/2003/role/periodStartLabel' xml:lang='en-US'>Warrants start range exercise price</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_WarrantsStartRangeExercisePrice' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Warrants start range exercise price.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_WarrantsStartRangeExercisePrice' xlink:to='lab_fil_WarrantsStartRangeExercisePrice'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CurrentAndPriorYears' xlink:label='fil_CurrentAndPriorYears'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CurrentAndPriorYears' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current and prior years</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CurrentAndPriorYears' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Current and prior years</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CurrentAndPriorYears' xlink:to='lab_fil_CurrentAndPriorYears'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AssetsDepreciationAbstract' xlink:label='fil_AssetsDepreciationAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AssetsDepreciationAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Assets Depreciation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AssetsDepreciationAbstract' xlink:to='lab_fil_AssetsDepreciationAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_MotorVehicleMinimumLife' xlink:label='fil_MotorVehicleMinimumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_MotorVehicleMinimumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Motor vehicle minimum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_MotorVehicleMinimumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_MotorVehicleMinimumLife' xlink:to='lab_fil_MotorVehicleMinimumLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_Warrants' xlink:label='fil_Warrants'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_Warrants' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Warrants</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_Warrants' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The amount of warrants.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_Warrants' xlink:to='lab_fil_Warrants'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_UsefulLivesOfTheAssetsTableTextBlock' xlink:label='fil_UsefulLivesOfTheAssetsTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_UsefulLivesOfTheAssetsTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Useful lives of the assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_UsefulLivesOfTheAssetsTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Tabular disclosure of useful lives of the assets.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_UsefulLivesOfTheAssetsTableTextBlock' xlink:to='lab_fil_UsefulLivesOfTheAssetsTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock' xlink:label='us-gaap_CashAndCashEquivalentsPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash and Cash Equivalents Policy</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashAndCashEquivalentsPolicyTextBlock' xlink:to='lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AccountingPoliciesPoliciesAbstract' xlink:label='fil_AccountingPoliciesPoliciesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccountingPoliciesPoliciesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounting Policies (Policies)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AccountingPoliciesPoliciesAbstract' xlink:to='lab_fil_AccountingPoliciesPoliciesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock' xlink:label='us-gaap_ConcentrationRiskDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ConcentrationRiskDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CONCENTRATIONS {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ConcentrationRiskDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>CONCENTRATIONS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ConcentrationRiskDisclosureTextBlock' xlink:to='lab_us-gaap_ConcentrationRiskDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill' xlink:label='us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Impairment of intangible assets.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill' xlink:to='lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_IssuanceOfStockAsCompensation' xlink:label='fil_IssuanceOfStockAsCompensation'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IssuanceOfStockAsCompensation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Issuance of stock as compensation</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_IssuanceOfStockAsCompensation' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Number of new stock issued during the period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IssuanceOfStockAsCompensation' xlink:to='lab_fil_IssuanceOfStockAsCompensation'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsMember' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retained Earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsMember' xlink:to='lab_us-gaap_RetainedEarningsMember'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Income tax expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_IncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense' xlink:label='us-gaap_NonoperatingIncomeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NonoperatingIncomeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net other income (expense)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NonoperatingIncomeExpense' xlink:to='lab_us-gaap_NonoperatingIncomeExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingExpense' xlink:label='us-gaap_SellingExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SellingExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Selling expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SellingExpense' xlink:to='lab_us-gaap_SellingExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfRevenue' xlink:label='us-gaap_CostOfRevenue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CostOfRevenue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cost of revenue</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CostOfRevenue' xlink:to='lab_us-gaap_CostOfRevenue'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesForPurchasesOfPropertyAndEquipment' xlink:label='fil_AdvancesForPurchasesOfPropertyAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfPropertyAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances for purchases of property and equipment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfPropertyAndEquipment' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>AdvancesForPurchasesOfPropertyAndEquipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesForPurchasesOfPropertyAndEquipment' xlink:to='lab_fil_AdvancesForPurchasesOfPropertyAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Current Assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrent' xlink:to='lab_us-gaap_AssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>cphi-20121231_pre.xml
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- NeoClarus - iFile Suite version 4.2311  -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.chinapharmaholdings.com/20121231"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DocumentAndEntityInformationAbstract' xlink:label='fil_DocumentAndEntityInformationAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_DocumentType' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_DocumentFiscalYearFocus' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_DocumentFiscalPeriodFocus' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='14.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_CONSOLIDATEDBALANCESHEETS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDBALANCESHEETS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_AssetsAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsAbstract' xlink:to='us-gaap_AssetsCurrentAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash' xlink:label='us-gaap_Cash'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_Cash' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashEquivalentsAtCarryingValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_CashEquivalentsAtCarryingValue' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ReceivablesNetCurrent' xlink:label='us-gaap_ReceivablesNetCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_ReceivablesNetCurrent' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherReceivablesNetCurrent' xlink:label='us-gaap_OtherReceivablesNetCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_OtherReceivablesNetCurrent' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesToSuppliers' xlink:label='fil_AdvancesToSuppliers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='fil_AdvancesToSuppliers' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_InventoryNet' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent' xlink:label='us-gaap_DeferredTaxAssetsNetCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_DeferredTaxAssetsNetCurrent' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_AssetsCurrent' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesForPurchasesOfPropertyAndEquipment' xlink:label='fil_AdvancesForPurchasesOfPropertyAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsAbstract' xlink:to='fil_AdvancesForPurchasesOfPropertyAndEquipment' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesForPurchasesOfIntangibleAssets' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsAbstract' xlink:to='fil_AdvancesForPurchasesOfIntangibleAssets' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsAbstract' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsAbstract' xlink:to='us-gaap_Assets' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_LiabilitiesAndStockholdersEquityAbstract' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_LiabilitiesCurrentAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableTradeCurrent' xlink:label='us-gaap_AccountsPayableTradeCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_AccountsPayableTradeCurrent' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_AccruedLiabilitiesCurrent' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_TaxesPayableCurrent' xlink:label='us-gaap_TaxesPayableCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_TaxesPayableCurrent' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableOtherCurrent' xlink:label='us-gaap_AccountsPayableOtherCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_AccountsPayableOtherCurrent' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CustomerAdvancesCurrent' xlink:label='us-gaap_CustomerAdvancesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_CustomerAdvancesCurrent' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent' xlink:label='us-gaap_DueToRelatedPartiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_DueToRelatedPartiesCurrent' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesPayableCurrent' xlink:label='us-gaap_NotesPayableCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_NotesPayableCurrent' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_LiabilitiesCurrent' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent' xlink:label='us-gaap_DeferredTaxLiabilitiesNoncurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_DeferredTaxLiabilitiesNoncurrent' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_Liabilities' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_StockholdersEquityAbstract' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue' xlink:label='us-gaap_PreferredStockValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_PreferredStockValue' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_CommonStockValue' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapital' xlink:label='us-gaap_AdditionalPaidInCapital'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_AdditionalPaidInCapital' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_RetainedEarningsAccumulatedDeficit' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_StockholdersEquity' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquity' use='optional' order='5.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract' xlink:label='us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent' xlink:label='us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AllowanceForDoubtfulAccountsOnOtherReceivables' xlink:label='fil_AllowanceForDoubtfulAccountsOnOtherReceivables'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AllowanceForDoubtfulAccountsOnOtherReceivables' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment' xlink:label='us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare' xlink:label='us-gaap_PreferredStockParOrStatedValuePerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_PreferredStockParOrStatedValuePerShare' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized' xlink:label='us-gaap_PreferredStockSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_PreferredStockSharesAuthorized' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued' xlink:label='us-gaap_PreferredStockSharesIssued'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_PreferredStockSharesIssued' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding' xlink:label='us-gaap_PreferredStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_PreferredStockSharesOutstanding' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_CommonStockParOrStatedValuePerShare' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_CommonStockSharesAuthorized' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_CommonStockSharesIssued' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_CommonStockSharesOutstanding' use='optional' order='12.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues' xlink:label='us-gaap_Revenues'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_Revenues' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfRevenue' xlink:label='us-gaap_CostOfRevenue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_CostOfRevenue' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryWriteDown' xlink:label='us-gaap_InventoryWriteDown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_InventoryWriteDown' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_GrossProfit' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OperatingExpensesAbstract' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SellingExpense' xlink:label='us-gaap_SellingExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_SellingExpense' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense' xlink:label='us-gaap_GeneralAndAdministrativeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_GeneralAndAdministrativeExpense' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment' xlink:label='us-gaap_GoodwillAndIntangibleAssetImpairment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_GoodwillAndIntangibleAssetImpairment' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_OperatingExpenses' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_GovernmentSubsidyIncome' xlink:label='fil_GovernmentSubsidyIncome'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_GovernmentSubsidyIncome' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract' xlink:label='us-gaap_NonoperatingIncomeExpenseAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_NonoperatingIncomeExpenseAbstract' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest' xlink:label='us-gaap_InvestmentIncomeInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NonoperatingIncomeExpenseAbstract' xlink:to='us-gaap_InvestmentIncomeInterest' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense' xlink:label='us-gaap_InterestExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NonoperatingIncomeExpenseAbstract' xlink:to='us-gaap_InterestExpense' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives' xlink:label='us-gaap_GainLossOnSaleOfDerivatives'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NonoperatingIncomeExpenseAbstract' xlink:to='us-gaap_GainLossOnSaleOfDerivatives' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense' xlink:label='us-gaap_NonoperatingIncomeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NonoperatingIncomeExpenseAbstract' xlink:to='us-gaap_NonoperatingIncomeExpense' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit' xlink:label='us-gaap_IncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_IncomeTaxExpenseBenefit' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ProfitLoss' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease' xlink:label='us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax' xlink:label='us-gaap_ComprehensiveIncomeNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ComprehensiveIncomeNetOfTax' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareAbstract' xlink:label='us-gaap_EarningsPerShareAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_EarningsPerShareAbstract' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_EarningsPerShareAbstract' xlink:to='us-gaap_EarningsPerShareBasic' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_EarningsPerShareAbstract' xlink:to='us-gaap_EarningsPerShareDiluted' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ChangesInStockholderSEquityAbstract' xlink:label='fil_ChangesInStockholderSEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ChangesInStockholderSEquityAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementEquityComponentsAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalUnitsMember' xlink:label='us-gaap_CapitalUnitsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_CapitalUnitsMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember' xlink:label='us-gaap_CommonStockMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_CommonStockMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember' xlink:label='us-gaap_AdditionalPaidInCapitalMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_AdditionalPaidInCapitalMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember' xlink:label='us-gaap_RetainedEarningsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_RetainedEarningsMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember' xlink:label='us-gaap_AccumulatedOtherComprehensiveIncomeMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_AccumulatedOtherComprehensiveIncomeMember' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ParentMember' xlink:label='us-gaap_ParentMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='us-gaap_ParentMember' use='optional' order='6.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding' xlink:label='us-gaap_SharesOutstanding_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SharesOutstanding_1' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues' xlink:label='us-gaap_StockIssuedDuringPeriodSharesNewIssues'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_StockIssuedDuringPeriodSharesNewIssues' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_IssuanceOfStockAsCompensation' xlink:label='fil_IssuanceOfStockAsCompensation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_IssuanceOfStockAsCompensation' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NetIncomeForTheYear2011' xlink:label='fil_NetIncomeForTheYear2011'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NetIncomeForTheYear2011' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ForeignCurrencyTranslationAdjustment' xlink:label='fil_ForeignCurrencyTranslationAdjustment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ForeignCurrencyTranslationAdjustment' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation' xlink:label='us-gaap_ShareBasedCompensation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ShareBasedCompensation' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ForfeitureOfContingentlyVestingShares' xlink:label='fil_ForfeitureOfContingentlyVestingShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ForfeitureOfContingentlyVestingShares' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NetIncomeForTheYear2012' xlink:label='fil_NetIncomeForTheYear2012'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NetIncomeForTheYear2012' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ForeignCurrencyTranslationAdjustment1' xlink:label='fil_ForeignCurrencyTranslationAdjustment1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ForeignCurrencyTranslationAdjustment1' use='optional' order='10.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss' xlink:label='us-gaap_NetIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_NetIncomeLoss' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationAndAmortization' xlink:label='us-gaap_DepreciationAndAmortization'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_DepreciationAndAmortization' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_StockBasedCompensation' xlink:label='fil_StockBasedCompensation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='fil_StockBasedCompensation' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DerivativeGain' xlink:label='fil_DerivativeGain'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='fil_DerivativeGain' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BadDebtExpenseBenefit' xlink:label='fil_BadDebtExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='fil_BadDebtExpenseBenefit' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill' xlink:label='us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived' xlink:label='us-gaap_ImpairmentOfIntangibleAssetsFinitelived'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_ImpairmentOfIntangibleAssetsFinitelived' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_DeferredIncomeTaxExpenseBenefit' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:label='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract' xlink:to='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables' xlink:label='us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ChangesInAdvancesToSuppliers' xlink:label='fil_ChangesInAdvancesToSuppliers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='fil_ChangesInAdvancesToSuppliers' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInInventories' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayableTrade'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsPayableTrade' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccruedLiabilities' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable' xlink:label='us-gaap_IncreaseDecreaseInAccruedTaxesPayable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccruedTaxesPayable' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable' xlink:label='us-gaap_IncreaseDecreaseInOtherAccountsPayable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInOtherAccountsPayable' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInCustomerAdvances' xlink:label='us-gaap_IncreaseDecreaseInCustomerAdvances'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInCustomerAdvances' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivities' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NetInvestmentInBankerSAcceptances' xlink:label='fil_NetInvestmentInBankerSAcceptances'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='fil_NetInvestmentInBankerSAcceptances' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesForPaymentOfPurchasesOfPropertyAndEquipment' xlink:label='fil_AdvancesForPaymentOfPurchasesOfPropertyAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='fil_AdvancesForPaymentOfPurchasesOfPropertyAndEquipment' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesForPaymentOfPurchasesOfIntangibleAssets' xlink:label='fil_AdvancesForPaymentOfPurchasesOfIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='fil_AdvancesForPaymentOfPurchasesOfIntangibleAssets' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivities' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromNotesPayable' xlink:label='us-gaap_ProceedsFromNotesPayable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_ProceedsFromNotesPayable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt' xlink:label='us-gaap_ProceedsFromRelatedPartyDebt'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_ProceedsFromRelatedPartyDebt' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivities' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease' xlink:label='us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue' use='optional' order='6.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue' xlink:label='us-gaap_CashAndCashEquivalentsAtCarryingValue_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_CashAndCashEquivalentsAtCarryingValue_1' use='optional' order='7.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract' xlink:label='us-gaap_SupplementalCashFlowInformationAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_SupplementalCashFlowInformationAbstract' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid' xlink:label='us-gaap_InterestPaid'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_SupplementalCashFlowInformationAbstract' xlink:to='us-gaap_InterestPaid' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaidNet' xlink:label='us-gaap_IncomeTaxesPaidNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_SupplementalCashFlowInformationAbstract' xlink:to='us-gaap_IncomeTaxesPaidNet' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:label='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AccountsPayableForPurchasesOfPropertyAndEquipment' xlink:label='fil_AccountsPayableForPurchasesOfPropertyAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:to='fil_AccountsPayableForPurchasesOfPropertyAndEquipment' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AccountsReceivableCollectedWithBankerSAcceptances' xlink:label='fil_AccountsReceivableCollectedWithBankerSAcceptances'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:to='fil_AccountsReceivableCollectedWithBankerSAcceptances' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_InventoryPurchasedWithBankerSAcceptances' xlink:label='fil_InventoryPurchasedWithBankerSAcceptances'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:to='fil_InventoryPurchasedWithBankerSAcceptances' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesForPurchasesOfPropertyAndEquipmentPaidWithBankerSAcceptances' xlink:label='fil_AdvancesForPurchasesOfPropertyAndEquipmentPaidWithBankerSAcceptances'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:to='fil_AdvancesForPurchasesOfPropertyAndEquipmentPaidWithBankerSAcceptances' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances' xlink:label='fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:to='fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances' use='optional' order='5.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract' xlink:to='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINVENTORY" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureINVENTORY"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINVENTORY">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryDisclosureAbstract' xlink:label='us-gaap_InventoryDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_InventoryDisclosureAbstract' xlink:to='us-gaap_InventoryDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosurePROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosurePROPERTYANDEQUIPMENT"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosurePROPERTYANDEQUIPMENT">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract' xlink:label='us-gaap_PropertyPlantAndEquipmentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_PropertyPlantAndEquipmentAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINTANGIBLEASSETS" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureINTANGIBLEASSETS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINTANGIBLEASSETS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract' xlink:label='us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:label='us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract' xlink:to='us-gaap_IntangibleAssetsDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesForPurchasesOfIntangibleAssetsAbstract' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AdvancesForPurchasesOfIntangibleAssetsAbstract' xlink:to='fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureRELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureRELATEDPARTYTRANSACTIONS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureRELATEDPARTYTRANSACTIONS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract' xlink:label='us-gaap_RelatedPartyTransactionsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock' xlink:label='us-gaap_RelatedPartyTransactionsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RelatedPartyTransactionsAbstract' xlink:to='us-gaap_RelatedPartyTransactionsDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureNOTESPAYABLE" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureNOTESPAYABLE"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureNOTESPAYABLE">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NotesPayable1Abstract' xlink:label='fil_NotesPayable1Abstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NotesPayableTextBlock' xlink:label='fil_NotesPayableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_NotesPayable1Abstract' xlink:to='fil_NotesPayableTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINCOMETAXES" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureINCOMETAXES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINCOMETAXES">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract' xlink:label='us-gaap_IncomeTaxDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock' xlink:label='us-gaap_IncomeTaxDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeTaxDisclosureAbstract' xlink:to='us-gaap_IncomeTaxDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureDERIVATIVEWARRANTLIABILITY" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureDERIVATIVEWARRANTLIABILITY"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureDERIVATIVEWARRANTLIABILITY">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DerivativeInstrumentsAndHedgingActivitiesAbstract' xlink:label='fil_DerivativeInstrumentsAndHedgingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativesAndFairValueTextBlock' xlink:label='us-gaap_DerivativesAndFairValueTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DerivativeInstrumentsAndHedgingActivitiesAbstract' xlink:to='us-gaap_DerivativesAndFairValueTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureFAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureFAIRVALUEMEASUREMENTS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureFAIRVALUEMEASUREMENTS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueDisclosuresAbstract' xlink:label='us-gaap_FairValueDisclosuresAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock' xlink:label='us-gaap_FairValueMeasurementInputsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_FairValueDisclosuresAbstract' xlink:to='us-gaap_FairValueMeasurementInputsDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureSTOCKHOLDERSEQUITY"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureSTOCKHOLDERSEQUITY">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityAbstract' xlink:label='us-gaap_EquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock' xlink:label='us-gaap_StockholdersEquityNoteDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_EquityAbstract' xlink:to='us-gaap_StockholdersEquityNoteDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureCOMMITMENTSANDCONTINGENCIES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CommitmentAndContingenciesAbstract' xlink:label='fil_CommitmentAndContingenciesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' xlink:label='us-gaap_CommitmentsAndContingenciesDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_CommitmentAndContingenciesAbstract' xlink:to='us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureCONCENTRATIONS" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureCONCENTRATIONS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureCONCENTRATIONS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract' xlink:label='us-gaap_RisksAndUncertaintiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock' xlink:label='us-gaap_ConcentrationRiskDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RisksAndUncertaintiesAbstract' xlink:to='us-gaap_ConcentrationRiskDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureAccountingPoliciesPolicies"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureAccountingPoliciesPolicies">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AccountingPoliciesPoliciesAbstract' xlink:label='fil_AccountingPoliciesPoliciesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations' xlink:label='us-gaap_NatureOfOperations'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesPoliciesAbstract' xlink:to='us-gaap_NatureOfOperations' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock' xlink:label='us-gaap_ConsolidationPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesPoliciesAbstract' xlink:to='us-gaap_ConsolidationPolicyTextBlock' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Reclassifications' xlink:label='us-gaap_Reclassifications'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesPoliciesAbstract' xlink:to='us-gaap_Reclassifications' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_UseOfEstimates' xlink:label='us-gaap_UseOfEstimates'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesPoliciesAbstract' xlink:to='us-gaap_UseOfEstimates' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock' xlink:label='us-gaap_CashAndCashEquivalentsPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesPoliciesAbstract' xlink:to='us-gaap_CashAndCashEquivalentsPolicyTextBlock' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock' xlink:label='us-gaap_ReceivablesPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesPoliciesAbstract' xlink:to='us-gaap_ReceivablesPolicyTextBlock' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock' xlink:label='us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesPoliciesAbstract' xlink:to='us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryPolicyTextBlock' xlink:label='us-gaap_InventoryPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesPoliciesAbstract' xlink:to='us-gaap_InventoryPolicyTextBlock' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' xlink:label='us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesPoliciesAbstract' xlink:to='us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesPoliciesAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesPoliciesAbstract' xlink:to='us-gaap_RevenueRecognitionPolicyTextBlock' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock' xlink:label='us-gaap_CostOfSalesPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesPoliciesAbstract' xlink:to='us-gaap_CostOfSalesPolicyTextBlock' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy' xlink:label='us-gaap_ResearchAndDevelopmentExpensePolicy'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesPoliciesAbstract' xlink:to='us-gaap_ResearchAndDevelopmentExpensePolicy' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock' xlink:label='us-gaap_CompensationRelatedCostsPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesPoliciesAbstract' xlink:to='us-gaap_CompensationRelatedCostsPolicyTextBlock' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock' xlink:label='us-gaap_AdvertisingCostsPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesPoliciesAbstract' xlink:to='us-gaap_AdvertisingCostsPolicyTextBlock' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock' xlink:label='us-gaap_EarningsPerSharePolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesPoliciesAbstract' xlink:to='us-gaap_EarningsPerSharePolicyTextBlock' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScheduleOfCreditLossesRelatedToFinancingReceivablesCurrentAndNoncurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfCreditLossesRelatedToFinancingReceivablesCurrentAndNoncurrentTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesPoliciesAbstract' xlink:to='us-gaap_ScheduleOfCreditLossesRelatedToFinancingReceivablesCurrentAndNoncurrentTableTextBlock' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock' xlink:label='us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesPoliciesAbstract' xlink:to='us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' xlink:label='us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesPoliciesAbstract' xlink:to='us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock' use='optional' order='19.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureBASISOFPRESENTATIONTables" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureBASISOFPRESENTATIONTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureBASISOFPRESENTATIONTables">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BasisOfPresentationTablesAbstract' xlink:label='fil_BasisOfPresentationTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:label='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BasisOfPresentationTablesAbstract' xlink:to='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PotentialCommonSharesWereNotIncludedInTheComputationOfDilutedEarningsPerShareTableTextBlock' xlink:label='fil_PotentialCommonSharesWereNotIncludedInTheComputationOfDilutedEarningsPerShareTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BasisOfPresentationTablesAbstract' xlink:to='fil_PotentialCommonSharesWereNotIncludedInTheComputationOfDilutedEarningsPerShareTableTextBlock' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINVENTORYTables" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureINVENTORYTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINVENTORYTables">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_InventoryTablesAbstract' xlink:label='fil_InventoryTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_InventoryTablesAbstract' xlink:to='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosurePROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosurePROPERTYANDEQUIPMENTTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosurePROPERTYANDEQUIPMENTTables">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PropertyAndEquipmentTablesAbstract' xlink:label='fil_PropertyAndEquipmentTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentTablesAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentTextBlock' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_UsefulLivesOfTheAssetsTableTextBlock' xlink:label='fil_UsefulLivesOfTheAssetsTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentTablesAbstract' xlink:to='fil_UsefulLivesOfTheAssetsTableTextBlock' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINTANGIBLEASSETSTables" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureINTANGIBLEASSETSTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINTANGIBLEASSETSTables">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_IntangibleAssetsTablesAbstract' xlink:label='fil_IntangibleAssetsTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_IntangibleAssetsMedicalFormulasTablesTextBlock' xlink:label='fil_IntangibleAssetsMedicalFormulasTablesTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IntangibleAssetsTablesAbstract' xlink:to='fil_IntangibleAssetsMedicalFormulasTablesTextBlock' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_IntangibleAssetsAmortizationExpense' xlink:label='fil_IntangibleAssetsAmortizationExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IntangibleAssetsTablesAbstract' xlink:to='fil_IntangibleAssetsAmortizationExpense' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINCOMETAXESTables" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureINCOMETAXESTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINCOMETAXESTables">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_IncomeTaxesTablesAbstract' xlink:label='fil_IncomeTaxesTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_IncomeTaxesTableTextBlock' xlink:label='fil_IncomeTaxesTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesTablesAbstract' xlink:to='fil_IncomeTaxesTableTextBlock' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ProvisionForIncomeTaxesTableTextBlock' xlink:label='fil_ProvisionForIncomeTaxesTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesTablesAbstract' xlink:to='fil_ProvisionForIncomeTaxesTableTextBlock' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock' xlink:label='us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesTablesAbstract' xlink:to='us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock' xlink:label='us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesTablesAbstract' xlink:to='us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock' use='optional' order='4.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureFAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureFAIRVALUEMEASUREMENTSTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureFAIRVALUEMEASUREMENTSTables">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_FairValueMeasurementsTablesAbstract' xlink:label='fil_FairValueMeasurementsTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AssetsFairValuesTablETextBlock' xlink:label='fil_AssetsFairValuesTablETextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_FairValueMeasurementsTablesAbstract' xlink:to='fil_AssetsFairValuesTablETextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureSTOCKOPTIONACTIVITYTables" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureSTOCKOPTIONACTIVITYTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureSTOCKOPTIONACTIVITYTables">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CompensationRelatedCostsShareBasedPaymentsAbstract' xlink:label='fil_CompensationRelatedCostsShareBasedPaymentsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock' xlink:label='us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_CompensationRelatedCostsShareBasedPaymentsAbstract' xlink:to='us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureFUTUREMINIMUMCOMMITMENTSTables" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DisclosureFUTUREMINIMUMCOMMITMENTSTables"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureFUTUREMINIMUMCOMMITMENTSTables">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_Leases1Abstract' xlink:label='fil_Leases1Abstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock' xlink:label='us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_Leases1Abstract' xlink:to='us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_BASISOFPRESENTATIONDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_BASISOFPRESENTATIONDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_BASISOFPRESENTATIONDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OrganizationAndOperationsAbstract' xlink:label='fil_OrganizationAndOperationsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_OrganizationAndOperationsAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PercentageOfShareOwned' xlink:label='fil_PercentageOfShareOwned'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PercentageOfShareOwned' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PercentageOfShareOwnedofHelpsonMedicalAmpBiotechnologyCoLtd' xlink:label='fil_PercentageOfShareOwnedofHelpsonMedicalAmpBiotechnologyCoLtd'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PercentageOfShareOwnedofHelpsonMedicalAmpBiotechnologyCoLtd' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PercetageOfAcquiredByOnnyInHelpson' xlink:label='fil_PercetageOfAcquiredByOnnyInHelpson'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PercetageOfAcquiredByOnnyInHelpson' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_BASISOFPRESENTATIONBasicAndDilutedEarningsPerCommonShareDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_BASISOFPRESENTATIONBasicAndDilutedEarningsPerCommonShareDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_BASISOFPRESENTATIONBasicAndDilutedEarningsPerCommonShareDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BASISOFPRESENTATIONBasicAndDilutedEarningsPerCommonShareDetailsAbstract' xlink:label='fil_BASISOFPRESENTATIONBasicAndDilutedEarningsPerCommonShareDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BASISOFPRESENTATIONBasicAndDilutedEarningsPerCommonShareDetailsAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NetIncome' xlink:label='fil_NetIncome'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NetIncome' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesIssuedBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_WeightedAverageNumberOfSharesIssuedBasic' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract' xlink:label='us-gaap_DilutiveSecuritiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DilutiveSecuritiesAbstract' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_Warrants' xlink:label='fil_Warrants'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_Warrants' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_Options' xlink:label='fil_Options'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_Options' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BasicEarningsPerShare' xlink:label='fil_BasicEarningsPerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_BasicEarningsPerShare' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DilutedEarningsPerShare' xlink:label='fil_DilutedEarningsPerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_DilutedEarningsPerShare' use='optional' order='8.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_BASISOFPRESENTATIONPOLICIESDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_BASISOFPRESENTATIONPOLICIESDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_BASISOFPRESENTATIONPOLICIESDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BASISOFPRESENTATIONPOLICIESAbstract' xlink:label='fil_BASISOFPRESENTATIONPOLICIESAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BASISOFPRESENTATIONPOLICIESAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WarrantsWithExercisePrice' xlink:label='fil_WarrantsWithExercisePrice'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_WarrantsWithExercisePrice' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsWithAnExercisePrice' xlink:label='fil_OptionsWithAnExercisePrice'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OptionsWithAnExercisePrice' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalWarrantsAndOptions' xlink:label='fil_TotalWarrantsAndOptions'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_TotalWarrantsAndOptions' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RecognizedAnImpairmentLossOfItsIntangibleAssets' xlink:label='fil_RecognizedAnImpairmentLossOfItsIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RecognizedAnImpairmentLossOfItsIntangibleAssets' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CompanyContributionToRetirementBenefitPlans' xlink:label='fil_CompanyContributionToRetirementBenefitPlans'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CompanyContributionToRetirementBenefitPlans' use='optional' order='5.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_INVENTORYDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_INVENTORYDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_INVENTORYDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_INVENTORYABSTRACTAbstract' xlink:label='fil_INVENTORYABSTRACTAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_INVENTORYABSTRACTAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_InventoryRawMaterials' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryFinishedGoods' xlink:label='us-gaap_InventoryFinishedGoods'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_InventoryFinishedGoods' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryGross' xlink:label='us-gaap_InventoryGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_InventoryGross' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AllowanceForObsolescenceRawMaterials' xlink:label='fil_AllowanceForObsolescenceRawMaterials'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AllowanceForObsolescenceRawMaterials' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalInventoryNet' xlink:label='fil_TotalInventoryNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_TotalInventoryNet' use='optional' order='5.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_PROPERTYANDEQUIPMENTDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_PROPERTYANDEQUIPMENTDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_PROPERTYANDEQUIPMENTDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PROPERTYANDEQUIPMENTAbstract' xlink:label='fil_PROPERTYANDEQUIPMENTAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PROPERTYANDEQUIPMENTAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PermitOfLandUse' xlink:label='fil_PermitOfLandUse'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PermitOfLandUse' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BuildingsAndImprovementsGross' xlink:label='us-gaap_BuildingsAndImprovementsGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_BuildingsAndImprovementsGross' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PlantMachineryAndEquipmentGross' xlink:label='fil_PlantMachineryAndEquipmentGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PlantMachineryAndEquipmentGross' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_MotorVehicleGross' xlink:label='fil_MotorVehicleGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_MotorVehicleGross' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FurnitureAndFixturesGross' xlink:label='us-gaap_FurnitureAndFixturesGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_FurnitureAndFixturesGross' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ConstructionInProgressGross' xlink:label='us-gaap_ConstructionInProgressGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_ConstructionInProgressGross' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalPropertyAndEquipment' xlink:label='fil_TotalPropertyAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_TotalPropertyAndEquipment' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_LessAccumulatedDepreciationDetails' xlink:label='fil_LessAccumulatedDepreciationDetails'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_LessAccumulatedDepreciationDetails' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PropertyAndEquipmentNet' xlink:label='fil_PropertyAndEquipmentNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PropertyAndEquipmentNet' use='optional' order='9.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_PROPERTYANDEQUIPMENTAssetsLifeDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_PROPERTYANDEQUIPMENTAssetsLifeDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_PROPERTYANDEQUIPMENTAssetsLifeDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PROPERTYANDEQUIPMENTAssetsLifeAbstract' xlink:label='fil_PROPERTYANDEQUIPMENTAssetsLifeAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PROPERTYANDEQUIPMENTAssetsLifeAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PermitOfLandUseMinimumLife' xlink:label='fil_PermitOfLandUseMinimumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PermitOfLandUseMinimumLife' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PermitOfLandUseMaximumLife' xlink:label='fil_PermitOfLandUseMaximumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PermitOfLandUseMaximumLife' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BuildingMinimumLife' xlink:label='fil_BuildingMinimumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_BuildingMinimumLife' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BuildingMaximumLife' xlink:label='fil_BuildingMaximumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_BuildingMaximumLife' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PlantMachineryAndEquipmentLife' xlink:label='fil_PlantMachineryAndEquipmentLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PlantMachineryAndEquipmentLife' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_MotorVehicleMinimumLife' xlink:label='fil_MotorVehicleMinimumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_MotorVehicleMinimumLife' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_MotorVehicleMaximumLife' xlink:label='fil_MotorVehicleMaximumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_MotorVehicleMaximumLife' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OfficeEquipmentMinimumLife' xlink:label='fil_OfficeEquipmentMinimumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OfficeEquipmentMinimumLife' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OfficeEquipmentMaximumLife' xlink:label='fil_OfficeEquipmentMaximumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OfficeEquipmentMaximumLife' use='optional' order='9.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_ASSETSDepreciationDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_ASSETSDepreciationDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_ASSETSDepreciationDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AssetsDepreciationAbstract' xlink:label='fil_AssetsDepreciationAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AssetsDepreciationAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DepreciationExpensePropertyAndEquipment' xlink:label='fil_DepreciationExpensePropertyAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_DepreciationExpensePropertyAndEquipment' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AmortizationExpenseIntangibleAssets' xlink:label='fil_AmortizationExpenseIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AmortizationExpenseIntangibleAssets' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_INTANGIBLEASSETSSFDAApprovedMedicalFormulasDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_INTANGIBLEASSETSSFDAApprovedMedicalFormulasDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_INTANGIBLEASSETSSFDAApprovedMedicalFormulasDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_INTANGIBLEASSETSSFDAApprovedMedicalFormulasAbstract' xlink:label='fil_INTANGIBLEASSETSSFDAApprovedMedicalFormulasAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_INTANGIBLEASSETSSFDAApprovedMedicalFormulasAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_GrossCarryingAmount' xlink:label='fil_GrossCarryingAmount'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_GrossCarryingAmount' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AccumulatedAmortizationIntangibleAssetsSFDAApprovedMedicalFormulas' xlink:label='fil_AccumulatedAmortizationIntangibleAssetsSFDAApprovedMedicalFormulas'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AccumulatedAmortizationIntangibleAssetsSFDAApprovedMedicalFormulas' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NetCarryingAmount' xlink:label='fil_NetCarryingAmount'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NetCarryingAmount' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AnnualAmortization2013' xlink:label='fil_AnnualAmortization2013'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AnnualAmortization2013' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AnnualAmortization2014' xlink:label='fil_AnnualAmortization2014'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AnnualAmortization2014' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AnnualAmortization2015' xlink:label='fil_AnnualAmortization2015'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AnnualAmortization2015' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AnnualAmortization2016' xlink:label='fil_AnnualAmortization2016'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AnnualAmortization2016' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AnnualAmortization2017' xlink:label='fil_AnnualAmortization2017'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AnnualAmortization2017' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AnnualAmortizationThereafter' xlink:label='fil_AnnualAmortizationThereafter'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AnnualAmortizationThereafter' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AnnualAmortizationTotal' xlink:label='fil_AnnualAmortizationTotal'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AnnualAmortizationTotal' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CompanyObligationToPayLaboratoriesAndOthers' xlink:label='fil_CompanyObligationToPayLaboratoriesAndOthers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CompanyObligationToPayLaboratoriesAndOthers' use='optional' order='11.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_RELATEDPARTYTRANSACTIONSMemberOfBODDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_RELATEDPARTYTRANSACTIONSMemberOfBODDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_RELATEDPARTYTRANSACTIONSMemberOfBODDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RELATEDPARTYTRANSACTIONSMemberOfBODAbstract' xlink:label='fil_RELATEDPARTYTRANSACTIONSMemberOfBODAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_RELATEDPARTYTRANSACTIONSMemberOfBODAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AmountAdvancedByMemberOfBODToTheCompany' xlink:label='fil_AmountAdvancedByMemberOfBODToTheCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AmountAdvancedByMemberOfBODToTheCompany' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_InterestRateOnAdvancesFromMemberOfBOD' xlink:label='fil_InterestRateOnAdvancesFromMemberOfBOD'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_InterestRateOnAdvancesFromMemberOfBOD' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_RELATEDPARTYTRANSACTIONSOwingsDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_RELATEDPARTYTRANSACTIONSOwingsDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_RELATEDPARTYTRANSACTIONSOwingsDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RelatedPartyTransactionMemberOwingsAbstract' xlink:label='fil_RelatedPartyTransactionMemberOwingsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_RelatedPartyTransactionMemberOwingsAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AdavanceOwingToBoardmember' xlink:label='fil_AdavanceOwingToBoardmember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AdavanceOwingToBoardmember' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_NOTESPAYABLESDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_NOTESPAYABLESDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_NOTESPAYABLESDetails">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesPayableAbstract' xlink:label='us-gaap_NotesPayableAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NotesPayableAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RevolvingLineOfCreditWithABankRMD25000000' xlink:label='fil_RevolvingLineOfCreditWithABankRMD25000000'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RevolvingLineOfCreditWithABankRMD25000000' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AnnualInterestRate' xlink:label='fil_AnnualInterestRate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AnnualInterestRate' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' xlink:label='fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_INCOMETAXESUndistributedEarningsAndIncomeTaxRatesDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_INCOMETAXESUndistributedEarningsAndIncomeTaxRatesDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_INCOMETAXESUndistributedEarningsAndIncomeTaxRatesDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_INCOMETAXESUndistributedEarningsAbstract' xlink:label='fil_INCOMETAXESUndistributedEarningsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_INCOMETAXESUndistributedEarningsAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_UndistributedEarningsOfHelpson' xlink:label='fil_UndistributedEarningsOfHelpson'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_UndistributedEarningsOfHelpson' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany' xlink:label='fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_INCOMETAXESEnterpriseIncomeTaxRatesAbstract' xlink:label='fil_INCOMETAXESEnterpriseIncomeTaxRatesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_INCOMETAXESEnterpriseIncomeTaxRatesAbstract' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_EnterpriseIncomeTaxRatesForTheYear2012' xlink:label='fil_EnterpriseIncomeTaxRatesForTheYear2012'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_EnterpriseIncomeTaxRatesForTheYear2012' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_EnterpriseIncomeTaxRatesForTheYear2013' xlink:label='fil_EnterpriseIncomeTaxRatesForTheYear2013'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_EnterpriseIncomeTaxRatesForTheYear2013' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_EnterpriseIncomeTaxRatesForTheYear2014AndAfter' xlink:label='fil_EnterpriseIncomeTaxRatesForTheYear2014AndAfter'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_EnterpriseIncomeTaxRatesForTheYear2014AndAfter' use='optional' order='6.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_INCOMETAXESProvisionDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_INCOMETAXESProvisionDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_INCOMETAXESProvisionDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_INCOMETAXESProvisionAbstract' xlink:label='fil_INCOMETAXESProvisionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_INCOMETAXESProvisionAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit' xlink:label='us-gaap_CurrentIncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_CurrentIncomeTaxExpenseBenefit' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredFederalIncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DeferredFederalIncomeTaxExpenseBenefit' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalIncomeTaxExpense' xlink:label='fil_TotalIncomeTaxExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_TotalIncomeTaxExpense' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_ReconciliationOfIncomeTaxesDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_ReconciliationOfIncomeTaxesDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_ReconciliationOfIncomeTaxesDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ReconciliationOfIncomeTaxesAbstract' xlink:label='fil_ReconciliationOfIncomeTaxesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ReconciliationOfIncomeTaxesAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits' xlink:label='us-gaap_IncomeTaxReconciliationTaxCredits'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_IncomeTaxReconciliationTaxCredits' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NonDeductibleStockBasedCompensationFromAbstract' xlink:label='fil_NonDeductibleStockBasedCompensationFromAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NonDeductibleStockBasedCompensationFromAbstract' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CurrentAndPriorYears' xlink:label='fil_CurrentAndPriorYears'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CurrentAndPriorYears' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_EffectOfTaxHoliday' xlink:label='fil_EffectOfTaxHoliday'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_EffectOfTaxHoliday' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OtherPrimarilyTheEffectOfUSTaxRates' xlink:label='fil_OtherPrimarilyTheEffectOfUSTaxRates'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OtherPrimarilyTheEffectOfUSTaxRates' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance' xlink:label='us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate' xlink:label='us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate' use='optional' order='7.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_ChangesOfDeferredIncomeTaxAssetsAndLiabilityDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_ChangesOfDeferredIncomeTaxAssetsAndLiabilityDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_ChangesOfDeferredIncomeTaxAssetsAndLiabilityDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DeferredIncomeTaxAssetsAbstract' xlink:label='fil_DeferredIncomeTaxAssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DeferredIncomeTaxAssetsAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AllowanceForDoubtfulTradeReceivablesDeferredTax' xlink:label='fil_AllowanceForDoubtfulTradeReceivablesDeferredTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AllowanceForDoubtfulTradeReceivablesDeferredTax' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AllowanceForDoubtfulOtherReceivablesDeferredTax' xlink:label='fil_AllowanceForDoubtfulOtherReceivablesDeferredTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_AllowanceForDoubtfulOtherReceivablesDeferredTax' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_InventoryObsolescenceReserve' xlink:label='fil_InventoryObsolescenceReserve'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_InventoryObsolescenceReserve' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExpensesNotDeductibleInCurrentYear' xlink:label='fil_ExpensesNotDeductibleInCurrentYear'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ExpensesNotDeductibleInCurrentYear' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost' xlink:label='us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards' xlink:label='us-gaap_DeferredTaxAssetsOperatingLossCarryforwards'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DeferredTaxAssetsOperatingLossCarryforwards' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalDeferredIncomeTaxAssets' xlink:label='fil_TotalDeferredIncomeTaxAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_TotalDeferredIncomeTaxAssets' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance' xlink:label='us-gaap_DeferredTaxAssetsValuationAllowance'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DeferredTaxAssetsValuationAllowance' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NetDeferredIncomeTaxAsset' xlink:label='fil_NetDeferredIncomeTaxAsset'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NetDeferredIncomeTaxAsset' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DeferredIncomeTaxLiabilityAbstract' xlink:label='fil_DeferredIncomeTaxLiabilityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_DeferredIncomeTaxLiabilityAbstract' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredTaxLiabilities' xlink:label='us-gaap_DeferredTaxLiabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='us-gaap_DeferredTaxLiabilities' use='optional' order='11.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DERIVATIVEWARRANTLIABILITYDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DERIVATIVEWARRANTLIABILITYDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DERIVATIVEWARRANTLIABILITYDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DERIVATIVEWARRANTLIABILITYAbstract' xlink:label='fil_DERIVATIVEWARRANTLIABILITYAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DERIVATIVEWARRANTLIABILITYAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_IssueOfWarrantsForPurchaseOfCommonStockTreatedAsDerivatives' xlink:label='fil_IssueOfWarrantsForPurchaseOfCommonStockTreatedAsDerivatives'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_IssueOfWarrantsForPurchaseOfCommonStockTreatedAsDerivatives' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ValuePerShare' xlink:label='fil_ValuePerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ValuePerShare' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_DERIVATIVEWARRANTGAINSDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_DERIVATIVEWARRANTGAINSDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_DERIVATIVEWARRANTGAINSDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DerivativeWarrantGainsAbstract' xlink:label='fil_DerivativeWarrantGainsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DerivativeWarrantGainsAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DerivativeGainsRecognized' xlink:label='fil_DerivativeGainsRecognized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_DerivativeGainsRecognized' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_FAIRVALUEMEASUREMENTSAtReportingDateUsingDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_FAIRVALUEMEASUREMENTSAtReportingDateUsingDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_FAIRVALUEMEASUREMENTSAtReportingDateUsingDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract' xlink:label='fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BankersAcceptanceNotes' xlink:label='fil_BankersAcceptanceNotes'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_BankersAcceptanceNotes' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_Total1' xlink:label='fil_Total1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_Total1' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BankersAcceptanceNotesLevel1' xlink:label='fil_BankersAcceptanceNotesLevel1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_BankersAcceptanceNotesLevel1' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalLevel1' xlink:label='fil_TotalLevel1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_TotalLevel1' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BankersAcceptanceNotesLevel2' xlink:label='fil_BankersAcceptanceNotesLevel2'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_BankersAcceptanceNotesLevel2' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalLevel2' xlink:label='fil_TotalLevel2'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_TotalLevel2' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_BankersAcceptanceNotesLevel3' xlink:label='fil_BankersAcceptanceNotesLevel3'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_BankersAcceptanceNotesLevel3' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalLevel3' xlink:label='fil_TotalLevel3'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_TotalLevel3' use='optional' order='8.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_PreferredCommonStockAndWarrantsDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_PreferredCommonStockAndWarrantsDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_PreferredCommonStockAndWarrantsDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_STOCKHOLDERSEQUITYPreferredCommonStockAndWarrantsAbstract' xlink:label='fil_STOCKHOLDERSEQUITYPreferredCommonStockAndWarrantsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_STOCKHOLDERSEQUITYPreferredCommonStockAndWarrantsAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CommonSharesAuthorized' xlink:label='fil_CommonSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonSharesAuthorized' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PreferredSharesAuthorized' xlink:label='fil_PreferredSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PreferredSharesAuthorized' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NumberOfCommonStockSharesToPurchaseByWarrantsOutstaningAndExercisable' xlink:label='fil_NumberOfCommonStockSharesToPurchaseByWarrantsOutstaningAndExercisable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NumberOfCommonStockSharesToPurchaseByWarrantsOutstaningAndExercisable' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WarrantsStartRangeExercisePrice' xlink:label='fil_WarrantsStartRangeExercisePrice'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_WarrantsStartRangeExercisePrice' use='optional' order='4.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WarrantsEndRangeExercisePrice' xlink:label='fil_WarrantsEndRangeExercisePrice'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_WarrantsEndRangeExercisePrice' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WarrantsWeightedAverageExercisePrice' xlink:label='fil_WarrantsWeightedAverageExercisePrice'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_WarrantsWeightedAverageExercisePrice' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WarrantsWeightedAverageContractualLife' xlink:label='fil_WarrantsWeightedAverageContractualLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_WarrantsWeightedAverageContractualLife' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalIntrinsicValue' xlink:label='fil_TotalIntrinsicValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_TotalIntrinsicValue' use='optional' order='8.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_StockOptionPlanDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_StockOptionPlanDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_StockOptionPlanDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_STOCKHOLDERSEQUITY2010StockOptionPlanAbstract' xlink:label='fil_STOCKHOLDERSEQUITY2010StockOptionPlanAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_STOCKHOLDERSEQUITY2010StockOptionPlanAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NumberOfCommonShares' xlink:label='fil_NumberOfCommonShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NumberOfCommonShares' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NumberOfCommonSharesPurchasedByOptions' xlink:label='fil_NumberOfCommonSharesPurchasedByOptions'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NumberOfCommonSharesPurchasedByOptions' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_StockOptionsGranted' xlink:label='fil_StockOptionsGranted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_StockOptionsGranted' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_StockOptionPlanFrankWaungDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_StockOptionPlanFrankWaungDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_StockOptionPlanFrankWaungDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_STOCKHOLDERSEQUITY2010StockOptionPlanFrankWaungAbstract' xlink:label='fil_STOCKHOLDERSEQUITY2010StockOptionPlanFrankWaungAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_STOCKHOLDERSEQUITY2010StockOptionPlanFrankWaungAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_VestedAndUnexercisedOptions' xlink:label='fil_VestedAndUnexercisedOptions'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_VestedAndUnexercisedOptions' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NumberOfDaysOpposedAfterTheEmploymentTerminationDate' xlink:label='fil_NumberOfDaysOpposedAfterTheEmploymentTerminationDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NumberOfDaysOpposedAfterTheEmploymentTerminationDate' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CommonSharesGranted' xlink:label='fil_CommonSharesGranted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonSharesGranted' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RecordedCompensationExpense' xlink:label='fil_RecordedCompensationExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RecordedCompensationExpense' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_FairValueOf185000OptionsCancelled' xlink:label='fil_FairValueOf185000OptionsCancelled'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_FairValueOf185000OptionsCancelled' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_FairValueOf100000CommonSharesExchanged' xlink:label='fil_FairValueOf100000CommonSharesExchanged'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_FairValueOf100000CommonSharesExchanged' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ClosingMarketPriceOfCommonStock' xlink:label='fil_ClosingMarketPriceOfCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ClosingMarketPriceOfCommonStock' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_StartingRiskFreeInterestRate' xlink:label='fil_StartingRiskFreeInterestRate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_StartingRiskFreeInterestRate' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ClosingRiskFreeInterestRate' xlink:label='fil_ClosingRiskFreeInterestRate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ClosingRiskFreeInterestRate' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExpectedDividendYield' xlink:label='fil_ExpectedDividendYield'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ExpectedDividendYield' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExpectedVolatility' xlink:label='fil_ExpectedVolatility'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ExpectedVolatility' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_MinimumExpectedLife' xlink:label='fil_MinimumExpectedLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_MinimumExpectedLife' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_MaximumExpectedLife' xlink:label='fil_MaximumExpectedLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_MaximumExpectedLife' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NumberOfOptionsToPurchaseCommonStockGranted' xlink:label='fil_NumberOfOptionsToPurchaseCommonStockGranted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NumberOfOptionsToPurchaseCommonStockGranted' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsExercisePrice' xlink:label='fil_OptionsExercisePrice'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OptionsExercisePrice' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CommonStockSharesGranted' xlink:label='fil_CommonStockSharesGranted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_CommonStockSharesGranted' use='optional' order='16.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CompensationExpenseDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_CompensationExpenseDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_CompensationExpenseDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_STOCKHOLDERSEQUITYCompensationExpenseAbstract' xlink:label='fil_STOCKHOLDERSEQUITYCompensationExpenseAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_STOCKHOLDERSEQUITYCompensationExpenseAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RecognizedCompensationExpenses' xlink:label='fil_RecognizedCompensationExpenses'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RecognizedCompensationExpenses' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_IncomeTaxBenefitRecognizedFromStockBasedCompensation' xlink:label='fil_IncomeTaxBenefitRecognizedFromStockBasedCompensation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_IncomeTaxBenefitRecognizedFromStockBasedCompensation' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_UnrecognizedCompensationExpenseDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_UnrecognizedCompensationExpenseDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_UnrecognizedCompensationExpenseDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_STOCKHOLDERSEQUITYUnrecognizedCompensationExpenseAbstract' xlink:label='fil_STOCKHOLDERSEQUITYUnrecognizedCompensationExpenseAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_STOCKHOLDERSEQUITYUnrecognizedCompensationExpenseAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_UnrecognizedCompensationExpenseRelatedToPerformanceBasedStockOptions' xlink:label='fil_UnrecognizedCompensationExpenseRelatedToPerformanceBasedStockOptions'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_UnrecognizedCompensationExpenseRelatedToPerformanceBasedStockOptions' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_UnrecognizedCompensationExpenseRelatedToFixedStockOptions' xlink:label='fil_UnrecognizedCompensationExpenseRelatedToFixedStockOptions'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_UnrecognizedCompensationExpenseRelatedToFixedStockOptions' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalRemainingUnrecognizedCompensationExpenseRelatedToRestrictiveStockGrants' xlink:label='fil_TotalRemainingUnrecognizedCompensationExpenseRelatedToRestrictiveStockGrants'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_TotalRemainingUnrecognizedCompensationExpenseRelatedToRestrictiveStockGrants' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_EXECUTIVEOFFICERS2010StockOptionPlanDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_EXECUTIVEOFFICERS2010StockOptionPlanDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_EXECUTIVEOFFICERS2010StockOptionPlanDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_STOCKHOLDERSEQUITYTOEXECUTIVEOFFICERS2010StockOptionPlanAbstract' xlink:label='fil_STOCKHOLDERSEQUITYTOEXECUTIVEOFFICERS2010StockOptionPlanAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_STOCKHOLDERSEQUITYTOEXECUTIVEOFFICERS2010StockOptionPlanAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NumberOfCommonSharesIssuedToTwoExecutiveOfficers' xlink:label='fil_NumberOfCommonSharesIssuedToTwoExecutiveOfficers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NumberOfCommonSharesIssuedToTwoExecutiveOfficers' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NumberOfNonQualifiedStockOptionsToPurchaseCommonStock' xlink:label='fil_NumberOfNonQualifiedStockOptionsToPurchaseCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NumberOfNonQualifiedStockOptionsToPurchaseCommonStock' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExercisePrice' xlink:label='fil_ExercisePrice'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ExercisePrice' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsExpiringOnMay252013' xlink:label='fil_OptionsExpiringOnMay252013'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OptionsExpiringOnMay252013' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria' xlink:label='fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_QualifiedStockOptionsGrantedToFormerCFONonQualifiedOptionsToPurchaseCommonStock' xlink:label='fil_QualifiedStockOptionsGrantedToFormerCFONonQualifiedOptionsToPurchaseCommonStock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_QualifiedStockOptionsGrantedToFormerCFONonQualifiedOptionsToPurchaseCommonStock' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExercisePrice1' xlink:label='fil_ExercisePrice1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ExercisePrice1' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsVestedOnApril282013' xlink:label='fil_OptionsVestedOnApril282013'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OptionsVestedOnApril282013' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria1' xlink:label='fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria1' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_GrantedDateFairValueOfTheOptionsPerShare' xlink:label='fil_GrantedDateFairValueOfTheOptionsPerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_GrantedDateFairValueOfTheOptionsPerShare' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_GrantedDateFairValueOfTheOptionsTotalValue' xlink:label='fil_GrantedDateFairValueOfTheOptionsTotalValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_GrantedDateFairValueOfTheOptionsTotalValue' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_GrantedDateClosingMarketPrice' xlink:label='fil_GrantedDateClosingMarketPrice'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_GrantedDateClosingMarketPrice' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WeightedAverageAssumptionsAbstract' xlink:label='fil_WeightedAverageAssumptionsAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_WeightedAverageAssumptionsAbstract' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RiskFreeInterestRate' xlink:label='fil_RiskFreeInterestRate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RiskFreeInterestRate' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_DividendYield' xlink:label='fil_DividendYield'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_DividendYield' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExpectedVolatality' xlink:label='fil_ExpectedVolatality'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ExpectedVolatality' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExpectedPeriodOfLife' xlink:label='fil_ExpectedPeriodOfLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ExpectedPeriodOfLife' use='optional' order='17.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_OFFICERS2010StockOptionPlanDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_OFFICERS2010StockOptionPlanDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_OFFICERS2010StockOptionPlanDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_STOCKHOLDERSEQUITYTOOFFICERS2010StockOptionPlanAbstract' xlink:label='fil_STOCKHOLDERSEQUITYTOOFFICERS2010StockOptionPlanAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_STOCKHOLDERSEQUITYTOOFFICERS2010StockOptionPlanAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NumberOfCommonSharesIssuedToExecutiveOfficers' xlink:label='fil_NumberOfCommonSharesIssuedToExecutiveOfficers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_NumberOfCommonSharesIssuedToExecutiveOfficers' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ValueOfTheOptionsGranted' xlink:label='fil_ValueOfTheOptionsGranted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ValueOfTheOptionsGranted' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExercisePriceForOptionsGranted' xlink:label='fil_ExercisePriceForOptionsGranted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ExercisePriceForOptionsGranted' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RestrictedStockGrantedToCEO' xlink:label='fil_RestrictedStockGrantedToCEO'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RestrictedStockGrantedToCEO' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria' xlink:label='fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsVestedOnMay252012' xlink:label='fil_OptionsVestedOnMay252012'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OptionsVestedOnMay252012' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_RestrictedStockOptionsGrantedToFormerCFO' xlink:label='fil_RestrictedStockOptionsGrantedToFormerCFO'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_RestrictedStockOptionsGrantedToFormerCFO' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsVestedOnApril282012' xlink:label='fil_OptionsVestedOnApril282012'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OptionsVestedOnApril282012' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria1' xlink:label='fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria1' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_SharesForfeitedDueToNonAchievementOfPerformanceCriteria' xlink:label='fil_SharesForfeitedDueToNonAchievementOfPerformanceCriteria'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_SharesForfeitedDueToNonAchievementOfPerformanceCriteria' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ShareBasedCompensationRelatedToTheFixedShareAwardsWasRecognizedOverThePeriodTheSharesVested' xlink:label='fil_ShareBasedCompensationRelatedToTheFixedShareAwardsWasRecognizedOverThePeriodTheSharesVested'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ShareBasedCompensationRelatedToTheFixedShareAwardsWasRecognizedOverThePeriodTheSharesVested' use='optional' order='11.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_SummaryOfStockOptionActivityDetailsStockholdersEquity" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_SummaryOfStockOptionActivityDetailsStockholdersEquity"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_SummaryOfStockOptionActivityDetailsStockholdersEquity">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_SummaryOfStockOptionActivityAbstract' xlink:label='fil_SummaryOfStockOptionActivityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_SummaryOfStockOptionActivityAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis' xlink:label='us-gaap_StatementEquityComponentsAxis'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementEquityComponentsAxis' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_NoOfSharesMember' xlink:label='fil_NoOfSharesMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='fil_NoOfSharesMember' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WeightedAverageExercisePriceMember' xlink:label='fil_WeightedAverageExercisePriceMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='fil_WeightedAverageExercisePriceMember' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_WeightedAverageRemainingContractualTermYearsMember' xlink:label='fil_WeightedAverageRemainingContractualTermYearsMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='fil_WeightedAverageRemainingContractualTermYearsMember' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_AggregateIntrinsicValueMember' xlink:label='fil_AggregateIntrinsicValueMember'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementEquityComponentsAxis' xlink:to='fil_AggregateIntrinsicValueMember' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OutstandingOptions' xlink:label='fil_OutstandingOptions'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OutstandingOptions' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/periodStartLabel'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OutstandingOptions' xlink:label='fil_OutstandingOptions_1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OutstandingOptions_1' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_Forfeited' xlink:label='fil_Forfeited'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_Forfeited' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_Expired' xlink:label='fil_Expired'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_Expired' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_OutstandingOptions1' xlink:label='fil_OutstandingOptions1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_OutstandingOptions1' use='optional' order='5.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ExercisableAtDecember312012' xlink:label='fil_ExercisableAtDecember312012'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ExercisableAtDecember312012' use='optional' order='6.0' preferredLabel='http://www.xbrl.org/2003/role/periodEndLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_COMMITMENTSANDCONTINGENCIESDETAILS" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_COMMITMENTSANDCONTINGENCIESDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_COMMITMENTSANDCONTINGENCIESDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CommitmentAndContingenciesAbstract' xlink:label='fil_CommitmentAndContingenciesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_CommitmentAndContingenciesAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PaymentsMadeForConstructionInProgress' xlink:label='fil_PaymentsMadeForConstructionInProgress'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PaymentsMadeForConstructionInProgress' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_FutureMinimumPaymentsAsPerPurchaseAndConstructionAgreementsAbstract' xlink:label='fil_FutureMinimumPaymentsAsPerPurchaseAndConstructionAgreementsAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_FutureMinimumPaymentsAsPerPurchaseAndConstructionAgreementsAbstract' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ForTheYear2013' xlink:label='fil_ForTheYear2013'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ForTheYear2013' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_ForTheYear2014' xlink:label='fil_ForTheYear2014'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_ForTheYear2014' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_TotalAmount' xlink:label='fil_TotalAmount'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_TotalAmount' use='optional' order='5.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CONCENTRATIONSSalesAndPurchasesDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_CONCENTRATIONSSalesAndPurchasesDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_CONCENTRATIONSSalesAndPurchasesDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CONCENTRATIONSSalesAndPurchasesAbstract' xlink:label='fil_CONCENTRATIONSSalesAndPurchasesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_CONCENTRATIONSSalesAndPurchasesAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PercentageOfNoCustomerAccountedForMoreThanSales' xlink:label='fil_PercentageOfNoCustomerAccountedForMoreThanSales'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PercentageOfNoCustomerAccountedForMoreThanSales' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PercentageOfOneCustomerAccountedForMoreThanSales' xlink:label='fil_PercentageOfOneCustomerAccountedForMoreThanSales'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PercentageOfOneCustomerAccountedForMoreThanSales' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PercentageOfPurchasesFromOneSupplierOfRawMaterials' xlink:label='fil_PercentageOfPurchasesFromOneSupplierOfRawMaterials'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PercentageOfPurchasesFromOneSupplierOfRawMaterials' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PercentageOfOneCustomerAccountedForAccountsReceivables' xlink:label='fil_PercentageOfOneCustomerAccountedForAccountsReceivables'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PercentageOfOneCustomerAccountedForAccountsReceivables' use='optional' order='4.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20121231/role/idr_CONCENTRATIONSAccountsPayableDetails" xlink:type="simple" xlink:href="cphi-20121231.xsd#idr_CONCENTRATIONSAccountsPayableDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20121231/role/idr_CONCENTRATIONSAccountsPayableDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_CONCENTRATIONSAccountsPayableAbstract' xlink:label='fil_CONCENTRATIONSAccountsPayableAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable' xlink:label='us-gaap_StatementTable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_CONCENTRATIONSAccountsPayableAbstract' xlink:to='us-gaap_StatementTable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems' xlink:label='us-gaap_StatementLineItems'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementTable' xlink:to='us-gaap_StatementLineItems' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20121231.xsd#fil_PercentageOfAccountsPayableToTwoSuppliersForPurchaseOfRawMaterials' xlink:label='fil_PercentageOfAccountsPayableToTwoSuppliersForPurchaseOfRawMaterials'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StatementLineItems' xlink:to='fil_PercentageOfAccountsPayableToTwoSuppliersForPurchaseOfRawMaterials' use='optional' order='1.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>chart.jpg
<TEXT>
begin 644 chart.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4`
M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@``
M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,`$PT.$`X,
M$Q`/$!44$Q8<+AX<&AH<.2DK(BY#.T=&0CM!0$I4:UI*3V500$%=?EYE;G)W
M>7=(68.,@G2+:W5W<__;`$,!%!45'!@<-QX>-W--04US<W-S<W-S<W-S<W-S
M<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<__``!$(`-P`
M\`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`.OO+N*RM7N)CA$';J?:N.N?%M_)(3!LA3L`NX_B36OXS8C3(@#P
M9>?R-<36L(IJ[,Y-FS_PE.J_\]U_[]K_`(4?\)3JO_/=?^_:_P"%8U%7RHGF
M9L_\)3JO_/=?^_:_X4?\)3JO_/=?^_:_X5C59>PN8R0\85@I<H77<!C/(SGI
M1RQ"[-#_`(2G5?\`GNO_`'[7_"C_`(2G5?\`GNO_`'[7_"LNXMI;9U29-K,H
M8<@Y!Z'BDG@DMIFAE7:Z]1D'^5'+$+LU?^$IU7_GNO\`W[7_``H_X2G5?^>Z
M_P#?M?\`"L:IK:TFNV=8$#%%+M\P&`.IYHY4%V:?_"4ZK_SW7_OVO^%'_"4Z
MK_SW7_OVO^%9YTZ[7?F$X2/S2<C&S^\/4?2JU'+$+LV?^$IU7_GNO_?M?\*/
M^$IU7_GNO_?M?\*QJ*.5!S,V?^$IU7_GNO\`W[7_``H_X2G5?^>Z_P#?M?\`
M"L:IK6TFO)#';IO8`MC<!P/K1RH+LT_^$IU7_GNO_?M?\*/^$IU7_GNO_?M?
M\*S6LYUM1=%!Y);8&W#KZ=:;;6TMU+Y4";WP3C('`Y/6CEB%V:G_``E.J_\`
M/=?^_:_X4?\`"4ZK_P`]U_[]K_A67#;2W`D,2;A$A=^0,*.])-!)`RK*N"RA
MAR#P>1THY8A=FK_PE.J_\]U_[]K_`(4?\)3JO_/=?^_:_P"%8U%'*@YF;/\`
MPE.J_P#/=?\`OVO^%'_"4ZK_`,]U_P"_:_X5EVMM-=SK#;IOD;HN0,_G4;*4
M8JV,@X.#FCE079L?\)3JO_/=?^_:_P"%'_"4ZK_SW7_OVO\`A6-11RH.9FS_
M`,)3JO\`SW7_`+]K_A1_PE.J_P#/=?\`OVO^%8U%'*@YF;UOXLU".0&4QRKW
M4J!^HKL-/O8M0M$N(?NMU!ZJ?2O,:['P2Q-I<KG@.#^G_P!:HG%)7*BW<D\:
M?\@V'_KK_0UQ5=KXT_Y!L/\`UU_H:XJJI["GN%%%%603V,R6]]!-(NY(Y%9A
MZ@&K.JJ)-0N+F*XC>*1F=6#C)![8Z^W2L^BE8=SHK^6UFLIAYEL\B06XB.5+
M;APPS].U2,^G+>713[%L-S#LX0C9QNQ[5S-%+E'S'0V\>GAYP[6FQI9E0;AG
M&/EZ]O3'YU2T"2.&>Z:5XU!MG4;V`R3T%9=%'*%S:L=1:5;LSO$FRS,,*'&.
MHP!GK5M5T[^U9Y-UGY'F0X&5Y!'S8[8SG-<U11RA<V)I;>WTUA"EJ\IN)%Y"
MLP0C`_\`K&KLTEB!<;!9?+Y!BP$Z_P`=9%OI%S<R2Q1F/SHUW&(DACWP..OM
M55XBB(Q8$OGY1G(YQS2L@N=#`FF_;YBS6?D-<.`-R_=*''_`<XZ=_I6=X>DC
M@U%GFDC11$XR[``DCI671@XS3Y0N;L<UHVD6D4YB55O`TD:/D[,8)QDFI[:6
MQBOK=_,@20-/N964+L((3IQ]*PHK.26SGNE*[("H8'.?F.!C\JCAA>:58T^^
M_"@]SZ4K!<W8)+2*T?RI(%5].9&&Y0QESR/6E=K%?M#)]CW?9HMG"$;\_-CW
MZUSQ!!P1@BBGRA<ZF."WDN[I[2TBGC2Y5OW81@R;3E0">!G_`#Q5"1+66P\I
M_*M;H2;3G;@Y<YSW4C\L5DI/(D?E@C;G=@J"`?7FF%V9RY8ER<EL\Y]:.4+F
MIHP2Q\0QB>6-5A=@SEL+T(ZFKFEM8K'"+G[(2;IQ(7V$^7MXY],USQ.3DT4.
M-P3L:L@@73(1`;4EE*3;R-ZMNX8=^G''%9UQ%Y$[Q"1)-IQO0Y4_0U'132L)
ML****8@KL/!/_'M=?[R_R-<?78>"?^/:Z_WE_D:B>Q<-R7QI_P`@V'_KK_0U
MQ5=OXS1FTN)@,A91GVX-<113V">X44459`4444`%%%%`!1110`5);NL=Q$[C
M*JX)'J,U'10!IWLQAU&[GBG"N9_-B(S\P))!'X$5:&IV5Q?">5!"TELR.0I(
M60Y^;CG!]O6L+)/X45/*5<UUU52EW'.P8-MDB,8('F+@9Y['OGTJ2&]M1I3P
MR7&Z5X&7!0\-OR.W/U_E6)11RH+F_=:C9RP7BQS[5G$'EQ[#\FW[PZ8I;JZM
M;J2UCMY@[I=%RQ4K\IP<]``.#7/T9(Z4<H<Q/?RI/?W$L7W'E9E^A-04450@
MHHHH$%%%%`!1110`4444`%=AX)_X]KK_`'E_D:X^NR\%(PL[AR."X`_`?_7J
M)[%PW.@N;>*[MW@F7=&XP17)7/@ZY$A^S3QNG;>2I_E78T5BI-;&C29Q'_"(
M:C_>@_[[/^%'_"(:C_>@_P"^S_A7;T57.Q<B.(_X1#4?[T'_`'V?\*/^$0U'
M^]!_WV?\*[>BCG8<B.(_X1#4?[T'_?9_PH_X1#4?[T'_`'V?\*[>BCG8<B.(
M_P"$0U'^]!_WV?\`"C_A$-1_O0?]]G_"NWHHYV'(CB/^$0U'^]!_WV?\*/\`
MA$-1_O0?]]G_``KMZ*.=AR(XC_A$-1_O0?\`?9_PH_X1#4?[T'_?9_PKMZ*.
M=AR(X2X\+7UO;R3NT.V-2[88YP!GTHM_"]]<V\<\;0[)%##+'."/I78ZM_R"
M;W_K@_\`Z":31_\`D$6?_7!/Y"GSNPN57.3_`.$0U'^]!_WV?\*/^$0U'^]!
M_P!]G_"NWK(N;FXC\1QPK([1&T>3RN,%@12YV/D1S_\`PB&H_P!Z#_OL_P"%
M'_"(:C_>@_[[/^%*NM:@+=<3.WGVT4CO_<9I2IQZ<<5>5]6O+25K>\$26MU/
M&7=L?*"-K$]P.:.=AR(H?\(AJ/\`>@_[[/\`A1_PB&H_WH/^^S_A706NKQ-J
M)AG:1992H2,C`0$$J#_M$`GVX%:]'.PY$<1_PB&H_P!Z#_OL_P"%'_"(:C_>
M@_[[/^%=O11SL.1'$?\`"(:C_>@_[[/^%'_"(:C_`'H/^^S_`(5V]%'.PY$<
M1_PB&H_WH/\`OL_X4?\`"(:C_>@_[[/^%=O11SL.1'&V_@Z[:0>?-$B=RI+'
M^5=99VD5E;);P+A$'XGW-344G)O<:204445(PHK*U#Q#9V4ACYE<<';C`]LU
M2_X2^V_YX-_WV*KD;)YD=%17._\`"7VW_/!O^^Q1_P`)?;?\\&_[[%')(.9'
M145SO_"7VW_/!O\`OL4?\)?;?\\&_P"^Q1R2#F1T5%<[_P`)?;?\\&_[[%'_
M``E]M_SP;_OL4<D@YD=%17._\)?;?\\&_P"^Q1_PE]M_SP;_`+[%')(.9'14
M5SO_``E]M_SP;_OL4?\`"7VW_/!O^^Q1R2#F1L:M_P`@F]_ZX/\`^@FDT?\`
MY!%G_P!<$_D*Q+GQ1:W-M+`T+@2H4)#CC(Q26OBBUM;6*W6%R(D"`EQS@8I\
MCL+F5SIZC-M";D7!C4S*NT/W`]/I6#_PE]M_SP;_`+[%'_"7VW_/!O\`OL4N
M20^9&TMA:*DB"VC"R##C;P1G./S)_.GBU@$'DB)?+SG;C@G.?YUA?\)?;?\`
M/!O^^Q1_PE]M_P`\&_[[%')(.9&Z;2W:Y%R84,P&`^.>_P#B?SJ6N=_X2^V_
MYX-_WV*/^$OMO^>#?]]BCDD',CHJ*YW_`(2^V_YX-_WV*/\`A+[;_G@W_?8H
MY)!S(Z*BN=_X2^V_YX-_WV*/^$OMO^>#?]]BCDD',CHJ*YY?%UJ6`,#@>S`U
MM6=Y!?0^;;ON'0CN#[TG%K<::9/1112&%5M3F:#3KB5#AE0X/H:LU2UK_D$W
M/^Y36XGL><S,7E8D]Z92O_K&^II*Z3`****`"BBMJ\/V6+2ELN%DC#MM_C<G
MD'U],4FQV,6BNCNM)L)-1N]A=42XBB"QD`#?U[=CFH;71+:5]DDDN?MCVP*D
M=AD'I2YD/E9A45H_88#IHNU9SY;M',NX<''RD<=#4NB_\>6J>UOD>QS3N*QD
MT5LOI-N+(RJ\OF?95N.2,<M@CI2'28'N;2.&5_+NPIC9B"1UW9XZCI2YD.S,
M>BMBVTNTN9S$D[;\<1L=I+9.5W$8S@<?_6J2+2[68Z7`RR(UR',CAAG()'I[
M4<R"QAT5M)I%K+;QR*\P,EO)*,D<%#CTZ']*:=)MDN+:WDG?S93%D`=5?J1Q
M@8X[\T<R"S,>BN@MM'M!J%DI\QXY99496(YV=.@Z'TJEX?VG7K8`$(6(VDYX
MP>M',%C,HK1L;9;O642=6:)I]K8..N<#]*T-*LH4O[6Y`;$MR\:ID$*`._'-
M#D%CGJ*DFC=&W,C*K$[21@'GM4=4(****!!70^$+AUU$19.UP01]!D?RKGJV
M_"?_`"%XO^!?^@FE+9C6YW=%%%<QN%4M:_Y!-S_N5=JEK7_()N?]RFMQ/8\W
M?_6-]324K_ZQOJ:2NDP"BBB@`JQ;O>;0MN9L`Y`3/!]15>NFL8UC\21Q1#,4
M=L`N/0QYS^))I-V*2N8`FN[7*>9-%N(?&2N3V-.6[O@ID2>?"OO+!C@,>_U-
M;L-K%>1Z/!,A$6)08G)WCJ=V>.,@=OSJI91V\]A/((&C19H59/,8JW.#G_/&
M:FX6,QY3):[8XG49!F?<2&;G!/IU--@DN8XY/(>54(_>;"<8]ZWKBTC9]1#0
M2*BW<:[(R1N4L>V<=.GUI4M8;5+_`,A5EA>V5P!N&07Z$'D'C]*.9#L82W5Y
M(!$LTS97R]@8G*^F/3VINVY5PH$H:$9`P<IW_"K.K0+IVL31VVY%B<%.>1P#
M5C6I(9'2\@8;KV,,Z#^$@X;\R/YT[BL4)+J]68O+-,)#@DLQS[4U+RZC$82X
ME41DE,,1MSUQZ5NW=E;J][+-#)+Y$,+J&D;OC(SZ55^SV*V'V@V[?/"S+G<<
M/NP!QQC&>:+H+,SVN[V(A&GG3"D`%B,`\_D:1+J\?RHTFF;RS^[4,3M/M6[<
M:?`9KMY(7E,26Y3<['[V`1UZ5G/;+;>)5MX5.Q+E0HZG&X4)I@TRH]U>QR+Y
MDTZO&Q9=S$%2>I_&F>9<V\_F[I8ICSNR0W/?-;=W907%WJ;2`K.LCLA?(4@#
M.,CH>_/6I9K%;JX@,T+.J6MOGD@#)P>!SZ_2ES(=CGS>W1*DW$IVMO'SGAO7
MZT^&[OB[>3/.6)WG8QSGUK;MM(M/-=)+=GQ?FW!+$?)@GM2Z38QP2VTL49=G
M%PKOS\A`(`_+^=',@LSGI99I`JS2.P3[H8DXSS4=7[E%.CV<K?ZS?(GN5&#^
MA)JA5(EA1113$%;?A/\`Y"\7_`O_`$$UB5M^$_\`D+Q?\"_]!-*6S&MSNZ**
M*YC<*I:U_P`@FY_W*NTR>%;B"2%_NNI4_C36XF>6O_K&^II*TM4TBYLIV#H=
MN>&[-]#5'R)/3]:Z=S`CHJ3R)/3]:/(D]/UH`CI[S/(J!SG8-H/?'I2^1)Z?
MK1Y$GI^M`$>3GK1DU)Y$GI^M'D2>GZT`1Y/J:,GU-2>1)Z?K1Y$GI^M`$?6B
MI/(D]/UH\B3T_6@"/)]35V/5KN*W$$;E8PA3`)P0<YR,X[^E5O(D]/UH\B3T
M_6BP[D>3ZFC)SFI/(D]/UH\B3T_6@1'D^IHR?4U)Y$GI^M'D2>GZT`1Y/J:,
MG'4U)Y$GI^M'D2>GZT`))*\BHK'Y4&%`Z"F5)Y$GI^M'D2>GZT`1T5)Y$GI^
MM'D2>GZT`1UM^$_^0O%_P+_T$UDBVE8@!>377>%]'DM2;JX4J2,(IZ\]ZF3L
MBHJ[.CHHHKG-@HHHH`.M)L7^Z/RI:*`$V+_='Y4;%_NC\J6B@!-B_P!T?E1L
M7^Z/RI:*`$V+_='Y4;%_NC\J6B@!-B_W1^5&Q?[H_*EHH`38O]T?E1L7^Z/R
MI:*`*FJJHTF\PH_U#]O]DTW2%4Z19Y4?ZA.WL*?JW_()O?\`K@__`*":31_^
M019_]<$_D*?074M;%_NC\J-B_P!T?E2U6N+^&WO+:U</YER6"87C@9.32&6-
MB_W1^5&Q?[H_*LW^W[`/(&=E6,2'>1PVSAL?2FR>(;*.!I'64,KA#'M&[)7=
MZXZ>]`&IL7^Z/RHV+_='Y5!!>PW+H(=S!HA+NQP`>F?<_P!*L4`)L7^Z/RHV
M+_='Y4M%`";%_NC\J-B_W1^5+10`@51T`'X4M%%`!1110`444V66.%=TLBHO
MJQP*`'456_M*Q_Y_(/\`OX*/[2L?^?R#_OX*=F*Z+-%5O[2L?^?R#_OX*/[2
ML?\`G\@_[^"BS"Z+-%5O[2L?^?R#_OX*/[2L?^?R#_OX*+,+HLT56_M*Q_Y_
M(/\`OX*/[2L?^?R#_OX*+,+HLT56_M*Q_P"?R#_OX*/[2L?^?R#_`+^"BS"Z
M+-%5O[2L?^?R#_OX*/[2L?\`G\@_[^"BS"Z$U;_D$WO_`%P?_P!!-)H__((L
M_P#K@G\A4=W>6-S9SP"^@4RQLF=X.,C'K26=W8VMG!;F^@8Q1JF=X&<#'K3L
M[!?4T*S[^RFN-4TZYCV>7:LY?<2"=RXXXJ?^TK'_`)_(/^_@H_M*Q_Y_(/\`
MOX*5F%T8,GA:64/$TR")5G\HC.29"",_2K]EH[1)>27<4,\DY5EC;E1M3:.2
M/KVZ5?\`[2L?^?R#_OX*/[2L?^?R#_OX*+,+HSGTK4$NK=[:["1C#3`$C<VX
M$G'<;1M`/0`5M56_M*Q_Y_(/^_@H_M*Q_P"?R#_OX*+,+HLT56_M*Q_Y_(/^
M_@H_M*Q_Y_(/^_@HLPNBS15;^TK'_G\@_P"_@H_M*Q_Y_(/^_@HLPNBS15;^
MTK'_`)_(/^_@H_M*Q_Y_(/\`OX*+,+HLT5%#=6\YQ#/'(?16!J6D,AO;E;.T
MDN'&0@SCU/85YYJ&I7%Y<-))(2<_E[#TKM?$O_((D_WE_G7GM;4UI<RF];#O
M-D_OFCS9/[Y_.FT5H0.\V3^^?SH\V3^^?SIM7='LDU#4([61F4.#\R]L`G^E
M#=AE3S9/[Y_.CS9/[Y_.K[::%TDWC),LGG^4L;#KD9ST_"F6^F3F[ABGAD"R
M,R_)M+$CJ!DXR/2E<+%/S9/[Y_.CS9/[Y_.K"Z==O`)TA)C*LX.1R!U/X4TV
M-R(A*8B$)49)'&[IGTS1<+$/FR?WS^='FR?WS^=37-A=6B;YX2B[MA.0<-C.
M/RJRFG*^DQWB+*[M-Y91><#&<]*+A8H>;)_?/YT>;)_?/YUH:AI3V^I36EJ&
ME$6T%F(&2P&/YXI&TJ1[6T>!7>:?S-T9P,;".E',@L4/-D_OG\Z/-D_OG\ZG
M.GW0.#%QL#[MPV[2<`YSCK3197)B,OE'8`3GV!P3CT'K3N%B+S9/[Y_.CS9/
M[Y_.IY=.NX83-)"1&`K$Y!X;H?H:L:;IT=_!/AV6X12T:]GQR1]:5PL4/-D_
MOG\Z/-D_OG\ZO_V<@T?[9N<RF41^6.@R,C]/YU7.GW0?883G#$\C`"]<GMBB
MX6(/-D_OG\Z/-D_OG\ZTKG2D@,F/-;;;+-Q@[2?7V^E5#IUX`I\AOF.!['&>
M?3CGFBZ"Q!YLG]\_G1YLG]\_G5V'3&,=W]HW1O#")5`P0P)'Z<U'IEBU_<-$
MN251GP.K8'3VS1<+%;S9/[Y_.CS9/[Y_.IKRW6&4F'>\!.$D*\$]QGOBJ].X
M#O-D_OG\Z/-D_OG\Z;10(EBN98G#JYR#D'/(KO/#VIMJ-F?,.98\!CZ@]#7G
MU=7X*/SS_P"X/YU$U=%1>IK>)?\`D$/_`+R_SKSZO0?$O_((?_>7^=>?44]A
MSW"BBBK("KFDWJZ=?I=-&9-@/R@XSD$?UJG10,T(]0B33?L9B=A]H$V[=CH,
M8_\`KU<_MZ(7%M*MJX$$KR!=XY##ITK#[UT%SI-HB3D(5"6JS*58LV\]B/[O
MOVJ6EU&KE6#6(X;:*'R&/EQ2Q9W==YSGIVI'U:$V1MEMW4$19/F9Y7KV[TR?
M2Y#L:-$CC$$;NY<L#N.`>F1GTI&TB9+5W=@)A<"W$7.2V,_X4O=#4?J.K)>P
M31B%D,EQY^2V<?+C'2H?MT9TJ.Q,;92;S2X;KQC&*5](NHR=^T(`Q9^<#:<'
MMZD?G5F+1O.LBJM']J%UY(;?E6&W/&*>B#4=-KJ37%Y(89$6YV'Y),,C*.,'
M%2:5J4<MQ:1RGR_($Y:22088N#Z^]4(='N9X4D1HQOW[5+<DKU%,.FW`@\XJ
MN/*$VS/.S.,TK1V'=EN#6C;M;JD;;(8_+(R#O!.2#QT--&LXA"B`!UBDA7!^
M4*YST]N:=?Z,PU"6.U`6$/'&F]NKLH.*KII%R8][E(_D=]K$YVH<,>!1[H:D
MUQK"36LT`@8>;#%%G=TV'.>G>JME>FRDBEC!\R.3?UX(Z$4ES826RJTCQE6C
M612"<,">,<=:F%I%!I"7TJ^8\TA2-"2%`'4G'.:>@M1\>K[+4QF+,OVD7.[/
MRY';'I3VUE#<SL(YC#/&Z,C2YV;L$[>..156.S-X#);J(XU*HQ=N-['``JK+
M$\,KQ2+M=&*L/0BBR"[-236(W$H%NPWVJVX^<'&._3VI)-5MY=16\>VDW,,R
M()?E+;<9''\\U%I%K#=&\\Y-WDVSRKR1R,?IS46GV7VZ653((Q'$TI)!["BR
M"[+<NLQRB7]PP,ELMO\`?'&._2HK#4TM+5H6A;>)1-'+&^U@P&,'(.1U_.I+
M/2P8IWN<?\>CSQ`$YX.`?IUK*H26P79>U2^AOW62.V,+_P`8#94GU`QQFJ-%
M%-*P@HHHIB"NK\%??F_W!_.N4KJ_!7WYO]P?SJ9_"RH[FMXE_P"00_\`O+_.
MO/J]!\2_\@A_]Y?YUY]2I[#GN%%%%60%%%%`!WK3?6YS(TB11)(T/D;ADX7V
MYZUF44FKCN:+:S,R>6T4?E^7'&5YY"'*GZTC:S<NK[U0NUP+@-@Y5QZ>U9]%
M%D%V:`U9A=33"VA"SJ5ECYP^>O?CGTHM=7DM$1(H(MJ3^>!SUQC'7I6?119!
M=FE#K4L"Q*L,9$9D(SG^/KWJ,ZK.;?RBJY\D0;^^P'./Z9IEI;J]G=W3#/D!
M0H_VF.,_@`:M:I%'IK6T$44;[H5D=W7)<G^0^E+2X]1'UVX><RM%'S(DH7G`
M=1@'KZ5*E_:/8".Y>4RL'+LCD')).,8QSQW`IZ:?#?:=;-$%AED:9A\N<A>0
M":B&F"XBML/'&#;/-N"')P3G//6EH/4J7ESFV@M$F$T4.2K;2O7MSZ<_G38[
MYULS9R(LL.[>H.05;U!JS_8W^EB'[0""B.IV\D-CMGMGGFF/8;+:^5L>;92`
M%AT8%BI_7'ZT[H6I';:B]NK(L49C9U?9S@,IX-/34E:827-K!*Q9V=F3)?=^
M/;MZ50HIV0KEJPOFL3,4C1_.B,3;L_=/7I3[?4C;']U;Q!3&\;#)^8-UYS["
MJ5%%@N:*ZQ*L6PPQ,?LYMMQSG83TZ]JIW$PGD#K%'$-H&U!@<#K45%%@N%%%
M%,04444`%=7X*^_-_N#^=<I75^"OOS?[@_G4S^%E1W-GQ%&TFD2[1G:0WX9K
MSLC!(/:O56574JP!5A@@]Q7G^LV<5O?SQQY"H>,FIIO2Q4UU,JBG;11M%:&8
MVBG;11M%`#:*=M%&T4`-HIVT4;10`VBG;11M%`$MO<F*&>%AF.90&QU!!R#_
M`)]:4WT[11QN5<1C"%U!*CTSZ5#M%&T46'<M0ZI=P)&D;KB/=MRH.-W7\Z%U
M2Z14574!(S$/D'W3U%5=HHVBE9!<MC5[P$G>N2JI]Q>BG*]NU-EOY)(;A6_U
MERX>5L`9QR`!]3FJVT4;119!<;13MHHVBF(;13MHHVB@!M%.VBC:*`&T4[:*
M-HH`;13MHHVB@!M==X+B8">0CY<`?J37,0Q*QR<G%>C:;:Q6EE''",`C<2>I
*)[U$W9%P6I__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>hbm.jpg
<TEXT>
begin 644 hbm.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4`
M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@``
M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``@$!`@$!
M`@("`@("`@(#!0,#`P,#!@0$`P4'!@<'!P8'!P@)"PD("`H(!P<*#0H*"PP,
M#`P'"0X/#0P."PP,#/_;`$,!`@("`P,#!@,#!@P(!P@,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`&D!
M_P,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/W\HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHKG
M_&>O76D>(_"5O;R!(=5U:2UN1M!\R,6-W,!ST^>)#D<\8Z$T`=!1110`445S
M_P`6M>NO"WPJ\3ZI8R"&]TW2;JZMW*A@DB0NRG!X."!P>*`.@HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`\6_;4_:6U_]EGP7I6OZ9H6D:]9ZCJ=OI#Q7-[):RPR
MS%@D@*QN&08Y'!^M3?MC_M$>(/V5/V?[GQU!HVCZ^FC"!=2M7NY+4LTLL<(:
M%@CY`>3D,`=O?(P?-?\`@L/+;K^S!H<=S<FTCF\7Z:IE$GEL@S(2RMV(4$Y[
M8S7.?\%4/@G9>#?V'/%NHKXH\:WTD4M@(K?4->GN;><M>0C#1L<-A26'H5![
M5]QD^68.M'`>WCK4JRC+1^\KP5KW5K<SU7KT/S#B/.LRPTLU^K3=J-&,XZQ7
M))QJ-M)Q?-?E6COV6Y]?^$+Z^U/PMIUSJ26L5_<VZ2SI;,S0HS`$A2V"0,XR
M0,^@K$^(W_(X>`?^P]+_`.FR_K:\'7,=[X0TJ:&1)89K.%T=3E74H""#W!%8
MOQ&_Y'#P#_V'I?\`TV7]?%5?C>EM3]*H.]..M]%J=8<]NM?/?A']IWX@^._V
MC/'/PVM/#/A"PU+P19VUV][/JMQ-!?"X17C`5859.&^8G=@C@-UKZ$KXV\`^
M$++QW_P58^-MK+K>LZ9<1:#I1C33-3DLY)/]'@#%MA&[;E>N0-_O7NY%AZ%6
M&)E7BGR4^9-W=GSP6R:OI)[^I\OQ3B\51J8*&&FX^TJ\DDFE=.G4E:[3MK%-
M6UZ=3W?]E3]I)_VC/#GB$W^AR>'/$'@_6[CP_K%C]H%S#'<PXW-%*%7>ASP2
MH/7C&">F^/?_`"0OQK_V`;[_`-)Y*\$_8"N-0\'?'/XT^`;#49/$?@;PMJMO
M<:?K$R1M<27MS&9;N*:=%'VB57.&=\N"HR>0![W\>_\`DA?C7_L`WW_I/)7/
MGV$IX?&RA15HM1DEKM**DM]5OL]5M=[G9PICZV+RVG5Q+;J)RC)M)7E"<H/X
M?=:NM&K)[I*]EUE>&?MA_M>7O[(-]X2U35-$TZ]\&:_K,.D7U^+YX[K32ZLQ
ME\KRRKJ%1V^^#\N.X(]SKPW]LKP)H7QIU7P5X`UV>WB@\6R:I#$KD>9O73IP
MLB*>K1LZN/0J*G)(X>6,BL5'FIVDY+6]E%MM6ZJUU^)7$\\7#+IO`3Y*MXJ+
M=K<SDDD[]&W9]==-3T'X[_&K2O@'\%_$'C;5&673]#LFN@BN`;IS@11*>F9'
M*J#TRPJG^S'\5-5^.'P/\/>,-6TZPTF7Q':)?PVEK<-.L,+J"@9V5<MCDX&!
MG'.,U\B?"_5_%'QK_8S\:>#_`!G8W%M+\$M!UO1-1GF_U6IW\=G-#:E2?O+#
M;,S,6ZN\+CI7T;_P3EUF'7/V'OAI+#+',L6C1V[%&#!6C+1LI]P5((]J];,\
MEI8+`3O:52-51<D].5Q;C;I[R7-?>S2TLSY_(^):V9YK2Y;PHSHN:BU9\ZE&
M,KW5_=;<+;73>MU;VNBBBODS[\****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`,3QA\-/#?Q#-N?$'A_1-=
M-GN\C^T+&*Z\G=C=MWJ=N<#..N!4&I?"'PEK.@66DWGA?P[=Z5II+6EG-IL,
MEO:DYR8T*[4/)Z`=37145M'$58I)2:2VU>GH<\\'0DY2E!-RWT6OKWV10\-^
M%M+\&Z1'I^CZ;8:380Y,=M9VZ00IDY.$0`#)]JPOB-_R.'@'_L/2_P#ILOZZ
MRLCQ+X7;7]9\/78F$0T/4'O2I7/G!K6X@VYSQS/NSS]W'?(SE)R;E)W;-H0C
M"*C%62Z&O7&W_P"SI\/=5U.XO;KP)X-N;V[D:6>>71;9Y9G8Y9F8IEB23DGD
MUV5%72KU*=W3DU?L[&5?"T:R2K04K=TG^91\-^%M,\&Z1%I^CZ;8:3I\&?+M
MK.W2"&//7"(`!^`K!^/?_)"_&O\`V`;[_P!)Y*ZRLCX@^%V\;^`M<T59A;-K
M&GSV0E*[A$9(V3=C(SC=G&142DY-RD[MFL(1@E&*LET->L+Q)\+O#/C+6;;4
MM8\.:#JNHV846]U>6$4\T`5MRA'925PQ)&#P3FMVBG"I*#O!M/R)JT85(\M2
M*:[-7,W5?!FC:[IE]8WVDZ9>V6IR"6\MY[5)(KMQMPTBD$.1L3ELGY%]!47A
M'X?:!\/X9XM!T/1]$CNF#S)86<=LLK`8!8(!D@<9-:]%/VU3E<.9V?2^A/U>
MESJIRKF76RO]_P`PHHHK,V"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#YY_:@_:;\9_"+XHOHVA:*E_8
M3:9;O;S_`&8S,;Z>TUUHH,!P6+W%C9*,#`#."074CQ\_M^?%)O$-[#?66D:'
MI,&EQZH+N;2)3(L@L=*:>Q57E5'N([FXNOD9X_,62.%&67:[?<U>/^/?VH[C
MX>^,/$5M=>'[F[L=!NH;-+>V;_B87WFPVLB72"39$+8O/)`7=U`EMRNXEBJ@
MT>2#]L[QUIWB;PB[-HNH:-JWB/4-(UTK`A;08HM6L;>&61XY"(E%N]P&$H#;
MIXG.U4(;>_:2_:L\:_#OX\WOAGPQ%IU]9WOA:UFTO%I]LD&I7<UW!;S%$D#M
M`)8[?<<!,/MWAI$K8\=?MI7EOI-XEIX(OSYEH9+>._DA<7NZ/4^&1)#M0-IX
MR222)E4JI(-)?_MR36>B_9X_"VL-K$.H6VG27$MND5@SNID=Q^^+B/RU=5?D
M&4%1G:U`'C/C_P#X*!?%[3_!>O>(M$\.636MI;6VJ6UG<Z9(\S6K:7?W5P(]
MDFYVA:U0L"`VXJ@!\Q2/1]0_:$\?ZOX4UK4=*U[3$NM+N?%$;VJ:?#=>3_9_
MF?9(V"2%D+!%)#X=MV<`$5WGB;]JK4O`GQ!\2VFJ>$[JX\,Z/JL6D6VJ6-Q&
M\DTSV"7AW1,P(4!FCW9Y<(H!+'9ROAG]N_4+F'2I]5\)ZG!"VG13:B+>UW-]
MH_LZ>]E$),F/+!C2'YOF24.C`$%E`-_Q;^T5K/@3]I7X7>"+J2*>P\2Z7*VI
MW;6>UKB[9#Y"QX8;`3#.SMRB8CC.7N8!7C&L_M\_%+0?B+XETN;PY;3:;H.O
MZE81W4.DS-]JM[+49;F3;\_)_LA8XMXX^T,SX('EU[]X]_:TM?`'B+0K>YT'
M49K'5=*^VW$T#I,]C<2+YEO;OL+1[6BANV>4R!$\E,;A)E<V[_;@TZRLVFD\
M&>,QL6_=HTAMI9%^QQL\@(29N6V$K@D,K1OG9(K$!'D5O^VO\5I?%&DV,.C:
M=>VNKZ_+IOVF/2IPMM9+<06-O>$[L-]IDU32+T#HD#72\F)F&_\`#7]MW5+K
MP!IE_KVN^%TO;S3?"VH3;Y((Q";[5Y;74E^24J%@@6-CDYB+@R<G%=G_`,-Z
M:;+/#Y7A'Q/]F)#33R>2JQQ_8XKEF`#DLV9XHE4[=\A<`G:,HO[>>GWA@-GX
M0\23H\RI(\C01*B8MM[#+]FNHT7=M#LKC(V\@'1?%+XMZ]!\2?!5MX2N]"N?
M#UZE]=:W?3R1O:P0VMY8P3`S!QL=4FN5`4,?.1`P"AR+'[+OQAN?BGX.:?6-
M9TJ[UV9Q+-I]M:/:R:2_V>V>>R8.Q\U[>6?8[KC;O1'`<-GM?AKXLM?'?@;3
MM9L[.XT^WU.,W"P3PF&1"S$DLI`Y)R<]\Y[UN4""BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
I**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`/_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>footer.jpg
<TEXT>
begin 644 footer.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4`
M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@``
M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``@$!`@$!
M`@("`@("`@(#!0,#`P,#!@0$`P4'!@<'!P8'!P@)"PD("`H(!P<*#0H*"PP,
M#`P'"0X/#0P."PP,#/_;`$,!`@("`P,#!@,#!@P(!P@,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`)4"
M_0,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/W\HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HKRG_ANWX)_\)CJOAX_%SX;+K>A?
M\A&R/B.T$UC\VT^:ID^3#$*<XP6`."0#>\$?MB_"?XF>-[+PWX;^(_@KQ!KF
MI"<VEGIVKP74EUY*J\P38Q#,B.K,H)(4Y(QS0.QZ11110(****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHK#TCXF^&O$%WJUO8>(=#OKC06
M9-3CM[^*5].92P83!6)C(*."&Q@JWH:`-RBN>\+?%SPIXYTN^OM$\3^'M8L=
M,!-Y<6.HPW$5H`"29&1B$P%8_,1T/I70T`%%8WB#XC^'?">AVFIZKKVBZ9IM
M^R);7=W>Q0P7#.-R!'9@K%AR`"<CI6S0`44R*YCG>1$D1VA;9(%8$HV`V#Z'
M!!P>Q'K3Z`"BLKPKX[T/QW%=2:'K.DZS'8SFVN6L;N.X%O*.L;E"=KC(RIY%
M7;35K34)I8K>ZMYY(25D6.169""5(('0@@CGN#0!8HK"\;?%#PS\-([=_$GB
M+0O#Z7>[R&U*_BM!-MQNV^8PW8R,XZ9'K56?XW>"[5-6:7Q?X7C70'$>IEM5
M@4:<Q?RPLV6_=G?\N&Q\W'6@#IZ*J2>(+"+0FU5[ZS73%@^U&\,RB`0[=WF;
M\[=FWG=G&.:B\/\`B[2?%OA^+5M*U33M3TJ=6:.\M+E)K>0*2&(D4E2`00<'
M@@T`:%%4AXETXZ:MZ-0LC9LR*)_/7RB7*A!NSC+%E`]2PQU%6+_4+?2[1[BZ
MGAMH(_OR2N$1><<D\#F@"6BBL5_B5X<C\1W6C-K^B+J]BB27-B;Z(7-NKLJH
MSQ[MRAF=`"0,EU`ZB@#:HIEO<QW<"2PR)+%(-RNC!E8>H(ZBJU]XCT[3/MGV
MF_LK?^SK<7=WYLZI]FA._$KY/RH?+D^8X'R-SP<`%RBHC?P"VDG,T0ABW;Y-
MXVIM)#9/08((/I@U!?\`B'3]*T*75;J^L[;3((3<R7<LRI!'$!N,A<G:%QSN
M)QCF@"Y16/I?Q#\/ZYI.G7]CKNCWEAK$QM["Y@O8Y(;V4!B4B8$AV^1^%)/R
M-Z&J6H?&?P?I&@Q:K=^+/#5KI<]T]C'>2ZG`EO)<(65X0Y;:9%*."H.05;(X
M-`'2T5EZ7XYT37/$-_I%CK&E7FK:4%-[907<<EQ9[AE?,C!+)D<C<!FH;CXE
M>'+33M1O)?$&B16FD77V&^G>^B6.RN/E_<RL6PDGSI\K8/SKQR*`-JBL+5/B
MCX9T/6KO3;WQ%H5GJ-A:-J%S:SW\4<]O;*,M.Z%MRQ@=7("CUJ]X8\5:7XVT
M2#4]%U*PU?3;G=Y5W97"7$$N&*G:Z$J<,"#@\$$4`7Z***`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@".\>9+25K>.*6X5"8TD<
MQH[8X!8!BH)ZD`X]#TK\V_\`@I)\"?\`@H!^U_H]QX-\&W_PC^&W@K4]T-VV
MA>);R6_NXCD%)[N2UBD6,CJL$2DY(8E217Z450\4^'(?%V@W.FW$^H6UO=KL
MD>RNY+2<+W"RQ%9$/^TC*P[$4#3/Y-/VC?V2OB+_`,$?/VN/"%GX@U3PKK/B
MNW6/5A9Z%J371,#NT;6UPNQ70S1[E*E3N23C-?N;_P`$@_A_\;O&/B1?B7\1
M/A+X"^''AR[M'MO#UK?S7<_BJQLY6#D!21#`LA"M(S1QS3%5,@PJ8^K/A/\`
M\$_?@I\$?&,GB3PU\,_"=EXGEE,[ZY/9"\U5Y"<ES=S[YRQ/4E\FO#_VN;/Q
ME:_M\Z%J_ARP\0W]II>F>')OLEE;WB)J+G6;F*ZC2YC_`'$;);3)+*LJL'AC
MVDQ@B14D-NY]0_%4^-VN-+C\'KHBQO\`:/M\NH;B8_W1\G8HZ_O""3GHN,<Y
M&9XFC^)GF64FE/X9`&DC[6DPD.Z^V/D)Z1[RAYY.*\6NO'_Q"TS]N72/&QL=
M9F^%6NW5S\/9+2-+AVM7BC^T0:M);>3^[C-W%=V_G[RK1W%LV`OS'COV/M2\
M4>$_VE/%_P#PGGA[Q1<^%M1\;>(HO!NHK9W3VNE2-?RDK=1%252:W$)MKDY@
M$:-&OEL<SLD]TTX?'*RMK2VE;PE=2#3Y`]P\9`6Z6UC"%R'!8/.9"=J+C:>B
MD5=U2U^,S06WV>Z\*&18)7D80L@,XMR(U*EF_=F;#$!MW(&[`)/S%\.M+\01
M?\$_OVB;>.RUL^,;W3?%YTN&/0]1MM6S_:&K_8`LCDB8F-[4V_DJK!-H`("D
M>X_L%#5O"\OCG0=?TW7M'O[C58M9L+28W%QI$=C-96T:&PGD1?E:2*626`A7
MBGEE&S8R.X!Z'X>M?B8EV\FJ7?A^51IMR(XX(3'&;PF/R"X)9@@"N2%8\R$<
MX4C+U*T^,J#4H[2]\'/LMV&GRRVTF9)?-CP9<.-H\OS``H.2<DC`!X7PU\&M
M+M/^"BOB!AH=_'HMOX-TK4K.<K<"S_M3^T]0>=UD)V&<H;<N,EBA0,"N*\KN
M1XATS]D1);FP\6&\M/V@'NIHTT^[ENAI`\:M(7$:H9&M/[-P>`8S!Q]SB@=C
MZ+6U^,T5_=!+KPDUNXB:)IH7D(D^QXD&%9,1?:`"#DMR?X>G3^(K#QM>?$'3
MH["[TV#PQ#'!)=R;<74\BRY=!P0$9.O0],'K7C?Q*^)<<'[<_P`*_$J6WBF3
MPA-X(\20W$T.BWTD'VLWNDBU$J+$=LC(EYY>\`E3)MX8Y3]GKX;:KX<_;`\?
M>&;V36I_`W@B2+Q!X2%U%-Y*W&K"5KR!9V^6=+5XG,:`GREU#:1B.(J"/IJF
M74_V6VDEV/)Y:EMJXW-@9P,\9I]1W<!NK66(2/$94*[TQN3(QD9!&1[@B@#S
M#X2?MF?#[XQ>%$UFQUR'2[26XM+6+^UBMDTTMU:0WD")O.'9X+B)MJDL-Q!`
M((&M%^U!X`N]9BL[7Q?X9O%:.>26>#6+1XK4Q?9\K)^\W!B+J`C"D8D3)&]-
MW`>"_P#@F_\`#?P!I&AZ?IL6JKI_A^2*6TM9I(9H%=;9;:1O+:(J&EBCB\QE
M"L7B60%9"[MB_#+_`()LZ/X:\%#1O$GB2\\10QB58ECT^VMH=LJ6BRJZ.DGF
MAC90X$A8*BB/!4`4#/7="_:;^'GB2\NK>R\:^&9I;34(M+<?VA$H>YEBAECB
M0D@.72>+&W()<`<Y%/TK]I?X<:[9)<V/C_P5>6TD4DZS0:W;21M&B.[N&#D%
M52.1B>@5&/13CD+']A7P/8>)-.U53J\]UI=S'=6_VN:.[V,MM96S<RQLQ+KI
MUFQ<G>'AW*R[GW5KO]@#X?ZA8V$-S%J5R^G:!!X<CN)'B,_V:`7`MV$GE[DD
MB%U-AHRN[>-X?:N`#LO!W[2O@[Q9X#L?$<VLZ?H>G:E>:A8VIU2]MX#<264E
MPEQL(D*.%6UFDRK']VA<X`.,GQ7^V3\/_"-U>V\VO6%W=V[RP6T%G>6\\FHS
MQ6LUU)!$%D^618[>08E\L;@%!)(IVM_LA>#?%_PKM_!WB"WO/$&D6^L7&N9O
M95$LES<33S3%C&J`HYN9U9,;2DK)C:<5GW?[$GA&X2U6.\\06ZV-O!:V^VZ1
MVCCBTZYT[!+HQ<O!=S;F<LQ<A@01R".DL?VG/`=]\--'\7KXGT==`UV[MM.M
M;H74;HUW/(L<=N2A($F]@K#/RD$G`!-5?AM^UCX!^)O@G3]<M?$NC6$6H7"6
M7V6]U"WCN;>Z8`BUD59&`FP0=@))!!&0:AT;]E;P_H?P_'AV"^ULVT>M6FOQ
M7#31&>&YMG@>+!\O:5S;ID,IR"WJ,<QHO_!/;P#HVI:=>%M7O;C2WC-NUV\$
MP5$0H8]IBVX8;26`W@HI5E.209T_B_\`:X\$_#WXM'P=K^H2:+?[%D^UWBK%
M8`-;SW`W3%L(/+MISN?:H,>,Y9`U'Q7^VOX!\*:EXELWU6WOKGP[H9U]$M+R
MUD.L0K]N$L5IF4>;-$=.N@Z';M*<GKC5\7?LQ>%_'NJ^.K[4A>7$WQ!T1/#V
MH,&C5H+14E3;"X3>A/G.QRS`M@XX`KD+[_@GQX&U:WO(KR\\1W::A!/#<B2[
MC'FO+)J<AE.V,8=6U>^*XPHWKE3L7`!Z#X8^/_A+Q1J$-E'KFE6NH7=[-I]I
M9SZA;_:+R:%5:18T61F)4,-RD!E[J.,T-._:=\*7VJ7L<ES<6.E64]Y:'6KM
M!!I<EQ:726=Q`)F(`D6Y?R@&`WLCA-^QL4?!G[)?AOP)\0V\46-[K9U6:622
MY:2>,I=!A%A&41C`1H592FUOF<$LK%:;)^R9X<VW<%OJ7B&SLY-:?Q):6<-X
MOD:7J$MW]LEN859#DR7&]RLF]`99`JJ'8$$;D?[2_P`.)O$$.DQ^/_!4FJW#
MQ116:ZW;-/(\HA,2A`^XEQ<0%1CYA/%C.]<R:1^T7\/O$,-M)I_CKP??1WMU
M'8V[V^LV\JSW$@0QPJ5<[G;S$PHY.]<=17`:+_P3^\#^&+NSDTNZ\0:?#I[6
MIMK>.YC>*(6PT@1+\\98@#0]/SEB3Y;\_.V<GP9_P3M\/6'ASPZOB#7-9U;7
MM"ELY3>V[);03FSF6:T7R&#J%B=`RDY?YY`7*NRD&>H:?^TQ\-]6A$EK\0/!
M-S&S2(&BURU=2T<:R.`0_)5&5CZ*P)X-=O7B&B?L,>'O#?B;0+NVO[RZLM&U
M*#5WBOE$EPUQ;0RQ6YCDC,810L\N]623S`5'RX.?;Z!!1110`4444`%%%%`!
M1110`4444`%%%%`!116!\0/BKX;^%5E;7/B36M.T2WO)5@ADNY1$LLC,JJ@)
MZL690!U)8`<F@#?HKDM/^/'@S5=5FL;;Q-HTUW;RQP21K<KE)))(XD0^C-)+
M&@7J6=1U-=;0`5XY^S]X`\1^!_B+K*-9>)-+\-RF^GN(]8U>#4([Z]GOFG2>
MR$3$PPA'FW*ZQ%O,B^0LKNW7WG[1G@/3[W5+:?Q=X?BN-%)6\C:\0-"PF6`K
MC/+"9TB(&2)'5#\Q`.IH'Q8\,>*]7L-/TS7](U"]U333K%I!;W2227%F'5#<
M*`>8]SHNX<98"@#Q?Q-\"/'%[X3FM-/N-6TZ2`^-+^"*QUEK-)[R]OY)M,:7
MRW4.-DKOA\JC$;@#7,P?#GXO7'Q,UR_U;3O&-QX7N-42:72],\4?9I;J,?VJ
M!]ED:_W1H&ET]V&ZV#"/`BQ'L;Z%U?XW>$-`UC5-/OO$FCVE[HD?G:A%+<JC
M6:[$?,F3\N4D1L'DAU]15:T_:'\"W\^DQ0^+=`DEUV0Q6*"\3=<.)3`4`SD-
MYP,6#@^8"GWN*`/,A\*?$?@SP5\+)IO"`\8OX9\$7/AC5-$2[M0?M$\%@/,+
M3NL31#[)-$Y#%MMQE58;A7,>&O@7\5-2\;-#K=[XBL=)DUEWO4TWQ!);6#V'
MVMI+>.V*77FH(K;;$P2&VW<[A-PX^@]>^+_A7PMXL@T'4_$.CV&L7,7GQVEQ
M=)'*R8D8-@G@$12D9ZB)R,[6QDP?M-?#RYL+6Z3QIX;:WO;@VD+_`&Z,!Y0(
MV*]>,+-"<GC$T9SAUR!<^:M/_9U^,.@P7`BE\7)<ZHT%Q?75KXA$DTUVNCZ;
M:0SDO>Q@^3-:W?F[PZR>="QCGVD1_1/P4TS5O!%O)H>KP>(=0U#4YM1UBXU&
M]OFO+:'=>$0VP=G/ECR639'&H15B;.&/S=/X3^*?AOQWK.IZ=HNN:7JE_HS^
M7?06UPLDELV]XR&`/'SQR)GINC=>JD#>H&V?*O@OX<?$WX;Z1;PZ)X2UJUTS
M2TM;&WL&U333?I%'I^IPBW2Z1X_M&GP3S630FYQ<#,K%20HK"?\`9\^+UKKQ
MU6=?$MW>75G:VM]):>(,2SVT5S/(T"@7D&)"TT4@8.F4AF0N-X23Z4O?VBO`
MFF?VH;GQ=X?MDT20PW\DMXB1V;B=;<H[$[583,L>"<[SMZ\5MQ?$/09];&F)
MK&FOJ)O'T_[*+A3-]H2`7#1;<YWB%ED(ZA&5NA!H"YP6M?#OQ+XK^#'@3PEJ
M1N+Q;G[##XMN[J=&FDMH(?,GC?!(E:XEC2"0+D%)Y3G@9\S;X-^-O#WQ3TG5
MM+\/>*[SPWX<\1:AKVI:3J&N65T->N+F2[$,NGJTBI"L1NY)2DWD9*Q</(I<
M_1GC/QSH_P`/-$.I:YJ5GI=B)$A$MQ($5I'.U$7NS,>`HR2:QM,^/W@?6M3M
MK.S\6^'KFYO+07\"1W\;>;`8S*)`0<$>6"_^X"W0$T"//_"/P_U*]_98U[P-
MJGA:[GN;2SEM3IXO5M(;@3K]H%K:W`SA8%F6!9"`N^'&0H)'F5]\+_C/JWB"
MS6'3-9L]-%\DRW#W]E:W=Y#)*1=?VG%:726CRF,8#1P3;U9.875MWT[%\4?#
MD_P^B\6)K>F/X9GMUNX]3$ZFUDA;&V0/T*G(P>^16?#\?/!4^J:98KXHT07F
ML()+.$W2J]PI9U4@$_Q-'(%S]XQN!G:<`[GA_@G]GSQ7X)_9B\1:`-"U*YUM
MM?TO5HK8ZI%,+Y('T^640-)-LCQY$J!6,:[EX^4ACE_&WX>_&+XT>-M8N-)T
M76O#.EWULUM;VVI:G!/:[/L\11YH([]XC(+I6.V.-3L7)F)<JGT=X4^,7A7Q
MUX=O]7T7Q!I6J:9I8)N[FUN%EC@`C$F6(Z`QD.#T*D$9!!K)L_VG?AYJ%U!!
M#XS\.R3W-W]ACC%ZF\S_`+K]V1G(8^?`.<9,T8ZLN0+GD_PG^&/Q9T?XS^'K
MGQ+J&OW>FZ8HBN+N/5`]E>A8KN.62:$W/!GF:.X1%MW,0DBC$B+#MJS??"_Q
ME9+<Z)8^$4DO8?%5YK:>*_[0MXB;2[U07+0PX?[0)1;N('5U1-EO\KM\BU[3
MJOQ8\+Z'%XCDO?$.C6B>$(!<ZXTMY&@TB(QF4/<9/[I3&"^6Q\HSTK>M[A+J
M!)8G62*50R,IR&!&00?3%`CY2_9XT'QK\'?$^F:#/;^*KOPYX-\/VUU>Z8M\
M][<-J\C-9+`DC2,CVQ@7[3Y7F?NV9'94)`KM?VDOA;XH\2ZS\1;?1=!N=8M_
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M6%-J1Q@*`9)5JG\2?V>_'WCKPU<06_ASQAX>C.L>*6+:->Z/_:4\&H,/(7]_
M.T`M)$>3S0"MPKQ0[-HW-7V/10-,^:?@3\$/B%X3U?PY!+IFB>&+WPM:ZXMS
MJI1=0T_5&U'48+M8[>)+A+C:J1MN:;RRKJFT2KDUJ?$#P5XJU?X>?M!:=:>"
M-7GN?%ETQT-!=:>HU02:7:V7FH6N`(PLL#N?-V-M92`S94?05%`7/EK]HCX2
M>+_C;JWB*UA\`ZKI5I')'>Z7<VT^EHUU=O;0PSWTDGVGS#>16YE@MXV3R!)$
MC2NZ%?*]3_9*\!Z]\/\`P!J]OX@CU5;K4-=O-1BEU:2UDU2YCF97\R[^R$VP
MEW[U`@P@C6+@-N`]2HH"X4444""BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`*\@^-/[2.J?#'Q9XMTO3]%LM4F\/^#/^$FM
M4FNC;_;+@W$L*6[/M81H3&/GP2-W0XY]?K.U/P?I&M74T][I6FW<]S;_`&26
M2:V21Y8=V[RF)&2F[G:>,\XH`\$U+]MW4-:^$GCKQ5H&C6UM+X#F@MM1TK65
MD@O;.X:-3-:3*I(25'=2&4LCH5="Z.CGJ;O]H'Q%I?QO\2>#Y],TV5/#'A*Q
M\0SWL*RE)9;EM301<GY%!TX$9R6$I'!4;O5-2\*:5K-I>6]YIFGW=OJ)4W4<
MUNDB7.T`+O!&&P%4#.<8'I5>]\`:#J.OG5KC1-(N-4:W^R&\DLXWN##AAY6\
MC=LP[C;G'SMZF@9\\>!_^"@NI>(?@GX?\7OX-DU0ZAXA72M0L=)ED>^M;3^R
MVU"2Y2U=!*TD:K_J,;Y8E\R+?YD2ONV_[==C<1_#6>WL(=3TOQ]J,]M+JUF[
MO9:9;O/+:Z=.[A2`+NY$$:;B`2[X)VXKVJP^'V@:7>07-KH>CVUQ:A%AEBLX
MT>()&T2!2!D!8V9!CHK$#@D4L_@+0KJ">*71=)DBN1&LR-9QE91'(9$#`CD+
M(S.,]&8D<G-`CQBU_:E\3Z?X;UW4-1TS0)?['\?:9X'"V[RIYINM0LK1[CYL
MXVB\W!.YCP3\V0[0?VP=2UK5O"]VFB6<FA>*_%.N>$UA25Q?Z5/IB:@WGSC&
MTI)_9T@*84QF>'E\G'L[^"-%DMYXFT?2VBN;M=0F0VL966Y5E99V&.9`R*0Y
M^8%0<Y`IL'@+0K76[S4XM%TF/4M04I=7:V<8GN5(`(=P-S`A5&"3PH]!0!X/
M\,_V^CXZ\(ZG<WOAJ?1O$FB>'(-4O?#TCM+<O=W#A+..W=5Q/!=,R"&5%^8D
MJ561)(TZCX._M8CXO>)?AW:PZ8EC!XT\)ZCKUXD[LMQI5Y975A:S6+*0/G2:
M[EC;."K08QSQZH/!FCB.V0:3I@2R2*.W7[*F(%B8-$J<?*$8`J!]TC(Q523X
M6^&)=3MKY_#F@O>V4\EU;W!T^(RP2R2"221&VY5WD`=F')8`G)YH`W:K:W<W
M5EHUW-96JWM[%"[P6YD$0GD"DJA8\*"<#)Z9S5FB@#Y:^&'P<^.W@6:+29M?
MAFT4ZQ+K#7D=TBW+RW2VUQ+%(LPFS;)=_P!H!D1@62ZB$9C$0Q:T[X:_M"2Z
M7IT,GBQ;>ZDTV&.XFFNK69;:\\JY%VY"6J[XY)&MC``,Q^6Y?@^57TW10!\T
M:5X*_:`N]8\/7%[K,EK!!?/+J,$=[9NDMN^H6+;#^XR2EG_:"`*1\[1<D@,.
M4L?@#\??#/PUL;/2-=EMO$T/AO3M-N]5EO[2XNKV\MK#5T9GGD@9Y(3>3Z=(
M-^6"B7H2X?["HH`^7_!MC\7_`(L+\;]`U/4/$?AR?6--O--\*7\]L+>UTF8R
M7D4<Z2*JNS[7MRK1EU$<"/D2.V;_`(>_9Y^(^C^.#J?AO4K3P#X<OM2L4O/#
MEK.DT*6J6CQW5Q&?+*K</*(=@7"E8B[_`#R%5^D:*!W/F#0_A=^T-+HD`U;Q
MK*NJ)I6J"5[`V:6S:BT-BEHP62)F-N)$OY`-RL#,@(50%3D?&6@?'KX=ZOI4
MX;4;N76+_3KC6+C0+*">:[BMX$6XB+>62CR$!$\Z0HH:3]Z=BD_9M%`7/EGX
M*?L]?%;P'XB\&V]UJ5U:>%?#NOF^DTVWU*%(_LLMMJ<<D(5(QOB266Q<1N3@
MAR#E15.X_9E^*NB_M1>.?&OAZYLM-TK7+]S'$;Y%EFLG;0!*D*!-JS2)8:EA
MIBPC:Y0H8S+.U?65%`7/E?\`X5[^TI<3R6UWXGMH[>2SL(FNK*YM1.)%GTIK
MATWVX56,*:JG*$,\B,"`R)!W'[.GP@\<>#/CWXX\1^,+B'4UUFQ@TVTU!9XB
M]Q#;:CJ<ML#&D:;-MI=VR-G.9(Y3T(9O<**`N%%%%`@HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`*Y/XT>"[SQ[X/L[&P,(G@UW1M1;S6*KY5KJ=K=2\
MX/S>7"^!W.!QUKK**`/G+5/@QXWT^?QC;V>C2ZA'J7BRS\26;RZ^!:21P:K:
MWAB2`K^YD:.)P6Z%@,G!S7O_`(;O[W4]#MKC4;`:7>RKF6U\]9_).3QO7AN,
M'CUJ]10!\A6O[(7Q!T7XZV_B^&*._CT/6M3U86-UKN^POUNM16=([.#RL6C^
M27DDW'#W$<62P_>KZ%\/_@OXT\-?$KPQ=RVMA96T6C^*#>WUM>+,=,O-8U6W
MU".*.-T'G)#Y!0N0H8E3M`R![W10!X#K'P:\;:%\6+_6]"LI+B2[N5NM5NYO
M%MS;P>(HO[-BLS&+-8S#:7`>..02(O'V=?W@\UPF#X!^`7CG0-0TK2-0T.%_
M"SZLVN74RZQ'<:I)-_:<UW;QWEPZ!YTMG99P$)+N^PN41O.^G**`N>$>/_AM
MXXUKQGY%YH>F>+M"T^T^U0M-<V]BFN:@(Y?+-^@C),4>8XT1!@?,[;SM5>,U
MC]FSQ_XHT3Q)<W.F64GB'Q[H.I^'=:NKS4XU6VDNXK6-+N%(T*K;QQP[/(!+
MD0Q$L[,\E?55%`TSQ?\`9\^"WB3P+XET(:S;Z=;67@KP]<>'+2YM[HS2:V);
MB&07+KM7RB$MHR5)8^9/*.BAG]HHHH$?-?C7]BG6/B-X'G\+WNNWEGHWB#Q5
MK&LZVGVD7<(M);G4)K:"""12B,S74$CG'#0=S@B[\%?@!X]T'X^Z;\1/%+:%
M<:K<Z%%X7U:&VD)!2*WBD;4D8J,SS74;1.G&8!:Y;,)5OH>B@#S']JOX8:S\
M5/!6C6NC?:?,TS6[?4K@66H?V=J#11K)Q;7.T^5(79`Q.-T1E3<N_(\I^`'[
M+WCOX5QZ+INHV>C7%EI_B%/%#7T>HE[G]WHXT]+1LQ+YEPQ1&DN/E5P\IV@D
M*?J2B@+G@OA3X&>*IOV5=!\,ZS;*+S2]/AMKO0K?5OLL=W)#<+(LB7T2>;$V
M$!7;CG`)7EAS^K_`SXC:YHWA^QNM,2\BT76AK-HM[XMGNX!;"\:;[!?)+&WV
MIQ`$6*1B_ER-N#`1*9/IJB@#R'X$?#_Q?I%O<:QX@1M*\0WDJR:E!#);S6VH
MJD06&WA"K_H\$/(1<ECN9G9F)->?^._V/O%.O^!;2RLK^XL/$?B^S>W\9:G9
M:C#';2M-=&YF!26WDD=(C-<+#Y31/M$:,P7#)]/44`?)GB7]A;XA:OIGC&R;
MQGX5O(==L[>9GFT"=6UN]C_M!RUR!>?*!/<PRJ4.U3#&`@1`A^H/!6FWFC>#
MM)L]1FM[B_M+.&&YDMXC%%)(J`,R*68JI(.`68@=SUJO\,_'-O\`$_X;^'_$
MMI#-;6OB+3;;4X8I<>9$DT2R*K8R-P#`'!QFMN@;9YE^U;\)=?\`C'\.+72_
M#>J/I-^-0C2>5;F2V/V*XCDL[PJZ<B5+:YFEB[>=%#R,9'@4G[%_QIO$TR:?
MQO!]KN[;=K9CU*X1)KR>>6RGG4`<B/2;EC&O`^T6L)('WA]E44!<^9_@;^S?
M\3?A7\6KC5]6UN'7_#ELDD>FZ4=4E!@,#BQLY&9E();3B\DJ]#.>_P!^L^[_
M`&-M;T6ZT*6+1M-UW3+.YMK_`%72Y-5DC&H3J-661@7!!.V]MP`<*RQ",X5%
M`^J**`N?)=K^Q)XTF\-7TNI:E'?>)9-%N;:&\;6KI\7@TG3K>T?<V"1%=V]S
M(&(R&<2XWL2+_B/X(>*M,O/#EO=^#O\`A(VE\4/-K,\?B"<1^((A9:PRSSQE
M?+A4--;##G!?9%]R*%C]2T4!<^-M/_9#^*MVQ_X2&[.HNFCK97\ECK:;=8N(
MI[!K>4K<0.TP$<%QO%PX4M*XC6('>?5M5^%_CCQ'JO@VYUG1M*OY=#T^*RD%
MMKUQ!#97H-G(VH1Y4R.`4N(PKEG*JJDE9Y=ON=%`CY.L/V./&6L^'[ZWOS'I
MWE^%;FPMH8=?N7\S7?L\*+JOF+M97DE5G#'YU:-9#B1CM^A/@MX!F^&GA"YT
MEUCCMH]4OI[.))&D6&VEN9)(D&>1A&`V]!T'%=;10`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`>
M/ZQ\;M2LOVD=.THR&/P;J7G>'A<")<)K"Q"Y1A*<@@QK+%M(XDCQSD"N$\)_
M&_QA)X$\+W(\3SZU<^(_".J:G?R-:V@DTB:WC5H;E/+B50K.3&5D5@3MQC:P
M/T/-X'T2XA,<FCZ5)&TQN"K6D94R'J^,?>/KUI]EX0TG3K">TM]+TZWM;H8F
MACMD2.4?[2@8/XU[E/,<+&"7L4W9+5+6REKMOJGY\JN?,5<GQ]2I*3Q#2;;5
MG+2[@[;I-+E:5]4INVQ\V>+_`([^,_#_`,+=;N;+Q1/?31_#F/Q2=1-I:&32
M;_Y-L9"Q"(QS`NP5T+#R7P<$8W?C-\5O%_PS\3^*/+\0WESX:,%M917,-I:R
M7?AV^>,-#(P\HJ\%PY\MBZL4=D((5B4]V3P?I$>D/IZZ5IJV$C;FMA;((6.<
MY*8P3P.W:G6OA32[(S&#3-/A-RBQR[+=%\U5&`K8'(`X`/2M%FN%4D_8)K6^
MD=;\OEHU9VTMKJG>5\7D..<6EB9)V5G>6C2G?2^J?,KW=]-&FH\OBT?Q=UB?
M5-3NK[6]7L9M-\<P^&XM-M;6UD3R/,B6,3"0!\W*-O$BL-HD0@`*V=?XV>,?
M$_@OXKZ=I]GK-_!IOCC39M*TD1VMO(NEZNCHZ2Y:(LRM`9Y"'+*!:OQ\W'J<
M_AG3;K68M2ETZQEU&!=L=TT"--&.>`Y&X#D]#W-6KJRAO559X8I@A)`=`P&5
M*GKZJQ'T)'>N7^T**G&2I*R335E;96Z=&K]VKI[MOM_LC$NE*#KN[:::<KV3
M=^O5.UEHG9K9)>!6OQ^UY]6\<V,VH3065YX=N=8\(:@;>$/(+,-#<."5,<NX
M_9[@';C%P1MPM:>J_&#4%\,_"=8?%#+J.J7^E+KY$=L6GANK.X=?,!CVQB2:
M$`%`A[#J*]9?P'H<D4,;:+I+1VZ-'$IM(R(U;.Y5&.`<G('7)HC\":'%IEQ9
M)HVDK97F!/`+2,138Z;EQAL>]:RS#"-IJE;Y+MR]NVOG+4PAE./2:=>_SEWY
MN_>\?*'NZV/$/'_Q)\7^'Y?"HTCQ!JNLRZWK>O6IMHETZ)[F.VCNS!$CO!M7
M:T"?-R3EL[N*]P\$7\>I^#],GBU5=<1[:,?VB%11?$*`9L(`@W$%L*`O/'&*
M6]\$Z+J5O;0W.D:7<0V:>7`DEK&ZP+Q\J@C"C@<#TJ_9V<.GVL<%O%%!!"H2
M..-0J(HZ``<`#TKEQF+I5:<8P@HM7NTDKW;:V[)I?+KI;OR_+Z]"M.=6HY*2
M5DVW:T8IVN^K3;WWTMK?S3]FD.?V,OA]Y5U)8R#P7INVXC"%X#]ACPXWAER.
MOS`CCD&O'Q^T7X]TCPQI]MJFLRQZW::3:SW5[#96_P#9]_975[8PKJZYC.UX
M89[@R1AA&KP[BOEE<^__``0\`3^!O@'X/\+:Q':W%UHV@66EWJ+^]AD>*W2*
M0#(^925/4<CM736VAV-G:QP0V=I%!%&T*1I$JHB-C<@`&`IP,CH<567XZC03
M56FIZIZVZ>=GO?;;KND9YMEF(Q33H5G3LFM&];VL[)K56T>^ZV;/`OBQ\0/%
M_A>S^+$.D^+;];7P#X<77+6^-I:32&Z>TO";*0M$4*H8K>?A0^)@"=I`KL/B
MKXOU[X5?!$:F/$$U[+?ZKI\+ZK<VT`.CV=U=012S$(BQL(4>1PS+@<%MP4Y]
M&@\(:1:Z*VF1:7IT6FN<M:K;(L#'.<E`-O49Z5:32[6/319K;0+9B/RA`(P(
MMF,;=O3&.,=*UEF-%N'[I6BTWHES)*.[MU:;ZK6VIC#)\0E5_?2O.+2]Z346
MW)JRO;1-*^C]V^C>GC]QXCUNS^-VE^$?^$SNIM$U2._O?MRQ6WVJ"6&&R\O3
M_,\O9DB:XN,E=Y50,[5;/#VG[2GB_18_`7B*\OI=4T:[-_9:KI\%I"&U.,7I
ML[#4(L)YBF61K8D*WEE;@D``"OHL^!]$;04THZ/I1TN-MR6?V2/[.ISG(3&T
M'))Z58;P[I[W\=VUA9-=11B))C`ID1`<A0V,@`]NE:4\SPR24Z*EI9Z)7TDK
MZ+1OF6O1Q3UZ8ULEQLI.5/$.-W=:R:6L&EJ]4N5Z:<RFT[):_.%G\3OB%?\`
M@+P;''XFO[[Q#K/BOQ#H=P;*VT^,7"VHU)8`OFQ;55&M(CGEB"V=Y(%=W\-O
MB!KNB_%3Q!I7C/Q):N-,T+0`\4<<,5JFHW;7$,IB.P2$22Q1A%=CR^`.0!Z9
M;^"-%LS;F'1]+B-I(98=EI&ODN<99<#Y6.T<CG@>E.NO!FCWVJ?;I])TR:]+
M*_VA[5&ERN-IW$9R,#'/&**^98>HI1]DDG?9133<^;1VZ1]W_@:!A<EQE%PF
MZ\I.+6CE)Q:5/E=U?5N7OON_/4\!^%?Q.\3>,O`VL3:WX]O_``^XLM32PU.6
M'39%D>"_N(C<+$(,CR(X858/\K_:.@8*:ATOXT>+]5^"[ZI?>)+[1O%MIXKT
M30]6TO[+:$Z2)KRTMY5^>#+">*9IU8C@2H%QL.??(_AOX=B1U30-%595VN!8
MQ`,,@X/R\C(!^H%27'@'0KN25Y=$TB5YF#R%[.-B[#."<CDC)Y/K6LLUPKFY
M>Q5G).UHZ)/6.VS6_GM9-Q>$,AQZIQA]8;:BXM\T]6U92WWB]NZ;YKR49+RN
MQM/&6N?&WQ1X43XC:S:QZ3HFFZE#-'ING,PDNI]31QM:`_*HA@VY)(\L9+;F
MSK_LK^*_$OQ#\&R:SXBU)II[:231)+6-8/):ZLII+:ZN@4C5AYLT;E4)*JBH
M<`L0/2(?#]A;ZK+?QV-G'?3KLDN%A42R+Q\I;&2.!P3V%+H^A6/AZV:'3[*T
ML878NR6\*Q*6(`R0H`S@#GVKBKX^%2E*"II-\NJC%6LK2V2^)V?EMU/2PF4U
M:5>-5U9-+GNG*33YG>.C;^%77GH^B+5%%%>6>Z%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
J1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>cphi.jpg
<TEXT>
begin 644 cphi.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4`
M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@``
M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,`$PT.$`X,
M$Q`/$!44$Q8<+AX<&AH<.2DK(BY#.T=&0CM!0$I4:UI*3V500$%=?EYE;G)W
M>7=(68.,@G2+:W5W<__;`$,!%!45'!@<-QX>-W--04US<W-S<W-S<W-S<W-S
M<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<__``!$(`$`!
M(`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`.UHHHH`**S-8M-0G,4VG77E219_=G[K_7_Z]9W_``E+VD;Q:C9/
M'=H.%'"O_A^M6H.2T)<DMRSHMS/-K&J1RRNZ1R`(I.0O)Z5MUPFE^(/L>I7-
MS+!N2Z;+A3RO)Z>O6M=]4U+67,6D0F"#.&N)./R_R3]*TG2=_(B,U8Z2BJ]C
M!);6D<,LS3.@P7;J:L5@S4****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`:S*BEG8*HY))P!7$>*
MK^#4+J,VKF1(5(9@/ER3VK5UV,WNOV6GRRR+;R)N95.,D;O\*VX+"TM[8V\5
MO&(B,,N,[OKZUM%JG:3W,Y)SNCS+K7;^&-2M380V+2[+F/(*/P3R3QZU7T"S
MMO[<U(>0A$$@\O(SLY/2M+6])M+RVEG>/;,B%A(G!X'?UK6K.,GRLB$6M4:M
M%9/AF:6?187FD9VRPW,<G`-:U<LE9V-D[JX4444AA148GA,IB$J&0=4##/Y4
MY9$<D(ZL5X.#G%`#J*3/..]+0`4444`%%%-21)`2CJP!P<'/-`#J***`"BBB
M@`HHIK.J+N=@H]2<4`.HIAD10"SJ`W3)ZT^@`HIHD0N4#KO')7/-(\L:,JNZ
MJ6.%!.,_2@!]%)G/2EH`***:[J@R[!1ZDXH`=12=:6@`HHHH`JZE#=3V;)93
MB&;((8C]*R(/$$]E)]GUNW:)^TJC*M^7]*Z&N<\7WML;#[()5,^\'8.2![^E
M:T_>?*T1/34R;OQ!'-KMO?I;ML@4J%+<L.>?;K6S-XH294BTNWDN+AQ]TK@)
M]?7^7O7$5TW@Z]MK=IX9Y5C>4KLW<9QGO714IQ4;VV,83;=KDT-MK>D2R:AY
M4=QYYW3QIU'^<]LU+>^*[-]/98HI&FD4J4/&SC')KHY9HX(S),ZHB]68X`KS
MC69XKG5;B:%MT;ME3C&>*SII5'[R+G[BT9M>'O$-K8V0M+I739E@XYW=\8[5
M=2]U?6I5-BGV.T!SYKC);_'\/SKC!U%>G65[;7L(DM95=?;J/J.U56BH/F2W
M%3;EHV3]N:J:M.]MI=S-$<.L9VGT/K5RHYXEG@>%QE74J:Y5HS=G*:/H0GM[
M74!,1(7#YW=>:KP:K<Z5=:@\,"21FY.\L>G)X%7[?PQ-!>1L+AO*C<.HSP#4
MTWAZ22&]C$G_`!\3"4>W)_QKHYXWU=S'E=M$,:[\GQ%?SQIEDM-XR>#A0<4:
M?XDNKF]M8I[:-(I\@,"<Y]:MMHTC7MQ/OXFMO)QZ?*!_2HH-!DB;3R7_`./4
MMGWR<U'-"VO]:%6E<J-XIO"3-':1FV,FQ"2<_C70:C=-::=-=(H9HTW`'I7/
MR>%I=[+'.WD[]ZINX!^E;>L1O)HUS&@RYCP!2ER-JP+FL[F7IWB*XGO;>&ZM
MDCCN!\C*3UK*TG5[C3$*)`KP/<D,Q//;@?@*T-%T*;S+6ZN)7*QKE49L[3Z"
MI/\`A'9/L1@\SG[3YP/X8J^:"NA6D]0O_$=U#=W*6MK&\-O\KLQ.<_\`ZZ+S
MQ'=0M:K#:HYG@$N"3P3G].*-0\-R7%W-+#.R)/RZAL`GWJU%HSI>6$[,"+:$
M1D>O7_&IO3L.TBE?>);R"XN8X;6)D@(^9B>A_P#UU-8>(II[R2.ZMUBB$)F7
M:<G`&>:DN=">:;4&#X%T%Q[8(/\`2G0Z&RWD<KME!;>0P_#%%Z=M@M*Y2M_$
MM[)/;^9:1+#<2!5()R!G!_&KWBS_`)`4O^\O\ZHP^&9X;B%OM#,D,@9%+<`9
MSTK9UFQ;4=/:V5MI)!S]#0W!230)2LTSD[S4IKR'3X)+5H1"R@.6SNZ#TK7O
MO$=U;WDRP6R/;VS!9&8G<3[>E6;[1&N;6RC0A7M\;B,<\"J]_P"&WN+V26*9
MEBF(:1`V`35<\':XN62V(3>1P^);J]&2BV?F8]1A3BJ;ZC=ZEJ>ER7,*1KYA
M,93/()'^%;9T,&_EE+?NI+?R<>G`']*I6OAJ>"ZMY3.SK`^54MD`9SQ0IP!Q
MD06VI/IUOJ=Q#&&876"&)(Y)YJY;>))V:\%U;*GDQ>:BJ>3TP"?Q%+)X?D>U
MO(?,_P"/B82`^G)J1]&87-U<-AQ+;>7L]PH_PI.4'_7H.TD0:?XAO9[ZU@N+
M:)4N,D,N<XP<=ZF\9?\`('7_`*ZK_(UDZ-IETFJ0S-`46$$X+9SP?RJY'HUY
M?:5(ES(WF2S"7DYQP1CGZTWR*2:%[SC8?>:]=V4QM8+>.01P*^YB?0$DTZX\
M17!M;+[);HUS<J6(;.T8X_H:L2Z+))>2S;_]9:F#Z';BJ\WAR1K*U6*9HY[?
M(#J<'!.:E.&@[2-VTE:6VB:4!960,RCL>]35C0:1/'JEO>O,6,<(C;)ZX&*V
M:R=NA:N5=2MY[JS:*VN#;R,1\X].]5M-T*ST\;@OFS'K+)R?P]*TZ*?,TK!9
M7N<G?Z79+XHL[=;=1#,A9T!(!/S?ET%;M[HUC>P+#)`JA!A&08*CVIMQIC3:
MU;:@)0!"A79CKU[_`(UHU<IO2S)45KH<[%X79Y`M]?2SVT7^KCR1Q[^GX5H:
MCI=B^F21FVC"Q(S)@8VG'M6E4=Q'YUO)$#C>A7/ID5/M)-ZL?*DC"\)V-K_9
M:W)A0S.65F(SQG&*EN/#B+<K<Z9.UG)GY@OW2._'].E7M(L#IM@EJT@D*DG<
M!CJ:O4Y3?,VF)15DF)VI:**S+"BBB@`HHHH`*2EHH`3I2T44`%%%%`!1110`
>4444`%%%%`!1110`4444`%%%%`!1110`4444`?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>cphi2.jpg
<TEXT>
begin 644 cphi2.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4`
M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@``
M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,`$PT.$`X,
M$Q`/$!44$Q8<+AX<&AH<.2DK(BY#.T=&0CM!0$I4:UI*3V500$%=?EYE;G)W
M>7=(68.,@G2+:W5W<__;`$,!%!45'!@<-QX>-W--04US<W-S<W-S<W-S<W-S
M<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<__``!$(`!D!
MX`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`-Z=6M(KF506MI"XD3&=A[,/;U_/UJU/=R1M,(E7$&SY".7!]/Y#
MW%2+=6F]HE(4E]ARA`+8SC.,9J2)H;@+,JAL$@,5Y&#@]?<5=^Z$1ZG_`,@R
M[P>1"YX/3@TE_%%);;I(ED91A`PR-QX'ZXJR40@J54ANHQUI=HP!@8'05-PL
M5+M8X-*DAR`!"47)ZX4_X5#YTEND:JJ`K:,XRO((V\?3FM!T208=58`YP1FF
M3>2N&E523\H^7)/M33"Q2>]N$63)B)5(G!VG`#L01U]J>;J=6:)FCWB78&"_
M>&S=P,]1]>E231VMQ;<$*K$#*KR<'IC'J.E3^5$8U7RTV@Y`*\`^N*+H#-.H
MW#6OGKY0Q:"X(VDY.,D=?:I]6&Y+;Y58_:$&&Z'K4J26;*=HC"A,\I@%?4>H
MIS2VS)EP,(0,,AR">G&,T[Z["*=G/Y%CG=AVGVLK=(2S?=^@[>O%3Z;P+@%E
M)\]N@QZ5.GD3JS*JL&^5LKUQV.::J6S`,BH%C.X$+@#MG-)L=C*<'[%,/+39
M]N`SGG_6@=,?UJ^UXZWR0C88VE\LX'3Y-WY_AT-3$VHC!*+M9N!L^\>O`QS2
M%[3"3$1_.P4-MY)Z#_"G>_05BC+<%5M9S&I99IE^1>,#<,X_#)JS-=2`LL;Q
MDK!YH8CY7^G/3_$5)++:0.J2!%.>/DX&?4XP,U(5@W+&40E>57;G;[^U%_(9
M4>_D4.2J+AH0`PYPY`.>>O)IVK<V\.`&/VB(<_[XJR1!)*<HC.HP3MSCOC/Z
MTR$6LFX(JMD^8<KUSW'Y=:5^H%1)&AN]0D81HX6/')(Y!]J>MW(X4.J$BY\H
MY';'7KP:O&*,[LQH=PPWRCGZT@AB`XB0<Y^Z.M%T%BG'=S&9/,,>QII(\!2"
M-N2#G/\`LU$-1G,<A'EDJD3J<<'>Q![]...E:0BC!!$:`@Y'`ZTT6\`&!#&!
M[**+H+,9:S.[3I*5+12;`5&,_*&Z?C^E5+"..XM7>Y4&;S'$A/52&.![<8Q5
MYH(F()C7(;=T[^M.\J/S/,V+O_O8Y_.BX6,^.1X+N?9LV/=A&7;SS&O.:>MS
M-^[5/*4O<R1$[#T`8YZ]?EJ[Y4><^6N<YZ=_6CRHQC]VG!S]T=?6BZ"QFRZC
M,EH)1Y9=8W=ACKM./7@?K5J_C$T`4RQI_%B095L>H]*F-O"0`88R!G'RCC/6
MGE$;;E5.WID=*+KH%C/G@AN;*`R6ZK)(JHJD?<SUQ]!G\J)BP>X;_EJDT:Q>
MH4[>GL3N_6M$@'&1TZ4A52P8J-PZ''(HY@L4Q';_`-H*\<BB0%M_S\N2/NX[
MXZ^V*8)'AAU)XN620E<\X^1:NK#$K[UB0-ZA1FG*BJ254`GDX'6BX6*UHQ66
M2$[6"JK"1?XLYZ^_'ZU:I%54&%4*/0#%+28PHHHI`%4]9_Y!%W[1,1^57*1E
M5UVNH8'L1FFG9@RHP-LK.L<,3R.J#;SD?ISR:A^WSBTCGQ&02RN,'Y<$C=P>
M@QS_`#K0:-'38Z*R?W2,B@11C.(T&<]AWZT[H5@0DX.Y6!`Z#]:J:D';R%BV
M-(7.$D^X_P`IX/\`2KBHB_=4#C'`[4,JNNUU##T(S23LP,M)7:&(*V$2WW@3
M?QD=<\]L>_6K4DY>VD#0SQ+Y)8N,<<=!SG(^G:IW>+S8XG`+-DJ"N>E/S\VW
M!Z9SCBFV%C*MDG9)HL()`(FPAQ&Z9_0G!!_"B02,G[H*JO<#R8W^XWR<@^V0
M<>^*U!&@4J$4*>2,<4K*KKM900>Q%/F"Q029TT??'N5P-I+<[/FP3]!SCV%(
M\DB$VZ[57S54RKGH03SSG.0!U_B%7A+&)O('WMN[&.,=*<(T";`BA?3'%*X6
M,N=I9%C6-(O,1W4(P_=R`#K['_Z_UJ4,&CTME+X+@9<\D>6W6KQC1E"E%*CL
M1Q2E%8@LH)7D9'2CF"Q6_P"8KU/,'K_M4Q+:W6^=TC5-B'<PX)+>I^@_6K,S
MQ0XED`!)";@N3R<#]34FT<\#GK[T7"QE%3`+Q(D\M-T9RC97:3AC['&2?PJY
M:_+<7"(`(E*[0.@..0/TJ4/%'(EN`%+*6"A>,#&?YB@2Q1R>0HPP3?M"]J&[
MA8DHH!R,T5(PHHHH`****`,ZWL_-GG:;S`HN?-1>@.%`!]>H-,AAN(]IB#J[
M";.[.T$ME<CI6I15<PK&5)'<-`YB$ZYA`923G?GM^N3T/%.E2X3S1&)C%YZD
M@9+%-G.,_P"USCZUIT4<P6(+9-D<:L968*<&0\XSW]^E-U"(S0JH5B-X)9#A
ME'J/>K-%*^MQF;%;RJMN9E<J@D!V'#9)&&..Y&<^YJS;I=A(O-DC("8<%/F)
M^N<?I5FBANXK&5:V3A'CD5UC>+#`]8VST0_W?\!4DUK+(DLD@+&3RUXX954D
M[ACOR3^7TK1HI\S"Q1A@G_LV:'=B1@XC<\$YZ$^]1O!*\;+$LBPXC_=,W/#9
M8#GTX]*TJ*.8+&=-;RRH0?-\KS@R-G]Y&-O4=^OZ$TOE3"PMXW3+K,A.T=0'
MSD^^.3[UH44<P6*MW)EO)-O+(AP6*J,'VJ+R9EG<IO#M,'W9^4IQD$?3(_*K
M]%*X6,U+6?RQ$K.C'S!*Q.5;.<$>^2#^=3V\;F>.1D*".'80>Y)'\L?K5NBG
MS!8****D84444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!45W&\MLZ
MQ,5DQE2#CD=/PJ6B@"C;QW#S,)@ZQ/\`O1\YRI(QLZ]NOUJ.&*\#1JY<J1Y3
MG><X4\/U[C(_$5I457,*QG31W<<[M%O=4<2J"Y^8$8*?S/Y5-<"5+39$)'9"
MN['5AD;L'Z9JW12N%C/,.^2W^2<1`2$[B<C.,#CD?2HPMT8(]WG>9]C*MR?]
M9Q^O7FM2BGS!8S"LT?F@+.5*1'J3SD[OTQD#K3%\Q1;)/YP!FE!`+9*_,5X!
MSC&*UJS[[_D)Z?\`[[?^@TT[B:()+>X,1W"4R+;,$8$YW9^4$CJ>E32>>;Q&
M5)@!(N>N"I7G\,]OQK1HI<P[&8D$HMX<^?O,WS_.V=N6]_0BD@2XC9#MG/[N
M4$%C_>&SK[9K4HHY@L9`CG>&5"DI4O"R@@]F&[KSVJ8),C;2LI@$YR,DG:5X
M]R-U:-%',%C.BBN%E@+;F94E`9N<`L-@)^@J)(YFWN(IUD-J58DG._V/]16M
M11S!8RYHYR9&43Y$46S!;[P)W<?3%.\QS>_-YWEB?AQG!&,;>.VZM*L"V_Y&
M6;_>/\JI:W$]#2L_-CEEWB1D."&8$'.3QCV]1_2A!*;UQ(DN0^8W!^0KMQ@_
MCGCUJ[147'8RC'=-:G'G"7[,ZRC)YDXP1^.>13C%,LK,GGX$L17YF/'&_P#3
(-:=%/F"Q_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ETBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>NOTES PAYABLES. (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Oct. 26, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RevolvingLineOfCreditWithABankRMD25000000', window );">Revolving line of credit with a bank ( RMD 25,000,000)</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 3,970,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AnnualInterestRate', window );">Annual interest rate</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">7.54%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000', window );">Outstanding balance due under revolving line of credit (RMB 30,000,000)</a></td>
        <td class="nump">$ 4,761,073<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AnnualInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Annual interest rate</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AnnualInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Outstanding balance due under revolving line of credit (RMB 30,000,000)</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RevolvingLineOfCreditWithABankRMD25000000">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revolving line of credit with a bank ( RMD 25000000)</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_RevolvingLineOfCreditWithABankRMD25000000</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E6OAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Summary of stock option activity (Details)<br></strong></div>
        </th>
        <th class="th">
          <div>No. Of shares</div>
        </th>
        <th class="th">
          <div>Weighted-Average exercise price</div>
        </th>
        <th class="th">
          <div>Weighted-Average Remaining Contractual term (Years)</div>
        </th>
        <th class="th">
          <div>Aggregate Intrinsic value</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OutstandingOptions', window );">Outstanding options at Dec. 31, 2011</a></td>
        <td class="nump">310,000<span></span></td>
        <td class="nump">3.03<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_Forfeited', window );">Forfeited</a></td>
        <td class="num">(50,000)<span></span></td>
        <td class="nump">2.54<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_Expired', window );">Expired</a></td>
        <td class="num">(235,000)<span></span></td>
        <td class="nump">3.19<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ExercisableAtDecember312012', window );">Exercisable at December 31, 2012 at Dec. 31, 2012</a></td>
        <td class="nump">25,000<span></span></td>
        <td class="nump">2.54<span></span></td>
        <td class="nump">0.4<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OutstandingOptions1', window );">Outstanding options. at Dec. 31, 2012</a></td>
        <td class="nump">25,000<span></span></td>
        <td class="nump">2.54<span></span></td>
        <td class="nump">0.4<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ExercisableAtDecember312012">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercisable at December 31, 2012</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ExercisableAtDecember312012</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_Expired">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expired</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_Expired</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_Forfeited">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Forfeited</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_Forfeited</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OutstandingOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Outstanding options begining balance</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_OutstandingOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OutstandingOptions1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Outstanding options ending balance</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_OutstandingOptions1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E6AAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>2010 Stock Option Plan (Details)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Nov. 12, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NumberOfCommonShares', window );">Number of common shares</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">4,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NumberOfCommonSharesPurchasedByOptions', window );">Number of common shares purchased by options</a></td>
        <td class="nump">125,000<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_StockOptionsGranted', window );">Stock options granted</a></td>
        <td class="nump">100,000<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NumberOfCommonShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NumberOfCommonShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NumberOfCommonSharesPurchasedByOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of common shares purchased by options</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NumberOfCommonSharesPurchasedByOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_StockOptionsGranted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock options granted</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_StockOptionsGranted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>26
<FILENAME>0001010549-13-000144-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001010549-13-000144-xbrl.zip
M4$L#!!0````(`"B$;D*_4AU:B;0``&`."@`1`!P`8W!H:2TR,#$R,3(S,2YX
M;6Q55`D``PPT0E$,-$)1=7@+``$$)0X```0Y`0``[%U9<^,XDG[>C=C_P(V9
M:.]&2#;OP]75$RI?I>AJRV&KNJ>>-B`1LCA-D6H>/N;7;P(\!(J@1%*T+5=I
MCFZ9!#*_3&0F$DD0_/D?3PM7>,!!Z/C>QR/I6#P2L#?U;<>[_WCDA'[?-#6K
M+QW]XY?_^L^?_[O?%ZZQ?^:B(`Z%ON!<.BX6[F(GPAD-03V6%4D2A'Z?]'B:
M!*X`++SPU,;.QZ-Y%"U/3T[(Y>,03X_O_8<3N'$BBY+4%Z6^(AVES6>.FS=_
M?'P\GLX=#RWG*%B@N>\2?.'QU%^0GK(DY_T*?2@;/[B'1J)RXGAAA+PISC@\
MA4ZA]:.2M95._OG;E[OI'"]0O]3+=;P_>?TDR[).Z-VL::EE$0^Y/4'ABC+<
M=1K@C\/^/4++O,<,A1/:.KW!42H,J"I+QB8F28NL@Q<O^(WM*#B)GI?X!%K@
MP)GF'7RO1A_?ZZ_U(XWL-0-)0>DGR<TC,*C_^)EH[32D8W.+9P)5^"FA^O$H
M=!9+EZB'7IL'>/;Q:+J<._W,1HZ?0OM(.*%TP.I.S_TIH/"B,707IKX7X:?H
MEO3Z)LE'OTAB_]>?3];;E3K?@!B^?>'9YRCB4"&\^_`_12K2*G3+B0[@EDUN
M7[KHODQLAMP0)W0*+?/^%U[D1,^W^-X)HP!YT35:<#"=?1Y>#X2;SX/;WP;"
MY]&7\^'UU5U/&%Z?'2?$>636>)P!ZP"Y0\_&3[_BYS(3$?Q($G5=55F::]UR
MHF=Q$!!AG'"*W&\8!94*[;/:K.JV#M9?+'SO+O*G?]Y!",'A*(Z(,Y$P(L2>
MDY!/;AT56`XE150D]4BP\=19@/KATO7ET2^JHAF6IAD%V39P60-$`F=P!D#O
M_8"CNSO@!`V$6[ST@XB`!-I+Y#VS[`HTU@5.])+WOXM0!"&[Q.@;#@L2<+NM
MT?[==V,O0D$"@$/TVF=IKC5?(_8'=MU?/?_1N\,H]#UL#\,P!LFW$*WH5G+.
ME6%<PA4.5N*>1<=<ZU)!,G'?"J*7WW@DF2Z4:!JF3\]0.%\9X=>[\Z(%7@#%
MDO6)LF6(YL\G+(UF1"4.44TT-74+T8N_8N<!N2!5.(C.4!`\@YW\CMP8-Y1!
M$B7-$(O<JHEWA:,LMJEHQ`1:P+C%4PSM)BX.KW&4^DY#+>BZ9&@%/7"I[LBW
M++5NZ1"^-+T)WU$TQT$70INB85DKSM5TNV!?EEW31*4^>TA$3P?V`\F\PK%_
M%R^7KD/"7D./-25=(<Y50:XU*XYXAF&:JK2952;\T'L`06$".8<8Y?IA'.`Q
M$/_DPB16#FP_N=$'6`3@^Z=^_Z?[Z`/Y>RF$T;.+/_[T5^Q''WX;W%X-KT]%
MQQ/(_R5Q&7T0QA?_'/<'7\>CNYO!V<5ITC+K/R$_KD?C"T$6?D*+Y8>_29KX
M`9*1WR^NQZ/;;\>DT<DD:WZR)+^$,N<OP^N+_N>+X=7G,62AL$QP/PAK:``,
MPYOP\B;ALENRN4*)]D+(G[`M^#,!;$R8^:[K/T(H.5WC&!&[$QX=.YJG7%55
M2W[PE(OBR!=6_^B+QX9&U/S'\'S\^511E&.#_/EI='M^<=L_&WWY,KBYNSB=
M`GNT#'%*>`I3Z!+9=*677!*9.^$234MW5H"#`JY4/9)R;+&J2)K:!<%D3>((
MED+]-!J/1[^=_FTFDO_F$GRYN!RO+MX,SDF^FC6&`8"&@[-?KVY'7Z_/B;BC
MVU.2M8((Q(E7/2@=[5A=Z4HRS273X):*D;8H")5C&8]N2OB2;B6`I"F@2\6%
M^<2Y]U)Y)WX4^8NB'YQ$=I72C#U2F?8>%&::>Z0Q74O\<=^5)NV39Q[\\KOT
M2V6/-*;+^Z:RY&=PF&;?QCHM-4N`?)+_9%3D/=*D(>[)7,+)E),L_\OPZOIT
M"F+@X(/0)'D66'8)`<Y"896UG\.*;3'!@:!(/8&W1CA,=UU';VOO_4,_>$=S
M[SA,.X<L\EUED=M7=X^.9_N/I'@E2,M("'W7L7^DI=Y;!2#R..4P%Q^"QOXI
MK,;2\ZV"QGZL0]\P9$C=)"@:K8-_;QF*EE;W7WOPFS[XN$6/P@+!&#O(#6M'
M_O<5QUYE++Z[VO9;63`3O@+G?A[M$+UH?V:(\G76WYG'B/DO01%[DF7V3$D7
MOM<<:!]<X1`\OO<"_(\7.F2U9\EBSY0U?NBHFPM]AXG0>\B"+AW/">?8%NY]
MW_YNTZ`W#V/ONP+TW8:T77X)1L^"O$DWU>\W9WIKOSF$F1^G9G0(,KP@H_54
MS>B9BG+(KO;,V0ZQZ7LO`_WH`4E0S)XD6SU-%`\ISB&,[(6ZWEU!Z!!$Q)YB
MF#U=,P\IS![81M,"T8"\`T1>R1)F?B#X$U@QX'"*R86^$/P(S]#>/.0=,J?W
M%O28\/<_4L_0K9YEJO][R*$..=0^J.N00[W;<+)/OX0^]^IA1]2^/!1N_(9Y
MML5M[$?(%9SLS?`6&V3?643>AYT.[_P185F%&^&^VYA=L8%*[RF:U=,.&Z@.
MB=Y>:>Q]/Q+\P8-*_<I9\I,<RT+^6IT5M.FXG,*Y.N=XAH,`VV/T-`A#'+4_
M+,G2#=V05A`V4.X$`>=`(5V79;TY@N1F.ZDE2=84";+!%=L"N9:,RL*1,PI%
M4S?U38S8DY0N_>`F#J9S%.)P-+L)_"4.HN>!9Y-3PY:+YJ**Q9.:MM/O&A)'
M*8:HR$K'N(9>A+Q[!WPJ4?";G3.EL>=,#<Y_'UR?7=P)EZ-;X>;K[=GGP1W\
M-;H4AM?CP?75\-.7"V%P=W<QOCOFODB[ST=1"7Y@XT"(?`$_+9%GTV.HO)B^
M&.S/A`6VG:GCX5!8("^>H6D$\<P62,,%"O[$Y.RJR3/ME)X_V1.<2(#Q%.C;
M/'#;@6A(QR^`WB%,E=$<KMEXB>$?8'<NFO@!@HCI`!="V">GK86T^$WH+E/[
MR.'`0@GN+6(7A<?"P(WF?GP_%^XNSP<"6BX#'Z8;`&`+GA\)$XQ!Q$F$0`8[
M(PFTU@D)**+,;!0!BO0TKAQTC_[I3_Z%IY'S@$OW!6<%-U4#T6C"ER+K)\@`
M0XFS3PK[I&=1`O@7^`<E/?7)J;6@ZF-AS'`(Z(%T.!FRR(E<3)A&C[ZP!"D\
M@!7-0:P`N^245+A58CU-`IC[#`.R`0(0*;PL3E[A3*`DM.V<X1R!=HC>P9B<
M@`!^#UYP$SA^X@+$9,E9JM1F.290L-7H>4G4"=JC8N>C!`F("YJ!F$?,/P!S
M0V#!U+1M_(!=/XFWP,&&YL$"3),27QL>:E&91RXPF#D])@X&Q8[!#'TO,\-[
M[)%SDG-?388&D;/\IH@V3(6AHTNH,C3RP5[$(7$7<&L;9R[-M`/7=UPG>DYL
MZM%QW?1N@CTWA*0'^"68#9$]=J,>_,KTR"B-\'5LG%HIZSJ3^#GD:R3P%\5Q
M>,XUQ%P"E\G53X[`"\DA>P4.#A7<)8=VYFI.O)5<61,]5U'.GBCR^#U8]B#3
M=X5GYS&V8%2H:%(H&^J(%*A\]X'$:6:."".\3$>1]J.CFPX`N1Y@&GUF)'(^
M@R]`U![.N.,+`Y=%>SN+R$L?G%%XG&.O;.P,LC08AOGXI!.XJG\(F1$D8RU,
M71AGTCF,8ALFK,>Y`_X)S!\P6$^FL;6`G@2`8M=$Z.30QC!QBCB,J?P1^A,G
M!N.#>Q/[0A`FW%GBBT0E5!4"G1N3P`%.,XMPP./#3@*]U.&(:X%H`1;">+)P
MHBBQ]E48ISQY=LR&!C)S.2ZVDWDY-VX!,H.%#UXS)9D9G=.I>%2L"8X>R;R*
MR>**QDWR@UQ9@)O/J5#+`),%*461X*MT*Q;.RA&+%GLL?%WF?3(?K;"%WDH'
M#CGS.2RJ80I)J3,C#'$>/+*X,$5>'M8H<DQDKF95B'-)/"8VG'A7;\WIX`Y,
MBY!")`,UP:L9W$E%>W+(LWUB/C"+%WQF%7P**<JZ!^7SU;L(3U\].[5W,@]6
MY5W%!#'`-8+[*I9SXWCJV:5\J!C@A=^0A^XQG:S!L!U`D(27,#DJ'=!B!(%C
M?0P(*\!X#[\#88(`'X64Y=F`F(1>B&@DS^5+"`LG0HT(`-/Q7W%B%'&NKM4P
MDU"*RG$ZI%E8GG2F\SD1"V9CL$,R\T+>F=UQ`NHJ=-,)G0#@K@/T(.#`R/0`
MO.#,UJ?924#$3T-NAJBWWHJ=C,L")*&")@)4:;/8RZ-8-I[9V;@Q^"):^+$7
M99>6Z'E!\TZ:M*3=&-[)0-,038>&"K+N[RDZ>IT-192''S)<R.!Y='52&O,\
M>H;D<PHK")P`@3,Q:6VJ5S3=4(!V61!(YT)J!9Y06D&L8M!T"M8%S5R8I8HZ
M66:I+>'"#C'/+Q@K2?V,T"53,<B0+MB3_#%;LA-*3KYHIZ9-;/(]Q)ZQ3R-I
M#QPE'T6R;)TA.AV"RM+HG.B#IR]@0[L4<E<R#3H>H4B.=88``$H$DT"/1*/$
MM[SGG!^US05ZIDQ9EF%,%@SYW/?9?X2%0T!M)<")=Q-EQP%*%H]IKK1F&6E*
MDA'ESKU@AZEG9Q+8/DZB!Q?,*A7`1$C@[D1A[LZ0^R1F';+2,#;/R^"I%M-F
MN?523TQ#?%.?>P_F-^"LJ8NQX)'4!B:N<X_2A`%T4UDL*68/?]=[JJ'W1%$4
M8I(VI;DCLV9\0!`88`Y;YFZ\*F8P(;G2]+FUF)6"-M4%*XM\A8)M5CV\<9$7
ML27$:]RX/"XJDFDQ7ZW81+L;$)RO*2B*:DI&"Q#K^H+[%T]3-R8!_\KW[639
MT4@CLBK)A>]XU.'1+:BRAA31E`N/,1J#2IHU?8R@*[)B69*R7MUO2II3(]=T
MQ1*!]F;2,'M#3A/>H&?R-&D<P+S=[HF(;*J2J3-?*ME`NA,(G$&4)%DQM580
M@AC;7QPT(74F"&\M=2#*TAI_/MT.N'-&W%1%ULGK<1^C)YPIJ*74JJR;[`,X
M#LF=6/+=5=&4^BS7+(%^4Z7EDS_14LW"X[AJTIU`X'P22)95U6R.X"P.(T@'
M@VQJ;*D`2]4LD_T.$Y_LSJQYS_U,534:LCZ/\=B_34K$-RAH[]V2HJF:SCA8
M->4N`'#&72=!O3'_:S_:T<,AGY-$@^',(;D32XZ'6XIDJ%I]ECL';TG594,Q
M&2FW1,[=`[9B&*;%3AA;.#([&YB6U[XW;;=U0[,*YK2%>G=0.*J034A66F)A
M6C0><T.&W%CGCD`K'KQ1MD2CL`2HXG$3I%+3;S2V^6B=R*;X)6([,2L+UH`9
M\^G)-F*IBF:RG^);H]:>%><K@Y!6U&4UL&V'K$R1>X,<>^B=H:5#=E(W3)\4
MS1)ED;&/"KH[\RY+*RN02&A*0]ZW.-G2<($"4N8.(?^(R2H<IB'P6V?J-,^I
MP/M5168BX78>74+B>*VHRJ8._VD-B;F=9&3^8AG@.?9"YP$//5*8^^*'9&$Y
MFD&8:ZHRS8)D2"MF@4WXO1A6CBY5`T97-[K!2IV1?&,;!R&I6T3/C8.^J4EZ
M(9,KT]R%)4\#LFHJHE6?)3-'##Q[=YG+A89M'+J#4ZLXT0A._I;RI1^<^_$D
MFL5NM@I:?2JS9;*KRI;%9IZ-F+T03$Z"K"FZ*NX$DY9)-_0:>>O?'FVJ2LLT
MLP]]-N+S$O`X*C0MN3T\3BP[QQ#%I@Y]A`>_DZHW6/-@0;Y7_6]ZO;+TVE2W
ML%A1V#595SA>7SC.R"B6),GJ"PM'#L.,\!>R"6*]W,OP8^DV3>TL%1883`K1
MG.-+`N;5U53)9%/1'0$7UP4W*!@%Y)OMV*;)]`T.Z(?H&9"AG5VLL=@Y%D6I
M:@U2Q>NEX'&61QW#H_?#01S-_<#Y-]W0D,)*[FQ7F";2_U1A6F?0(1;.2QL=
M8QF2S58M=+(%04*V(^X-EM"-N(_B*`3?)(^F.E<`0[M+'(U5486#6:"_;'BI
MP>A%@&T-+#L`VSVD6"4_WD"^*QAEE70(HVT@417-L#3-V`"!X\XMV7/K5G('
M['<*)3544,.-.X@E-911!>06/V`OWKB4^,:;6E5--$358JM%":'FU#D/?B1)
MUPUE&_4S/XQ&L_160P$44]=%4V*?K;'46O+AS/NR9)AZL9I;Q2=_F_6/`)+0
M<_]Q4SK+$THR=*OPJ+),<1>&&R>Q+:RN`C\,89DRVUB9Y`JEBH8N:\P,P-!J
MQ8-3%S9AY2YJUG8>=]AUP8<NGI;8"QL;G0:.RMI<D5I;1IQUC:I8FBS78G25
MO$9"5I3V@GPN(0H0>?&NI8B*I"@BLP3<0KXS*!PE&)*NL"7()E!NR*:\$-9W
MG`))0Y68@$.2V72OFG0W&'CE?5-D'[S6QI#M_0*EK2V(AXLE<H(MQ0[NW&$I
MHL5@J<.B6TP;`UEC.*,E)G:4>U=C^P"7D67&3DL$=V!7%M60=55D:QY\=J1*
M>.4_X,`C`M_%D]"QGY-'%8T#N&291E)WK*"X$T=>64?2#7D[QY(&5H]B&MNT
MJ(F2Q%'JBN1.+#ESEBS*FL&UFPJ>9(H.(Z**I,&0OC0>-O5?U5+74@P>T=TY
M\TQ7-!MS3BZVF\WZBF@JAL;R+)!KS:HL6U_6-/"3>JRND..1X1UY=\C%H]DY
M#IP'.I<U-5PV\%43[80Y9QFKJ++>`L&U[_E%6V\]O)`I,5Y;2;@#]IQMZJ8N
M&V)3[BOGO@S\Q1GP<+P8>J3>[WOA)SSS@_2Q,MTH>O$$F0Y]:PD%S\,(+^C.
M(O(.@D_3PI:!0--%J;!1Y06A[84*>$'8D"2+33)?5P?0/[613Y#<-E]<]2U3
MH0\%MY#=F34GX"FJ*BN:UHQWLB1K,4.K.JR.V17>BE(;!IP4VY)U2U?EK1RJ
M=H!`*HZ=>R]Y8CU]'I-SQM`T?=I'_W*I`0WL?\7)O)?M%[F!..E#MCH-,`KQ
M.4[^W31-DPU59'<HO!;._5,.[_&-*8KL[/PFRN'PJ[%%B1NZ34LRM&+]N(IT
M)Q`XH5-55`M,KCF&;$-:5N[_A$)G6N/A`C?_.6:S=B[ECGCS'FRPB71SWN>.
M&T=L\;Q#R5/:G?%O*CV/?^-*N?A_TV0[)VD7<LKFJJ@6RN:;:^5M^-,Z?$CJ
M\%SVV@OR1OG6UB5RH$NJ"\ZF6%F354-_02A!NI44IZ-<KH'`ZMD0V1TPW:MC
MM7^#OL<[9:.-0Z,-Y[!'\K*7]8*HDH-$.<<@&I9B2$9]A1`32YYXG<?D6*UD
M.DDZ7>/'87(XRT8\X*6;'8:)U?7XO0S$#3ZU'PCK>AYY7"/M!>*M#KHGBFWA
MP_N!O,+/VUL`J6T.TS-&1C/:<1"2#`J4L;85KI6O2[)&-QALY=,9F@UN+9%7
M)5X-25WWA96_J!NO"*R.E[Z>EMKYXJOAJYQ9+5BI-\$!:Y!\;3>>XV^@?5F4
MI,W+G:T3Z0;*NW+>/#^^'..Z?O.B(+;ZR*I.\X*::.\;+P.HRAD:Z8)7VUBO
M9G3@%778=(IIN[^\-J2&GO3:\.K.0Z^NMA9NEU?VW@)PA5NVP]1Z%;K%+<N[
M"SM>!6]VP;4WE#OG7;],LO[N<.=0ML]=Y;=TN]='"R<JO_':.:RJ&8SSINEV
MUI_(H<?\=))7/M^R4EK;BLWGT`&(30NDUP!0>UVD2KK\"G@:%2U>2B<[5B1>
M"%:EMTA&S9%)IYX9=LA7*$:SY$GV/?V"P>\X)+\31]NV$MOB/7U-S.L,M?AU
MCFZ#6_6UMT16U]_>%&2#7/`---A^'?8F>"O<MA4D_FI.WF6FV[A$E7?EW+9L
ML2OC3LH6NX+8ZD;Y_I475$3758M=`56X0R-5U%D^;:Z>U'.*6GRZ1=5-W:);
M4"]0N>@68)>UBXY5UV;AE6W:>AO(56EF.U2M5X=;/+3\GF;'J]/-OKAVFEOG
MO.L7,-8/7NL<2HT"1NGDL^[UT<:/2L>+=0ZK<DE6/IV+R]K&SND%)'W1\TT\
M<9WII>NC%M^VY)+AOQ7:_/1W10<;`W$XKX663UJOR87W>H]BF+IF;N!2_T3\
MIA):,GFIT&ARZ'Z7B#C:T"5+5<EYFPT1Y:\=9!E4%[NJ"\1:LJFSM[J:#WM>
MTMHQ28U?7--EH_BMWTK2G4#@?0[74$WV1=YM$(@-T(?9#2M&E:6B:H*[\.,-
ML2Z92BU^_]_>NS8W;B2)HI]W(_8_8&,]XW8$1!,`G]T>1ZC5:EMSNJ5>23T^
MOE].%($BB6D0X.`AM>;7W\RLPHL$7Q(I`E+MK&V*!*JRLO)=69GYM2"\,+3[
MA:?E,1XS=,6-AO0^TYH)WC/G`Q_%3[JT01>*):HJQWO";*NO#J^?+9/$V1W9
M9:DCBFMYU(1M1V)<*FRPW31[!VU]"81'`)46?M[3=9Z.U3:+:?T;AM\;*%6W
M[\U!19OT+>\7E>Y`7/CIU720>#O40*S$D-$>#JRB1-UIM@/!62%+#`,O9I7[
MQNP/T-1@6E_>NYK$^GCON+L.KL+H>X*CZK[LT.P:'6L_<%1U3MG],FFO7;S.
MLMTL^P:LBI2&YL`L&FG[@FRAW<J."#,[O5*3IFVFV"],%3?,NX/^8"U-/1:F
M8L>672FK-["L[C:8*DZR9[`J[L0-\=A_OU"1&%L@QAVQU>^LE9E5,^P;J*JF
M"):Y=@,?`=9B,YB=#?RNV3;6P;0XP3[AJ2`G`^S:P:/A`8?PC$73+Z*9GO/^
MX6N$UD96$^/4!EO\,6+*ZG6L0?'0?/N9#@%@58DQJV\5KT[M"&!VBI*7TWC/
M_&\\O`%ZY//X,<15/!9:-^R>`*A0>@/3Z`QW@2+%WA?9%?,V.+6I6>UCBCQ7
MFY[='FB7POWPK6<Z!(!5-_*!E(HM[1X)X`KZ$WOP%%8\Z0P'H*&MC:1>,=4A
M(*Q`8;=G=@?#WI,A_()MS;E#122*K:!V589#\'4*^%HU[-/GWE#A=L=I"UV^
M'C#BL&M8<FB52ERM&WH_,%291]U>?P4.UL*P@F(^NCX(JZ>PCV$.>J5"8]O/
M=`@`-Z/LD?"=C\?<CJ_&Y]_M*?,G_!IP?>7C2""R\#\HMNZ8QW>OY6=A'X_"
MK?4=9CH,B%6]1HP2$A\-8_4C>ZDU<F(:1K$+V2Y3'0;&JH8C@WYO<#`83X&T
MP_`!J/A1;;O:W7:IJ?!6D^P9K'8%>PS-]F#CQAX6K`IUT#:'_?;&O5P'5EJ#
M";N$[1KG&`XZ5BFFD`_UN#FJBJD,VD9%\;B*.;*R4_C;^L/7RM48UF#0+8=(
M%D9\RH05I-ZUS.[0W#@AG7Z6'>CR(6AJO#[!A`?9VK?2%CJ[SG4@**NZ;UE&
M=V]0%GHI!9X'JH0[?[CQ],DN8L?J=@;IO>Z=)SL0F!5%^@P,=[>?"F:6H9"B
M?S](-$%%#=KIY?@MY]@O4!M0MC-0U1D,5:2*W+\7+!K=3GN0'G;O8_[G6TRE
MV_5,R\C/.*.];879I[ZX3YSTX(#OB/;=@#XC.SVZ\-/!;H.;9#[W7![N3-EM
MH]-/4Q+6C?OTR2M+VAI&W]AA\B+V1.P)2':O&OP$:['W^A6[M>5\!X-U*Y+:
M,Y`[I)Y5'WF:QJ!M=;>"<ZNLN*?"6!61,X9@LCX!QFW2.\"Y]A),U4RKQ^^(
MR<6:^#O-=2`H'YWKLA[`JW#"?)FR=A;X4>"Y3IK.]@5\%AB2_KP:RS@/\ZC%
M$T6B/[B1[051$O);`/2]%]C?EG#[ZU^]^-U_GYSPR?>3D[].XG?X]UR+X@>/
M_^VO_TJ"^-WGT^O?+B[?MEU?PW^,]CQ^I]V>_]_;D].OMU<W7T[/SM^*)]/W
M1_CA\NKV7#.TO[+9_-W_&-WV.^WJ^K?3RXO_[_3VXNI2.[W\H-U<_'9Y\?'B
M[/3R5CL].[OZ>GE[<?F;]N7JT\79Q?D-#O7S*!WTYSE^TI;A^W1Q>7[R^_G%
M;[_?OO6#$+;@G;8`,X!<@!`A\D?1?,_#I@LO[IG&?$>[9'@-30O&6E[7.%];
M$4-G4]A%[<N4P73:[X&'=!'I&CAQ+5UCVB6_8PZ#/0SG02C'CW#<#V!BST8\
MU"Q#U_!&CZX%]WX$>]7^"\WK^P]:?JRC?7)G+A:C?(,__(1#OP_=V(VFVC_<
M<`(KNX@\@#PJ3J5K\93%&OP(J_'+X__.D/JTW[DWCP"HS]QQ;>:)E>$_VGLW
MB+D]]0,OF#QH9P$LYU,,\\LW"`1,/6<`9R#P1\EE#JPIGG+-8_>T4/S\A0=S
MC_^5S8/H7:1=\SFE9N.O`GUOZ*'KLY]:Z_!).^."A(RHTX'+**V&P3Z%,OM*
MBP-MRD/N$I9QT#,!82NG(*T)E'GE5Q'(:MR@D(B2V0RC[K`O(=T#R$ENQL,)
MC#0.Q-;,$_@I(O*FF"GF]^/W$<HA_+;\]C@,9@`.;"CB&E`LB1J&P?I2,7Z%
MK\<\G$6T20"-N+-!%`!D=CH).4DX^AF/U_"'SP(LAZ#.UFOVQ7J+>W8[Y:L6
M=0\[S>;S,,#<QM&#%A5:36M3@20";\;^&838VUH295"XW2#NMVB1N,<:%+!O
M&BDT#2`;1).\CU24'1>^DT1Q")I&.V,Q`X9.>`X!,9^4:)W^N_(3\-7@W4_:
M/P,7;^)JKFAG!V@FYD)Z3!_K`6=_%EV'",7`>;!#-J<=QZ<OF;C%`[B]XUXP
MS\CA&@O&S^@%&!^W]HWD7CQ%BF+M#K82OW;%MP^<A;0GZ0^ZQND0P+WCVM^9
MGS"`P&J+??M)LST&HXY=@/L.1$:01$#?`B$\^GF41*[/(^PS`TM$0@9*U1P7
M!J0NWC:`,*$4N[?:&_<GC0,-)B&;P&C(3F.);3?#]CMX#)[#Z&3H8N0$V:/J
M,5PZ/`K/`O%.W1&)=^*UY:=;N*T:BEH)^D,&N.8'`"5V@1$;0_*8*!PX7*PF
M7P-J!/Z@D6TT@F4B4SHKT`&*#U1.O'*A+>U4BQ_FI#:6?T5M`[LS=><9*F@+
M?2&!2(;9/(GI]7118H=!9;&J$3D&?>>A"^M:H-F/%^=%:@4VAO4A7J;LCM.$
M]R`)@.7#DA1`7<)%OWM7!I0C@EL@,H.!EJ*Y0FS`7!H\R$"#18!C;1:@4`0Q
M"B2GC4*PZ*8H@U".X`X[R!#N*(GQ;R)`+B;'1YU((`2%\9A>Q<6)MW6`V86Q
M7+'#.+7-A-`N*+8B]Z5[UPA1E1H>,^#7,;/1W!((F['P&[I!$^QF!D8"?D>X
M@EU9(!O@&R>QX5D0%_<<MAS^.W(#>\IGY=^!:&!8%P08&@A!1!<(Q71SNL:`
MVB5FKH<Z`XQN4DC`.T$RF8*:T*1YTB(])#$/_`/./3:%D4NIVHIT]\!B^2<(
M*)R>^+.*-Q!,'ME`+"4[*I/'+6$3,I&JXF26'.FR;$`WM^E(EE0`)X0"RER8
M@E1>JB[1$&0/FME%V=GN(A<`TX4/0C0"B9\+;J%+KB`@"WK]WHV![A,@6#'\
MG(5T0KXPI$!AG+<-6-+?DKA1=Z#">@^$P9*"Q4JGY>#CXLA_3WRNH65$T.)V
MIFL/*8+-A>8YXP#+V+6E=7-*LPFII9VGK(QF`/QXG@F92*RI0I]*(084@4"0
MY<1F($W90V:B9@0`=BZUSN%XQ$^G^O3['Q^OSK4W?P#B@2C3*:Y(].00_$06
M61)E2Q7&"&"Q"1Q>Y)4IRPQ#[!<#N$5Z$I1,K'O"*%`(RY])3P3I,_&8>!+$
M*.IZ(*L@C,?@4@>X5W_`AO!0>&QHBZ#&H]?Q8R-PE'F@I4@!+0C[(Y#Y7`P:
M5/N@B&G`G\`U4M@XC2P(DYY""T(7CCCW4<[@;5U4_/1>Z&#02)`[$T=`.`K0
M(`PRQ\L=$]%:TD/Q(_=),L%7G^P6"F$0N*<S%-N,UH#^`O^.8BT2;Y2?=H#Z
M61BUEA=@9^A`\Z-J-0":ESA"N;.T:23.&60.^X*JS'CSGKCN1"CZHB\)%@TH
MD0A8D:0%<7HL+EB3P&>>B)R319N+L")J02?,`%R)(+NXJXT@R`IU,4Y\6UKN
MMBQRD%KB*=-=<Q]6/7);5>HFE(V%$6L\[>E(GJ0LE4"X`BZO)`Z-"?4+&$:K
M&T80:3Y:B-(\\V@I307V3X10<2JO<$EB838Y9'DHEM$+1RH2'X%1\`(J,H.<
M`6\[1FA(>@%9R:1DT['QP2H,5A$PPB2).&7$]%J_1O?ZM=+%?DW<["]8A2+\
M$OAD;(]+?F\^N;1O4[@),0)PH/B(9$6V@)2:04\%!2)F^;8+N,C81>Q444:&
M0[R"+^-/$5D##UF<H*#]%[$@D!XE7DS;D3/SGKDGE;L+;'2`T&4ZTS5/'5%;
M"/E\PA-M45?.\!J4#68+WM(-%]Z,4D26I*243F#0<1XCB2\&D`Q\#5XA9UN.
ML!1D(ALTU38DF"->`<"4.6#72K<[-8)*X!0HO;2/R#K@QTRUL1?<1\3`N&C!
M7E$Z/7<:(2VSS3W-M288E"[&X8KQ8K'!0NV*S0><K%!KZ18A^^Q7(X><[*U(
M1L-\$*<S*3R*:O)-[E=_SAXJNM=`.S/VC:,7+%8J='T4);.YI$_RX05QY&(4
M)>],*&J,"JX0U3):Y&0G(?2TG=6#6_FBF,J11C[)IPH,Z]D,54!)7165E95#
MO2HJ%0+:#."\PA2IU(+-\AP90)+"E?S[#%O-HFS,(10&-GXH9!.N.`Y)'R<>
MYX4LW]1@2R,M8"\Q0BL^[0?^R=(/(^9_`V4T#R(7]VT&JNY!A@<RDT]L9S2%
M33G!^#.]Q,.B]F6%G(=YFJ0C6&N&QSR"?(ADT'&%:>*IT/`82VG$<4&V6^+^
M;-9$/<_C(C2!=1O<DY)`L9OV1<\>7^%<T)"9B1T6KGRC\K99&+K"I@I"=^+Z
M%,Z["\#MS3D+,8GA`U8"P$D!2`>7CD#Z4%3]E)S6LZ6Q-*+]1%L"B(6".`[R
ML<OO27!()>KZX$*Z3D*VBKAG5_8;`#S)HE(^4USECH2LQD'^@$UD%T\VA'Q+
M!4,6CQ-G7-D<"%TY;B1@(_M-/I2]!#Z9&VM3%R.`&&#"`"2(H9C+4PKZO:5=
M+(JW#*HTJIF.C'$Q<68#J$&!A::N+F45Q2+0V=3<O*^\6+@+R"')^I!)^[F\
M+`4<YZ0HD%9$OJWW)/Q&/-4U:))C&.[.30/X9-FP"5JC<155I6/2JF,1KJ8-
MA_E<AX+<B>^YW[@(YHWP%YFB"(@A8U,>YLQ#M#%M7@S7($$5*1A&$.B%@1X"
MM/M]<;[0TL[R'91N7_'`"`?*([_I6P0I84-&S2F4/0DY8#T4;L8]V/,9]:;$
MLY$O3I?-.5-'0WH5:V8V]0]66S>LCCYL#X4VBA@M'#5T8)/9[E2M9([$@OBI
MFA=?SFV#/!(J-HJV`\%HEJ;+[O7"HO.4,)*;Z2^$P)0P5FG`U=3G1ADWL<)D
M43894172BIN&I^%G&<K,7R$H<@ZGTQD\>)MBA%R&O%O::>4,1*#T!XV]0$%S
M>1&.B%18B1DP=,PN@JJ%P;,XZP)0Q7E2;E])KF*^I370(.!1-,P7R#*""QY>
M@3[RGX$<R"[-`A(H-T)A[4:H3C4?+!T0'I[[;T+3'5[;T,GMI\:D%"G,(B/T
MT@BCAK`_B[K6S68-1H!2'MD<?T+77-X^*VXZF5@TF\@&R"#&YMWXDH"4)`:I
M&YAZ\;@^5W=V,!')(<Q?!0=Z?>$=S?:#H?=[0WTXZ!`#_-#.@CPHER*,SA2S
M!3+'%1]&+Y>TVUR<!GL/S2(=O)>3V1^?`G]R\HF82X2U5@=_;7FO1^P9&;,>
MOBT*/J4.$W$PVAY2.16T/O/]A)Q)^!KI`*1YJ*$O%`N'722WDG?JAG8RBZ0]
MC585':N02H@K0)FQ!SH!(YN`CJE),VA_(+71>1$:7G=D>J`Z$D?4&?4`=>+!
MF?!9$Q^]0I0>W"D&$80=(#SB[!"=7LC/2PD)60B8)D1;$`8D_X)P?B>/W$(^
M`XF%B_#<<7D$,KXD4&0";<*`3(`1T].Y>QD;W-$!(N0I^)C8^1E8ZB^B'VJC
M_2S!6!P^!5H"Q>G(N0))^7B+Z)(3RO45>9??$4%R@;0*DJHP2\2I-UJ;,RR5
MFN,E0T=JDDM;U<W2*]-AR685U$E2PUD4(CGA8C"3I$9W:.GM8;<D+%;)BI9V
M&10'P2/(P@P%=W_-*$91X-V`XX@7O[5.LP1.FEQ-2,[2JZL%3>E9GN5\DY+.
MU!AI`K`-T9GW2?N([4-<2_MPRL*)H$(98,'0.]BKPA05*0#_%.()#X7S:+DL
M_(M[M!R'Q^PML&RE47R"Y(6F?@PDE(%9##07(I*%_19!'22H@F!HUI9>R^.6
M:T'0JT\-TP?)8\J<*RQM7#0&BE%IP$Z4,#J-D,?9F7@+0]00>28`22II#>H@
M#E!LA-GI0&;AX:BI%Z++DW1T3\#[$-;)V/V.ADZ82134'KH\2Y:.AO!328*R
M*,`G'B@:2>[GAW1J)^`B%X/FTS"BZA4!24_P,(MB+JWCTB)"-_HF-&LD`(]E
M%D2X_+0`L!!GD!$H>H^F"4:BE+1>^5CF,DO(/#:/\%DIW(J;$E!F26E/<E44
MNF2_:V@0B10XZ8YL,ZE`!S!)A&\*S;"P/2+W+",>H5DJ]TPB'(,I62S7=LF#
M\%*ME.Y_87JPY0+OKFG'`6=DOX]3%EOI*8JGLJ"SE$^@`,&>QXAGZGWI@!'?
M\2@&1.)3QCW%>5Q^J!I%`=;.3<.;,LZ?YE=)S9RS8N8L-@JYU^`KL-`68>9"
M+NDJ*5=XVBEDGA+6'%<FG@GO-@@=,FYRE*;YBD(OP%_B^)7"4B1(6JMG0%TH
MC1GDDW0W%^V+S2Y-Z]`H?<Y3T$PCIW57,1M\C6^3RCJ2[S+U+8VB4*P>I#U*
M%$JR%('9N)A)%]()%;R1)O_RV=P+'C@O6@<C"<L<82E<9Q@]"*DHPJP3-+9]
M,DB$-"Q\L3`$G89QZ4TL31.,/'>2)ZE0A/F[2_62:-/'"?&K>-/)(%[,:"D;
MZQD2,.IG6I8^Z/2$"VWT>GJ[;XA@THHU/\G)ULY*&R!$.69K"5QLM/J:)8!.
MG3M,**3L"93A*XBW^)@0!3(="E<O+:P,`:6==%R')`;]2L?C;&FLW?:K60C&
MU#>1^/O!]8B>SV7##13$:825VDB4#MG%>[SX;/%BASP;$+&S$:+YSJ5@/H;9
M1'I-Z@O?<W<RA<=.TN":GQ!B*397NBI2.!-8\B-:&?PEF`0P"Z=8P!@3,N+D
MJ7F@S0,\`7$I+(/W+LB*<G!`?*X$QN+VQB*JZCKQ5.Y%9VB)#U7W!%F".9;9
MOT[:K7X7;PS^<?'A]O>W5I^N#[Z_NOYP?GUR=O7IT^F7F_.W:'ZC52J'M;GG
MS?%DR)_(P=N%7Z(YLY=^R<$-2U!)D@$_'<%8?-8IK<OJ&!7KDK"^O[J]O?K\
M]G_&;?Q?MH1/YQ]O\R^_G'[X<''Y6_HP4"4\>'KV?WZ[OOIZ^0'7>W7]EDQ]
MT>$D?X/&Z;8Z.:K,;F]>>.":UB&?**\J`^;VZLL2@.*])0CQ40!/KO<./.&)
M+Q<\"F(PY\NL]'/LK,*:T373S0EP;])AJFCD6+@TC$X]<%DAV<15VD\7OUV^
MM>E6RCMM%V&G%:<3`U1(P8]2PO])$OX<)7R5=5;8:O$Q5'RU-UJ(@_DS,-6]
MZSO!/5[RUHQYK%$2G>*PPW-8T5Y2K%5CUNIOQMB1>*AKM;JOFXG0S]C`/%5;
M:M:(!XS6H":;N(D/!K7E@T&K5Q,<'I$1#*5%ZK?YNX8A+K-HP-;"3.FG9]F9
M/.[T@];1>T9?[W6'FE(Y2N6\+-HVAKK9&^J]CEE-W$J--&!#13!Z*9"\,GR\
M3V7S?#M6:_U2,/M"W(8G6'WT?CY9Q]*[_:'>[?:5^CFV^GE&8J^UQCDHM7>`
MV@?#%<:6TD<'#8[M01F=RXO:X_P`,>*VO/OX5JF>PX4NE=3?.=BK1/Y:G"EI
M6P=I2]KVXO+#^25`10D2Z^3O'Y0@+3.%E*0]FAXL9"[5\I-V4OFM\C&4ME':
M1FF;+;7-U3PO6*^.+Y3F49KGV%)4G:P<G^V>$+D:MEZ@<ANV&G&.DJ;0'^<D
MI<YZ[T@;J$Y5GJ1WGF/77KCF>8F$OX<#EG;+[*:+>S%J2BRJ_FJJXNY9E%U0
M>_G*J"G;5$BS.:`OU6X9QLM58<^RUR];A2EVV<Q"G8Y2A@TEF]77GI4ZK-5&
M*76HU*%2AX=D%VT_/+25.A0?L?;#`:.G>QCV2UK98B&&EY5*6NP((ZIV9)51
MG355-2)9OES6T1`%R?-Z8@SF/<ERX!C64<$ZN<4<.%5!H]Y&4"WRDE4%C0;<
MR%05-%X17ZDB&L=A,E5$HSG<U6RG^F7SD:JCH=SE!ETQ4W4T7K0BV8.7G]YY
M$+6H^7=LZ(XU8;%VN.C98+7:;:QT"1\&[</$B%_#)8F#!KH>$>XUNFV]#3NK
M=-B1==BKN+A0,^K?G2.4,FL`2<@K%;(CL[^@SDB;F:UN1VJS3O_5G7@V9B?W
MSMQ*V]5#VRF/K8[<81E/5WW62[Q^8=7G^L5NMPMO@YAYKT6KU6B7#N:OF>V7
MKL&>8Q=?N`)[!8Q0R1R=WG;ZJRFY-PT;-@T*GX7<<6/M&GLP%H+#.&M%&V0V
M$RW&L;=61;OQQ?2B$?.H`6(TY=1P&[N'88>L0JNMO[)Y$+VCQG`!=I9$1\\6
M,%%?2-<7C0PQ0PE^PKZV8Q<;H&*6DVAK2UUG1<>^Q9\$Y!K3(F`.=^S:3#2H
MJYJJW"H*W,PQX!'[GTX"Z@XEGI2=>],.8YS9TZSG8[J6'`H[P$YXV.I4N\!&
M==B2%]NK9CW$1;\I)TA&\3CQ<J1BCR;1Q#E_4B*5328AGV!G9,J^PK0N;&3,
M$>^?F<]$M]`,KZ([,<+;B%Y5MPM=.*D+.C9;A@='S/^F.9S:QU*OS!D+7>Q)
M"C(=&^5JP3VV6,7'L*FR+1HL"ZQ]N3YK:;^[L%$A4('G/>CY2/`(_"S?*W3H
MQ$)N7',2GO70I%GFH#_L!VR,.P^#&'NU88\J,5@01I)W.KUWV(&9`\FG7>UP
M$GAEEG@3T=97\_F]]AZF#9-Y#$-^8O<(S&DR`8I"\Z&GRWP[3*K[>^+S'.O4
MB:S=UV7C1&Q21Z15:#::MC)S9W./B")+])MQ%E%_QO2140X$_)QA`\A6H$\T
M$J?^IX5'/78OFZ_YC#IDXW`"C3G:]3*[I\B)<OQC*_,1QVUDVM2=(",7>\(V
M@FXS@7HA]UR[1EI!N9J+U34M&$DHY=U::?U`W=28CMJN4ZMX_"LE*M&`,=U_
MQ"&3+<Y02,CFO=0%=<X>J#$ARJNT&Z+#1U+,W+F%AT7Q0IQ3=$K$QV#&*`X3
MT8T1XW0%EFK4UEQS/!L%@7'J^R!FL2?\J1"XN.(;O.7.0F=-R\R/F6"O>D][
M'\!_M#<IC????3R]>9_^-7CW$W6;6S&I]G7N(,$4WCZ]^5I\&8]O3]I=7?LB
MM&C&S$A%(9]RGQI(7U"%_90L0@["@$=IQUH?6"OKM6J7WI-]^MQ(DUI:R$X,
MR0*H<8ES<P5'$C%KW`DO)V(9LJ-H)+M2EP%.,X\#GTMCHAH4F-HEM<YD:^,$
MVXQF4ZY\,:!%QO<!D#.8Z0C/*!']E(&\29:N6@&\/$]MC=1:605<IA%28$"Y
MV-^F@>?PDA9`5,0/>8=J[KG8NSE.NU,6)#8A)\<BY6WG"H#1`W]G?L+`J)&M
M*$7#XL7FU9DE5D(=8@"='](^F_&(G<E9&,LMBWCY_4H4-D$>`%])9NKHVD?F
MAMH_P*;CVF>A%`DE!<8_A2\<(?R`*$[MJ0O*4).],E>\+EIL1K8G#,UKP0UB
M$`#G:^NFI?UV>OJ%'KSX>'VC"RK`'M6`Y#M./5TG":":>L'[VC2XI^Z\8A)M
MC/.B*9IQ.E"-AZU@1=?>",1\UC,^$_K9O&5F95X4Y!R+F?+(`K"Q^2SIQ+0Z
M)UM9M`\*%F.(AX1KX4@FS.XM%,UWJ2'15"9Z%ZU;7PIA7@8M0LI)&SC[EHM]
MN_`=#JMR8W[R"=`()`/2%*P!]+E.A:.#EM<%X,,-<;TZ^B\SL*UTDGQ.P$5+
M>;G)>B[6R0D"+R6QD6HUG`0Q]Z^$@4G`Y*:!!HEHY^'AM/<\QT:[))W!*X(-
MGP6P5Y[[#0D0[$2?YB.#$<S<P#^9!(%S[WH>3)$MQJ/%D*N&0[@$OV@4SL".
M!"(6[I&<$E%1GM0'C1Y%2$LHKX7+1M0!\./RQ`+<#"]:C(83M08F0R!K?/W&
M;?&63F*09<UF";#,J<MY@9C*3;W+W"_^2;(56O615.S:/2X&"5KTQBT*:NRU
MR^$'D>7;+K06GC)L5%SV6F6E:?\54+]Q@IVP<P$*&!P%0,=7XS'L"+&$)'M$
MUB=IP+IH#6=BS%EZF^6O>/DKDD9#/&O&T=%Z(!^0+)?L0A70URA]I+#-F8@F
MTAX591U2+MC>04CPBL;%:`&`$4^47):"EB[(*N1Q&*0=P#4VGX.O*0RGE%:%
MN,QD9"IP,TC<2,8$<!#A4=!Z&!B`P$>X&&2(G)8J7#-`6N()81P`Y&F\HQA@
M(=^-(ALY%?SR<Q*=3!B;O[T2G=[IQ;.,/.&/4]\IVJ]7X\RFOLG(-=_X6_X]
M?@^>_+=?_^L__^.7=/`O(0(5/V"#^Q@&/`?$S/'-BA?)_($_KOGX;S_^:9@_
M_HK@_O?)"9]\/SE)W8,RY2Y0J3BY$2F:7V^O;KZ<GIV_K7`O+J]NSS5+.P''
MZ.K+^?7MG]KIY0?M_'^_7GSY?'YY6Y5Z65]N3'%,[,)3!&>FA9/:\>*:']#S
M%A?]K/3>W>X7_4Q31,V?_ZJ?U1IN.B,UNW4Z(S4&@RT.'8;'/K<QZG38-6P"
MQNJ6F&C6`FG'RJ;/Y6[QHI96)>45)RA.4)SPV!0EI7Z5^JT#QFJ=:/*Z)=`C
MKW@J'E`\\))X8$^W.Y7*/5Z:W1<*VU/F`P9>DFC[:RY*FBDWHG$%NI]4)U'K
M=/IZV["V3[!6/*)XY-7QB*D/^X,GWA-2%L&Q+(+WB>OMU'Q%R3@EXQHLX[:_
M7:5WC*%NF%VE_A5K*-8HLX8U[.OFH*>T?DW(8^<X`*:VZ-J,V5/7Y^%"&H82
M>$K@'9NB:R7P>KHU,'2SO:+-EV(-Q1JOES6,04<WNT]J^J-L@2/:`I^#.`BU
M.SYU;4\=!RCY=G0"KI-\VU0@$$\(!CN48%%LH]A&L8W1Z>K6DXN+*9/A6";#
MU7B,U3-5P$")O]K0<(/$GVF:NME7>06*;13;[%3OL*-WNZ:R&FI".KM:#7A1
M-PX3F^X5NU3>:A+R*%)B\)AB4"54UUHF:I;>&PST;J^OS`7%)XI/'EO.O&OH
MW?Z*;N;*=JB%[5`N9]YJ4X&&K2KOY:7-U0VMHPM*Y5<=4S9JAJ5;[:YN*H-!
M\<$KYH-*WACJ?;.K#SO*#J@+>>P:0_C$H^@MEJ=+9HE'!>D<+/MNNU3N2PD\
M)?".3=%'4_QO.GBHH%M]ZR?%!XH/7B\?``\,#=TP.]5\H+1\[;5\YMB7RD1F
M=3AUS>>Q<O?K(>V:%1=="VUCY6#EQ6WP=MJ6H0^&*U*S%8<H#GGE'-+3+:NC
M#XP5H;*"I2`^OMHV<:N.[LL%F[/KA'J>&JC3(]F[=A!1CPJJD4\=8.!GGXL?
MJ4*YZ-Y2>`4[-E`Q]#&S12,A-`:RTOHSYB?P2RSZ"B7S2<@<'K4*NWR%9<M%
MAYKTNJ,;R54X<I*TR0G5G$[G$4\E$5]81!$!U)K@CI:"/0+6WJNDO[)X!7>*
M0'XHA#%P4*R_GQ!>?>PO!SR/I'WB86<$T;H`9A7-M60/-D[UG+#-&_8]B-(*
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MB*<\+"7K+XV(N0$83`_Y'?<3WM(^!N*`6YR2<!^?*_6`S!K:8W<JO3RZ!()F
M^6'0-?1VIT_/_M#M=O6VU<-F[FDG=.^AT,,^;S.^2R?P4@OQ"S]F_L0%JA*-
MY&O0.;P#>OOB\O;T\K>+]Y_.M=.;F_/;FZHDROH2:X[5-*LAQ!W';N\R;400
MT(P[K@VD.88Q$P_VG\WG(25IP#?%K(_1`[U'K>&!V@*'".1#F$RTTP))PY-O
M\+FTA7W_W<W'#Z?I7X-W/R'UGDU=G[6TV[SCO>:XCN8'`-(H9O`$OE3*.2&H
M!)P:/K\`M^:(G):4!59P@$%`^X',K;GG(0>\V+#NR!V[N.@PF`&+WC'?YA'R
MMKN$1X`.1VII'[::TM3IB72=,!MW$;V5B\/9"<NX?%QJX/.EI8J4G@+0/W3;
M?=WH=[:`7B`=,X061W4C;<1Q/6P6A+'[[Q09"(Z#>TXP9:"BJ,C60NDU+N"F
M(KUFS$5VC1O&G/M2/N$28$+<<)0]-KX!X$X92$2&LL9U$I@$)DK@"T&Q@%X<
M":<I#-YJ`C.>ICRUS&U`@-LA'+.8B#=2?,-S+F#==]P[PI;WH+D.L#?0!&4I
M5>X%J1E[2O.*V6!/`//E_2DF6UW$.#7L@<<9B(P0_AWX,,&#-@^``'&F>`H_
M,\V>`JUQY(_-F59+B+"#Q(.%V782IB/XR%1@H\R`N3D"*2:(TM\=/D,Z&DO-
MYX`H$I1%@P.B(LED!<Q&RU.WM%.Q`65=6%3PRT*`-&4/%&G?[$A-.>SI7;.;
M@;.M(BXJ5IV^7]3U.-H6%D1+^[R(U/AACE_`7CD!,=LV#";HBA5Q`HK=#9R6
MU@1>*RH5CNL#&H1]8$CT*]B0]LR%5]Q0I![&.1,"0DI\B`S$?6([FY!#)%U\
M&3@K5;2T6^7!")`QJ#\?C"\/5@K?XWLE;9BJR]Z[*%V#3'4<L4CF.?I%#@-H
M(N`@'__P>:S9+()9O`#$?.!P3^1D@G0@A47YI'X,5,'NF.N1L)BQ\!N\!U"R
MC(*)`_#6*.KX-.FS"L(,#CE*-`4DM+0+P>HV"\,'G%<06[4``"JV.7>B!=$Q
M3F*P`\M+BI!+BA@'8Y%R2T$=!1-?"%*Y!!PURH3.(B1I4N@81EH+72HU81*'
MHT0B*2PMHAS:PB94`@Z2)A+<EWAQ.E6^OU'94BC,1`+6C5.5Z;G?0%B(;U=@
M^#Y8%K'W+O@6(]Q7\`,S=2,AS:%,I:W$C(>_QC@<K@4L?#3/`/N"DV)N3WV:
MQ@Y=@-=EF=E2-%=HIGF(4GE"W('F?81TC+,(?P?>*2%(7]QC'I6$<CP-(EXE
MFM&H`W%LZ>UA61RODL8M[3*HF"RU#E.BVM+$+"K/)@C,94\A3U2/`@\IK2P$
M*^V875*FNX]/F>[U12#F^9.F30)D?2C6&%2M[&BAV$Y[8R#+E.@]9O#/Z-4)
M:9OO`=4!9_TZQ?R[UA:WI^J`M88%YNN`,D5HF["VY4F>TA]*?]0(9]U.:A`%
M:`^EPU@;47FL6U^&_//XJ'WNBS#IT431TZ@ZC%`RJ4;\I632(4R-8]W`JXW=
M<2S9@V&2#3)'&=R*"UX^%QC[T;S]EO'R%"\MJOYY?;^%>&"0!<W9#&/VVXNT
MAFGVY]B4%Q=#:`@E%VKV:%W=ZO;U[@MNL*DH^750<@_K4>J=?O=)Q1Z4;WO,
M_3PM5)TNII*\6#7;$->A9M*I*>1<+)EKZL-.1^^;O1=;.EK1\FNA94MO=PQ]
MT'Y2^>=VR^RFT+\832L65?_=O*0,LU?ARC[+EKSHZ%P%!I^_A.U37`-3[QBF
M/NB^V#+-BL9?/8V#3AZ8>F^+!HRO_#[F`2\0Y#G=;#()^023]YGOXY4)5G59
M!+.,*;-?)G7[2&MCO)V1WW?")&?.QC%>E=HM8=;H="HX<JN$6:-59(9ZU1CN
MU3;9I--_C3?`LV.N/X%F7_YA;PW*'O2&=>6`;A-Z)1V.`W+5<DHNE;:?4]_]
M",7G8Z+7*0?-MF$IH7=,H?>,D;TFR+GG[?12B`]V34,?KCI15C+O9<F\CI)Y
M2N;5AL*/W@"[*`;;7;W7M908K!N1'$(,5E=!4V)0B<'7+@:M7D<?]@=*#-:-
M2`XA!GM*#"HQ6!L*KY48-`;ZT!HJ,5@W(CF$&.PK,:C$8&THO$YBT.R;NC7H
M*3%8-R+9NQB\S1(7E#!4PK`V=%XG8=@QP28TE&M<.R(Y7(K`;1`S3V7)U$,T
M-BE+YOFS49_E*'E3;O;*O-6\A<06G2!*G2.N18'B+RR,'VYQQQC5TZ]#!XE>
MV@"A"[MX??[I]/;\`^SF]>V?VNWUZ>7-Z=GMQ=5EPWI*+#0\6%_=?*DNKJXQ
M;2:^DEFR%;6D1P$+J0JYXX;<C@/,G17]#$KEI[4?.EC?MYW57N_JO7Y[H4L)
M5=3.NB&,L&2OB\*<1U3BFVFAK,EMM-I_P1KGM*IB^5Z2\?E+:;8OO/+#4!]V
MQ$)_Z.O&H)TV1%BL0+U=&?B6G"J#-KC/JAQSB12).U'>V-"M;D?O]F2;ED'/
M@#\LS"H&X+;>D.7:\TR6/`X17AR-2C//V0-R:U0DZK0Z.$C)V,UK.3/;%EM$
ME<:!&5&\T8,CYN':M&C*J1'%P2D^%RP["`H2,&/7>WL9Q#SZ(A9^-#'2+V(<
MO[D!(?+GZ?M/Y\V2'%>^=L/GL:2_-M%?NUSNG.PL:GB`J>S8V"CP[I"(/-<G
MEK/A5S<&RR">PN\CYG]+FR.(:V_XS/7G]YK9!<'0QG^T-U2P^CNE\GL@-$`9
M][69ZWFP^3^UM-.,V\0XBS,AIV$Q=*QF3A6_R_TYI!23/*L+R"C['T@GY1F-
M4NUC;-Y`<F'TD!51]Y#A$FPU@4I57!(8R;[CP!^`LRN0@(@QLY=R;+F5C,_O
MI5Q,0,"$'C$=S9[!$K$9)V25Y%H*Y(BD4UDJ8HL!(1KYO_#"@Q1"7Z[/BH)Z
M[`6B$GOD?C^9`5=,J1-6BJE4M/9:W1[(5B_!Y6EXQ0`9#T8UNG])$9A-J*>;
M*PK`X^CI./U6M_,7A&^YW/I^MY%VX=%[AH@-DC@".P:_R60>3D];)!LKK*)M
MD+B+)/R#I0]AK?U.]Z<5Z[^=XGT2P0,X0J$S$%9F!X$;A/$)-5+!38\RTG1W
M$MDK9B^0J3&HZG@T3K`!R9RY3I%9BQ@!\!<0@6@-EN@?!H;?@)D3%!1IJQ3L
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M(1X,BS0B`7R0S^%]R:P!DNM'<9B@D(CPK73$!9NF^%39D1.X%!W(BK"F8D:V
M)*+'2GTK5]KX"\TI@9+Y+?M>@YC"@+I2GEU]/M=N3__O>=."!WS,0Z'5$*5:
MS+ZG_6:0VCR7C5R/J)C$]8RSB-1\$B$!<)^))H'PEMCR8M]`V'GLAQ3@SU(.
MT1Q2'#U(=2:[.($;,@]"%F+3R3$`Q4G7X*3%,4?"$;XC38STS./80Q.#[@?#
M>W:,G.VDRUJS'B#[4G<\>-)C]T3O8BWEYE787ZD$OVB_)KM`B<9PLE$68H5:
M%J%T;83D_(JMRN+0'26(9]@8GQ0MH.AW[LVCP"^90B6/(PBY._&U*!E%+HB9
M\$$'88C*!%M",OM?B1N1_M.EX,MHH^@"&H;5ZJ0^8+4"@AW&SE(I;#IJO'ON
M>?A?$G/^'4@>0CNL3H)-FUR>RK1:5CJ3+FT0T84MHS`71!S(0I=>@.71R,*V
MU4F+ABBC,3@#^OUKZZ:EC;E#C0"1(JD5:\Y.0!34WX\4-C9J<ATNKYT'?DO[
MBC9:AGQ7@!R7EIH2'+9U$D$X',-WB%3)Q+QW(UXV5N^I<2.L!?;EG\@4\0*D
MR`T5H+[!WFB(-'0+_YE(A*+&2S<:^428)]%/PMH'_3<-R#23@Z0*+?=16["A
MHF\:R]=8M(83O]C2*^5>@K@@F5+V?4A[KLU#C!EASZL%I8>6CL>_2\D510$V
M5>8"6*+,Z<,<42=>AG]L+(L'H+W3IL$]!_FBEV&J6#YHL0=$<<E0@)\2M&^U
M.18DR)=*2RFMH1&"X=."`@!&@)6Z8"B*8&KBI_8ZKFT>"%Z/%F5VS+Y1>\;B
M9H8<[`^TG[!S8Y2`"LA?QZG^F3@3,0`UN2NW+Y[!=IR(CGLG((']$Z"&O)TQ
M/`QF"!)EWIH1W\_[XLU`>,=9"\)LXI9VGM68R!TM(/(Y"'6/L)"Z9@#7PN*S
M1Q#ZK%4H.?M(CN`8"5H77F'>(/1V&@;)9+JI1_%4>M5I.UD22`\K=R#M3CAE
MCD!_:XF=TAW8(BK>'B).J\',NU!.L;TK7YYBJWY_A+8`D")Z7*=M;/EWEHJ-
MQ@02/K,0R-F@^$B[+[;QDDDO\`L/0#05=>A9X$]"V1&3FG"#!(TB&4/$.,,Y
MDN(\!"FO"=-7`]M7^\3NM3?G%[?XX:<T.).AM32YZ`]^!M+6=KU\&C>*$CG-
M!<I+%/9"0%_SB12(.7G(J5)[+0B^%2RNOS,_`>6?XU20S4!89NFK".2:F5S@
MD@B%9^(+`L?W`%H30QB@D4#;.[!Z8%'[)-/*/$..L/$^2DE]D3X`V)-^&"SD
MX\5YA*+=0WS#JAXT#*>ZXP?IA6?A!W#H:/3O-I\+V=`$XBL&(#"`%]A2EF'$
M$40R.G<AGY#M(_81Y0.CP"_8-6B!QV4&9A201O67DZ/8S;QK>;:]HT#J!I*J
M(2<[/L9)5P\NK9LR=*VE4`H=_I-L$\(W!09I(QN+FL>RO,9/:J2+I8[X!.R:
MG%BUC$;E&>KR^0?Z,*[4=;+#NVBN#I.P.U@0J?UL^C$ADLPE\$QA->2NIY(3
M2QBD?5Q1^Z#]E63F'0;G2%E,W<E4J*K`"R8/!0('$2Z(5+K1TF<IC%"&WHVD
MA29:S!9L06%/8J4CX<=E\F5A=[:H@V1VTK)$NS<./58=I&W*4`]K58<17SY^
MH=,-.4%FMTXH:T9)7</8G$@U\IC][5ESJ`;/A[PPN"^TNC.W0>FQL@NK[;!K
MD),;4@ZW3#;=DU@Z5C/`>LBHAM5G4S)SO<Q\7M9Y=1J]SE6\%&L<QIQX/J0]
MHQE1)RH')[`&9H"298>OSB5R47:ZA:>DFI)JS:3WS5*M?(>DOF'29@U[2\'4
MX,Z-,&".T<72F2V=7U.D6QYG98&]S<&[SJ#J\N)6P3NK9Q8HO%Y%S*UV56WV
M8\D+TQPTX4:?N@.Y>S_YM'\24'TAB%7;$OJ&V:T%7O<A:XMQET@[7SI4WD](
M3@D;)6SJ@;'!9HP=2:KTC%;WY<D5S$EY3#RW1G1MM`;UV)<FDW:O%AC<,V4;
M2CLV?3O/1!+(UH)):=P#B*7GP]B+4K*;6EP8>L?HZ$;?4&KW%='WB]&TF\C;
MTCO=@=[M#93N;>8&I]?FE/)]G3[!R]'$;SI66S>[[>I6\TK3O@)B?C%J]XW1
MTTW#JB9EI55KOW]9@"*M\)9=19"7Y1X1CE.*]T7)JI>C>#?X"!L\B.'`TH>F
M<H]?+2.\&*6]A:_<,76K6]T!3N4>'7C8C]DE0;Q,2`51\`ZQF]5Q**<BR4(*
M>$%27-E/ZTW07<<X"!_$34EY!7%U5M,6J4O#1]\[M'I]P2O/G[PT>(GVY>#X
MPKIA=EX-,#8P:H2Q'C!H$Y"FR$R1V7$NN*G`A.+HFF"LGY)94[)>K;;X\^B8
MW8-!OC;=504]Z\4I2K;LWUHX5LQE&].A(3(D2VU5$71%Q`TFXNKXMU)ZM=\[
M+)O#XL6@H*CTIP23\L6;1L];Y+.VV[HUK#[$4,2MB+O!Q(U=_OKZ<#A4VKB9
M&WP9^"<.UBV/J>)R%`?VMQ-1.!L+5W,_$J=]V-%'"3`EP.J$-$5FBLS4@<QK
MTUAI`6QJS1"Z@6@2'"GEI*1&TTC9Z`SU7J>C2%>1;M-(U^P9NF%6GR0H)5K[
M[3N7S5O&=,5B2MU`'Y0<4G*H:83\IM?MZL-.?_L[C(IX%?'6A7A-W;+:>K?7
M4_<6&[J%5]C03T='=,9"%WO>%IK1CK6O-WD[)26AE(1J&GF_Z;?U3M]0VE71
M;N-H]T3IU&9NW%G6F!UF2L3Y(\.KB,RWN9)$2A(UC:"-7ENWVFU%NHITFT:Z
M;XQ>3S?;*VI$*65:^PV\J*ZDH\30D<10L[+_UT);"_I^WEHZBB442S2=)519
MG>,.>UN*$&.\N'`&J[%9D/A81"<.M(C=N?XDPL=^D.=<E/;T0W9N0+5S<`C*
M@=+XTM5@#>_[T4MX9TK7[J>N/=7N&3S[K\0%2L14*IAJQ"+7IN<<UTMP?AC0
MI]GG,%(T!78B.-JMMA@//W4+/^X*2<BC.>#`O>/>0TM#I,1\-@]"%CX`#(`?
MX%^;1Q+B"3RG4?=M63[(D65XBZ4"613Q.*(Y/)>-7,^-`:$`&RQ7-$9;JBWD
MN'=K&]^M*D#TI-YI@+B"4%'MT^IOB"NS8-\8:V#[-,FV1T=MA0YZEB[WJL.:
MDD<O51ZI@I^U%3NJ&9OB`L4%JG%;';?^T67N/ZQT7]\^0M8I?:_Z7ST#TNJ$
MLQ>D4E\WH2FM57NM=9HF7U&0UPF243Q./`T0X7`L"\_=.XR0J@QG)48:1]OY
M(<_33I)[O8[>&9J:\D\5%[Q>+NA:;;W3,ZJY0&GZVM/!"DT?X"TGI>F5C&LR
M;3]%L.WGD];7.P-E(BCV4>SS..M"'U@#95LTE(`N_#M8+%9\#D91`$:$C0E>
MF`?&PSN5E:Y$8N,H^H"BSNQU]<YPA;!3MH)BC%?*&`=DN9/*;Y6UT4P2/!>7
MW2+-#V*M4.$:GDLKB&*FNC([E'1M&FD_LURTVG@!6%DBBE<4KVPTVX?ZT.PK
MHZ&AU')#-]F6VU\H*T%)OJ;1\C-+ODY7[_=72#YE)2A>>:6\HAE]4Q\:*B.B
MJ:3QM773TGP>:\&<AV`,^!/-"Z)(LUD8/F"6Q#T+'94/H81>XRC[@$)OV.[J
MO=Y060.*,11CE+*$C8%N6CUE#324-&Z#F'EK:L\H.T")NT;7#GN:KP.>SE`W
M#)6VH#CAM7."U>WK5M]2FKZAFOX?JO1\O42:*CQ2$\=&>S/L&GIGEYYK=>*'
M%Z3E%4O4AB7Z0T,W5K&$4O>UH`.JTW1Q^>'\$N!J(U3K*..2QZL=?64**+E7
M>WI_C@O?PUY?[_57'&\J4T"QQ.MCB2YVS#%5C+^Q=."MJ=&7U9579?IJ(OEJ
M'^I\=J35"6<O2,6^;D)3BJOVBNO"CYD_H5MNZC3Z^/)"F>1+%%VHE!VZDVG\
MA$+9]/[>C?=J'[>K#WLK3O*4_E7\I/AIS4&X.="'[169H`6;0GQ,6\W17XY[
MM_\@?P;&JQOVE/K(+75DTZF;VEDPFS/_09NRJ"+9G4?:.`QFFAWX\%V"7\L'
M`C^B2H%??1=[QMW$+,:'N0._>D6_>9Z$\P`'PAYRIM[K67K?,F1S-VK1=L=<
MC_JLQ0$\-`;[11LG<1+2^TQ<W<?A=,T=:P"K3GW>^/>Y&XKO\*)_$G%'%\":
M;7,(:PN#9#*%/RRS52#+"Y],I"C"M2`"0@[,\.^T9QP`F87^\^0^7?O,?#;A
M,RP>`+B(7%@F-JCC5![1C34WTF8!0.RYW[CW``,SG\""#RBP`!?S(*2D`L`9
M\[RT`6#%9"`=X7=\>91"QYWB$K!C7N+%[@Q0GH(OAJX$'F%S^!S[\@'TR1P>
MQ)DGW)<;B>]5(EQSDC!%$^RZ&S@15E$06Q=/85=+_?I&7+R4EUS`QH`8.EF^
M-D$[G\3NTN(J$3T/@W]R&^FL&DZD!Z(UC_G8NA#8!9;&)RXG@&?LFU@&8$)L
M/HY?G/4]7?PDW#"_\$RZ31Z_X[1G,$0<A*X--%X!@X0S8XYJ:(,['I9P&N0X
MK:8(1%89K3:`.<HQ6"+0$?=<@#>2=(F4E)%ESO!$99*\BA0Y`KH8NW&TCD)9
MM43)>CPN4&O(`1E\6=X`NNY<[!:)N&*H`Q<3;S0V8:X?P3KBJ!(2%"HR*4'T
MII3'L1M!7&A#V00Y?KN`/N9%`=)40DBY8T!,220KM@**.(@MO,J,O3.1-$%>
MA*Y'(FZ4@/@#$D\?0\SS$^8X`KGX51*.@,20!>,P(9).?T$Z%-L4):$]9>&$
MB\Z;-'/4TDX!OL2?,]>1/4T%`0,5>(*)I00:,8_V.)IR253,ML,DA4&;LP=D
MFR(Q?1`":6$GBW0E2M7"&``]X`;X`?N'PE#$&J0?TL:K+`$9%DJICU_^#K0&
MKQ%9^K8+/#Y!7O7I55<`_>7Z#/14#&P#</Q@=`Q].)"D9[4-O=<WRY25-E[%
M#1MQ[B.`08B(AB\*PT?)"(3=0R8CQ&R`$+$N(=1`IN'#1-H%/8RSTT[S*0>1
M>9=)FMTZLQ:8X)>?D^ADPMC\K>@B?\N^?W`C&P0YR+-;,,3?>X'][=?_^L__
M^"5]\`,(LSN&BXY.?><C<T-,I,L?)AL"_KCFX[_]^*=A_O@K3O??)R=\\OWD
M)+7]RARRP`WBZ%Z8OE]OKVZ^G)Z=OZT(WU]>W9YK8'DBW?R/T06C&^SPBW^<
MWE[\XUS[X_3Z^O3R%NSET_<7GRYN_ZP*Y]=7"%SY(.H?-+./F]<>",83WUEM
M\5V9(=PH0I8"K0M>#Y`.&%ESXEO0WH9N=MMZN]T6G7R)KF"[9\C;,>X9&"\_
MF*U!N]#M%R>L',QJ;S'4<)`/M<@H_#L/;3<B52DT@E"0@CU#+NF86@;#?!D0
M2%C`N5BY@8?X"84=MLBE"I.QX.>(.$7PHLW06B0L%5<"^C0&A1@+WF2@;U**
M7IKR'G0:F,NHR"74)'%2JS3;$K%-P%K:&5B$*"AE$V,Y4F&.0N-B&AWEQ,1'
MY9Z*'E@-F'U5S"]^$4\61B3=*7HW"PDUM#JZV6L_L6-SE9C8Q/TE49']_)DS
M%"@HTR[\>1)'%4+FN>6&T2X*CH^G%]?:/TX_?3W7/I^?WGR]/O]\?GE[TRR9
M@?@6.E[X`F-B%J!QI`'^W2;2)*;APF&Y#Q+/$>Z'U*;$C\(RCM'^).V.M(RA
M%##+@%UR^GT#3_+O;BR&_"FE7_@+M.H<U"H,,`O`JF/.'3`!V*UHN(!Y\@U=
M/TF;V53YN"Y9YZ@]0S1F<6HF3),1C^]1N<HQY@Q\+9R*=*68?9;3FN8`DP-/
M!^F7VCC#$#B78.0#=X%4>\BU-H\P1.&"J>)((1)B&_603!\-K0R`#_`Q8]_=
M&5K4."5(&6+6$=:YE1X`4CEQULSUEYY,_*5G4?3`IN4@)>A+"W%(7@DQN!PW
MSE>$H^:KPF<J>J2C?U3HD*Y](C?'*#+`_P(1"?/1%LX4(SD@,2W<'!<]2_*)
M4JL\+$[1DN.:Q7&OEI`B#5?TG%,X@%Z\!-N@:_\J@8&31H`]CX754^H++P#<
M'MJ[9>!U?$M,N[Q'Q`C2S0*++0Q&04BZ8?10?%I2'%`42]=I%=?Y=7E+P=:;
M8S1`C`4`Q\*G\X-T-`(3*8J<2#1*R1IUR1@7%N`]N=\%IHYY.".^3BBTD:K`
M6>``C>C@J$<VVN*H)5DTU<:PXT`L8`$[@1=,"&<%K,;<GOKNOQ+\FJ&^\W!S
M2Q`@;$6W50"01Q1RXLM8)7)!HXV!4H`'9[G#^L_$F0AO.T1&P\`&#%)4-/65
MK46GC%BSL.X%=BQHYE3]Y[(-O5X4M^#,X;:-6.121`5-E>*8;I3*4J"5AUR`
MH7RV:8?A=;)7,K#(3]P`6R8EA&/F?^.A).).[QTY9GP>D[?F![$(+4P#SXE:
M5;'?XN0T<"3]]\7U1Y)8B[Z_H$DTI#QAU+$1>$DKY]D"5B:M*>%U85P)5(^,
M/\[!./Q.D;0B=C:N:LH]83\*T4EKJ!:OQ8D+Z-\4GGB[2/P4(2\=G'0&PXJ3
M$W%T8?5ZXNQ"GD&<77WZ=/KEYORM#?"R><3EFS;P]1S\?EB`?+]=^"6:,WOI
METUY`&:KW]V4"&#TC#J=E)EM\>?:@QZQKN.>E1E6C=`V;`C2!MT:(:UG-01K
MBM0>@;1>G4BM,V@(UA2I*5)3I%9?I"E2VX2U+5-DE6FL.+M62%.FL2*UY[J:
M8J31"CO`P$(Z3)THT.C5!)?[O,M&AS]TVJ85CMLBC<4;[K$II79TIE&21BFU
M.LJ48MSZ,;=A%5D_IP(]TO6)%ZE-KSGE<?L3[0-F7W_%XZMZZ=%C[79]E.I^
M)5UDA^X\:P6D!%T=]/>Q+H2]2&6.Y\Z*MFL32CT2;=<GKKI/VI:)9(J\%7G7
M!87[)V\EO15YOV#RMNKE7[W*..4>=O6]3-2<!U%%DJ827,JE:CR)[[\`C=$V
M]&Z_K;A#J77%'3ORSHGB&L4U+XEKE#90=%T/%+X8;;"E[VBU7J3K2,NJ/ZE0
MZ\V7*_2>8Q=>MG_8$#I6[F$3>:/A]L!KY8W7ZQPJGGE]/*,T@:+J.F#PQ6B"
M@F,H/J8%JNM;B6;EL*ITR&LXHGUI`K\.2%-7212IU<>X>#ZDU2?2K$A-D5H]
ML*9(39':`;"FLA>/3J2*LY5IK$BMODA3I4/VUBL.^Z'P\`G-XL0`Y:U394:4
M`GQ]4DDIP%K)'U62I$F*694D.0Z7J/(E]5?6JGQ)HX5BPW,I7[3XP\X:B@]J
M$_JM<[;,B^8#519%L8)B!55"1;&"8@55;N5%NH"JW(IR`1OF`CX^X?E9<L:U
M@:5W#5-3O*,,!,4[3[AO4?6M8BK%5*^'J90J451?#Q2^%E6RI=>J"KT<DY)4
MH1?EF1X=@\V3B"_?FJ@!YS3<F%"<H]Q2Q5**I90:432O:+X6:D0=I!Z=&QLG
MP>J`-'7Q19%:?;3E\R&M/D%;16J*U.J!-45JBM0.@+6":2P^IM47?_DYB4XF
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M+OD=<QA\%P;)9*HQ;<;#"0`!/^%SV7MV$,Z#D.'-.&#.&)[T'<WU83@WCC2?
MWWL/6L3CDV2>#ADEH\AU7!8^Z.(-'&_I-VW$\7HE_@;$=.?>X5^%R5K:.;.G
M\,UL!C-'L'0.P[$0N#4F&"(D3RV@.WM:`/0<P[<X"/R)H\KU.+A>Q!%+@(M@
M:)MY`#*0[!T/8R[7PE9,%(0+\XR+JRF!VP1JNP78SX+9G/D/FDLHF0:A^V_`
M`NYG%"5<&W;U=KN-_PA<1+CF(G*`[GYHM]IM0P.AB9(J`7SAAE2].`_YF(<A
ME]NU_&I+0Y@6'M-F#.E#0(0[!!06NC`BD5.4`%TX/`()2:@'@,3[W+<1N@A)
MW!'#PY^A.YG&\-]_)2!4Q[#]]`[NK.?.W%C^"03B\)B',]='*`*/`Y&,'FBW
M)<9H3_['Z/3>1=HH8*&#"W3<D-MQ$$:M)NS_'X*LHR;`>AH)^54I'%,BGC(G
MY=6H)`20(/EW'MIN1%5]@;[G20AR,N+PF\8FDY!/I"@TNHMDF^VXR`I/R9]H
MD\7IP$BW+I"<!M-/<%(2OS]80.$X'WP8M+4YP)X*E:D+E,N_SX%FM,]`XD:/
MUF2UM--XU4JSU>%2F7;/D9RY<\)`?+$)7X`%@8=Y.Z5Y*]X".X"YOA"Y/EA`
M=@S<`0PQIA':K8[VP%D8$1I!26"^`0K*T/4CUQ:L15.U6Y5QO@:0U_EL[@4/
M'#4B[NH5R?=&,`;01AM5/QAR[AW7OGC,;P+88.E<!G>"Q)&X<1GZ*OGZ/I6O
M'U+YJC$'=#!WA*X)"F:3*0<C@R0J&*T:F\]#F-*A6>B13X$_.;D%,;^`0.T-
M/I)"T*_$L?QQ\.ZGE)4GP$XE<82?V<CUP%9&"3`A&Z)H0*`^XA'PD1WG.E'*
M%0"6VZZPM(32HJ4"(X\1O7@G)?%QC=+VXI*"84PGQQ*\`2P=)5Z,4D-'/0=*
M'N3#_30`_>EYH%A!GO&M7D_MG71]\///,"`A.K7D0"\+)5Z!,\U.0G2L0)>"
MU17<1QHL1>/D3&AH7SHT!=B.L*;.&L,#,500-3"?,%LKA*9A=M<,(JA'[,5Z
MI;`$2VD?21R/./?%)L-F)C[07$YI940TPCH`#D6M!/C#)1BEG9>F6'P?G*!F
MJ$:A5!25V$.:*6W$6GR1NW(?I"^"DK,3^C$8@PE'O(VT1#0EJ*]"B(#7Q,?:
M>?;NE7B7O(%TU_S`/Y&6(7<6MKBXMB438=$F`)@K5+'9ZG:*JAB7B^XS:M[L
MJ14RL#2#=&H<V!]X#YDZR+Z`(6@YNK`MI`]4V$I+QV>$S"ISQQT((^XL/&X2
MDY0?O.?"A\074F#`=^3\!&`DK]`'%(<1>G9R2>"^N?R.`@Z$,'"WP.8HRK.3
M$:#6H3')%`E=L,!=5MI0$!Q1D&T7$@.^#1@5N_L1'&,?I*:7[>XS[V@1Y:?P
MF*>9@ZV17GKAZ&AO@HQ"RB!B."''?HS5%#-S%)>?;K6P3OM&<:^`;7[HM_4N
MF.6N+X253M)`($3BMS!\RJHS%G[C\4HJ2$T2?%L()7QIR>AF($-G`KRWH.&C
M;^`P@`'JXC5CW-]0JIXV#/X7HBQ.9H+CWKD.ARD>7.Z15=0N_GP7>&`TD,T!
M/_7!>/^+L-O]_)G4LC=:;;+L!8L1\)(:@/KGW(^$^8'O^1&Z"3CT718]&KO?
MEW@*\0?F0S#Q*9``]I:0ZH`=-W!*>R((OZ7=K)IW<;YEHLUF%99,:68?S`QW
MO/AB2M\PO!MI,QXW(U1S`?:(X[BX6GU!/I<U<RH:-]@]3U2WQ&,.BL4?+*.O
M=V&B$M-4<TJJM`1="W-XF7V`((!,*3;C>0]ZY>KZBXM;-*-3JWB%TB\(X[+@
MK]:`^I:R.'*_'T`2B]FKT+"DM%:A8;V2/)1J.@PZ9(RPDJ51^OA!C'R=(6UY
MQ"+(\-.8NR17DS`-09--"R(6OEUR*3;(2I)9(H):$)%"+0@/9PL)64)_(Q3Q
M^7@,J@4YK$PI9?;%+?D(M/M-^X,E_D3?BC:I[D86F0=2!))QB&Q.P4$3!`2_
M7(*A][^9H5<,X^3/D<G'\'UA.H'GGSFU93<4G.\[-T@B+V<V>/4S:$J"'`T&
M<(S_F?AV?A22#NF*0#0./'53QYS`9!G`V0LI:O@B`H>2W*HB:DB!XH6,FS*D
M('DA\4E`RG[80/"LY.M1$H,B2*W:7)NZLQD'7S[&H'<%[P/*YO,@$B@9MM'I
M``=L'$LZ+JRWB`T4^RTMIQ.B<P";?E@@$]P#U&%K`P#E#<%(`F([W3@\([A#
MK2,948[="&8ZM>T@Q+CUHOI#L4&8*>SI#]VNWN]W\Y!$I>DF)%4REY*9?[=Y
ME)'^LME<PG-^[@*OT=$B8;MHRL53,`5(GMHH9ST/(W-NB[?TC.9R4PWUP<*<
M/YAF=VF"#=M?/5"W1^]L88U4K%1X"=U>P98O&BV2+H4&6$;:LB&,6Y%0-"A*
M5<M[C]G?3F[L:>#!FJ2`^@(0X0.?`X>##Y(_G;L/VWL+!AC\0/3P8?AHMZ'7
M:_57NPV`(IS!:!GB7*`9)O15)LGZPG[)!%K.3-*@J@H0E`AEJRA?>D"^.6ZP
M;(KD/A9SO4285M)B6F'4+)M)3=B4VP7I)HVB'XR.H??--FW4#\:PIQL#2TJ`
M9>&V8+E%JTPWL>W@,5'8?2X4$<I8C`!R']QR3]"\`UK+!4M:>)]RFFC1MLLC
MUJ4#<1IB(D[I\.,L<(H'S0N18R%,TB,U"L7'[#OXLCX?NW$1)UDV1PH&C5-E
M@Z+H^<'JZAU+(K`SU-N=7B:U'X.DEM:L`[UE$<TQ@40F;M#680``F6;&XEQ7
ME+W37>1VX>&"L*;"8:0\8Y'98',ZD9ZS$*Q!-I\"!9Q7"&%W(0P%MDT<A.@3
M+XCJ;<+%XF"Z'$A-D*(+H\+"41!F&,E.A$I6'*H9.5"F%O!WA"25FEETMI1$
M(;,G(A>&%38Z.&G3P$E/S^#IP.<G4^:-L^!=Z$Y@8J]T*HT#2A]L<2@<(XG*
M\A.W35KBZ4JE8I]+&2)E<[I^/",$10E:(>0L"GS*%X"MP+'1?!+0EA!51(0`
M#17T"2EHTLO(>,*]$_:/I(:JP_;<JEHB@:^M&Q@]I,2]!ZG&[22\XV0Y"7<`
MS#!R0]Q93L7-T`2G&O#,3`8(2EE6#$40^6:K<D#HG)(,QVC)C8</OI1UPCV(
M.%'GB(-E]79A"<L]G[L=LR+M5"X$D\BT_%\G;9GP*7-$V[V66<C_K%E+:-/L
M'R"A=LW]IGY[9<9LGH;[%O@KYDTNY[+U1=#>X%GQWP7J5!M02L.O8NW#;<!0
M8;]$_IUGQ7YGH-"OB+\NV!\\+_9[AKB!WI`->):ZW7^D!_)55T04\]28>0YR
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M'E;Y==NS$O67VH]/]T(<ND;PW56Q7\IR`Q+CA9UH-6)/MFZ@;!FB<ME+4EA-
MVZ&7=.35,-SOJ5^Y9K7:EN*A!O!0,PZ_FH']O?BSBA?J[/T<_2"K&;C?F1.4
M&W.4320W]N+RP_DE0$4K6;>M'].ZNLJ#J:\'4S#"WH@JS#\IW5-[^:?<FUJQ
MSB.8C0J1*TZKOY6G/)Z:R3G%"\KC:3SNE<?3C$W<S>,Y_XY-Y??J[]0M*Z\V
M._-X"TY[8UI=Y>DT0^XI3Z?IGH[5,H;*TVF`=:<\G9K).<4+RM-I/.Z5I_."
M-G%#KIKY&&-.^4"UL^W2'N-*4S5`4S7M3E'#-F)?*6[JP*<A#-7`&T)-VXI:
M?M+:K8Y2>4W@T,9=.VK81NQ)Y6W->">5WRKGL"%TDSJ'LJ(5M?)5SF&]]TPY
MAXW>-.4<UF,CE'/X,O91.8?UV8I:?E+.X;')0CF']=B(9CB'XB.Z(@>D1#7L
M?H8]K7`6=2V>\I!K]RS2_$`+T^866N*'W`XFOOMO[FAV,)MS/V*Q&_@:_XZ?
M.3SKL1A^C`,<0QN[W^&/*`[L;UHPQR>CEG8+/Y1&FO-PC*#Z-C\9L6B+L9??
MD*,3S#\8?;W7Z>K:*(E!/GF>%OC>@S;"(;))W3%!6!A)LT,0#B%.Z4;:C,<$
MZI/Q$/(H#ET[=N^XQ`2[9Z$35?KIK7QS?_DYB4XFC,W?WN!;T\!S>!B=_RMQ
MXX?+(.8?W,CV@B@)^2U(T_<>///K?_WG?_R2OG46S&9N/.-^')WZ#I;M!="Y
M;[L\JG@5EN&C5+[FX[_]^*=A_O@K0O+?)R=\\OWD)&7K,JTMT)7(T17E=K[>
M7MU\.3T[?UL1J[B\NCW7#%,CBOX?HPN"]>SJ\^>+V\_GE[<WVNGE!_C[\A8$
M[?GEV<7Y357LHKX,=0Z(#&:NK7'_S@T#'S=`.]%NDA&>WL<N\X`4&=*D($#8
MICGS'_[*YD'T+@(ZYB$3I,R`]&`P)[&1DF`>?/S+]9FN,=\1+`JDRXNC(.%&
MR>B?W(Z1]*(YMV%"'"5RG7Q@>#T"E>6.71M`TD(W^H84#N\\S.$K@C"*`G@7
M9[YWXRE1.?.!=E((@0TD2%]]O&BJW<3P=(3+.IT!%]F,V`=Y@89W?=M+'`[`
MSP)X-T#X(UWP(!@!,<ZK:SS%'L+H\0D`7\"C`'WL)5A^6JQ%PH"(@!5I=A*&
M0.,/P(CVE`&]:P`K%S)G`=/`EXD'0X[#8%9$^XR1J&#.'0#($17C,:<M&#UH
M8M!LV@QR@=,@Q;;CEJ#+-JT\PB2`*6AA\!8.A;PIT`W`S>4F>NQ>K#ODD\03
M0.)HL7OB^F/Q!0L?0&`QY&CX+4,"0(*+0,$D!@"!$).H8Z,P8(X`*J1]PT\@
M\Z:!0WL8L^\T<FF_8#&P[YD('[.[(*208W%17C""Y<R8'0;9;HZ9'0>AP"WS
MHF`)NV56(+G0Z978H=4$YK\`1#MB\_4U3![R.^XG'+G5X8@AGY59/'TPVTD8
MYYK[\.#(U=Y<?W[_DZZ!*6M/M5D2Q4BN8JO%*$`T8KODZTA5(R$K"B00@'*4
MX,&,+>T]O$-_%:@&I_W\7@RYP&*NI!E\HSCJN/)!(C=X#K070,'F\S``L[DP
M?X$9&K'3Q3+X!4U;5&H%F:-1W;AT<^9)"`P#DA'QA[(Y#D&B$9=.0L[%0$X2
MHHQ%]#QP%L((#KR_9#`@T<`0/A<#D/"0FY@/"VAFFL_OD0]=D%@/4AS0;@#;
M,S]!#A4SNC/<'`%%2\O1]Q4`0`F`(CV'4R^IGQES0"BR![$$2<\@0!*?:.T'
M2S>,MFX9PVV7E^J0;$Q2BAYH)U!>\`)89J65PI0`/4`7@>R0T]M"=SW@?"":
MB$RC*>=QM06F?4P`$UP#9G-GR0PU7[:[28J#XDXA2`#'./"\X#YZNT!FY`B5
MO&2K8U2XR9+86`($DO_KI"VK)@HGU^SV"A[KV=6G3Z=?;L[?VC`UFT=<#FMS
MSYNC'/(G<O!VX9=H#D2P^,O3#_6ZA\C:S3UW7.S5]5O@.1\6`'(E7GOD-S16
M1@.:Y?NG1O/'0-`=56O5SD4::(%XWS[BA&]PB'/8QVY9;W5\=9\[=J@S[5=)
M_CL0>>DRI['I,B<(8DN1\7XPOV5H43-`.5N6WAD.#IS^H5AESZS24:SRG*SR
MI)#ZL#?0![T5QUG;LM@V77^:QV7[J0]^,$:[#6+F[9/3GG@4=DBV6]Z*M<`>
M2V-U=*-MZE97::QG]VV4HGD\PI[[K#0_2=KM3&CA.,G'[@<B&GOM1M_J<(AD
ME0^1+L]`E%^?WEY<73;LU"AU[]?$PN#?3+.3"*@*OL2H5N)CO'<,KYKM5N<O
M&&&+F"?CLE7M#'0M\/FJ,8QVRZ0QY-<8IK:Y>X?$V=*V`S"-;,I3%:9%R7SN
MN?`,10:3.4(ZH%E"=@]?XGDK'GZD[[6T8^S6[C0X!D)?"9EA=/^RT]::.IXO
MK]B7F3CC8PA788\#&HPN`U?MU^U]D"$_6MQILV7\A8@$]MSZBYZ>-KEWW'O0
MTZ!\<8.B0ARX&.]-]\W9.IY+^X#8*W-F441MEC,EP73),%Q[-;[*C_`>(88>
M?RT[G##?_;<X_D><"G@0BSE$N3`J":RIZS/MRY3!=-KO@8>[&>G:A6^WD-<O
M^1US@.6#<!Z$<GPZFZL@G^`>EFVT!8%<^;`U%_X=CTC4:Y_<&9W0OL$??L*A
MWX=N[$93[1]N.(&5740>0!X5I\*X/H@0#.$GH5\>_W<&</O:[]R;1P#49^[0
M$2BM#/_1WKM!S.VI'WC!Y`&(!9;S"0R$-_(-`D$&Y8&."7\`7AY<IR//]&R(
M!W/0CO)`[)K/DY'GVOBK0-\;>8#T4VL=/FEGW)A.QR/7<5E(QU)T(C;F82A2
M-?!(W24L%XB\59GZ5%]5<N57$<AJW-`!2C*;T1$DTQ`#19(#@32!D<92B@''
MPTX0>=.A;\KT$9[^X[?EMTD-?.`>IKQP1+$D:A@F2C#W0"8*@9B91>EY6'IZ
MCKK(UT[3DQ;Z^0M0*O[P68#E$-39>LU^*F;R/;NE`\K*16%BCSB+%*?[42'1
M1IL*)!%X,_;/(,1S,TF40:$6`YX/P9`1=17%0Z<<FN6DGOJ2#:+IHSRY+<B.
M"]]),'\)CSD9.,#!).$Y!,1\Z7E]_UWY"?AJ\.XG[9^!Z\<>IJ9$B4`S,1?2
M8_&D_[/KNS`1H1C-5![:/#M@OA19#A[@%G14,,_(X1J/M6?B!#:B(^LWDGLQ
M_RJ*M?0DVXURW43GIO('7>.4@(#967]G?H*9%%9;[-M/Q9/&.Q`908*'F@(A
M//IYE$2NSZ.($A^(D(%2-<>%`=$ET6P`81+@HV^U-^Y/H!-!"X=L(M5P>D[N
M9MA^!X_!<VG&F!!*58_ATN%1>!:(=^J.2+P3KRT_+6PW2@X2H#]D@%/.CXT'
M[V)C2!Z/Y1FO6$V^!CKI?1#Y="-8)C*ELP(=H/@P(V#E0EO::9IK5/$K:AO8
MG:D[SY/GQ-DN22"2839/1.)-NBBQPZ"R6-6(=/X^#UU8UP+-?KPX+U(KL#&L
M#_$R97<BM^H>)`%'>ZLH!5"7<,K%P[WG"&=$<`M$9C#04M)D0YA+@P?!0@/E
M"VC*33NKK8W`F;6G*(-":<([R!#N**'T'")`+B;'1QUYOH[">$ROXN+$VVER
MB"NSNC`?@`FAO2+/)MV[1HBJU/#(\Q;2_"46?N.P#^#28@::2+E"7&&2:9EL
M@&\PL2Y"97_/8<OAOR,WL*=\5OX=B`:&=4&`H8$01',W1GL8AX:?[E#KA3QF
MKH<Z`XQ3D?8Y#8-D,L44FRR_II@.,N)@EP-QIC94U5:DNU?(YR/^K.(-!)-'
M-A!+R8[*Y'%+V(3,EAD?J25'NBP;T,UM.I(E%<`)H8`R%Z8@E9>J2S0$V0->
M4`39V>XB%Z`9_R!$(Y"XR%S5;C%F`P*RH-<I:25*[*D<?L["V.5+0PH44LR'
MR6R7!?TMB1MU!RJL]T`8+"E8K%_@29>RE'SM[PFXPF@9$;2XG>G:A1O%A>8Y
MXP`+YDD*Z^8TS5Q"N7:>LC*:`?#C>29D9!9?A3[-<[S2_)2(S4":LH?,1,T(
M`.Q<2B;F=ZZ#01I,SH'?__AX=:Z]^0,0#T293G%%HB>'X">RR)(H6ZHP1@"+
M3>#P(J],6688QJZ?`&Z1G@0E$^N>@'?+Y\AV,^F)('TF'A-/@ABE7$,-K+]X
M''AN@'OU!VP(#X7'AK8(:CQZ'3]69F$O^YF+\3$*BM-/7S"9\^%)<;%'.Z0E
M0&A][UGDDC7]!80$9IOB+]4NZ>UBPM08&8>XB2Q\D?%$JG'$.29;<8R_4NXB
MOA<ZE%Y%U"^##C@*D"0,,L>X!<EFD6*<;MN&/&(1SH+-YM]1RD7BC?+3#F9`
MA3(SM;0`.T,'6B-5JY&9R5FR6)(F&A>2@LN:,V/5>V+"$Z'WBZXE&#B@4XI)
MUF0EI$ZO3$.3&92Y1"NB%E1$(3'4+NYJ(WBX0GN,$]^6AGR6V2H-\Y0'TRS7
M5I7V2?-F$6ORIH5PX@F%'LO27RN)`T.BM,<@#L`(+Z>(YPXNW@!Q8/^`T"0=
M>"X;8=JDNSR;'+(\%,OHA2,5R7`:1_E#S"!G^`V4$L7QO"#*0J;IV/A@%0:K
M"!AADD2<,F*"\@\!E(G`0'>@J@%AZ.>@+SSC!2-11&,"GXLTS:(;G$\NS=T4
M;D*,`!PH/B)9D2T@I>:%[&962&B6^>1,YN]74$:&PQCM!A&.BL@X>,C"!@5C
M8!$+`NDBQQ^&JLPD+X4=5XKODIR_YJE3:!\AVK@XNY:+\1-M46M2S-T&`P8V
M#*V:!;@E#DL"<F-^K(&OP2OD=LL1EI.2YP5%DUT#60)@RAR,>PL'/#6'2N`4
MB+RTA<@UX-%,M3&FW!+O4CB:."M*I^=.Y58O[6!I?[]&H./!LG-G)#N><W-/
M<X69`5!0TV*#A<9E:5[W"HV6;A%RSGZ5L<P:CV1<S`=).I-RHZ@AW^0>]N?L
MH:*C#;0S8]\X^L,2U:3FHRB9R:M\PIO/KX<("8I"=R9T-,8'5TAI&3=RLK,#
M>MI.#SSCE2^*J1QI[HL[C,L8SJY@50(EU514UE.%$Y)%78#F@KA*D`HLV"S/
MD:$D*5?)T\^P54G99=HMFZ?`+7CD"_]!1PQ<&%S'4>U4Y%\RO_%#`:@5AR7I
MX\3W/'\\L]_2.`R83XQ0C4_[@7^R],.(^=]`-\V#R,6]G('F>Y#!@\P"%%L<
M36&C3C`Z32_QL*B,!<\(0RX_"2-VFZ&S($B*R`C=6I@FG@J%CY$6K5(-;;--
MB_I('OH==3?!K8<M.$W-YQPJ0N,I7HT@Q8*B^D.0C.)QXF6/K_!%:,B*TTUY
M"X2%H2M,L"!T)ZY/P<"[`)SFG!L1TQA\8"4`G!2`='#I-Z0/1=5/R6D]6]I6
M\N8QVC6."`'AI9H[E]^3L)&*U_7!`76=A$R;\@FOE'E^RM92IE-4YHX$<WXA
MLG`N(F1B*DP6[I9E<R!TY:B3@"TJI!%D+X$+Y\;:U,7XX4-Z60QH1QXQB]];
MVL6B2,R@2F.BZ<@851,G/H`:%')H&>M2OLG+H[!P%R!SPX("<0$Y(W%'*=40
MZ=T?/;M;E]DN^;;>D\"D*]XBQH4A9HS5N&GXGZPA-D'C-:ZBJG1,6G4L@MWR
M"BY=GJ7(FN=^XR(42'?N/(]NA@)BR#:51T%SO!@&9%@,]B!!%2D81A#HA8$>
M`G03?'$ZT=+.\AV47F+QN*F<$I"^)2XA(39DS)T"X9.0XP&^\$KNP?S/J#<E
MGHU\L:(^P&K6S$SP'ZRV;E@=?=@>"@TF\A9(JP<V6?E.U4KF2"R(G\JZ!/!R
M;D_D<52Q4;0=E/^PPNY;(2E+`O4F=]J_2*$.$OD&<RD>\ORI\^^X3$#CI\"?
MH'[(?SJ.`#YU[@2Q`.9N\L0/%+[I+[0+*76M4K.K2=B-,I9DA<GR+!,BS2QC
MA"RD((VFYJ\0%+F8H`,B//N;8I!>1MU;VFGE#$Q<'O5<66*B3(8@*,1E.Z1T
M89YFP-!)OXCK%@;/0KT+0!7G247&2IH7\RVM@08!5Z;:"=D?E96(%R/-/LKP
M8]H"&1`%[[1`8OG/6*T@+L914'Z%PE*/4*UK/EAD(,0\]]^$:;"'$M`B&*U(
M8JE[_2R@0R^-,-@)6[RH\]ULUF`$N\(CF^-/&%%`+8$2JT`W9`K2;"*G(8,8
M'``ZF1&0DN0BM0=3+R8=Y&HWJQ7"_%5PH,<:WM%L/QAZOS?4AX,.\=`/[2PV
M]4"7_U;=!,:'11I>,9^KDOI6D4F9EC+=?!5^<".P%)AW-49*_(0\(P)DQZ2S
M?\#^9$83PG5"@,G0W>H`-UJ.%!NF#28+W<.W/7H[]0Q)8J#!)#5JP51AOI^0
MUPQ?(]&`"@HU=/IB$9G(JR'8;F@GLT@Z"6@*TDD2Z;&X`A0LD("'?K)6#1(V
MI?/]@:1)1V1H+=Z1O80Z=.'^-9`RGA4*YSSQT?V5>7^%:(DP7H3KG^4-T`OY
M$3$A(0MSTX1HP#I$!M+@NY.GC'E=',\=ET<@BU$")0MBK,>`S/D1TU.J01D;
MW-$!(F1`^)C8^;%?ZABCPVW3[>]QY?`IT!(H3J?L%4C*QUM$EYQ0KJ]TR?^.
M")(+I%605(4M)0[ZT42>N3Z=.4J\9.A(_0AI8(,SBVE7Y%F)8<G0%M1)(L99
ME#@YX6+`ED1,=VCI[6&W)%E6W\&_#(J#X*EK88;M,C^-HG2\`6\82QAIG6KI
M]`C!4Y)<7T(,%<8/F"P6@UI%5YIRAHXIK5*@:(<RB*JE5.E9GCXK+(I,89+.
M`6L8PQN^J.I">X_(DQ;QE(430<)I82I&%KHPOD7*Q#^%;,MJ/D@OE_(<<(.7
M#RHPVPUL>>D&G"!MHG,3`_UE8!8C\86X;8%81.@+J;$@52KI8=OM7(B+4!#N
M6A#JL0]E)31:`9SJG;_.2\,4'$_@*[]HH!2C_(":*&%TL",3!3(I&H:HB/(<
M"Q*(TLC50>J@=`JS@Y;,<,514P]-ESD*Z+J!9R8L)E'6#1U&*;A02>GRE%XZ
M8<*')T'-H@"?H*)2";GF']*IG8"++!>:3\,(M5<$)#T,Q?R4>5Y7+E\$%I<2
M"CP2@,<ROR1<?EH`6(C!R.@=O4?3!",4M;CJJL>R<(*$C&INP+-2AA8W):"<
MG=*>Y!I/E)ECHCP7)1=*+VN;204Z@)TB?%,HH(7M$5E]&?$(!5:Y9Q+A&&BR
MBY>!%NOXX02%Z<&^#+R[E<<K&QAO(6TBBJ_&-^S(X<LS\C?&*?NM=([%4UF`
M7THY+#LXP;2[S.'4`5N^XU'LC(2PC">+8\_\['JARIH\4TFSVJ1QD+-IYA\?
M/`&@>#*Z:H<6Y&T$4LK&Z'4A2?=<K%2\^,P25\!#."Q`M$KL%IYV"DG&M%6.
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MP9;&VFU;GU,K;=BJTK:>@_6,UYV^\/`&4Y:/N:V8BRD2TS^X'C%;"AUJCS3\
M3F"64C_$>[SX;/'BD3Q]$E'1$6XNF)VXCQA`%?E>:>#BGKN3*3QVDH9-_82V
MDZ*NI:M,A5.G);^ME<%?@DD`LW!."EP[(5-8YG($VCS`,S91"Q?O!9$MZN"`
M^%P)C$6B6JZGUQE:%<4&MJJG9XG64,]?3\_<HH1+=9W`8Q51D*4'UU91,/=3
MPN5)E2>,;MK_`781UI4.4T4C1ROA873J@<L*,2VNO7^Z^.WRK4VWIMYINP@[
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M>G`_#8H.]TD[J?Q6^1A*VRAMH[3-EMKF:IXW5%#'%TKS*,US;"FJ3E:.SW9/
MB%P-6R]0N0U;C3A'25/HCW.24F>]=Z0-5*<J3]([S[%K+USSO$3"W\,!2[ME
M=I<ZR39=38E%U5]-5=P]B[(+:B]?&35EFPII-@?TI=HMPWBY*NQ9]OIEJS#%
M+IM9J--1RK"A9+/ZVK-2A[7:**4.E3I4ZO"0[*+MAX>V4H?B(]9^.&#T=`_#
M?DDK6RS$\++Z3HLMBD35CJR,K;.FJD8D"^3+.AJBY'U>E8W!O"=9#AS#ZBU8
M`;F8`Z<J:-3;"*I%7K*JH-&`&YFJ@L8KXBM51.,X3*:*:#2'NYKM5+]L/E)U
M-)2[W*`K9JJ.QHM6)'OP\M,[#Z)J-__.0]O%@K58@5TTV+!:[396NH0/@_9A
M8L2OX9+$00-=CPCW&MVVWH:=53KLR#KL55Q<J!GU[\X12IDU@"3DE0K9)]Q?
M4&>DS<Q6MR.U6:?_ZDX\&[.3>V=NI>WJH>V4QU9'[K",IZL^ZR5>O[#J<_UB
MM]N%MT',O->BU6JT2P?SU\SV2]=@S[&++UR!O0)&J&2.3F\[_?4LN3=Y:Y\-
M[7I*K7UN["EW$H]?C<]"[KCQ)^I0*OL]W08?76R,"H-=9]W:HS/LA41]1"\#
MT1C)CV_QER-U'B2XM6OL8UD(#2.&*CI6LYGH/H]MORHZT2\F%XV81TTDHRFG
M1NK8V`R;=Q6Z@/V5S8/H'?6R"[`[)[IYMH")>FNZOF@&B?E)\!.V(!X+K#)/
M=B"F!L&BL^'B3P)RC6E1WN]^U53E]E3@9(X!C]AM=A)01RKQI&RRG#8_X\R>
M9GTST[7D4,!..J*QK':!O?6P>S(VL\UZPXL>5TZ0C.)QXN5(Q0Y-HM]V_J1$
M*IM,0C[!)M:4>X5)7=ASFB/>/S.?B8ZK&5Y%(VF$]_#]L?8P[.U")U/J;H]]
ML>'!$?._:0ZG9KW4;W3&0A?[NH)$Q[;$6G"/;6KQ,>Q_;8M>V`)K7Z[/6MKO
M+FQ4"%3@>0]Z/A(\`C_+]PI=3K&,&]><A&=]2&F6N>@F"00Y#X,8V\AAARHQ
M6!!&DG<ZO7?8+)L#R:<-]W`2>&66>!/11%GS^;WV'J8-DWD,0WYB]PC,:3(!
MBD+CH:?+;#M,J?M[XO,<Z]3]K-W79:]'E!E$6H6&K6G[-'<V]X@HLC2_&6<1
MM91,'QGE0,#/&3:`;`7Z1,]WZB%;>-1C][+AF\^HF3D.)]"8HUTOLWN*G"C'
M/W:='W'<1J9-W0DR<K&O;F5_O8-(WI)LKQA"3/6_"</FPA>BESSL^!'%]X6D
M,.T:*1.E>"[$U_2B)!&8]]<E;`,O4>N],5`H=CST)_A72L*B$V5*;;AC3+93
M0Y$DVRU3;]HY>Z`.C2@=T[:0#A])H7;G%AX6A1)Q3M$R$A^#&:,X3$1;2HP)
M%ABXBA`>NTTK]/@EOS\50AB&_!(&/GRT16=R()PS1`N/+OSB,]A?$Q@L.E9/
M4CSN!2EXZ@M8'2T'3KO!B_LL=-:T*/V8::NJ][3W`?Q'>Y,R;O_=Q].;]^E?
M@W<_40.]%9-J7^<.TF7A[=.;K\67\43ZI-W5M2_"-,@D%!)KR*?<I\[B%]0T
M(*6^D(.$XU':KM@'>9'UO+5+[\G6@VZD2=-#*`2,,@.H<4D<Y5J;Q'S6*!5>
M3L0R9`?72+8K+P.<)E,'/I<64C4H,+5+M@J3/:\3;.N:3;GRQ8`6&=\'P#7@
M>2`\HT0TV@8N(@6Q:@7P\CPUH%(3;!5PF9I+@0&-:7^;!I[#2ZH-41$_Y*W+
MN>=B4^\X;?-94$.$G!R+E(J>:S5&#_R=^0D#2TWV]!3=JA>[FF?F90EUB`'T
MYTBE;L8CMJQG82RW+.+E]RM1V`2["?A*,E-'USXR-]3^`88JUSX+34\H*3#^
M*7SA"!D+1'%J3UW0\)IL_[GB==$U-+(]83U?"VX0@P`X7ULW+>VWT],O].#%
MQ^L;75`!-B@')-]QZJ$[20#5Z!3`1-/@GKHABTFT,<Z+]G7&Z4`U'K;>%5V2
M(]`F"(C,>I"Z)9NWS*S,BX*<8S'Y'UD`-C:?)9V85N=D*XOV0<%B#/&0\)<<
MR83958RB3R(5,=K_1.^B!^Y+(<S+H$5(.6D#9]]RL6^@F#FLRHWYR2=`(Y`,
M2%,P.M"1/!7>&YJ3%X`/-\3UZNB4S<!@U$GR.0'L*^)1;K*>BW7R[,#U2FRD
M6@TG0<S]BRP")C<--$A$.P\/.SS&H7V.'8M).H.K!QL^"V"O//<;$B`8OS[-
M1U8PV.Z!?S()`N?>]3R8(EN,1XLA_Q.'<`E^T;"=@7$,1"Q\/CDEHJ(\J0\:
M/8J0EE!>"S^4J`/@Q^6)!;@97K08[3-IT`*@6:/Q-VZ+MW02@RSKGTN`99YJ
MS@O$5&[J,N?._D^2K=!5B:1BU^YQ,4C0HMUO45!C^V`./XC$Y7:A1_.48<?G
MLBLNBV?[KX#ZC1/L/)X+4,#@*``ZOAJ/84>()239([(^23O91:,[$V/.TMLL
M?\7+7Y$T&N+Q.8Z.U@,YMF2Y9'?$@+Y&Z2.%;<Y$-)'VJ"CKD'+!Q`]"@E?T
M8D8+`'P%HN2R%+1T058AC\,@[;BNL?G<0Y,<A6%*JT)<9C(R%;@9)&XD`QTX
MB'!<:#T,#$#@(UP,,D1.2Q7^)B`M\80P#@#R-(A3C!J10TKAFO4^YSZ\A!4.
MR&+XD:J?P*#RXO?S^YJJT;:Z)EC#M`5U3;`!">?JFN#Q^4HUVG[)'*;N"#:$
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M\185N>C-Z`\>\LL@OI!5T"[\VRD_R]MW7XWEF(M3/G_)$-6%7)47J=N1M2HO
M<JQ`HRHOHOA*51AI+).I"B/-X:YF1QQ>-A^I(B,JEM"@^W>JR,B+5B1["(&H
M+N3-W;LG!?)4%_*:Z+!7<:NC9M2_.T<H9=8`DE!=R%_*3NZ=N96VJX>V4QY;
M';E#=2&O?UM?U86\";NDNI"K+N3'4V"O@!$JF>-Q7<A_^?G`:3HKN@-=^-B(
M-P@?SH[5.3R#(.O(YZ3M+T6J#:QIBV2;3K>"7;9+MK&L5O\XZ396:[C)3C&[
M=;)3C,%@"\8?'EUVU@AEVTC*HR-L4*?88*\K^+'N2#/JQ)F*+U\D7]8I/;!G
MU@UE6X<#E)H]!'4..ZD!5$J]JY.WUV_71)<<*SDB]TR*>7?:(Q*'E+K;67H/
M:\\?/<4=NW.'4CO*BFR4%5G;4&)M7+V&)?$J7:R$QO%=SV,)C7KXH<U/=^YN
MD2'6/`NEVY#,B6MVK\T8[+'+O!WJ$M=H-S;+L6?9BQ<7VSX6!1^NF-^&(A&:
MU=:-X4`?&+WMDPH:9@/5@164\'CI`?C7)SK,CCXTV_K`[#XI9?`E&D)-L((^
MNKX;3;FC38+`>;%FT-'%6+,C0"]6I#TITZRO#\%NZ@U6%,%Z"3;3L?E&B9G7
M$S-20J;RLI+>Z?;U@64IZZIFS*9DTTL/`[UV@:19`]TPAWIWE[LFRL118D0%
MA%Z3$-'62Q'PD:S^0.]U!\J$J0%M[!H@.L4[0,RW\3I0J`4C\!AX9'/\XD0+
M7\,9VM%%GK*<ZB?TMK:AWAAZOS?4AX/.3\J&4C94'="E;*C&BI,Z?=JE/;/*
MB&J`J9>EN%'%$,U-;X8_(D&V81*Y#ID.#3\B7$;A6G`;*[-7)%#U=*L[U+LJ
M@4H9>K7"6+./!%^Y4-D^<B8^'KC-5E4_K/4%;$I5;[Z$P9R'\<,7C_GQJ>^<
M_RMQYS-\YUE[64DH-.8[&D]!>%KQ&ZM=P63;%;\Q34'RDH)5\9NGF=HUN+AC
MU.E^\;`)&*M;9>S7?;]ICQ4+%"<H3GAUG+!EJ$NI7Z5^ZX&Q6E<Z?=T2Z+'E
M"10/*!YX03RPI_OV2N4>[VSI"P]G;HS!%0\#+TFT?9\5)<V4&_'28KN;BIAW
M^GK;6''G0_&(XA'%(\`CIC[L/RVI6%D$Q[,(WB>NA^<92L8I&7=LVJU3LI]F
MZAUCJ!NK"FHHUE"L\7I9PQKV=7.P(LM*:?W::WU*_M"U&;.GKL_#A30,)?"4
MP#LV1==*X/5T:V#H9GNH;`'%&HHURJQA##JZV5U1?DG9`K6W!3X'<1!J=WSJ
MVIXZ#E#R[>@$7"?YMD'Z&7A",-BE+HMB&\4VBFTZ7=UZ<G=[93(<RV2X&H]=
MFZN`@1)_]:'A!HD_TS1ULZ_R"A3;*+;9A6W:';W;-9754!/2V=5J.`O\*`X3
M.W8#7X,?YV$P"7FT?<4R)0950O5KDXF:I?<&`[W;ZRMS0?&)XI-'V@Y6U]"[
M?4/9#C4AG2I"(7*ZN/QP?@EPM5MM*M"P?:4L=4.K'H)2^57'E(V:8>E6NZN;
MRF!0?/"*^:"2-X9ZW^SJPXZR`^I"'KO&$#[Q*'JK,=M.9HG'L%"4P^<AMUV&
M404E\)3`.S9%'TWQO^G@H8)N]:T=2IPK/E!\\-+X`'A@:.B&N:+4O]+RM=?R
MF6-?*A.95:K4-9_'RMVOA[1K5EST-16N'>IMR]`'PUTZXRH.41SR>CBDIUM6
M1Q\8*T)E!4M!?'RVRLZ;BS133>>QZ[W]&O%QXGUR[WAT-;Z=\M,HXG%4+@#]
M'!6=/Q3\<,V-8,K9/*%*SK[&8.20X=Z<>*[/M1&+X(G@CH=4Y)E'L3LC9SZA
MQ6@>KB8M`<UH0?`?60PZVEP*VK*J2M1O50K:[%H%AFA>(>@C"9L:&Y^'+(]&
MS*:TZ^&T:[>N!-_MU0)_SUT.,--:G]PQMIY\X"R,5#2])ENOR@$V6Y8]8^3P
M58JO3AM$5K^MQ%4]MEK5*E-"2@FI12%EHI"RNDI(U6.K56DE);J4Z-I.=!G*
MM*K)+JLB,$I(*2%5*:2Z8%XI0567G5:E)Y2L4K)JE:RR3C;Z@>63Z5]^WO9,
M.#M`OO!CYD]<^$T\]ID[KLV\CP!WXC'Q5O2L1\DY1.GA;]X7.`H\[CU@R/KF
MXX=3C<WG87`'W\\$U-I8@KW;>7'W\>?%O;Z@PN<_,38)D/5ZR!C4J5F[T6EO
MY&*S!NW:C5Z=D+8YBZ<...O7R>#I6EOD/M4!:PVS2NJ`,D5HF["VI1NC](?2
M'S7"6;>3&D0!VD/I,-9&5!XKY<V0?QX?M<^=!91>SR@VY-YP'T/)I&/SEY))
MAS`UCI5^6!N[XUBRYW4TY59<H+A@`Q?LJ2UWOV6\/,5+BZK_H<9O81!%FLW"
M\,'U)QJ;!<DN)QL-T^S/L2DO+H;0$$HNW+C3NKK5[>O=%]P>0U'RZZ#D'E:3
MT#O]%;U@E6_;@/T\+=2,`@4;QNZ_=ZP9U3`UVQ#7H6;2J2GD7"QX8^K#3D?O
MF[T76_A)T?)KH65+;W<,?=!^4O&F=LOLIM"_&$TK%E7_W;SD\6MQ99]E2UYT
M=*X"@\]?@.8IKH&I=PQ3'ZSJ?]M\W:MH_-73..CD@:GWMFB?4)6,NEM^Z<JT
MU-."SW;^?<[]B#]'+NIMJ3X1FTQ"/H&/&O/]A'DE3U+C$JQQ$&J<V=.T@I&/
M^SQV[[@LEX$W`N'[D+-QS$,LEK1+LJK1Z51PPU;)JD:K2(CU*F[4JVVB1Z?_
M&E//LR.F/X%F7_Y!:PWN6_2&=>6`;A.J#!^.`W)=>$KNC+:?$]?]",7G8Z+7
M*0?-MF$IH7=,H?>,4;4FR+GGK9%:B,UU34,?KCK-53+O9<F\CI)Y2N;5AL*/
MWCJJ*`;;7;W77=&]78G!ER4&JZ]?*S&HQ.!K%X-6KZ,/^P,E!NM&)(<0@STE
M!I48K`V%UTH,&@-]:`V5&*P;D1Q"#/:5&%1BL#847B<Q:/9-W1KTE!BL&Y'L
M70S>9HD+2A@J85@;.J^3,.R88!,:RC6N'9$<+D7@-HB9I[)DZB$:FY0E\T+;
M;6[*BUZ9,[K7U-5\ZNI4U(J<TD+^J1W,^"W[SH_03/.K[_!0LY,0:4Z+V7?-
M8_<:/(7II%^NSW3Z<!;,YLQ_H`12'[G$\[01UZ)D]$]NPVL!/2422_$R!@FO
M>>A&'(;"U='((8OY%FFG9J==P7C;U4@]5MKI-C=NA[6Z<H(O'_].UP81;-:I
M,+31C-N#AK%9;XT\!N+E.576X/F0%P;WA:I^YC8H/98Q=Y[+2:$%-%`#VC7(
MR?TD?NY)+!VK[F$]9%3#TN&5S%PO,Y^7=5Z=1J]STK1BC<.8$\^'M&<T(^I$
MY4;W+S4P`Y0L.WPR-/G7NQUZ**FFI%HSZ7VS5'O6D-V*,%P6J/L2!G=NY`;^
MQR`\:M"N:A%[P`W>0)^G:Z2[Y7GPCA=;(\G;YEF\;W-,KS.H.D+:*J9G]<P"
MX=?K*KG5KKHA?RPQ8IKU:+ZG3J+VC;%>6D&J*1TKS&XM\+H/A5$,QT3:N>^`
M`-Q_.PHE;)2PJ0?&!ILQ=B2ITC-:W9<G5Q[97J).=&VT!O78ER:3=FW;SCZ%
MLO?4,D)IQ^-MYYG(#5&)9L<42\^'L1>E9#<5&C'TCM'1C;ZAU.XKHN\7HVDW
MD;>E=[H#O=L;*-W;S`W^P,<<M*^CE._K]`E>CB9^T[':NMEM;]\XHDZ4_((T
MK7)PGT[+1D\W#>LI?2.45JU#@(+N4A5O*,BZVH\(QRG%^Z)DU<M1O!M\A`T>
MQ'!@Z4-3N<>OEA%>C-+>PE?NF+K5K:[#MS(E2>0.;9491'E$270R86S^]L:>
M<B?Q^-7X?#SF=NS>\>Q%O/]QS>W`MUW/I2N#SY]B]#&[RX=W_K2P!`XF`)53
M@YAGIQT/8Y$;Q!T>@G*-8A8G<1`^T.V_]*;@ZBRC+5*)AH^^'FCU^H)VGS^9
M:/`2[;W!\85GP^RN&F!L4*?N@CU@T"8@39&9(K/CW$-3@0+%T37!6#\ELZ9D
MH5IM\>?1,;L'_V5M^JD*0M:+4Y1LV;^U<*P8R#:F0T-D2)9JJB+:BH@;3,35
M\6BE]&J_=UC=AL6+0<%@K*VZ"JH$T^OTQ1M"SUODE[;;NC54S7T4<;\XXN[J
MO7Y?'PZ'2ALW<X,O`__$X4YBQUBH%(8*[&\G(Q9Q1[.#&6;"B-.^<0@3*P&F
M!%B-D*;(3)&9.I!Y;1HKK5.-1;+FH1N$V@.&Q95R4E*C::1L=(9ZKZ.:7RO2
M;1SIFCU#-\SJDP2E1&N_?2+AE(JXL>_:%(\@V(.20TH.-8V0W_2Z77W8Z6]_
MIU`1KR+>NA"OJ5M66^_V>NH>84.W\"J>\E!'1W3&0M=[H*L-/-.N7V_RKD=*
M0BD)U33R?M-OZYV^H;2KHMW&T>Z)TJG-W+BS*?,GV#409TK$^2/#JXC,M[F2
M1$H2-8V@C5Y;M]IM1;J*=)M&NF^,7D\WVRMJ-BEE6OL-O*BN;*/$T)'$4+.R
M_Y^_87B]:]LHEE`LT726>'R9FWT4KEE1`2>M<@HCG$81CZ-3W_GDLA$,$KO'
MZ*^%C;!B/IL'(0L?-,>%A0)!V3S2[J>N/=4FL&B-NC;+>C:.7$&QEARCI5"J
MDB<7\Z`!8<(/LG/64K$;Q[U;VS#M(,VU6NUB8SG57ZO^EJ'24_O&6`/[:TFV
M/3IJ*W36LW1'5RVXE#QZJ?)(582LK=A1W;H4%R@N4)V]ZKCUCZZ#_F&E^_KV
M$;).Z7O5(.D9D%8GG+T@E?JZ"4UIK=IKK=,T&XAJASM!,HK'B:<!(AR.=<JY
M>X<14I5RJ\1(XV@[/ZAYVM%FK]?1.T-34_ZIXH+7RP5=JZUW>D8U%RA-7WLZ
M6*'I`[QVHS2]DG%-INVG"+;]?-+Z>F>@3`3%/HI]'F==Z`-KH&R+AA+0A7\'
MB\42Q,$H"L"(L#'!"ZR*B(=W*DU:B<3&4?0!19W9Z^J=X0IAIVP%Q1BOE#$.
MR'(GE=\J:Z.9)'@N;E]%FA_$6J'D,CR7EK3$0I;*[%#2M6FD_<QRT6KCC51E
MB2A>4;RRT6P?ZD.SKXR&AE++S11OBRWW8U!6@I)\3:/E9Y9\G:[>[Z^0?,I*
M4+SR2GE%,_JF/C141D132>-KZZ:E^3S6@CD/P1CP)YH71)%FLS!\P"R)>Q8Z
M*A]"";W&4?8!A=ZPW=5[O:&R!A1C*,8H90D;`]VT>LH::"AIW`8Q\];4GE%V
M@!)WC2YF]31?!SR=H6X8*FU!<<)KYP2KV]>MOJ4T?4,U_3]4+?1ZB315>*0F
MCHWV9M@U],XN3<#JQ`\O2,LKEJ@-2_2'AFZL8@FE[FM!!U2GZ>+RP_DEP-5&
MJ-91QB6/5SOZRA10<J_V]/X<%[Z'O;[>ZZ\XWE2F@&*)U\<276SA8JH8?V/I
MP%M3HR^K*Z_*]-5$\M4^U/GL2*L3SEZ0BGW=A*845^T5UX4?,W]"M]S4:?3Q
MY84RR9<HNE`I.W0GT_@)A;+I_;T;[]4^;E<?]E:<Y"G]J_A)\=.:@W!SH`_;
M*S)!"S:%^)CV/J._'/=N_T'^#(RJ]FH[=46CSFICUWLK'OW(W!#/C,5CY\_>
M/.TLF,V9_Z!-N>=0@S31\`SSU2O:HL%JL)Q?$#K@WK)8&P/TU/Z;>J4%8ZW8
MZT?##AST.C8A>%O82\')%=W1AA7<G+8_ZPE^DGSQC-W/3.K#MMXX-7IU:FUL
MF&WQYUKA8\K^<L>4W\;FQEW/:$$V!&F#;HV0UK,:@C5%:H]`6J].I-89-`1K
MBM04J2E2JR_2%*GM*6RK3&/%V;5"FC*-%:D]UW&ID48KRJVHZT2!1J\FN-QG
M?@6&S#2*F6F?.8N2D,\`#9'&X@VY%4JI'9UIE*112JV.,F6''O6*K(^N0(]T
MI/<BM>DUGP<AU2?ZP&*N?8W@8[WTZ+%VNSY*=;^2+K)#=YZ5IU2"K@[Z^UA)
M"B]2F>.YLZ+MVH12CT3;]8FK[I.V/_$[[FF&(F]%WG5!X?[)6TEO1=XOF+RM
M>OE7KS).N8==?<_\;SS\*YL'T;M(8[;-YS'U0/:#>)=6QTIP*9>JIB2^_TL1
M1MO0N_VVX@ZEUA5W[,@[)XIK%->\)*Y1VD#1=3U06!]MH&W[8+4VV-)WM%HO
MTG6D9=6?5*@<_,L5>L^Q"R_;/VP('2OWL(F\T7![X+7RQNMU#A7/O#Z>49I`
M474=,/AB-$'!,10?TZ(I!RJ4<LAA5>F0UW!$^]($?AV0IJZ2*%*KCW'Q?$BK
M3Z19D9HBM7I@39&:(K4#8$UE+QZ=2!5G*]-8D5I]D:9*A^RM?K$-R^#A$PH8
MBP'*6Z?*C"@%^/JDDE*`M9(_JB1)DQ2S*DER'"Y1Y4OJKZQ5^9)&"\6&YU*^
M:/&'G344']0F]%OG;)D7S0>J+(IB!<4*JH2*8@7%"JK<RHMT`56Y%>4"-LP%
M?'S"\[/DC&L#2^\:YO8=:A7O*`-!\<[R?8O*:_R*J113O1JF4JI$47T]4/A:
M5,F67JLJ]'),2E*%7I1G>G0,-D\BOGQKH@:<TW!C0G&.<DL52RF64FI$T;RB
M^5JHD8)+*CZF)69^^7GL>F]/HXC'$5ZKH5LUT2W\?'X+5/'>"^QOO_[7?_['
M+TET,F%L_O;&GG(G\?C5^&8*^_R>1=PY"V9S[D<,4S]O8GCCBK)`HU,[=N_<
M^`&'X]EPFAWX2''7?/RW'_\TS!]_19#^^^2$3[Z?G*0@/FU33K4HF<U8^*`%
M8Q@(9PT()HU)F#06X6_%5'X-NY/I&O,=S9XR?\(CS4E"3&".IUQ[X"S$#[[&
M?8<[FAMI\Y!'>,#M:"/N!?=O<]2OJ(73[9@5+"D7PI(XT/)_G;1E3$:R3+O7
M,@O\4+-2.:;9/X"`7A.+Z+=7"I!<*KV]G[HQ;W*8:VL%V1L\*_Z[0)UJ`TH6
M2A5K'VX#A@K[)?+O/"OV.P.%?D7\=<'^X'FQWS.$9=Z0#7B6?,8_N#N9@B5X
M\ICD7L4\Q]0<A[A;O49SO&+T[S&=5_D;QV8;Y6\HD^OU8E_Y&\K@4JRCO)5F
M,L_I'0_9A"O6:1CK*%]%^2K*5U&^2M,V0&D-Y:O4$_W*W%*,HSR5^K+.-9\Q
MU]]<.5`Q3]V81_DJQ]8ZDTG()RS>I'>4I_."F$YY.LK3>;W85Y[.D77.^7<>
MVFZD7)VF<8YR=8[..V>!'X?,CA/F:8I_&L8_RMLY,O=<`/.X?N3:RMNIQZ[7
MP]MYX@7'%^/Z/`L/THW`2.FNQFW<`N_MMGE;.%T'XT+E@2UNY9?0M97[U;Q]
M>Q(+;N&]'8P%E2NWO)FW/)QI;_[D+(Q^4KS8-*ORX&4SE%^W/2M108K]^'0O
MQ*%K!-]=)7$4,Q_+4&@L7BJS8;RP$ZU&[,G6A64LHZVWV^T=JC/57V$U;8=>
MTI%7PW"_ISI.FM5J6XJ'&L!#S3C\:@;V]^+/*EZHL_=S](.L9N!^9TY0;LQ1
M-I'<V(O+#^>7`!6M9-VV?@S",8>%.,J#J:\'4S#"WG3)E_E)Z9[:RS_EWM2*
M=1[!;&:KVU$>3P.L/.7QU$S.*5Y0'D_C<:\\GF9LXFX>S_GWN1ONU]^I6U9>
M;7;F\1:<]L:TNLK3:8;<4YY.TST=JV4,E:?3`.M.>3HUDW.*%Y2GTWC<*T_G
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MD9.MCE'!RA(BEL2!EO_KI"TKNPA&-+N]`E>=77WZ=/KEYORM#5.S><3EL#;W
MO#ES\#13#MXN_!+-F;WTR],##]U#9!;DT@47>W7]-@Z9#PL(`?%KPQ)#8Z7$
M:I9\2H,0P!9$=U112CL71]6%4,3;1T0A!H>(%3UVRWJK;<!][MBAXFZODOQW
M(/)2PKFQ*>'<;!N6(N/]8'Y+\T<S+-VP++TS'!PX1*U89<^LTE&L\IRL\B2S
M?]@;Z(/>"I=[6Q;;IC)Y\[AL/S4,#\9HMP'X)/ODM">ZZX=DN^6M6`OLL316
M1S?:IFYU-VNLLM]<Y>`^UB,E!W?L>F^_\!!+6+))ZBU?W?O<`9?1%=[J%QC^
MQY+_>@[^J^9PVX551W_[\>+RXX^_&JTV_-\O/Z\><<.$P?AW[LVCP/_,'==F
MWNEL_MX-8FY/_<`+)@]GP:?X`%!M-6T9=#'$J?VO!"\7OG^X\OV'"U\.\V0(
MUXZ>`7+)XPL?/'R>S_?UYL./2V&&Q>DZ/:/?ZP[%?-D@.PYK+*]B:/:&O8Y9
M-6Y*LG]P=S*-N2-;REXFZ`'*K8@NHBB!U;+(M?.IQ4];+,KJ]H?=;C]GCVWG
M.@B`R^CI6)W^<#`</A)`Q.D?+`0Q2:&<7?9;4E;Z]F[#+2]DU7`RE/8XX.3+
M.PVV$K3B8!N0_<'U$OA6X+R827\X`EPUY2'!?0(YK@47L4TT>LY";',;@?BB
M)PL;%SGIEUM00\LPQ!Y6CKJ'.2N(IM7I;#.G1,3>5[IBW+W,NVZUF^9-&?P/
M-YZFC?&H/</NO&%T<P6W<MBG3URADW::6,H-?.#4?^*2"Q.O'G8/,R^OV3)V
MFII<@Q0WI[ZS)'FW7;'9SN==,>A3)ZT08[WM)[WF=C#QW7^#B/,O9G/FAF@B
M?PJBZ&I\$4<78!?Z$Q?LX],HXCMKV>[0:@^[`I(=9SH(A"NUXV.!P[,SYC]0
MGS]WE"!N;X-K'H.)B@.\YSX?N_$7C^UL`YB6->CT!'0[S+)WR"KD1Z_7[AN/
M@RS5JQ?^'?P<A`_7[/XSBWGHPOAKX*CR$*RV,1P,C%ZNK2M'?>*\R^LW.T.S
M/3"[CYKW(_BC$;BHOP6!L^N"^\!-O4&G8M[2J$^=>'G%W4ZW/["LQTW\6PA<
MM.O6#@QSV$495CW<8V>J4`QMJS_H=0=K9T)*/\7#8.;;_&,07HVBP.,1>,TV
M?P(!GX#+.1P.I.FQS01E79%!"G[EK@CN6=UAU^@5E$1QM$?.LPZ]Z^<!0VOF
MQE?C3V!'?XW6>=E5J^ET^FW#RF(%Q9$>-4.%2NV8P_Y@]0PI\;Q/7`\=`52U
MH$?"X$[D%#R&"<R.,32*8F;MX'L"HT+<6<.^.>CM`@9A"61^_)G94]?GX0,\
M>OZOQ)WC@X_!10\E0EN&9S8,O1<0EO'0,P8=L]O9#83/`5#Z/_C4M3W^F'4;
M0-D#::,LC?7(62HT>J=KM=?.DN[]QP0<(XRKPI(_NM_QT^-H&_ZO7U`H*\?=
MP^P5)-WN=+OFKK.#D1/%86*CD7/A?PF#"3SVJ-5;O<&@VRM$1=8,O1<0*@1S
MU^BB$;<M!)GXAI_F/(Q+-+\K45M6NVOB^M>.^L1YE]<,<JP[[!C;3OL)$'!J
MV\DL\4#_.A_X/(3Q*$WN`X^9N[N^[P#-6WVIJ#8/OR](EC%Q8EE#PS`[.T-2
MA;#=K8]AVS(&PU245@_YI"DKI+=E=09&?\LIRQH^/4-RQP6S8;M3C$Z[TF8H
MC+AR4O;]L9/V5TR:CYC'#*4N?\(233E;Q5#+TSQ^459W89J*U:S6RH^9T6AO
MTO6ER8N*\PGH["ZKX2J,EGY_/%:-"JU?A=FK\=BU>;;P)ZQ/2K_5`ZZ<\_&K
M[%;/6;'.HNP[_XYIT7Q'Q5,5RQETC79'RIXM9]@K1!4>?;?;MGJ/@^AT%H2Q
M^^_B\T\,$_8,HY\JHRU&WQLD%7@9]KIF=W=(R%`Z8V'X`*()7DQV-HJZ5K??
M34W]BN$>/565)V."Q]S=/!7HQ">M"3Q8<Y"Z3$N#/7*:JB##`*Q)8],TI[Z?
M8!Y#OJN8E;KK-IG&,-VEZ@'7S]?9=;YVM]>UULS763]?=V?7I),%.JH'7#]?
M;]?YP!"TAFOFZZV?K[\K2?9-:]!;,U]_S7RW4QYR-HYYN&N`RAP,C958S8==
M-S?Z*T_AOQ5#+AX87(T\=R)__L(>/K%1$#(P#EQ.QT<QP+IS\*;3[V4'4CM,
M4Y3SP,BGSAV&1YWW#Y^Y.(9_?_7A-@#LR3%W3?D96NUVKG6VF6&O$%5IGVXO
M-=YWA>@"FRWS*+X&%^[*E^]%'\-@5GASG>%4?2#?-M*-VVJ"?8)3=4[_6'`*
M[FV1`Q;U^<W'#Z>G<PII.C+O[6,0XHL[^_KF$'2LF4J:)T__7"NIBA6T.\8@
M8Y0]KL1AM&E7]Z"K;X/W`0N=F;C^M&L\J=OIIN&DU:,^=>)EU`QZ1K=G;3WO
M-;\+O#OX^1-XDE?CLQ`0$U,:PGOF?[O^_,&D!(EV>PT8%X9AM,W>LAX=]O-#
M_ZTGVBMH55OS:("$MBHR^3IAL0HK(##Z9?U7'/&1DU6NLY"MNF:B0JK8>^8A
MN7Q(^%>\@UJ)H>O/[ZWVHTDB37=Y])R'!;O23NKWC'8:(-T#X/"T&XG,A#RI
MZVJ\E)*\G9@QK$XAG6?]V`5%>`=4@`YTEJQ\"J*0NQ/_)AE%KN.R\`&^V,IH
MJ#3R+*L`U>[399">(\7.0Q?=7$Q2OF7?D7@C\33>4\7B6+MSAM%-@=MNAMT`
ML@X.D+4;0!VP7T_+/L*V@)F[`9;-5#XC2L*0ME^^)T,7,A5G1QO9Z,#_2N=$
M:T??%R`5/GZG.^CV!CL!4D@Y*#^T(Q*&`VMH%H^-%L=[PFQ5*^V85K>[:;H4
M#Q_XF`,FG(\<!./RLX_;]I..U09BS+&]W2S[!JS"&#5ZIF$]":Z<H3C,9KN>
MB'S"%T*/[!J\-$`I6,-2-MB&"?8(3H4/V>OWA\44]NW`(==<L!1(E2^A&X2B
M,L&NR!CVTESJJN$>/U?%*7[/,$QSB[G.QV-NQU=C6/+O>,V-[1HI..EUN\,T
M@+\\VF,GJB!O5.;=7F_C3!0@@:7.6.AZ#Z`2TF>_WJ2J8M<U]MN=-(:ZQ>C;
MT/#9%'Q"4&`ID\(#PCO\!_,2>B++>=N5S'IMJYP=^%0`GG,]E6*M9S[_@E:(
MR]-8BM.;F,4)INJ5C)!':L^#P'*D5:[1VH=;9FK>4_)D*4.41SR\VW5?S%ZW
M,QSD7L.J87/I)B".+H/X`W<P56CD`2U*T8LB=T<(P,;([-V-8^\+C`H],AR:
M_9W`6+0^,C:$#^EW<JAB<2W03G*[H^KJ6V=!M.L16Z?;[_>7[:%]0G3<)5=D
M*_;-H6$<<\U7<V#5&.,/Z=GI.`CO6;AS1O\0E?UPS5)6SW00""NS7DVK]W@(
M,R<F?3&3:X_*%#"&\#^CF$Z^8MRG3UY!>%:WGZ7O;9Q\)<9VLA8JSQ:&7:/3
M6<?U&\R!IX)48<#T85OV!-(GEXU`7<;N6ANVDIVZPUZ%<U@>\ZG35M"%.1BV
MJ[EX<5Z*#Q<N>GP(DE$\3KS;D#F@<&WNWF$QBJ@PQ*ZY-.!_#<WE*R5;S'00
M""L\5*O=Z1G[AY"\EKW@L-\9K,'@FGD.`E\%!@?6X&GP7?*X6G;M:MSW^L7,
MF^HQGSAK58RC9Z9'JYMG_<!#P$3LWO'?F.M'^57/QU5E6#G<$R>LR%>W.F9O
MZUGQ)(V'F,C-YS&2!!BQ.TM0HVUTTPR$Z@&?,E_%":K5-<RMIB-]:SQA.6*`
M7<9;"^["<-70?^)W?&>@UZ)?C/CT:5?>A-YJ6EK\4Q97&&#G05>"7C7HFN68
M>^<-,>S3YWX$GRQ,G:/B*:LLC++SR)N99WML[9JDN7F3K*=/^Q@.LBK0^,C%
M%0;8>=`M."@?%%SC6>"+VA.G23P-PK(JJZI*46V<MPOGU-6C%B[]2)W^]'E+
MTZX<-[=19(D?"2#60Q?/W@9?DM">LHB_?T@+:L@4!<PU]IUB6ZF=H2P69=D+
M"-F"T@=O8A;&UQ@_7E%+967)G,J\W=9B"9D5XR_!<>X[>X1BL`!%Y>A+,"R4
M==H/*)T%4-9-L@FB,Y@M9':<`#L^XL)+N]59"\O"\(OGUW$()J9KH\N^:VRB
M*$C*`ZWB,*+LW1FFFE?HY;4SI1R$%02W*;!S`0K1V&W^Y2GV"E&E^*`$ND>!
M5&SY\!L2RR8ANP$C%>,]?JYJ"R47E>LFVYW.5JVL4U0A:RGN'SQ"+O.=KSZ7
M_+Y=':<+PVQWS,'R8@?YQJX9?&G1']A#=#6?!_`(I0CA(>YL[@54`?46+X;Z
MXH+OQLS*:KB&"]C89;Y*TV)+TEN!I166Q2))H-L<.N5P_^8LG56S=KO]?J&X
MU8J!L\D_,C<D27@U%KLJ]^X,;43/6QL>6`6"F5Y6VSAX)1B$MB+"SK_;=,3\
M&%BZ^26/[>;(Z<`+(KK2&W[C,>G'DO&SA49>!5.[U4UK:*V?HR"BP(R!!Z_=
MZ-O'D//M4Y!70=!N&YU46JT>>Q$9>YU_6,+!VNF1:FVL`N#>N0[WG3]=[JTM
M+[QNXN+Q[M*@2U/^(_"`<3PW?GC<?+WL\LSRB/G%:7'3.'UBDW6UAK#DS>GE
M\?*YQ`WCI\YEM&2$M6*\)<$O^3YW%0I$_B096^&@;#%7GK$DGMW5U%XI^%II
M7G_5P(L:)G>AEE"P\\S=)56S-'I)WX@P;85BV#VWSNBGQ1;6#[R/^:MJ6?>,
M@;73_%E$7IZXYZ_A12U"W-+Q^ZY))-V.E>6^[S[;X4"M*"(V;*<5'9\$ZE<_
M7(?^:T[7LX`K>3C&"OQ@`=!@16-YUZA@O]?IIO<>GC[[SDOYZ'Y_$OSMW6!?
MFJ[L(5_S&7,QY++M>-<<;XI@/SV>"\='KF&?$*SUE42U]=O@]CX`X6HG^*XH
MH1%N=&:,=M?LKC73=YUQ"=3+P/_?A'GNV"UO5:4V>AR\%2IOIUD+%LZN6J\:
MH%SKK2V9#)OOAD`<5_YG]F!VR[=D=D%`(:JP>NC%V6\#=%2O_-LIV)B?89;I
MJ>_#3H81"Q\6I0(^"L.=A2Z5N-P7F$^!(5M/Y49+%0\R`H;@X=G'JR))')0&
M]PQ/-74:^R=/8Y%"1"#CRC^=AZYG#O9)GQ5#[Y,^C3H0:(Y/N?D85"FXW+=3
M+F?9H2[^*M#;K32_8]O)MH:.--FF(/,JN/KM0K6<;>>I`FTY,+`7#E@[0VZ@
M[^SEK]JE=CN=>:U[OX-;OWJFE):W<.?99G=^)=VU.U7N/"NY\^E/L$UNX%R-
M-_O8*TR3\DS%X;8RDO9E(6V(XZ^<+H]`+U+_LL>[+8M91C^[D+IJV&HE@B6L
M5\V^)Z6R-$7!Z16FKM23F8(\.[]ZW*;T\SU9,_8J-7/C?C^R$;0[!*L4=FKS
MF4^V958-O&H75UH[3T;6MA-M-F(>B95MC!AS?]2U=Q/F$2#DT7:"`'`\YBYJ
MRX3?!F"_GMI3EXNRXE?CPF!/XY`"^3URWC+<2Q&:S-L&,2E""/C8*=V&^(,5
MDC:O[NB$3&@9^"#`$=O^"$&]N+##`%95#F3+`VOC__E!,([D;TMJIB`6EH9^
MTJSW,NV!B;2']-1TC@JD*J5EN?+((A09R:R?_$_#7+?DD\*.92,^9HZ=%IAK
MTN4YR:]_ZJI,*Q<2<L#=)]AQS]*SK<7YEO=P@^`[7[^XHOQ;'OIITSYR%P\-
M1Y@&&>T\70C$X.P!;]>OSCG:.UAL,@GY!`28FR84W:$UNBI`NF[^0H+<:?R!
MVU2@RS(V*^_MJ6/-%/L!XY'4\MQP/9)Z#@[FCM2T#3QI8^'/S$&_Y*RRE\*.
MT7X+=+V5"K>M)BCJC\KZ2%L6TS,L*[L8OJ(04KD,T:ZW]'J#0:]=,7Y>RI8B
M-H\J.6QTC#:HH>(-T84RP,5VQY?!61+%`1CXI[:-3W$'(/H<A/QVROP;YA4/
M2;<MF6FV"U7_=YGJ,"!6E=$$'.T1Q"N?'P"-A:3M'><Z$)"5]4CW"V0:I:<Z
MIC#*33*?>RX&@:K;C#T-E]O-=C!`J_!I9MV.]@3HBJV0GZ/"-<D#4VC%C`<%
M^,G4NBW`Z7.@H_`A.KU--P@]['3SMB>-%57[3*,"^,?-_FP+J1:^UOX70H'A
MJW&:[U]ZH7#F=QMR*MT;Y?=)-T6J@2.[9G]%I#K-O'G\[,^T`JN];&&U][L`
M"I'O<N*V`K-F=JFE-.+3YJE8O]E*K;SE>>3[FNL(X8=?_L<O0*OR[`7^P).?
M&`^90RVRIWS&__;C-([G;W_^^?[^OA5QNS4)[GX^N_@_0//M-EBS/:H,E[\F
MQORY,.@O<XH[R0DBS):E?'$TMD_:!OS_+S_GWXJGN._DS\#_6P8.Z61/_/)S
M/N@O/\MU+:WQPK#`VNX<99W@@X"[&N,*K).V=8+9PNEWVZ_@_$B[5(`^P_]C
MH#>.#;WQ>.C_/!+T)0XQMN`0X_$<<FZT_Y_-YBXX5"ARHL,M&-;%)]1QZ)?O
MH]!SW+?\.ZA!VXU%97_-<>'7"'S?O_V8EES!LFD4ML=V1?$#QKX#'SWFT^\N
M@)H5C14+^(H+$(/]\G/E'+\"&B40VU-0^RGT#]@E/1.AGFDF<G,]63O<,L=Q
M,5K"O#ES'=>7E-Q(/)]F:_D":[GP)5'7#N<A]H[TN<-E;?1&(OM:+B(M\%X[
M++.\(4>`A7]`BLQ#/L7EWG&7TLP;B?A"HQ$J:'167)=(GZ_=7LP9EHEL)+J_
M$.BUPBA85<KB.++51WN@[)(C[X"R7NJZ,\K&J<]>*$NH:3NF[*5CQ'&4576X
M2."YLI<.BEME"3T_SI6-\RR4K:R7VNR%LDOVB5%,ZE86QP:K[\#GV[0'RBXY
M\@XHZZ6N.Z-LG/KLA;*$FK9CREYZ?KR?*ZOJH/EHREXZ)&Z5)?3\.%<VSK-0
MMK)>:K,7RB[9+T;;Q\[1?D(VT84!4YN]8Z_`.(%%8.^ZQZQ`="<X_AY@,/!Q
M*Q`EE8^\`K#,.R?FX)%41!58CDY%[>X)EOY_7'R[4,B@2;*1BJ(%5V-QR:M6
M,>Z-Q6::AN=US8MJA?F%FC1-P_/>Z?FY8S^*ZNN[/^>*-P[D62BJKPGFUU<9
M:OA.9%7^S_+%82\MK)=3/YY855BI:9MPFJZCW+^P5OA.:P<<UP]I#\@/Z3]Z
M!=:Q(PIB!5B/8[L5X%$+@7]35*DSSJ(DY+\*/?O+S^G?]#J^4GX7"UF57W2C
MH&,:_;?PR^:W"W4>Q"@.E>&6:\/G+I,9R(\XD&RR>9[_D#,MO$B#?>!^0-W[
MEH>K6&\ZTN);O_R<0UFU*BJ>4D;*'/Y5C0W!A/#A_P=02P,$%`````@`*(1N
M0@XA(FV"!0``%3P``!4`'`!C<&AI+3(P,3(Q,C,Q7V-A;"YX;6Q55`D``PPT
M0E$,-$)1=7@+``$$)0X```0Y`0``W5M+<^(X$#YGJN8_>#,'3L9Q,MF=I,).
ML>!DJ")``3N[MY2P!:A&ECR2S./?KP0X,<2R<2I3R'MQ8KM;W5]_+;GUX.[K
M*L36`C*.*&G4W/I%S8+$IP$BLT8-<6I_^7)]8[NUKW]^_'#WFVU;/4A;&+"8
M6[:%[A&&UBA&`B9M6)_KEU>N:UFVK30P(C]NU64".+2D+<(;YW,AHEO'62Z7
M]=6$X3IE,^?RXN+*203//WXX.]L(WZXXVE-87B7BKO/O8W?DSV$(;$2X`,3?
M*7)TRS?/N]0'0@$K-FEI)=2=G8C9ZI'M7MI7;GW%@Y2C4X3WS/AS1$`T!RP$
M<XI5/'G=IZ%LT[UT98A2JJKQDE%YI;*+BWMS<^-LWJ:E97.!>!9/MW[M;%\>
M2*,<=YYC+?D]VQ+,*(9#.+74W[^'G5)Q<)22@P+VU.KW1OUNI]T<>^V_FMUF
MK^6-OGG>>'1N;1#=BG4$&^<<A1&&R;,Y@]/&N1_-D9VTJ(CYE-^@\^*[#[`?
MXTV:=.7]GBFX$I`$,$B,*5??'9QR9><+IG[:?@VK_*6LEL9:2[,X!7RR82;F
M]@R`2!EV'8@%3YZHJ+CVA;M+V$^[QT]-SJ'@K9@Q2$1B`(,)Q(U:MHQ3UM'7
MI,@^\M0,%BI[^)B.XBC"2`X;!^9U4FD'4JPUV;XO@/E)@_+?#64U;3+O)!P>
MA^&F-5N.96&B/V4TU(4CL4GU#ELQE[9II-H%N&91%D"V&V27$,WF8GM3.K+O
MDP(MP.?>SQ@M`):`>%.T`&-KF</?`8ZA)B<*E(SEZ%C0V91=&D19#C'5"+\N
MR%>&!+D-IU`"",9@M<73@R)_H,S3,)Z27+C93'TVA*D.64@O*5M+ES74[(D8
MS\4^H.S@7QL2_+Z80S:$/I1CZ03#XEZ2HV`\,7E@LVGZW1":RC!447)*\?*'
M(;QL4>56WN]=<M]3-HB9/Y=S2=Z?=HB<QLV0C%JF*R44S4@0745>A/I7%>EE
MN!@P&D$FUDT2J.(T"E_WT9+*5>(D&[W9E?AA'LF!QUOY.%9K``^4!DN$L;8D
M.4+5//[*(3>[Q$\R;H`!$>FTTQ>2N2KFLI6/]`WEO5GP#FH#LROF+@(3A)%`
ML&#A+4/P5%6*[[,8!D=[KI<_=0[I(>SEDQZOV8MY<O8.^0"L516<3U&69#7(
MR<1H=IG0BKF@(61)X9-/C4ZZ&O1HL9I="\@N3V,BDL3:S/0+!SFM1C6HRL5L
M]II?.X9C.H0RK#`8`%;\2<I1J`99>8C-+GAZ5!SY4<J2K`8[F1C-7A(\Z/UC
M!H(">O(TJD%3+F:S5PI3`(OG"P9LFJ6\Z5'B'[MSEJUF4'85;)YI8+]AVF`@
MSN,G1*94WBF/FR08">K_4$=T(.-J"42LB[M2MII!1.7BTK!G^CSV:*+^)]1D
M297I6'?.(=RNO/^51_-&8WE]]'KC4?^^/_"&S7%'OFWVVJW^XV#H??-ZH\YW
MK].3M]Y[G-PK9>^T!_M*N7J:_O7`*.<#1J=(]TE.2YQLSWH!2:PM=YY?G[K#
M9P1S?U\Z@6'VF-NB7/2G.V]U2U-[,H8'_@#0$>.I;<(IIG^81-RF2U)TENE%
MT'`BLJ`=L1IX2C;Z$602-9EYJP@2KAV$7LN=;B]S@=1/+^XI:]-X(J8Q3F:[
M^KU,O<JI4TI+P,&V9@YHLX?;!T@D0BQ+Q&80(H*X4'@7<(=7]UDNT*H$;870
MS9Y3)L<;I/\'IR`Z8000RSBV4TJU&AP>%02S]WQ&$.,7F+H9YKY0)<@Y!&;V
M7LXSI`Z1DRO8E;5$T=<V)?E.)_(>Z`(RHK)V%$\X"M9;$QG'[W22QF3&ZS`F
M!^^T("NR/%D`,;,<?<.WQ&!H&=V_5"6M72C:O5`7]2M3^>0_4$L#!!0````(
M`"B$;D+`NF3^+2<``&V;`@`5`!P`8W!H:2TR,#$R,3(S,5]D968N>&UL550)
M``,,-$)1##1"475X"P`!!"4.```$.0$``.Q=77?;.))][CEG_H.WYR%/CN-\
M='=R)CN'EFA'9V11*]%.9U_ZT"1D<9LBM"!I6_WK%Z"^2`H`08D4"U[E(;:E
M`EAU+P@4"@7@G_]ZF05G3XA$/@Z_OKE\^^[-&0I=[/GAX]<W?H3/?_OMT^?S
MRS?_^L^__^V?_W%^?C9`N!,X)(G.SL_\:S]`9^/$C]&ZCK./;]]_N+P\.SL_
M9R4"/_SS"_OOP8G0&7U6&'W]>1K'\R\7%\_/SV]?'DCP%I/'B_?OWGVX6`O^
M_/>__?13*OSE)?)S!9X_K,4O+WZ_[8_=*9HYYWX8Q4[HK@I&_I<H_;R/72=F
MAI4_\DPHP?XZ7XN=LX_.+]^??[A\^Q)Y&44G?I![C#OU0V<^=<C,F>*`X1F]
M=?&,UGGY_I)"E"G**J^(RDZ1%2Z7GS]_ODB_S4K3ZKQX(YZM_=/%\LN"M"]1
M9X,UY?>G)<$.<0D.T`A-SE:_WHUZN\_SP_C"\V<7*YD+)PA^/DN5_1(OYNCK
MSY$_FP=H_=F4H(E0C[7BC)!/C(I_L-HN#M9I2A4A;O*`SNFG*&1-ND8=>;4?
MKO.FKG,/39PDB&O4>+?N6O7%,\>O$^"=JFO0-JWH?(9F#XC4J6JNWHR>:R6+
M&JKT*A>IRKY'_NAB-Z%8Q.N?1NB98>S'BUXXP;1XK-2RW?G4/U]7GJJM7'?&
M(MIT_-!GG_;IG[F'HI<8A1[RUH]E^C=I<:K4!4>KNO'O6(.QU>]U#=OL7AE]
M8]`QQ]],TQ[O"[JXPJ,C+5:%:;)2)<!N]OEO`C888_(F:^J;[,LW<:*']'5)
MHO-'QYFS!U]>H"".UI\P4"[/WUVN1M]_K#[^8QP[,6*4V\Y#@-9/")P'%'Q]
M(Q"Z:%E5R@_JT5^C,G6W@BVI;$01BB/C(8J)X\8"=0M"656W;=(@>:5I%[NN
M;M7;YG4N[8[7I2<$SZ30K1^+A1J?)1%].IXS/9W@S1DF'B)+C[A5W#L)(:PS
M4X&_*-LJ"_QFL\O`CH'@B.@XT52`>_H5`)@%K22+]M(*D.":_YOX3TY`#8B,
MN.,0LJ"#S[T3)**^O*20/H3(+.=3];X]JD;(151;.GI&`Q2O+!0PQ)?5@QB!
MG7P^/K3'AQ5/$:E"BJ2`'LS(+.;3\W$?>G8=\(D?_&%X3RSN$=EXG,SG@8](
MT7<32<$&5V@;']%/[37X7OA$;<!D07D7-/&<"&S<^5;Q0?^E/="[:(*H#9[M
MO"Q-*NUF9"7TH$1J,Y^A7X%,%%0F")JP4+"+C_MO]7?PUY@,$^).G0A%UF1(
M\!R1>,'"2=1;F\]V0:Y8&`#Z9>.`"@0U^J=5^.B%L1,^^G3X7YJBS,5.0>UX
MV#4=G$^Z;BK#P%E&8-?M13QD2XL`Y4C-W!I=TKH<J'P#HEJ:+VZ0L&#O#<;>
MLQ\$0L=*H2APMM3,!^?V<ONYPI?`D9?W5RUZMWW?>?`#"A:*Z.L[CK'[)UO\
MH/,?]BK3(4\>=U4NKD%`7!T*<)&IC.IJ\7))@5:9JMH<!?S!CZD;KHN3,(Z&
MSH)%<FSB>*AD!B,I`84SE4F-S'"(-)$$>;LFBDD2R.M%D<AH<#V?[;R@=5N2
M4\.3U(@4KJ'@IC^%MSN-5U?JUG(E-*)':CBX>5`GB6(\0V0]S993))+6B!ZA
MP>`F.]T$V7B$`NJQ>D.'E`\YD@(:$20S&]RD:8!CQ4&')ZD1*UQ#P<7_E;TS
MO=TR=7]LKS6!VE?+,OH.<.BJ+IGQBT'AJ?*LM!P0<#YU1L_R%TE?9G)F@O.D
M*X?BH`;?#J&H>A"N1:=Z2%:O>JJU+'V/)]ER@+0**UQ#P85N.G@VPV$I%SMB
M&A&Q:R*XL<3P/'^IS=#QO5[8<>9^[(@6V432&G$B-!C<"#-",34=>:9#0K;9
MQ7#=9):D,S#JM/BN+\YM+2VH$6$J,(`;:S)*+D-->#8G:,KV_CVA7NCB&>KC
MB"WP6A/J>8IC;Y5JT8C5R@"!"P3MVJOL^.E$%,],<`&?,A]VS]5Q?1WS<D#4
MWJ=ZC7:VV3O[)``4MU&N='[W]A.53G<O?W%Q&*.7V`Q2N:]O(O3(2P:\:'^;
M[=`8F0/[FVGW.D:__DVWA>KA;,$M*';:D*NJZLZK`7=#;A#@9[:,<XU)%R</
M\20)UNMOV\TQ)<N.E>K0('NI(B@U3M<%R<L2?:RPN)&IP-(>%0"F:!\XX$WD
ML],BZDJ[?GJ@!/T]0"G2H6?,,(G]O]+/A8G!Y5.1PZH'W`[JAQ)<3.&:X8WZ
M=([E%9.-,U9GK1.TASTJTH#Y?>`!%WO(AW^'#K%(:KV7QB"'B(RI`Z<6^A86
MUH!+51C`!1;RBJ=:1D823S'Q_T*>$F\[A;3C:]=L<$$'GL*]*$HJ<;0JH"D_
M:W/!I9SPE+62F)T,R&:M%0C*EM*4I9SAX#)2,HMD%<<JE9(:4*8$`)^VSR!H
M4QRB9"7THDEU<+I\!X@?Z=`DDM:1%_F@=`DCY4%U2)(6T9$=A<'HLAA&.:U"
MU+@*,;;I_[?FP!Y;U];0'!EVCWYK#+H=ZW8X,K^9@W'OWNP-Z)]F'<L2E9[7
MZCI%)4U/"Q>O;^%BA)Y0F`BS:C=?:]#O;DT!F/@7Q=9DI:!PV,O*:(!WP2AP
MRP.;0[R^$S]&7?PL"NQR!#6`GV<>N.#[#<%1-"1X(LS<RTIH@'K.('!Q<&N.
MB!/3L=]\F:,P0F5'1(OE-:!"8BRX`/<8!<%64Y%7D!=JE8+2EI2;'Q2L`S?^
MWJ"0FA.P54QO1H%DIL3^$Y+S459*'X)*[0<W>-,N]LEGMX9PDA.$H6Q)$7VX
MDEL.;X1?'=)%VU9A_;@WFSL^D218*!75AS@U).#[#*J^@D;4<&RLT47@9YO=
MX"=$0D;Z.'F(?&^Q3/'GI)6))`'[8%(#P2U;;^C?[K(H:^092<`T2`T$MT(]
MP"'.*[IZ'4MF*>7E-*!(P7APZ]0LQ!#%S+2EQG180X1^(HFC<,5;I4>YU16#
M*WS+P<UMUJK)YS)%*1TI*=@);LYR0^UF7:\5CIT`69,N(OY3.L\2#3>R$OHQ
M)+4?W,1%:&+544A#IB2V@YN?;%V::VIX!X=4Z83JO?)Y<!A=H0DFJQVTZ9F$
MY@NUG&KNAPY9I",R.]R&EJ2@!JG))>-8<T_4P%-I%'!P25T;*U9OP!4*D7BU
M0B2M#:T<0^$E<BW75R33M(R`!LAGS8&7H24ZB^":ON+^8[C<GN<N;.*$$1U.
MEIN!TK^"M#<PO/])EJ[R^N2"(1WWL4=K(<B)4!<M?XIFW,=ZO`8-Y7A4*&:A
M'3=1L&AVR5$ALA(:D"TU6,!/B^[R^BR:=7YV2<Q&**X!,V)3!;2TZ!T7=;UR
M(M]5Y&0IVRHA9:U*1LO*5'`!F:*>73](8F$:NDA:6UHVYJK%9TZ)S@TE.H]M
MJ_/O;U:_:X[&YG_=]>P?=:<V<YX`)IF9H]LI?5E5U>6!2<Q!P2%B]V"_^*69
MS-PRS;WH4UJ2N,D#.J>?,A]JNVU?\.+G\.>^]'RSQ>-+69?0UOB3-Z.;=O>B
MT8<KV^#8LR;KW,NI)>!,UA!S8Q#?9'BNP:'4_'%Y''+0Q$F"N$EVJ"7ZO5JK
MDU/O*.;1;<Y_*LY-=P7;=>AD#2\W*^58".XURNRPD[.P(Z<)";OV@5OL%!PJ
M+.5#7D8/;DKL!K?,63Q+6$J00%@/9D26@EO15#@(6/X:*9?7@[@*>(#;V#%T
MV.&%4KIR(GHPDK>JQGQ.?JKL`%N3Y59Y+I!<$=A`\JVJ,2.3#^1WY#].V7%M
M3X@XC\A\H7-D/T)#XKO\+D6Q$'RP52RO,;]2"?X18IK2H8CE4+#P:>($-B*S
M'\@AXI:^1R7:T:.$3(VI(H+S8!\?"7JDPTZ/*N'3T<9-3R`2,B.7AT]"B;WP
M\D`T/$]!]9`;+4^V43_.IN4[*I;G(743VLH?ERD02]4'Z#G]2MR.E`KK0)4B
M##7&%?B=+'L0.V2:^D),)2-BG11U[7DG[9;+`T9>P=@:@P,"1QK%FXPA>XK8
M<,I>$YX_+9`$#K#0P!HG^7QH>3E8Q:PK#LY*Q8"#KF8ZN*GY.DD$>9(NIT08
M,#-E9C8^:Z?-8H+\."&TNUMFB3]278/%/8K8[\NAAO]**)0#C'P%XQN?\?,[
MQ/?*/?Y[Z$`+#6Q\-J_2[?&&5K5RP&%7-%YMCG[*\6HHQZMCC+]=]ZWOM5RF
MQ:\83$;75J53(M?KBYO0;K[C1-/T\!O:CJX6=Q&[D&1SL('AQO[3\G*_DL,"
MJE<$N"L^!!YPH9G-4"[9V967:7=G[=Y-LL!<^:$<+9*2O>ZI<,N3@")9B5=`
MF!20QL-E:=RH;-(J$=28`)GYC4?.MF<5W.RF9'($-,>Y:&[CX;,KQ^NBAUBZ
MR5HLISG:`N/!1<RVY]19D^)E<.:+&R3,;U\?<R<8':K5H3&Q>X(&[G`TF?[+
MRP$#=CG@'G1G2[]RHG-`@3MXK;NZ(*O:61=EI5X!I:7``#R2+;^5/V/R*A.Y
M9'Y<H8)70'`5N"`>35-0?GT.,)V7E%Q7O5\=K3)>O6G+F9:"U?AEXYTI'2!0
M1-7PGEA*0&3C<3*?!SXBO$4QJ;B&M)1#`&Y'RZZAZRLV_`JO5[:,AKPI@@%N
MFXOX]1\Z"_;.V\3QQ(=C*A5^573RX0&W5X:K.$F0U_>=!S]('8`JK!:+OC9.
M=Z"!%V00J9V>)+AJCE4IS95]C9SFP8$71-BUFKE<A4Y&?4K"*_RJ:.7#`RYR
ML*MX)XEB.E<F:Y].F=.=@J^*SUU8P(4.U&?4!R^MZ\QM%9C`A0P$RB^/LZ\A
MC4)6D;YI%%)X&E_R33,$MM<-7#GAGXB,Z=B`YC&OBU4K`S%XI]`,<VF?<E`:
M#^&L^_)K3.@(O0S\#Q/B3FF?$M%?"3M#/5X8H<>VW\T%.P#VJ45S\O8"KO'W
MK$2KXI).=2IW:GC=-.X"!BXJM%([LK'ATI9&T+KI#0,GC"4O[AX5:$SV/G"!
MBQ2I0W"PR_,:N*X"%[@8DD#Y:S^D'58-;JZL(GW=7"D\\/IN@EV$O/02D@&.
MRT*#0G&([ZI"0RU<("&``EPZ<5;5$4K/=!HZ=`1A^6\*S.T4>67L[4(";AE4
MW>B#^]37P&X5N,#UL>9D@ESJU9LO;KI6/Z*-TPJ9/=398S^8P_?D!$A\ZW:E
M*C08.ZM!`LX+YBM:Z4:>2E5HP&@U2,#YNGSU#=KK$+*@'4QZAE,E*HMEM>5P
M!P1PZZ)IOE-JGA,PY:\#_-P+)YC,EON+Y+,3U=(:$*@,!,`ET.7=A>RX7^%B
M9T:D73*JM3?>_;I+.\%-+#*W33(-J=LE7GDN"NI+R:[-X.8+:YO8C9_TUVT`
M*?0X3G#7C]P`1TGI!6('5ZM!IW@X=(T?@E)(46%+`=57P"K7T2IW=37HS3)*
M=0B;7]I<Z;3-B>_@(*`3'^1]]^.ITAIT]3I>):T5(&S^L,55CO9BW<+4V50N
M^JI(5`>L\1WHV=56>?_`?`'UM[2.:E\5Y_4`W?B.>;Z:VT7WJ(9FH%;;_P/V
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M.KS$;&6M]N5;-5J`M&N.>O?4`[TWOQLC^M+8_9YQU>L?<,V\4MTM`B[1J@7\
MKXW>Z-[HWYFW=)RX&RU/23X<>GZU+:+.5Z@%P,>VU?GW-ZM/F\&8N:AU-'1.
MG2U"S=&F!9QIKW;;LU.:Z62@8Z6S67-0SPQ?5GF+R,O4:H4"ZI8.J"M4D]-7
MJ*]5H'.:M#']62X;L1NY<."[/HK6/VN8\HCK;G.:(]:J!?ROC'&/SK*&(W-,
M&T+:#M+(:`WPBZMN$7VQ4FT&!NN"O%@AA"!A>_#R@FAU(2VI&UC8L,WFG0_=
MU-?*N?4""B2VB?EF&EP?W,4J84SSVP.9.PFK"VY9Y=`FGNU1D$[.K&&ZY->Q
M>_=T=E87`>*JVYZ,<I5JH_W?V:P%]`:]V[O;S&2MME=`7G^;;X%<LZ-QP7%C
MNRAV_&!O]"4U'AUOB2XM[5LY7796(55KB(C+\OL?V<7/[.9/ZSG<N3%!(@@X
M55UF7N-9ROP'X\DW%,PC'-XBSW>=P)C-KWP<(W<:X@`_+CJX'ZN#KU:;E@PI
M`M5X5G*JW5*YU;DRWM7""L-%+UPI*&)+7D@'4DK,5LLJ/B44UN\]7#F1[QJA
MU_6#)$:>Z9"054!)Z^#9#(?I:U2_BU'IL1#\D$H*GYP5^,[*YD)*3J>[_0YX
MWYHQ`MQ.U>_(?YS25\5X0H3V_H.$&;H:EZ->%"5T'&`OE8!YY>*`*:H.!;AM
MK6E_YS^A,7(3HG*4F*2`!DS)S&U\Z]-WAQ!G]XB9W%>`,<R;T/C&("NMFP?6
M^AO@6&T,`'?6BJ"_6OD^RV[+2N(H=D+F1E7KP86U`*9K;V!J/(E%=*$L'3<R
MWFBJ`^>=X,L!AEQB7(UGHPAN0=YQ\D6PBB2!`RLT4.T@A=-$O/Z)^'JC6OUS
M[6+-$*;319U.,V;X,^:U;\=V!9LOB+A^A(;$=WG]HE@6>,\H,;+Q./_*(62/
M-L(RA"7"P"&6F=EX$-[&L1.L2697H@IG$2))X.@*#6Q\^CI"+GX,_;^H>QQN
M+PGOXX@=+!!'"A=+5*T!.!65`6E\SMS!5(UPT:'^$/$?$O8@&X]0[)/4DM5]
MW^R:`^[EO!5*`Z>F$A"GXRZ.XA1O,H</=(%WZCFZP[NCP<F]A>3>UG42Y^K,
MK)'S?$N5(KX3B*^!Y,D"[B-+C`2WV+31\YJB&$V1=X.Q5\I&7E@G.@IF@ELV
MVBAZ0ZB[4\;#4D@G_%=F-7\:7A#@9W;JUC4FUD-$C8E<1/^4]#G*Q0#CK6YZ
MXRYS.I_:\+Y[WC)?!CBV'*-.3NY1G%S>3JT#_5U9E4=W?67*G+Q@2%ZP,$EU
MYL?6I.^$WMW.W2@\">!=W8Y!X'S7J\1?OE)&Z/5F<X*?4HLBF>LD+P.8$D6C
MFT_&9E=YWCJL8T,D=]HM#W:5$H!!5S*X<5_V%E/!>S3UW0")0-Z5`0XKQRAP
MEV%=)X2BQHZ@8(<%O[#?I)V+6!XP&0K&@LNSZN`PBDGB,HUZX9#@1ZJLE!I9
M"0W(D1K<>*Y4.NM1O*Q#+`L8YA(C&\^;ZE,R#==-9DEZO6<7S0ER_?1^G]4<
M@(.T0B'@D*N8W?@--3S*^=$*D21PE(4&\J']?(I<-!^Y6"Y<]_W)H5O$U"H'
M$<W85>L4U]`NKG%+&\\LF3$6RT,<66'HG:3$S&/L4\\]W'FI@'%&6#.,LV8V
M'K=8QTWD#9@G!1Q5KF&-QR0V3Y6V59Z4+G"6M\X:%\O$0291+R`O`!SD,G-K
M##B4A]3D/8)($CC"0@,;#Q;DGBSM'422.D%;WDO4&":P)A/?19MW1=YP)<+`
M`9:9V7@XH/AP:0N6"&N&<7D[/L4%:HX++$\^Y02]]HT%B"L\^OQ?K,IIS@]_
MSI_ES7R9HY!M,U**_JN6!-X[*@/0_$7;,TQB_Z^L)@K[@51*`:=`R7"UJ,%I
MI#IX@TG^M.[Q==<PYFGNB;<Z&_`:$[:*$QV\!:7RDUK8I%)9Q].@!W_02Q?3
M.PXA"W8C](Q=.<+I67E2P'M2KF'-#US;==UL5U[LPR4O#V]<.[Q2X&35`5OC
ML?0!BDM?E%T9X,ASC&I^ETH8)NQ<W2W15.0#K^'S!8%#*C*O\7`Z]\$?57']
MJ"6N'X\0-N<^^),JKI^TQ/73$6+FW`?_HHKK+UKB^LL1`N;<!_^JBNNO6N+Z
MZQ&"Y+L/MJ>((&<2;XV1HIL1UP[CK*EJH?)ZD69YJFH@IY+ZX;LT4#!#>5?[
MH2[60^`_KIX\=!9]YP$35@4[PS;TK)C2+3G41:DT<`XJ`2'@I3AU/`7=#@RZ
MC<R^89O=H3&R?]@C8S!FUUA9@_$M6IZ=>F5U#PRV57C"T8-L%70[!=?@!]>6
M,VK#>V+G$GA7BPR--J8#ZJH'XB]E*)4$WL4J`]!X8*Y'^SF"HGA$5;;"E4;1
M-;4GHQ.'"+5RP&E0-/ZTKM3J$&<]LT(-C6[YRL$,;'FU3F.:!F.:YZ3=1\J<
MC:^P0[Q\[Y0=QL3"P+M,F9EJ@]6IGSRPGQQ8MCD>&C^,J_[!YYQSZSIZ+\C5
MXM3IP>_T1N@)!T^465:S->D0Y/EQ>B+UE1/^.;KMOO_T+OW'Z0/5RP+O$BN`
MT/PZ>QH_R_JUPMA@3@@XQ#RS&E_7SMQ`<^4$;-#K)NB.=GF$R_CH]NK#.V%K
M/Z`RX-P<`M/IPM(C9>QUK%O3-GXWQY08/UH>UKV]N(8='I7>?V@[+^SE.CQO
M;\_GM9"]MZ>F)^\$OG?"9=2:B&^)+BD`O",N,_<(L<0G.CHS'3=W4AO7F"#_
M,1PG#Y'O^0Y9T`^D$=X]*@'.RSZP-.[<9#H^D[E5<^*SE/IL5R>XH;1J:>CL
M5`&B\11`D0K+YO$#.805X3"B6!`X&:KF-YXRJ*0(+S53L>!KX$&8NEECBJ&2
M(A^IEV8(DHTJ5O`:>,G`H9:J>)I?U3>_&A+\Y$>'[]Z55=GF+&E'F=-$"-)$
MJ*8#51-"4G=UU<>L=ERNKO,2J%]2"'#/JFHVN"//NVB"J,K>-:*:L/AH%;X4
M"VO`FRH,Q[D5L_AXCE/"EP.,M,2X4PCW.,DQB*KD^L'R%`)KLB'BX&"M0LW'
M3XLIU^GD=[P^OV,[J<GQ3S]8KAV);T`K*P>X;ZU@?.,1W`'SZSUVL#QMN.,8
MNW]>.1'R6%B2]O:I/BP[4A(9K%H#8&+V`J1Q'V/EI-(Y_I#XF+`Y/W<_"D\,
M.-A\TYJ/N4XFR(VM"7W3ON'`]QS>L@1'"#B:/+,:CYNFVX(H>S.'^,'"GJ*U
M%G?C=:R*EQRA4`HXVDJ&@[LY13#F=*9.^(AZX7IB1066!TW<.T&22FQNE:PV
M(E>I&##A=<)7XV[R1MN$8%9MQ*M9-T,L8==@YB+3U9K'GL_0MZ7\7WO7UN2F
MCH1_T:G:9+-5YY78GI2KQF;6]DPV3Z<(R&,J-G@%.#/[ZU?B8H/=$@(DW,SA
M93=GW!+=7T.K+U*K+:AJ1^7'H+MCT)U]R)&]+;[DLQJR[YEY*H^^\Y-I,W[O
M&(6W>53O87D;)L<X'5.<7G\]]C1,?L;;9+^ACL<^(9?X)XY.5%K,H"W%#6=`
M;+);`6)^8S?`4>IS=E*1;(8!JD@*B/DM5<5%X)5KUDE$Z`DJ`DC)D8,O%]5\
MQ)YY2]$RC"_9F7F0YP]XW@"*X.L'(4==16QTMZ;>!$'L'\7?<H'*V33F0N1.
M<+1F+@FY2;=-PJBNHJGU48C?";,0HTM6W(AI'UF,%//S)45+TVU(?SO4$WE0
M3688HMYE@/1S+:P@,!#5P$7DB,&O%U5C'SM#'XYR&N^#Y.DZ).(TMLE;DAA^
M9Z`RFI`6,=PU0AKOCG?SX',R0E*P5!B$''(5L76VS]-NE`I^_9OB4`TQ8L74
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M<81&ENN28\P3DLL0WBLK($1N/T7B&7?#TU3])U']X1-VW`KVC6]>@!7T2$X$
M1$]*CAQ3N:C&-R^D*A4"6_X5.8X508R?+)!H#>J'(R5'#JQ<5.,]5RYZA8`M
M_XH<QXH@QNO?$JU!C8*DY,B!E8MJ_!ZWBUXA8,N_(L>Q(HA:_7F,(SO&D4\T
MK\B54L16X!59Y([1H^+LO<>,BGR-D2+^2#'7(,_$1U82[T(J2+8)")';1)%X
MQB/%\R>B`*V8%CFZ$B'-WQ.>9'<JE4Q0QL4F+`IW7]\+BY1W%>?7;P?>[(U0
MUX\`ZZ!O7N2*TP2>\>BV8(%)1.,5/RZ6/Y\\4?]FGZ'*".2*J178>&1<<#`+
MO$:`P_0#@5L@K/'@N'C^=^*_[OBV@A.ACCKFTF$#@5XNNO$X6\#&A`4:?*]C
MPB(J?]M`!]<#AZF%&_'[B<+G[*E^$/ENND-$%(U?42%'&!1LC,Y[B<Y3Q\9.
MG_NT=[HVT17,UGOT+>!CC+;Q1]M7?G?J<M?'(!D9<CL'BV:^QQSPV"*$\;Z^
M9Y^)*L;`P`&B#HEO/!PO&:7H&W<IP$P'1(4<85"PL4WM/=;O!P;_K^].TGE7
M5NV\]U[3;SD:5W?\J_L+B7@(%7C/`<G#6$^\`,FHD=M$J:"]+?E3YSVRC\>0
M/3R]H(2W2606('Q/WT5"#^SCXUQ,;SO'M9X&N6+:06.^RVS).Q$[!Q`5<KQ!
MP8QGQ?E^<39II<N&^'H`&35R>*6"&L^$/S@^3?,U]O;3G_S2Y=S$3?@>E?T>
M?(?KQR"'7$%HXUGQ,@_IU;[ESVSVYJ9]`^O0EPP<D`IDXAO/C4_V(=_XOW#H
M+Q*G"?E*Q1`RX34CD"-?*[#Q-'A:]V,LK/SHUP,EI.;N=2DY<K#EHAKOGY+K
M6A%H&35RG*6"&N^BPI=KE[E%4__D>RQ:_N&3/62Z83KDT`J$T]D>18[J2[AG
M3A%OSB*!M$0T$#S+8BFV-ND`YH+!<$@.Q<,%]5Z("CF<H&`"/#5&>POG305/
M@`H[GI!@`CPUAGM%4)][XI<M6B771!Q5-QF-'/]&0`CTHO-VDHR-NLTZ(!ER
MI&'1!)!JC/QN]B/69HMN29%#*Q91`.]XO[+FJA*03>IZW8)XQOYO51#S,M:0
M\->0+KU``$5"9:2:`<BM89VXQHM)YS:7>1/K"T/\)C[XCCY`"ZVF0:Z;=M",
MW;QZ6<2>`RK[=#HN:(JS][ZX*?(U+G3X%[H:5:[(GO=99#$>H=N0O1F!FUTM
M4-Z/!1AB+=,B-\QZH#.^M*JR^>"_:5/K[5P?1)<`2,:W;:1'%U:$2\ELLBJG
M*Q+%U'=Y=[M+1D9X9X.NZ9&K62^4X_;37GRLV7]FDV?>3-1^>)A/9JLU(_F'
MWC,E31[1N[?5A+G1Y<+O<D&'!=*VU\S4;'Z'LS?B)MS6V-NM[Q+P(OC&4R"W
MR\TAZ6U[ZS(,_ITX>W_K5Q=^L.PA456S>0:BKX;@&'>5ZHI`@ZK^*)5]-!8X
MS]6FHT_9<F0'"^?]\[\8&=202T*,'%:9F,8WLYZ_#[YWWPXVC)8LF,.ULX*`
MV3<:.?3].E[DI(S1"?5C0GU'K(Q.LPY#:]V`,[YE%C2&>661!8^,.4(G#W;9
M;#9<3G0_`;G:M0-J?+=NQ6I#S6"O")`KX%H<XUMO<_5E9YOLP#I2?__Y3_DJ
M!!$CQU4FIO%-MQJ,*?1F:YEV&'KK")WQ_;ZYB>0'RTKG&#8[DO,ON<-(>2AR
M3:E#8'ZC<!TO:5Y2U&VGP>"!JZ0,@_D-QR5N;D^<R/4`T`\'>DA8\]N1KUI;
M65&4'#*M2^YQ51B$''<5L<WO758\7C/$<S5-#M3HW'9<=Y)F4"=HU$[.:`R4
M*T=,')63,\[@3LXXTI,S6D/.[*G,H_%#S]X*CGJ`9`,!M"J:`-+K*'2LO':L
MO)HKN&*LLX[EU0]?7NU:6_U0A=5[5%5O0C[QR2(A*7+(Q2+V6_Y\"&DMQC4#
MD"-=)VX/'8"RC6%Y>>)<EYC,;"BZDE`C1UHJ:-]%T[7_IKUDVF).Y"K3`)KQ
M<NE5$:0HQ'^NK_1<2(>A!D!$XY7(JX]66#RM-U7BH<C15X?@?G5-A;>]3(P<
M<9F8?=<UF]L\A:IFFTF'H;-.L!FO:&:Q"_MBM\3GA8R$;,(E`Y'%]^24RF=O
M2VQ*EOZV,R'78FN`S)<_4]9N#JF>SU>P4"D[5\/)K-\.]:+O3G0YYVJ?TM:I
M60Z0_2.3-#,Q(OT:>MH0W@%30"M69,>L:]=VZ\GAP&RNO2WY+!8_?>3'[WDB
M,OV%3\/,\^R_"?NA=0_V5@_KOS%[*S;'=*TJJQE@W&B$`?O/R'KS:S.WX!AS
MEF#'1E(W^4G^8']EILV_=(`06(8*_J!5@,469T'K;,:=U'@EQC1=2@3J@VD-
MKFN%LO[P*FP)="9[$<LJ%(BL,8&-1#5_&0T?+LHA6R?9QR:U\Y<P3$#\:4V<
MHQ\[^V>&>;2H^&97R@,([^HL2E^\LJX@"=%]1J4]_'(MW-`-1`FW\FFL%NG1
M@>5Y?L;-D^-[\R!_<:3ZD(\9AFYJY-989=*CIQ7WAP/BS1S*NQS(S9:`>!B:
M$4FJL2*EZ=-QW>20I%&X'>\(Y;)1LN-K[XED#;[DGY'R^&$HK@$>&HM0>G3Y
MY%`FFU1=%9)A:*0JE?':U#)DH7R:70*!!$EP`PE+9;RL)+NW6PBMPB#\8*M(
M;KSB=,7$N;50Z>9N?L_7#^)0\9O>8I+!J4<)&>-%).OUE9)7MNQ4;P(7:D9.
MCU\)-?+JK/Q\F/VC=A)'L1/P;+2X$1Y`A+PT!(EE?+OGN1H)0'CY#3ER)2%Z
MV,%Y]*E@JV;V"W*PS@*8;U=S\T*#NS<`*N00@H(9WV29^T^\9&+%4^*F(OSS
MDV"#DHP:.;Q20=6BS;'$W?7N!WNQF&\6L^5F;2VG$WNYF2^_S9:3^6P]G6VL
M^>.Z]1T0]3/W?Q=$/4]CI1J_8_CDI/<V1PO'XZ<-6"`3Q31Q^=LS#YYHR%SM
M"/(5U<8AMYJ*PIOW*),XH22_4JU@RN+-/(IV3U;@E;FS&&<DHQ+W&=`Q*W(%
M:@'.N/_+7JW-CO"D@*#CTQ4!=M"OQ#'N%%<>^*4.OR^#PN]+#UYPVH'&.H1)
M`)F)\J_(D:L(,GJU/7FURPES\E;69FXOUVMG3R)F4POS&G6]W4QM]CMXMTI\
MC1[N`#Q<%AFS>9U7PEL[3Y(H#@^$6J[+S0CQF#5>A)1L=DZ0JAGR=1O.@-R*
M-@;$N/];YL@.2%<=*4TQ("6I06+<C2VS=+:$_+HVQM\Z.1[W/F_*L')^+YST
M$,Z^3D^*DPQ(4ZJP&'>9%5Z?_-_\I`SQ3WR1:/E=01,-2&=-X%%SU4>?4ZO/
M66B"Q?=<!*T>IV#N._N;`JY&;W-8WN:5&M-;7XH5@9]I+5:+1HMFRTD'9)#;
MPJ;FIOX=C7/^=_X_/QEP["__!U!+`P04````"``HA&Y"58=J$4=I``"QM`0`
M%0`<`&-P:&DM,C`Q,C$R,S%?;&%B+GAM;%54"0`###1"40PT0E%U>`L``00E
M#@``!#D!``#D75MSX[BQ?MY4Y3_@;+8R,U6R+<\E<]M-2K;E75=LRVMI9C)/
M6S0)63A#$5J"]"6G\M^#!DB)DG@!V1#-K9.JC3TT@&XTOL:ET=WX\1\/<Y_<
MT5`P'OST['"__XS0P.4>"VY_>L8$WWOW[LW[O<-G__C[G__TX__L[9%+RH]]
M)XP%V2/LE/F4C&,6T;0-\GK_Y:O#0T+V]J"&SX)O'^#_;AQ!B:05B)^^GT71
MXL/!P?W]_?[#3>CO\_#VX&6__^H@+?C]G__TW7>J\(<'P=8JW+]*BQ\>_.OB
M?.S.Z-S98X&(G,!-*@KV0:COY]QU(NA8-4E26`+^M9<6VX-/>X<O]UX=[C\(
M+\/HE/EK9-P9"YS%S`GGSHS[($^Q[_*Y;//PY:$44:8J-%Y3*EM5$KD<OG__
M_D#]-5M:-N=%R^+9UM\<Z#]NE&8E["QE+<?WNQ]#[M-K.B6*YH?H<4%_^EZP
M^<*GWR??9B&=YC?GA^$!U#\(Z*T340^$^QZ$>_@W$.Y?DL_GS@WUOR=0\M/U
M62%G[]?:TI4.VN+QBH:,>\.@&;,;M5OF>APY883@.U._-<XG<K:AC7C.U&R/
M6QXY?C-N5S4UMWI"A0_G\K<UINE#1`./>BG;T$Z)'BLR:J:`AM.6N9MM\YD/
M,R@/GV4E\<Q=S-A>.H^I?LK)[S<)!I<&D7-+1]-10(]C$?$Y#0>NR^-`=N64
MAQ<\I).9$XP=GXJT3=69GYXU:N(@RSJTL\9\2`6/98L;E.2/WS`,*[D^JY`K
MD'H&"YZD"DLI#?8^C9_]?463\"GA`25N0I8X*5TRY2&92\HDDJ2)`-H_'JQZ
MT-4^>]R-Y]`X++DM]7T0NH2''@V3O4M6%$[HIA_DKQ4]2$H<N%PN;8MH+QU`
M57T:\GE#A*8<<<08'-A1T$L^FH[EAH2*"SJ_H6&.`FX502E8$4&,`EWR?3*:
M$J&:[1(RBCJ;'?ER\2)&-H;61M-C/I_S0%,X$R*&]6/X0-TX8G<2;%/FRL4O
M;]AKU<=AH@FK*,`H@C#CN(ID`AW"%%$2<4)3LK*0IFMKMMU99ZNF6MN=;EV9
MF@AN3=.:(QJOAI<\^#5V?#9E5&Z.N?MMM(!Q$A-^)<$RDT>YA"WX6XDZUFO'
MBEHV8MV.>@8\V/L]I4T$$"!<4P?`+A+Z2T1#`=N*NK/NFRNL;3$\E>HV$F6>
M"B.TH+DJ?W'"T`DB\86RVYG<DPWN:"@W;,<\B$+'C20_YVRZB:8:%5'*6H\Y
MC':FE,A]0HHXFI:$WY(8D6-#;6FB_;Y5J9Z=/K:M9O7DE-6K)@@U4:2L=7'J
MB!O5I5CLW3K.`JR>AP?4CT3Z!53N<*]_F!A2_Y)\_NV$3FD8RF7:>1@(02,A
M?TF_#1\6-%#J#C_5>`X"[X@&=,HBH1;Y(SD=>-D"QUQ$&U#;*:G&BMV&`#!3
M@6J=@!W:@[5GV3[Q$N9(Y#QT14/:$&:J4^W!J?ER=A;<R1F0AX^C&R%%)UPJ
M17=-!0WO\A:QTN*HI<N$$0Q*E^T3GB%`0DW!UB)EJQ=52U/SWK2]')E()+L(
MF2.L.>@'02`7L\&<AQ'[MQ*Q+/(J!^X%!5%`+R>.@;ANF3B9I@FT;0O<>,ZK
M8-VD!VT#NEP*62B;H`<Q<U].!I<_GQV=#P?C\7`R'I^>#`:+1<COJ'=!/>8Z
M_BD/Y['OB,&-4#NXO`F]02NX>;XYVZCI?TF6:+H$").4,DE(DY1VEQ"'$-G:
MS(H=:@N'9A;-A@\T=)F@5R';`DEY63M'XR(6[)R&9>M@057-DP6T+\!V\\.K
M_7X?K#3REW=]LJ"A-KQ:/QQC>F=^'K;8RR<['A=)*O=$7([%YHHQ"F^=(%D<
MY+Y_)$6F?B^;LJOKH!3%F"6,PF2)$"?P"%^2Z1)8C&61!4W-\<&<W>1QF\K#
M))4GRANY5RY;YPO+(D]M%2S@UNSCT<603`;_&H[)<]W^BR[!H[+WZP<;HQ%H
MSZ`V=,(`G`^O:*CL#%?<9^[CA#Y$1_[V]9-I+;29RY`M#+".',%<->V<,#\&
MPVY*5*U9^M:`C+NT=-64SJ8)JM:HM0?!K%7KFOK@UP;&+6$&1=/::$C69!,#
MS6L:L9#"+HPD1D!R)0MT9E5L*))-/#8:.@M6SO1BT(,=W9$3?)/Z,'"AL^"X
MG.<!8US5CO73D$$[EM#TRMC3._H;1>ZOSH*+CP(\[U*JUJVC%GMI;BFUT=LG
MLYX:2BS7DEH+N>U-_I<T.G;$["KD=\RCWM'C)\GB67#*`LF67*P&;L3N6,2V
MU+)!`^@EH#ZS*-\7&A$@1U)ZY.:1+&F1A-AC5Y#:7$B;ZT+3(6T/M7(;'U*I
M3"=4_SP+4CTK!FIY'30VC5BRLF+L=PUQ1EW?!%F-X6@/5U=A<B.LO)4^.WZ\
M.>1E)=$8*B&/BFI(F]7N:#WR0W^_WS\D"R<D=T#D(WG3Z_?[\%_JBNK$T4P.
MQ;^I]Y$$?,-!E8>$QQ'$F4'@7-?@6"+%31!6CF*+GC4QG?!D%W[EA#"['L>2
MM:#0/Z:X`M[+I9(9E-TQFLD#_L)Y5!88LD="30D`":2Z!JAJ:6PYFQB.37OP
M.F?.#?/5HCT(--PA[I6&8OA[+'<Q!5;+VM71T*O+*`:(YV>#H[/SL\G9<$P&
MER=D/!D=__.7T?G)\'JLSR1D^.NGL\G7KB&RKI`V\=EL.-O<WR5[';D5+=S.
M98I8V+UM$[2R6?O0->CD]71[;U8DV^;6GY/$1"#Q-@PBB;&S8,K#N;Z@*;XR
M,:J&LOK480P#B92.,GEK2B1#JBLXJ2N2K+&C_F`A+FU7&]`DXN`P[YHVIQ3N
M8K:8+&I+M&HV#2<I/>:UR/)B+?O!'XOW*KMD#NN$ZG_>.#X8YKJDEB7"6+OZ
MKL(\0NG2V)[/5$2C8,P>+G@0S09!P"#!C!,^7M%0J;SLB'*9AH*2D>.011)'
M3IZ*HMO$*;2M+J'4?Q5!=B=;)Q`YQA[('#B1Z\62%;@937E)G/WO-#?$3=BQ
MIGEMRJ523]N13^L*;4O&:^IO5Y^:3Q:Y88$_@RL7A/F"ER,-CT]'V0#"FI&X
MMBF@)I(==1<SK?Q:$*AZJ[D"=9HJOHAD#$);R2JTM:W8WB<46]6L\U3B:WL:
MVM$09">EG6IJ\RD*`K]<R<()@YNNP/O*J._E3#3YY5#312EIC-*G#1,O:9D\
M0M.V]!7-=Y76->"_;84IE4$6]@:X:0Y>[40@5DX$ESRBXIS>43_O*%Q:'`5E
M$T9PGH*J_8Q[B)QL)06B2)!#6]"VU8\JA&/ZTS;436221;PYRA"1@[[/[Z%M
MN6Z<\/@FFL;^)'0\>DU=RN[4K5(FW#='%^JV@(LU;,8N*@@Q):D2MGD)41(!
M51*NR!I'AW>DOY6AB[;[W7I<8S/9K04\8K!M.9SW;9[NY1>T'\[[UHHFY0?#
MOMUI.&\MSAN&\Y;VH!/AO&]ST6V`GO;N*8]BIG-'#P+O;*ZB.&$HY,F&BR(_
MM/(ZZ)M,(Y90N[&$0%?P4ZOCFS>=-08#E7IWSJ+1]-P)O$\B+]QVLP0V<6X>
M.90'F6H2HDM]N+V,A;68602S51/?9$9AUHL#Q?ABJPO$$6!(CF0QSXEH9]PJ
M2\2RD:>V&#/-P7KJL%`YPEU01\0Z"J8ZLM&D%@K4-=C"`/UT<'9-/@_./PW)
MQ7`P_G0]O!A>3KH9^%A#)%G<U!ZJ-MUO(0(Y>H1@*^5$\'O,%L!?51":044+
MSKFFS.%\=345Y25"4Q*0ZTXP$77.-=)<*-NNM_6&K#T4PJ,E7NS3T73I!Y4X
M;RHMJ<*B<74T(NLR:B=>K:M0K"N-34`V&[?V8'E-)5<QG.+Y;<!@SV,6H%M=
M#PU$8]9P0;F*",E0Z1H$C>6PB;V:8]1JH%6:+^'*85Z9.^Y601LA507$,3A2
M(7T+V9ZR$3)%`\R`W8L[*.Y_3C!5J?2?/)XTR;_2/)XTKX%=Q9.6,&L]GG1)
MBZR(=0V']<5D&%%:.:A/&5$Z<-TP5B9R4"H5JU0\]QG4W4&$:0F+*)NW;E9/
MBFF<5F?,(XW$41U]6CED3XQ%L&.!E5(%SV6N<NI@LK"-W6"SBF4,1M6-5OHP
ME=#9RU188>:6[X\!V2HI&4'7;&01T3LTE"W"JRP_.RS(,0!N%,!%Y.020\7>
M+%LDM[)):^$)S3DU,5Y[;#JEH<HI?4.C>TJUL?J&\V\Z;EO!'C[!0VPZ!:1Z
MNTU[SO6(N'<6\L<TCF+9D1YL>.^=T%N^G"`_K13'6\D(WA`-%7MBGTQF3!#J
MZW1(*EY:>34"69`E>>YS(5[`1MJ/85,C/]$DT55G%+!XK-;"ETHPC'AVB$9Z
M>W[*0SFJ7Z5PH$R.#A65Q#T=5$X>NZ%-SD]PE`)$/,KFX7;YI;6G?_#LFZC:
M`NZ3>:`NBD(.";]DAP#8RY[I,*@>":BZ1,J>&WOD?L;<&9%ZXD11R&[B"";?
M5$L6#AB1.J4+%5)=>^?'!)0M&F?!_5<_%782AW*221ZY5?DI+NF]^E/1ILBP
M,MXP6XM)E%E6MJ3\G5;3/EQK9E\`Z0KNF@EGRTK;8`A;3:68NJAKC@;+-"H%
MD"RK82-E8A4[*$M:DJ)3)Y792AS3->`92",G0Z+9Z+0\`:XE:TA?8M,<7CGZ
M=C<]#)PPX<J%##:`%3D^;+1L9^JTTST,M+-LJ&O8Z)$$RT<`$Z@O\R=E=]$K
M?KJ&?XNBS9V5;4+G"5\T`UME>>*EDAKVWQ?;9@=W$%[Y/<N-`A#H&DP-)%#Y
MME?1B-2%E:#N_BV_._`HTXB2OVP"27[Z36>[V%HM,I'X&T-N6*DQG.HQA0HW
MTYE,UO<"FA(9=2])7#W!I$!K,EP(?U'G4=E>+AP/3EW'7)EC7-C,GP57(;^5
M9/.R))O5P_F6UF$-Y0>5$")SL//"(3Q+"XQ,*35KGJBVNU9E=[#3Q=8]4^N(
M:<U?M3XZT8E*(+,!]4;!8!$R_^6[`KM;26$;J45*F+"1,^1.-0^>S(H`>?FN
M9]4"9Z<7IAD^FO3FB=)VE$@D)Q]');J:@SV)HS]Q(KIT[AU-)S.:D$[?F\B!
MOG%5E"+491"C%@DMY=)/II):<D23QS8PQJ9&,NN/?^VBCU5*8[.O;2M177EE
M5:H9:A%7.,EAMBPE1<)3WK5.C=JXJY[Z;**N?Y;VD*ID)VG&%&N70KOI:)6Z
MV>UPZW<^]86V=@_4%,7-U2Z;CE?GX95%^ID,,A`[<"II?OOBQ,%M27A2TY90
MZHAD'V6^S)!.4AC#+JJOS^=$DU=O&A'%`%$<=`FM2.%ED6ME\'>2IB7OM>O2
MXKM*TV+EY>N*M";67L"VU0]DFI9.O8=M(A/#-"W6WL9>=Z<127##]E5H>5F+
MGF0Y+%AT*A/@>I@TOQO_LH;\5^&\83^>UG\K1Q;%KER%>$*`>WA]]GDP.?L\
M_#*XOAY<3M*W!+Z6)3.OKH2#NS%3*-POJ9"$#%G2(?_W\C_6P&^U-Y&<[NAY
M@RYU2@>,1;*F##5AUUPK,D^>/$[DCDHXRKY[0=79X5XEVBA6CSJU47K2@$U4
MY.+P?#`9GI"KP;74D(D<@?'@>'(VNAP33:Q+$&L@FRS6&H\APM8_G3*7+N/'
M+YP'-H_GYVR:9_`L*8RS]5<R@;+UJ]8S^0#FNGWB2P+6#/U6NF#B;9MR'PL*
MZ=F@$RHQ"P]N]WRY9GL]LI@]"N9"WBIUH0]%E6LYV#4#2%[M@Q>[%[O*&_<F
M%BR@0L>!R$VZ+!G1`+S1X5I-]MOQZ3X9/CCS!61_2WS552:8GJR<Y`#J2<;<
MF6PHW$B_D'63!U$*H#F-PX"!8_U&J@;=N&P/6HX4-SZ;,YTPN"=KK@]E;Z.A
M*7M(O/7A7^#(&<NE*],^?!9\&MT[87>"LLSPLW8M8JB(S>>%"8\<O^0EH?PR
MJ%F@D"0JU`D:):L$#`&-;*D\BM\J33]VPO`1(EN3)$S/?7ZOS:<N%\K!?NZ$
MWVCT0B5BTE<6R:L;1,PHC?2]AG*V7[X,27REYKZOKCIT-KN5<CII[D,!VJZ4
M7$!B;E<[`RT;>DP)"?*<IOF&(RYGBCF$M,@V9]#HPE%O#21A#?#J80"W*FG$
MKOOH^K1'F)ZY:/BB4^I8.+99+:S`/RKGF0O8N*6)#^#H/J`>G_Y"_86`_8`'
ML_M@OCAB/*+N+.`^OWT\YN=1GGD`TQHVEQJV&R@OF"7YI=LIX<`!A(X?RZ7*
M(5?RX]PAOW"]ALEYPH6R"8,DX9#\52Y]'\D:E^28[_>(Y-1B+K<VA%7I5V-7
M:`T%]P09X[#"W\@N9T?CVDR0LPQ[-<V,4UC!0DJ<*F;PT<]IW"]9$5-KX7H6
MY#0'\+)X5U!K+JKM=#EF`]>F%WEJ;X0H[*530A4"*ZM9\"<W8VQW!L%#*P;!
M7?3G#V\2K"N4;;_Y.O!#^,_`Y5*25..PQ`"87P[G$U-&&N7],IH,Q^1J\'5P
M=#[L"B`J>[SFT5$M;40Z>.].G:].>9@ZBHC1-$WZF,WW"`FKOK!HIJ\DQZLK
MR3P7=RO-XE+-6^P8*DE/PH=:XU,G))$$L.>E$%4IS^XE/_+L"PSI!ZZSU]O6
M7.G;EE%E"OR69=6VRMN4]UJR?>O:UF(HMB-FDD/X`5S>.3X$'^AH\<T4.@6[
MLUI-X(.U&S",S=Z1MDN>IRU#(A>5I:XK^,:(9RN<N_&`MIC\:RXGGQ!T"A+1
M2AVZ97)]UF&-IRQ@$54W)`60-:V-3_A5CTU4CHNET9;?"%E0N"HE$CS6P$0'
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M5/M=0921$+(Y``P'`O'Z3C;)VNL<`\A&`=R;.KG$,(-^NI$&\+4MBT)S5JML
M`[58;OM@G]_MM==\2O"`L-[=WH;T5BX:<KX,62"8F[P8!%Y\>6:YTO(X>YL)
M*RA#6DJ`+"GH[5^7@&`DA373C?F(6`D\/_:YD&OHA?+HN8),M#DP*2]O*\2\
MF!5K<>6N)I$X,.G,NSL(),?UI%;T>-T>/6&X>+%4"F+$J[#67`$^!:M8F>-,
MSDUX]ST0-'&&GO!3]D"]3,1AWM5&\[90BH/N`D:ILL37DI82JLG+@X@^NT0<
M/&/E+SJ^.@G`MJ5SK0BA2A]W*8RVU14MT*PJ6](,FX'H.6S4"C\OJV\YZ-R`
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M`CJ:'H?48]'UQ=&KOOY?CHH@&L.%"J,[@0HE7E%?1MMY,24Q,"!/F`D'1!)2
M\3.N8H(\EVR05_WT.OR%M:#C5H11F7UT]T)I/1H7+=BU:%U+NH+))K0(J<NR
M>\T\1\0</3>MB<PT5(L]7-ZA%:GT=%W@R&HO#Y'UWE5G);+2R_:S%-62U'K.
MH@8X143H7H^NAM>3KX/+$S!A7%T,+R?:*0*"\$NL6885<7&WM9A#A=@FE(@D
M19:TB"9&SBOR:[0>Y5E++FL!G0U&#9U_/6_79>/2PN(5Q,CN3<(.[@7@Q)VD
M4%BEGNW4*;G$=F_9$K_T!9ZHZ,^26:JH)`IW%>11+GR7GZ5&CJZ_DN>Z\4[M
M)BLZGAUQ(\&W^%Z:.Z->[,NM:7HJ3;.#'SF"N7)E/6$^'%H5NU4!NTU;P[^+
MANL&:H64[*734YJG)9`S5@A#IGV>/1KP.0OTAVRJ)M?Q7?`^3:K>`*^ZAN9V
M90CI7))Z2Y+?>BK-!H+:#:,Z]?G]I124_!646T#R&X@7E@,>N/`[.`JSB%&Q
M>M>MXJU!=+-6PJUL=`QU=QHO%OIA;<<G"2-DR8G2DR4O9,7,AZZIB"U9YL5K
MV4/)4\<>#J(T(U9IX(Q1W1U%&Q:PB+KQ`DP#DM4O&5K$B<@1O64!3(*P.&AW
M:IO)(JQW4C\"/HZ<,#K__]/?8>`UZNT0\K*9]+,[\:0%LC(+)"U54CNI%/0;
M:J-I)AQ[,Z0EYRQ4MP5K"1)JL&LO%X(FJJ+[LZ'^;#-&JO0(W9$>U\ML8*7G
M3YF\H(;TBO(4U,8W*EB'LMM`OS3KZG3'^JPS\/XW%E'!?811-6Q@CS%CR'`?
MH$/<A!")5I2(LR1E,0C(:K>JE2MM59YEY7HFV8OE[H\`=M7I=A%R%]*1PJ$X
M94:N[2*^$<QC3OA(IGJ;*K?W0I*A^KU/E>8W$5WRMCA36UO]9ZFN7#4?T@4$
M;$*FT53`R?%[]1?M3;,,]XR<ATXI=YTAVPAKJJDC[>WNKQS()9L;"Y5;!+U7
MSR.(45N=4#C[9KOVQB+ZZ7;;*=N:LE^:GJVB#UW1@3(9;&XJBT'S)-D=2@&^
M7<YF?@=[4,\^2TX&ZA*E:]`H['=)UH4G!HFS8%+[/@4L$N4HV2YHP7!11-P:
M3K039^=P4MCQ[=-IN=C;0\HE#Y;ITL\"E\]I>;",>3TTCHQ90UTNJZST3#6O
M,\U+`B\Z9[\UEL4FTFJ.4YNYH.]H$&^ED-SZLX4\S^N$<*$OJJVNH6.SB]O9
MF/.$V>)^7+9%Y3E!A_Y5A(P85L+OV8V80E[+:@IZU>K5"RIYDDVPD4RVML4U
M1JH]T.E,;.>0B6W3O#18I5P:9#(N%0"Q04-H<#9G'F6E+4Q%%6R;*+N&W>8B
MV\0S=L!WE9!JJ"Q)7ZCO_S/@]\&8.H+_M[VO;6X<Q\[]*_BP-S53Y9Y,]TPG
MN]E/:EON4:UM.;*Z)WU3J10M0A:R%*E+4K:UJ?SWBP.`%$F!!,@#T>A[-Y5D
M[#:(\\('(%[.>4[,=83<K>8"W]P>14QEI0H&BE(``0GO_@HB2"&#2"&^P,_:
M&U66JAYO!I&@.;^[G-XM%Q-1R/`AB`2'?'GJWA&99_LD+H6SGWJHO6--%!&R
M"!=&2FF^H&F`8VHICD->'()U8;_=!NEAOJY0.JAHCT,7V8+-8SB.A1Z*X<*#
MA!Q1Q:A"]$$")<LG6/7Q28U)H??;&@ZHJ:KT]C7AG]@@XA(T\-$T0H&E72CJ
M`U84K7LNNW5URX93V'2GUE/QL6'<;GP5M":,8"!*TQ6#Q!\]@UK][TA@:D3A
M,"D[)/<NZ=`&JVE&HJVZXX-08W(=?ZTH0"SH3EC2YNO*E8-N(6=X`K>`LU,'
MM7#3<-Y5R2Q`CC-B#G?F&.NN(LT:?45JYYK:2K0/\H8/B=^#%%@$LVD<+KB'
MJ6EV[FZ/&@Y6JF`&0R&`4+YS24$$H<4,Z93?TIDEIG%06I1!O*[6)J]B9:P<
M4QT%/>`V9B5$>5J[#%[EH=:\N""Z2;),!,BND_0E2,.VRYD^/3BHC]A;712Q
MS4\//\E8K;**-)_*,K("0:20Y`LJ$4XZ+34X\*4BUM+K-5^ES]=<Y&])Q,)`
MN]T[;81;5;<*12VM1:\JP(]L9,?.5M@HE8U!E$+E?_@_^R3_LU)<_D+$O4Y&
M5+`CM'JD,5VSG(10EY+O$46@94#^:Y^R+&0K<?@A(C%%[9]0%%R!&7TKST5$
M<W79SKM34=$9_!KR?N%T5R8T"$>R+=PU0`_\$0BC?*:@2Y"+,P?RN.<K#)KY
M%2O=_JIJVP,#IA%#*LYIRK^<&96W_5S"(LA%X/61A?Z#;IC9/8@;>KV40UX?
M*$E$BB)<%A'"!.2J]00^.!NFSLTS[I!=F3GZ,.GEJMK0&8!31&9/'.^AB/KQ
MJJ^EZD=+0UR>3J=PU$6OZ+E^Q^NR&`A><^-':X`%H^?-='JAEAYC@9[A(/ZT
M9Q'P@MVR&$A!@4U&@V!=*Q1\.\1BL%MT2[:R7Q(9&(!&U-F*FE6IO<_H>A\)
M[6&U$R6"O8XOJB[(;G/(&)1DDI$6-;Z&.$FW_"\<>N%>+CB+=9#(6HF3'$(U
M:`RDQO`)X`8'$?V)3%^#[0[N/?E:*MJ'E'#%N*A'97!V0;;!:L,[2AO<71?B
MUT3$28(/13+->I_&+-^GM%&65W8NRN@][G.A3<2V3!+-7O`GUW#45>F[WM&:
MO<+/F90)G,Q[H)X]]@__G"7KG&]#_#H:Z`!.=:`;!]F(\5&%YT6NOO3[YY1O
M]5HV_>WM\=%.)E50$;X-S/F"&FOC3\*3[%X$FAH,JD5/8M.):D=C%P1B'4J@
M0"%[EQ7$Y1:U<N@H2R_^]/%7V&[^X9>??OUG._*;\>TSTJ:>Q<XW8B_K\)6&
MT,R(R+=@N#HY9.-C^(8%CRP2!"D]&:[Z]>:0X6J0&9CQ6@@4^UO%_`AK@8I0
M;Y8#CMS53DN%>.T87K]&)&QEL])>X\3F*23?G[5:&/Q5RO<J]%4%V530>4.C
MC+L2``S).6+((T"FR*4O#G_QQH]/AFCMP#HQ8D^TCIBG1W/@LKF7Q^KAI\.7
M#*+3-21;IL2]_AWA,_D&*X\*'@'"(R`G4WP0)T1M!__2_`8[ZB3O#_F:QR1K
M$'PPV3*9K/@>+2TIM>_YV\P[F.,'=."`Z*&OLJ@$,A6X+?B"O"96'^Z?4XZ%
M86\311*TIF)##2%*,=QX\]ZCPU=)92CSV31K&[OGL#1!]JHA>8*4(!F'=A1%
M"J[+S)AS_Z:66501QUOX!N0\]EYJL//TQ>9X,_YG&M,TB/A8GH1P&@[?'[C<
MUV\C;)]"S^V6:F&&F1(AYO"@)J2H.>@-_'IZI3F-]WI;XT&OLDV6S%5MBPI-
M0S3`VH5C,"5YEE2'U0,1WY#4;GX3/";GCTF/DM.,+TE@A]P-&%U+!Q0HK>)1
M:6L;OJ]]E]-T"S=T4`Y2BO`-,1WFG_*<&-P_'F;DV8%2PK`;U[=%XZ93!=2>
M6DTS4H!W^^=.NYN0L?#]>3/Y[_>/$5M=1TG0A(>^C8.,?8U(!UGZLE<BNO4%
M$ITVG^;BM_H94;Z+IA"U&CS1"M?M-5=N'E-15X#1=+Y>!"^W`9^*61#I-ID#
M.L&5]1JL-.J@HY1:IT86YW9)3$FF1,.?T^"%;`OIKO:CY[7;M#D]C_UC[U:'
M^[!6!@V)>'1J+RPA)OD570EBOE_>MP5,=[1VD?;;I8:#)&!QYQ/DI!!`?GE_
MX38:VHT9Q@('WYD]EDG/@\QYHS3H+I=HDJ+-(V;X$!9E'>;KY8:J*)#/D']W
MPC'7V10U>$T*8$:NZ+L@&%=5!LF3[-\5REWH;X+X4#O&AK?)%U5LVZ')$>W$
M^_;/4='`'?'$>X<?'47EX*RNQW!%^W%/>!-;U&YT*_O$>W<0K'"J,!MR'N:8
MG(>=AYR'G8V<I[?"_<AYC(J_*3D/LR+GT6`$!U&X1+E+^/H"\B,@EF>FBE3D
MD!S6`EG#0V@(VRF%A31($3D782D'TD96ZM`.,@%=PMR=43:P1QKW%D/!SD'-
MH=$'BV=.%/X5[N_6^0F[Z(`.SI\X?*+L6`G$O\K[7!`]:BKQ((-=IA1;&NYE
M<O&)\WHG&;=@VV6R,1>6TJ!E`'8V=YQX?*J(Z_3CHX3S)2$/LV)(*K*=-6^?
MD'SJD>ZTY#:$#0>]R%PKJG+*^C\:K.M:H2#>(185X).67$&B/K2QGM&(.IMP
MW%OWL>';87\5M4:L(*[T(`;UMLB3K@:CZC)G;9[`7=;9J8.ZF0,1K;GASF[?
MW!EBDX(OH2VNVD!PFW7D28R((".)S+T/^1K`JZ,@2[_5KM?Z`!+!.3%YF#W,
MK^\7TX?IW5+PD=_/;V:7L^E#!S.XS5,X3@I[M5`<%2"&S*])51`I)/F$H!X.
MJ?$8]'U1F,1#M0(WI,=VMT4F&1I4<!%2);IWET'H0&.;O,$]WPF&+%M%2:9"
MZT7*40:+8+Y;JNPA/<K0M?)0/3'0"E<CAM`G2?C"(HBO;B8M7I5OPQ![V*\/
M?'C]$)51.;M\8KK[//MT,R63AX?ITIMY%^61DT#[X6]Q1`($B-L1M;6#"-(2
M(2MS%J^!RDB4D^@&JNW3>(*#?FJB0K`KHDB9J4HJTKP+KNWIG1/^@B%O<7Q6
MY'*J5T?QGR3C:0LT34\Y8S\VJ.6$6Z-*S.H;^"S]T$9J;/5^$+N=(+RBCWDG
M9-K;X78T7:)1>Y@@)"'ON<A,(S\H\M\?G85OH'4W'LV6&WW8OA=7A8IBN+!K
MM0G2)ZAX^!2P."N)OY,XNY`12NLU_YJ2EPU;;0C+R)-,;8L.!3$R_SEY"3B$
MQ05)F.P?<V#V"U8KD'Z\-MGMTUTBL[E3N-R#4[:4KBA[AC4EEU:RYZFTG.,?
M+P3Q<5R<7`B"CF"W2Y-7MA57,[Q_E@K>\I0&$?N;B!]\%H%6/^3'(P]:Q`_P
M[AZYZ4D4B=^[W^GHF](N7-2VH>;Q].84'26-.I:BHZNC<U%T6"CODJ*C%$>.
M\KQ;!PUWE25)A_6+'@_;TR"-@27TGJ8B=_Q3D+%5"WSU;=$([50!]Z'C'?D&
MLDYKFSBR\/B(>SVH[[-)(NZO#,Z66TM!6CR`W]$9E4%MXBJ]_T/`O^U_)E*(
M=W.6V0\GVS7+MX((=PB?8=$$015EGL]\W3S$T`4^V#V("X'HI1PJ&$))$LO$
M8^H77R2>E-SNA-7;6F=<B=M;Z<O8Z>^H6NS$`)".-TG/@<Y[<=Q[P$JDD]Z@
MXP'T)&U6!C.^1._U?58DV-(-NS;@QOWU3Q=__.-[<2O\AU_^>/&G#^\O@%`=
M]E#LF4;>Q%[;>[(YS=N^UW-EPE^I>6/)NVU`Y.3/J/QWG2#4J9GJCT"'ON"@
MS=!JOGN[2]&,X<`N1<-Y?!L</GQL29MM;>J"+;Q5`=0$HC+4GD7G$`O"NR<?
M/KI-+W5A@2T;>']+QO[NFKRAX?LV(`I1Y7XYO_S+;_.;J^GB8?JO7V;+;[S)
MSY5JZ!!2TU7NOM?SN+KW0U1%[8`J`HF4"%CZF0B91`HE(-4G=`UR4Q5RB%<Z
M'(>"Z.N&\G6'+O^S^E<4AC1B,`B1]&2B/_+>U60Y4$?3_/@IB/\*G-=\#<C1
M(]:&\B`^MS5B;"1K'%'%:2LH$+OV8MG,-S97:M'<7$16".IUV_>>/>#V\</4
M16WH]1N+I+D/@9*7\N(U#UZ=[>S/9Z]QB^_:[M$W^\-\5]OU8[`]WO;_F-5$
MP2<L8N*E7FZ@2/4L/BDP`>P&,DJCL*_EF,!!Q^CC!'?&H:ZVA#C(4'TN^J\<
M.=15\V40N/=@\[C!-3Y0]4PH!U,.>7WSN#RMXWZX%;PT\_6G^97FZV7W'+:F
MB;UJJ`A))8BD7!)L!X/RE!9N8Z4T.`CC\AS6-G%KG.FSY,K(\0.4>SBJ4<6D
M+T(1RT$15Z*$A)\.%1'+9+FAE\EV%\0ZIA#;)W'+OW[JH99],L)&H2LDCX<Z
MMHIH(272V8+/O866=SER_&Q+&Q^3(!6%VT/&5WL</U[%%/7T4VU1-P2IPX?4
M;<(;?J4;MHKH;?#:4;*WK25JR!C$8X:(Z)H\R[[)5G;NM'ZO`^6M:O@JU34U
M?-_]O8;O]UK#UP">ZI1@-?(0B].[K].[Y7SQ;?+I8;F87"X[CI?;V^(6H285
M<*DYJG-2].X3#HRFUU9;=NY'K+#$_'$=L%1P#(H$M&E7$J3A`=QZRDH9U#)*
M3I<@@@@9SA9*SE2WR(O<1R=YD>H[\`R&B<!LK^8^.^_45D4]8#9B5?.BP-WQ
MP.TRI2'+_W4?`-/<+`Z9$&Y7:W=P=_B:Z$A#G)P+P!:2+%CV5U^@ZLH[)S75
MG;SG\6"^H!GE[MI,XO`*KG<2L;12>1#W2<16S2UWGR?1X.VA'@:GA1BQI*P(
M\F9F'>"/)C)[OZ\1*W>V56:4:IGF5NO'\54[>RJ*(LRIUNDL!1$IR3=<]G7,
M2;'.0:]P^%JX6N6I:PFL;X=:^7:*Q@#F;KZ</I#["=]`W$S)?[__'U<+7K3&
M?!&0T1L;M;U1V>;PAO^9\25Y?75>JX/FS??#Z)/J@MP"].=+UN""6?@[RS<R
MAN9A4H;0#,G@Z.KMK&D=%F:<.]<#4,A"\L*5((]""YE:5`U+<L83-)(_7&2'
MH/WB6^Z(A6_[))18CYE1%X@K2D-Q]UB=G=H7A/KF+A:`G8H@%WRB;WD=QK)L
M+R['FM\47Y!IZQ+-4L_BY8P:PI12/@:NJ/SO+)ZHS)WB$Y@&84>8DLW#+D*1
M>BB)"K.%CH[)2PIT_E"N#?.()GRH]WL;E0!"QC?=G'+!ZMNXH&TX%8G:C="\
MX`$J:4L$78IO0-):KB%8://V>+"X3+;;)!;)`2([/YOQ;\1)23)3:S14#&J@
M8AU%US+GXX)DHG?Q)?2GGI>E%YH`LGH;(Y:6UH07%S-@Y>2Z,Y.W7Q_X4M1#
M5#Y#^/TQKS<F>?UC68E-]PVN@[QW4NAZ^!L?NVIZ&V:1C`YZ(:CUUGPYN?&4
M5U1/2M#E2V126FO9ANI?\4EI[LHTR*2TB=/J#`-5-)Y86JKZ)IEG[4486M\\
M.LE\F4"F[SQ^8*^W29QO)G',GFF:!>GAGJ:"3Y0K_HGO#D)HR.*GRY2)2M&Z
MM$D'G;I(7'=@E(L4]SP1N>'PC<S8*]F"*B0XZ@)[@4(9\@C:B/9`V+92^C@C
MAQS7,[:I\^?VT!LEVCOPLB8EW]FH&CYI_$[9TR:GX83+#9Z`=6>_E<IUA%1:
M/(0:]/9*809U(84H,:0BQR<(VGNC"K&^[V@XA"!5[2EF?Z,A!/K3.!-S1%&I
M40,?PP,HZ-@I@PNJ*22(X.U"1$&7Z^SJR9TEIKD;8]'8@\'.*]6!T`=MPP>!
M9%>9Q.&7F*KJTJ&:Y34CH*LU"OX6:F"P+[L7H3O[HX"B1KTKY#LRP@3[X<:,
M#7H+AU01;XTN1*&W5&4BRU._R3[?)"F,,0W8V]OBBKN95,!=6A8<#.JT-BB[
M=U;3S87^?9*QXGV1B1@G,9=+Z5:PH.^:MOX`00;'?Q1,197V&1<<'4B02_9W
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M\1_;+A7PZSY]QH_3SS+6`+LO=7]#WN0[W>6,DT^W&5%CAJP^<^E)>E@$+[>!
MN.>(VB(>]&T=!*1VJ(#ZM@<O9%MTZ`MDK*P^C3$U>MYI6711K`>R.UFTSVE8
MJ>6C@L]@JWU%\X!%78M$5SV[+J^.,0\#2'T)=J&-3!>6^I!"(3C2(44@(^CD
M"XC/X%=#)7<\;C"5-#.6S=?W'&C%]TIDW'="W_@,LL*FI4KNX?J#%/2C5UBT
M=4>]4&.O5S1BM;+5AH;[B,[7=_1%!45RL/-E0\Q_7(EZQ1D?"Y*A-"L3#D0;
MOGUEP,=ERG1W+`1?%>TL1B./!KC,Z$#X9D2H$)*C3/*0\QD[2$/O%A;G<>1)
M*;8SPN<M1IID5H&4#)HM:,376.$RT3"P9"HDF9MVQ]^%_,6*MN<\LAR.NS.X
M`)7`(=3QDNGGK#YK'VEGP\V(`XX]Q6S-5D&<%PG#7,N'_6X7'6`AQW+))*/8
M'F^2^(GO=K;'/QE'F3L!^*'EW%@G>?YY0H0.3-R`\&W'I$8^?;G/\F3+_^;=
MJ'/NSI.A=B;P#-]Z7/&M_G,`A?UF,5^4[HO/ZF\T?+(IWSVL#]369+#*&'!?
M31>SKWQ_\G5*?I\L%I.[);F933[-;F;+;[[@&.6<ZL8%^4(](..Z*GEN!A-R
MZ;HX'RE7A\*HD*?%_'ZZ6'XCD[LK4:KL_I;OLUT1+IW;JDXN)KUIOHQ%C&NL
M"<>,$!WSF%_>I`$?2^OI?J6)@T/]4X&HW4"0;239#F30%K>;OL%)9_7I67Z;
MGT=<AN=\\R#6,J**.@1I)['XBKRRMMN?[F?PBV4;E3`(*@5<$"F"'&60?P<I
M_^$;G*Q\<K*(M7]/XP&N<EXO3NI;EJO&YFB8F13!(*QV;2-Z_Q??$&4ROPDF
MNQ<Q8D9^&#(XJ`\BF#YG\66P8WD0M<"HK34^9[];#=PVO>A:?.[>L9BL9.^^
M8<G@A),<?YN7,2(#CCKF*`X_N@E*VEKC&7"ZU7!RX"..=5:^'NL8/'#"?F/S
M)L:F"#%\SAJ-'%&&N/QT^4P:8OI&=7FW+Q`RNOKI*7G^QY`RB0'^0_/5\W_Z
MSZE(I_F:1/LX#]+#-8OXR&J\L?9V@P%@%(U:OHB.2=DSD5W[`@JC[04N+/V.
M2,2C*=P,!T]TOFYR_27+EZ0\7:_0HL[7'0%VCCK%I?8Y,PIU(%9J(<K3-*@C
M1;G"EX1DY?5%E9L7GDAM0_[\=8TI+G8T%XV>]>?,S;7T0,?CRAGMQX)N`P:;
MJ\LD%E^N?1`M:;K]1H,TD^4<-=/$@$Y<TH+T4-H%3<B[@B:DE$LJ@@E<OI$?
MA&ROPM&&.ZV#3:3WJQZ.5"!J6'')]X)E=;YN*?6I;89"6Y=@U-)&]:MX8T5=
M3(<5/K%JFZ;\`>J/#?DN%U1!;<;,<-@^+.>7?_EM?G,U73S`C=/RVW(^_;?I
MY1>X%YY?7\\N^1_X4S\+[E3)S@"7-AUWY^@N4</!E4&H8_.*#D0J099S4JI!
M"CT(*"+Y=HE4A8`N/H'4E3^K@':+D.'@+XL>SM?O__CQYY]_5NPCEW!*$D5:
MEA#S,RCX6JN$P>=U6;L2ID4II^"3(:M"DJN9WJE)IFD?;]K8`\S:/=41U!.%
MB`5XD*8!7_XW%E93Q==SG[*3]V[]&&Z1W4,QU+):R2$O!0U?H-;7!6<1V8$L
M5Z/%M5VF`>/"OM'W"CU\5-L=]$8E@F@-1F=Q!:@9(?6_X\C4=*(PF!<=BAO9
MS)1!-XJ>1H8T>WU'IT33V5PC06O'`8)B.=_0E,-Y&Z0L.BPW=+I>\RW$?/WE
M81F\`C6`[CC5YBD<2;*]6ACX"C$7,&U)08+QBPI1L"CX\@!$)8+DP=EQIV/+
MC"S&;BP<G:38WDLU%N*^N!SS1ES<I)8$,8JN\Q.-Z9JU7XQW/N3@?MQ&*51D
MH90@4+9+DV>6<9QZPS76SP^GE^7V;V?X#`WL!)G(?YC%O]%HER7QY#I)^<(D
M?M@_9BQD<`67I!SM$(T6Q,TZX`,[0<W?PY7&@.THE;"8*+D7)(!;&A!-LE)V
M6>MJ)<6[FM[/:[AIMC^3`\:>_8<[L?HQP&(>=86]9?RK<Q/$X9>,WK(8Z$I;
MSOD[&F.OG`U*(*^2>>_BK%S0#?/-WU9*<'KV[\8(*TY9I3VW!(I'@1'"NB1^
MXK\\TY`OHC:'C*V"B`0B)@::AC#.8!3%4-H@XH,I#O=R:?6XSUA,,YD$&">Y
M"*N/0RIC[+G=041_(M/78`O)VD",%^U#*MQYP1]F$23!91=D&ZPVO*-4DC31
M(OWA0OR:P(*'@"M%[=SU/HU9#@6N:VU5Y[P_Z#D7VD2,.U:PV5[P)]=\/UOM
MN][1FKW"SYF4"1/&'OAMC_W#/V?).G_A.Q-O/NYV^&G<9EL-11S9R:H9]JN9
M%/3MT*0FK:)11":"88=6P[.='@:@%;<9_H$H7"2HI(_U,'^(DBS[L5$64QA(
M^:"45L(C*TDB)'FE>>-]#%/C/L^`Q0*NU<-]"O^!3E*Z2U+!<2&[\VJX=+JZ
MR>YBP.?P05*M:J`R\2^3+,^$$%$[YCXXR+3,]KO%`9V@AM=PI7%I-P)R\D(P
MD*FI7BWEAKNE"C?LR\3LOHIJZS(0UDA-97@`N:NR40:W@RHD$"G"2T(J.S_4
M]P+V;V7,.L$97VT\\(5@=I]$;'4PY6MW/."@6K!)&=0Y4)*)K^N"/M-X[\]A
MH[WUIX6"[=[%B&G(?!/+4I@&Y^D5RW8)WV+PQ2S?P=S`!D8BWPYH@[K"IS4C
M#,#>8I4,Y2#NG9"GID#?H(KQTDFZ-/H]CY@,M.++^+WX^(MS?E@4I'3#UP6"
MJP-6[-K`WO[/XU.(^JJ*RBXZ"B-"&JF)(U*>;RCN[:*3Q*1AKW-\5@AU+=`V
MTS9:.>.&:(A%K@HEW;VJG^<;EEI,;N.&T+IZ3-Z>HJ02;-YD7:69J";5`I&.
M!QQP\IB409T2ES6W1/<713TN63S+-QB9?7%*3F/W9A!5/Z(H>8%0O>LDO4KV
MC_EZ'Q6)-O-83'P5:D+-?K1G![AJ(8.417W["HGBD"Y4,H]Y6["D$Y_$]"C7
M6:61LUEKK$(BXE;EBC6H>>#$6!+N1=9:$!.5@?K"\@WC;HDI.=`@%;7Q*C<8
MP+84R.K5AU5$+\C+AJTV?->6\E$KKD.@&EZ^"7("IY^T2)Z05?'V_+L;1?Q?
M8*OMR_@>_K)J15,0`VF\C\L-"QY9)/GI8CDM;9*(^SF3A#4MGQCC8^@/C:UB
MF-E@.5].;DIJPMGT0="C57,(9(E&E6GA"S[[NJCY%>KW\L;#HBB#I;)!NPE`
M="W1B.L0C]QNI5#Y4Y0P*Q*#?8-2A^U-]!A]?UZ6AP5]8G`*&^=WP;;Y.EN;
M.>!XT`MV0/%P[)A`S[Y`PV3Y*<%#E\\QZ:^5&'K^+57Y*)]!CC:/RO``,B76
M1AE<<JS*C1`BY")-)1D]22GN\F1=V6+.F,78-'[RK(U?ZFFT]HA#A-[+7J>O
M.P;1`?/X-CA\^,B;Z0HA=S3&!=H;E4#%URM44-4][,>X`/+AXP4DM#JKG.S&
M"F,L/<*:T0/HC1ZIQ<U;H@N1/9X'(NH%"DY<IY0:ZIAV-L=E?5LH@HO(D/V3
ME`L@:R[A/'5.7=DAHY!$;S?_CYAD&L<8>T9/JK?P22UAWGK@((N\\H[Y5)&Q
ME4A+TPQA72M\85>]6-2A@:B$RHI^94JXTUJNPW6VJ^+:0_>QX=MA_TGAUBZL
M()@;)K/%U\G-E^GM=/+P93$%GOR'2;XHPC"O^,#XDD%AA_:8KOY]X)@=AJJ,
M8GK@0HF02JIBR20GI6`"DHD0[1/(!ONKQI.`>\>8(C3R"JE,(RN.\PZ=56>,
M#R'+S-@JA<%<(:6(MX8DP:@0Y`V[=S]_U$O)]'M+XQW-%IIQG62,3QD"55YS
MM!S5VCR)/KKMH9Z;N*_C+5I88!+`&'@9`-;#.\W#WMYO#W%S'<?[()IL8?K\
MFQ#!FWS4W5#K&^)NHCN%HX[_1<^0+U)V#9O_C\YNE=&:&V^/!U@P^G5MIQ=J
MU[(6Z!D.XCN:7P9I>H#OOL@0TN#WM`T*NJTB,:CEG9*5ZE7E.KD"+$I?$U9[
MZCTV3%MMKR+4@(_AX%S05?(4L[_1<!(?`WFA@NE\/<NS9LZ#!KI]>T`!>Z"Z
M&-@?14(`#"N%$DCL@V!OED/F;9GS8O[>>V*P:=RX-WSLH370>=6!AT(W\GBL
M(!";Q*$Z7&\[(M.TQ!^3M8O''Y65/'"\<\5%ZFS(.%#>[LRLKQ%O<G#6[HB3
MPS,3BA!D%@5KSW62EAM9FG569;=_#D=QT4<U7!RS$D2X))50080L9T07KDTQ
M#@/>\SY(25B6T83/0KNA7N6I]_)6C>&A/RC'3`>-LR1BH7AEM@FA'8\X2`DU
M*X1+"JWT+TA$@%<@DT"D68%>7Y#7QRVGV:*V+VH\O-T%P.HR7\]ER/?I&J6C
M(1I;[<)1`2?I4Q`7AQH`*"D&$'44Y!N>VEW11)'I18R'G9)6^EB&V52GK?,1
M-)YL%#K#_9AO6+)Q0Q-5]B\&<1JL,B6.*1*7,E&$AK^S?/,IB/]*TP?>BMLG
M*@_J#HI[]X$[0QZJ,C*Z7&8N'7-XR*H0*W)WR*,0+#,9,DAU*N0[.X(^I^'&
MT^DS.6#T$^RA3JP=;N,0/^)2`LXXLXU87H<T_'3XDL&UIZ1@A(-/24W$3L;U
M@`[P2X_>RF*/WD$<^:+H`DLYY"C(%^0.=]')4F7@"QTS/W^5TB"C5U3^=Q;/
MB]Q'53W9L*#IT8&#K/Z^RJ(V9AO^FR"E++@N82T='?/,O`G.&.Z?4W:`86]S
MS*"-'?\H,GE='X?5.\_68(WV)QP$:1C5P04'';L7\*M>6/L&/PM?G(9B6+Z;
M-V'8J6K'?XZH1DT^M_,1DA^@X%;._S8M^&!;T.BL>Y?\/$X,=47?$U8QS_]W
MIP37Z7Q]`[]K;W8P_3C$S9L$VU52M>^X8SN3HHV/N0RSZU0,`V]!IR9*R=8B
MZ\HP3]_`;.N3CL@ZB[?U)H00*KO;L*KM>,`E"42+,JA5JZHU<N/Q.M7L@0YV
MA\[W<:XT_2MU8"-KRD[C\.HT9:^]'2I1OU,T:FVI.B:R9\*[%KD-OJ#%:'PU
M6=_"\8CTF21=4Z9/S#_^#9?NTA2!.J8O.G-6DW2(=L;:HS9:CIY&T[2TEAZC
M?]>8X$4^B3$XR:R4[BU2[)<)E[>EZ>7U7(,[ZT>1X8K]%,3%*1:RBB("=3H%
M8-=:"X&$2W07G^C>0G-@HBM+QP]([.>M>B3B$,2BJ26^<K$TG,>37<JB#W_L
MII;0-79!+=&AA`MJB6?1/6R6A0#RX8]GH99`6F%++3'$FC>BENCPB(9:PHBN
MX6!797JFBHFPI<R6KA4*WAUB,;A6W1Z)%5V6TT+J;$)Q;]W'AFZ'_57,&K&"
M2"C:`R7U?'TI2@9)QE@-6K7-<&E%'8)1UYNBWVH5)-&UL^PBI-I6I=^"5P';
M6&\*%&K:LOQ(<BK9B\DC',L2*JC2BF"$%7\"2J/!>>WC(0I>_(J;[?)F+67)
M"#],"30(6LB.00MW24ZS&_I,HP^:D=#9'%D0S:P(9F2H_BL!*E!XC^-)B"`?
MW-5'<V.'::A@[!D;Z#8^J=<SLT796U\;]+HL.-<5@8OA,6MFGVE9('P!E9T_
M["X%'"8GGS!,B%0VW8*BM2TV6;E;!6SD5*BA"!%PZ?RNCFZ"31[S,%/>(*6Y
MVQV-U&8;5(T:TR6U@-S/>,4'G'@C+27:)_DUY9X-H@?^XO9<I</Q^=-+CO/(
M<!$9YMYDW,1>PEO5BR%UU7R!^UD]J`DO.Q=JT$Q^=14T7P]].Q=L?GK1^"1E
M=@)"QY1^PQ6WV9)F?#O*]Z%0ET/%#V@L@E+#CQ(O8L,)K74?&4US")`)6"R*
M$B=0M3QG\5Y0VI:915Y]E3J=KF$2[$*J2THC(4XS8-I:.B8UJHE'!:%I.(%$
MY^>C->JM^Q!>(Z,-;T]L5/-#-[.1!D.(8_.$-_Q*-VP5T<]IDNF.(4_;X([,
MVT2B#LRA4_(L>W5V4([1M%^]^6U5?_($POBV`*Z`Q'S.O_9>S<2MGJD=H'?C
MQDTYM/ECQO7-5I3_N@A>;KFG4A9$IB)HK8\Y*WUF4@PU4=?+?54DD7<D#5[(
MMI!VCC)G+BPS3N-.+!Q]7N_AI;:J8G;('/$`DD7[G#W3!\K7H+*\5'?H:,<#
M^(-(HS*8835=K^E*3,>ADD.R4I!W0:1F7YP<1%J^&01-$.7OCX_J)SI?BPNC
M^4NLC1IL:8@C`NH4C@'&L6<`A[@0)`ET#M=_EQL6!^2>_^,V(+\E4<AW4!FP
MY@B^B3@^J%S/K8Q*WKJ,2\2;;)J(1S5]=`:A3O?5*(,L\#K>G+R@JRC(,K9F
MJT[*EM-VZ!FX530N\K'>J2\8,1K=G&$-#A\3(2)3ZCY(\\,R#>*,3_*@SY'<
MPT0JU:<'!ZCJK2X*;].;R7)Z1>XGB^4WLEQ,[AXFE\O9_.Z!_/?[_W$Q.9_9
M,+XFS.A-;^O\&U>]O7,ZX@;"].W'HF$=;7SL;*/.Y9KZ^P>C:57=[STA3CW"
M9\'NPO>(]_S%;H*,`H5M@[^VHUQ(SPYP)R&#E$6=B5Q]G=Q=3A_(]7Q![K\L
M+G^;//#?YM=D=K><W'V>?;J9DLG#PW3YX-51VC!/U4X/$.]UO%FP2LI7XT&<
MQ&&5YW&^ON:;BGC%Y+4GA;U#CV6+<S'H6?9<AJ/R)A:?)W>S_SV!B5B61Y]]
MOIM=SRXG=TLRN;R<?[E;SNX^D_OYS>P22J@[7A:]I4\ZUTY]'>/+3')NQS8_
M>N<=9N/-2O+(;[Z>OJX$VQ'$5<QCX*SBAL!_@#?B.8A`[989IU<7Z-EDB,)N
MSD0+B01$DH(<*HD%KYEOXV"(FYH8'_YBWY*^['*?Y<F6IL6JH`6U%@^>@:ZL
M33G4PD_U10`!9*4D^!.YTM\;9E*R[G<U'OSNTV3-1#&-%IA5&J#A="H,&U<L
MPZ-\`\JIG4U`M'EUO!?_.6"QJ*$2/_`)<+Z^HBF?"N%RJ0T)74^@H6&A#HHI
MI.R./'%)O@'&POHF@JS?QH@;Q()H4<7KF<['VMOCMVPF57`YZZKS(B33OZME
MH_TGVP&[=S%F%0V1LP@\"S)Q<;[/LSR(X8:R!4^=CSBHHF%6"(,JV3\1`BZ*
MG-7D*,,WB-GXX[1\ANT;>A.@W0?I/!6[W%`0Z=_35*AIQEOKDRYA9U+/'?IV
M00IAYIF0Y5<Y^@%^Z4"AW7L;<SFN`O^'X-'R80?+^#Y*HL)V"DG?$3#[>>=T
M8]#_'8YY$0KI)C2<!BDDG60U2M<U6['VJU#C@PXN0VV5PT6Z2"F$*C&^X<_>
M#:?WH/U>TJBG%'HNX+N3+&FK1UR<9!@5PDU\.L;H"Q)3<9(;M))-K\D??KWX
M\,^_7/SRS[^(A__`?_S3^XOW'WZ](-PPH,+A>\3(NXQ\&X]J3E$LW_&HD7VJ
MQDL&M3,ZJ:'U;5U$^+6K@,K)3(.0`OB:I7TN")>5D:`6\Q\F^\=\O8^.#TAT
M_OKA3Q=_^O5C@<Z/O_S3Q:\_?_0;G9TNU<00FE[K>'@L+^U$<<P6(#8:H1&H
M%XJ!7MDC^7?1YW_XAA"]R4UH=#GZ7,S/$RXO!)G74=`\.CG].XKI62L*=354
M=$B@1U_>>:NI53[G#K<B>)SW4#E2$=O=!P=Q&S_)^+Z@"!R"F\TDSO)T+X+8
M)D\IE7?V'7%E+GK%<4>[,PN#-JD&*?@/=TH1R./DZPRR4[J(+]>JH@T)2G5\
M@:ACK]8XI%VC9?APD(>():GUU9XNDSLN<+5A]%F(G*^Y7L!$#,N2RY2)7#S-
M$!C:$PKV2/51WU-YOKPN9)-P3X%#(@8T'^7#DFUWU("LE`JNTI]&\(`I/^J,
MGAA[P".]61WD3L;#\(&M.+6A!$)9UG:^7FZHXB$6%`KB7S5CN<?#J.';7TG,
MB%72!)4`67-Y\OBSX)<I"-ASP9MC/!E]>SM-X]*MO6,/Q?X^JXZ^H0@>/N!*
MKAW%7`7T5D\Q^QL-K[E-XC#Z$_^R\^_Z%NZ'==4*!W>#&H08Q3'#4=&C<<$E
M&U-:BI:1;+(RPB-(!RKB4KRK<7ENTTTC]$PN&'NH8MQ8';1X[*,K14Q?:;IB
M&;U/V0EJ6INYJ`ZA%8R+L9'3.U4=DQWT[+@:Q&"M;>M`V&L_-NB[/*"I^]"!
M&#R)_E5PR.:[7<+'QF3-EY'\.S?=[J)$["R7P-H>RTJ1IV2>@[MQ0L(_1'%4
MQ&O);!]RR7P))$23`&2+11$MI9/\*%XLH5PS^9_+=B,%[YE\,#I!+\*/.H[_
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MK,754L1/UPI7`ZI=+`;31;=E:3&71?R0.O>IB+;/*,1A@?:P<8J2^.E=Q)YI
M>$%VFT/&5L"W+8OW[#-!.B]V4C%<[D1PTQWN90;YXSYCL8CTBD.H&L5;YC0.
MX;0O22&`*XCH3V3Z&O"=!Q65@*)]2`E7C(MZ5`9G%URQU89WE)[$-\*O"9?-
MMW+<AR)B;+WGGW!Q+U]KJSKG_4'/N=`FD@2%?+Q>\"?7C`_@2M_UCM;L%7[.
M+M1M_G:WAQWDL7_XYRQ9YR]!ZA=U<P=P:K6P3(-L^"B_X1"H!0<?(U"O((98
M2]YL\1!J#K!7"C,E@)1_:8^_#:4D5W.$6YMLI@PE"Q)EC]SF51,OX+>(RK`7
M/D1J//T_I))*"[Z8.Q6<R^<8",]MCO1BS);#6,P2/_*))\C))LC((Z5Q]3Y!
M34JJ($96!-)Y-33MWU=UI/8=&6/FQAVC>&;Q?9H\<<!FNC(#-D\XR(4SJH/+
M@:N$='&X[90`7Q#6PPVG*6^6KP55QDX>[NB.Z,N_8<O4U46XH8]PQ8TU6,5.
M0BL[FHNSZVCU\2AYI/A\O1,4%Y"M%T$M#%@@POS-OPDL"<M,EF-](UB*'3\&
MHBE\6>`SD\OC'-B9PY=%KDUC*'?$58N@.:Q#N=5^?0U._-RHN:<;$F,2#]7I
M!>T9^FR>=$`]9*T>[HRT02WIFBC/L1V=4\6),;Z,A@'..*50Z@FZ,4?2,Y\8
MD_1PU,EPQMOUA(.18U0'-V*^3N^6\\4W;^;:'H:?HLKR17PG-*LFQATG?;\M
MH:I3)I__G\E"C91`[L&"W%T4E4AFL2ST_G`L]*X[<3(_@]^-V*B$WZ64)5CX
MKO11R/F'8)=D?\[@)*H0YW1[X,HNJVU#D&V`Z6@=)2_E/B%N,;QFLC>?H%Y^
M.]D&V&-T^`!2=*^SN&"<7"8/^]TN8MREFK'3V1PU;&P409WB*%Y;CIB26)1O
M&K-"AK.*\ZX,,0T1E$%C#P(;IU3Q;X^S$5/F(??)E.U@:(Q/H>]4`IWZ]\[?
MF'P[#YQDUEN\!P>SIPCCWR01=\4#T(WDAXZ0,INGW,RE9K4<3:D50<42A`IY
MOJ"GIUNT<Y'MZWH#:E5Y9MC!UZQKZ8Y.]52\@QPJD2ETK%CO"Y(LC&]E46US
M_HC\SG"W(VFF6Y!2;8'G;SX5ATMVA3L#>87@&QXTIIZ0,[>Y]@T.)7^'U.RK
MY*5M`:-IZ.X(\D0X;KI0O=;*2?L&CW;;6P\?6SP_'E@FBJ%+A;\*GJ]NZK*N
M)]#PL5`'@Z,&C=E.2O$-1Q9.:`+*^J7@:]AUGQXX/S0XTUF!=C_M+E3YO,<"
M09H>X.Y;Q6D%64&-\!A$(G@YVU":2_X$X(ST_NS`\LC`^4F!+9&:&DK7+%L%
MT3<:I-,XU.2D=C9%T:N9%$#M\63?1'9.H'?"NR=7'N5-VOB@2L%F]Q:&3X;5
MFN+SF)8U?>0T3,/KI/@YJW!":N;+@1VAIE2<\ABHU2O2)S$M:SX5'V454*YA
M&G4V.Y_??-,$?C8WC#UOXUQ9G=I=C(/AP_EWRIXV7,KDF>_BGVB-\^"V+5O+
MXB'4,+57"C,D"RGOE!B/F2OL'5)%5M_7-!Q%"Y;]]3JE=*9"$A=ZU@IM,Q12
MN@1CL`']DC7ON(RR)*E#0@FLVJ9I=H#Z8T.ZRP55$)LQ@R=C4<51!/W?+,OV
M-%PFRY>$#YC5'M)"YB*O2KOKZ]V%$Q*6O@J[(6!9R7HYJDP3$W)%;/)+`G.G
M%*V2T-QM*<]ILSWQBCO;WXITI:__=(0KPU".X+I=SB__\MO\YFJZ>)C^ZY?9
M\MN7^)@>5;WT5-0:'1>3P_O"\=UB34!=>U>$$RF=5,63JGRB%/`)O&COU?A=
MW2``P61^Y+5\_S/\3W4\%06;0PUV+1_$\9'W4@Z#RNL:L:D4UIA@:2'/U5?$
MO76F;X<K*T=G4._EJ1I)^@"4.EN\'>LK+I."D_W3X?<@!5K9HN8BBY^@9([<
M"&EJ@[CKU^4R#V>:V[6?X#95\(6$YZ(\P..!O"B%B@*>XIP>$J"/.IUI37A^
M!_5?*)[/46^\@,0YNV-5Z6*D(:832#P'S@](M](3UP*E;<<"LV\/N"EBF+JH
MR2")WX6E3(EP34BE"&WR"K_#7%5#*N;5.F'VF\+QQRYE&2W9!.$DQ)+<S_BT
M*WX_6S5QR7@5BK^C0%*AYA8R?<+@`!>U4/WU>Y6(H(<*QXG:#C73475!$!9/
MX8(B[-5"!4E4&5Z4''(4I)BCG$5-N#7*R/2&-F[T*`E[!]6B)OJB$4%&+TZ^
MRF*<JE)4"Q=<1V,<,;U1"53B:(-=C&Q5S3"7#'%N3+`BBE/::XCBR-^)XKY7
MHC@S?FI,_Y8#<?B\<,6B*B=O2S7[KI:H&<$@'C,=J*[+FN"B7*#8\+J:"QPH
M;S,1'#G?XB,]T@]`X/-C@\&'!,\!BPI*'LK'J33X9-_/GU*_[V/@`Y)[5T'R
M$^[3@NLGI8+MA_]6=!^'S8Y3V8-@B'M)]E%(-L$SE41QU6[Y#+7?%AW#]92D
M<FU>7*G^)#51$$4D!!_#U=4NX9-5SL24IGW"T@BO9@,#@JI3@=7P&R\ZO1&[
M41R55*_>^!:4K1I#I_?CZ+CUOHIBIAS1$7DIXG8"%;?3`.P1I[Y`<:BOFK'N
MP][JB$G$JPT-]Q&=KVOU4F]HD-&B:.IUDEX&.Y8'D?CG3!2%-K%O.>@8GYSL
MS#C4W=F7Y9?%E-S.[F:W7V[)Y?SV=K:\G=ZY)_$:U]Y.CJ]VHWT;X>Z<=I+K
M[7@(O,6LH,]7%^>IJN;69,47(RP_])P5!G?L<%;`&H>*\Y"KSIVDCE1BSC<A
MC&%JYX2@M=??N0#KK_:YP`WP$=D@BO`:[N2*7;20U'4Q8?$0+LO#6BE41L=B
M?C]=++\)#C4()[J'+Q+Y04KZT1<T]G-(+3&AYVM",(WP!3P3;%!<UF42PW:2
MQBO6B2*+AW`\(]9*H5+0*@LX`-+E7+#O3>]\HM[KYXX:O4C/ES3BJN3(=Y))
MOA,HAF1/"&S_/'Z-T5=55R&CDNVF"!QUO9PXAU7=JX8VTWP99X-=<[)`&`;.
M\49?)XU42R/T.')/$O7=(*J;",K&X6.RN*BXAC[L[!V/.&!V,2OD+*#%.16[
M&]T-'.Q'`WQ#OHT#3DEJ;.&$R`5(4LJ>8IFNOSHLTR#.(DDU'/[77G*COM<L
M>^V>PV4"]%$-=9@I!9&5DD3RHR@2E+*<L9<Z-\Q<4['H5M[@<?WV$=R^`?N;
MN%=,DQ6$#`"+2:%-_$2R_6/&0A:D![(N>*:/Y9]DA,%:.4]2$59X@R&T0%4,
M.5[.E2Y6?"G'O\"M'U2L4L5)\N#5JRN\7N^LEHW0?Z",2#X5A@Q4":+[@(6S
M6!W;:C/N[9[!$U#9J(0C'BH$$)#PCL5$R?`%;[U<<4)$9?]Z1N30A'`A.!I,
MZ8;&&7M64:.ZP1&L%-&]=JC<T7R^YI_$>W'+SWM)X8KABLK_MD!V-/%XML^1
M'84*Q!,Q8*NJLD78RKORLV#XIOHVY,;V_PF+Z9L@=5QJS()P'^PJZ!1:-U0M
MS9W09'8I@MI(%607YMIQ;\62V66ZCBO3_!*&;T$^)\\TC:'_!['>/+36,FQK
MB=IF&,1C@'#L6BVE#X[+"3K0W2)*7X4EMEKCU4+=X)+JTMP*3B/21B=)^,*B
MB,_HC?2`V787L'3;3@EK]2B>:+J'@JCYL^Q-EJGT-"-DB%M.V*I[O[CQ\'B?
M)L\L@YS")+U*]H_Y>A\5%'`M..Q\!(T_&X5P<9U04OPQ)]0O!I(^]C<!9O]&
MQ@0675.^D`TKN=;S8[AL*[:ZGW(`+RNU4,$:A0A9S./B.P@6MO3**>YZO*U1
MV=:+6N]M6RVH'%%LGMJ.P'KVXH*5?8C:J&.RHTB5[:7;Z?N&UH&.TK"Y#W_!
MXZ'YA@6/+&(Y.V$VUK5`HU`C#H.P99('$:ETZAN8-/8V@=+JWS$CB-1]S`V+
MZ8S_V(8%34,',4%MPG%QQ*I7\N_0+Q$=_X=O\&BW_30.IMOSYV+-GXH[-47%
MOBBNVD";?1,DQN8H]GP;13"`D?V3@DB_E$"D"%^08^N**I&^_4MQ0Z9_E^BH
MOV^3E"XW0?P0F%GT;7IP1I_?0UW4PKU&&!\G;7SQ6RX8[MAC`FGV9V',=VQQ
M/ZI\)Y:_)4E^#^^UL>/WQC>"SN.X8U)Y%)JQIVF$H^]H%8JZ+:SD;<N,&6>C
M`Z>PS!?G$VJ:WWR?ND_C\+O3W#3M:!0GC_2)"99"567)ISFFW1LUH@_#4'5)
M4;V<SZ^O9Y?\=][XYTHNUCUW7B^":KN>'--3]U+?5?!TD6.PG)-".@'Q\KB.
M2`4(:.`3]I#.Z^:F'O#R$=\[.2B6R5>:Y?-XR=O2VR3.-Y,X9L\TS8+TP#_%
M:R`]XBX1&8?0E(^G2RCDF+)`]X%TT"ONB^K.+-0G6,VC>4+@1I\D0"$%U3FV
MH`L)CLH`B4JA#9'<FL]2'[)2"CG[C(SK&^-W9RP?C?Z!<N?GVA?-]=A"I&]&
M2<:[M2P"U-4:E[!I5@.5J2F[)^EY2P,YLL)827.X-:-GGIH]4DLYM<47@M1-
M7;&5>2*22[)C;6=Z`D?R9J<.!OR%B"+.-`]>55#(O_@$%4M/U'B_^KR9-TB"
M6U"PF45,C&3^#Y=<6=8:"&)^SETZG$DUU!T5`"P7.2][4?X\525]/WS\7[X@
MKK=#6O/,[%[6\`FKC33Z.DF7&PI58ODCOVCF+<L'4=-7/^60MQ5M9.$ET^,!
MB@"#0%<?=/?FF;[MSLP<>_KNYZKJ+#X$IPAN]#C>!U&579HW^2?-\&EIB&-`
M[Q2.BCP1/0,?ZI$>'/IV1G..UMP8,SW`@M&YS#N]4*,OMT`/XNZ1>RZ_+;BF
MJR0_+:SEA@=P-XM6RJ`N$D%"*[FV4PYS=\88[PAQ1HU^'VCEF-KU7P_,(8:"
MHO*:W%V51%Y=_&5=S7'#P$(1U"#0<Y;]]P<GG!,N+>CDF]";X172+=Q0P[DU
MI,9-&8QA[_4Y3;+V_6:MD9/TP%.AN*1`U2,17?J"DFZ#=:F`;6X>/N])EMCW
M'5-=LP5J=FL1AV(0\9X9N,/PZ@30Z>BWX.J=KM<4J$/K&ZKF044OEMX!73KD
MYQUN$.K(H9#:W(J3NF1O4CE=.JZ=MQ8+!41-O48!J%L:0HF?ZR2%O`-)F9VU
M87I`![C*>H.41:;0%TF?4B11,DDAU-5*\7RV&8N^\*[W04K"DMT+#I9QEH_]
M21GFO5I-002.Q_L@P35>QO=]7[@WTCQ@<=[."FSW#/J38J42ZJ9Y?G?)ES"+
MR7(VO_-F(=/+_.;,W^.5O"G1I`%974^<@V;R7&53?<.4A>D6'(UOCR>U2>M#
M7-KQB+O-]-F(2[_R>6J^^/:3>]I2-YH;:$L+]?T;#V;S6X\(SDA:6A`8W`<'
M6![PM4)1J#V;KW7U`G1W8KW[P%V7#549F<,MA)*=E"JN77>%7%AM[I3D^HF]
MLYNV<QIMO(0KC$_IBK)G8?\JB2*^X:,A>6'YACP&\5]I*AFS,\AGXN,!HA2]
M6F(/=F+M#@^']O$^7G<TOPRRC:`M"6GXZ?`E@Z`HR4'&XB=51\:\^A[0$?I#
M-UQYU#J=BR374?*B"'U+<>0HSYOP.+RKFA\<[(L>=:%?(V&<Q8)<HC$VV]?\
M-@^[6/[W4!*5CB!81=2G*?-P\=/'$9I]0>_7-7Q!Q,=`R1-Z##32\;:WM40M
M;@SB,2"Y.]9";L:,O7>U3'&@ODV!9Y&ZG\1JV;6&@LPI@?K.C?+.)0?Z,<@9
M2J"_;-AJ0QA?I^1YRA[W>5$`6CP9I":&^K'7+0:O5E<G5J`<;Y[6L/T8"*&Z
MGD#/R!;JH)8/WP&MDX4+FA.P]2L9E7PLW=.PPAFD:#U:4-7>W@6A6+<JR&TG
M=%[0*'JSF[(V7D,'9O,BSDSCP^6E032+0_KZ%WIHO-SV=BZ(>_2B73#VR)Z)
MZ)KPOGW!BM%X#4=/E^,121.O.Y;24+.6*_Z"2WNH=X]ZI[(K9QD+_34SIB28
M-1P]V:!N92V;0/=^AP-IP??#*8/3+Y'%_SD-@+IFF5Q.YQIP=;5&`<Y"#0P(
MC]V33)`V/$D!L%+F(ER!TY$5)L`BK!D;R!8>J8+;&E]ORB:AVT([Z?:M^22<
M;,Z=DB4X*Z\VMG=&I93P:HOOTM..224&'![H)Y';X)5M]UO^+1871RU)2;I6
MJ"'>(18S8E6W8FLFOBHN$XZ0.IO&46_=QQX.'?97T6W$"N(<>`]5WN9KJ'>>
MQ))UO;CH"S\=VCD$+1_$G1+W4@YU:"PDP1'J2L@J:/:+J^^0/!Y<T^&YM\XT
M'EQ9.?K!<"]/U<Z)!Z!T^&#Z)*(#LDD9%@#%RW6#IZ4A:K!T"\<,#M5S)=R!
MQ-"WJX&`U]P$_#8++GQ">;<;JJBV@0\BT2#+]G2^_CU(88>552(_RG$$^Z]E
M2J':P22[XJNGYP!R(G10Q_2&2T'`FX$*,03Q,-6^*`5JH535.5CLTG.I!@DR
M$AX5<9:R,(XO3,/P[#X9/9D![]=:9H.KL3)\\(L2&RW44IK1W=D<-7QM%,&,
M3UE+)&RE!W,U]%S988P70-@S]K"Q\4EU7-BC#/'5$UD&(LF@K(#6D5_<V1SW
MW;)0Q%4Z!2DE^`0/&P_4IDWK=X&X"IG>3);3J_O)8OEMN9C</4PN19*3K)(^
M7W^:7W6@I<_3N*N2_FJBKDZD."+DD:I`(B62^9IPF3ZA:X"+:K<00U\E@J8V
MV>Z"^#!_C-B33#!.[H/#3?"8I-`%Q*G&LNJ8[A/=YVD<C6U_-;%12%P<24IY
M<%Z^"PXDJH@4:0JB&IVS+_J9[#02W[JT=W0JW/X^JU'C#L4P@EI)D^)P1[6L
M2BTM<81*W>(Q`^>^FL%3=BYB2)V1*>&U-^?"UTH\0R&AG`0I)1L:B7/,("94
MA@S!)G.?0:2BC'Q-DW"_DH&U*<GVNUUT@+WG4Y*$<OQD-'UF*PBAA4<A;(LO
MK?E@D^/J`AZ#/P3AEL4,YGK!D\'WL;LD4T.P5*>\>X#!*C,."+!%)%NV(H\T
MIA#66R^'E,0R9/G/15AO4*FL&=)=2E>*>X-,7X/M+N(R^7H_VO.NN8_""_*X
M9Q&4#,E:*=8NCA,%@5<J<KO6^S1F.=`*U.G89.>\/^@YAZ,S$K$MDU9Q=ZS7
MW%O5ONL=K=DK_)Q)F5`4=)]SL<?^A<^3=?["'>;5=:4!QS4B+)M9`+T&N$QB
M&<HMYL`%S5DJR@1^DD`"UKF.-8#5TR[6`'W4=+$&6%7DP4!+2XGE$-N!3,=+
M`-=FVBX!7)C[1BN`/B[3K`#Z(WB\8.W?*7O:P+G<,TV#)UI</5VQ:`\Q2Y9%
MR_OV@@[L'J@V9MBJOLF+$OTND+(;UY(>US@?Z+1FF#CJ98^:WL*_]C#.8)T-
M8Y`K0^,57W?;,T;T[,1%$LP`I7'T-R6)GR#XO)S?+6=WGZ=WE[/I@VNBB?.9
MUTD]T6FC;Z-TF(\T>4&#@8M@K`B?!;%`/?&^R7W5Q??6MP<<6\4P=5%)0U=?
M)W>7?&1=SQ?D_LOB\K?)`_]M?DUF=\O)W>?9IYLIF3P\3)</SFA>SFQJY]#K
M8^]W8*M-`BQLX/DFLLYW%RB=3KE)V)$)3YX*>+69'.C+&BD'9DB/MUXH]L*"
M!+VZ(38P<)B?0Z\*K%5#G;!Y3?/=VQ7-#V+/US0J[E:4AMDUMW-!Q7G9?<`5
MO:*/'9!K?\0%VHP*H2+SDC1-7N"@3Q*YI%(&)/?GWB1&]G&&!FJ6K^<M25E.
MLWU;T&;UZ!D(6=H5=)FU73E2CHZ2?(-A'^^8.5I,[P]1GQM"O42B"IQ]<0<7
M"Z7F.K^E(:ZZ=J=P#&AD76R9JK2J].ULR8I7W69E&CP]I?0)Z-"#+?#SP/(S
MYN`+LLV%N-G(#^^DD72[BY(#I7QRWNYCFJJ;F^6&960;',J;&[B:>@XB&2`I
M`R#AWBH&UA<9IGY1KP_%FZ7-9$_UA+IJ"<+_VF=BYRK6RO*>)LTD?5W=^V22
M'?7/03<:R1-EX(^)>5<A?VE<PLN&QF051"NXCX(\,[BC@L<(WQ.#=446@;"4
M_STHV;3(7E1N!4-9'/*%_2HG6YIODM"K=7HW@&JUSRU&WH@E$"Q/F,]PAGR6
M4^)/002;'9>'9B@])=?20\[7'VU;=#]5GL8A0N$WJ>%@>X#NS1'Y-$AC6(??
MTU3HI([P6X9@6VOT0#2HX>#2QC>H&"QN`L;*\Z,2/%79_40(DY'BJ?4)%R1/
M)G50V?\U_D;?D&1AO(;FR>YEG(OHZ4HM5:]9QM=D0(-WS?^EN?WL:HDB>S*(
M1TTWJFLB^R;0.1&]^X(;"P=4*9^L7L#P[:*Q(K;+RM?N*UQ?GZN*]?FJ5?=2
M>>Q-C+GR]'DJ3%?2U.3:3-'T:`#9VA0;@=:I`#+<[)B=J()4%+V2P\@RM/H6
M861#S'B#B+%.5S3"PRRPA#R,4VP![8C6M<(?P^G%XL_@U*F2:P0C=3:!M[?N
M;W)\I+?_Y.RH"RL(L"[GEW_Y;7YS-5T\P.WC\MM]JI(G*^-D$H=%HG%'YMKP
MOG#`QYJ`2Y`HLFC53"DQQZ610IQ7@,/ZJ@9+-^\;F8!^0Y]I]$$#Q^I?\>GE
M=3'X;'+1'_G@-'6\OXY#R5`*]4D.<GU"N,81)^GA.E`,1^&164'A_'/`XJYY
MTO``"JMVRJ`VVZ6$@IJ#/($,GT!@YX4J+OJ\$PQ)[G,2/;/XZ8;%P-/!9TJ6
M_\[RS00&VN+VZL/'G\7_:%!C_RR20+>GBJB<\$(8X5U)4A<A3Q;0"D0)+?(#
MX5+)AX\77"C\WX_N6';/8*J9<[>'R5)\I\'C$_'V=%J=EG<0AE&U_(ILR$GE
M/KP9!?EP?369["#EDH:-$L&:D>B@4VRU/T=&(2-ZRD336JS!K!E92T`34JAR
MMEK;X[K%HD#@^=TS>EBR,Q<WR@<Z'4^(1'Z:;ED^7]\$<?@EHXI+M865MZ,Q
M+IW?J`1JPRIZA^\.I'^+7/>MHKYUR=;KQ@B;Z*I">V[)>A\)(X1U2?ST+N+K
MN?""[#:'3(PI->#VF6"]$B?R,=`\1Y`F"XG^\.0CA![13(8H0OXZBW,:A_P1
MF>&?!1']>S;]F6<:,WYJ"?660_$-RF1?`^W#AH:?@3&BY9Z^I;&[TMA:)5!7
M<*I#283A"W#L[&ZM*=WA?=0G947SX(DO=R<K/NY2P24<QX=9_!N-=IDV3-?B
M(>PGQE(IY*=&2I&\)%(.!'R"))A_E2R'WQR'5IF^/2ZL>X-9U=)#C=FU%QH1
M@R7)(8TOB*H<W+_3%$B+9_([&\YB_M6_%)\R\6K*%/AFN-82PFRZDE[/*0TW
M/,_O!M2X+M1K<#"\<`W5@DGJ6*RQ5D<U8;"$BM*!*DVA,(GLP]E,X(<#S;Q4
MCWSWDC9R5NM.;?KSU&E^K=O.[_G:U#36$!XQS#-\IGP/#.D/ETF69_=)Q%8'
M$V.&Z2E\N*>=6J@3I:,((F3X`NR>/CB)_.SS;MY@BV*'L-;F[K8I9\!4V?=/
MLG/?(&6RO76SX@F(O@#?_#3+V38X+5_2T@@-&+U0Y&$V!&?#S%/VZQM4]%8W
M`=+EZ_%@<1VP]"LD*-[2`-8UL`J:Q?P+W(,$JE\?:%`-4AEUAC*9+<C7R<V7
M*;F=3AZ^+*:2*LDQ^=/9[.HDH&DQSK<Q-<@YS2&'`*H;SJ?@`"+GZPK/BXYB
M5'>5.:`79]Q//=5&+BTK/$!2,.RU:I1`NRK9<7E&?A9^I#.8;KR0/),+WI(:
MJ:<;V^B1!B%_5!*19$MODDQ0FTA2N3U?JLQWBB$@^T3Y2Z5EM1.:35_S-.!O
MA<5!>ICE=)O=<:\"(6H2<?V>9C&?O6G6ECAX3HDN*$O.[0[<CD-4TWD4.E1J
MZ_BWH!S!D1I2E'&`-=[HG!?L%5-%;=,RID[;H4="JVA\>/*1DZ-@[/$-O:W&
M-S%G</R(I!L0#K])(NZG;"IH7UJ@HFF(I]UH%8X'2[5O11@C1?B&F78GG)!%
M&%[!B(3*0;8!#9Z#2-#*YI=!FAXXG,66HP5!AH?PA,E62N$872#S0**IFG_@
MW3QDYXH3HN`>+VA<K'4@R@UN7*`#^I$Q3?`#/3K21W1T8<!9+O7\[G)ZMUQ,
M1(&Q!M=$1RZ*W7.X+.L^JJ%`41-$"DE$B?(%&KU]4DM>[O^^$,FA<"MZPEFF
MN#67R7)#K]FKJCTP>0G2,/L]R!9TE3S%[&\TG#]3H`VX%\12_`=Y._N5K]7U
M&=%GE(9+,#V_&S"P%T$`[TY9$DN&USP141AK4%*&#)!`J$E>@HRW*A0ER3.5
M-!62"TS\J,(0GH6Z[H@7_7"IZ<S,%]>.GB9\_M=32R0>:^0CDCP95&.+PV^,
M1KK)J_YW7`JG3A0J8U-U2$2/KH;P8#5-@\Y>W='32G4FU[)(VU&`S')?T&W`
M(%KI2WR<5:JC11UNE(-FH>A>V3,5>UG!&]%:EMU5]_@\>\>&X@\WTD(ALJ]H
M5/\<J#.RZF<A/:JEV'.>C&P0WX.S3*-W!D77XHRMC@3%E=I<!?6PY#+Q:6R?
MPY\GQ`-G&6;#9Q9;+?B7=0UI4MR!XBM=Y:/1S"A.ND7-)"X-P\P@7_K,&+NC
M,HKSW'JP^.P;TX0QEH_&GE!<^KDZD;@?76@&/SOR/N>\?>>B[#LG6=^Y>?I\
M9^BS).<[!R]?P4(E6-D7W'ET^DK3%<OH/?_$ZC*\34^@0&RI#@;0A0@^27(9
M)`4A?%:54L@.Q+B"MT-K++CSOT_#3&/8PBJO3HDL75,=WKU&%.*[)'FU)W'(
MNTU2(*[5ECK7-<-]F3H$HSY-LE]QY;6#G@63L+L:Y4BUC5^G_NJ/_GWJ<$'M
M`V7$#"*F5]!37-$=7^$QX<N.F[N.QK@(7:,2J$!<R<!1[=XG%)B-K\606KZ"
MX8BX37C#KW3#5A&]97$'&TU;2Q06#.(Q0!!=DV?9-]G*SIU2T#A0WHI_1JFN
MX9\A?^>?^5[Y9PS@J<X"5B,/OVWIV)^XV8BXW'&X7GV['K3'0GR*P]2O\L]-
MLW5+:&>'P&+>NN$S539?<]^HNM`F\@RKQW"'N#T40QW2%A/WLYP+85:6$[6S
M(U?'E@SCE=BWVND5]OLXJW8NVAN0X\95\AU#(^C3+N_>[EDGD9G6*CH)W10_
M5&01/S/T>SE&%^+9\^6AR&Y5$KL0P&A6_+=K&VE^"$M6:ZF4H_S]HGOR0_&3
M5_S)]OYH4*3V>DLC3FU@;IS+[*T%R_YJG^!O]2A^8NNAH,/H8\=9_*ZMZ$S>
MKYOBR^@9XHJ3^;@WY$9,\]WN`I;*3.0F]_'T5>W#@9ORA451RY#JUP<^%7>(
MRJCDVE(@K&!9DTK;FX4LRD$G2;/#7^KPQ<0LR_80.S!?RRH^F:[`>64=T=T>
MM82P4@6%*B4`,"7C28*L%HKB:B/HS!+3#O!NOWVD*=@3TQ=E$^/":4C"?0K+
MI&,LNC>#QMI#U951#]R--Y4O:!ZP^,@P>$OA=;3,V2V-T9-SMQ*8\5+T3(JN
M?4&0G>G-^=7F!8S-]K$,7E5`UR<:TS7K9NHX;>V(9:-5#0<,&7GP6H3X^88?
M@_%Z5@O#2Q@/07=)7-(W2-647BT8:F^/1I%1%0R.[FBN[K$4R\H/"D[>;/BM
MW=!$E.4K&9&[@@JRE6X@-1KA.2NT0C&043UZ2VJBM_B$G*+#SV.>_&1\0[*@
MSS1NYZ&HM7%PEJ,1B0OYS<1.,I5=^@8'K;VG9QJM/G9#+XAB%1R+3'!L#D$S
M:]XY>`/'IPLT2_5ET`SS51LGH)]4@/+01\4@MLRY]39XXG>=2'Q:91$2.C'>
MM+_%Q*LU^H37O=W1?1&1T=5/3\GS/X:423#P'YH8X/_TG],X9_GAFD4TO0QR
M^I2D30ZQME:#<6`0BT&"[):(?DG1L2]0,-A=@*'3WU5;;OA/_-^*?^+_#Q+8
M^+_\7U!+`P04````"``HA&Y"F=/*ET<P```L-P,`%0`<`&-P:&DM,C`Q,C$R
M,S%?<')E+GAM;%54"0`###1"40PT0E%U>`L``00E#@``!#D!``#M?5MWVSB6
M]7//6O,?,C4/>4HE3B5U6UW?+%J71*MD42W126=>:M$D9.,+1:I!TK;ZUP_`
MBT11N)$B!<!V/W0Y-@">LS<N!^<`!W__G\=U\.H>H!A&X1^O+WY\]_H5"+W(
MA^'M'Z]A'+WY]=>/O[VY>/T__^\__^/O__7FS:L9B`:!B]+XU9M7<`P#\&J9
MP@24;;SZ\./[GRXN7KUZ\X;4"&#X_7?R?S=N#%[A;X7Q'S_<)<GF][=O'QX>
M?GR\0<&/$;I]^_[=NY_>E@5_^,__^-O?LL*_/\;PH,+#3V7QB[?_O)HNO3NP
M=M_`,$[<T"LJQO#W./O]-/+<A"@F_N0K9@GRKS=EL3?D5V\NWK_YZ>+'Q]BO
M"+J"P<%GO#L8NIL[%ZW=NR@@>,8_>M$:MWGQ_@)#5*E*&F^(RE&5`I>+WW[[
M[6WVUVIIW)R?[(I76__X-O]CK33DB+/#&O/[MYQ@%`5@`5:OR'^O%Y-&.+PE
ME=Y"'_TUC+QT#<*D_*\5^J,P@<EV$JXB7)TP^<.K3+G?D^T&_/%##->;`)2_
MNT-@]<</WN8.OBD;)QS]MW3;;_<:;1"(<;'L]U/\BX//@L<$A#[PRP\3#?K4
MF8A5R!5$7E64UP'IX1%Z787@]3$$N'/^Q?N$=1,GR/62LIW`O0'!'Z^EJ[UM
M*F*U*\;`^_$VNG_K`T@0NB`_$/$OWKR[*,;9?^-?_95_?@%N(?EJF,S<-:@)
MS"Q6%;#*K84.A7615S:)?\R(?<T<"46)MQL7X?;>8-8#OZR]0M&Z`8"E$!%'
MAU=IC*6)-J2B&[Q^%2$?H'S./@O^I2(.;I:"^\&?#</[4#4ZSN_/C?,<(!AA
M'?RAF_``/RQG*/(U9>D4_'0N"BPLDD_$&@?N+07ZP[\;!GE-.3K4'\X%=2[V
M`(N#W&""E]7'/\&6.:W7RQD&/4-9.@4?ST7!($5$T3&,/3?X!ES$GG.810TC
M@JTRG8N?SSP<HO4Z"I=)Y'U?8C,2Q'::$*N;F)+LL<&K9!@_,C#0F?KEO$R1
M'3`:X)YS&R'VM'58RD@N:HK2P?_US,,D'\4+L(E0@OO$$N.8QNP!0B]N)!TL
MU>F\_'9>7KY$08I!1'FG81-2+V<D$T?*,K9I[\[+P5<0!'^&T4.X!&X<A<"?
MQ'$*$),+5GDC.6$JS^#F['OHO>$QQK^AC1!62</X8"K,8.+LN^Q<L'S[*<=%
MM:S1;!PHS>#C;%ON7(=Y>A-`;QQ$;MT722]C&/X4)1FX[_;??W][I-P4_Z)K
MY_O`GBWMZ61H.:/AI36U9H/1\O-HY"S;>MS9#2IPL[.%.:5KK]SX)NLU:?SF
MUG4W>?\&01*7OZEW].+7?Q%K#60.1_<FJ.^S&85.&H4=B(KY`1/\8WV"Y!14
M-#KY*).QR%.N)R][>P:L.`9)S`C1,`KI@OQ1IZFB7U=,4^2+K984`?6RBGF@
M=YUC#HY4U(Z*@1O?,9#/_J0%T(R>4L4[UT-+>$?_2N&]&V`%8BL9N`AM\8KZ
MQ0U2U@(EJ&02)3S=>PH'MB=K`3R`I<5K6CP#2:$A@R-Z65.H86C:4W2P/2-V
M<@=0$UHX%4SAAJ=SAS%%^F$6R[\G9Y!B)UJFFTT`C[V,K%*ZP\O4KJ<@8?M.
M/PGOL0X1VF+F&=W\H(CNR-/UZBD>V![V(5@!K(/ON(^Y2L+)AE?#%%*X6O<4
M">QHXR"S83"&AYIF'88!^1/].$+S%'EW;@QB>S5'T0:@9$M\;]ARVZR/86Y8
M60O\1>N!#`@=6JM-&)E@O,);B`V!7!5I-HXJ&LC$L?+:6:AE9YD';NZR+GL,
M>_'F5M&6)3F%>SKT=HHQ==B%L)2C1R](B5?[4Q3Y#S`(F$:61%7M^9(#0#LC
MF#K;U?ZH/?;\64NAK3N%[@T,8`)!C(=P=A",1'KP?H@,9[ST\7VRTM6-<)?+
M@Z&=QZHBNIPWG5-!,5=-NR2#0?T][I;G16F8Q'-W2_P[#G)](-C1<&KHPYK,
M)H>GNHY$H13XQRJR:6*4-XTDEMK:S7^.^PC*WL0GAU;2*%JHJFJW':J-\,R7
MW6AR.ZAA%$%<U;7;%PW2.(G6`)4;;SY)K-)&$<146;O-SS`%3K0``;9>_;F+
MQ$L/IX)1%/$4UVX3-8L2R<6'5M(H7JBJ:A<=D+;43#?1Y&VSDR\.=1)/J\@[
MBT)/-JA&KZ8/4XWWJ6)(M+.P*W**!Y/)W!PHJIU=W=A%IZ]3[A22FCOG%)K8
M<U0,]TQJWH$_6DGEKM,FO%!5U<ZA4[GVS#U^62]F%!7'2FJWIEB^#W-IYB[T
M)^'`W<#$987A6*6-8H6ILG8KS0(D+@R!/W)12&[^6)Z7KM-L1X;-%^A!]HE8
M846C*),!0KLUIR)D[H"*UACH.Q#&\!Y,0B]:@VD4DR"PO<)6*-LGUZ@5HWAM
M#)%V[J%C?:6-0+.HHBFJG1M(9,^VC*&K9JJCO10#$L&84GTY=VXM1C/G\\B9
M#*QI]U=U:\WK='&W)IHN$]PL7=\`9*_R=$5S%V6V+>Y<V10^A+$71'&*_]1X
M6]R\9=47AEO>;=9BMF_-(_5V<8&$=AO-E[O=JAFP@B!Z(%&^<82&47J3K-*@
M#-#N[U8)(M.-VM"%MZ,N=V#[-H.E0UH99]XY\MAA_29<C:<6#6A-4AM`]//M
M5'?)&&(/9@#CGP.0(1WZUIJD5OMW]GOF:7+QSO2TYK7N"=V#J9V;:0Q#F(`I
MWG+[]1/J%:VKVC%Z1(N&C."^#4#:N:,.XP+8W+-1IKV?F7US@#([4"HJPJQL
M!)NR0&CG:SH4/#?;K32YBQ#\-_"EF#NJ9"!CQXIKYX>B"9RE9VS"4E'!6(9*
MA;4[FT03EIU\6K:6L3Q)))Q6>'2I$D-MN&;)U#2"-"D(>DJ*W`EQDDL5KX9I
M1,DN4J>G3.Z0(>X2Q2IM)C/\Q>GT9,D=LB)>FG1\%>%$?B06I7T>904AJJ6#
M__]J-'.6]MB>CQ:6,\%_M6;#@7TU7XP^CV;+R9?19(;_.>HB9M7H>XJ#6(UD
M-3.`\Q+`>$8!C`6X!V'*/'2]^[,N:'-GVKTRVN$\B.+$7A4",I>Z:ADC$*^I
MI5V88)<+[BN""1A&#RSW+J6@$030%-3."?\)17$\1]&*>:BS6L((W`]4TLX?
M;F\`<LFS0J/'#0ACX7$5=GDCR."HJYVC>PF"8"\IR]PY+*28!&%O.K!Z:OII
MMQ)_`B%6)R`Q37\-P^R%W@3>`SXCHEHF421$0+ME'$^T]Y`\3T\YKL!T:7.J
MF,067W?]UOHBUQON7;5X\F2]<2'B'+J0JFH2=7)8Z&\]R%H-1I%#T;)#8X%^
M#NU3=`]02&A?IC<Q]+?Y/1#*@3-62:WM,:Z*V@6R=QU@?QE'U-$K);4F@JNB
M=C'K611&AX(60U*P:Q'7,X(D"?6UBUP3MT.<$-5RB?'R!C"^O'<$J,45$R3=
M\^HN%[KNVNUU2M'X>YMZ*3-)J6FJW1[FDPM#,@';X=(-@+T:`@3OLWT7:]GA
MU3"1(RX"VFUDF"HV78V,Y(JCO7;[E;UQ,\:*#Z(0"YUBN0OK)PKC2["*4''I
M.DMP.7K$FF/)8>BB;;8RD^Q(N";&-,A4%JQG_7W1")NE5\BU.^ZUTZ(8`Y<@
M!.Q8!JNT0<125-7OB%<>?>%LVRH%C,"^JI!^9[=822S&>)C#VS"_S.=M'>2&
M,5Y4\FM#V;^"'&K__Z>YV5RFO,C?+\>M(.#&8`CR_[+VX.?ZO!%=Y7QDB,ZG
M*3E$6%=;D&>&5\,(NKDJ,QA2:#J7J8S*$]P"/PZSN!'<L)5E$*/04J[+>NG&
MT)-D)2^KF!)1S^(14RBKG9.F+N<0!FG"/*K.*FTP,3N%!3X;Q4>AEXX]^/.S
M/1V.%LO1/ZXGSK>N#S]3OJ#1<6>*=-U$Q09W;G@+XDE8R>.RY&:?E:VE^EBS
M_BET&N)O9GJ<7!=B1$4A($_$/T+A07-J'5T,$O&9<[K*VE%4Y">]#F$27P&2
MLXEEPA\7U(4,7N\Z,.(INNI'R/ZR$I^/HW+&T7&LJ78Q(T8Z7RXS_#JFL21`
M0+NH43V;+Y<J1F'3.&+IK%V@2"(E+W]H2=<WC<(&R&AWHGZ>P<$E[J"(:=P<
MZL<^1O=J4R;`F.;:,X7-)$T`BD%64KE]?N1?>U:W/Q7:%[*7\`V]>2]_W;[Y
M\-ED\1(L!TK4#J*V%/YU82B)6'#.2&I%XRCT%<^$>!>2I^T8I@CKF$?C<M5G
MX"'[$WMVE*IL!MF20'1H]]-]DN1#)#^JO<I$LF*R3F-SB)8B4EQ>:^PEU.W0
MDJ?#/0/)+H#MW(%OP$5DJ%"`9I74'F*FBKW?.J$="J@?`Z`@+55->]CEE-?N
M<DH9L00^9^(1%-::&Y&B'=Y288Z*%8!)BO"DEQ]@O,6R!MLO("8_YTL.?5A(
MU-,:^P;J=WCSI,G,_UYZYG^O/]1,%3L\Z-I^YJ<MLG+UM`=>4GW1T5;%YPX&
MUO+S>&I_[>1]('K#&ITRV`ME9NS^Q7_VC+*GX9E]X,9W68H&/"PNM]<Q2:._
MNW9K>0F\S]\G$UQE;=Z0+@QRK;LV`.G(LO"*^&$9U3>^6G?+&G?B:^,*::D^
M55)[H81!$J_&DZ","TF'T0>ZM9FYCD1[5DY!HRG@`="[MW)_DY;<L:4@7BM@
M/-)UA7MW4%ZZ_A#<)-P+@.QRQN/-4%^[LP#[O$KVJOZ<T>C1"U*R)2G3,C%6
MB69M&$UM2]BT\Y;RY,\?N`K(`U<M"*_6?O)4'T"E79J@81'7;78;6U3K29`J
MA$;#!$*'%TTK*A='/`4[Y@8-/`F*FP"F8P*%FO!E!LOR26;V\ZOMVE#,>?/N
MS>>:"U?OS^?N+@A9_CTY)1`[T3+=;`(($"U"QBUN)#%B$+0[VG>L:)DJ'C88
M8M4Z1C(G"8=V]PC84\#<W9)Q[R#79R=TDZK\Q`BE`Z3=)02JX"@%_A2Z-S#(
M#($FO-:K/CU6C\#1S^W`$CO+?%5TR*:D'M1]FJP>PJ.?6^%8:V)\U28:^0T*
MK?(3(Y8.D':^A&/!!VF<X+TS*JT[:5:/*CXQ1H^!T<Z9(+_#/CG\;C:[38#2
MSHG`$#Y/Q]S!80M>0R8?MN`"U'M0.#M%L$^8?>F&WP%:XA4";!+:1"M71T^7
MGD17/#@3RH>E=[=..:./(X17ZCPD,$^1=X?GE1C_B$@&X&1KA3ZYJKIA7!-H
MTXKQ]+6"KO>Q)I"J'NYI3N91"T^=R&/(M/,4%6+'3F1YN*\A4':^>>"&"6?P
MMFC`:+K;`*:=]T@>@I.-GZ?!=A/`M/,K,80?PQ!/6AV8O+R&3#9YN0#I-X.C
MR`/`SU+ISZ)$Y#!D%M=SO$ITUEH2=`88VAU`KHJZ`%GRG+F+UQ%R4DZ"NZ,J
M3XZ_8U"T"Y/**WWRS/HT^&T"F'8S[6BU`AZV\$>/7A;-7^#N:8=$'VSVD?\0
MT^_>#0#[7=E&31BQAC8#13N+F"YHH[<E&C5A!*?-0-'.[J6+;^&9!Z$MGF2^
MN$':C,QZ78-9/(*ALY1PNN2TZIU^4W)?R2K#";":F0^+'*S+X'$#HOPXB!XF
MX2I"ZYPC_F97MK8174`:"NVBLN6#;B1Q+S.:7BFBFHYF?8[V^&BNJ7;[U,HC
M?$1";,&S#S?4"YI,RK'6VFT_2YW(4XCXQ[U7,O0I.ZHAC+T@BE/ABTHG-ZN:
M=NG5\33P>D_`4SL)1:),S0.LC=M0S%Y7G7H7HVL.8O^Q\T*F_46,010$>!\-
M_*\PN9,ZYM"\C2=*;`,0>X^AE]<"MF4?D^=3NNH3HU$>LMX3(53#^?PY@M@$
M\B.UBV:?&.O=0-U[X@:ZF/MS'7$''4&NM6?!OR2P`H_CF3+N[96T%Y^LV>1_
M+6=BSZS9<#GY-)N,)P-KYEB#@7T]<R:S3W-[.AE,1JW3\+7\FH+<?"TE5;.%
MLM&M&Q9)C@91&$<!],L$2/,*8/:JZ.9NL-M>B(Y-=-.VHKWE2<+ONX"#.]8E
M%O-['QC1/J-XGNRT/QV\V=TY'YT]9E%_"^;L\^]D]F4T<^Q%ZR=5:4TIG3GW
M8JAR^A5&N;33B%=#F>?R2"31=,2MHOSRCI"30P\F3_NG,_CG"WL^6CC?L(%!
MWA6>DTS`I\\#U%:53@E4B90=7:,?>1;,$>)ZZL[BT063GSD:-:%X)I'FKW8T
MKP%&3V=^F>#=RNS3Y'(ZLI;+D=/!!NZH1<6F1DT:-4.PS`^(>U;]VHRT#=*L
M#76!;89D8N-$7%/QS-**Q5HP7(S.TYE<K.$7:S88+<?V8GZ]&'RVEJ.E/>Y^
MRI'\CM*)2%+&\SAV\]['F&]:-'`F?W3^5=9$TJ8%11-*>XYD/<Q'4#V=664Q
MFI*'4>86WBXX"VNVM`;$!=O!/,)L6>G,P91*S0I?O;B2O1J$>R?&0N0N%E93
M9+"PY)(W7)JTH-B`D>7N\`7[!@`]G5EF9CNCY=SZ9N&U^?29Y:`UI;/)@20=
MI3&I7$6\X!@5]')=Y5*I-,ZS$.CE%-H!7/1V*5'HVCV=X3:9#>RKD6/]LXL8
M<K4QQ=Z'O2"*SS<W"'6P:Z@^I-W$F\"IHCS4(>2$>EC[B:^XP]%B\L5R)E]&
M7ZT%MG.=Z<2ZG$PG3@>!3T[;2B<(CEQ=OWXT"7$72_-(?.A_!OZM3)*,=FTH
M>P6C%)2(-W8ARBZ!B>8*836%UD%K_@Z?P!#A\G1FD;$U67RQIM>CJY&UO%[D
M3Z>>/H'0FU4Z=]!%4C/R=GUJ+Y[((<"MHF@"V<ET!5PB4)Z`<),VB6,T:T.Q
M*2+#6W4F:0C0TYE6EHX]^/.S/<4+]I(<4.C"**&TJ71"H<BC*!7)OU*8;`7S
M1ZV0LG>F<4<G".,.FDM$MNKRLX5\?<4S!9V3PU>II:%X.O,"WM]?39QLZ;5F
MPX&=G?H>S;HY"\]K7.E,P1.LFWW+(%JO898`F.1XB$)R&P.$'G^C(E%)U5WF
MG61Q733YN:)A(PIW+?+L'=Q9;@C24YI%9@,\F!961X',6GN*YXH#611%^6#\
MG72JZ]`#*'%A*)$7E%]'V42"I0D3E!%()&PR?4A451V@E.'I<,Z0P>/IS!3%
MM7!<=AX%D$R-Y7\[.$;%;EOMT2FV7)TF+*!\@'=$2EQ)5=Y.-R'7$U?%TR51
MR,S/>5Q0Y8$H:18.<FY2E-4NR]#!E;9,JZW$;,VN8AQ+?`"T2SVT`%[@QC%<
M08\[@([+&<<,157M4M->QWB`C^($KMV$F6RX5L@X(NI*FI),5FXVDZIK'&>2
MD&B70[;R1+8<?YP*QI'&4UZ[9S:7\#;,YN8P*<]YXPZ7I?[;[OTEHT<O2(DQ
M/8W"6[Q'6>__)'1`=_<!XWI"E^!J^(QGF7E*:H0SBQO'*EMQ_=+`KC<N1-G+
M6@CO=S=1[`;VBO2S*;P'?GZ)0Y*_-DV9QVTKP+1[KI-YVUB.:^GJQO$K#PQC
MC_].I5&%YYT48/,BPLN*_$Y?7,\X&B6@8/"GU$D3)_9JZ4H;Q9P*QC'&4YY!
ME5+_3`PP&F3O-<1=+8@VN:&V`6$,<OF9@TU<TSCRI.!@L*C0K8/M:")A'KK)
M;YF1;B@]^N1J&\>F-"P,1A6ZB"S_'J_>,"8OKLLS*:IE'(-"&!C,*?0(C5P4
MDF#<'*#E'89$CCE1+>.8$\+`8$ZEA\B[`WX:`'LU0,"'R33"FZ"XF#B<:)>_
MMN+V&J0(Y6=S2,+;_!\.[^)DO]\RKI?T!#FC;RGT(5$TR37^1^H&,-E.0A]F
M'X^END_KYHSK(>V!8W0"A4ZJ?6^?@8<*'"@*\8\>V!W8RUY(C"=AM0S$*&QP
M_Y>?63KYB'$=IFN0&=WH-V59Q"^MY61IC^>+T7(T<[+#@%G7[^#<$KMII<>6
MV&)U<VKITHUA]JK`7K&\?<ZA)7$=Y9-,W00C(GMD9PN#E"ROS>R49JTIG#:D
MV:3/&@U1Z_T-H'F$1U0"W8`$RZ(PDRG^"A"81<DD)`$U\C*R<P?(;C<MDWL7
MTM:5X7+>]]=,Z1.]HRXXI:4N+WI7ZTB]03URI'>Z9NQBH\*5@E52^?JP$VS0
M:N,JJ*YPM`NXH<_[(C0$$[T6^<R[&K^<MK7+;=[IJ*8]+"4<X!*5=(N.MXZ+
M:S&^Y5F2BHB?TYJ[CL$J#<@1"VR.8/.AR"XJ,LNDJAG#B#P0^EE*AUF&NS.8
MJ.UJE?"]8_.IEE]7;$5Q*W3V+N?A5ZX`\2X&XPBMT\`M/LH;J`T;4&HDR3"P
M?WVS&3"]3Z1'Z9W7$4J*=Z^*>+T$/;1:QG)"A4"_&727R+&[R;/>I"ZI*CN>
M,G=/S4O,EJRRG0V_PP_PYT166:5#38#F?I0Q->W?]X>B>QCCYO$\VP1QN7HF
MH"^)@';W'BO^Y-4*>'G:P4+\A9MD!SI##P9P[XMLX(IOWJ3N7'>#FW;W+??J
M#(OD"%B/8K4._2ET;[`J)#-#PQ[0K#7SR&^(EN"&IQZI,[LR=WB-ZY=&LU,3
MB)8T46P,R=3JZMV=K+/N/IA]9<1]9H=?0>'(;8#U[BD=@?:ZN="S-(WV/'MV
M?.!,ODR<SB)@[*;5)Z:DBM59LCGJB>LRDDY>/]GRWD1OV8CRY7TO6U7Z+)&C
MG77XN$@PO6VXTK=N6&W2NI:]@&X-M`?WZ:2K&E\[9$F=S"97UU>5K)&=617\
M]M4:%GS9NIFZIH"\_,9[=:=>0OFD,TY)QJ8K&,)UNLZD*\<5WBT/W`U,W"`7
MNN&DT[IAA9,.@S_ZC-(>.=-G%,I9RB%(7!BTGD,X+2J8-3C2=#-/V.C6#0LO
M.]Z5[K.E<68.<1UE2;?QXKP+UK+FA<-""L>X-/:'V;0/==0NI]U.0#PNP`3_
MR$K,12FH.,LHO?]0T:\HU[_?'""2R]2]+8U'^R$$/F5@,@KJ@NI1A]BYQ1D*
M*D(V6GT&P2:.PB(L;*TWES!*@'<71D%TNQU$TT0>?KG6#.5($JH.`QH<(G/A
M+.]?*<1FR^76#L/M)"P$9/'%KV0&+0+%!7$$=:9:[3)"Y:!YY9QZ]_9<H\_J
M8?0U$KFC:T2G2<&[;-11RZH-'#.LS(YY?+%%G[4M.@-)'@2EC.O]WW3!CKEL
M5M3HS05R_N[^%<#;.SR@K7N\D[P%LW1]`U!AKL63.$ZQ<4"&/F,02%?7FM[F
M8&AWW":;E^$]6`(O1;Q76"4J&,$53^$.3\'0I[2O+D)NF-27AH,_:8WBH1(=
MY@=GN`SS(!7-,5C\17NT=BIHEX&;,6L5EEH^>=EI$B=N2+80S69R9BM:$]8:
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M;!8A-46U"X;N!/V$L`TI8B(O9!8#A6*];U:L((@>W-`#XPC9-S'6)?8`_B=G
MYI&NIC7B\LKWOA?)MJH[YF>`9J(=E]$>78I:>NP>:#DV3]Q(\)I4L*?@B=/1
MX6K*%W@)1'G%5=NY9FPR9!!_V6<\DWT&\\;#&B;V:NJ&_C4U.V"]A"XX,A>1
M(Y6TZ\:7*<SG8BOT)^L-BN[S1"(\TY1?1VM2)-7N_W8/R7%\Y9(U$:"#K+PT
MX&5J:`V[E,J][Q:N(ESP"[B#7@!8,!^7T1Y8BEH=&OT=/:^6HA"2*_V8]S%\
M)#]QIQAV>:WID%!7N_.9@RC$9ECJ$8DFX1Q%MUA8+CF\&D;0PU6Y]S.6V<Z2
MEI"=M7&FEM4::(&:O9^WG&(Z+<]+2>[K!/A#@!'R\I24Q4:2@K5$)>U!EU%<
M<""SDZRX1Z33_4*LDMKCS%21#NZY'R.D[K:SPPE3N#KU_K%<XYKXC8X%Z]&#
MM/M64U_2<4757@V#O4I,%E[\2R_^I;TSIDPNACN*V-54+:P+NK)>IP-%SXZR
M^]@`Y4IAXU"N*MJ[_ZCT7_$[,:V4]KA25>O=-[3[*K>_TDJ9`ZBXAW88%F:[
M^UAS`;^"]C"+%.[0\2-V;_+G!59)[3%FJMB[T^;@R]PY@E72+'#%<T6'[AI[
MM8(>V(T7?N?E%-8>8IZBO;MEZA_G]F).8>-0%O?E<_MG\@<;*=ZYMCX9=H,*
M_#!L83HZ]9?M\*OM<_PMG,*J=_9F^%C$:+_X59ZU7Z7:-8IG+26C6[(U=<&=
MN>)(0]`[&90W1B6N;,K4TIX$*=7U>&ZU_G3S<CRTK$UV#,FOO=Q[\AW!QE]2
M<HNPL91=W3.4_C#W!F+S5E0O?V88'R?P\V*5/&NK)#O-,W`1VN)Y!R\-*=4"
MH972!4_F0D=5K7_+8G^LI+K2UI=8S@BE&1ZG-ZH]75T`UWM`:082X6`Y+J,]
M]A2U^K^4&(8I>3=B3S4N\A.M\],+:@\J2\'>8TK4#W^01?:#H<A^.$/LB/KA
MC[+(?C04V8]G"!Q1/_RS++(_&XKLSV>(&E$__(LLLK\8BNPO9X@4'7_8N0,(
MN*L$("E\*\4-1+FJK"!>U`O6Y."\',Q921,1SE5D[%G>=9XHS;X)X&WQY;F[
MG;HW$2)-D+3\H6\GF'!.HC2IVMJST`@*!C/G?@I^,9I:SF@XMQ;.-V=AS9;D
M471[MKP">:;T2WMXHG^TP1<4^$4;2-=1]D?Q!SE^T":U53O:S/!_MN#CQ>_Y
MK/V>N9O#\N])9B#_<EOI*4Z$+9MB&:`'`:5JZH([V]Z0A:!W,B8A-B)!G"RP
MR'982!2/L3X5F6@!):EZVA,AJ;X>,5G65&L_D$H]F1F'C6MD81P*UI%Q`3(G
M^-Q%R=9!;AB[V0WLHB]D'^09%PUJJU[-##$NFO/Q8EP\;^/"=[,Y/.L<3G09
MN<A?9]V%9D^P"^N"+MN$X"@J0/E,R]7,=D;+N?7-NIR>_(01M2T%BQ%5#C5S
MQRQ*0#QWMV3X"9ZJI!95/>7IOP+)(/VRW#SKY68![J/@'D\8Y*/V:H"`#Y/L
MS9E+-_R^N!J^__@N^Q_57)2MJPOVS,6H`0S]6P"9+[^ZL6-&*@X*:0\R3;'>
M3]U4'O>\=`-B<`Q3<(U74T3E?'%U^=,[9H\_H3'MV3D%*,&!G[,=^1[85R/'
M^N=HB>6&<?Y:S?[!3)*(,GN_W7$?2>\[_>!WR^\I.?[=4M:N#H$+/L\[^2U9
M5;5-HK\]V(:)%_OP6=N'U#YBKSZ#8!-'(66X"BKH@C)S&10I?(:`QCVVCHB,
MD[#XJC6.$("WX3*]B:$/7;3%O^`&FEHTHCTS;8#IW;RL3*<C8MAN$"1WXJHK
MJ=S:)JRM/S]-H.C]B#A+A+R#?`,N(E4HG$A6U)X.60!Z/U(N)0CM\+YDQ:?!
M!/-P?X='T*4$^8"W`A;C&&K#!IX&,Q5`!$?9S[_/G:/H'L:G)S?A-:EVMWHD
M3N?K]NX+<@OU<7'5FQWC-IY,Q%\VF\]DL]G1NPHI0MEVH)B[BY04Q8/4##8$
ME71AAKIFR2JN'5-#L`)89'\,L"0D!M"$,<G*1C`G"T3O&]?B\<7#SU-6/GHY
MK;'FJ*='H&(!O"CT8)!G,[)7.SE/#DE(M*SB!*18JJZBV<P/<8\]BFNIMC',
ML/$:X/]BZKV8>HT>]"[WYP==#/\B#T>SW_@6U=.%'Z[9(*%^[X&)&=F#^^1)
M+]R1EDGD?;]T8^`37SM>7#-YR+T#SD3;M`6MJ6D%2>]F7;$SL$)_CF"$B`N+
M>NV65DQ[N.G*]1]*6*V`E]@K/-H^1P'T75K$C5)(>SQIBO4>#LCN/V/^UBZ"
MP=:Y`Z44U\O2_4H[>2512WN\I537[O5*QMHSN'/#6S`)RQTM+I!GV?KB!FF.
M>Q!$#^0@6;.UN4G#6E/>)8`=)M'IM5<P'!I64C@\"&(I%FE[$'!IUD%:?L/D
MOM(65D&&H#/Y._*>'MNKLJOOI,P[/%[0I]"]P<HFVQ,=(&T^I<`CTD;,;I9?
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MXC@%]NHKWC*Y84(NY<U3Y-WAK;&]PGOC=11F1ZX<!$B.32L>`@3O,6[WU!,D
MI[2F"S]L!^`I4/5.)#'JP1R@S+5!H>;P[]J#75-'C]S*1[/J)VLR.S5K);]1
M'2R$`X&ZVJJ48Z,83I]<&/(#Y-P*JM<C0ZP"*=1?+()G;1'L.TG6.\@9J=L0
M_AOXW%%9+ZL+MAR?`5--/3(CCZW)XHLUO1Y=C:SE]0+_9^8LK60!-N0!JO!V
MB#6\CLD/IZT_C;^C8$EJ+&,W0T'ZLYR%JWD;JF=2,]:RUMR\+&_/>GDCN88!
MBBW/`YN$Q#ZRQ-V4@<LHJ`NJS(6-I6#OR&:1P0M6P/-"?^1*!7H_-T6G:`KN
M`14_;G'M4>4KV_NYJ8Q4)K35OVJ/Y($JO=\AX_!&2^G'+:X]M'QE>T\:MV>6
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MA"EP+BU`,/*S[V3ENR9M%/J-**.7-X8PAKJ]^T;*[W\%\/:.'*RZ!\B51YU;
MS1CP^<KW[F9AB#&(PLSB3O%F&JX:L%"O:"H/1P"<QPDSP5^%80R][)0<RQE3
M*Z4]QE35]'#.9!:$G4DQ#]Q3'X)@M*;`^<*0I"]G"R[RKO;)1@X67GW5^W93
MG2H2G+PX4IZU(Z6VF<KV4>*M95Y,%T1E=XJ%<DHP+7>F_N4V'XNR*%,J&HD[
M#8#>/2V5N2_^1&P\JAN+5DI[C*FJZ?$Z0VW%&6/IOG]UTY,/LPK;56]D'<MT
M1G-K__%3#2]*2ZI7_"=D@K%Y>C'&GK4Q]@7$Q/T0^M<A*)Q`/MM:X)76!5_F
M\L55]6P6VM#=QO9F$^&/9P]4DHSB>#6*MEG?`&B-EP$BQ?`XQ7+K9K2GIATX
M_3_,4#$FV;8<K93VB%-5ZST^16Y%X48/LJ2QGS'CE=8>8*ZJO1^V';L091Y/
M>W7QZ\=W[]X5$]V`'/,+`FH_%M?1'G0)M7N/+U5E>$?^5QUJHT<ORR(NPI]3
MT2@2>`#T'F4:!!&YL'7EHN\@R4);!Q%\VE0NJ*$]]D*5>P\H9?%Q+,("QM_'
M"(`)>:X;6UZ4)R.$Q;6'FZ\L.]:DR<F#HK=(4L4KK3U37%5[SZ1'%GX/FUA#
M>`]]$/K?(`AH2P"]G/;@,M3K,D4>']<O48`1(0GZ.*!6"AF#:%4Q47J[T^&\
M@B%<I^ORXXPS&+12V@-*58V!:(<[R"OW40912BG]$:6IQD"TPRUDZ2HH+/O]
M`<R*F</>JS>IK3T#C:!@,-/E(X&Y&**#=-1BVF--5XX!:H>[R:,3QT(_U'%1
M[<%E*\D`^.<SAQ<I3IQ3WSQCMZ@@I,B1IJ]@(N63C4*(O/JJHU.F!@XE.'D)
M%S[K<.$^K1FEK]`BAH(*NJ#,7)I$"O>?4+?,05^\-;,7B+Q23G^_G,)#JV:T
M9Z<=.'HD?[T.$:]OG6A?2+:NP-:0E*PONT/P^48VB&Q;JI<_4^V1AER]V";/
MVC81])8%"$@>=2>:`[2*\#P5>OF3;=5CK91AWTFSNC#&7$F[`4\;CL?PL3-B
MC]MZ,FQ28.K]4%5V+6\!UBXD5^1E)5T`/-=#C^17WOLUF:_A==6\]D1W"Z8>
M9_E'_QP-KLES`?9X/!E@8X!RGOE$Z[C))Q28R$W$Z\M.=FP9*1J9RPV;5&V8
MF6HUMV/NQ7A^UL8S[?Y<]D`17BZ<AVCT"+R4K!?V:@4]@&2O$G*;T(4)YNK:
M')2S\32+PG^D;@!7\-"`HP:!.60U:\<8QAK"T[O1*PJ*&Q8-EPJ#=WCH8Q=]
MWT"$[28[O'*W[S_B8K3,L9S"V@/+4[3W2P.[,4)N2MFA@\N"JRA,[JPPQ+,<
MBEVTK>__25$LZ`#!!"#HLNDXJ553>#L-NMZO)E"GQ.*LA1.-L7``#<9V=?)L
MN*QT_07MB>\<TMYO11S,W;0W#&H%M*>@KE#O5QP*`O/[I'9H;1`,WO_*7XUH
MA;5'EJ>H()&6%JL1K7=WTJPIS)T(7N_W(HJ)DESGK=P:<^Y`(3_G_5GIJMIS
M)0]"_Q<J1+)D_F96EL`&E8TGI0I$_Q<S*M(<W_#C,T$I;Q+X-'7[O[912\MI
MQ7&ZSGGG.+PE*FF/O(SB_=_QD+R0:.9-Q"97$+N\GB&Z>VC8G4.YNX8=;IX/
MKN2Y,G<-70/O&KK<NX:=;D/SK\ZSN\WVBG$UCEK,&$@/E6.`^LN9X^O]A=7U
MC*8K#:)W%SM_"9GW&3)_B92_1,I/CY2?&B9_8C%R%0'RHYTZ^\(LLZCVH+.5
M/&\D>QPA(<J""MIC+5+X#$GS\M.:18QI%UP:C&S:IIA36GNLN:J>._Z]A(^=
M1[];M*D]:1W`UGODNQ;)*D]5T%['9A8UA0B*DKT'E6L#EQD'%T]8[*K:XR\/
M@KH0M42/KQ;6'G.>HN<.43>?^20"U&T:-86UDX#K/3B=[V7PJ%T!2*)1*7"B
M&081:P[N,_WL545,CA'0MB7M>6P-4?^1[$RTH\O_NRM0>.N47WXCQ:P'%_GQ
M5S?>YP^P[[/LX[D#%_^0:YI/,RR&>_J:&;V@+ZA%P?5S/3"3KM=X6K)7E:7=
M(C?H8+(MO,C97T@S>`8;_2O%?VC]ZDRKCZEXBJ:5H!T-<,ZW>:YUF6JJG;6&
M^-$;,&"FTSSOL&16BT+\S]AZA$+_.;6.+G.XV)5.5[E_KWJ$NU$V\5\!XE"F
M.<[K170!E==+=F[R(_UZAY3WQC,39(E*)L$N@T'O+O.:$+OK^I77GLG;-M^`
MB]B]OT4C!A,EA5'OGG?K]A:!6ZS%X2O23([XY4VB0Z!YAZ[XES!WAV'N#B<M
M.TWBQ`V)]<].H4,II`N:;-\313'V6JS)2QTMV?C+!%\@36I._V[%R"CT.^5C
MY_*BT+#_F_;85]3H?3'-[C0S3@CD?]$>KIT*_8>BCP8%-51`*:4]B%35V`%@
M+89[L6\@"[25#(&7F4$_73#B:;S2VM/#594=1^Z`IG/E\K>OKB;.U6CF+*W9
M<&#/G,GLTV@VF(R6PY%C3:;+UCG]Q2VKR.TOEJJ;04).`,*$="XK],F^#0L%
M0@\"WJ4IB4JJMQ1F.&/ET3?3%?N\-W8=N@7G;O::<GSE^N0X(^XJN'ND'OG@
M))RC"&_\8]KN0JZ>+I@SUS=)]7NG89PF*0+%LV2E4!:Y[%VF!<G'\4XZ"TL&
M\E+LZ;2+5K6GL!/H>G>@X,[EW`'BL&1D!JD5T!_VFD*][Q@//OA!A.`'PQ#\
M<(9M9):EP%I':4B;+*I_U1Z[`U4$YX7/MI.8#;!9O;"<B3U;+MT`VUJA7\Y!
M\:DOA,FUKF1'(2591[L*_L=X6PO)FJHM6T/V%\UX>-ED/.]-!D`>0>(6D%RL
M@S1.HC5`EN>1^1OX>"&\BA!P[MPPZTFT[4;#%G3A@;WQ:`K)64FR0W`J2U)-
M&$63'"B][R2J(NTF7/+`&99OF6XV`207<!?NPY6;':\.1$Q)-F(45[+`]+YK
MD>A`Q<_D##2`]V3B;CFV:`T9Q5H3@`2[)25&?RGHW-T2*3LU^1EM*S?X&7+U
M8>[7/B5M[+/JJ;8O333U!1R\&/HOAGXQF==Z2O9&1KD,DTMBY1+=R%9IV:@N
M;$FM@FV!$[#+7A&+OY#_N\'MXM_\'U!+`P04````"``HA&Y"0,1[](P:``#Q
M+0$`$0`<`&-P:&DM,C`Q,C$R,S$N>'-D550)``,,-$)1##1"475X"P`!!"4.
M```$.0$``.P]VW+;N)+/9ZOV'[AY6,\^.+;L>";))G.*UB5AK2SJ2+0SV9<I
MFH1LG%"$#B^V=;;VWQ<`P3L(@K(D,EN<AXEM=C>ZT;ATHQN-3W]]63O*$_!\
MB-S/)X.WYR<*<"UD0_?A\PGTT>G[]U<?3@<G?_W]7__ET[^=GBHS@(:.Z86^
M<JK`"72`L@QA`&(:RKNW%Y>#@:*<GA(,WWH$:U/!C;C^1QO`SR>/0;#Y>';V
M<N\Y;WU@O7U`3V?XP]G%^6!P>CXXO1R<,/`5=!+PY^?GM]8C=,W-H^FMS4?D
M$`[]MQ9:$\R+P07!,X/`@_=A`";(6X_`R@R=X/-)Z/XC-!VX@L#&PCE@#=P@
M!Y#Y')C>`PAFYAKX&],"#=NG?.=PGB_?(N\!@YP/SOZXF2YI=\0"OCC0_<$#
M'WSX\.&,?HU!2Y"T_QCIRS/R^=[T04(9?X4">.CZ@>E:.7@[R"N'`5^=11]C
MT-`_?3#-30*[,OU["LL^<!3IAFL^+W;@G07;#3C#$,"#5H*`7`D<Y)[&>'BH
M_>63Z;HH,`,\",FO^/?-!KHK1'_YRR?211_C?EJ`E4+[]R,A]?F-#]<;![QA
M?WOTP.KS&VOS"$]CW?ZY\<!;S%P,XB$'HU7V+_E\AE%\/-0H1].TX9B$Z5DE
M*B7]8R)H`[P``C]1\INS_8AD@U53D3`*=&%7!7+,^Z8"813@=%$6RW2:RH)1
MK-`Y\'`C-`PL@T)^N%UH.7IU*V3$)[2]/T?0MQSDAQZ8+_3Y>&%\5V>C\=]N
MM?G->&88YKT#_#<*M#^_D8:.N&1LI@/U]_/S\XO+<[Q;I53P+S$A!5-2$E+*
M+Q&Q__AT5B23I1[ZP-;=W^G/Q5G.,!E(%59^(LGA%/3+06)_BG5T4+UI,T.=
M?=&NIV-UN1P;2YZV2C`"'0W.2SI*T94(O]<*7RM#_>9&,\@`7N+A/-1GAC;[
M,IX-M?%R-#94;9K1C@2L0$M7[XB6EKACJ1F%?\[0HW,I1U'YA='L)U3MA)KI
MQG@Y5[^K>+SS)E/NNV@BE1<[BJHPW%X359-HMM2GVD@UQJ.E@?]/Q[0^61KZ
M\+^^ZM/1>+$D&X7Q/3N9I'$$&CN_*D^JE*Z2$E;TB9(E_>_F!OG_J40M]'KE
MZY5G,HQ`8$(G8V&(@`2:N[PL:J[*KF#$^G6P0DM%4V$Y&:GJ!INC3\"^`3;$
M/!*?';/IEY2W`ZY(I[\6=5JR0Q32@A(WH;`VE+B17MOUVK[#LT)??.?HLO!%
MI*F+LJ88]MM>!TU,>6S$83OMCW&%%9]^%MD=[S@&/,%4*&JOAGHUL,%;[?X6
M040^[P5''0R[]W)E=:*.[M39<+R<Z(OY[6+X55V.L7DGX_M*8HHFU*"DP9BH
M@JDJ"5EB%I;VJ+>]<NN4.U&UQ9TZO<7&M;J\740V=O7D$X&+)N*O)3422@HE
MI61I]:=/TJK##M(0=]E"-33L*O&T58`0S;,/)07ED7MU-/.8A^KRZV2J?UO6
M.\HIJ,@_+EGD`O^84%0HR5YMM;N;9:'0#3#L'#G0@L"/_^7N:-70HN6O?*Z;
M$E)B"LHO\4_]XE>EMO%"N\,+TMWXF[I8J#/CBZK-EB4'2@PF4-2[TM%N2DIA
MM!1*K/>M=ET9R=E0M*?0L_>;^6+\=3Q;XAZ.7*7Z!;.6@F@=Y1S>5ZZC:4/L
M6#_3%'/L>NWSM;\,D/5#WQ`>YH[IEJ9HQ7?1W/RMJ#G<ZKE""2D1)860ZF=F
M`^O_UB"&MS;3;FYO,E$L@0,@QA!M@N_+/@`EIC!JN3!:[P;4KJX9ZYQ9$_[<
MW))N*\TV*6A1R)-G?68HQN:,KS":_22L4^!B/"4[SEQ=&-]Q-V*M#&E7WH#U
M/?#TU;4^*JFQ`8[HR+BTD#*Z"B6L9"DK$6E%7RF8>*_5Q@;J5%.OM:EFE$_Y
MZT%%F^'E5;VAFA#L];9+@%3U?1#X4[@JKZ=RX*(Y6#)#*X*F$56%D.VU6*?%
M:W6I8?\`&^E+HA"R@I54)X`1&2\?BOJB=(B3D*74JVBGB)LHV%,$$BGI2AA]
MZVW*YF$X80!.Z&>7K?TT,-TK8*>PC'1`1GC2+QV*Z;7$UY(^F6C#\6))CA_J
MCCDD8$5N5RFY(Z;7GWWLJ#SN?%&#!=@@CYS&CW!?W_KDAZ(J&V.*S/=2MF-5
M.%0-E*0%A32AT#9Z1<NOI=6.%F]!%4"+5M6RZ2%RR'JEU<<,KM4IS?/X.LYE
MEU2#B*R1TD*:._5G=)2(4*\<:>]JCKN0WIJ0\+**L"+O>"#G;<4D^]6P=C5$
M5DBZ,OY7=>VQ&\!@J[DKA-$)<YG54`9:--VBK"V&G?W1=&TE(J5D:/5:V^6&
MH.S=0*&FRGD__(.H7D5U*A+=D1%"B<R*WTKJZ>^^[,NFF*L+/+"_C@UMJ$YE
M+(P"@FA:E>[$".P-)4^WUV.S@)G^3)"D8V5Y<)$1\KY!F"RBVMLA.]B0UZ8/
M+6QAC*`3!L`>FYY+",R!-T3K-7*7F&XY`O-:0B+%G\M9G[0]:M&P%I6X264#
M/"5J5*&M]@-#?A_E:+8Z/E`-+(H3E"\55$1S^H"!4&GC/\;#6W+"T>1(M`F2
MZ&RTY",FA/M3TGU>,J@LE<"_<5`-+K)SR]$B84V%7F]269<3SW1_?#-#SFEV
M+:3H]+ID&57,,TI5H63[.5?KIZ#U!K@^96+\0G[DY/%5PXCT54I>R-)1&*%>
M0W4:BBX5C@"6VH*4E9*"JD%$!F<I&L2NV&?I].K9O2Z3*+^$"RDR'GE7O(NU
M$7K#459556XZ3UF5L"++HGP%O-J-[]55L34]FNX#\/75"*R`YP%;<S$@,,R7
M*#T1.]U3:-Y#!P;;\IZU`[)H,RL?K44-*&BEV*P)!=(VE,!\4<PH@Y+XZ4[<
M3K^8UJG\UL4[#WIPX3^!+6.92,*+'+K2L4N69F^R[*3&;,&T<I26^U5DJ)0,
MR5Q5M65?<:;!SJ<OOJ@S[;_I21-V<)?:EYDVT88J-B:&0_V6>KMQ@)NW&S;"
M%\4JRC&F+&GJ?&>(*RGU)/[>*ULJ.*C/J:ZPK7&G&8(*-]7`(KNT(E2H1(24
MF%)OF];%F?">XUK83*!LZ*O$7`&<(%,]K,B4*64EY>D1BR8U9$`?7FIX*W)I
MXG&.S<MYZ%F/IL_1GR2\R&KAU:W,WHRD1!5,54G(]GJLO8[E,4.>1>[(R2+N
MPF^FYYEN4-:C)+QH+I9NN"8TDT@>/=\DFHSI]HJL/9`.UVO3V^JKS'FS:@7P
M*77VZ!="!GC^^!\A_I`YI=X)731=2]XC:X*LM3Y5,(H.L$W63*ICY7^R;2E1
M8__;:[ZJO&5R<VONH2?H\XY+14"BR5J*_>7N>26D^OG90$NWK@U]]G9,DCR!
M5[O$IEG@[N85GMV1@DB_I:.`G'YS[:1)%V1ECII2<%L*;>S_XPCX=)9YU07_
MDGORY1-<D]LB2O3HT!19](O@&1SRVVG\%LXI^=/IX.+T<O#VQ;=/%)?["E#%
M0SIG31DHOGU#FO]`FA_\*M5\Z>V<5W"`W-EKF<@\QM.8D<PK0X2!JZJFN<\2
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MZ,1%>G17#QZ!MP`6@$_T,$A6[(9$]R0Z?YI6R_X%/0'/)6TNL530WD96@:20
ME=C[&;I-A='<)]P<\K;Q0+._P>#QVG1_`(]4<@(;NOG*JE">7#OBQL,I'4=#
MY#C`"EXI]PYT6QJ]A>I<^UNSFM-MJ0=&&/<)8SR!+R9T9;?0`E([P_?:M$?@
M/F#QR6O@8J]`5D$5N(<Q:L1;HX;='_<!XG98C#ZQ08K&D&@_K*92TQ^O%3EZ
M._-C`%Z":P=9/W85VX@)-),S@W9@09L9K#.$/6(V_0<-+=0*W,-K*MNP?,>6
MF<[@MK,TS$!`-E\_(*UJ+F_'85S7`[8^?^:X9[&C8CJ9JS7^-^`!W.787G)"
MF^3Y&(^`I&V$`0N/E6_F4$1C%]T>E(/CSLO$)HLBLPUG9B7V<84@MZ&H(9$>
MGNTDC@2=P^Z(/%.HR`%_%Y3!;'WFWOH`>VU3;"?A7L;3@VU9A0D0"20'V\H>
ME\Z=PMXKI:DZK-:U5&2P\(1;Q&])7TVQ6M9<DBLAJ[1*A`[H*\\;1S65`*TS
MG\3+\$"I%402N-6A-3&A=V<Z(;@!)LF%(HU(#C(IU-8U%DWOA%?*X+CLK=1`
M[5F,P@DE$0%_MH@16QYRT0?S`>@K:H'ISRZP94V_"N2#,QPUJ5IX<_>`?;W5
M77>KN5^!L_&1[#F%#*'C]SQ:L<;9EJ&N-]<06]C6HXL<]+`=HFGP.O5(MG!D
MH_5U502:FK;[:JVE<SGJF#8X2<_`M\1QG*@ER7`*WA*_48:3++L)]*LWG&C!
MH(.-=Z:)QVC18V[@S7%P#\MPA9,O>Y!<A;VGI8D>5%0/51*-&+_@)13Z8.Y!
M2Y9M`?YA&6>CD+2KNKMP+B)P6-8-%)A.W'%X%6XV_2JQC[N'<=\B:+8QB4FT
M$K+'TVX-`WTU-5W[UI<=2B6L=GC']((;DV3A`2]W&H09]V6'5RV55F2[00'R
M[L`CM!S01!H.7CNZX9S183M%5B=5V*^TV!E`R-O-]-4*+X5)<S?F"UR':_(@
MB.SZ*B!P0+ZS&F_.="7V`3F^#B%-EFW.+1?S@)P6UKGF#(L(=&#[2I[2V<=&
MQB%VQ.D*W5=.URR!8TW7QDQ78A]CNC;FEHMYQ.G:F&$1@4/R76F"-.&]ALB1
M8ZV%@B_+R4A5-QL//0&[$"YI&H?=A7(K-A"UOX;8<=GB+E/7)"M,-C>2A]F*
M#-CJVDD"#MYA8Q$2;S;6Q20:D=C#H?XADAII7[/T*?MZFV'=0"Q)PW2W2>1"
M%OPXTC8<FPOPA)PG/!JF>,G35T-*EQYOD%R>Q<WHXNJ<_I<H6!ZAQ9B-ZKJA
MZ6AN`#S@!^1Z5:(NSI=V8\MUE]+J0LW2^)T<@%R>]5427V+9'350G10MFQG'
M.%7QM@K@@QNEZT.,AO]07E-VP>S*(!Z3J;7QH`_R=RD;C.-Z$BTN+57,1>KX
M#DR/7%V-I9*%[KI`EXT$NNR^0.^P=:^N,&`CP3)8W31>Z$%_(@#+S\]%`<H?
MN[)R).DZ#98*#DZG\M@7P,&#R)Z;7K`U/-/U2:T&DEA`C<3G1AMT;(`UH-C2
MA3[;I-8PY<9`U\CT[#7E3_K.8C6!PP['\ILW-?5:ZL;J*P@>=@D5AQNSF>IJ
M&#PBCU0VC(6J^MHFQTFW5C$M`&B3[UD8^8N9T1`Q:*#XWL[U-AX<>A@0TN1$
MP+59_)GPDAP9[(?843;OBHR(F+LE7ENP?^8^@$*</9]#4`G6!1G&KETO0050
M%_C_ACV.1[S9J$_`,VO$$,,>8X;Q#X8K^!LBERZSH>E$9[M":4K0G70XF7U'
MMC8?6C21MF#ZY3]U:-FC4,D][^MMDJ#"7=<JH5LU9<M;/>>YF.;V@I!(UU0H
M4EB[W&:ZT/]"YGAJ&7`_=7\HI0^A[&50\<BUJ;`[X),%V+5O7<`V$[NP+`A!
MVMMRXL$_,K>^OMD@S!4]-#`>P7B]<="6WK8C<5(W>G<C<SZ]&VY77(7"Q.)^
MZN362:K9>C:W'GSJ>`M`.BE4<IU&7PW>D[`,FQM#TH[CI'J2`.R\@#3HE!UP
MXQ>+OK;`E5($W:;E/7203Y.SO!\@H+9SSIE+)E8=6(O'K]0CP\PMH/]CX@'`
MB\*)85IDGG6LB'<A2)O'WG@M(C6"1O`)VL"UOT/@)&._XF,'V+U#I*HD>>FD
MR&OV2WN;.4M@BIG*.HO<3RUR&F5&<CGE?>J"[\`VFO1X*K.*%8R)1BAMKN&,
M0>YI"?];JSM.\:B0;\-QOG?,0^+89<W](B&1?=I`>ZO5LQ"]9>1GC5<15,=T
M6?-$4W.]2A/LI)U+3^\68&U"<EI?(PL+$!IH`4B'D]KP(%T<_=R)X-YH=BKH
M6O-41L.`JS2U/=T4K;\+/T/#T`_0&GBL4"*P)\B[01XPL`]#.=SA_KL4U:/)
MJ+O@$$+*D3V:E,DHFGAHC7F+JP_KJX7Y?(.GG`=-9Q<Y90D?=V).5&UQITYO
MQS=C=7F[&$>/;P<+0$IP8PKD,.N6.%<-I^@.=-M9R*,">7Y:((^6_9.^H,Y'
M[I(H4_`$G,&K!(I)M+C5-I(BA]$Y7=3G%M;JXJ)]7<A*D</HG"[JTR)K=7'9
MOBYDI<AA'-:!8,_J:F[FU:-E].A1G:L@A7H<Z[;BJ$3S_9`FPT4O2ZE^UCY/
M4B+%0-U,5F4I[</0\X!K1=F,T1,SJOWW,$J`3[9X*=B?5\Y!$T'KMZ;##DG,
MXPK@QCT:=G")B86;<;8D'HM_SJ<"2`)W4W5)7:A<&GBBK,K//Y,T%V)I]G,[
MX4@/I13+BK[JD90RL7:.^.B2?DU2G1JMZIGD%@YR6[<KI9^CF9OPE>]H[*6I
M3O53.B+]`W6/9`OM3(3$6-O]I2<QB98>DLEHPJ0)/ID#G+T]_B1-N9.=L(>%
M78KJ<0_$TI=@-+S[>?1A-7*Z_!78#^2X*GK8%38^L]Z![I&/Z-%Z#:DMB[E*
MK$*KN:0RA(XK&CM7QK!SY$#"2?QO0]%D"!V_O+NZ)F>J_^1ER$F!=BM2E#&)
M6(QKB/S`ITX)-9K8JK'#L&Q,^+BB3P%9`IN^K5/".NS!CNX]F"X;0;1L)8BP
M:Z_=22"V&O+FU%>>ZU-MJ(V7=:))H78\54%UM?7&A!XMK81\LA,'?GDS+N8N
M2*)U4GA6J('>)")U+#`J":<',"K<S]Y0(XGX?G81D49I^1;W'1Z+^N*[>KTT
M%NK0J!O$`H1.9F!DGQ/5[WV$W2,+FQD@'TUE^[84;!?/5-@M,?9($ZT6FKL^
MEOW06?[Y3DU&CIW\J7:&W13X)`P4DE)L)'L7;#Q@P>CB1U1I/]V8ZR%;72*B
MQ3G+5^U+C0*,3B[Q65:9O2L:C-+@G1268]Q7;>!2H%U<3Z)B85GVLZ5PJK[^
M-)*\$TKR[B>2Y$HHR=5/),FO0DE^_8DD^4THR6\_BR3&(_"`F:T4)8;Y2:0B
MAI!`H.AS)VTBYA7I]PY\8,S.S>W4O$=X`T,>I.FY>O!(#_1SCI0<RH&M)&%N
M:/8RF9Z$*$@.9Z:L:.:X30:XDTK,F*K9<5<T"P2%B3.GI*^FU,DN8N5Y2/'O
MZXCX*`2WK@T\;@W6Q<WUY7F^5NMK*+3J*Y`3']>"3F0;DS!-\GAC;0%B&=16
MA9L1C\P.K8`,3GYTGLSA.D$;D^FD%Q&E.9'8S1P3\4C*2;IJ<[]U,[-FO%H!
M*]!7>*!]10ZTS?0V*^=+-V6@&R#NZK7I06=+"DXPUF^7<3',9&61`6UUEHU8
ML;=D_K.05,VLJD7KINJ2H[G<>2/P@?>4B<Z)8#JY.L3W$V<H2-<ZC>5&!F1!
MR-X9KX/LUGB<0O.>7FYO/"0YF)W4'G4B*B94[D"V$J:;DRU[OC]"X7VP"AW#
M,VT\F2P`GP@/?BP2%H87%I!"^WFDI]M!<^F%:)T<TC,0\`=K)H6V"J#EY2=.
M"&(5#K^8L#Z*7H?5S1&:<DW93</'9;%*`)WT!.DBV>@ZVOYNHC6W1-BH9]'I
MM'.)-_*J3.;=2+=RX"9[G7X.O!7RUJ1QRGJV$J%DK^RGJ4[WT@2^'+1K./2/
MFXM5KE=AZ.,_QL-;0[L;ZY.)-L0?7E,'M*HL1M-FCEY/E-QK(RHRGM'X!5@A
M6;2C5P>E,[Z;DSV*E#/D_BTT';B"^;''K6O44-2&M`]:7VB79[9?^;)V(WTD
M%9DVD$Q6W;TQMQ=74I'<0DDG#H%C<&X@<I-.=XU'#X`;Y)*GR5T\GCT?+[K%
M59]=NAMZD"8B-1/Q=2T=M"^XPYU5JL(+/&8,>,.)GIT8>YAO>V_U>#-1UIPL
M(AUC1$=E?757W7C0N7C??"YR"71]+LIJ9#]-'72DL2E`RJYDBJX:CX#Q/F>8
MDA++DVO'/ZOCC[ID<C7WY03.$CR6(LLE9YL+PZ-Q7$N[\*Z#BNW`==2G#6UI
M&4*'+)^Z4_E9%B+EHAZ266Y)VHZ6HC4K2]&:;9>BC;F94W1]U>!E:S[JL<LZ
M&KJ4ERE;U%&27!?JW/*<3X[G6>^Q-O>"V]D32WM6H:QL]?<VB^'FK%UR?8/+
M>QU4FP,N+M#)?)+$&1F.]31%1@#2)N\%RW8)7QH[F5P3>1="'>B'V(N)SQ,N
M*KR<S/<.C;Q*;[AB&`K@.Z2+U*.LTD8.H@.<[SX)!GN;3ONO5]7LZ2?Z=U:'
M"GLB(3#0#+FJ]0C!$V!%(5()BJO)SNA=3`5/+Z!SKJ@;"._'432$@*G/IF?[
MW\Q,A%1_HD\1168D_B'JFVCLY_KK4$T<.CL[JH=@(U(7FY/\\/#@@0<L1_XI
MO1OV-BU+=1`#M2M!P6]-"H!G7C@DKTO19,N\6+M@=DK6G-DFE(T+V:XL,Z2O
MHIF0Y[S\]W9+^8?K-5YW6!G*:.-@U69J$]WD<%O=4M.$^L)+=+POW>)T4,UJ
MR]MSYNEA-1@!BX[CRT'6QA*"=*$49N:5L?0/K3)&XY%9GY7]VD6C)*Z%<V/:
MQ)_&.PHI6D7?M=?<N8?P?NI+5\&7HW7DPO<AJ7_*WHM**O^0P$4<!HRJ5R6L
MJIA-L$OAH;VTU,H@R!4=E0WX%9':Y[S^VC2'\W=M%LQ0UZ3,6)/TPABC[==`
MV,]^)H=X?V^"<(FW^9#-_PWF(&"N!E>$I!4,1)I%RWD6Y$!'<P!X*1;\($ZD
M(TDIO@F%7(OH?!"D:Y!GF"-H'5ZX8U"0HU^(CZ>CDZ>/9T@DJ2<_$F$035MS
MX(D*_S3H@G'4$$9:ZQ)2E`K>LEN,6(Q-;.Q29`--IP_`_7P2%S>@Z0&YST:_
M.#D#V+T&,@%02P$"'@,4````"``HA&Y"OU(=6HFT``!@#@H`$0`8```````!
M````I($`````8W!H:2TR,#$R,3(S,2YX;6Q55`4``PPT0E%U>`L``00E#@``
M!#D!``!02P$"'@,4````"``HA&Y"#B$B;8(%```5/```%0`8```````!````
MI('4M```8W!H:2TR,#$R,3(S,5]C86PN>&UL550%``,,-$)1=7@+``$$)0X`
M``0Y`0``4$L!`AX#%`````@`*(1N0L"Z9/XM)P``;9L"`!4`&````````0``
M`*2!I;H``&-P:&DM,C`Q,C$R,S%?9&5F+GAM;%54!0`###1"475X"P`!!"4.
M```$.0$``%!+`0(>`Q0````(`"B$;D)5AVH11VD``+&T!``5`!@```````$`
M``"D@2'B``!C<&AI+3(P,3(Q,C,Q7VQA8BYX;6Q55`4``PPT0E%U>`L``00E
M#@``!#D!``!02P$"'@,4````"``HA&Y"F=/*ET<P```L-P,`%0`8```````!
M````I(&W2P$`8W!H:2TR,#$R,3(S,5]P<F4N>&UL550%``,,-$)1=7@+``$$
M)0X```0Y`0``4$L!`AX#%`````@`*(1N0D#$>_2,&@``\2T!`!$`&```````
M`0```*2!37P!`&-P:&DM,C`Q,C$R,S$N>'-D550%``,,-$)1=7@+``$$)0X`
<``0Y`0``4$L%!@`````&``8`&@(``"27`0``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EPH">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (DETAILS) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PaymentsMadeForConstructionInProgress', window );">Payments made for Construction in Progress</a></td>
        <td class="nump">$ 3,110,319<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ForTheYear2013', window );">For the year 2013</a></td>
        <td class="nump">13,133,498<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ForTheYear2014', window );">For the year 2014</a></td>
        <td class="nump">968,860<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalAmount', window );">Total Amount</a></td>
        <td class="nump">$ 14,102,358<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ForTheYear2013">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For the year 2013</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ForTheYear2013</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ForTheYear2014">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For the year 2014</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ForTheYear2014</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PaymentsMadeForConstructionInProgress">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Payments made for Construction in Progress</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PaymentsMadeForConstructionInProgress</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total Amount</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_TotalAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E1KAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS At Reporting Date Using (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BankersAcceptanceNotes', window );">Bankers acceptance notes</a></td>
        <td class="nump">$ 101,570<span></span></td>
        <td class="nump">$ 83,512<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_Total1', window );">Total</a></td>
        <td class="nump">101,570<span></span></td>
        <td class="nump">83,512<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BankersAcceptanceNotesLevel1', window );">Bankers acceptance notes Level 1</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalLevel1', window );">Total Level 1</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BankersAcceptanceNotesLevel2', window );">Bankers acceptance notes Level 2</a></td>
        <td class="nump">101,570<span></span></td>
        <td class="nump">83,512<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalLevel2', window );">Total Level 2</a></td>
        <td class="nump">101,570<span></span></td>
        <td class="nump">83,512<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BankersAcceptanceNotesLevel3', window );">Bankers acceptance notes Level 3</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalLevel3', window );">Total Level 3</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BankersAcceptanceNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Bankers acceptance notes,</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_BankersAcceptanceNotes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BankersAcceptanceNotesLevel1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Bankers acceptance notes Level 1</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_BankersAcceptanceNotesLevel1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BankersAcceptanceNotesLevel2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Bankers acceptance notes Level 2</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_BankersAcceptanceNotesLevel2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BankersAcceptanceNotesLevel3">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Bankers acceptance notes Level 3</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_BankersAcceptanceNotesLevel3</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_Total1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total bankers acceptance notes</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_Total1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalLevel1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Bankers acceptance notes total Level 1</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_TotalLevel1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalLevel2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Bankers acceptance notes Level 2 total</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_TotalLevel2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalLevel3">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Bankers acceptance notes Level 3 total.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_TotalLevel3</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EZMAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PermitOfLandUse', window );">Permit of land use</a></td>
        <td class="nump">$ 447,013<span></span></td>
        <td class="nump">$ 442,978<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Building</a></td>
        <td class="nump">2,419,125<span></span></td>
        <td class="nump">2,397,286<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PlantMachineryAndEquipmentGross', window );">Plant, machinery and equipment</a></td>
        <td class="nump">6,381,209<span></span></td>
        <td class="nump">6,184,254<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MotorVehicleGross', window );">Motor vehicle</a></td>
        <td class="nump">147,080<span></span></td>
        <td class="nump">145,300<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Office equipment</a></td>
        <td class="nump">222,273<span></span></td>
        <td class="nump">204,552<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
        <td class="nump">3,688,567<span></span></td>
        <td class="nump">351,571<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalPropertyAndEquipment', window );">Total Property and Equipment</a></td>
        <td class="nump">13,305,267<span></span></td>
        <td class="nump">9,725,941<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LessAccumulatedDepreciationDetails', window );">Less: accumulated depreciation details</a></td>
        <td class="num">(4,273,373)<span></span></td>
        <td class="num">(3,391,124)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PropertyAndEquipmentNet', window );">Property and Equipment, net</a></td>
        <td class="nump">$ 9,031,894<span></span></td>
        <td class="nump">$ 6,334,817<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_LessAccumulatedDepreciationDetails">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_LessAccumulatedDepreciationDetails</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MotorVehicleGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of motor vehicle gross as on the date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_MotorVehicleGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PermitOfLandUse">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of permit of land use as on the date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PermitOfLandUse</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PlantMachineryAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of plant machinery and equipment gross as on the date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PlantMachineryAndEquipmentGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PropertyAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PropertyAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalPropertyAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total Property and Equipment</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_TotalPropertyAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross amount, as of the balance sheet date, of long-lived, depreciable assets that include building structures held for productive use including any addition, improvement, or renovation to the structure, such as interior masonry, interior flooring, electrical, and plumbing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6812-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BuildingsAndImprovementsGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross amount, at the balance sheet date, of long-lived assets under construction that include construction costs to date on capital projects that have not been completed and assets being constructed that are not ready to be placed into service.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConstructionInProgressGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross amount, at the balance sheet date, of long-lived, depreciable assets commonly used in offices and stores. Examples include desks, chairs, and store fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FurnitureAndFixturesGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAF">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONCENTRATIONS Accounts Payable (Details)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercentageOfAccountsPayableToTwoSuppliersForPurchaseOfRawMaterials', window );">Percentage of accounts payable to two suppliers for purchase of raw materials</a></td>
        <td class="nump">12.10%<span></span></td>
        <td class="nump">10.30%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercentageOfAccountsPayableToTwoSuppliersForPurchaseOfRawMaterials">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of accounts payable to two suppliers for purchase of raw materials</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PercentageOfAccountsPayableToTwoSuppliersForPurchaseOfRawMaterials</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EWAAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IncomeTaxesTablesAbstract', window );"><strong>INCOME TAXES (Tables)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IncomeTaxesTableTextBlock', window );">Current Taxes</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Under current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:</p> <table width="240" style="MARGIN:auto auto auto -0.75pt; WIDTH:2.5in; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:12.75pt"> <td width="96" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1in; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="25" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:19pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="119" style="BORDER-BOTTOM:black 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:89pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" rowspan="2" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Enterprise Income Tax Rate</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="96" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1in; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Year</b></p></td> <td width="25" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:19pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:12.75pt"> <td width="96" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1in; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">2013</p></td> <td width="25" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:19pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="119" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:89pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">15%</p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="96" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1in; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">2014 and after</p></td> <td width="25" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:19pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="119" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:89pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">25%</p></td></tr></table> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ProvisionForIncomeTaxesTableTextBlock', window );">Provision For Income Taxes</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">The provision for income taxes consisted of the following:</p> <table width="483" style="MARGIN:auto auto auto -0.75pt; WIDTH:362pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="167" colspan="3" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:125pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Years Ended December 31,</b></p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.55pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>2012</b></p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>2011</b></p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Current</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.55pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp; 1,414,171</p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp; 3,458,568</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Deferred</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.55pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">(430,250)</p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">(16,213)</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Total income tax expense</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.55pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 983,921</p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp; 3,442,355</p></td></tr></table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Effective Income Tax Rate Reconciliation.</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Following is a reconciliation of income taxes calculated at the federal statutory rate to the provision for income taxes:</p> <table width="490" style="MARGIN:auto auto auto -0.75pt; WIDTH:367.4pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:18.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:18.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:18.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:18.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:18.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:18.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="174" colspan="3" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:130.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Years Ended December 31,</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">2012</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">2011</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Tax at statutory rate of 25%</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp; 1,400,395</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp; 5,677,999</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Non-deductible stock-based compensation from</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">current and prior years</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">149,644</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">261,122</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Effect of tax holiday</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">(655,947)</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">(2,330,566)</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Other, primarily the effect of US tax rates</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">(70,471)</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">-</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Change in valuation allowance</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">160,300</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">(166,200)</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Income tax expense</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 983,921</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp; 3,442,355</p></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred Tax Assets and Liabilities.</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">The temporary differences which give rise to the deferred income tax assets and liability are as follows:</p> <div align="center"> <table width="483" style="MARGIN:auto auto auto -0.75pt; WIDTH:362.05pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="167" colspan="3" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:125.05pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>December 31,</b></p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2012</b></p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2011</b></p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Deferred income tax assets:</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Allowance for doubtful trade receivables</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 664,492 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 530,461 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Allowance for doubtful other receivables</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7,482 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5,838 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Inventory obsolescence reserve</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 265,498 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Expenses not deductible in current year</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30,200 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 29,927 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Share based compensation</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 45,777 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 172,911 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">U.S. net operating loss carry forwards</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 905,669 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 618,236 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Total deferred income tax assets</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,919,118 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,357,373 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Valuation allowance</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (951,447)</p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (791,147)</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt">Net deferred income tax asset</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 967,671 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 566,226 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Deferred income tax liability:</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Intangible assets</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 95,963 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 128,909 </p></td></tr></table></div> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IncomeTaxesTablesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_IncomeTaxesTablesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IncomeTaxesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabluar disclosure of Provision For Income Taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_IncomeTaxesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ProvisionForIncomeTaxesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabluar disclosure of Provision For Income Taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ProvisionForIncomeTaxesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Publisher FASB<br><br> -Number <br><br> -Article <br><br> -Subparagraph <br><br> -Name Accounting Standards Codification<br><br> -Paragraph 2<br><br> -Section 50<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Publisher FASB<br><br> -Number <br><br> -Article <br><br> -Subparagraph <br><br> -Name Accounting Standards Codification<br><br> -Paragraph 12<br><br> -Section 50<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EHH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Compensation Expense (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RecognizedCompensationExpenses', window );">Recognized compensation expenses</a></td>
        <td class="nump">$ 141,720<span></span></td>
        <td class="nump">$ 196,183<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IncomeTaxBenefitRecognizedFromStockBasedCompensation', window );">Income Tax benefit recognized from stock based compensation</a></td>
        <td class="nump">$ 35,430<span></span></td>
        <td class="nump">$ 49,046<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IncomeTaxBenefitRecognizedFromStockBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income Tax benefit recognized from stock based compensation</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_IncomeTaxBenefitRecognizedFromStockBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RecognizedCompensationExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Recognized compensation expenses</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_RecognizedCompensationExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EEHAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Reconciliation of income taxes (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax at statutory rate of 25%</a></td>
        <td class="nump">$ 1,400,395<span></span></td>
        <td class="nump">$ 5,677,999<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CurrentAndPriorYears', window );">Current and prior years</a></td>
        <td class="nump">149,644<span></span></td>
        <td class="nump">261,122<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EffectOfTaxHoliday', window );">Effect of tax holiday</a></td>
        <td class="num">(655,947)<span></span></td>
        <td class="num">(2,330,566)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OtherPrimarilyTheEffectOfUSTaxRates', window );">Other, primarily the effect of US tax rates</a></td>
        <td class="num">(70,471)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance Reconciliation</a></td>
        <td class="nump">160,300<span></span></td>
        <td class="num">(166,200)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax expense Reconciliation</a></td>
        <td class="nump">$ 983,921<span></span></td>
        <td class="nump">$ 3,442,355<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CurrentAndPriorYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Current and prior years</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_CurrentAndPriorYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EffectOfTaxHoliday">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A tax "holiday" refers to the tax benefit derived from a jurisdiction that provides an exemption from income taxes for some defined period of time as an incentive to attract business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_EffectOfTaxHoliday</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OtherPrimarilyTheEffectOfUSTaxRates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Other, primarily the effect of US tax rates</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_OtherPrimarilyTheEffectOfUSTaxRates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of the difference between total income tax expense or benefit as reported in the Income Statement and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to changes in the valuation allowance for deferred tax assets in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e32123-109318<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 47<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the differences between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to tax credits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationTaxCredits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS Member Of BOD (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AmountAdvancedByMemberOfBODToTheCompany', window );">Amount advanced by Member of BOD to the Company</a></td>
        <td class="nump">$ 493,004<span></span></td>
        <td class="nump">$ 595,670<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InterestRateOnAdvancesFromMemberOfBOD', window );">Interest rate on advances from Member of BOD</a></td>
        <td class="nump">1.00%<span></span></td>
        <td class="nump">1.00%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AmountAdvancedByMemberOfBODToTheCompany">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Advance from member of board of director.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AmountAdvancedByMemberOfBODToTheCompany</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InterestRateOnAdvancesFromMemberOfBOD">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Interest rate on advances from Member of BOD</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_InterestRateOnAdvancesFromMemberOfBOD</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E4BAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>EXECUTIVE OFFICERS 2010 Stock Option Plan (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>May 25, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NumberOfCommonSharesIssuedToTwoExecutiveOfficers', window );">Number of common shares issued to two executive officers</a></td>
        <td class="nump">100,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NumberOfNonQualifiedStockOptionsToPurchaseCommonStock', window );">Number of non-qualified stock options to purchase common stock</a></td>
        <td class="nump">50,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ExercisePrice', window );">Exercise Price</a></td>
        <td class="nump">$ 2.54<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OptionsExpiringOnMay252013', window );">Options expiring on May 25, 2013</a></td>
        <td class="nump">25,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria', window );">Options to vest on three month anniversary performance based vesting criteria</a></td>
        <td class="nump">25,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_QualifiedStockOptionsGrantedToFormerCFONonQualifiedOptionsToPurchaseCommonStock', window );">Qualified stock options granted to former CFO non qualified options to purchase common stock</a></td>
        <td class="nump">50,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ExercisePrice1', window );">Exercise Price.</a></td>
        <td class="nump">$ 2.54<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OptionsVestedOnApril282013', window );">Options vested on April 28, 2013</a></td>
        <td class="nump">25,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria1', window );">Options to vest on three month anniversary performance based vesting criteria.</a></td>
        <td class="nump">25,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_GrantedDateFairValueOfTheOptionsPerShare', window );">Granted date fair value of the options per share</a></td>
        <td class="nump">$ 0.71<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_GrantedDateFairValueOfTheOptionsTotalValue', window );">Granted date fair value of the options total value</a></td>
        <td class="nump">$ 70,580<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_GrantedDateClosingMarketPrice', window );">Granted date closing market price</a></td>
        <td class="nump">$ 2.54<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="nump">0.54%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DividendYield', window );">Dividend Yield</a></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ExpectedVolatality', window );">Expected volatality</a></td>
        <td class="nump">70.40%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ExpectedPeriodOfLife', window );">Expected period of life</a></td>
        <td class="nump">1<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DividendYield">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Dividend Yield</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DividendYield</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise Price</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ExercisePrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise Price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ExercisePrice1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ExpectedPeriodOfLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected period of life</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ExpectedPeriodOfLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ExpectedVolatality">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected volatality</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ExpectedVolatality</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_GrantedDateClosingMarketPrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Granted date closing market price</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_GrantedDateClosingMarketPrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_GrantedDateFairValueOfTheOptionsPerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Granted date fair value of the options per share</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_GrantedDateFairValueOfTheOptionsPerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_GrantedDateFairValueOfTheOptionsTotalValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Granted date fair value of the options total value</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_GrantedDateFairValueOfTheOptionsTotalValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NumberOfCommonSharesIssuedToTwoExecutiveOfficers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of common shares issued to two executive officers</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NumberOfCommonSharesIssuedToTwoExecutiveOfficers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NumberOfNonQualifiedStockOptionsToPurchaseCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of non-qualified stock options to purchase common stock</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NumberOfNonQualifiedStockOptionsToPurchaseCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OptionsExpiringOnMay252013">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Options expiring on May 25, 2013</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_OptionsExpiringOnMay252013</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Options to vest on three month anniversary performance based vesting criteria</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Options to vest on three month anniversary performance based vesting criteria.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_OptionsToVestOnThreeMonthAnniversaryPerformanceBasedVestingCriteria1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OptionsVestedOnApril282013">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Options vested on April 28, 2013</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_OptionsVestedOnApril282013</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_QualifiedStockOptionsGrantedToFormerCFONonQualifiedOptionsToPurchaseCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Qualified stock options granted to former CFO non qualified options to purchase common stock</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_QualifiedStockOptionsGrantedToFormerCFONonQualifiedOptionsToPurchaseCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Risk free interest rate</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_RiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ENGAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Preferred Common Stock And Warrants (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommonSharesAuthorized', window );">Common shares authorized</a></td>
        <td class="nump">95,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PreferredSharesAuthorized', window );">Preferred shares authorized</a></td>
        <td class="nump">5,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NumberOfCommonStockSharesToPurchaseByWarrantsOutstaningAndExercisable', window );">Number of common stock shares to purchase by warrants outstaning and exercisable</a></td>
        <td class="nump">150,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_WarrantsStartRangeExercisePrice', window );">Warrants start range exercise price</a></td>
        <td class="nump">$ 3.00<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_WarrantsEndRangeExercisePrice', window );">Warrants end range exercise price</a></td>
        <td class="nump">$ 3.80<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_WarrantsWeightedAverageExercisePrice', window );">Warrants weighted average exercise price</a></td>
        <td class="nump">$ 3.40<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_WarrantsWeightedAverageContractualLife', window );">Warrants weighted average contractual life</a></td>
        <td class="nump">0.4<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalIntrinsicValue', window );">Total intrinsic value</a></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommonSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_CommonSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NumberOfCommonStockSharesToPurchaseByWarrantsOutstaningAndExercisable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of common stock shares to purchase by warrants outstaning and exercisable</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NumberOfCommonStockSharesToPurchaseByWarrantsOutstaningAndExercisable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PreferredSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PreferredSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total intrinsic value</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_TotalIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_WarrantsEndRangeExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants start range exercise price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_WarrantsEndRangeExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_WarrantsStartRangeExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants start range exercise price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_WarrantsStartRangeExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_WarrantsWeightedAverageContractualLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants weighted average contractual life</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_WarrantsWeightedAverageContractualLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_WarrantsWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants weighted average exercise price</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_WarrantsWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
        <td class="text"><!--egx--><p style="MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:"><b>NOTE 3 - PROPERTY AND EQUIPMENT</b></p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Property and equipment consisted of the following:</p> <table width="430" style="MARGIN:auto auto auto -0.75pt; WIDTH:322.4pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>&nbsp;December 31, </b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>&nbsp;December 31, </b></p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2012</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2011</b></p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Permit of land use</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 447,013 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 442,978 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Building</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2,419,125 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2,397,286 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Plant, machinery and equipment</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6,381,209 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6,184,254 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Motor vehicle</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 147,080 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 145,300 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Office equipment</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 222,273 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 204,552 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Construction in progress</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3,688,567 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 351,571 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; TEXT-INDENT:10.05pt; MARGIN:0in 0in 0pt"><b>Total</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp; 13,305,267 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9,725,941 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Less: accumulated depreciation</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp; (4,273,373)</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp; (3,391,124)</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Property and Equipment, net</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;$&nbsp;&nbsp; 9,031,894 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;$&nbsp;&nbsp; 6,334,817 </p></td></tr></table> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Construction in progress consisted of machinery, equipment, construction costs incurred in connection with the construction of a new facility and required manufacturing upgrades.&nbsp; Once the machinery is in production and the the facility is in use, construction in progress is moved into plant, machinery and equipment and depreciated.&nbsp; Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:</p> <table width="337" style="MARGIN:auto auto auto -0.75pt; WIDTH:253pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">Asset</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="75" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:56pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">&nbsp;Life - years </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Permit of land use</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="75" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:56pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">40 - 70</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Building</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="75" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:56pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">20 - 35</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Plant, machinery and equipment</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="75" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:56pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">10</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Motor vehicle</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="75" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:56pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">5 - 10</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Office equipment</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="75" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:56pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">3-5</p></td></tr></table> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue. For the years ended December 31, 2012 and 2011, depreciation expense was $851,047 and $555,036, respectively.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>39
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%]E-#!F-C,V,%\X,#1E7S0W-3E?868Q,E\S
M8F%A93,Y9&,Q.#8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO930P
M9C8S-C!?.#`T95\T-S4Y7V%F,3)?,V)A864S.61C,3@V+U=O<FMB;V]K+FAT
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7T)!3$%.0T5?4TA%1513/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0T].4T],241!5$5$7T)!3$%.0T5?4TA%15137U!!/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7U-4051%345.5%-?3T9?3U!%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].4T],241!5$5$7U-4051%345.5%-?3T9?4U1//"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!
M5$5$7U-4051%345.5%-?3T9?0T%3/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^3U)'04Y)6D%424].7T%.1%]324=.249)0T%.5%]!
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^24Y614Y4
M3U)9/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#`X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4%)/
M4$525%E?04Y$7T5154E0345.5#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P.2YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/DE.5$%.1TE"3$5?05-31513/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$P
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^041604Y#15-?1D]27U!54D-(05-%
M4U]/1E])3E1!/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#$Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^4D5,051%1%]005)465]44D%.4T%#5$E/3E,\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3(N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.3U1%4U]005E!0DQ%/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#$S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^24Y#3TU%7U1!6$53/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#$T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1$52259!5$E6
M15]705)204Y47TQ)04))3$E463PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-2YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/D9!25)?5D%,545?345!4U5214U%3E13/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#$V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4U1/0TM(3TQ$15)37T51
M54E463PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970Q-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-/
M34U)5$U%3E137T%.1%]#3TY424Y'14Y#2453/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$X+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^0T].0T5.5%)!5$E/3E,\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,3DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y!8V-O=6YT:6YG7U!O;&EC
M:65S7U!O;&EC:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#(P+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^0D%325-?3T9?4%)%4T5.5$%424].7U1A8FQE<SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970R,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DE.5D5.5$]2651A8FQE<SPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970R,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!23U!%4E19
M7T%.1%]%455)4$U%3E1?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(S+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^24Y404Y'24),15]!4U-%5%-?5&%B;&5S/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#(T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^24Y#3TU%7U1!6$53
M7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970R-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/D9!25)?5D%,545?345!4U5214U%3E137U1A8FQE<SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R
M-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-43T-+7T]05$E/3E]!0U1)5DE4
M65]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,C<N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y&55154D5?34E.24U535]#3TU-251-14Y44U]486(\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,C@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y"05-)4U]/1E]04D5314Y4051)
M3TY?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970R.2YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/D)!4TE37T]&7U!215-%3E1!5$E/3E]"87-I8U]A;CPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970S,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D)!4TE37T]&7U!215-%3E1!
M5$E/3E]03TQ)0TE%4SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,2YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/DE.5D5.5$]265]$971A:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,R+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4%)/4$525%E?04Y$7T5154E0345.5%]$971A
M:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#,S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4%)/
M4$525%E?04Y$7T5154E0345.5%]!<W-E='-?/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,T+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^05-315137T1E<')E8VEA=&EO;E]$971A
M:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#,U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^24Y4
M04Y'24),15]!4U-%5%-?4T9$05]!<'!R;W9E/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,V+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4D5,051%1%]005)465]44D%.4T%#5$E/
M3E-?365M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#,W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M4D5,051%1%]005)465]44D%.4T%#5$E/3E-?3W=I/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,X
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^3D]415-?4$%904),15-?1&5T86EL
M<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970S.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DE.0T]-
M15]405A%4U]5;F1I<W1R:6)U=&5D7T5A<CPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T,"YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/DE.0T]-15]405A%4U]0<F]V:7-I;VY?1&5T
M86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970T,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E)E
M8V]N8VEL:6%T:6]N7V]F7VEN8V]M95]T87AE<SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T,BYH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/D-H86YG97-?;V9?9&5F97)R961?:6YC
M;VUE7W1A>#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970T,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/D1%4DE6051)5D5?5T%24D%.5%],24%"24Q)5%E?1#PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T
M-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D1%4DE6051)5D5?5T%24D%.5%]'
M04E.4U]$971A:3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970T-2YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/D9!25)?5D%,545?345!4U5214U%3E137T%T7U)E<#PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970T-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!R969E<G)E9%]#;VUM;VY?
M4W1O8VM?06YD7U=A<CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T-RYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/C(P,3!?4W1O8VM?3W!T:6]N7U!L86Y?1&5T86EL<SPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970T."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/C(P,3!?4W1O8VM?3W!T
M:6]N7U!L86Y?1G)A;FM?5SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T.2YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/D-O;7!E;G-A=&EO;E]%>'!E;G-E7T1E=&%I;',\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T-3`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y5;G)E8V]G;FEZ961?
M0V]M<&5N<V%T:6]N7T5X<&4\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-3$N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y%6$5#551)5D5?3T9&24-%4E-?,C`Q,%]3=&]C:U\\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T-3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y/1D9)0T524U\R
M,#$P7U-T;V-K7T]P=&EO;E]0;&$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-3,N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y3=6UM87)Y7V]F7W-T;V-K7V]P=&EO;E]A8W1I=FD\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T-30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#3TU-251-
M14Y44U]!3D1?0T].5$E.1T5.0TE%4U\\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-34N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y#3TY#14Y44D%424].4U]386QE<U]!;F1?4'5R
M8V@\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T-38N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#3TY#
M14Y44D%424].4U]!8V-O=6YT<U]087EA8FP\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-3<N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`\+W@Z17AC96Q7;W)K
M<VAE971S/@T*("`\>#I3='EL97-H965T($A2968],T0B5V]R:W-H965T<R]R
M97!O<G0N8W-S(B\^#0H@(#QX.D%C=&EV95-H965T/C`\+W@Z06-T:79E4VAE
M970^#0H@(#QX.E!R;W1E8W13=')U8W1U<F4^1F%L<V4\+W@Z4')O=&5C=%-T
M<G5C='5R93X-"B`@/'@Z4')O=&5C=%=I;F1O=W,^1F%L<V4\+W@Z4')O=&5C
M=%=I;F1O=W,^#0H@/"]X.D5X8V5L5V]R:V)O;VL^#0H\+WAM;#X\(5ME;F1I
M9ETM+3X-"CPO:&5A9#X-"B`@/&)O9'D^#0H@("`\<#Y4:&ES('!A9V4@<VAO
M=6QD(&)E(&]P96YE9"!W:71H($UI8W)O<V]F="!%>&-E;"!84"!O<B!N97=E
M<BX\+W`^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%]E-#!F-C,V,%\X,#1E7S0W-3E?868Q,E\S8F%A93,Y9&,Q.#8-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO930P9C8S-C!?.#`T95\T-S4Y7V%F
M,3)?,V)A864S.61C,3@V+U=O<FMS:&5E=',O4VAE970P,2YH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P15=)044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&]C=6UE;G0@86YD
M($5N=&ET>2!);F9O<FUA=&EO;B`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,30L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&]C=6UE;G0@86YD($5N
M=&ET>2!);F9O<FUA=&EO;CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%;G1I='D@4F5G:7-T<F%N="!.86UE/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#Y#2$E.02!02$%234$@2$],1$E.1U,L
M($E.0RX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1O8W5M96YT(%1Y<&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/C$P+4L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1O8W5M96YT(%!E<FEO9"!%;F0@1&%T93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^1&5C(#,Q+`T*"0DR,#$R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;65N
M9&UE;G0@1FQA9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^9F%L
M<V4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5N=&ET>2!#96YT<F%L($EN9&5X($ME>3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^,#`P,3$P-C8T-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0W5R<F5N="!&:7-C86P@665A
M<B!%;F0@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^+2TQ
M,BTS,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^16YT:71Y($-O;6UO;B!3=&]C:RP@4VAA<F5S($]U='-T86YD:6YG
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,RPU-SDL-34W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M;G1I='D@1FEL97(@0V%T96=O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/E-M86QL97(@4F5P;W)T:6YG($-O;7!A;GD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#=7)R
M96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/EEE<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^16YT:71Y(%9O;'5N=&%R>2!&:6QE<G,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/DYO/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@5V5L;"UK;F]W;B!3
M96%S;VYE9"!)<W-U97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/DYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$;V-U;65N="!&:7-C86P@665A<B!&;V-U<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^,C`Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L(%!E<FEO
M9"!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^1ED\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N
M=&ET>2!0=6)L:6,@1FQO870\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?930P9C8S-C!?.#`T95\T-S4Y7V%F,3)?,V)A864S.61C,3@V#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4T,&8V,S8P7S@P-&5?-#<U.5]A
M9C$R7S-B86%E,SED8S$X-B]7;W)K<VAE971S+U-H965T,#(N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$4T3$%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-/3E-/3$E$051%
M1"!"04Q!3D-%(%-(14544R`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT
M($%S<V5T<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`T+#`R.2PW,#@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0L,#4P+#@U-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%N
M:V5R)W,@86-C97!T86YC97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P,2PU-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX,RPU,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1R861E(&%C8V]U;G1S(')E8V5I=F%B;&4L
M(&QE<W,@86QL;W=A;F-E(&9O<B!D;W5B=&9U;"!A8V-O=6YT<R!O9B`D-"PT
M,CDL.30U(&%N9"`D,RPU,S8L-#`U+"!R97-P96-T:79E;'D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8V+#$W-2PU-S`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.2PV.34L-34V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/
M=&AE<B!R96-E:79A8FQE<RP@;&5S<R!A;&QO=V%N8V4@9F]R(&1O=6)T9G5L
M(&%C8V]U;G1S(&]F("0T.2PX.#$@86YD("0S."PY,C$L(')E<W!E8W1I=F5L
M>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#`L-SDY/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-34L,#,Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!9'9A;F-E<R!T;R!S=7!P;&EE<G,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0L.#$V+#,U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4L-S<X+#@T,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV96YT;W)Y.CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S8L,S4Y+#4Q-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P+#,W."PV
M-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1E9F5R<F5D('1A>"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/CDV-RPV-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU-C8L,C(V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!#=7)R96YT($%S<V5T
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$R+#4S,2PQ.#@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,3`L-C`X+#8X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^061V86YC97,@9F]R('!U<F-H87-E<R!O9B!P<F]P97)T
M>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3<P+#,R,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^061V86YC97,@9F]R('!U<F-H87-E<R!O9B!I;G1A;F=I
M8FQE(&%S<V5T<SH\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y
M+#(V,RPY-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS-BPQ.30L-#DT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT+"!N
M970@;V8@86-C=6UU;&%T960@9&5P<F5C:6%T:6]N(&]F("0T+#(W,RPS-S,@
M86YD("0S+#,Y,2PQ,C0L(')E<W!E8W1I=F5L>3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.2PP,S$L.#DT/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPS,S0L.#$W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1A;F=I8FQE
M(&%S<V5T<RP@;F5T(&]F(&%C8W5M=6QA=&5D(&%M;W)T:7IA=&EO;B!O9B`D
M,BPY-#0L-S(V(&%N9"`D,RPP-#$L.#`T+"!R97-P96-T:79E;'D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-#$R+#@U-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,#@R+#8W,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5$]404P@05-31513/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-C,L,C,Y+#DQ,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$U-BPS.3`L.3DQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-U<G)E;G0@3&EA8FEL
M:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1R861E(&%C8V]U;G1S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(L.#0Q+#@V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,3$R+#,X-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!E>'!E
M;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`R+#$X-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X
M-"PP,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%C8W)U960@=&%X97,@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BPT,C8L.#(V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPP.#(L,S4S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!P87EA
M8FQE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP.30L.#@V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.#(R+#0T.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^061V86YC97,@9G)O;2!C=7-T;VUE<G,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L.30U+#DX-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S@T+#0W-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@
M<&%Y86)L97,@+2!R96QA=&5D('!A<G1I97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L,S4T+#4V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C@V,2PU-C,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H;W)T+71E<FT@;F]T
M97,@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PW
M-C$L,#<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,RPY,S$L-S0U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!#=7)R96YT($QI86)I;&ET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PV,C<L,S@S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,L-S<X
M+#DX-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3&]N9RUT97)M(&1E9F5R<F5D('1A>"!L:6%B:6QI='D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDU+#DV,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R."PY,#D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L
M($QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-"PW,C,L,S0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3,L.3`W+#@Y-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E<G,G($5Q
M=6ET>3H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')E9F5R<F5D('-T;V-K+"`D,"XP,#$@<&%R('9A;'5E.R`U+#`P,"PP
M,#`@<VAA<F5S(&%U=&AO<FEZ960[(&YO('-H87)E<R!I<W-U960@;W(@;W5T
M<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@<W1O8VLL("0P+C`P,2!P87(@=F%L=64[(#DU+#`P,"PP,#`@<VAA
M<F5S(&%U=&AO<FEZ960[(#0S+#4W.2PU-3<@<VAA<F5S(&%N9"`T,RPU,CDL
M-34W('-H87)E<R!O=71S=&%N9&EN9RP@<F5S<&5C=&EV96QY/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,RPU.#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,RPU,S`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N
M86P@<&%I9"UI;B!C87!I=&%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,RPU.3`L,C`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C,L-#0X+#4S-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5T86EN960@96%R;FEN9W,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P."PY,#0L,S(U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`T
M+#(X-BPV-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8W5M=6QA=&5D(&]T:&5R(&-O;7!R96AE;G-I=F4@:6YC
M;VUE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PY-S@L-#4X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,30L-S`T+#,V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5&]T86P@4W1O8VMH;VQD97)S)R!%<75I='D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T."PU,38L-38W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30R+#0X,RPP
M.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1/5$%,($Q)04))3$E42453($%.1"!35$]#2TA/3$1%4E,G($5154E4
M63PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-C,L,C,Y+#DQ
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,34V+#,Y,"PY.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7V4T,&8V,S8P7S@P-&5?-#<U.5]A9C$R7S-B86%E,SED8S$X
M-@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E-#!F-C,V,%\X,#1E
M7S0W-3E?868Q,E\S8F%A93,Y9&,Q.#8O5V]R:W-H965T<R]3:&5E=#`S+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%3$5!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#3TY3
M3TQ)1$%4140@0D%,04Y#12!32$5%5%,@4$%214Y42$5424-!3%,@*%531"`D
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%L;&]W86YC92!F;W(@9&]U8G1F=6P@86-C;W5N=',@;VX@=')A
M9&4@86-C;W5N=',@<F5C96EV86)L97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-"PT,CDL.30U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#4S-BPT,#4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%L;&]W86YC92!F
M;W(@9&]U8G1F=6P@86-C;W5N=',@;VX@;W1H97(@<F5C96EV86)L97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Y+#@X,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,X+#DR,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C
M=6UU;&%T960@9&5P<F5C:6%T:6]N(&]N('!R;W!E<G1Y(&%N9"!E<75I<&UE
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,C<S+#,W,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M,SDQ+#$R-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06-C=6UU;&%T960@86UO<G1I>F%T:6]N(&]N(&EN=&%N9VEB
M;&4@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L
M.30T+#<R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,RPP-#$L.#`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@4W1O8VLL('!A<B!O<B!S
M=&%T960@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F5F97)R960@4W1O8VLL('-H87)E<R!A=71H;W)I
M>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R969E<G)E9"!3=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!3=&]C
M:RP@<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]M;6]N(%-T;V-K+"!P87(@;W(@<W1A=&5D('9A;'5E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]M;6]N(%-T;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.34L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDU+#`P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;6UO;B!3=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#,L-3<Y+#4U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0S+#4R.2PU-3<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!3=&]C
M:RP@<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT,RPU-SDL-34W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-#,L-3(Y+#4U-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?930P9C8S-C!?.#`T95\T-S4Y7V%F
M,3)?,V)A864S.61C,3@V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V4T,&8V,S8P7S@P-&5?-#<U.5]A9C$R7S-B86%E,SED8S$X-B]7;W)K<VAE
M971S+U-H965T,#0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5--$%%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/D-/3E-/3$E$051%1"!35$%414U%3E13($]&($]015)!5$E/
M3E,@04Y$($-/35!214A%3E-)5D4@24Y#3TU%("A54T0@)"D\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U-"PU,#<L,#0Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X,2PQ
M-C8L-S,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;W-T(&]F(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,X+#8V,"PX,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU,BPQ-S@L-C@P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E;G1O<GD@;V)S
M;VQE<V-E;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<V
M.2PY.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y'<F]S<R!P<F]F:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$T+#`W-BPR-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR."PY.#@L,#4Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]P97)A=&EN
M9R!E>'!E;G-E<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4V5L;&EN9R!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,RPU,S4L,C$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPT,SDL-3(R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!A
M9&UI;FES=')A=&EV92!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,RPS,3,L,S`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,RPW,38L,SDW/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"860@9&5B="!E>'!E;G-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-S$L-C$R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`X+#`X
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^26UP86ER;65N="!O9B!I;G1A;F=I8FQE(&%S<V5T<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-3DS+#`Y-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&]P97)A=&EN
M9R!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PS
M,3,L,C(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-RPR-C0L,#`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y';W9E<FYM96YT('-U8G-I9'D@:6YC;VUE/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#$L.3@W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`Q+#8W,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26YC;VUE(&9R;VT@;W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-2PY,#4L,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C(L,#(U+#<R-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/=&AE<B!I
M;F-O;64@*&5X<&5N<V4I.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y);G1E<F5S="!I;F-O;64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0L.30T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-RPR,#@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T(&5X<&5N<V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,P."PS-S4I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C4U+#$Y
M."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1E<FEV871I=F4@9V%I;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/CDS-"PR-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!O=&AE<B!I;F-O;64@*&5X<&5N<V4I/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S,#,L-#,Q*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8X-BPR-S`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DEN8V]M92!B969O<F4@:6YC;VUE('1A>&5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU+#8P,2PU.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,BPW,3$L.3DW/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@=&%X
M(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DX,RPY
M,C$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,RPT-#(L,S4U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T(&EN8V]M93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-"PV,3<L-C4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL,C8Y+#8T,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@8V]M<')E
M:&5N<VEV92!I;F-O;64@+2!F;W)E:6=N(&-U<G)E;F-Y('1R86YS;&%T:6]N
M(&%D:G5S=&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,C<T+#`Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4L,#@P+#`Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]M<')E:&5N<VEV92!I;F-O;64\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-2PX.3$L-S4P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R-"PS-#DL
M-S0P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D5A<FYI;F=S('!E<B!3:&%R93H\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:6,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XQ,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XT-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&EL=71E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C$Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C0T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-#!F-C,V
M,%\X,#1E7S0W-3E?868Q,E\S8F%A93,Y9&,Q.#8-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO930P9C8S-C!?.#`T95\T-S4Y7V%F,3)?,V)A864S
M.61C,3@V+U=O<FMS:&5E=',O4VAE970P-2YH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P135904<^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0T].4T],241!5$5$(%-4051%345.
M5%,@3T8@4U1/0TM(3TQ$15)3)R!%455)5%D@*%531"`D*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y#;VUM;VX@4W1O8VL@
M4VAA<F5S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D-O;6UO
M;B!3=&]C:R!!;6]U;G0\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^061D:71I;VYA;"!086ED+6EN($-A<&ET86P\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4F5T86EN960@16%R;FEN9W,\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^06-C=6UU;&%T960@3W1H97(@0V]M
M<')E:&5N<VEV92!);F-O;64\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^5&]T86P@4W1O8VMH;VQD97)S)R!%<75I='D\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4@870@1&5C+B`S,2P@
M,C`Q,#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#,L-#`T+#4U
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0S+#0P-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(S+#(U,BPT-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XX-2PP,3<L,#(T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PV,C0L,C8Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$W+#DS-RPQ
M-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DES<W5A;F-E(&]F(&]P=&EO;G,@87,@8V]M<&5N<V%T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<V+#DY,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S8L.3DQ/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M<W-U86YC92!O9B!S=&]C:R!A<R!C;VUP96YS871I;VX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$R-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3DL,#8W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3DL,3DR
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.970@:6YC;VUE(&9O<B!T:&4@>65A<B`R,#$Q/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Y+#(V.2PV-#(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Y
M+#(V.2PV-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9O<F5I9VX@8W5R<F5N8WD@=')A;G-L871I;VX@861J=7-T
M;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#@P
M+#`Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4L,#@P+#`Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!$96,N(#,Q+"`R,#$Q/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,RPU,CDL-34W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#,L-3,P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,L
M-#0X+#4S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$P-"PR.#8L-C8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,30L-S`T+#,V-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T,BPT.#,L,#DW/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R
M92UB87-E9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-#$L-C(P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#$L-S(P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&;W)F96ET=7)E
M(&]F(&-O;G1I;F=E;G1L>2!V97-T:6YG('-H87)E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-3`L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4P*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@:6YC;VUE
M(&9O<B!T:&4@>65A<B`R,#$R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT+#8Q-RPV-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-"PV,3<L-C4Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&;W)E:6=N(&-U<G)E;F-Y
M('1R86YS;&%T:6]N(&%D:G5S=&UE;G0N/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,C<T+#`Y,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PR-S0L,#DQ
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y"86QA;F-E(&%T($1E8RX@,S$L(#(P,3(\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0S+#4W.2PU-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,RPU.#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,RPU.3`L,C`T/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`X+#DP
M-"PS,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-2PY-S@L-#4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,30X+#4Q-BPU-C<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V4T,&8V,S8P7S@P-&5?-#<U.5]A9C$R
M7S-B86%E,SED8S$X-@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E
M-#!F-C,V,%\X,#1E7S0W-3E?868Q,E\S8F%A93,Y9&,Q.#8O5V]R:W-H965T
M<R]3:&5E=#`V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%631!1SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY#3TY33TQ)1$%4140@4U1!5$5-14Y44R!/1B!#05-(($9,3U=3
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#87-H($9L;W=S(&9R;VT@3W!E<F%T:6YG($%C=&EV
M:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!I;F-O;64@9F]R('1H92!P97)I;V0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-"PV,3<L-C4Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q.2PR-CDL-C0R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97!R
M96-I871I;VX@86YD(&%M;W)T:7IA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PT-C(L-S<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ-S0L.#(R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!B87-E9"!C
M;VUP96YS871I;VXN/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-#$L-S(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3DV+#$X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&5R:79A=&EV92!G86EN+CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#DS-"PR-C`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"860@9&5B="!E>'!E;G-E
M("AB96YE9FET*2X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@W
M,2PV,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,#@L,#@U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y);7!A:7)M96YT(&]F(&EN=&%N9VEB;&4@87-S971S
M+CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3DS+#`Y-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN
M=F5N=&]R>2!O8G-O;&5S8V5N8V4@<')O=FES:6]N/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#<V.2PY.#0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!I;F-O;64@
M=&%X97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0S,"PR-3`I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S<L,C@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D-H86YG97,@:6X@87-S971S(&%N9"!L:6%B:6QI
M=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5')A9&4@86-C;W5N=',@86YD(&]T:&5R(')E8V5I=F%B;&5S+CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PP.3@L,S(R*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q+#,Y,BPQ
M-30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#:&%N9V5S(&EN($%D=F%N8V5S('1O('-U<'!L:65R<RX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#$T+#<V,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(U,2PQ-S$I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M;G9E;G1O<GDN/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T+#<P
M,BPU-S4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,BPY,C4L,30S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5')A9&4@86-C;W5N=',@<&%Y86)L97,N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S,#8L,#0P*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L.3(X+#(U
M.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%C8W)U960@97AP96YS97,@86YD(&]T:&5R(&QI86)I;&ET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-#8L.#$W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4X+#<X,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06-C<G5E9"!T87AE<R!P87EA8FQE+CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-C@S+#,U-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU.3$L-#<P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!P87EA8FQE<RX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<T-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#,R-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061V86YC
M97,@9G)O;2!C=7-T;VUE<G,N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-#4L,C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-3$X+#<Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T($-A<V@@4')O=FED960@8GD@3W!E
M<F%T:6YG($%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L-C0S+#@R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4L,C,W+#,R-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H($9L;W=S(&9R
M;VT@26YV97-T:6YG($%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!I;G9E<W1M96YT(&EN(&)A;FME
M<B=S(&%C8V5P=&%N8V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH.#(L,30Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^061V86YC97,@9F]R('!A>6UE;G0@;V8@<'5R8VAA<V5S
M(&]F('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q+#8Q,BPV-S`I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061V86YC97,@9F]R('!A>6UE
M;G0@;V8@<'5R8VAA<V5S(&]F(&EN=&%N9VEB;&4@87-S971S+CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPR,3@L,#,U*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4L,3DQ+#,X-2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!U<F-H87-E(&]F('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$U-BPX-S@I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S4R+#,V,BD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!#
M87-H(%5S960@:6X@26YV97-T:6YG($%C=&EV:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#0L.3@W+#4X,RD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U+#8R-2PX.38I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D-A<V@@1FQO=W,@9G)O;2!&:6YA;F-I;F<@06-T:79I='DZ/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S
M(&9R;VT@:7-S=6%N8V4@;V8@;F]T97,@<&%Y86)L93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-SDS+#(R,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)O<G)O=VEN9W,@9G)O;2!R
M96QA=&5D('!A<G1Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M.3,L,#`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-3DU+#8W,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T($-A<V@@4')O=FED960@8GD@1FEN86YC:6YG
M($%C=&EV:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(X
M-BPR,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU.34L-C<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%9F9E8W0@;V8@17AC:&%N9V4@4F%T92!#:&%N9V5S
M(&]N($-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V+#,Y
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$U,2PV-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYE="!);F-R96%S92`H1&5C<F5A<V4I(&EN($-A<V@\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Q+#$T-BD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-3@L-S8X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M87-H(&%N9"!#87-H($5Q=6EV86QE;G1S(&%T($)E9VEN;FEN9R!O9B!097)I
M;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,#4P+#@U-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M-CDR+#`X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V%S:"!A;F0@0V%S:"!%<75I=F%L96YT<R!A="!%;F0@;V8@
M4&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#`R.2PW
M,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT+#`U,"PX-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5P<&QE;65N=&%L($-A<V@@1FQO=R!)
M;F9O<FUA=&EO;CH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V%S:"!P86ED(&9O<B!I;G1E<F5S=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,CDX+#0S,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(T."PP,3@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@<&%I9"!F
M;W(@:6YC;VUE('1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#$S."PX-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT+#4S,BPU.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5P<&QE;65N=&%L($YO
M;F-A<V@@26YV97-T:6YG(&%N9"!&:6YA;F-I;F<@06-T:79I=&EE<SH\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N
M=',@<&%Y86)L92!F;W(@<'5R8VAA<V5S(&]F('!R;W!E<G1Y(&%N9"!E<75I
M<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U,2PW,S$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-#,L,34Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!8V-O=6YT<R!R96-E:79A8FQE(&-O;&QE8W1E9"!W:71H(&)A
M;FME<B=S(&%C8V5P=&%N8V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT+#,U-"PX,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XV+#$P,BPU-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5N=&]R>2!P=7)C:&%S960@
M=VET:"!B86YK97(G<R!A8V-E<'1A;F-E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPW-C@L.#`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-BPQ,#(L-3<P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9'9A;F-E<R!F;W(@
M<'5R8VAA<V5S(&]F('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0@<&%I9"!W:71H
M(&)A;FME<B=S(&%C8V5P=&%N8V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#4T,"PX,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!9'9A;F-E<R!F;W(@<'5R8VAA<V5S(&]F
M(&EN=&%N9VEB;&5S('!A:60@=VET:"!B86YK97(G<R!A8V-E<'1A;F-E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R-RPY,#D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V4T,&8V,S8P
M7S@P-&5?-#<U.5]A9C$R7S-B86%E,SED8S$X-@T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]E-#!F-C,V,%\X,#1E7S0W-3E?868Q,E\S8F%A93,Y
M9&,Q.#8O5V]R:W-H965T<R]3:&5E=#`W+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^3U)'04Y)6D%424].($%.1"!324=.249)
M0T%.5"!!0T-/54Y424Y'(%!/3$E#2453/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]21T%.25I!5$E/3B!!3D0@
M4TE'3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4SPO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/4D=!3DE:051)3TX@04Y$
M(%-)1TY)1DE#04Y4($%#0T]53E1)3D<@4$],24-)15,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CPA+2UE9W@M+3X\<"!S='EL93TS1"=-05)'
M24XZ,&EN(#!I;B`Q,'!T.R!415A4+4%55$]34$%#13HG/CQB/DY/5$4@,2`F
M(S$U,#L@3U)'04Y)6D%424].($%.1"!324=.249)0T%.5"!!0T-/54Y424Y'
M(%!/3$E#2453/"]B/CPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@<W1Y;&4]
M,T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQB
M/D]R9V%N:7IA=&EO;B!A;F0@3F%T=7)E(&]F($]P97)A=&EO;G,\+V(^("8C
M,34P.R!#:&EN82!0:&%R;6$@2&]L9&EN9W,L($EN8RXL(&$@3F5V861A(&-O
M<G!O<F%T:6]N(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$R+"!O=VYS(#$P,"4@
M;V8@3VYN>2!);G9E<W1M96YT($QI;6ET960@*$]N;GDI+"!A($)R:71I<V@@
M5FER9VEN($ES;&%N9',@8V]R<&]R871I;VXL('1H870@:6X@='5R;B!O=VYS
M(#$P,"4@;V8@2&%I;F%N($AE;'!S;VX@365D:6-A;"`F86UP.R!":6]T96-H
M;F]L;V=Y($-O+BP@3'1D("A(96QP<V]N*2P@82!C;VUP86YY(&]R9V%N:7IE
M9"!U;F1E<B!T:&4@;&%W<R!O9B!T:&4@4&5O<&QE)W,@4F5P=6)L:6,@;V8@
M0VAI;F$@*'1H92!04D,I+B!#:&EN82!0:&%R;6$@2&]L9&EN9W,L($EN8RX@
M86YD(&ET<R!S=6)S:61I87)I97,@87)E(')E9F5R<F5D('1O(&AE<F5I;B!A
M<R!T:&4@0V]M<&%N>2XF;F)S<#L@/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%
M24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/B`\
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M<W`[(%1H92!R96EN8V]R<&]R871I;VX@;65R9V5R('=A<R!A<'!R;W9E9"!B
M>2!S=&]C:VAO;&1E<G,@:&]L9&EN9R!T:&4@;6%J;W)I='D@;V8@=&AE(&]U
M='-T86YD:6YG(&-O;6UO;B!S:&%R97,@;VX@1&5C96UB97(@,C$L(#(P,3(N
M/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP
M:6X@,&EN(#!P="<^)FYB<W`[/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(
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M97-T('9E<G-I;VX@:7,@=&AE('EE87(@,C`Q,B!V97)S:6]N+"!E9F9E8W1I
M=F4@2F%N=6%R>2`S,"P@,C`Q,BD@8VQA<W-I9FEE9"!V87)I;W5S(&EN9'5S
M=')I97,O8G5S:6YE<W-E<R!I;G1O('1H<F5E(&1I9F9E<F5N="!C871E9V]R
M:65S.B`H:2D@96YC;W5R86=E9"!F;W(@9F]R96EG;B!I;G9E<W1M96YT.R`H
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M<R!T:&%T(&$@9F]R96EG;B!I;G9E<W1M96YT(&5N=&5R<')I<V4@*'1H92`F
M(S$T-SM&244F(S$T.#LI('-H86QL(&YO="!H879E('1H92!W:&]L92!O<B!M
M86IO<FET>2!O9B!I=',@97%U:71Y(&EN=&5R97-T<R!O=VYE9"!B>2!A(&9O
M<F5I9VX@;W=N97(@:68@=&AE($9)12!E<W1A8FQI<VAE<R!M;W)E('1H86X@
M,S`@8G)A;F-H('-T;W)E<R!A;F0@9&ES=')I8G5T97,@82!V87)I971Y(&]F
M(&)R86YD<R!I;B!T:&]S92!F<F%N8VAI<V4@<W1O<F5S+"!W:&EC:"!I<R!N
M;W0@=&AE(&-A<V4@;V8@=&AE($-O;7!A;GDF(S$T-CMS(&)U<VEN97-S+CPO
M<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN
M(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/DAE;'!S;VX@;6%N=69A8W1U
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M:')E92!P87)T:65S(&]N($UA>2`R-2P@,C`P-2X@5&AE('1R86YS86-T:6]N
M('=A<R!A<'!R;W9E9"!B>2!T:&4@0V]M;65R8VEA;"!"=7)E874@;V8@2&%I
M;F%N(%!R;W9I;F-E(&]N($IU;F4@,3(L(#(P,#4@86YD($AE;'!S;VX@<F5C
M96EV960@=&AE($-E<G1I9FEC871E(&]F($%P<')O=F%L(&9O<B!%<W1A8FQI
M<VAI;F<@;V8@16YT97)P<FES97,@=VET:"!&;W)E:6=N($EN=F5S=&UE;G0@
M:6X@=&AE(%!20R!O;B!T:&4@<V%M92!D87D@86YD(&ET<R!B=7-I;F5S<R!L
M:6-E;G-E(&5V:61E;F-I;F<@:71S(%=&3T4@*%=H;VQL>2!&;W)E:6=N($]W
M;F5D($5N=&5R<')I<V4I('-T871U<R!O;B!*=6YE(#(Q+"`R,#`U+CPO<#X@
M/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I
M;B`P<'0G/B9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/E1H92!#;VUP86YY(&AA<R!A;F0@
M8V]N=&EN=65S('1O(&%C<75I<F4@=V5L;"UA8V-E<'1E9"!M961I8V%L(&9O
M<FUU;&%S('1O(&$@9&EV97)S92!P;W)T9F]L:6\@;V8@5V5S=&5R;B!A;F0@
M0VAI;F5S92!M961I8VEN97,N/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(
M5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/B`\<"!S
M='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P
M="<^/&(^0V]N<V]L:61A=&EO;B!A;F0@0F%S:7,@;V8@4')E<V5N=&%T:6]N
M/"]B/B`F(S$U,#L@5&AE(&%C8V]M<&%N>6EN9R!F:6YA;F-I86P@<W1A=&5M
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M;B!E;&EM:6YA=&5D(&EN(&-O;G-O;&ED871I;VXN/"]P/B`\<"!S='EL93TS
M1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB
M<W`[/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)
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M;'5D960@:6X@=&AE(')E<W5L=',@;V8@;W!E<F%T:6]N<RX\+W`^(#QP('-T
M>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T
M)SX\8CXF;F)S<#L\+V(^/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^/&(^4F5C;&%S<VEF:6-A=&EO
M;B`\+V(^+2!4:&4@0V]M<&%N>2!H87,@;6%D92!C97)T86EN(')E8VQA<W-I
M9FEC871I;VYS('1O('1H92!C;VYS;VQI9&%T960@8F%L86YC92!S:&5E="!A
M="!$96-E;6)E<B`S,2P@,C`Q,2!T;R!C;VYF;W)M('1O('1H92!$96-E;6)E
M<B`S,2P@,C`Q,B!P<F5S96YT871I;VXN(%1H97-E(')E8VQA<W-I9FEC871I
M;VYS(&AA9"!N;R!E9F9E8W0@;VX@=&AE(&-O;G-O;&ED871E9"!S=&%T96UE
M;G1S(&]F(&]P97)A=&EO;G,@;W(@8V%S:"!F;&]W<R!F;W(@86YY('!E<FEO
M9',@<')E<V5N=&5D+CPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@<W1Y;&4]
M,T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQB
M/D%C8V]U;G1I;F<@17-T:6UA=&5S/"]B/B`M(%1H92!P<F5P87)A=&EO;B!O
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M=&5S+CPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'
M24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G3$E.12U(
M14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQB/D-A<V@@86YD
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M(&]R(&QE<W,N(#PO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G
M3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQB/E1R
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M=6)T9G5L(&%C8V]U;G1S+B!!="!$96-E;6)E<B`S,2P@,C`Q,BP@=')A9&4@
M86-C;W5N=',@<F5C96EV86)L97,@:6YC;'5D960@)#,P+#$S-"PY,#D@9G)O
M;2!S86QE<R!T:&%T(&]C8W5R<F5D(&UO<F4@=&AA;B!O;F4@>65A<B!P<FEO
M<B!T;R!$96-E;6)E<B`S,2P@,C`Q,BP@=&AA="!-86YA9V5M96YT(&)E;&EE
M=F5S(&%R92!C;VQL96-T86)L92X\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^(#QP
M('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@
M,'!T)SX\8CY!9'9A;F-E<R!T;R!3=7!P;&EE<G,@86YD($%D=F%N8V5S(&9R
M;VT@0W5S=&]M97)S/"]B/B`F(S$U,#L@0V]M;6]N('!R86-T:6-E(&EN('1H
M92!04D,@:7,@=&\@;6%K92!A9'9A;F-E<R!T;R!S=7!P;&EE<G,@9F]R(&UA
M=&5R:6%L<R!A;F0@=&\@<F5C96EV92!A9'9A;F-E<R!F<F]M(&-U<W1O;65R
M<R!F;W(@9FEN:7-H960@<')O9'5C=',N($%D=F%N8V5S('1O('-U<'!L:65R
M<R!A<F4@87!P;&EE9"!T;R!T<F%D92!A8V-O=6YT<R!P87EA8FQE('=H96X@
M=&AE(&UA=&5R:6%L<R!A<F4@<F5C96EV960N($%D=F%N8V5S(')E8V5I=F5D
M(&9R;VT@8W5S=&]M97)S(&%R92!A<'!L:65D(&%G86EN<W0@=')A9&4@86-C
M;W5N=',@<F5C96EV86)L92!W:&5N(&9I;FES:&5D('!R;V1U8W1S(&%R92!S
M;VQD+CPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'
M24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G3$E.12U(
M14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQB/DEN=F5N=&]R
M>2`\+V(^)B,Q-3`[($EN=F5N=&]R>2!I<R!S=&%T960@870@=&AE(&QO=V5R
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M<GD@;V)S;VQE<V-E;F-E(')E<V5R=F4@;V8@)#$L-S8Y+#DX-"!A;F0@)#`@
M9F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,B!A;F0@,C`Q
M,2P@<F5S<&5C=&EV96QY+CPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@<W1Y
M;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M/CQB/E9A;'5A=&EO;B!O9B!,;VYG+4QI=F5D($%S<V5T<SPO8CX@)B,Q-3`[
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M87-S971S(&%T($1E8V5M8F5R(#,Q+"`R,#$R(&%N9"!D971E<FUI;F5D('1H
M870@=&AE('9A;'5E(&]F(&-E<G1A:6X@;V8@:71S(&EN=&%N9VEB;&4@87-S
M971S('=E<F4@:6UP86ER960@86YD(')E8V]G;FEZ960@86X@:6UP86ER;65N
M="!L;W-S(&]F("0U.3,L,#DU(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E
M<B`S,2P@,C`Q,BX@3F\@:6UP86ER;65N="!W87,@<F5C;V=N:7IE9"!D=7)I
M;F<@=&AE('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,3$N)FYB<W`[(%-E
M92!.;W1E(#0N/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[
M($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/B`\<"!S='EL93TS1"=,
M24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^/&(^4')O
M<&5R='D@86YD($5Q=6EP;65N=#PO8CX@)B,Q-3`[(%!R;W!E<G1Y(&%N9"!E
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M:7-P;W-I=&EO;BX\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA
M;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$
M)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SX\8CY2
M979E;G5E(%)E8V]G;FET:6]N/"]B/B`F(S$U,#L@4F5V96YU92!I<R!C;VYS
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M<R!R96QA=&5D('1O('1H92!S86QE(&AA=F4@8F5E;B!R97-O;'9E9"X\+W`^
M(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P
M:6X@,'!T)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO
M<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SX\8CY#;W-T(&]F(%)E=F5N=65S
M/"]B/B`F(S$U,#L@0V]S="!O9B!R979E;G5E<R!I;F-L=61E<R!W86=E<RP@
M;6%T97)I86QS+"!H86YD;&EN9R!C:&%R9V5S+"!A;F0@;W1H97(@97AP96YS
M97,@87-S;V-I871E9"!W:71H('1H92!M86YU9F%C='5R92!A;F0@9&5L:79E
M<GD@;V8@<')O9'5C=',N/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/B`\<"!S='EL
M93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^
M/&(^4F5S96%R8V@@86YD($1E=F5L;W!M96YT/"]B/B`F(S$U,#L@4F5S96%R
M8V@@86YD(&1E=F5L;W!M96YT(&5X<&5N9&ET=7)E<R!A<F4@<F5C;W)D960@
M87,@97AP96YS97,@:6X@=&AE('!E<FEO9"!I;B!W:&EC:"!T:&5Y(&]C8W5R
M+B!297-E87)C:"!A;F0@9&5V96QO<&UE;G0@8V]S=',@=V5R92!N;W0@;6%T
M97)I86P@9'5R:6YG('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q
M,B!A;F0@,C`Q,2XF;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4
M.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SX\8CXF;F)S<#L\+V(^/"]P
M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@
M,&EN(#!P="<^/&(^4F5T:7)E;65N="!"96YE9FET(%!L86YS/"]B/B`F(S$U
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M("0R,S,L.#0V(&%N9"`D,38V+#`W,2!T;R!R971I<F5M96YT(&)E;F5F:70@
M<&QA;G,@9F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,B!A
M;F0@,C`Q,2P@<F5S<&5C=&EV96QY+B!#;VYT<FEB=71I;VYS('1O('1H97-E
M('!L86YS(&%R92!C:&%R9V5D('1O(&5X<&5N<V4@87,@:6YC=7)R960N/"]P
M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@
M,&EN(#!P="<^)FYB<W`[/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^/&(^061V97)T:7-I;F<@0V]S
M=',\+V(^("8C,34P.R!!9'9E<G1I<VEN9R!C;W-T<R!A<F4@97AP96YS960@
M=VAE;B!I;F-U<G)E9"X@5&AE($-O;7!A;GD@9&ED(&YO="!I;F-U<B!A;GD@
M861V97)T:7-I;F<@8V]S=',@9F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E
M<B`S,2P@,C`Q,B!A;F0@,C`Q,2X\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^(#QP
M('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@
M,'!T)SX\8CY"87-I8R!A;F0@1&EL=71E9"!%87)N:6YG<R!P97(@0V]M;6]N
M(%-H87)E/"]B/B`M($)A<VEC(&5A<FYI;F=S('!E<B!C;VUM;VX@<VAA<F4@
M:7,@8V]M<'5T960@8GD@9&EV:61I;F<@;F5T(&EN8V]M92!B>2!T:&4@=V5I
M9VAT960M879E<F%G92!N=6UB97(@;V8@8V]M;6]N('-H87)E<R!O=71S=&%N
M9&EN9R!D=7)I;F<@=&AE('!E<FEO9"X@1&EL=71E9"!E87)N:6YG<R!P97(@
M<VAA<F4@87)E(&-A;&-U;&%T960@=&\@9VEV92!E9F9E8W0@=&\@<&]T96YT
M:6%L;'D@:7-S=6%B;&4@9&EL=71I=F4@8V]M;6]N('-H87)E<RX\+W`^(#QT
M86)L92!W:61T:#TS1#0Y,R!S='EL93TS1"=-05)'24XZ875T;R!A=71O(&%U
M=&\@+3`N-S5P=#L@5TE$5$@Z,S<P<'0[($)/4D1%4BU#3TQ,05!313IC;VQL
M87!S92<@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,#X@/'1R/B`\
M=&0@=VED=&@],T0S-#$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F
M,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[
M(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!W:61T:#H@,C4V<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B
M;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A
M9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I
M9'1H/3-$,34R(&-O;'-P86X],T0S('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#$Q-'!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S
M='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQB/D9O<B!T
M:&4@665A<G,@16YD960\+V(^/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED
M=&@],T0S-#$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R
M9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG
M<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!W:61T:#H@,C4V<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M
M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M
M=&]P.B`P:6X[)R!V86QI9VX],T1T;W`^/"]T9#X@/'1D('=I9'1H/3-$,34R
M(&-O;'-P86X],T0S('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E
M>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q,31P=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO
M<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\8CY$
M96-E;6)E<B`S,2P\+V(^/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@]
M,T0S-#$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R
M+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U
M;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W
M:61T:#H@,C4V<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1T;W`^/"]T9#X@/'1D('=I9'1H/3-$-S$@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O
M<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K
M9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=VED=&@Z(#4S+C5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\8CXR,#$R/"]B/CPO<#X\+W1D
M/B`\=&0@=VED=&@],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#$N.#5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@
M=VED=&@],T0W."!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT
M(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3@N-C5P=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO
M<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\8CXR
M,#$Q/"]B/CPO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,S0Q('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C
M9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R
M.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#(U
M-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F
M,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M
M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^3F5T(&EN8V]M93PO<#X\+W1D/B`\
M=&0@=VED=&@],T0W,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T
M97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M
M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3,N-7!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@
M,&EN(#!P="<^)FYB<W`[)"`T+#8Q-RPV-3D@/"]P/CPO=&0^(#QT9"!W:61T
M:#TS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R
M+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U
M;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W
M:61T:#H@,2XX-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#<X
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('=I9'1H.B`U."XV-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS
M1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB
M<W`[)"`Q.2PR-CDL-C0R(#PO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H
M/3-$,S0Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#(U-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%
M24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^0F%S:6,@=V5I9VAT
M960M879E<F%G92!C;VUM;VX@<VAA<F5S(&]U='-T86YD:6YG/"]P/CPO=&0^
M(#QT9"!W:61T:#TS1#<Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#4S+C5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CIR:6=H=#L@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'
M24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$<FEG:'0^-#,L-3<Y+#4U-R`\+W`^
M/"]T9#X@/'1D('=I9'1H/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`Q+C@U<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@
M/'1D('=I9'1H/3-$-S@@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F
M,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[
M(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!W:61T:#H@-3@N-C5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CIR:6=H=#L@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'
M24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$<FEG:'0^-#,L-#<Y+#@Y.2`\+W`^
M/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#,T,2!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`R-39P=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR
M:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1'1O
M<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN
M(#!I;B`P<'0G/D5F9F5C="!O9B!D:6QU=&EV92!S96-U<FET:65S.CPO<#X\
M+W1D/B`\=&0@=VED=&@],T0W,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`U,RXU<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1T;W`^/"]T9#X@/'1D
M('=I9'1H/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C
M:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('=I9'1H.B`Q+C@U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D
M97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I
M;F<M=&]P.B`P:6X[)R!V86QI9VX],T1T;W`^/"]T9#X@/'1D('=I9'1H/3-$
M-S@@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M
M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T
M:#H@-3@N-C5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1'1O<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H
M/3-$,S0Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#(U-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$=&]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(
M5#IN;W)M86P[(%1%6%0M24Y$14Y4.C$P<'0[($U!4D=)3CHP:6X@,&EN(#!P
M="<^5V%R<F%N=',\+W`^/"]T9#X@/'1D('=I9'1H/3-$-S$@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3,N-7!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$=&]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)
M3CHP:6X@,&EN(#!P="<^)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[("TF;F)S<#LF;F)S<#L@/"]P/CPO=&0^
M(#QT9"!W:61T:#TS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F
M,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[
M(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!W:61T:#H@,2XX-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$=&]P/CPO=&0^(#QT9"!W:61T
M:#TS1#<X('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#4X+C8U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M
M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M
M=&]P.B`P:6X[)R!V86QI9VX],T1T;W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W
M:61T:#TS1#,T,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C
M:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('=I9'1H.B`R-39P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1'1O<#X@/'`@<W1Y;&4],T0G3$E.12U(
M14E'2%0Z;F]R;6%L.R!415A4+4E.1$5.5#HQ,'!T.R!-05)'24XZ,&EN(#!I
M;B`P<'0G/D]P=&EO;G,\+W`^/"]T9#X@/'1D('=I9'1H/3-$-S$@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#4S+C5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT
M;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT
M;W`Z(#!I;CLG('9A;&EG;CTS1'1O<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.R9N8G-P.R9N
M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P
M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`M)FYB<W`[
M)FYB<W`[(#PO<#X\+W1D/B`\=&0@=VED=&@],T0R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$N.#5P=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR
M:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1'1O
M<#X\+W1D/B`\=&0@=VED=&@],T0W."!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3@N-C5P=#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O
M<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG
M;CTS1'1O<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'
M24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X\+W1D/CPO='(^(#QT<CX@/'1D
M('=I9'1H/3-$,S0Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#(U-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,
M24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^1&EL=71E
M9"!W96EG:'1E9"UA=F5R86=E(&-O;6UO;B!S:&%R97,@;W5T<W1A;F1I;F<\
M+W`^/"]T9#X@/'1D('=I9'1H/3-$-S$@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P
M.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N
M<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4S+C5P=#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O
M<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H=#L@3$E.
M12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$
M<FEG:'0^-#,L-3<Y+#4U-R`\+W`^/"]T9#X@/'1D('=I9'1H/3-$,B!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q+C@U
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-S@@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL
M969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD
M+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED
M=&@Z(#4X+C8U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ<FEG:'0[($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@
M,'!T)R!A;&EG;CTS1')I9VAT/C0S+#0W.2PX.3D@/"]P/CPO=&0^/"]T<CX@
M/'1R/B`\=&0@=VED=&@],T0S-#$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M
M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@,C4V<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T
M>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T
M)SY"87-I8R!E87)N:6YG<R!P97(@<VAA<F4\+W`^/"]T9#X@/'1D('=I9'1H
M/3-$-S$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@
M<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#4S+C5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F
M,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y
M;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M/B9N8G-P.R0F;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF
M;F)S<#LF;F)S<#LF;F)S<#L@,"XQ,2`\+W`^/"]T9#X@/'1D('=I9'1H/3-$
M,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F
M=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC
M;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H
M.B`Q+C@U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-S@@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O
M<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K
M9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=VED=&@Z(#4X+C8U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D
M97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I
M;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)
M3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#LD
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#`N-#0@/"]P/CPO=&0^/"]T<CX@/'1R
M/B`\=&0@=VED=&@],T0S-#$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!W:61T:#H@,C4V<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE
M/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SY$
M:6QU=&5D(&5A<FYI;F=S('!E<B!S:&%R93PO<#X\+W1D/B`\=&0@=VED=&@]
M,T0W,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S
M;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!W:61T:#H@-3,N-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P
M.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL
M93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^
M)FYB<W`[)"9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N
M8G-P.R9N8G-P.R9N8G-P.R`P+C$Q(#PO<#X\+W1D/B`\=&0@=VED=&@],T0R
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T
M.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O
M;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z
M(#$N.#5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0W."!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R
M9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG
M<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!W:61T:#H@-3@N-C5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.
M12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.R0F
M;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@)FYB<W`[)FYB<W`[)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[,"XT-"`\+W`^/"]T9#X\+W1R/CPO=&%B
M;&4^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4
M.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SY0;W1E;G1I86P@8V]M;6]N
M('-H87)E<R!W97)E(&YO="!I;F-L=61E9"!I;B!T:&4@8V]M<'5T871I;VX@
M;V8@9&EL=71E9"!E87)N:6YG<R!P97(@<VAA<F4@87,@=&AE:7(@969F96-T
M('=O=6QD(&AA=F4@8F5E;B!A;G1I+61I;'5T:79E(&%S(&9O;&QO=W,Z/"]P
M/B`\=&%B;&4@=VED=&@],T0T.3,@<W1Y;&4],T0G34%21TE..F%U=&\@875T
M;R!A=71O("TP+C<U<'0[(%=)1%1(.C,W,'!T.R!"3U)$15(M0T],3$%04T4Z
M8V]L;&%P<V4G(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`^(#QT
M<CX@/'1D('=I9'1H/3-$,S0Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F
M,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#(U-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P
M.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT
M9"!W:61T:#TS1#$U,B!C;VQS<&%N/3-$,R!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q,31P=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO
M<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\8CY&
M;W(@=&AE(%EE87)S($5N9&5D/"]B/CPO<#X\+W1D/CPO='(^(#QT<CX@/'1D
M('=I9'1H/3-$,S0Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#(U-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T
M:#TS1#$U,B!C;VQS<&%N/3-$,R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W
M:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R
M96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3$T<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!,24Y%+4A%
M24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1C96YT
M97(^/&(^1&5C96UB97(@,S$L/"]B/CPO<#X\+W1D/CPO='(^(#QT<CX@/'1D
M('=I9'1H/3-$,S0Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#(U-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T
M:#TS1#<Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T
M('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`U,RXU<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[
M($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^/&(^,C`Q,CPO
M8CX\+W`^/"]T9#X@/'1D('=I9'1H/3-$,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q+C@U<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^
M/"]T9#X@/'1D('=I9'1H/3-$-S@@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4X+C8U<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1C
M96YT97(^/&(^,C`Q,3PO8CX\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T
M:#TS1#,T,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R
M;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`R-39P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT
M;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT
M;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(
M14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/E=A<G)A;G1S('=I
M=&@@97AE<F-I<V4@<')I8V5S(&]F("0S+C`P('1O("0S+C@P('!E<B!S:&%R
M93PO<#X\+W1D/B`\=&0@=VED=&@],T0W,2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U,RXU<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^
M(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P
M:6X@,'!T)SXF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@
M,34P+#`P,"`\+W`^/"]T9#X@/'1D('=I9'1H/3-$,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q+C@U<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-S@@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M
M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3@N-C5P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN
M(#!I;B`P<'0G/B9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P
M.R9N8G-P.R9N8G-P.R`Q-3`L,#`P(#PO<#X\+W1D/CPO='(^(#QT<CX@/'1D
M('=I9'1H/3-$,S0Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#(U-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,
M24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^3W!T:6]N
M<R!W:71H(&%N(&5X97)C:7-E('!R:6-E(&]F("0R+C4T('1O("0S+C0W('!E
M<B!S:&%R93PO<#X\+W1D/B`\=&0@=VED=&@],T0W,2!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z
M("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L
M;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@
M-3,N-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[)FYB<W`[)FYB<W`[
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#4P+#`P,"`\+W`^/"]T
M9#X@/'1D('=I9'1H/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F
M,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I
M;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('=I9'1H.B`Q+C@U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D
M('=I9'1H/3-$-S@@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O
M='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4X+C8U<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^
M(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P
M:6X@,'!T)SXF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF
M;F)S<#LF;F)S<#L@,S$P+#`P,"`\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W
M:61T:#TS1#,T,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C
M:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('=I9'1H.B`R-39P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.
M12U(14E'2%0Z;F]R;6%L.R!415A4+4E.1$5.5#HQ,'!T.R!-05)'24XZ,&EN
M(#!I;B`P<'0G/E1O=&%L/"]P/CPO=&0^(#QT9"!W:61T:#TS1#<Q('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R
M;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`U,RXU<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M
M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M
M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M
M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#LF;F)S
M<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@,C`P+#`P,"`\+W`^/"]T9#X@
M/'1D('=I9'1H/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('=I9'1H.B`Q+C@U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B
M;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A
M9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I
M9'1H/3-$-S@@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q
M<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#4X+C8U<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP
M('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@
M,'!T)SXF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#LF;F)S<#L@-#8P+#`P,"`\+W`^/"]T9#X\+W1R/CPO=&%B;&4^(#QP('-T
M>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T
M)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@
M34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)
M3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\
M+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)SX\8CY#<F5D:70@4FES:R`\+V(^)B,Q-3`[(%1H92!C87)R
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M965D960@36%N86=E;65N="=S(&5S=&EM871I;VYS+CPO<#X@/'`@<W1Y;&4]
M,T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N
M8G-P.SPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'
M24XZ,&EN(#!I;B`P<'0G/E1H92!#;VUP86YY(&AA<R!I=',@8V%S:"!I;B!B
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M;B!!=6=U<W0@,C`P-BP@969F96-T:79E($IU;F4F;F)S<#LQ+"`R,#`W+"!W
M:&EC:"!C;VYT86EN<R!P<F]V:7-I;VYS(&9O<B!T:&4@:6UP;&5M96YT871I
M;VX@;V8@;65A<W5R97,@9F]R('1H92!B86YK<G5P=&-Y(&]F(%!20R!B86YK
M<RX@26X@=&AE(&5V96YT('1H870@8F%N:W)U<'1C>2!L87=S(&%R92!E;F%C
M=&5D(&9O<B!B86YK<R!I;B!T:&4@4%)#+"!T:&4@0V]M<&%N>28C,30V.W,@
M9&5P;W-I=',@;6%Y(&)E(&%T(&$@:&EG:&5R(')I<VL@;V8@;&]S<RX\+W`^
M(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P
M:6X@,'!T)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO
M<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SX\8CY);G1E<F5S="!2871E(%)I
M<VL\+V(^("8C,34P.R!4:&4@0V]M<&%N>2!I<R!E>'!O<V5D('1O('1H92!R
M:7-K(&%R:7-I;F<@9G)O;2!C:&%N9VEN9R!I;G1E<F5S="!R871E<RP@=VAI
M8V@@;6%Y(&%F9F5C="!T:&4@86)I;&ET>2!O9B!R97!A>6UE;G0@;V8@97AI
M<W1I;F<@9&5B=',@86YD('9I86)I;&ET>2!O9B!S96-U<FEN9R!F=71U<F4@
M9&5B="!I;G-T<G5M96YT<R!W:71H:6X@=&AE(%!20RX\+W`^(#QP('-T>6QE
M/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF
M;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%2
M1TE..C!I;B`P:6X@,'!T)SX\8CY296-E;G1L>2!!;FYO=6YC960@06-C;W5N
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M=V5R92!E9F9E8W1I=F4@87,@;V8@2F%N=6%R>2`Q+"`R,#$R+"!A;F0@=&AE
M($-O;7!A;GD@:&%S(&EN8VQU9&5D(&$@8V]N=&EN=6]U<R!C;VYS;VQI9&%T
M960@<W1A=&5M96YT(&]F(&-O;7!R96AE;G-I=F4@:6YC;VUE(&%S('!A<G0@
M;V8@=&AE<V4@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+CPO
M<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN
M(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/D%352`R,#$Q+3`T+"!&86ER
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M(&]F($IA;G5A<GD@,2P@,C`Q,BX@5&AE(&5F9F5C=',@;V8@861O<'1I;VX@
M=V5R92!N;W0@<VEG;FEF:6-A;G0@=&\@=&AE(&%C8V]M<&%N>6EN9R!C;VYS
M;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',N/"]P/B`\<"!S='EL93TS
M1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB
M<W`[/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)
M3CHP:6X@,&EN(#!P="<^05-5($YO+B`R,#$R+3`R+"!497-T:6YG($EN9&5F
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M:&4@0V]M<&%N>2!O;B!397!T96UB97(@,S`L(#(P,3(@86YD(&AA9"!N;R!S
M:6=N:69I8V%N="!E9F9E8W0@;VX@=&AE(&%C8V]M<&%N>6EN9R!C;VYS;VQI
M9&%T960@9FEN86YC:6%L('-T871E;65N=',N/"]P/B`\<"!S='EL93TS1"=,
M24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[
M/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP
M:6X@,&EN(#!P="<^05-5($YO+B`R,#$Q+3$Q+"!$:7-C;&]S=7)E<R!A8F]U
M="!/9F9S971T:6YG($%S<V5T<R!A;F0@3&EA8FEL:71I97,L(')E<75I<F5S
M(&1I<V-L;W-U<F5S(&%B;W5T(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@=&AA
M="!A<F4@;V9F<V5T(&]R(&AA=F4@=&AE('!O=&5N=&EA;"!T;R!B92!O9F9S
M970N(%1H:7,@;F5W(&=U:61A;F-E('=I;&P@8F4@969F96-T:79E(&9O<B!R
M97!O<G1I;F<@<&5R:6]D<R!B96=I;FYI;F<@2F%N=6%R>2`Q+"`R,#$S+"!W
M:71H(')E=')O<W!E8W1I=F4@87!P;&EC871I;VX@<F5Q=6ER960N(%1H92!A
M9&]P=&EO;B!O9B!T:&ES(&=U:61A;F-E(&ES(&YO="!E>'!E8W1E9"!T;R!H
M879E(&$@;6%T97)I86P@:6UP86-T(&]N('1H92!#;VUP86YY)B,Q-#8[<R!R
M97-U;'1S(&]F(&]P97)A=&EO;G,@;W(@9FEN86YC:6%L('!O<VET:6]N+B`\
M+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E
M-#!F-C,V,%\X,#1E7S0W-3E?868Q,E\S8F%A93,Y9&,Q.#8-"D-O;G1E;G0M
M3&]C871I;VXZ(&9I;&4Z+R\O0SHO930P9C8S-C!?.#`T95\T-S4Y7V%F,3)?
M,V)A864S.61C,3@V+U=O<FMS:&5E=',O4VAE970P."YH=&UL#0I#;VYT96YT
M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT
M+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL
M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DE.5D5.5$]262X\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^24Y6
M14Y43U)9+CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y)3E9%3E1/4EDN/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\(2TM96=X+2T^/'`@<W1Y;&4],T0G34%21TE..C!I;B`P:6X@,3!P=#L@
M5$585"U!551/4U!!0T4Z)SX\8CY.3U1%(#(@)B,Q-3`[($E.5D5.5$]262X\
M+V(^/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)
M3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%
M24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^26YV96YT;W)Y(&-O
M;G-I<W1E9"!O9B!T:&4@9F]L;&]W:6YG.CPO<#X@/'1A8FQE('=I9'1H/3-$
M-#0U('-T>6QE/3-$)TU!4D=)3CIA=71O(&%U=&\@875T;R`M,"XW-7!T.R!7
M24142#HS,S,N-W!T.R!"3U)$15(M0T],3$%04T4Z8V]L;&%P<V4G(&-E;&QP
M861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`^(#QT<CX@/'1D('=I9'1H/3-$
M,C4Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL
M969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD
M+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED
M=&@Z(#$X.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#<@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-7!T
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@
M8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@X('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8U+C=P=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E
M<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0Q,2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`X<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^
M/"]T9#X@/'1D('=I9'1H/3-$-R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D
M('=I9'1H/3-$.#,@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@-C)P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/CPO='(^(#QT<CX@
M/'1D('=I9'1H/3-$,C4Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#$X.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W
M:61T:#TS1#DT(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#<P+C=P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA
M;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\8CXF;F)S
M<#M$96-E;6)E<B`S,2P@/"]B/CPO<#X\+W1D/B`\=&0@=VED=&@],T0Q,2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`X
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$.#D@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M
M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T
M:#H@-C=P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIC
M96YT97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T
M)R!A;&EG;CTS1&-E;G1E<CX\8CXF;F)S<#M$96-E;6)E<B`S,2P@/"]B/CPO
M<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,C4Q('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$X.'!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#<@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M
M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-7!T.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C
M9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^(#QT9"!W:61T:#TS1#@X('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I
M;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V-2XW<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!,24Y%+4A%
M24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1C96YT
M97(^/&(^,C`Q,CPO8CX\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3$@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P
M9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R
M86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.'!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#<@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-7!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^(#QT9"!W:61T:#TS1#@S('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,G!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.12U(
M14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N
M=&5R/CQB/C(P,3$\+V(^/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@]
M,T0R-3$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R
M+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U
M;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W
M:61T:#H@,3@X<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SY287<@;6%T97)I86QS
M/"]P/CPO=&0^(#QT9"!W:61T:#TS1#<@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-7!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M(#QT9"!W:61T:#TS1#@X('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#8U+C=P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CIR:6=H=#L@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'
M24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$<FEG:'0^)FYB<W`[)"9N8G-P.R9N
M8G-P.R`S,"PQ.3@L.#$V(#PO<#X\+W1D/B`\=&0@=VED=&@],T0Q,2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`X<'0[
M('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B
M;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-R!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^/"]T9#X@/'1D('=I9'1H/3-$.#,@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C)P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H=#L@3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$<FEG:'0^)FYB<W`[)"9N
M8G-P.R9N8G-P.R`R-"PY,C`L.#(U(#PO<#X\+W1D/CPO='(^(#QT<CX@/'1D
M('=I9'1H/3-$,C4Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#$X.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,
M24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^1FEN:7-H
M960@9V]O9',\+W`^/"]T9#X@/'1D('=I9'1H/3-$-R!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^/"]T9#X@/'1D('=I9'1H/3-$.#@@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P
M.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N
M<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8U+C=P=#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O
M<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H=#L@3$E.
M12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$
M<FEG:'0^)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB
M<W`[(#<L.3,P+#8X-"`\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3$@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P
M9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R
M86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.'!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#<@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-7!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^(#QT9"!W:61T:#TS1#@S('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,G!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..G)I9VAT.R!,24Y%+4A%
M24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1R:6=H
M=#XF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@
M-2PT-3<L.#,S(#PO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,C4Q
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T
M.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O
M;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z
M(#$X.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#<@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P
M9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R
M86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-7!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@X('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8U+C=P=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR
M:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H=#L@3$E.12U(14E'
M2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$<FEG:'0^
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#,X+#$R.2PU,#`@/"]P
M/CPO=&0^(#QT9"!W:61T:#TS1#$Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#AP=#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F
M,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\
M=&0@=VED=&@],T0W('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@]
M,T0X,R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M
M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N
M9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I
M9'1H.B`V,G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=.
M.G)I9VAT.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P
M="<@86QI9VX],T1R:6=H=#XF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#L@,S`L,S<X+#8U."`\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS
M1#(U,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M
M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N
M9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I
M9'1H.B`Q.#AP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/D%L;&]W86YC92!F;W(@
M;V)S;VQE<V-E;F-E("T@<F%W(&UA=&5R:6%L<SPO<#X\+W1D/B`\=&0@=VED
M=&@],T0W('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X."!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V
M-2XW<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ<FEG
M:'0[($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A
M;&EG;CTS1')I9VAT/B9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N
M8G-P.R`H,2PW-CDL.3@T*3PO<#X\+W1D/B`\=&0@=VED=&@],T0Q,2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`X<'0[
M('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B
M;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-R!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^/"]T9#X@/'1D('=I9'1H/3-$.#,@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C)P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H=#L@3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$<FEG:'0^)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[("TF;F)S<#LF;F)S<#L@/"]P/CPO=&0^
M/"]T<CX@/'1R/B`\=&0@=VED=&@],T0R-3$@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M
M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3@X<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^
M(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P
M:6X@,'!T)SX\8CY4;W1A;"!I;G9E;G1O<GD\+V(^/"]P/CPO=&0^(#QT9"!W
M:61T:#TS1#<@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R
M9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG
M<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!W:61T:#H@-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@X
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('=I9'1H.B`V-2XW<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B
M;W)D97(M=&]P.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/B`\<"!S='EL93TS1"=415A4+4%,24=..G)I9VAT.R!,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1R:6=H=#XF;F)S
M<#LD)FYB<W`[)FYB<W`[(#,V+#,U.2PU,38@/"]P/CPO=&0^(#QT9"!W:61T
M:#TS1#$Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#AP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0W('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C
M9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R
M.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#5P
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X,R!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M
M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T
M:#H@-C)P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z('=I
M;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A
M9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ<FEG:'0[($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE.
M.C!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/B9N8G-P.R0F;F)S<#LF;F)S
M<#L@,S`L,S<X+#8U."`\+W`^/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-#!F-C,V,%\X,#1E
M7S0W-3E?868Q,E\S8F%A93,Y9&,Q.#8-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO930P9C8S-C!?.#`T95\T-S4Y7V%F,3)?,V)A864S.61C,3@V
M+U=O<FMS:&5E=',O4VAE970P.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E!23U!%4E19($%.1"!%455)4$U%3E0\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4%)/
M4$525%D@04Y$($5154E0345.5#PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y04D]015)462!!3D0@15%525!-14Y4/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM96=X+2T^/'`@<W1Y;&4]
M,T0G34%21TE..C!I;B`P:6X@,3!P=#L@5$585"U!551/4U!!0T4Z)SX\8CY.
M3U1%(#,@+2!04D]015)462!!3D0@15%525!-14Y4/"]B/CPO<#X@/'`@<W1Y
M;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M/B9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-
M05)'24XZ,&EN(#!I;B`P<'0G/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0@8V]N
M<VES=&5D(&]F('1H92!F;VQL;W=I;F<Z/"]P/B`\=&%B;&4@=VED=&@],T0T
M,S`@<W1Y;&4],T0G34%21TE..F%U=&\@875T;R!A=71O("TP+C<U<'0[(%=)
M1%1(.C,R,BXT<'0[($)/4D1%4BU#3TQ,05!313IC;VQL87!S92<@8V5L;'!A
M9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,#X@/'1R/B`\=&0@=VED=&@],T0R
M-3$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M
M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T
M:#H@,3@X<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@
M8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#<X('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4X+C)P=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E
M<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M
M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E
M;G1E<CX\8CXF;F)S<#M$96-E;6)E<B`S,2P@/"]B/CPO<#X\+W1D/B`\=&0@
M=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C
M:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M
M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M
M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$
M-S@@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M
M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T
M:#H@-3@N,G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=.
M.F-E;G1E<CL@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P
M<'0G(&%L:6=N/3-$8V5N=&5R/CQB/B9N8G-P.T1E8V5M8F5R(#,Q+"`\+V(^
M/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0R-3$@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3@X<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^(#QT9"!W:61T:#TS1#<X('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U."XR<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1C
M96YT97(^/&(^,C`Q,CPO8CX\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@
M8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#<X('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F
M=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC
M;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H
M.B`U."XR<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M8V5N=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P
M="<@86QI9VX],T1C96YT97(^/&(^,C`Q,3PO8CX\+W`^/"]T9#X\+W1R/B`\
M='(^(#QT9"!W:61T:#TS1#(U,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`Q.#AP=#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F
M,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y
M;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M/E!E<FUI="!O9B!L86YD('5S93PO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-S@@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3@N,G!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..G)I9VAT.R!,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1R
M:6=H=#XF;F)S<#LD)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#0T
M-RPP,3,@/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X\+W1D/B`\=&0@=VED=&@],T0W."!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U."XR<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ<FEG:'0[($Q)3D4M2$5)1TA4.FYO<FUA
M;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/B9N8G-P.R0F
M;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@-#0R+#DW."`\+W`^/"]T
M9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#(U,2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q.#AP=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN
M(#!I;B`P<'0G/D)U:6QD:6YG/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C
M9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R
M.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0W."!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U."XR<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ<FEG:'0[($Q)3D4M
M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1')I
M9VAT/B9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`R+#0Q.2PQ,C4@
M/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O
M='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D
M/B`\=&0@=VED=&@],T0W."!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F
M,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I
M;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('=I9'1H.B`U."XR<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ<FEG:'0[($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%2
M1TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/B9N8G-P.R9N8G-P.R9N
M8G-P.R9N8G-P.R9N8G-P.R`R+#,Y-RPR.#8@/"]P/CPO=&0^/"]T<CX@/'1R
M/B`\=&0@=VED=&@],T0R-3$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!W:61T:#H@,3@X<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE
M/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SY0
M;&%N="P@;6%C:&EN97)Y(&%N9"!E<75I<&UE;G0\+W`^/"]T9#X@/'1D('=I
M9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R
M9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG
M<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#<X
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T
M.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O
M;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z
M(#4X+C)P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIR
M:6=H=#L@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M(&%L:6=N/3-$<FEG:'0^)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[
M(#8L,S@Q+#(P.2`\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#<X('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4X+C)P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H=#L@3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$<FEG:'0^)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#8L,3@T+#(U-"`\+W`^/"]T
M9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#(U,2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q.#AP=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN
M(#!I;B`P<'0G/DUO=&]R('9E:&EC;&4\+W`^/"]T9#X@/'1D('=I9'1H/3-$
M,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M
M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T
M:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#<X('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F
M,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T
M<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4X+C)P
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H=#L@
M3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N
M/3-$<FEG:'0^)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[
M)FYB<W`[)FYB<W`[(#$T-RPP.#`@/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T
M.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O
M;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z
M(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0W."!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F
M,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A
M;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U."XR<'0[
M('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B
M;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ<FEG:'0[($Q)
M3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS
M1')I9VAT/B9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N
M8G-P.R9N8G-P.R`Q-#4L,S`P(#PO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I
M9'1H/3-$,C4Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O
M<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K
M9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=VED=&@Z(#$X.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R
M+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG
M+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^3V9F:6-E(&5Q
M=6EP;65N=#PO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^/"]T9#X@/'1D('=I9'1H/3-$-S@@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3@N,G!T.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C
M9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\
M<"!S='EL93TS1"=415A4+4%,24=..G)I9VAT.R!,24Y%+4A%24=(5#IN;W)M
M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1R:6=H=#XF;F)S<#LF
M;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@,C(R
M+#(W,R`\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^(#QT9"!W:61T:#TS1#<X('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#4X+C)P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H=#L@3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$<FEG:'0^)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#(P-"PU
M-3(@/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0R-3$@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P
M9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R
M86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3@X<'0[
M('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B
M;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@
M34%21TE..C!I;B`P:6X@,'!T)SY#;VYS=')U8W1I;VX@:6X@<')O9W)E<W,\
M+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M(#QT9"!W:61T:#TS1#<X('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U."XR<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ<FEG:'0[($Q)3D4M2$5)1TA4
M.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/B9N
M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`S+#8X."PU-C<@/"]P/CPO
M=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F
M,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@
M=VED=&@],T0W."!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT
M(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3@N,G!T.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C
M9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\
M<"!S='EL93TS1"=415A4+4%,24=..G)I9VAT.R!,24Y%+4A%24=(5#IN;W)M
M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1R:6=H=#XF;F)S<#LF
M;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@,S4Q
M+#4W,2`\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#(U,2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q.#AP
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L
M.R!415A4+4E.1$5.5#HQ,"XP-7!T.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQB
M/E1O=&%L/"]B/CPO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-S@@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M
M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3@N,G!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/B`\<"!S='EL93TS1"=415A4+4%,24=..G)I9VAT.R!,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1R:6=H=#XF;F)S
M<#LF;F)S<#LF;F)S<#L@,3,L,S`U+#(V-R`\+W`^/"]T9#X@/'1D('=I9'1H
M/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R
M+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U
M;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W
M:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#<X('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C
M9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R
M.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4X
M+C)P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H
M=#L@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L
M:6=N/3-$<FEG:'0^)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#DL
M-S(U+#DT,2`\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#(U,2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q
M.#AP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/DQE<W,Z(&%C8W5M=6QA=&5D(&1E
M<')E8VEA=&EO;CPO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-S@@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M
M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3@N,G!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/B`\<"!S='EL93TS1"=415A4+4%,24=..G)I9VAT.R!,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1R:6=H=#XF;F)S
M<#LF;F)S<#LF;F)S<#L@*#0L,C<S+#,W,RD\+W`^/"]T9#X@/'1D('=I9'1H
M/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R
M+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U
M;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W
M:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#<X('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C
M9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R
M.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4X
M+C)P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H
M=#L@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L
M:6=N/3-$<FEG:'0^)FYB<W`[)FYB<W`[)FYB<W`[("@S+#,Y,2PQ,C0I/"]P
M/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0R-3$@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R
M96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3@X<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE.
M.C!I;B`P:6X@,'!T)SX\8CY0<F]P97)T>2!A;F0@17%U:7!M96YT+"!N970\
M+V(^/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\
M+W1D/B`\=&0@=VED=&@],T0W."!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W
M:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R
M96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3@N,G!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@=VEN9&]W=&5X="`Q<'0@
M<V]L:60[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIR
M:6=H=#L@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M(&%L:6=N/3-$<FEG:'0^)FYB<W`[)"9N8G-P.R9N8G-P.R`Y+#`S,2PX.30@
M/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O
M='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D
M/B`\=&0@=VED=&@],T0W."!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD
M;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3@N,G!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@=VEN9&]W=&5X="`Q<'0@<V]L
M:60[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H
M=#L@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L
M:6=N/3-$<FEG:'0^)FYB<W`[)"9N8G-P.R9N8G-P.R`V+#,S-"PX,3<@/"]P
M/CPO=&0^/"]T<CX\+W1A8FQE/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/B`\<"!S='EL
M93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^
M)FYB<W`[/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!
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M<W`[($1E<')E8VEA=&EO;B!I<R!C;VUP=71E9"!O;B!A('-T<F%I9VAT+6QI
M;F4@8F%S:7,@;W9E<B!T:&4@97-T:6UA=&5D('5S969U;"!L:79E<R!O9B!T
M:&4@87-S971S(&%S(&9O;&QO=W,Z/"]P/B`\=&%B;&4@=VED=&@],T0S,S<@
M<W1Y;&4],T0G34%21TE..F%U=&\@875T;R!A=71O("TP+C<U<'0[(%=)1%1(
M.C(U,W!T.R!"3U)$15(M0T],3$%04T4Z8V]L;&%P<V4G(&-E;&QP861D:6YG
M/3-$,"!C96QL<W!A8VEN9STS1#`^(#QT<CX@/'1D('=I9'1H/3-$,C4Q('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C
M:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('=I9'1H.B`Q.#AP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CY!<W-E=#PO<#X\+W1D/B`\=&0@
M=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C
M:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M
M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M
M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$
M-S4@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L
M:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#4V<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B
M;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A
M9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ8V5N=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)
M3CHP:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^)FYB<W`[3&EF92`M('EE
M87)S(#PO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,C4Q('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F
M,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T
M<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$X.'!T
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@
M8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[
M($U!4D=)3CHP:6X@,&EN(#!P="<^4&5R;6ET(&]F(&QA;F0@=7-E/"]P/CPO
M=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F
M,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@
M=VED=&@],T0W-2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C
M:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('=I9'1H.B`U-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R
M+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG
M+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4
M+4%,24=..F-E;G1E<CL@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN
M(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/C0P("T@-S`\+W`^/"]T9#X\+W1R
M/B`\='(^(#QT9"!W:61T:#TS1#(U,2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q.#AP=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@
M<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P
M<'0G/D)U:6QD:6YG/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P
M.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N
M<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E
M<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0W-2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U-G!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/C(P
M("T@,S4\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#(U,2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q.#AP
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G/E!L86YT+"!M86-H:6YE<GD@86YD(&5Q
M=6EP;65N=#PO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^/"]T9#X@/'1D('=I9'1H/3-$-S4@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-39P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA
M;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CXQ,#PO<#X\
M+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,C4Q('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$X.'!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I
M9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP
M:6X@,&EN(#!P="<^36]T;W(@=F5H:6-L93PO<#X\+W1D/B`\=&0@=VED=&@]
M,T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M
M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N
M9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I
M9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-S4@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-39P
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIC96YT97([
M($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG
M;CTS1&-E;G1E<CXU("T@,3`\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T
M:#TS1#(U,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R
M;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`Q.#AP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT
M;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT
M;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(
M14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/D]F9FEC92!E<75I
M<&UE;G0\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^(#QT9"!W:61T:#TS1#<U('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#4V<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[
M($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^,RTU/"]P/CPO
M=&0^/"]T<CX\+W1A8FQE/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M
M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/B`\<"!S='EL93TS
M1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB
M<W`[/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)
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M8VEA=&EO;B!E>'!E;G-E('=A<R`D.#4Q+#`T-R!A;F0@)#4U-2PP,S8L(')E
M<W!E8W1I=F5L>2X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%]E-#!F-C,V,%\X,#1E7S0W-3E?868Q,E\S8F%A93,Y9&,Q
M.#8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO930P9C8S-C!?.#`T
M95\T-S4Y7V%F,3)?,V)A864S.61C,3@V+U=O<FMS:&5E=',O4VAE970Q,"YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DE.5$%.
M1TE"3$4@05-31513/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/DE.5$%.1TE"3$4@05-31513/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DE.5$%.1TE"3$4@05-3
M1513/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM96=X+2T^
M/'`@<W1Y;&4],T0G34%21TE..C!I;B`P:6X@,3!P=#L@5$585"U!551/4U!!
M0T4Z)SX\8CY.3U1%(#0@+2!)3E1!3D=)0DQ%($%34T544SPO8CX\+W`^(#QP
M('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@
M,'!T)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA
M;#L@34%21TE..C!I;B`P:6X@,'!T)SY);G1A;F=I8FQE(&%S<V5T<R!R97!R
M97-E;G0@=&AE(&-O<W0@;V8@;65D:6-A;"!F;W)M=6QA<R!A<'!R;W9E9"!F
M;W(@<')O9'5C=&EO;B!B>2!T:&4@4W1A=&4@1F]O9"!A;F0@1')U9R!!9&UI
M;FES=')A=&EO;B`H=&AE("8C,30W.U-&1$$F(S$T.#LI(&EN($-H:6YA+B!4
M:&4@0V]M<&%N>2!D:60@;F]T(&]B=&%I;B!31D1!('!R;V1U8W1I;VX@87!P
M<F]V86P@9F]R(&%N>2!M961I8V%L(&9O<FUU;&$@9'5R:6YG('1H92!Y96%R
M(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$Q(&%N9"!N;R!C;W-T<R!W97)E(')E
M8VQA<W-I9FEE9"!F<F]M(&%D=F%N8V5S('1O(&EN=&%N9VEB;&4@87-S971S
M(&EN(#(P,3$N($1U<FEN9R!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@
M,C`Q,BP@=&AE($-O;7!A;GD@<F5C96EV960@<')O9'5C=&EO;B!A<'!R;W9A
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M/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I
M;B`P<'0G/B9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/D%P<')O=F5D(&UE9&EC86P@9F]R
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M>'!E;G-E(')E;&%T:6YG('1O(&EN=&%N9VEB;&4@87-S971S('=A<R`D-C$Q
M+#<R-"!A;F0@)#4Y-BPU,C4@9F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E
M<B`S,2P@,C`Q,B!A;F0@,C`Q,2P@<F5S<&5C=&EV96QY+"!A;F0@=V%S(&EN
M8VQU9&5D(&EN('1H92!G96YE<F%L(&%N9"!A9&UI;FES=')A=&EV92!E>'!E
M;G-E<RX@365D:6-A;"!F;W)M=6QA<R!T>7!I8V%L;'D@9&\@;F]T(&AA=F4@
M82!R97-I9'5A;"!V86QU92!A="!T:&4@96YD(&]F('1H96ER(&%M;W)T:7IA
M=&EO;B!P97)I;V0N(#PO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@<W1Y;&4]
M,T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/E1H
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M92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$R+B!.;R!I;7!A:7)M96YT
M(&QO<W-E<R!W97)E(')E8V]G;FEZ960@9'5R:6YG('1H92!Y96%R(&5N9&5D
M($1E8V5M8F5R(#,Q+"`R,#$Q+B9N8G-P.R`\+W`^(#QP('-T>6QE/3-$)TQ)
M3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\
M+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)SY);G1A;F=I8FQE(&%S<V5T<R!C;VYS:7-T960@<V]L96QY
M(&]F(%-&1$$@87!P<F]V960@;65D:6-A;"!F;W)M=6QA<R!A<R!F;VQL;W=S
M.CPO<#X@/'1A8FQE('=I9'1H/3-$,S4W('-T>6QE/3-$)TU!4D=)3CIA=71O
M(&%U=&\@875T;R`M,"XW-7!T.R!724142#HR-C<N-'!T.R!"3U)$15(M0T],
M3$%04T4Z8V]L;&%P<V4G(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS
M1#`^(#QT<CX@/'1D('=I9'1H/3-$,3@W('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O
M='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$T,'!T.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C
M9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^(#QT9"!W:61T:#TS1#$V('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F
M,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#$R<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D
M('=I9'1H/3-$-S$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@-3,N,G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T
M:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0W,2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U
M,RXR<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS
M1#$X-R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M
M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N
M9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I
M9'1H.B`Q-#!P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0Q-B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q
M,G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F
M,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#$U-"!C;VQS<&%N
M/3-$,R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S
M;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!W:61T:#H@,3$U+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F
M,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@
M34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\8CY$96-E;6)E
M<B`S,2P\+V(^/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0Q.#<@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z
M("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L
M;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@
M,30P<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$,38@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P
M9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R
M86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3)P=#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O
M<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0W,2!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z
M("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L
M;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@
M-3,N,G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E
M;G1E<CL@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]P/CPO=&0^(#QT9"!W:61T
M:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0W,2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@-3,N,G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=4
M15A4+4%,24=..F-E;G1E<CL@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ
M,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3$\+V(^/"]P/CPO
M=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0Q.#<@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,30P<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)SY'<F]S<R!C87)R>6EN9R!A;6]U;G0\+W`^/"]T9#X@/'1D
M('=I9'1H/3-$,38@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@,3)P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@]
M,T0W,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M
M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N
M9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I
M9'1H.B`U,RXR<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#LD(#4L,S4W
M+#4X,"`\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^(#QT9"!W:61T:#TS1#<Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#4S+C)P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@
M<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P
M<'0G/B9N8G-P.R0@-BPQ,C0L-#<U(#PO<#X\+W1D/CPO='(^(#QT<CX@/'1D
M('=I9'1H/3-$,3@W('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#$T,'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,
M24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^06-C=6UU
M;&%T960@86UO<G1I>F%T:6]N/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$V('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C
M9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R
M.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$R
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-S$@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3,N,G!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!
M4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[("@R+#DT-"PW,C8I/"]P/CPO=&0^
M(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O
M<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D
M9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED
M=&@],T0W,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R
M;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`U,RXR<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M
M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M
M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M
M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L@*#,L
M,#0Q+#@P-"D\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#$X-R!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q
M-#!P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/DYE="!C87)R>6EN9R!A;6]U;G0\
M+W`^/"]T9#X@/'1D('=I9'1H/3-$,38@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3)P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D
M/B`\=&0@=VED=&@],T0W,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD
M;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3,N,G!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@=VEN9&]W=&5X="`Q<'0@<V]L
M:60[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.R0@,BPT,3(L.#4T(#PO
M<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@
M/'1D('=I9'1H/3-$-S$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W
M=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4S+C)P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@,7!T('-O;&ED
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA
M;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#LD(#,L,#@R+#8W,2`\+W`^
M/"]T9#X\+W1R/CPO=&%B;&4^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO
M<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^(#QP('-T>6QE
M/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF
M;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%2
M1TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M
M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SY4:&4@97-T:6UA
M=&5D(&%G9W)E9V%T92!A;FYU86P@86UO<G1I>F%T:6]N(&5X<&5N<V4@9F]R
M(&5A8V@@;V8@=&AE(&YE>'0@9FEV92!Y96%R<R!A;F0@=&AE<F5A9G1E<B!I
M<R!A<R!F;VQL;W=S.CPO<#X@/'1A8FQE('=I9'1H/3-$,30T('-T>6QE/3-$
M)TU!4D=)3CIA=71O(&%U=&\@875T;R`M,"XW-7!T.R!724142#HQ+C5I;CL@
M0D]21$52+4-/3$Q!4%-%.F-O;&QA<'-E)R!C96QL<&%D9&EN9STS1#`@8V5L
M;'-P86-I;F<],T0P/B`\='(^(#QT9"!W:61T:#TS1#8S('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F
M=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC
M;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H
M.B`T-W!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E
M;G1E<CL@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M(&%L:6=N/3-$8V5N=&5R/CQB/EEE87(\+V(^/"]P/CPO=&0^(#QT9"!W:61T
M:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0V.2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@-3)P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\8CXF;F)S<#M!;6]U;G0@/"]B
M/CPO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$-C,@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-#=P=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E
M<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M
M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E
M;G1E<CXR,#$S/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR
M:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;3X\+W1D/B`\=&0@=VED=&@],T0V.2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U,G!T.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C
M9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\
M<"!S='EL93TS1"=415A4+4%,24=..G)I9VAT.R!,24Y%+4A%24=(5#IN;W)M
M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1R:6=H=#XF;F)S<#LD
M)FYB<W`[)FYB<W`[)FYB<W`[(#4R,2PY.#`@/"]P/CPO=&0^/"]T<CX@/'1R
M/B`\=&0@=VED=&@],T0V,R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F
M,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I
M;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('=I9'1H.B`T-W!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS
M1"=415A4+4%,24=..F-E;G1E<CL@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'
M24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/C(P,30\+W`^/"]T9#X@
M/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F
M,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[
M(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T
M:#TS1#8Y('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#4R<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ<FEG:'0[($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@
M,'!T)R!A;&EG;CTS1')I9VAT/B9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N
M8G-P.R9N8G-P.R`U,#4L-C4S(#PO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I
M9'1H/3-$-C,@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R
M9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG
M<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!W:61T:#H@-#=P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT
M;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT
M;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P
M:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CXR,#$U/"]P/CPO=&0^(#QT9"!W:61T
M:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0V.2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U
M,G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F
M,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..G)I9VAT
M.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI
M9VX],T1R:6=H=#XF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#L@,S8T+#DW."`\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#8S
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T
M.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O
M;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z
M(#0W<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N
M=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@
M86QI9VX],T1C96YT97(^,C`Q-CPO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-CD@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3)P=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E
M<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H=#L@3$E.12U(
M14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$<FEG
M:'0^)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#,Q."PY
M,SD@/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0V,R!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F
M,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A
M;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`T-W!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.
M12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$
M8V5N=&5R/C(P,3<\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#8Y('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4R<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^
M(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ<FEG:'0[($Q)3D4M2$5)1TA4.FYO
M<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/B9N8G-P
M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`R-S(L,S@V(#PO<#X\
M+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$-C,@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-#=P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4
M.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CY4
M:&5R96%F=&5R/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR
M:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;3X\+W1D/B`\=&0@=VED=&@],T0V.2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U,G!T.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C
M9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\
M<"!S='EL93TS1"=415A4+4%,24=..G)I9VAT.R!,24Y%+4A%24=(5#IN;W)M
M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1R:6=H=#XF;F)S<#LF
M;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@-#(X+#DQ."`\+W`^/"]T
M9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#8S('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#0W<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^
M(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^/&(^
M5&]T86P\+V(^/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR
M:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;3X\+W1D/B`\=&0@=VED=&@],T0V.2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P
M9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R
M86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3)P=#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@
M,7!T('-O;&ED.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ<FEG:'0[($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@
M,'!T)R!A;&EG;CTS1')I9VAT/B9N8G-P.R0@,BPT,3(L.#4T(#PO<#X\+W1D
M/CPO='(^/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
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M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^041604Y#
M15,@1D]2(%!54D-(05-%4R!/1B!)3E1!3D=)0DQ%($%34T544RX\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0416
M04Y#15,@1D]2(%!54D-(05-%4R!/1B!)3E1!3D=)0DQ%($%34T544RX\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^041604Y#
M15,@1D]2(%!54D-(05-%4R!/1B!)3E1!3D=)0DQ%($%34T544RX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2UE9W@M+3X\<"!S='EL93TS
M1"=-05)'24XZ,&EN(#!I;B`Q,'!T.R!415A4+4%55$]34$%#13HG/CQB/DY/
M5$4@-2`F(S$U,#L@041604Y#15,@1D]2(%!54D-(05-%4R!/1B!)3E1!3D=)
M0DQ%($%34T544RX@/"]B/CPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@<W1Y
M;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
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M86P@<')O8V5S<R!A="!$96-E;6)E<B`S,2P@,C`Q,BX@5&AE(')E;&%T960@
M<&%T96YT<R!H879E(&YO="!E>'!I<F5D+B`\+W`^(#QP('-T>6QE/3-$)TQ)
M3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\
M+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)SY0<FEO<B!T;R!E;G1E<FEN9R!I;G1O('1H92!C;VYT<F%C
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M:&4@<')O9'5C=&EO;B!A<'!R;W9A;"!F<F]M('1H92!31D1!+CPO<#X@/'`@
M<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P
M<'0G/B9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G/D$@='EP:6-A;"!31D1!(&%P<')O=F%L
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M<RX\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE.
M.C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SY5;F1E<B!T:&4@=&5R
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M<V5S(&]F(&EN=&%N9VEB;&4@87-S971S+B`\+W`^(#QP('-T>6QE/3-$)TQ)
M3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\
M+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)SY4;R!D871E+"!N;R!F;W)M=6QA(&AA<R!F86EL960@=&\@
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M86P@9F]R;75L82!W:71H('1H92!S86UE(&QA8F]R871O<GDN/"]P/B`\<"!S
M='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P
M="<^)FYB<W`[/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[
M($U!4D=)3CHP:6X@,&EN(#!P="<^070@1&5C96UB97(@,S$L(#(P,3(L('1H
M92!#;VUP86YY('=A<R!O8FQI9V%T960@=&\@<&%Y(&QA8F]R871O<FEE<R!A
M;F0@;W1H97)S(&%P<')O>&EM871E;'D@)#8L-#<V+#`P,"!U<&]N(&-O;7!L
M971I;VX@;V8@=&AE('9A<FEO=7,@<&AA<V5S(&]F(&-O;G1R86-T<R!T;R!P
M<F]V:61E(%-&1$$@<')O9'5C=&EO;B!A<'!R;W9A;"!O9B!M961I8V%L(&9O
M<FUU;&%S+B`\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%]E-#!F-C,V,%\X,#1E7S0W-3E?868Q,E\S8F%A93,Y9&,Q.#8-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO930P9C8S-C!?.#`T95\T
M-S4Y7V%F,3)?,V)A864S.61C,3@V+U=O<FMS:&5E=',O4VAE970Q,BYH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E)%3$%4140@
M4$%25%D@5%)!3E-!0U1)3TY3/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)%3$%4140@4$%25%D@5%)!3E-!0U1)
M3TY3/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)%3$%4140@4$%25%D@5%)!3E-!0U1)3TY3/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\(2TM96=X+2T^/'`@<W1Y;&4],T0G34%21TE..C!I
M;B`P:6X@,3!P=#L@5$585"U!551/4U!!0T4Z)SX\8CY.3U1%(#8@)B,Q-3`[
M(%)%3$%4140@4$%25%D@5%)!3E-!0U1)3TY3/"]B/CPO<#X@/'`@<W1Y;&4]
M,T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N
M8G-P.SPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'
M24XZ,&EN(#!I;B`P<'0G/D1U<FEN9R!T:&4@>65A<G,@96YD960@1&5C96UB
M97(@,S$L(#(P,3(@86YD($1E8V5M8F5R(#,Q+"`R,#$Q+"!A(&UE;6)E<B!O
M9B!T:&4@0V]M<&%N>28C,30V.W,@8F]A<F0@;V8@9&ER96-T;W)S(&%D=F%N
M8V5D('1H92!#;VUP86YY("0T.3,L,#`T(&%N9"`D-3DU+#8W,"P@<F5S<&5C
M=&EV96QY+B!4:&4@861V86YC97,@8F5A<B!I;G1E<F5S="!A="!A(')A=&4@
M;V8@,2XP)2!P97(@>65A<BXF;F)S<#L@5&]T86P@:6YT97)E<W0@97AP96YS
M92!O9B`D.2PY-#(@86YD("0W+#$X,"!W87,@<F5C;V=N:7IE9"!F;W(@=&AE
M('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$R(&%N9"`R,#$Q+B!4;W1A
M;"!A9'9A;F-E<R!O=VEN9R!T;R!T:&4@8F]A<F0@;65M8F5R('=E<F4@)#$L
M,S4T+#4V-R!A;F0@)#@V,2PU-C,@87,@;V8@1&5C96UB97(@,S$L(#(P,3(@
M86YD($1E8V5M8F5R(#,Q+"`R,#$Q+"!R97-P96-T:79E;'DL(&%N9"!A<F4@
M<F5C;W)D960@87,@;W1H97(@<&%Y86)L97,@)B,Q-3`[(')E;&%T960@<&%R
M=&EE<R!O;B!T:&4@86-C;VUP86YY:6YG(&-O;G-O;&ED871E9"!B86QA;F-E
M('-H965T<RX@/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[
M($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?930P9C8S-C!?.#`T95\T-S4Y
M7V%F,3)?,V)A864S.61C,3@V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V4T,&8V,S8P7S@P-&5?-#<U.5]A9C$R7S-B86%E,SED8S$X-B]7;W)K
M<VAE971S+U-H965T,3,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY.3U1%4R!005E!0DQ%/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DY/5$53(%!!64%"3$4\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3D]415,@
M4$%904),13PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+65G
M>"TM/CQP('-T>6QE/3-$)TU!4D=)3CHP:6X@,&EN(#$P<'0[(%1%6%0M0554
M3U-004-%.B<^/&(^3D]412`W("8C,34P.R!.3U1%4R!005E!0DQ%/"]B/CPO
M<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN
M(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/D]N(%-E<'1E;6)E<B`S,"P@
M,C`Q,"P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@<F5V;VQV:6YG(&QI
M;F4@;V8@8W)E9&ET('=I=&@@82!B86YK(&EN('1H92!A;6]U;G0@;V8@4DU"
M(#(U+#`P,"PP,#`@*&%P<')O>&EM871E;'D@)#,N.3<@;6EL;&EO;BDN($%D
M=F%N8V5S(&]N('1H92!L:6YE(&]F(&-R961I="!W97)E(&1U92!O;F4@>65A
M<B!F<F]M('1H92!D871E(&]F('1H92!A9'9A;F-E+"!W:71H('1H92!N;W1E
M('!A>6%B;&4@8V]L;&%T97)A;&EZ960@8GD@8V5R=&%I;B!L86YD('5S92!R
M:6=H=',@86YD(&)U:6QD:6YG<RX@3VX@3V-T;V)E<B`R-BP@,C`Q,2P@=&AE
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M9R!L:6YE(&]F(&-R961I="!W87,@4DU"(#(U+#`P,"PP,#`@*"0S+#DS,2PW
M-#4I(&%T($1E8V5M8F5R(#,Q+"`R,#$Q+B!4:&ES(&%M;W5N="!W87,@8VQA
M<W-I9FEE9"!A<R!A('-H;W)T+71E<FT@;F]T97,@<&%Y86)L92!I;B!T:&4@
M86-C;VUP86YY:6YG(&-O;G-O;&ED871E9"!B86QA;F-E('-H965T(&%T($1E
M8V5M8F5R(#,Q+"`R,#$Q+B!/;B!/8W1O8F5R(#$X+"`R,#$R+"!T:&4@0V]M
M<&%N>2!F=6QL>2!P86ED('1H92!A;6]U;G0@9'5E('5N9&5R('1H:7,@;&EN
M92!O9B!C<F5D:70@86YD(&]N($]C=&]B97(@,C8L(#(P,3(L(&ET(&UA='5R
M960@86YD('=A<R!N;W0@<F5N97=E9"X@/"]P/B`\<"!S='EL93TS1"=,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P
M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@
M,&EN(#!P="<^3VX@3V-T;V)E<B`S,"P@,C`Q,BP@=&AE($-O;7!A;GD@96YT
M97)E9"!I;G1O(&$@;F5W(')E=F]L=FEN9R!L:6YE(&]F(&-R961I="!W:71H
M(&%N;W1H97(@8F%N:R!I;B!T:&4@86UO=6YT(&]F(%)-0B`S,"PP,#`L,#`P
M+B9N8G-P.U1H92!R96QA=&5D(&YO=&4@<&%Y86)L92!B96%R<R!I;G1E<F5S
M="!A="!A;B!A;FYU86P@<F%T92!O9B`V+CDP)2`H8F%S960@=7!O;B`Q,34E
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M;'9I;F<@;&EN92!O9B!C<F5D:70@=V%S(%)-0C,P+#`P,"PP,#`@*"0T+#<V
M,2PP-S,I(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$R+B9N8G-P.R!4:&4@0V]M
M<&%N>2!H87,@;F\@861D:71I;VYA;"!A;6]U;G1S(&%V86EL86)L92!T;R!I
M="!U;F1E<B!T:&4@;&EN92!O9B!C<F5D:70N)FYB<W`[(%1H:7,@86UO=6YT
M(&AA<R!B965N(&-L87-S:69I960@87,@<VAO<G0M=&5R;2!N;W1E<R!P87EA
M8FQE(&EN('1H92!A8V-O;7!A;GEI;F<@8V]N<V]L:61A=&5D(&)A;&%N8V4@
M<VAE970@870@1&5C96UB97(@,S$L(#(P,3(N/"]P/B`\<"!S='EL93TS1"=,
M24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[
M/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP
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M+"`R,#$R(&%N9"`R,#$Q(&%P<')O>&EM871E9"!T:&5I<B!F86ER('9A;'5E
M(&)E8V%U<V4@;V8@=&AE(&EM;65D:6%T92!O<B!S:&]R="UT97)M(&UA='5R
M:71Y(&]F('1H97-E(&9I;F%N8VEA;"!I;G-T<G5M96YT<R!O<B!B96-A=7-E
M('1H92!U;F1E<FQY:6YG(&EN<W1R=6UE;G1S(&)E87(@:6YT97)E<W0@<F%T
M97,@=&AA="!A<'!R;WAI;6%T960@8W5R<F5N="!M87)K970@<F%T97,N/"]P
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?930P
M9C8S-C!?.#`T95\T-S4Y7V%F,3)?,V)A864S.61C,3@V#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V4T,&8V,S8P7S@P-&5?-#<U.5]A9C$R7S-B
M86%E,SED8S$X-B]7;W)K<VAE971S+U-H965T,30N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY)3D-/344@5$%815,\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^24Y#
M3TU%(%1!6$53/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DE.0T]-12!405A%4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/"$M+65G>"TM/CQP('-T>6QE/3-$)TU!4D=)3CHP:6X@,&EN(#$P
M<'0[(%1%6%0M05543U-004-%.B<^/&(^3D]412`X("T@24Y#3TU%(%1!6$53
M/"]B/CPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'
M24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G3$E.12U(
M14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/D1E9F5R<F5D(&EN
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M(&EN8VQU9&5S('1H92!E;F%C=&UE;G0@9&%T92X\+W`^(#QP('-T>6QE/3-$
M)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S
M<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE.
M.C!I;B`P:6X@,'!T)SY5;F1I<W1R:6)U=&5D(&5A<FYI;F=S(&]F($AE;'!S
M;VXL('1H92!#;VUP86YY)B,Q-#8[<R!F;W)E:6=N('-U8G-I9&EA<GDL('-I
M;F-E(&ET<R!A8W%U:7-I=&EO;BP@86UO=6YT960@=&\@87!P<F]X:6UA=&5L
M>2`D,3$S+C0@;6EL;&EO;B!A="!$96-E;6)E<B`S,2P@,C`Q,BX@5&AO<V4@
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M/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I
M;B`P<'0G/B9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/DQI86)I;&ET:65S(&%R92!E<W1A
M8FQI<VAE9"!F;W(@=6YC97)T86EN('1A>"!P;W-I=&EO;G,@97AP96-T960@
M=&\@8F4@=&%K96X@:6X@:6YC;VUE('1A>"!R971U<FYS('=H96X@<W5C:"!P
M;W-I=&EO;G,@87)E(&IU9&=E9"!T;R!M965T('1H92`F(S$T-SMM;W)E+6QI
M:V5L>2UT:&%N+6YO="8C,30X.R!T:')E<VAO;&0@8F%S960@;VX@=&AE('1E
M8VAN:6-A;"!M97)I=',@;V8@=&AE('!O<VET:6]N<RX@17-T:6UA=&5D(&EN
M=&5R97-T(&%N9"!P96YA;'1I97,@<F5L871E9"!T;R!U;F-E<G1A:6X@=&%X
M('!E;F%L=&EE<R!A<F4@:6YC;'5D960@87,@82!C;VUP;VYE;G0@;V8@;W1H
M97(@97AP96YS97,N(%1H<F]U9V@@1&5C96UB97(@,S$L(#(P,3(L('1H92!#
M;VUP86YY(&AA<R!N;W0@:61E;G1I9FEE9"!A;GD@=6YC97)T86EN('1A>"!P
M;W-I=&EO;G,@=&AA="!I="!H860@=&%K96XN(%4N4RX@:6YC;VUE('1A>"!R
M971U<FYS(&9O<B!T:&4@>65A<G,@96YD960@1&5C96UB97(@,S$L(#(P,#D@
M=&AR;W5G:"!$96-E;6)E<B`S,2P@,C`Q,B!A;F0@=&AE($-H:6YE<V4@:6YC
M;VUE('1A>"!R971U<FX@9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q
M+"`R,#$R(&%R92!O<&5N(&9O<B!P;W-S:6)L92!E>&%M:6YA=&EO;BX@/"]P
M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@
M,&EN(#!P="<^)FYB<W`[/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^3VX@36%R8V@@,38L(#(P,#<L
M('1H92!.871I;VYA;"!096]P;&4F(S$T-CMS($-O;F=R97-S(&]F($-H:6YA
M('!A<W-E9"!T:&4@;F5W($5N=&5R<')I<V4@26YC;VUE(%1A>"!,87<@*$5)
M5"!,87<I(&%N9"!O;B!$96-E;6)E<B`V+"`R,#`W+"!T:&4@4W1A=&4@0V]U
M;F-I;"!O9B!#:&EN82!I<W-U960@=&AE($EM<&QE;65N=&%T:6]N(%)E9W5L
M871I;VYS(&9O<B!T:&4@14E4($QA=R!W:&EC:"!T;V]K(&5F9F5C="!O;B!*
M86YU87)Y)FYB<W`[,2P@,C`P."X@5&AE($5)5"!,87<@86YD($EM<&QE;65N
M=&%T:6]N(%)E9W5L871I;VYS(&EM<&]S92!A('5N:69I960@14E4(&]F(#(U
M)2!O;B!A;&P@9&]M97-T:6,M:6YV97-T960@96YT97)P<FES97,@86YD($9O
M<F5I9VX@26YV97-T960@16YT:71I97,L(&]R($9)17,L('5N;&5S<R!T:&5Y
M('%U86QI9GD@=6YD97(@8V5R=&%I;B!L:6UI=&5D(&5X8V5P=&EO;G,N/"]P
M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@
M,&EN(#!P="<^)FYB<W`[/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^5&AE($-O;7!A;GD@:7,@;&]C
M871E9"!I;B!A('-P96-I86P@<F5G:6]N+"!W:&EC:"!H860@82`Q-24@8V]R
M<&]R871E(&EN8V]M92!T87@@<F%T92!B969O<F4@=&AE(&YE=R!%250@3&%W
M+B!4:&4@;F5W($5)5"!,87<@86)O;&ES:&5D('1H92!P<F5F97)E;G1I86P@
M8V]R<&]R871E(&EN8V]M92!T87@@<F%T92!I;B!T:&4@<W!E8VEA;"!R96=I
M;VXN(%1H92!#;VUP86YY(&AA<R!T<F%N<VET:6]N960@=&\@=&AE(&YE=R`R
M-24@=&%X(')A=&4@;W9E<B!A(&9I=F4@>65A<B!P97)I;V0@=VAI8V@@8F5G
M86X@;VX@2F%N=6%R>2`Q+"`R,#`X+B!$=7)I;F<@,C`Q,"P@=&AE($-O;7!A
M;GD@87!P;&EE9"!F;W(@86YD(')E8V5I=F5D(&$@9F%V;W)A8FQE('1A>"!R
M871E(&]F(#$U)2!F;W(@9FES8V%L(#(P,3$@=&AR;W5G:"`R,#$S(&1U92!T
M;R!I=',@<W1A='5S(&EN('1H92!04D,@87,@82!H:6=H('1E8VAN;VQO9WD@
M96YT97)P<FES92X@56YD97(@8W5R<F5N="!T87@@;&%W(&EN('1H92!04D,L
M('1H92!#;VUP86YY(&ES(&%N9"!W:6QL(&)E('-U8FIE8W0@=&\@=&AE(&9O
M;&QO=VEN9R!E;G1E<G!R:7-E(&EN8V]M92!T87@@<F%T97,Z/"]P/B`\=&%B
M;&4@=VED=&@],T0R-#`@<W1Y;&4],T0G34%21TE..F%U=&\@875T;R!A=71O
M("TP+C<U<'0[(%=)1%1(.C(N-6EN.R!"3U)$15(M0T],3$%04T4Z8V]L;&%P
M<V4G(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`^(#QT<CX@/'1D
M('=I9'1H/3-$.38@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@,6EN.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R
M+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG
M+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS
M1#(U('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL
M969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD
M+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED
M=&@Z(#$Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$,3$Y('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@8F]R9&5R
M+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U
M;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W
M:61T:#H@.#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG(')O=W-P86X],T0R('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%2
M1TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\8CY%;G1E<G!R:7-E
M($EN8V]M92!487@@4F%T93PO8CX\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W
M:61T:#TS1#DV('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@
M,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q:6X[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[
M($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^/&(^665A<CPO
M8CX\+W`^/"]T9#X@/'1D('=I9'1H/3-$,C4@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M
M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3EP=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\
M+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$.38@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,6EN.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/C(P
M,3,\+W`^/"]T9#X@/'1D('=I9'1H/3-$,C4@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M
M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3EP=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\
M+W1D/B`\=&0@=VED=&@],T0Q,3D@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M
M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@.#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F
M,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@
M34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CXQ-24\+W`^/"]T
M9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#DV('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#%I;CL@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO
M<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CXR,#$T
M(&%N9"!A9G1E<CPO<#X\+W1D/B`\=&0@=VED=&@],T0R-2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q.7!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#$Q.2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`X.7!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/C(U
M)3PO<#X\+W1D/CPO='(^/"]T86)L93X@/'`@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@
M<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P
M<'0G/B9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G
M3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/E1H92!P
M<F]V:7-I;VX@9F]R(&EN8V]M92!T87AE<R!C;VYS:7-T960@;V8@=&AE(&9O
M;&QO=VEN9SH\+W`^(#QT86)L92!W:61T:#TS1#0X,R!S='EL93TS1"=-05)'
M24XZ875T;R!A=71O(&%U=&\@+3`N-S5P=#L@5TE$5$@Z,S8R<'0[($)/4D1%
M4BU#3TQ,05!313IC;VQL87!S92<@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C
M:6YG/3-$,#X@/'1R/B`\=&0@=VED=&@],T0S,#0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,C(X<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M(#QT9"!W:61T:#TS1#$V-R!C;VQS<&%N/3-$,R!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3(U
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA
M;#L@34%21TE..C!I;B`P:6X@,'!T)SX\8CY996%R<R!%;F1E9"!$96-E;6)E
M<B`S,2P\+V(^/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0S,#0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z
M("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L
M;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@
M,C(X<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P
M9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R
M86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V
M,2XU-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^/&(^,C`Q,CPO8CX\+W`^/"]T
M9#X@/'1D('=I9'1H/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F
M,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I
M;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('=I9'1H.B`Q+C@U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D
M('=I9'1H/3-$.#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O
M='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8Q+C9P=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@
M/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I
M;B`P<'0G/CQB/C(P,3$\+V(^/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED
M=&@],T0S,#0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R
M9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG
M<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!W:61T:#H@,C(X<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M
M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M
M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M
M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SY#=7)R96YT/"]P
M/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F
M,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\
M=&0@=VED=&@],T0X,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('=I9'1H.B`V,2XU-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS
M1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)"9N
M8G-P.R9N8G-P.R9N8G-P.R`Q+#0Q-"PQ-S$\+W`^/"]T9#X@/'1D('=I9'1H
M/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M
M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N
M9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I
M9'1H.B`Q+C@U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$.#(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z
M("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L
M;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@
M-C$N-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)"9N8G-P.R9N8G-P.R9N8G-P
M.R`S+#0U."PU-C@\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#,P
M-"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F
M=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC
M;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H
M.B`R,CAP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/D1E9F5R<F5D/"]P/CPO=&0^
M(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O
M<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D
M9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED
M=&@],T0X,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P
M="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M
M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C$N-35P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@
M<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P
M<'0G/B@T,S`L,C4P*3PO<#X\+W1D/B`\=&0@=VED=&@],T0R('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P
M.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N
M<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$N.#5P=#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O
M<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z
M("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L
M;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@
M-C$N-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^*#$V+#(Q,RD\+W`^/"]T9#X\
M+W1R/B`\='(^(#QT9"!W:61T:#TS1#,P-"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`R,CAP=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@
M/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I
M;B`P<'0G/CQB/E1O=&%L(&EN8V]M92!T87@@97AP96YS93PO8CX\+W`^/"]T
M9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W
M:61T:#TS1#@R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@
M,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,2XU-7!T.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C
M9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\
M<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN
M(#!P="<^)"9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`Y
M.#,L.3(Q/"]P/CPO=&0^(#QT9"!W:61T:#TS1#(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,2XX-7!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I
M9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F
M,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A
M;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,2XV<'0[
M('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B
M;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@
M34%21TE..C!I;B`P:6X@,'!T)SXD)FYB<W`[)FYB<W`[)FYB<W`[(#,L-#0R
M+#,U-3PO<#X\+W1D/CPO='(^/"]T86)L93X@/'`@<W1Y;&4],T0G3$E.12U(
M14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X@
M/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I
M;B`P<'0G/B9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@<W1Y;&4]
M,T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/D9O
M;&QO=VEN9R!I<R!A(')E8V]N8VEL:6%T:6]N(&]F(&EN8V]M92!T87AE<R!C
M86QC=6QA=&5D(&%T('1H92!F961E<F%L('-T871U=&]R>2!R871E('1O('1H
M92!P<F]V:7-I;VX@9F]R(&EN8V]M92!T87AE<SH\+W`^(#QT86)L92!W:61T
M:#TS1#0Y,"!S='EL93TS1"=-05)'24XZ875T;R!A=71O(&%U=&\@+3`N-S5P
M=#L@5TE$5$@Z,S8W+C1P=#L@0D]21$52+4-/3$Q!4%-%.F-O;&QA<'-E)R!C
M96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P/B`\='(^(#QT9"!W:61T
M:#TS1#,P-"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R
M;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`R,CAP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT
M;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT
M;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0Q
M,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F
M=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC
M;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H
M.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$.#$@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P
M9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R
M86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C`N-W!T
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@
M8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR
M:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;3X\+W1D/B`\=&0@=VED=&@],T0X,2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,"XW<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^
M/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#,P-"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`R,CAP=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR
M:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;3X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T
M9#X@/'1D('=I9'1H/3-$,3<T(&-O;'-P86X],T0S('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q
M,S`N-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^665A<G,@16YD960@1&5C96UB
M97(@,S$L/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0S,#0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,C(X
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@Q('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,"XW
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA
M;#L@34%21TE..C!I;B`P:6X@,'!T)SXR,#$R/"]P/CPO=&0^(#QT9"!W:61T
M:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X,2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@-C`N-W!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,
M24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^,C`Q,3PO
M<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,S`T('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#(R.'!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)
M3CHP:6X@,&EN(#!P="<^5&%X(&%T('-T871U=&]R>2!R871E(&]F(#(U)3PO
M<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@
M/'1D('=I9'1H/3-$.#$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F
M,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[
M(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!W:61T:#H@-C`N-W!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS
M1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)"9N
M8G-P.R9N8G-P.R9N8G-P.R`Q+#0P,"PS.34\+W`^/"]T9#X@/'1D('=I9'1H
M/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R
M+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U
M;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W
M:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@Q('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C
M9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R
M.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8P
M+C=P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B0F;F)S<#LF;F)S<#LF;F)S<#L@
M-2PV-S<L.3DY/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0S,#0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z
M("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L
M;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@
M,C(X<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO
M<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SY.;VXM9&5D=6-T:6)L92!S=&]C
M:RUB87-E9"!C;VUP96YS871I;VX@9G)O;3PO<#X\+W1D/B`\=&0@=VED=&@]
M,T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M
M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N
M9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I
M9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$.#$@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C`N
M-W!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F
M,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P
M.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N
M<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E
M<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X,2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,"XW<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#,P-"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`R,CAP=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E
M<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'
M24XZ,&EN(#!I;B`P<'0G/F-U<G)E;G0@86YD('!R:6]R('EE87)S/"]P/CPO
M=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F
M,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@
M=VED=&@],T0X,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C
M:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('=I9'1H.B`V,"XW<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D
M97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I
M;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)
M3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXQ-#DL-C0T
M/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O
M='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D
M/B`\=&0@=VED=&@],T0X,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F
M,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I
M;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('=I9'1H.B`V,"XW<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE
M/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXR
M-C$L,3(R/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0S,#0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,C(X
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA
M;#L@34%21TE..C!I;B`P:6X@,'!T)SY%9F9E8W0@;V8@=&%X(&AO;&ED87D\
M+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M(#QT9"!W:61T:#TS1#@Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#8P+C=P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4]
M,T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B@V
M-34L.30W*3PO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^/"]T9#X@/'1D('=I9'1H/3-$.#$@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C`N-W!T.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C
M9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\
M<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN
M(#!P="<^*#(L,S,P+#4V-BD\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T
M:#TS1#,P-"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R
M;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`R,CAP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT
M;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT
M;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(
M14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/D]T:&5R+"!P<FEM
M87)I;'D@=&AE(&5F9F5C="!O9B!54R!T87@@<F%T97,\+W`^/"]T9#X@/'1D
M('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R
M+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG
M+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS
M1#@Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL
M969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD
M+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED
M=&@Z(#8P+C=P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B@W,"PT-S$I/"]P/CPO
M=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F
M,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@
M=VED=&@],T0X,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C
M:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('=I9'1H.B`V,"XW<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D
M97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I
M;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)
M3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXM/"]P/CPO
M=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0S,#0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,C(X<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)SY#:&%N9V4@:6X@=F%L=6%T:6]N(&%L;&]W86YC93PO<#X\
M+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D
M('=I9'1H/3-$.#$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@-C`N-W!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,
M24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^,38P+#,P
M,#PO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T
M9#X@/'1D('=I9'1H/3-$.#$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!W:61T:#H@-C`N-W!T.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P
M.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL
M93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^
M*#$V-BPR,#`I/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0S,#0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z
M("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L
M;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@
M,C(X<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO
M<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SY);F-O;64@=&%X(&5X<&5N<V4\
M+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M(#QT9"!W:61T:#TS1#@Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,"XW<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B!W:6YD;W=T97AT(#%P="!S;VQI
M9#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M
M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)"9N8G-P.R9N8G-P.R9N8G-P.R9N
M8G-P.R9N8G-P.R9N8G-P.R`Y.#,L.3(Q/"]P/CPO=&0^(#QT9"!W:61T:#TS
M1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL
M969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD
M+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED
M=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X,2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R
M9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG
M<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!W:61T:#H@-C`N-W!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R
M+71O<#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@
M<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P
M<'0G/B0F;F)S<#LF;F)S<#LF;F)S<#L@,RPT-#(L,S4U/"]P/CPO=&0^/"]T
M<CX\+W1A8FQE/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!
M4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/B`\<"!S='EL93TS1"=,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P
M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@
M,&EN(#!P="<^)FYB<W`[/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^5&AE(&5F9F5C="!O9B!T:&4@
M=&%X(&AO;&ED87D@86UO=6YT960@=&\@<V%V:6YG<R!O9B`D-C4U+#DT-R!A
M;F0@)#(L,S,P+#4V-B!F;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q
M+"`R,#$R(&%N9"`R,#$Q+"!W:&EC:"!W87,@97%U:79A;&5N="!T;R!B87-I
M8R!A;F0@9&EL=71E9"!E87)N:6YG<R!P97(@<VAA<F4@;V8@)#`N,#(@86YD
M("0P+C`U('!E<B!S:&%R92!F;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R
M(#,Q+"`R,#$R(&%N9"`R,#$Q+"!R97-P96-T:79E;'DN(%1H92!T96UP;W)A
M<GD@9&EF9F5R96YC97,@=VAI8V@@9VEV92!R:7-E('1O('1H92!D969E<G)E
M9"!I;F-O;64@=&%X(&%S<V5T<R!A;F0@;&EA8FEL:71Y(&%R92!A<R!F;VQL
M;W=S.CPO<#X@/&1I=B!A;&EG;CTS1&-E;G1E<CX@/'1A8FQE('=I9'1H/3-$
M-#@S('-T>6QE/3-$)TU!4D=)3CIA=71O(&%U=&\@875T;R`M,"XW-7!T.R!7
M24142#HS-C(N,#5P=#L@0D]21$52+4-/3$Q!4%-%.F-O;&QA<'-E)R!C96QL
M<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P/B`\='(^(#QT9"!W:61T:#TS
M1#,P-"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M
M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N
M9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I
M9'1H.B`R,CAP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0Q,B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$,38W(&-O;'-P86X]
M,T0S('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O
M;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I
M;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('=I9'1H.B`Q,C4N,#5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F
M,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@
M34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\8CY$96-E;6)E
M<B`S,2P\+V(^/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0S,#0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z
M("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L
M;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@
M,C(X<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P
M9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R
M86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V
M,2XV<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N
M=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@
M86QI9VX],T1C96YT97(^/&(^,C`Q,CPO8CX\+W`^/"]T9#X@/'1D('=I9'1H
M/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M
M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N
M9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I
M9'1H.B`Q+C@U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$.#(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#8Q+C9P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O
M<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D
M9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE.
M.C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\8CXR,#$Q/"]B/CPO<#X\
M+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,S`T('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#(R.'!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I
M9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP
M:6X@,&EN(#!P="<^/&(^1&5F97)R960@:6YC;VUE('1A>"!A<W-E=',Z/"]B
M/CPO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T
M9#X@/'1D('=I9'1H/3-$.#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!W:61T:#H@-C$N-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P
M.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT
M9"!W:61T:#TS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@,2XX-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T
M:#TS1#@R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#8Q+C9P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT
M;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT
M;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/CPO='(^(#QT<CX@/'1D
M('=I9'1H/3-$,S`T('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#(R.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,
M24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^06QL;W=A
M;F-E(&9O<B!D;W5B=&9U;"!T<F%D92!R96-E:79A8FQE<SPO<#X\+W1D/B`\
M=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D
M97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I
M;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H
M/3-$.#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R
M+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U
M;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W
M:61T:#H@-C$N-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%
M24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[)"9N8G-P
M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`V-C0L-#DR(#PO<#X\
M+W1D/B`\=&0@=VED=&@],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F
M,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#$N.#5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F
M,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\
M=&0@=VED=&@],T0X,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('=I9'1H.B`V,2XV<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B
M;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A
M9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$
M)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S
M<#LD)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#4S,"PT
M-C$@/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0S,#0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P
M9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R
M86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,C(X<'0[
M('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B
M;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@
M34%21TE..C!I;B`P:6X@,'!T)SY!;&QO=V%N8V4@9F]R(&1O=6)T9G5L(&]T
M:&5R(')E8V5I=F%B;&5S/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F
M,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T
M<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O
M<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,2XV<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE.
M.C!I;B`P:6X@,'!T)SXF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF
M;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#L@-RPT.#(@/"]P/CPO=&0^(#QT9"!W:61T:#TS1#(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R
M96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,2XX-7!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8Q+C9P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN
M(#!I;B`P<'0G/B9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P
M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`U
M+#@S."`\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#,P-"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`R,CAP
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G/DEN=F5N=&]R>2!O8G-O;&5S8V5N8V4@
M<F5S97)V93PO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^/"]T9#X@/'1D('=I9'1H/3-$.#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C$N-G!T.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C
M9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\
M<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN
M(#!P="<^)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[(#(V-2PT.3@@/"]P/CPO=&0^(#QT9"!W:61T:#TS
M1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M
M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T
M:#H@,2XX-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@R('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C
M9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R
M.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8Q
M+C9P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.R9N8G-P.R9N8G-P.R9N
M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P
M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`M
M)FYB<W`[)FYB<W`[(#PO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$
M,S`T('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL
M969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD
M+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED
M=&@Z(#(R.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(
M5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^17AP96YS97,@;F]T(&1E
M9'5C=&EB;&4@:6X@8W5R<F5N="!Y96%R/"]P/CPO=&0^(#QT9"!W:61T:#TS
M1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL
M969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD
M+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED
M=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X,B!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,2XV
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA
M;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@
M,S`L,C`P(#PO<#X\+W1D/B`\=&0@=VED=&@],T0R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$N.#5P=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR
M:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;3X\+W1D/B`\=&0@=VED=&@],T0X,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,2XV<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^
M(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P
M:6X@,'!T)SXF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF
M;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@,CDL.3(W(#PO<#X\+W1D
M/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,S`T('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#(R.'!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@
M,&EN(#!P="<^4VAA<F4@8F%S960@8V]M<&5N<V%T:6]N/"]P/CPO=&0^(#QT
M9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@]
M,T0X,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M
M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N
M9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I
M9'1H.B`V,2XV<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#LF;F)S<#LF
M;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#LF;F)S<#L@-#4L-S<W(#PO<#X\+W1D/B`\=&0@=VED=&@],T0R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F
M,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T
M<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$N.#5P
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X,B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,2XV<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%2
M1TE..C!I;B`P:6X@,'!T)SXF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@,3<R+#DQ,2`\+W`^/"]T9#X\
M+W1R/B`\='(^(#QT9"!W:61T:#TS1#,P-"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`R,CAP=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@
M/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I
M;B`P<'0G/E4N4RX@;F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y(&9O<G=A<F1S
M/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O
M='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D
M/B`\=&0@=VED=&@],T0X,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F
M,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I
M;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('=I9'1H.B`V,2XV<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE
M/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF
M;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#LF;F)S<#L@.3`U+#8V.2`\+W`^/"]T9#X@/'1D('=I9'1H/3-$,B!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q+C@U
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$.#(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C$N-G!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!
M4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#8Q."PR,S8@/"]P/CPO=&0^
M/"]T<CX@/'1R/B`\=&0@=VED=&@],T0S,#0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M
M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,C(X<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^
M(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P
M:6X@,'!T)SY4;W1A;"!D969E<G)E9"!I;F-O;64@=&%X(&%S<V5T<SPO<#X\
M+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D
M('=I9'1H/3-$.#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@-C$N-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@
M/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I
M;B`P<'0G/B9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`Q
M+#DQ.2PQ,3@@/"]P/CPO=&0^(#QT9"!W:61T:#TS1#(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R
M96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,2XX-7!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8Q+C9P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@,7!T('-O;&ED
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA
M;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#LF;F)S<#LF;F)S<#L@,2PS-3<L,S<S(#PO<#X\+W1D/CPO='(^(#QT<CX@
M/'1D('=I9'1H/3-$,S`T('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#(R.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS
M1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^5F%L
M=6%T:6]N(&%L;&]W86YC93PO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[
M('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B
M;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$.#(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T
M.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O
M;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z
M(#8Q+C9P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.R9N8G-P.R9N8G-P
M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`H.34Q+#0T-RD\+W`^/"]T9#X@
M/'1D('=I9'1H/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('=I9'1H.B`Q+C@U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B
M;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A
M9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I
M9'1H/3-$.#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q
M<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#8Q+C9P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@
M<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P
M<'0G/B9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P
M.R`H-SDQ+#$T-RD\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#,P
M-"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F
M=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC
M;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H
M.B`R,CAP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M;F]R;6%L.R!415A4+4E.1$5.5#HQ,'!T.R!-05)'24XZ,&EN(#!I;B`P<'0G
M/DYE="!D969E<G)E9"!I;F-O;64@=&%X(&%S<V5T/"]P/CPO=&0^(#QT9"!W
M:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O
M<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K
M9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT
M;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT
M;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X
M,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI
M9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[
M(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!W:61T:#H@-C$N-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS
M1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB
M<W`[)"9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`Y-C<L
M-C<Q(#PO<#X\+W1D/B`\=&0@=VED=&@],T0R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$N.#5P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X\+W1D/B`\=&0@=VED=&@],T0X,B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C$N-G!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!
M4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[)"9N8G-P.R9N8G-P.R9N8G-P.R9N
M8G-P.R9N8G-P.R9N8G-P.R`U-C8L,C(V(#PO<#X\+W1D/CPO='(^(#QT<CX@
M/'1D('=I9'1H/3-$,S`T('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#(R.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS
M1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^/&(^
M1&5F97)R960@:6YC;VUE('1A>"!L:6%B:6QI='DZ/"]B/CPO<#X\+W1D/B`\
M=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D
M97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I
M;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H
M/3-$.#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R
M+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U
M;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W
M:61T:#H@-C$N-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z
M("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L
M;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@
M,2XX-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F
M,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T
M<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8Q+C9P
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,S`T
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T
M.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O
M;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z
M(#(R.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^26YT86YG:6)L92!A<W-E=',\
M+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M(#QT9"!W:61T:#TS1#@R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,2XV<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ<FEG:'0[($Q)3D4M2$5)1TA4
M.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/B9N
M8G-P.R0F;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#LF;F)S<#L@.34L.38S(#PO<#X\+W1D/B`\=&0@=VED=&@],T0R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F
M,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T
M<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$N.#5P
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X,B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M
M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T
M:#H@-C$N-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=.
M.G)I9VAT.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P
M="<@86QI9VX],T1R:6=H=#XF;F)S<#LD)FYB<W`[)FYB<W`[)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[(#$R."PY,#D@/"]P/CPO=&0^/"]T<CX\+W1A8FQE
M/CPO9&EV/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)
M3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%
M24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/B`\
M<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN
M(#!P="<^)FYB<W`[/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M
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M(&EF(&%N>2P@86YD(&5X<&ER92P@:68@;F]T('5S960L(&9R;VT@,C`R.2!T
M:')O=6=H(#(P,S(N)FYB<W`[($EN(&%S<V5S<VEN9R!T:&4@<F5A;&EZ86)I
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M<R!A<F4@=71I;&EZ960N)FYB<W`[($UA;F%G96UE;G0@8V]N<VED97)S('!R
M;VIE8W1E9"!F=71U<F4@=&%X86)L92!I;F-O;64@86YD('1A>"!P;&%N;FEN
M9R!S=')A=&5G:65S(&EN(&UA:VEN9R!T:&ES(&%S<V5S<VUE;G0N)FYB<W`[
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M8F5R(#,Q+"`R,#$R(&%N9"`R,#$Q+B9N8G-P.R!4:&5R969O<F4L('1H92!#
M;VUP86YY(&AA<R!P<F]V:61E9"!F;W(@82!V86QU871I;VX@86QL;W=A;F-E
M(&%G86EN<W0@:71S(&1E9F5R<F5D('1A>"!A<W-E=',@;V8@)#DU,2PT-#<@
M86YD("0W.3$L,30W(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$R(&%N9"`R,#$Q
M+"!R97-P96-T:79E;'DN/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/B`\<"!S='EL
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M:6YC:6%L(&=O=F5R;FUE;G0@:6X@=&AE(%!20R!T;W1A;&EN9R`D,30Q+#DX
M-R!A;F0@)#,P,2PV-S(L(')E<W!E8W1I=F5L>2P@=VAI8V@@:&%S(&)E96X@
M<F5C;W)D960@87,@9V]V97)N;65N="!S=6)S:61Y(&EN8V]M92!O;B!T:&4@
M86-C;VUP86YY:6YG('-T871E;65N=',@;V8@;W!E<F%T:6]N<R!A;F0@8V]M
M<')E:&5N<VEV92!I;F-O;64@9F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E
M<B`S,2P@,C`Q,B!A;F0@,C`Q,2X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%]E-#!F-C,V,%\X,#1E7S0W-3E?868Q,E\S
M8F%A93,Y9&,Q.#8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO930P
M9C8S-C!?.#`T95\T-S4Y7V%F,3)?,V)A864S.61C,3@V+U=O<FMS:&5E=',O
M4VAE970Q-2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/D1%4DE6051)5D4@5T%24D%.5"!,24%"24Q)5%D\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1$52259!5$E6
M12!705)204Y4($Q)04))3$E463PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$15))5D%4259%(%=!4E)!3E0@3$E!0DE,2519
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM96=X+2T^/'`@
M<W1Y;&4],T0G34%21TE..C!I;B`P:6X@,3!P=#L@5$585"U!551/4U!!0T4Z
M)SX\8CY.3U1%(#D@)B,Q-3`[($1%4DE6051)5D4@5T%24D%.5"!,24%"24Q)
M5%D\+V(^/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!
M4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/B`\<"!S='EL93TS1"=,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^3VX@36%Y(#(W
M+"`R,#`X(&%N9"!O;B!-87D@,S`L(#(P,#@L('1H92!#;VUP86YY(&ES<W5E
M9"!W87)R86YT<R!T;R!P=7)C:&%S92`Q+#(U,"PP,#`@<VAA<F5S(&]F(&-O
M;6UO;B!S=&]C:R!A="`D,BXX,"!P97(@<VAA<F4@86YD('=A<G)A;G1S('1O
M('!U<F-H87-E(#,P,"PP,#`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A="`D
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M(&5X<&ER960@;VX@36%Y(#(W+"`R,#$Q+B!#:&%N9V5S('1O('1H92!W87)R
M86YT(&1E<FEV871I=F4@;&EA8FEL:71Y('=E<F4@<F5C;V=N:7IE9"!I;B!T
M:&4@<F5S=6QT<R!O9B!O<&5R871I;VYS(&%N9"!R97-U;'1E9"!I;B!D97)I
M=F%T:79E(&=A:6YS(&]F("0P(&%N9"`D.3,T+#(V,"!F;W(@=&AE('EE87)S
M(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$R(&%N9"`R,#$Q+"!R97-P96-T:79E
M;'DN(#PO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7V4T,&8V,S8P7S@P-&5?-#<U.5]A9C$R7S-B86%E,SED8S$X-@T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E-#!F-C,V,%\X,#1E7S0W-3E?
M868Q,E\S8F%A93,Y9&,Q.#8O5V]R:W-H965T<R]3:&5E=#$V+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1D%)4B!604Q512!-
M14%355)%345.5%,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1D%)4B!604Q512!-14%355)%345.5%,\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1D%)4B!604Q5
M12!-14%355)%345.5%,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CPA+2UE9W@M+3X\<"!S='EL93TS1"=-05)'24XZ,&EN(#!I;B`Q,'!T.R!4
M15A4+4%55$]34$%#13HG/CQB/DY/5$4@,3`@)B,Q-3`[($9!25(@5D%,544@
M345!4U5214U%3E13/"]B/CPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@<W1Y
M;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M/D9A:7(@=F%L=64@:7,@9&5F:6YE9"!A<R!T:&4@97AC:&%N9V4@<')I8V4@
M=&AA="!W;W5L9"!B92!R96-E:79E9"!F;W(@86X@87-S970@;W(@<&%I9"!T
M;R!T<F%N<V9E<B!A(&QI86)I;&ET>2`H86X@97AI="!P<FEC92D@:6X@=&AE
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M<R!A<R!F;VQL;W=S.B!,979E;"`Q("8C,34P.R!1=6]T960@<')I8V5S(&EN
M(&%C=&EV92!M87)K971S(&9O<B!I9&5N=&EC86P@87-S971S(&]R(&QI86)I
M;&ET:65S+B!,979E;"`R("8C,34P.R!/8G-E<G9A8FQE(&EN<'5T<R!O=&AE
M<B!T:&%N($QE=F5L(#$@:6YC;'5D:6YG('%U;W1E9"!P<FEC97,@9F]R('-I
M;6EL87(@87-S971S(&]R(&QI86)I;&ET:65S+"!Q=6]T960@<')I8V5S(&EN
M(&QE<W,@86-T:79E(&UA<FME=',L(&]R(&]T:&5R(&]B<V5R=F%B;&4@:6YP
M=71S('1H870@8V%N(&)E(&-O<G)O8F]R871E9"!B>2!O8G-E<G9A8FQE(&UA
M<FME="!D871A+B!,979E;"`S("8C,34P.R!5;F]B<V5R=F%B;&4@:6YP=71S
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M;G0@:G5D9VUE;G0@;W(@97-T:6UA=&EO;BX@/"]P/B`\<"!S='EL93TS1"=,
M24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[
M/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP
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M86YK97(F(S$T-CMS(&%C8V5P=&%N8V4@;F]T97,@:70@:&]L9',N)FYB<W`[
M)FYB<W`[5&AE($-O;7!A;GD@=F%L=65S(&ET<R!D97)I=F%T:79E('=A<G)A
M;G1S('5S:6YG(&$@=F%L=6%T:6]N(&UE=&AO9"!E>'!L86EN960@86)O=F4N
M)FYB<W`[)FYB<W`[5&AE(&)A;FME<B8C,30V.W,@86-C97!T86YC92!N;W1E
M<R!A<F4@<F5C;W)D960@870@8V]S="!W:&EC:"!A<'!R;WAI;6%T97,@9F%I
M<B!V86QU92XF;F)S<#LF;F)S<#M4:&4@0V]M<&%N>2!H96QD('1H92!F;VQL
M;W=I;F<@87-S971S(&%N9"!L:6%B:6QI=&EE<R!R96-O<F1E9"!A="!F86ER
M('9A;'5E(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$R(&%N9"`R,#$Q.B`\+W`^
M(#QT86)L92!W:61T:#TS1#0X.2!S='EL93TS1"=724142#HS-C8N-G!T.R!"
M3U)$15(M0T],3$%04T4Z8V]L;&%P<V4G(&-E;&QP861D:6YG/3-$,"!C96QL
M<W!A8VEN9STS1#`^(#QT<CX@/'1D('=I9'1H/3-$,38Q('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$R,"XT<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$,3,@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.2XT<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^/"]T9#X@/'1D('=I9'1H/3-$.#4@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C,N-'!T.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C
M9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^(#QT9"!W:61T:#TS1#$S('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F
M,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#DN-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P
M.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT
M9"!W:61T:#TS1#8U('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#0X+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O
M<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D
M9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED
M=&@],T0Q,R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R
M;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`Y+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT
M;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT
M;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0V
M-2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F
M=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC
M;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H
M.B`T."XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$,3,@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.2XT
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-C4@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-#@N-'!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0Q-C$@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3(P
M+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0Q,R!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F
M,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A
M;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y+C1P=#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O
M<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X-2!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,RXT<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$,3,@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M
M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.2XT<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^
M/"]T9#X@/'1D('=I9'1H/3-$,C$Y(&-O;'-P86X],T0U('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$V-'!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)
M3CHP:6X@,&EN(#!P="<^/&(^1F%I<B!686QU92!-96%S=7)E;65N=',@870\
M+V(^/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0Q-C$@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P
M9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R
M86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3(P+C1P
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0Q,R!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y+C1P=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E
M<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X-2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,RXT<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)SX\8CY$96-E;6)E<B`S,2P\+V(^/"]P/CPO=&0^(#QT9"!W
M:61T:#TS1#$S('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O
M<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K
M9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=VED=&@Z(#DN-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R
M+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG
M+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS
M1#(Q.2!C;VQS<&%N/3-$-2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD
M;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,38T<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)SX\8CY297!O<G1I;F<@1&%T92!5<VEN9SPO8CX\+W`^/"]T
M9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#$V,2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3(P
M+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQB/D1E<V-R:7!T:6]N/"]B/CPO
M<#X\+W1D/B`\=&0@=VED=&@],T0Q,R!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y+C1P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D
M/B`\=&0@=VED=&@],T0X-2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD
M;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C,N-'!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I
M9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP
M:6X@,&EN(#!P="<^/&(^,C`Q,CPO8CX\+W`^/"]T9#X@/'1D('=I9'1H/3-$
M,3,@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M
M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T
M:#H@.2XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-C4@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O
M<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K
M9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=VED=&@Z(#0X+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.
M12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQB/DQE=F5L
M(#$\+V(^/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$S('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#DN-'!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I
M9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^(#QT9"!W:61T:#TS1#8U('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F
M,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A
M;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`T."XT<'0[
M('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B
M;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@
M34%21TE..C!I;B`P:6X@,'!T)SX\8CY,979E;"`R/"]B/CPO<#X\+W1D/B`\
M=&0@=VED=&@],T0Q,R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('=I9'1H.B`Y+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O
M<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D
M9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED
M=&@],T0V-2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P
M="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M
M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@-#@N-'!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S
M='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P
M="<^/&(^3&5V96P@,SPO8CX\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T
M:#TS1#$V,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R
M;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`Q,C`N-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R
M+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG
M+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^0F%N:V5R)W,@
M86-C97!T86YC92!N;W1E<SPO<#X\+W1D/B`\=&0@=VED=&@],T0Q,R!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y+C1P
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X-2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M
M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T
M:#H@-C,N-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(
M5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)"9N8G-P.R9N8G-P.R9N
M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`Q,#$L-3<P/"]P
M/CPO=&0^(#QT9"!W:61T:#TS1#$S('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#DN-'!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M(#QT9"!W:61T:#TS1#8U('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`T."XT<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)SXD)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[("T\+W`^/"]T9#X@
M/'1D('=I9'1H/3-$,3,@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F
M,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[
M(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!W:61T:#H@.2XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B
M;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A
M9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I
M9'1H/3-$-C4@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q
M<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#0X+C1P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@
M<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P
M<'0G/B0F;F)S<#L@,3`Q+#4W,#PO<#X\+W1D/B`\=&0@=VED=&@],T0Q,R!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y
M+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0V-2!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R
M+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U
M;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W
M:61T:#H@-#@N-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%
M24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)"9N8G-P.R9N8G-P
M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N
M8G-P.R9N8G-P.R`M/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0Q
M-C$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M
M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T
M:#H@,3(P+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/E1O=&%L/"]P/CPO=&0^
M(#QT9"!W:61T:#TS1#$S('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#DN-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W
M:61T:#TS1#@U('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@
M,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,RXT<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP
M('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@
M,'!T)SXD)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB
M<W`[)FYB<W`[(#$P,2PU-S`\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3,@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.2XT
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-C4@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL
M969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD
M+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED
M=&@Z(#0X+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B0F;F)S<#LF;F)S<#LF
M;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#LF;F)S<#L@+3PO<#X\+W1D/B`\=&0@=VED=&@],T0Q,R!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y+C1P=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E
M<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0V-2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-#@N
M-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F
M,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M
M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)"9N8G-P.R`Q,#$L-3<P/"]P/CPO
M=&0^(#QT9"!W:61T:#TS1#$S('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F
M,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#DN-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P
M.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT
M9"!W:61T:#TS1#8U('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E
M>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`T."XT<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^
M(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P
M:6X@,'!T)SXD)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[("T\+W`^/"]T9#X\+W1R
M/CPO=&%B;&4^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%2
M1TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M
M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^
M(#QT86)L92!W:61T:#TS1#0X.2!S='EL93TS1"=724142#HS-C8N-G!T.R!"
M3U)$15(M0T],3$%04T4Z8V]L;&%P<V4G(&-E;&QP861D:6YG/3-$,"!C96QL
M<W!A8VEN9STS1#`^(#QT<CX@/'1D('=I9'1H/3-$,38Q('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$R,"XT<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$,3,@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.2XT<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^/"]T9#X@/'1D('=I9'1H/3-$.#4@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C,N-'!T.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C
M9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^(#QT9"!W:61T:#TS1#$S('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F
M,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#DN-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P
M.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT
M9"!W:61T:#TS1#8U('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#0X+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O
M<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D
M9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED
M=&@],T0Q,R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R
M;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`Y+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT
M;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT
M;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0V
M-2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F
M=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC
M;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H
M.B`T."XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$,3,@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.2XT
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-C4@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-#@N-'!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0Q-C$@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3(P
M+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0Q,R!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F
M,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A
M;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y+C1P=#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O
M<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X-2!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,RXT<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$,3,@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M
M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.2XT<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^
M/"]T9#X@/'1D('=I9'1H/3-$,C$Y(&-O;'-P86X],T0U('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$V-'!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.12U(
M14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N
M=&5R/CQB/D9A:7(@5F%L=64@365A<W5R96UE;G1S(&%T/"]B/CPO<#X\+W1D
M/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,38Q('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$R,"XT<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^/"]T9#X@/'1D('=I9'1H/3-$,3,@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.2XT<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T
M9#X@/'1D('=I9'1H/3-$.#4@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!W:61T:#H@-C,N-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P
M.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL
M93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.12U(14E'2%0Z;F]R;6%L.R!-
M05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQB/D1E8V5M8F5R
M(#,Q+#PO8CX\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3,@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R
M96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.2XT<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$,C$Y(&-O;'-P86X],T0U('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R
M;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`Q-C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT
M;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT
M;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P
M:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\8CY297!O<G1I;F<@1&%T92!5<VEN
M9SPO8CX\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#$V,2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R
M9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG
M<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!W:61T:#H@,3(P+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.
M12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQB/D1E<V-R
M:7!T:6]N/"]B/CPO<#X\+W1D/B`\=&0@=VED=&@],T0Q,R!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y+C1P=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E
M<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X-2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C,N
M-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F
M,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E
M<CL@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L
M:6=N/3-$8V5N=&5R/CQB/C(P,3$\+V(^/"]P/CPO=&0^(#QT9"!W:61T:#TS
M1#$S('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL
M969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD
M+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED
M=&@Z(#DN-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#8U('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C
M:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('=I9'1H.B`T."XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D
M97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I
M;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ8V5N=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP
M:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^/&(^3&5V96P@,3PO8CX\+W`^
M/"]T9#X@/'1D('=I9'1H/3-$,3,@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M
M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@.2XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@
M/'1D('=I9'1H/3-$-C4@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W
M=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#0X+C1P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4
M.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\
M8CY,979E;"`R/"]B/CPO<#X\+W1D/B`\=&0@=VED=&@],T0Q,R!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F
M,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A
M;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y+C1P=#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O
M<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0V-2!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z
M("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L
M;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@
M-#@N-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E
M;G1E<CL@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M(&%L:6=N/3-$8V5N=&5R/CQB/DQE=F5L(#,\+V(^/"]P/CPO=&0^/"]T<CX@
M/'1R/B`\=&0@=VED=&@],T0Q-C$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M
M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3(P+C1P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@
M<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P
M<'0G/D)A;FME<B=S(&%C8V5P=&%N8V4@;F]T97,\+W`^/"]T9#X@/'1D('=I
M9'1H/3-$,3,@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R
M9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG
M<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!W:61T:#H@.2XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M
M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M
M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$
M.#4@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L
M:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#8S+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4]
M,T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N
M8G-P.R0F;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#LF;F)S<#LF;F)S<#LF;F)S<#L@.#,L-3$R(#PO<#X\+W1D/B`\=&0@=VED
M=&@],T0Q,R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R
M;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`Y+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT
M;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT
M;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0V
M-2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI
M9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[
M(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!W:61T:#H@-#@N-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS
M1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB
M<W`[)"9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P
M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`M)FYB<W`[)FYB<W`[(#PO<#X\
M+W1D/B`\=&0@=VED=&@],T0Q,R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`Y+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F
M,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\
M=&0@=VED=&@],T0V-2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T
M97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M
M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-#@N-'!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@
M,&EN(#!P="<^)FYB<W`[)"9N8G-P.R9N8G-P.R9N8G-P.R`X,RPU,3(@/"]P
M/CPO=&0^(#QT9"!W:61T:#TS1#$S('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#DN-'!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M(#QT9"!W:61T:#TS1#8U('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`T."XT<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)SXF;F)S<#LD)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[("TF;F)S
M<#LF;F)S<#L@/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0Q-C$@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z
M("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L
M;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@
M,3(P+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/E1O=&%L/"]P/CPO=&0^(#QT
M9"!W:61T:#TS1#$S('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#DN-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T
M:#TS1#@U('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T
M('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`V,RXT<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T
M>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T
M)SXF;F)S<#LD)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#@S+#4Q,B`\+W`^/"]T9#X@/'1D
M('=I9'1H/3-$,3,@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@.2XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D
M97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I
M;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H
M/3-$-C4@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@
M<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#0X+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F
M,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y
M;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M/B9N8G-P.R0F;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF
M;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@+29N8G-P.R9N8G-P.R`\
M+W`^/"]T9#X@/'1D('=I9'1H/3-$,3,@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.2XT<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T
M9#X@/'1D('=I9'1H/3-$-C4@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN
M9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#0X+C1P=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR
M:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ
M,&EN(#!I;B`P<'0G/B9N8G-P.R0F;F)S<#LF;F)S<#LF;F)S<#L@.#,L-3$R
M(#PO<#X\+W1D/B`\=&0@=VED=&@],T0Q,R!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y+C1P=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\
M+W1D/B`\=&0@=VED=&@],T0V-2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W
M:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R
M96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-#@N-'!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)
M3CHP:6X@,&EN(#!P="<^)FYB<W`[)"9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P
M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`M
M)FYB<W`[)FYB<W`[(#PO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$
M,38Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL
M969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD
M+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED
M=&@Z(#$R,"XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$,3,@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z
M("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L
M;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@
M.2XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$.#4@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P
M9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R
M86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C,N-'!T
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@
M8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#$S('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#DN-'!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#8U('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#0X+C1P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X\+W1D/B`\=&0@=VED=&@],T0Q,R!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y+C1P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D
M/B`\=&0@=VED=&@],T0V-2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F
M,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I
M;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('=I9'1H.B`T."XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D
M('=I9'1H/3-$,3,@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@.2XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D
M97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I
M;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H
M/3-$-C4@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R
M+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U
M;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W
M:61T:#H@-#@N-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^/"]T<CX\+W1A8FQE/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?930P9C8S
M-C!?.#`T95\T-S4Y7V%F,3)?,V)A864S.61C,3@V#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V4T,&8V,S8P7S@P-&5?-#<U.5]A9C$R7S-B86%E
M,SED8S$X-B]7;W)K<VAE971S+U-H965T,3<N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY35$]#2TA/3$1%4E,G($5154E463QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY35$]#2TA/3$1%4E,G($5154E463PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y35$]#2TA/3$1%4E,G($5154E463PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+65G>"TM/CQP('-T>6QE
M/3-$)TU!4D=)3CHP:6X@,&EN(#$P<'0[(%1%6%0M05543U-004-%.B<^/&(^
M3D]412`Q,2`M(%-43T-+2$],1$524R<@15%52519/"]B/CPO<#X@/'`@<W1Y
M;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M/B9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-
M05)'24XZ,&EN(#!I;B`P<'0G/D]N($1E8V5M8F5R(#,Q+"`R,#$R+"!T:&4@
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M;V8@=&AE($YE=F%D82!C;W)P;W)A=&EO;BX@/"]P/B`\<"!S='EL93TS1"=,
M24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[
M/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP
M:6X@,&EN(#!P="<^5&AE($-O;7!A;GD@:7,@875T:&]R:7IE9"!T;R!I<W-U
M92`Y-2PP,#`L,#`P('-H87)E<R!O9B!C;VUM;VX@<VAA<F5S+"`D,"XP,#$@
M<&%R('9A;'5E+"!A;F0@-2PP,#`L,#`P('-H87)E<R!O9B!P<F5F97)R960@
M<W1O8VLL("0P+C`P,2!P87(@=F%L=64N(%1H92!P<F5F97)R960@<W1O8VL@
M;6%Y(&)E(&ES<W5E9"!I;B!S97)I97,@=VET:"!S=6-H(&1E<VEG;F%T:6]N
M<RP@<')E9F5R96YC97,L('-T871E9"!V86QU97,L(')I9VAT<RP@<75A;&EF
M:6-A=&EO;G,@;W(@;&EM:71A=&EO;G,@87,@9&5T97)M:6YE9"!S;VQE;'D@
M8GD@=&AE($-O;7!A;GDF(S$T-CMS(&)O87)D(&]F(&1I<F5C=&]R<RX\+W`^
M(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P
M:6X@,'!T)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO
M<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SY787)R86YT<SPO<#X@/'`@<W1Y
M;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M/B9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-
M05)'24XZ,&EN(#!I;B`P<'0G/D%S(&]F($1E8V5M8F5R(#,Q+"`R,#$R+"!T
M:&4@0V]M<&%N>2!H860@=V%R<F%N=',@;W5T<W1A;F1I;F<@86YD(&5X97)C
M:7-A8FQE('1O('!U<F-H87-E(&%N(&%G9W)E9V%T92!O9B`Q-3`L,#`P('-H
M87)E<R!O9B!#;VUP86YY)W,@8V]M;6]N('-T;V-K(&%T(&5X97)C:7-E('!R
M:6-E<R!R86YG:6YG(&9R;VT@)#,N,#`@=&\@)#,N.#`@<&5R('-H87)E+"!W
M:&EC:"!E>'!I<F4@36%Y(#$V+"`R,#$S+B!!="!$96-E;6)E<B`S,2P@,C`Q
M,BP@=&AE('=A<G)A;G1S(&AA9"!A('=E:6=H=&5D+6%V97)A9V4@97AE<F-I
M<V4@<')I8V4@;V8@)#,N-#`@<&5R('-H87)E+"!A('=E:6=H=&5D+6%V97)A
M9V4@<F5M86EN:6YG(&-O;G1R86-T=6%L(&QI9F4@;V8@,"XT('EE87)S(&%N
M9"!A('1O=&%L(&EN=')I;G-I8R!V86QU92!O9B`D,"XF;F)S<#LF;F)S<#L\
M+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4
M.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SY%;7!L;WEE92!3=&]C:R!/
M<'1I;VYS/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!
M4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/B`\<"!S='EL93TS1"=,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^,C`Q,"!);F-E
M;G1I=F4@4&QA;CPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G
M3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/D]N($YO
M=F5M8F5R(#$R+"`R,#$P+"!T:&4@0V]M<&%N>28C,30V.W,@0F]A<F0@;V8@
M1&ER96-T;W)S(&%D;W!T960L(&%N9"!O;B!$96-E;6)E<B`R,BP@,C`Q,"!I
M=',@<W1O8VMH;VQD97)S(&%P<')O=F5D('1H92`R,#$P($QO;F<M5&5R;2!)
M;F-E;G1I=F4@4&QA;B`H=&AE("8C,30W.S(P,3`@26YC96YT:79E(%!L86XF
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M:61I87)I97,N(%1H92`R,#$P($EN8V5N=&EV92!0;&%N(&-U<G)E;G1L>2!A
M;&QO=W,@9F]R(&5Q=6ET>2!A=V%R9',@;V8@=7`@=&\@-"PP,#`L,#`P('-H
M87)E<R!O9B!C;VUM;VX@<W1O8VLN)FYB<W`[(%1H<F]U9V@@1&5C96UB97(@
M,S$L(#(P,3(L(#$R-2PP,#`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A;F0@
M;W!T:6]N<R!T;R!P=7)C:&%S92!A;B!A9V=R96=A=&4@;V8@,3`P+#`P,"!S
M:&%R97,@;V8@<W1O8VL@;W!T:6]N<R!H860@8F5E;B!G<F%N=&5D('5N9&5R
M('1H92`R,#$P($EN8V5N=&EV92!0;&%N+CPO<#X@/'`@<W1Y;&4],T0G3$E.
M12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO
M<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN
M(#!I;B`P<'0G/D]N($UA>2`R-2P@,C`Q,2!T:&4@0V]M<&%N>2!I<W-U960@
M='=O+7EE87(@;W!T:6]N<R!T;R!P=7)C:&%S92!A('1O=&%L(&]F(#$P,"PP
M,#`@<VAA<F5S(&]F(&ET<R!C;VUM;VX@<W1O8VL@=6YD97(@=&AE(#(P,3`@
M26YC96YT:79E(%!L86X@=&\@='=O(&]F(&ET<R!E>&5C=71I=F4@;V9F:6-E
M<G,@87,@9F]L;&]W<RX@5&AE($-O;7!A;GDF(S$T-CMS($-H:65F($5X96-U
M=&EV92!/9F9I8V5R('=A<R!G<F%N=&5D(&YO;BUQ=6%L:69I960@<W1O8VL@
M;W!T:6]N<R!T;R!P=7)C:&%S92`U,"PP,#`@<VAA<F5S(&]F(&-O;6UO;B!S
M=&]C:R!A="!A;B!E>&5R8VES92!P<FEC92!O9B`D,BXU-"!P97(@<VAA<F4L
M('1H92!C;&]S:6YG('!R:6-E(&]F('1H92!#;VUP86YY)B,Q-#8[<R!C;VUM
M;VX@<W1O8VL@;VX@=&AE(&1A>2!P<FEO<B!T;R!T:&4@9&%Y(&]F(&=R86YT
M+"!E>'!I<FEN9R!O;B!-87D@,C4L(#(P,3,L(&]F('=H:6-H(#(U+#`P,"!S
M:&%R97,@=F5S=&5D(&]N($UA>2`R-2P@,C`Q,B!A;F0@,C4L,#`P('-H87)E
M<R!W97)E('1O('9E<W0@;VX@=&AE('1H<F5E+6UO;G1H(&%N;FEV97)S87)Y
M(&]F('1H92!A8VAI979E;65N="!O9B!C97)T86EN('!E<F9O<FUA;F-E+6)A
M<V5D('9E<W1I;F<@8W)I=&5R:6$N(%1H92!#;VUP86YY(&%L<V\@9W)A;G1E
M9"!I=',@9F]R;65R($-H:65F($9I;F%N8VEA;"!/9F9I8V5R(&YO;BUQ=6%L
M:69I960@<W1O8VL@;W!T:6]N<R!T;R!P=7)C:&%S92`U,"PP,#`@<VAA<F5S
M(&]F(&-O;6UO;B!S=&]C:R!A="!A;B!E>&5R8VES92!P<FEC92!O9B`D,BXU
M-"!P97(@<VAA<F4L(&5X<&ER:6YG(&]N($%P<FEL(#(X+"`R,#$S+"!O9B!W
M:&EC:"`R-2PP,#`@<VAA<F5S('9E<W1E9"!O;B!!<')I;"`R."P@,C`Q,B!A
M;F0@,C4L,#`P('-H87)E<R!W97)E('1O('9E<W0@;VX@=&AE('1H<F5E+6UO
M;G1H(&%N;FEV97)S87)Y(&]F('1H92!A8VAI979E;65N="!O9B!C97)T86EN
M('!E<F9O<FUA;F-E+6)A<V5D('9E<W1I;F<@8W)I=&5R:6$N/"]P/B`\<"!S
M='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P
M="<^)FYB<W`[/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[
M($U!4D=)3CHP:6X@,&EN(#!P="<^5&AE(&=R86YT+61A=&4@9F%I<B!V86QU
M92!O9B!T:&4@;W!T:6]N<R!O9B`D,"XW,2!P97(@<VAA<F4L(&]R("0W,"PU
M.#`@:6X@=&]T86PL('=A<R!B87-E9"!O;B!T:&4@9W)A;G0M9&%T92!C;&]S
M:6YG(&UA<FME="!P<FEC92!O9B`D,BXU-"!P97(@<VAA<F4@86YD(&]N('1H
M92!F;VQL;W=I;F<@=V5I9VAT960M879E<F%G92!A<W-U;7!T:6]N<SH@<FES
M:R!F<F5E(&EN=&5R97-T(')A=&4@;V8@,"XU-"4L(&5X<&5C=&5D(&1I=FED
M96YD('EI96QD(&]F(#`E+"!E>'!E8W1E9"!V;VQA=&EL:71Y(&]F(#<P+C0E
M(&%N9"!A;B!E>'!E8W1E9"!L:69E(&]F(#$N,"!Y96%R+B!4:&4@<VAA<F4M
M8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4@<F5L871I=F4@=&\@=&AE(&9I
M>&5D('-T;V-K(&]P=&EO;G,@=V%S(')E8V]G;FEZ960@;W9E<B!T:&4@<&5R
M:6]D('1H92!O<'1I;VYS('9E<W1E9"X@4VAA<F4M8F%S960@8V]M<&5N<V%T
M:6]N(')E;&%T:79E('1O('1H92!P97)F;W)M86YC92UB87-E9"!O<'1I;VYS
M('=I;&P@8F4@<F5C;V=N:7IE9"!O;FQY(&EF('1H92!P97)F;W)M86YC92!C
M<FET97)I;VX@:7,@;65T+B`\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4
M.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^(#QP('-T
M>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T
M)SY);B!A9&1I=&EO;BP@;VX@36%Y(#(U+"`R,#$Q('1H92!#;VUP86YY(&=R
M86YT960@,3(U+#`P,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K('5N9&5R('1H
M92`R,#$P($EN8V5N=&EV92!0;&%N('1O('1W;R!O9B!I=',@97AE8W5T:79E
M(&]F9FEC97)S('9A;'5E9"!A="`D,S$W+#4P,"!B87-E9"!O;B!T:&4@8VQO
M<VEN9R!M87)K970@<')I8V4@;VX@=&AE(&1A=&4@;V8@9W)A;G0@;V8@)#(N
M-30@<&5R('-H87)E+B!3<&5C:69I8V%L;'DL('1H92!#;VUP86YY(&=R86YT
M960@-S4L,#`P('-H87)E<R!O9B!R97-T<FEC=&5D('-T;V-K('1O(&ET<R!#
M:&EE9B!%>&5C=71I=F4@3V9F:6-E<BP@;V8@=VAI8V@@-3`L,#`P('-H87)E
M<R!V97-T960@;VX@36%Y(#(U+"`R,#$R+"!A;F0@,C4L,#`P('-H87)E<R!W
M97)E('1O('9E<W0@;VX@=&AE('-I>"UM;VYT:"!A;FYI=F5R<V%R>2!O9B!T
M:&4@86-H:65V96UE;G0@;V8@8V5R=&%I;B!P97)F;W)M86YC92UB87-E9"!V
M97-T:6YG(&-R:71E<FEA+"!A;F0@=&AE($-O;7!A;GD@9W)A;G1E9"`U,"PP
M,#`@<VAA<F5S(&]F(')E<W1R:6-T960@<W1O8VL@=&\@:71S(&9O<FUE<B!#
M:&EE9B!&:6YA;F-I86P@3V9F:6-E<BP@;V8@=VAI8V@@,C4L,#`P('-H87)E
M<R!V97-T960@;VX@07!R:6P@,C@L(#(P,3(@86YD(#(U+#`P,"!S:&%R97,@
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M97(@=&AE('!E<FEO9"!T:&4@<VAA<F5S('9E<W1E9"X\+W`^(#QP('-T>6QE
M/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF
M;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%2
M1TE..C!I;B`P:6X@,'!T)SY%9F9E8W1I=F4@07!R:6P@,C@L(#(P,3(L('1H
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M,3(N)FYB<W`[)FYB<W`[5&AE(&5F9F5C="!O9B!T:&4@86UE;F1M96YT('=A
M<R!T;R!T97)M:6YA=&4@82!T;W1A;"!O9B`Q.#4L,#`P('9E<W1E9"!B=70@
M=6YE>&5R8VES960@;W!T:6]N<R!I;6UE9&EA=&5L>2!O;B!!<')I;"`R."P@
M,C`Q,B!A<R!O<'!O<V5D('1O(#DP(&1A>7,@869T97(@=&AE(&5M<&QO>6UE
M;G0@=&5R;6EN871I;VX@9&%T92X@169F96-T:79E('1H92!S86UE(&1A=&4L
M('1H92!#;VUP86YY(&%W87)D960@,3`P+#`P,"!S:&%R97,@;V8@8V]M;6]N
M('-T;V-K('1O($UR+B!7875N9R!F;W(@:&ES('!R979I;W5S('-E<G9I8V4@
M=&\@=&AE($-O;7!A;GDN/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/B`\<"!S='EL
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M870@=V5R92!C86YC96QL960L(&DN92XL(#$X-2PP,#`@;W!T:6]N<R!W:71H
M(&$@9F%I<B!V86QU92!O9B`D,C(U(&EN(&5X8VAA;F=E(&9O<B`Q,#`L,#`P
M('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@=VET:"!A(&9A:7(@=F%L=64@;V8@
M)#4V+#`P,"!B87-E9"!O;B!T:&4@8VQO<VEN9R!M87)K970@<')I8V4@;V8@
M=&AE(&-O;6UO;B!S=&]C:R!O9B`D,"XU-B!P97(@<VAA<F4@;VX@=&AE(&1A
M=&4@87=A<F1E9"X@5&AE(&9A:7(@=F%L=64@;V8@=&AE('-T;V-K(&]P=&EO
M;G,@=V%S(&-O;7!U=&5D('5S:6YG('1H92!";&%C:RU38VAO;&5S($]P=&EO
M;B!0<FEC:6YG($UO9&5L+"!U<VEN9R!T:&4@9F]L;&]W:6YG(&%S<W5M<'1I
M;VYS.B!R:7-K(&9R964@:6YT97)E<W0@<F%T92!O9B`P+C$T)2!T;R`P+C$Y
M)2P@97AP96-T960@9&EV:61E;F0@>6EE;&0@;V8@,"4L(&5X<&5C=&5D('9O
M;&%T:6QI='D@;V8@-C8N-R4@86YD(&%N(&5X<&5C=&5D(&QI9F4@;V8@,"XU
M('1O(#$N,2!Y96%R<RX@/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/B`\<"!S='EL
M93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^
M3VX@07!R:6P@,C<@86YD(#(X+"`R,#$R(&$@=&]T86P@;V8@-3`L,#`P(&]P
M=&EO;G,@=&\@<'5R8VAA<V4@8V]M;6]N('-T;V-K(&=R86YT960@=6YD97(@
M=&AE(#(P,3`@26YC96YT:79E(%!L86X@=VET:"!A;B!E>&5R8VES92!P<FEC
M92!O9B`D,BXU-"!P97(@<VAA<F4@=V5R92!F;W)F96ET960@9'5E('1O('1H
M92!F86EL=7)E('1O(&%C:&EE=F4@=&AE('!E<F9O<FUA;F-E+6)A<V5D('9E
M<W1I;F<@8W)I=&5R:6$N(#PO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@<W1Y
M;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M/E1H92!#;VUP86YY(')E8V]G;FEZ960@)#$T,2PW,C`@86YD("0Q.38L,3@S
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M9"!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@=V%S("0S-2PT,S`@86YD("0T
M.2PP-#8@9F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,B!A
M;F0@,C`Q,2P@<F5S<&5C=&EV96QY+B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$
M)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S
M<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE.
M.C!I;B`P:6X@,'!T)SY4:&4@9F%I<B!V86QU92!O9B!E86-H(&]P=&EO;B!A
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M96-T(&%T('1H92!T:6UE(&]F(&=R86YT+B`\+W`^(#QP('-T>6QE/3-$)TQ)
M3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\
M+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)SY!('-U;6UA<GD@;V8@<W1O8VL@;W!T:6]N(&%C=&EV:71Y
M(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$R+"!A;F0@8VAA;F=E<R!D=7)I;F<@
M=&AE('EE87(@=&AE;B!E;F1E9"!I<R!P<F5S96YT960@8F5L;W<Z/"]P/B`\
M=&%B;&4@=VED=&@],T0U-#(@<W1Y;&4],T0G34%21TE..F%U=&\@875T;R!A
M=71O("TP+C<U<'0[(%=)1%1(.C0P-BXR<'0[($)/4D1%4BU#3TQ,05!313IC
M;VQL87!S92<@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,#X@/'1R
M/B`\=&0@=VED=&@],T0R,C<@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q-S!P=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^/"]T
M9#X@/'1D('=I9'1H/3-$-C@@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U,"XW<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%
M24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/CPO
M=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F
M,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X\+W1D
M/B`\=&0@=VED=&@],T0V-"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F
M,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I
M;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#0X<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(
M5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/CPO=&0^
M(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\
M=&0@=VED=&@],T0X,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8Q+C5P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M8V5N=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P
M="<@86QI9VX],T1C96YT97(^/&(^5V5I9VAT960M/"]B/CPO<#X\+W1D/B`\
M=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO
M<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^/"]T9#X@/'1D
M('=I9'1H/3-$-C4@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`T.7!T.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X\+W1D/CPO='(^
M(#QT<CX@/'1D('=I9'1H/3-$,C(W('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3<P<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R
M+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG
M+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P
M/CPO=&0^(#QT9"!W:61T:#TS1#8X('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3`N-W!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.
M12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO
M<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M
M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M
M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M
M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^
M/"]T9#X@/'1D('=I9'1H/3-$-C0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M
M.B`P:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`T.'!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT
M;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT
M;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P
M:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\8CY796EG:'1E9"T\+V(^/"]P/CPO
M=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F
M,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X\+W1D
M/B`\=&0@=VED=&@],T0X,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F
M,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I
M;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8Q+C5P=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ8V5N=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN
M(#!P="<@86QI9VX],T1C96YT97(^/&(^079E<F%G93PO8CX\+W`^/"]T9#X@
M/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F
M,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/CPO=&0^(#QT
M9"!W:61T:#TS1#8U('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-#EP=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO
M<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^/"]T9#X\+W1R
M/B`\='(^(#QT9"!W:61T:#TS1#(R-R!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$W,'!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.
M12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO
M<#X\+W1D/B`\=&0@=VED=&@],T0V."!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4P+C=P=#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D
M97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I
M;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)
M3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\
M+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R
M+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG
M+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P
M/CPO=&0^(#QT9"!W:61T:#TS1#8T('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-#AP=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M
M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M
M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ8V5N=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@
M,&EN(#!P="<@86QI9VX],T1C96YT97(^/&(^079E<F%G93PO8CX\+W`^/"]T
M9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(
M5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/CPO=&0^
M(#QT9"!W:61T:#TS1#@R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C$N-7!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@
M,'!T)R!A;&EG;CTS1&-E;G1E<CX\8CY296UA:6YI;F<\+V(^/"]P/CPO=&0^
M(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\
M=&0@=VED=&@],T0V-2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#0Y<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E
M;G1E<CL@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M(&%L:6=N/3-$8V5N=&5R/CQB/D%G9W)E9V%T93PO8CX\+W`^/"]T9#X\+W1R
M/B`\='(^(#QT9"!W:61T:#TS1#(R-R!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$W,'!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.
M12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO
M<#X\+W1D/B`\=&0@=VED=&@],T0V."!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4P+C=P=#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D
M97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I
M;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)
M3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\
M+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R
M+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG
M+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P
M/CPO=&0^(#QT9"!W:61T:#TS1#8T('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-#AP=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M
M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M
M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ8V5N=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@
M,&EN(#!P="<@86QI9VX],T1C96YT97(^/&(^17AE<F-I<V4\+V(^/"]P/CPO
M=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F
M,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X\+W1D
M/B`\=&0@=VED=&@],T0X,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F
M,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I
M;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8Q+C5P=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ8V5N=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN
M(#!P="<@86QI9VX],T1C96YT97(^/&(^0V]N=')A8W1U86P@/"]B/CPO<#X\
M+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^/"]T
M9#X@/'1D('=I9'1H/3-$-C4@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`T.7!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@
M,'!T)R!A;&EG;CTS1&-E;G1E<CX\8CY);G1R:6YS:6,\+V(^/"]P/CPO=&0^
M/"]T<CX@/'1R/B`\=&0@=VED=&@],T0R,C<@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M
M8F]T=&]M.B`P:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q-S!P
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B
M;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A
M9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$
M)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S
M<#L\+W`^/"]T9#X@/'1D('=I9'1H/3-$-C@@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F
M,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!W:61T:#H@-3`N-W!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F%C:V=R
M;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4
M.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\
M8CY3:&%R97,\+V(^/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P
M.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W
M:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@
M=VAI=&4[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA
M;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\8CXF;F)S
M<#L\+V(^/"]P/CPO=&0^(#QT9"!W:61T:#TS1#8T('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#0X<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B86-K
M9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I
M9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.12U(14E'
M2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R
M/CQB/E!R:6-E/"]B/CPO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F
M,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z
M('=H:71E.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!,24Y%+4A%24=(5#IN;W)M
M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^/&(^)FYB
M<W`[/"]B/CPO<#X\+W1D/B`\=&0@=VED=&@],T0X,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z
M("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('=I9'1H.B`V,2XU<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B
M86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.12U(
M14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N
M=&5R/CQB/E1E<FT@*%EE87)S*3PO8CX\+W`^/"]T9#X@/'1D('=I9'1H/3-$
M,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B
M86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)
M3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/CPO=&0^(#QT9"!W:61T:#TS1#8U
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#0Y<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E
M;G1E<CL@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M(&%L:6=N/3-$8V5N=&5R/CQB/E9A;'5E/"]B/CPO<#X\+W1D/CPO='(^(#QT
M<CX@/'1D('=I9'1H/3-$,C(W('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F
M,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3<P<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%
M24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^3W5T<W1A;F1I;F<@
M870@1&5C96UB97(@,S$L(#(P,3$\+W`^/"]T9#X@/'1D('=I9'1H/3-$-C@@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z
M("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('=I9'1H.B`U,"XW<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B
M86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)
M3CHP:6X@,&EN(#!P="<^)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#,Q,"PP
M,#`@/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O
M<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D
M9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G
M3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P
M.SPO<#X\+W1D/B`\=&0@=VED=&@],T0V-"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#0X<'0[
M('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,
M24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[
M)"9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`S
M+C`S(#PO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B
M;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A
M9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$
M)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S
M<#L\+W`^/"]T9#X@/'1D('=I9'1H/3-$.#(@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M
M8F]T=&]M.B`P:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,2XU
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS
M1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^/&(^
M)FYB<W`[/"]B/CPO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED
M=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H
M:71E.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T
M>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T
M)SXF;F)S<#L\+W`^/"]T9#X@/'1D('=I9'1H/3-$-C4@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H
M.B`T.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI
M=&4[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F
M,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y
M;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M/CQB/B9N8G-P.SPO8CX\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS
M1#(R-R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M
M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#$W,'!T.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O
M<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!4
M15A4+4E.1$5.5#HQ,'!T.R!-05)'24XZ,&EN(#!I;B`P<'0G/D9O<F9E:71E
M9#PO<#X\+W1D/B`\=&0@=VED=&@],T0V."!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4P+C=P
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B
M;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A
M9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$
M)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S
M<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@*#4P+#`P,"D\+W`^/"]T9#X@
M/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F
M,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^/&(^)FYB<W`[/"]B/CPO<#X\
M+W1D/B`\=&0@=VED=&@],T0V-"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#0X<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%
M24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[)FYB<W`[
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB
M<W`[(#(N-30@/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T
M:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI
M=&4[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F
M,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y
M;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M/B9N8G-P.SPO<#X\+W1D/B`\=&0@=VED=&@],T0X,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z
M(#8Q+C5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H
M:71E.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T
M>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T
M)SX\8CXF;F)S<#L\+V(^/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F
M,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N
M9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@
M/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I
M;B`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=VED=&@],T0V-2!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F
M,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#0Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD
M.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C
M9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\
M<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN
M(#!P="<^/&(^)FYB<W`[/"]B/CPO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I
M9'1H/3-$,C(W('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O
M<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3<P<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F
M,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M
M86P[(%1%6%0M24Y$14Y4.C$P<'0[($U!4D=)3CHP:6X@,&EN(#!P="<^17AP
M:7)E9#PO<#X\+W1D/B`\=&0@=VED=&@],T0V."!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('=I9'1H.B`U,"XW<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B86-K
M9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I
M9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP
M:6X@,&EN(#!P="<^)FYB<W`[)FYB<W`[)FYB<W`[("@R,S4L,#`P*3PO<#X\
M+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SX\8CXF;F)S<#L\+V(^
M/"]P/CPO=&0^(#QT9"!W:61T:#TS1#8T('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O
M='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-#AP=#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D
M97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I
M;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)
M3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#LF
M;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#LF;F)S<#L@,RXQ.2`\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P
M9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD
M.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C
M9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\
M<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN
M(#!P="<^)FYB<W`[/"]P/CPO=&0^(#QT9"!W:61T:#TS1#@R('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P
M.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W
M:61T:#H@-C$N-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N
M9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@
M/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I
M;B`P<'0G/CQB/B9N8G-P.SPO8CX\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z
M("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B86-K
M9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I
M9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP
M:6X@,&EN(#!P="<^)FYB<W`[/"]P/CPO=&0^(#QT9"!W:61T:#TS1#8U('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C
M9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@-#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)A8VMG
M<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)SX\8CXF;F)S<#L\+V(^/"]P/CPO=&0^/"]T<CX@/'1R/B`\
M=&0@=VED=&@],T0R,C<@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F
M,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q-S!P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4
M.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SX\8CY/=71S=&%N9&EN9R!A
M="!$96-E;6)E<B`S,2P@,C`Q,CPO8CX\+W`^/"]T9#X@/'1D('=I9'1H/3-$
M-C@@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L
M:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3`N-W!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.R9N8G-P.R9N
M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`R-2PP,#`@/"]P/CPO=&0^(#QT9"!W
M:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O
M<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=VED
M=&@],T0V-"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P
M="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M
M.B`P:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`T.'!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT
M;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT
M;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(
M14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.R0F;F)S
M<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@,BXU-"`\
M+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R
M+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG
M+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P
M/CPO=&0^(#QT9"!W:61T:#TS1#@R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED
M=&@Z(#8Q+C5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z
M('=H:71E.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP
M('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@
M,'!T)SXF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF
M;F)S<#LF;F)S<#L@,"XT,"`\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B86-K9W)O
M=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@
M,&EN(#!P="<^)FYB<W`[/"]P/CPO=&0^(#QT9"!W:61T:#TS1#8U('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#0Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@
M8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[
M($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[)"9N8G-P.R9N8G-P.R9N8G-P
M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N
M8G-P.R`M)FYB<W`[)FYB<W`[(#PO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I
M9'1H/3-$,C(W('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O
M<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3<P<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F
M,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M
M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^/&(^17AE<F-I<V%B;&4@870@1&5C
M96UB97(@,S$L(#(P,3(\+V(^/"]P/CPO=&0^(#QT9"!W:61T:#TS1#8X('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4P+C=P=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO
M<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#LF;F)S<#LF;F)S<#LF
M;F)S<#LF;F)S<#LF;F)S<#L@,C4L,#`P(#PO<#X\+W1D/B`\=&0@=VED=&@]
M,T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M
M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%2
M1TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^/"]T9#X@/'1D('=I9'1H/3-$
M-C0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L
M:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-#AP=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4
M.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#LD)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#(N-30@/"]P/CPO
M=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F
M,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X\+W1D
M/B`\=&0@=VED=&@],T0X,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD
M;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V
M,2XU<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET
M93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P
M.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL
M93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[
M)FYB<W`[(#`N-#`@/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P
M.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W
M:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@
M=VAI=&4[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@
M<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P
M<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=VED=&@],T0V-2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('=I9'1H.B`T.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E
M<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'
M24XZ,&EN(#!I;B`P<'0G/B9N8G-P.R0F;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@
M+29N8G-P.R9N8G-P.R`\+W`^/"]T9#X\+W1R/CPO=&%B;&4^(#QP('-T>6QE
M/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF
M;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%2
M1TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M
M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^
M(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P
M:6X@,'!T)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO
M<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SY!="!$96-E;6)E<B`S,2P@,C`Q
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M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?930P9C8S-C!?.#`T95\T-S4Y7V%F,3)?
M,V)A864S.61C,3@V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4T
M,&8V,S8P7S@P-&5?-#<U.5]A9C$R7S-B86%E,SED8S$X-B]7;W)K<VAE971S
M+U-H965T,3@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY#3TU-251-14Y44R!!3D0@0T].5$E.1T5.0TE%4SQB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#3TU-251-
M14Y44R!!3D0@0T].5$E.1T5.0TE%4SPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#3TU-251-14Y44R!!3D0@0T].5$E.1T5.
M0TE%4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+65G>"TM
M/CQP('-T>6QE/3-$)TU!4D=)3CHP:6X@,&EN(#$P<'0[(%1%6%0M05543U-0
M04-%.B<^/&(^3D]412`Q,B`F(S$U,#L@0T]-34E4345.5%,@04Y$($-/3E1)
M3D=%3D-)15,\+V(^/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M
M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/B`\<"!S='EL93TS
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M=&AE($-O;7!A;GDF(S$T-CMS(&]P97)A=&EO;G,N/"]P/B`\<"!S='EL93TS
M1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB
M<W`[/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)
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M(%!20R!G;W9E<FYM96YT+CPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@<W1Y
M;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M/D-O;G1R86-T=6%L($-O;6UI=&UE;G1S("8C,34P.R!4:&4@0V]M<&%N>2!E
M;G1E<F5D(&EN=&\@<'5R8VAA<V4@86YD(&-O;G-T<G5C=&EO;B!A9W)E96UE
M;G1S(&1U<FEN9R!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,B!I
M;B!C;VYN96-T:6]N('=I=&@@=&AE(&-O;G-T<G5C=&EO;B!O9B!A(&YE=R!F
M86-I;&ET>2!A;F0@<F5Q=6ER960@;6%N=69A8W1U<FEN9R!I;7!R;W9E;65N
M=',N("9N8G-P.U5N9&5R('1H97-E(&%G<F5E;65N=',L('1H92!#;VUP86YY
M(&UA9&4@<&%Y;65N=',@:6X@=&AE(&%M;W5N="!O9B`D,RPQ,3`L,S$Y(&1U
M<FEN9R!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,BX@5&AE<V4@
M<&%Y;65N=',@87)E(&-L87-S:69I960@87,@8V]N<W1R=6-T:6]N(&EN('!R
M;V=R97-S(&]N('1H92!A8V-O;7!A;GEI;F<@8F%L86YC92!S:&5E="!A="!$
M96-E;6)E<B`S,2P@,C`Q,BX@1G5T=7)E(&UI;FEM=6T@8V]M;6ET;65N=',@
M=6YD97(@=&AE(&%G<F5E;65N=',@87)E(&%S(&9O;&QO=W,Z/"]P/B`\=&%B
M;&4@=VED=&@],T0S-#$@<W1Y;&4],T0G34%21TE..F%U=&\@875T;R!A=71O
M("TP+C<U<'0[(%=)1%1(.C(U-G!T.R!"3U)$15(M0T],3$%04T4Z8V]L;&%P
M<V4G(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`^(#QT<CX@/'1D
M('=I9'1H/3-$,C4U('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#$Y,7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,
M24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^/&(^1F]R
M('1H92!996%R<R!%;F1I;F<@1&5C96UB97(@,S$Z/"]B/CPO<#X\+W1D/B`\
M=&0@=VED=&@],T0X-R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('=I9'1H.B`V-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#(U
M-2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F
M=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC
M;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H
M.B`Q.3%P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[(%1%6%0M24Y$
M14Y4.C$Q<'0[($U!4D=)3CHP:6X@,&EN(#!P="<^,C`Q,SPO<#X\+W1D/B`\
M=&0@=VED=&@],T0X-R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('=I9'1H.B`V-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA
M;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#LD(#$S+#$S,RPT.3@@/"]P
M/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0R-34@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R
M96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3DQ<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)SX@/'`@<W1Y;&4]
M,T0G3$E.12U(14E'2%0Z;F]R;6%L.R!415A4+4E.1$5.5#HQ,7!T.R!-05)'
M24XZ,&EN(#!I;B`P<'0G/C(P,30\+W`^/"]T9#X@/'1D('=I9'1H/3-$.#<@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z
M("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L
M;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@
M-C5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@
M,&EN(#!P="<^)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[
M)FYB<W`[(#DV."PX-C`@/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@]
M,T0R-34@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R
M+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U
M;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W
M:61T:#H@,3DQ<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)SX@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!415A4
M+4E.1$5.5#HQ,7!T.R!-05)'24XZ,&EN(#!I;B`P<'0G/E1O=&%L/"]P/CPO
M=&0^(#QT9"!W:61T:#TS1#@W('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I
M;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V-7!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@=VEN9&]W=&5X="`Q<'0@<V]L
M:60[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@
M,&EN(#!P="<^)FYB<W`[)"`Q-"PQ,#(L,S4X(#PO<#X\+W1D/CPO='(^(#QT
M<CX@/'1D('=I9'1H/3-$,C4U('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F
M,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#$Y,7!T.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P
M.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT
M9"!W:61T:#TS1#@W('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#8U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D
M97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I
M;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X\+W1R/CPO=&%B
M;&4^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)SXF;F)S<#L\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%]E-#!F-C,V,%\X,#1E7S0W-3E?868Q,E\S8F%A
M93,Y9&,Q.#8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO930P9C8S
M-C!?.#`T95\T-S4Y7V%F,3)?,V)A864S.61C,3@V+U=O<FMS:&5E=',O4VAE
M970Q.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/D-/3D-%3E12051)3TY3/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D-/3D-%3E12051)3TY3/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-/3D-%3E12051)3TY3
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM96=X+2T^/'`@
M<W1Y;&4],T0G34%21TE..C!I;B`P:6X@,3!P=#L@5$585"U!551/4U!!0T4Z
M)SX\8CY.3U1%(#$S("8C,34P.R!#3TY#14Y44D%424].4SPO8CX\+W`^(#QP
M('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@
M,'!T)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA
M;#L@34%21TE..C!I;B`P:6X@,'!T)SY&;W(@=&AE('EE87(@96YD960@1&5C
M96UB97(@,S$L(#(P,3$L(&$@8W5S=&]M97(@86-C;W5N=&5D(&9O<B`R,"XT
M)2!O9B!S86QE<R!A;F0@870@1&5C96UB97(@,S$L(#(P,3$L(&]N92!C=7-T
M;VUE<B!A8V-O=6YT960@9F]R(#$P+C(E(&]F(&%C8V]U;G1S(')E8V5I=F%B
M;&4N($9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,2P@<'5R
M8VAA<V5S(&9R;VT@82!S=7!P;&EE<B!M861E('5P(#(P+C@E(&]F(')A=R!M
M871E<FEA;"!P=7)C:&%S97,N(#PO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@
M<W1Y;&4],T0G34%21TE..C!I;B`P:6X@,3!P=#L@5$585"U!551/4U!!0T4Z
M)SX\9F]N="!S='EL93TS1$Q)3D4M2$5)1TA4.C$Q-24^1F]R('1H92!Y96%R
M(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$R+"!N;R!C=7-T;VUE<B!A8V-O=6YT
M960@9F]R(&UO<F4@=&AA;B`Q,"4@;V8@<V%L97,@;W(@96YD:6YG(&%C8V]U
M;G1S(')E8V5I=F%B;&4N(%1W;R!S=7!P;&EE<G,@86-C;W5N=&5D(&9O<B`Q
M,BXQ)2!A;F0@,3`N,R4L(')E<W!E8W1I=F5L>2P@;V8@=&AE(')A=R!M871E
M<FEA;',@)FYB<W`[=&AE($-O;7!A;GD@<'5R8VAA<V5D(&1U<FEN9R!T:&4@
M>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,BX\+V9O;G0^/"]P/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?930P9C8S-C!?
M.#`T95\T-S4Y7V%F,3)?,V)A864S.61C,3@V#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V4T,&8V,S8P7S@P-&5?-#<U.5]A9C$R7S-B86%E,SED
M8S$X-B]7;W)K<VAE971S+U-H965T,C`N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5*1T%%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D%C8V]U;G1I;F<@4&]L:6-I97,@*%!O
M;&EC:65S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY!8V-O=6YT:6YG(%!O;&EC:65S("A0;VQI8VEE<RD\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W)G86YI
M>F%T:6]N(&%N9"!.871U<F4@;V8@3W!E<F%T:6]N<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/"$M+65G>"TM/CQP('-T>6QE/3-$)TQ)3D4M
M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SX\8CY/<F=A;FEZ
M871I;VX@86YD($YA='5R92!O9B!/<&5R871I;VYS/"]B/B`F(S$U,#L@0VAI
M;F$@4&AA<FUA($AO;&1I;F=S+"!);F,N+"!A($YE=F%D82!C;W)P;W)A=&EO
M;B!A<R!O9B!$96-E;6)E<B`S,2P@,C`Q,BP@;W=N<R`Q,#`E(&]F($]N;GD@
M26YV97-T;65N="!,:6UI=&5D("A/;FYY*2P@82!"<FET:7-H(%9I<F=I;B!)
M<VQA;F1S(&-O<G!O<F%T:6]N+"!T:&%T(&EN('1U<FX@;W=N<R`Q,#`E(&]F
M($AA:6YA;B!(96QP<V]N($UE9&EC86P@)F%M<#L@0FEO=&5C:&YO;&]G>2!#
M;RXL($QT9"`H2&5L<'-O;BDL(&$@8V]M<&%N>2!O<F=A;FEZ960@=6YD97(@
M=&AE(&QA=W,@;V8@=&AE(%!E;W!L92=S(%)E<'5B;&EC(&]F($-H:6YA("AT
M:&4@4%)#*2X@0VAI;F$@4&AA<FUA($AO;&1I;F=S+"!);F,N(&%N9"!I=',@
M<W5B<VED:6%R:65S(&%R92!R969E<G)E9"!T;R!H97)E:6X@87,@=&AE($-O
M;7!A;GDN)FYB<W`[(#PO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@<W1Y;&4]
M,T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/D]N
M($1E8V5M8F5R(#,Q+"`R,#$R+"!#:&EN82!0:&%R;6$@2&]L9&EN9W,L($EN
M8R!C;VYS=6UM871E9"!A(')E:6YC;W)P;W)A=&EO;B!M97)G97(@9F]R('1H
M92!P=7)P;W-E(&]F(&-H86YG:6YG('1H92!S=&%T92!O9B!I;F-O<G!O<F%T
M:6]N(&9R;VT@1&5L87=A<F4@=&\@3F5V861A('!U<G-U86YT('1O('1H92!T
M97)M<R!A;F0@8V]N9&ET:6]N<R!O9B!A;B!!9W)E96UE;G0@86YD(%!L86X@
M;V8@365R9V5R(&1A=&5D($1E8V5M8F5R(#(W+"`R,#$R+B9N8G-P.R!4:&4@
M<F5I;F-O<G!O<F%T:6]N(&UE<F=E<B!W87,@87!P<F]V960@8GD@<W1O8VMH
M;VQD97)S(&AO;&1I;F<@=&AE(&UA:F]R:71Y(&]F('1H92!O=71S=&%N9&EN
M9R!C;VUM;VX@<VAA<F5S(&]N($1E8V5M8F5R(#(Q+"`R,#$R+CPO<#X@/'`@
M<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P
M<'0G/B9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G/E1H92!&;W)E:6=N($EN=F5S=&UE;G0@
M26YD=7-T<FEA;"!#871A;&]G=64F;F)S<#LH=&AE("8C,30W.T-A=&%L;V=U
M928C,30X.RD@:F]I;G1L>2!I<W-U960@8GD@=&AE($-H:6YA)B,Q-#8[<R!-
M:6YI<W1R>2!O9B!#;VUM97)C92!A;F0@=&AE($YA=&EO;F%L($1E=F5L;W!M
M96YT(&%N9"!2969O<FT@0V]M;6ES<VEO;B`H87,@=&AE(&QA=&5S="!V97)S
M:6]N(&ES('1H92!Y96%R(#(P,3(@=F5R<VEO;BP@969F96-T:79E($IA;G5A
M<GD@,S`L(#(P,3(I(&-L87-S:69I960@=F%R:6]U<R!I;F1U<W1R:65S+V)U
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M87-E(&]F('1H92!#;VUP86YY)B,Q-#8[<R!B=7-I;F5S<RX\+W`^(#QP('-T
M>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T
M)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@
M34%21TE..C!I;B`P:6X@,'!T)SY(96QP<V]N(&UA;G5F86-T=7)E<R!A;F0@
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M=VYE<G-H:7`@<F5S=')I8W1I;VYS('!R97-C<FEB960@=6YD97(@=&AE($-A
M=&%L;V=U92X@3VYN>2!A8W%U:7)E9"`Q,#`E(&]F('1H92!O=VYE<G-H:7`@
M:6X@2&5L<'-O;B!F<F]M($AE;'!S;VXF(S$T-CMS('1H<F5E(&9O<FUE<B!S
M:&%R96AO;&1E<G,@;VX@36%Y(#(U+"`R,#`U(&)Y(&5N=')Y(&EN=&\@86X@
M17%U:71Y(%1R86YS9F5R($%G<F5E;65N="!W:71H('-U8V@@=&AR964@<&%R
M=&EE<R!O;B!-87D@,C4L(#(P,#4N(%1H92!T<F%N<V%C=&EO;B!W87,@87!P
M<F]V960@8GD@=&AE($-O;6UE<F-I86P@0G5R96%U(&]F($AA:6YA;B!0<F]V
M:6YC92!O;B!*=6YE(#$R+"`R,#`U(&%N9"!(96QP<V]N(')E8V5I=F5D('1H
M92!#97)T:69I8V%T92!O9B!!<'!R;W9A;"!F;W(@17-T86)L:7-H:6YG(&]F
M($5N=&5R<')I<V5S('=I=&@@1F]R96EG;B!);G9E<W1M96YT(&EN('1H92!0
M4D,@;VX@=&AE('-A;64@9&%Y(&%N9"!I=',@8G5S:6YE<W,@;&EC96YS92!E
M=FED96YC:6YG(&ET<R!71D]%("A7:&]L;'D@1F]R96EG;B!/=VYE9"!%;G1E
M<G!R:7-E*2!S=&%T=7,@;VX@2G5N92`R,2P@,C`P-2X\+W`^(#QP('-T>6QE
M/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF
M;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%2
M1TE..C!I;B`P:6X@,'!T)SY4:&4@0V]M<&%N>2!H87,@86YD(&-O;G1I;G5E
M<R!T;R!A8W%U:7)E('=E;&PM86-C97!T960@;65D:6-A;"!F;W)M=6QA<R!T
M;R!A(&1I=F5R<V4@<&]R=&9O;&EO(&]F(%=E<W1E<FX@86YD($-H:6YE<V4@
M;65D:6-I;F5S+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;G-O;&ED871I;VX@86YD($)A<VES(&]F(%!R
M97-E;G1A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M
M+65G>"TM/CQP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE.
M.C!I;B`P:6X@,'!T)SX\8CY#;VYS;VQI9&%T:6]N(&%N9"!"87-I<R!O9B!0
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M;G,@:&%V92!B965N(&5L:6UI;F%T960@:6X@8V]N<V]L:61A=&EO;BX\+W`^
M(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P
M:6X@,'!T)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO
M<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SY(96QP<V]N)B,Q-#8[<R!F=6YC
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M+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E)E8VQA<W-I9FEC871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CPA+2UE9W@M+3X\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^/&(^4F5C;&%S<VEF:6-A=&EO
M;B`\+V(^+2!4:&4@0V]M<&%N>2!H87,@;6%D92!C97)T86EN(')E8VQA<W-I
M9FEC871I;VYS('1O('1H92!C;VYS;VQI9&%T960@8F%L86YC92!S:&5E="!A
M="!$96-E;6)E<B`S,2P@,C`Q,2!T;R!C;VYF;W)M('1O('1H92!$96-E;6)E
M<B`S,2P@,C`Q,B!P<F5S96YT871I;VXN(%1H97-E(')E8VQA<W-I9FEC871I
M;VYS(&AA9"!N;R!E9F9E8W0@;VX@=&AE(&-O;G-O;&ED871E9"!S=&%T96UE
M;G1S(&]F(&]P97)A=&EO;G,@;W(@8V%S:"!F;&]W<R!F;W(@86YY('!E<FEO
M9',@<')E<V5N=&5D+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1I;F<@17-T:6UA=&5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM96=X+2T^/'`@<W1Y;&4]
M,T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQB
M/D%C8V]U;G1I;F<@17-T:6UA=&5S/"]B/B`M(%1H92!P<F5P87)A=&EO;B!O
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M=&5S+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-A<V@@86YD($-A<V@@17%U:79A;&5N=',@4&]L:6-Y/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM96=X+2T^/'`@<W1Y
M;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
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M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R861E($%C8V]U;G1S(%)E
M8V5I=F%B;&4@86YD($%L;&]W86YC92!F;W(@1&]U8G1F=6P@06-C;W5N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2UE9W@M+3X\<"!S
M='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P
M="<^/&(^5')A9&4@06-C;W5N=',@4F5C96EV86)L92!A;F0@06QL;W=A;F-E
M(&9O<B!$;W5B=&9U;"!!8V-O=6YT<SPO8CX@)B,Q-3`[(%1R861E(&%C8V]U
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M92!F;W(@9&]U8G1F=6P@86-C;W5N=',N($%T($1E8V5M8F5R(#,Q+"`R,#$R
M+"!T<F%D92!A8V-O=6YT<R!R96-E:79A8FQE<R!I;F-L=61E9"`D,S`L,3,T
M+#DP.2!F<F]M('-A;&5S('1H870@;V-C=7)R960@;6]R92!T:&%N(&]N92!Y
M96%R('!R:6]R('1O($1E8V5M8F5R(#,Q+"`R,#$R+"!T:&%T($UA;F%G96UE
M;G0@8F5L:65V97,@87)E(&-O;&QE8W1A8FQE+CPO<#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D=F%N8V5S('1O
M(%-U<'!L:65R<R!A;F0@061V86YC97,@9G)O;2!#=7-T;VUE<G,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2UE9W@M+3X\<"!S='EL93TS
M1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^/&(^
M061V86YC97,@=&\@4W5P<&QI97)S(&%N9"!!9'9A;F-E<R!F<F]M($-U<W1O
M;65R<SPO8CX@)B,Q-3`[($-O;6UO;B!P<F%C=&EC92!I;B!T:&4@4%)#(&ES
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M8V5I=F%B;&4@=VAE;B!F:6YI<VAE9"!P<F]D=6-T<R!A<F4@<V]L9"X\+W`^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y);G9E;G1O<GDN4&]L:6-Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\(2TM96=X+2T^/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQB/DEN=F5N=&]R>2`\+V(^)B,Q-3`[
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M;F-E(')E<V5R=F4@;V8@)#$L-S8Y+#DX-"!A;F0@)#`@9F]R('1H92!Y96%R
M<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,B!A;F0@,C`Q,2P@<F5S<&5C=&EV
M96QY+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E9A;'5A=&EO;B!O9B!,;VYG+4QI=F5D($%S<V5T<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+65G>"TM/CQP('-T>6QE
M/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SX\
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M<V5T<R!A="!$96-E;6)E<B`S,2P@,C`Q,B!A;F0@9&5T97)M:6YE9"!T:&%T
M('1H92!V86QU92!O9B!C97)T86EN(&]F(&ET<R!I;G1A;F=I8FQE(&%S<V5T
M<R!W97)E(&EM<&%I<F5D(&%N9"!R96-O9VYI>F5D(&%N(&EM<&%I<FUE;G0@
M;&]S<R!O9B`D-3DS+#`Y-2!F;W(@=&AE('EE87(@96YD960@1&5C96UB97(@
M,S$L(#(P,3(N($YO(&EM<&%I<FUE;G0@=V%S(')E8V]G;FEZ960@9'5R:6YG
M('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$Q+B9N8G-P.R!3964@
M3F]T92`T+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0@4&]L:6-Y/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM96=X+2T^/'`@<W1Y
M;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M/CQB/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0\+V(^("8C,34P.R!0<F]P97)T
M>2!A;F0@97%U:7!M96YT(&%R92!S=&%T960@870@8V]S="X@36%I;G1E;F%N
M8V4@86YD(')E<&%I<G,@87)E(&-H87)G960@=&\@97AP96YS92!A<R!I;F-U
M<G)E9"!A;F0@;6%J;W(@:6UP<F]V96UE;G1S(&%R92!C87!I=&%L:7IE9"X@
M1V%I;G,@;W(@;&]S<V5S(&]N('-A;&4L('1R861E+6EN(&]R(')E=&ER96UE
M;G0@87)E(&EN8VQU9&5D(&EN(&]P97)A=&EO;G,@9'5R:6YG('1H92!P97)I
M;V0@;V8@9&ES<&]S:71I;VXN/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU92!296-O9VYI=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+65G>"TM/CQP('-T
M>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T
M)SX\8CY2979E;G5E(%)E8V]G;FET:6]N/"]B/B`F(S$U,#L@4F5V96YU92!I
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M9"X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;W-T(&]F(%)E=F5N=65S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\(2TM96=X+2T^/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQB/D-O<W0@;V8@4F5V96YU
M97,\+V(^("8C,34P.R!#;W-T(&]F(')E=F5N=65S(&EN8VQU9&5S('=A9V5S
M+"!M871E<FEA;',L(&AA;F1L:6YG(&-H87)G97,L(&%N9"!O=&AE<B!E>'!E
M;G-E<R!A<W-O8VEA=&5D('=I=&@@=&AE(&UA;G5F86-T=7)E(&%N9"!D96QI
M=F5R>2!O9B!P<F]D=6-T<RX\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4
M.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E
M87)C:"!A;F0@1&5V96QO<&UE;G0N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\(2TM96=X+2T^/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQB/E)E<V5A<F-H(&%N9"!$979E
M;&]P;65N=#PO8CX@)B,Q-3`[(%)E<V5A<F-H(&%N9"!D979E;&]P;65N="!E
M>'!E;F1I='5R97,@87)E(')E8V]R9&5D(&%S(&5X<&5N<V5S(&EN('1H92!P
M97)I;V0@:6X@=VAI8V@@=&AE>2!O8V-U<BX@4F5S96%R8V@@86YD(&1E=F5L
M;W!M96YT(&-O<W1S('=E<F4@;F]T(&UA=&5R:6%L(&1U<FEN9R!T:&4@>65A
M<G,@96YD960@1&5C96UB97(@,S$L(#(P,3(@86YD(#(P,3$N)FYB<W`[/"]P
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5T:7)E;65N="!"96YE9FET(%!L86YS/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\(2TM96=X+2T^/'`@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQB/E)E=&ER96UE;G0@
M0F5N969I="!0;&%N<SPO8CX@)B,Q-3`[(%1H92!#;VUP86YY(&ES(')E<75I
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M:&4@0V]M<&%N>2!C;VYT<FEB=71E9"`D,C,S+#@T-B!A;F0@)#$V-BPP-S$@
M=&\@<F5T:7)E;65N="!B96YE9FET('!L86YS(&9O<B!T:&4@>65A<G,@96YD
M960@1&5C96UB97(@,S$L(#(P,3(@86YD(#(P,3$L(')E<W!E8W1I=F5L>2X@
M0V]N=')I8G5T:6]N<R!T;R!T:&5S92!P;&%N<R!A<F4@8VAA<F=E9"!T;R!E
M>'!E;G-E(&%S(&EN8W5R<F5D+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D=F5R=&ES:6YG($-O<W1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM96=X+2T^/'`@<W1Y
M;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M/CQB/D%D=F5R=&ES:6YG($-O<W1S/"]B/B`F(S$U,#L@061V97)T:7-I;F<@
M8V]S=',@87)E(&5X<&5N<V5D('=H96X@:6YC=7)R960N(%1H92!#;VUP86YY
M(&1I9"!N;W0@:6YC=7(@86YY(&%D=F5R=&ES:6YG(&-O<W1S(&9O<B!T:&4@
M>65A<G,@96YD960@1&5C96UB97(@,S$L(#(P,3(@86YD(#(P,3$N/"]P/B`\
M<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN
M(#!P="<^)FYB<W`[/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0F%S:6,@86YD($1I;'5T960@16%R;FEN9W,@
M<&5R($-O;6UO;B!3:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/"$M+65G>"TM/CQP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@
M34%21TE..C!I;B`P:6X@,'!T)SX\8CY"87-I8R!A;F0@1&EL=71E9"!%87)N
M:6YG<R!P97(@0V]M;6]N(%-H87)E/"]B/B`M($)A<VEC(&5A<FYI;F=S('!E
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M('-H87)E<RX\+W`^(#QT86)L92!W:61T:#TS1#0Y,R!S='EL93TS1"=-05)'
M24XZ875T;R!A=71O(&%U=&\@+3`N-S5P=#L@5TE$5$@Z,S<P<'0[($)/4D1%
M4BU#3TQ,05!313IC;VQL87!S92<@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C
M:6YG/3-$,#X@/'1R/B`\=&0@=VED=&@],T0S-#$@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,C4V<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^/"]T9#X@/'1D('=I9'1H/3-$,34R(&-O;'-P86X],T0S('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P
M.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N
M<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$Q-'!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.
M12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$
M8V5N=&5R/CQB/D9O<B!T:&4@665A<G,@16YD960\+V(^/"]P/CPO=&0^/"]T
M<CX@/'1R/B`\=&0@=VED=&@],T0S-#$@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,C4V<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1T;W`^/"]T9#X@
M/'1D('=I9'1H/3-$,34R(&-O;'-P86X],T0S('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q,31P
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIC96YT97([
M($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG
M;CTS1&-E;G1E<CX\8CY$96-E;6)E<B`S,2P\+V(^/"]P/CPO=&0^/"]T<CX@
M/'1R/B`\=&0@=VED=&@],T0S-#$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M
M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@,C4V<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1T;W`^/"]T9#X@/'1D
M('=I9'1H/3-$-S$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O
M='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4S+C5P=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO
M<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\8CXR
M,#$R/"]B/CPO<#X\+W1D/B`\=&0@=VED=&@],T0R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$N.#5P=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR
M:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;3X\+W1D/B`\=&0@=VED=&@],T0W."!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P
M9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R
M86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3@N-C5P
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIC96YT97([
M($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG
M;CTS1&-E;G1E<CX\8CXR,#$Q/"]B/CPO<#X\+W1D/CPO='(^(#QT<CX@/'1D
M('=I9'1H/3-$,S0Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#(U-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,
M24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^3F5T(&EN
M8V]M93PO<#X\+W1D/B`\=&0@=VED=&@],T0W,2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3,N
M-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F
M,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M
M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[)"`T+#8Q-RPV-3D@/"]P
M/CPO=&0^(#QT9"!W:61T:#TS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M
M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@,2XX-7!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M(#QT9"!W:61T:#TS1#<X('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U."XV-7!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I
M9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP
M:6X@,&EN(#!P="<^)FYB<W`[)"`Q.2PR-CDL-C0R(#PO<#X\+W1D/CPO='(^
M(#QT<CX@/'1D('=I9'1H/3-$,S0Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#(U-G!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S
M='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P
M="<^0F%S:6,@=V5I9VAT960M879E<F%G92!C;VUM;VX@<VAA<F5S(&]U='-T
M86YD:6YG/"]P/CPO=&0^(#QT9"!W:61T:#TS1#<Q('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4S+C5P=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR
M:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H=#L@3$E.12U(14E'
M2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$<FEG:'0^
M-#,L-3<Y+#4U-R`\+W`^/"]T9#X@/'1D('=I9'1H/3-$,B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q+C@U<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-S@@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3@N-C5P=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR
M:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H=#L@3$E.12U(14E'
M2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$<FEG:'0^
M-#,L-#<Y+#@Y.2`\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#,T
M,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F
M=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC
M;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H
M.B`R-39P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1'1O<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/D5F9F5C="!O9B!D:6QU=&EV92!S
M96-U<FET:65S.CPO<#X\+W1D/B`\=&0@=VED=&@],T0W,2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U,RXU<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1T;W`^/"]T9#X@/'1D('=I9'1H/3-$,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q+C@U<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1T;W`^/"]T
M9#X@/'1D('=I9'1H/3-$-S@@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!W:61T:#H@-3@N-C5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F
M,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1'1O<#X\+W1D/CPO='(^
M(#QT<CX@/'1D('=I9'1H/3-$,S0Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#(U-G!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$=&]P/B`\<"!S='EL
M93TS1"=,24Y%+4A%24=(5#IN;W)M86P[(%1%6%0M24Y$14Y4.C$P<'0[($U!
M4D=)3CHP:6X@,&EN(#!P="<^5V%R<F%N=',\+W`^/"]T9#X@/'1D('=I9'1H
M/3-$-S$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R
M+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U
M;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W
M:61T:#H@-3,N-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$=&]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(
M5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[("TF;F)S<#LF
M;F)S<#L@/"]P/CPO=&0^(#QT9"!W:61T:#TS1#(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,2XX-7!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I
M9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$=&]P
M/CPO=&0^(#QT9"!W:61T:#TS1#<X('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#4X+C8U<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1T;W`^/"]T9#X\
M+W1R/B`\='(^(#QT9"!W:61T:#TS1#,T,2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`R-39P=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1'1O<#X@/'`@
M<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!415A4+4E.1$5.5#HQ,'!T
M.R!-05)'24XZ,&EN(#!I;B`P<'0G/D]P=&EO;G,\+W`^/"]T9#X@/'1D('=I
M9'1H/3-$-S$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q
M<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#4S+C5P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1'1O<#X@/'`@<W1Y
M;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M/B9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N
M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P
M.R9N8G-P.R`M)FYB<W`[)FYB<W`[(#PO<#X\+W1D/B`\=&0@=VED=&@],T0R
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T
M.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O
M;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z
M(#$N.#5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1'1O<#X\+W1D/B`\=&0@=VED=&@],T0W."!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R
M+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U
M;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W
M:61T:#H@-3@N-C5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT
M;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT
M;W`Z(#!I;CLG('9A;&EG;CTS1'1O<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X\+W1D
M/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,S0Q('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#(U-G!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@
M,&EN(#!P="<^1&EL=71E9"!W96EG:'1E9"UA=F5R86=E(&-O;6UO;B!S:&%R
M97,@;W5T<W1A;F1I;F<\+W`^/"]T9#X@/'1D('=I9'1H/3-$-S$@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#4S+C5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT
M;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT
M;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CIR:6=H=#L@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I
M;B`P<'0G(&%L:6=N/3-$<FEG:'0^-#,L-3<Y+#4U-R`\+W`^/"]T9#X@/'1D
M('=I9'1H/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C
M:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('=I9'1H.B`Q+C@U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D
M97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I
M;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H
M/3-$-S@@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@
M<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#4X+C8U<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ<FEG:'0[($Q)3D4M2$5)1TA4.FYO<FUA;#L@
M34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/C0S+#0W.2PX.3D@
M/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0S-#$@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,C4V<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%2
M1TE..C!I;B`P:6X@,'!T)SY"87-I8R!E87)N:6YG<R!P97(@<VAA<F4\+W`^
M/"]T9#X@/'1D('=I9'1H/3-$-S$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4S+C5P=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E
M<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'
M24XZ,&EN(#!I;B`P<'0G/B9N8G-P.R0F;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@,"XQ,2`\+W`^/"]T
M9#X@/'1D('=I9'1H/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F
M,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I
M;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('=I9'1H.B`Q+C@U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D
M('=I9'1H/3-$-S@@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O
M='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4X+C8U<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^
M(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P
M:6X@,'!T)SXF;F)S<#LD)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#`N-#0@/"]P
M/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0S-#$@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R
M96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,C4V<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE.
M.C!I;B`P:6X@,'!T)SY$:6QU=&5D(&5A<FYI;F=S('!E<B!S:&%R93PO<#X\
M+W1D/B`\=&0@=VED=&@],T0W,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W
M:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R
M96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3,N-7!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)
M3CHP:6X@,&EN(#!P="<^)FYB<W`[)"9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P
M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`P+C$Q(#PO<#X\+W1D
M/B`\=&0@=VED=&@],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#$N.#5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@
M=VED=&@],T0W."!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT
M(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3@N-C5P=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@
M/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I
M;B`P<'0G/B9N8G-P.R0F;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@)FYB<W`[
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[,"XT-"`\+W`^
M/"]T9#X\+W1R/CPO=&%B;&4^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO
M<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^(#QP('-T>6QE
M/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SY0
M;W1E;G1I86P@8V]M;6]N('-H87)E<R!W97)E(&YO="!I;F-L=61E9"!I;B!T
M:&4@8V]M<'5T871I;VX@;V8@9&EL=71E9"!E87)N:6YG<R!P97(@<VAA<F4@
M87,@=&AE:7(@969F96-T('=O=6QD(&AA=F4@8F5E;B!A;G1I+61I;'5T:79E
M(&%S(&9O;&QO=W,Z/"]P/B`\=&%B;&4@=VED=&@],T0T.3,@<W1Y;&4],T0G
M34%21TE..F%U=&\@875T;R!A=71O("TP+C<U<'0[(%=)1%1(.C,W,'!T.R!"
M3U)$15(M0T],3$%04T4Z8V]L;&%P<V4G(&-E;&QP861D:6YG/3-$,"!C96QL
M<W!A8VEN9STS1#`^(#QT<CX@/'1D('=I9'1H/3-$,S0Q('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#(U-G!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#$U,B!C;VQS<&%N/3-$,R!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q,31P
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIC96YT97([
M($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG
M;CTS1&-E;G1E<CX\8CY&;W(@=&AE(%EE87)S($5N9&5D/"]B/CPO<#X\+W1D
M/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,S0Q('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#(U-G!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^(#QT9"!W:61T:#TS1#$U,B!C;VQS<&%N/3-$,R!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M
M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T
M:#H@,3$T<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M8V5N=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P
M="<@86QI9VX],T1C96YT97(^/&(^1&5C96UB97(@,S$L/"]B/CPO<#X\+W1D
M/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,S0Q('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#(U-G!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^(#QT9"!W:61T:#TS1#<Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U,RXU<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1C
M96YT97(^/&(^,C`Q,CPO8CX\+W`^/"]T9#X@/'1D('=I9'1H/3-$,B!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q+C@U
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-S@@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL
M969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD
M+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED
M=&@Z(#4X+C8U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ8V5N=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN
M(#!P="<@86QI9VX],T1C96YT97(^/&(^,C`Q,3PO8CX\+W`^/"]T9#X\+W1R
M/B`\='(^(#QT9"!W:61T:#TS1#,T,2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`R-39P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@
M<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P
M<'0G/E=A<G)A;G1S('=I=&@@97AE<F-I<V4@<')I8V5S(&]F("0S+C`P('1O
M("0S+C@P('!E<B!S:&%R93PO<#X\+W1D/B`\=&0@=VED=&@],T0W,2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U,RXU
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA
M;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#LF;F)S<#LF;F)S<#L@,34P+#`P,"`\+W`^/"]T9#X@/'1D('=I9'1H/3-$
M,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F
M=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC
M;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H
M.B`Q+C@U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-S@@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3@N
M-C5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.R9N8G-P.R9N8G-P.R9N
M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`Q-3`L,#`P(#PO<#X\+W1D
M/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,S0Q('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#(U-G!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@
M,&EN(#!P="<^3W!T:6]N<R!W:71H(&%N(&5X97)C:7-E('!R:6-E(&]F("0R
M+C4T('1O("0S+C0W('!E<B!S:&%R93PO<#X\+W1D/B`\=&0@=VED=&@],T0W
M,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI
M9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[
M(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!W:61T:#H@-3,N-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS
M1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[
M(#4P+#`P,"`\+W`^/"]T9#X@/'1D('=I9'1H/3-$,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q+C@U<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-S@@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F
M,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T
M<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4X+C8U
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA
M;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@,S$P+#`P,"`\+W`^/"]T9#X\
M+W1R/B`\='(^(#QT9"!W:61T:#TS1#,T,2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`R-39P=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@
M/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!415A4+4E.1$5.5#HQ
M,'!T.R!-05)'24XZ,&EN(#!I;B`P<'0G/E1O=&%L/"]P/CPO=&0^(#QT9"!W
M:61T:#TS1#<Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@
M,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U,RXU<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP
M('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@
M,'!T)SXF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@,C`P
M+#`P,"`\+W`^/"]T9#X@/'1D('=I9'1H/3-$,B!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q+C@U<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^/"]T9#X@/'1D('=I9'1H/3-$-S@@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P
M.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N
M<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4X+C8U<'0[
M('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B
M;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@
M34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF
M;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@-#8P+#`P,"`\+W`^/"]T9#X\+W1R
M/CPO=&%B;&4^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%2
M1TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#<F5D:70@4FES:SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+65G>"TM/CQP('-T>6QE
M/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SX\
M8CY#<F5D:70@4FES:R`\+V(^)B,Q-3`[(%1H92!C87)R>6EN9R!A;6]U;G1S
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M;65N="=S(&5S=&EM871I;VYS+CPO<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@
M<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P
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M<F]M=6QG871E9"!A(&YE=R!"86YK<G5P=&-Y($QA=R!I;B!!=6=U<W0@,C`P
M-BP@969F96-T:79E($IU;F4F;F)S<#LQ+"`R,#`W+"!W:&EC:"!C;VYT86EN
M<R!P<F]V:7-I;VYS(&9O<B!T:&4@:6UP;&5M96YT871I;VX@;V8@;65A<W5R
M97,@9F]R('1H92!B86YK<G5P=&-Y(&]F(%!20R!B86YK<RX@26X@=&AE(&5V
M96YT('1H870@8F%N:W)U<'1C>2!L87=S(&%R92!E;F%C=&5D(&9O<B!B86YK
M<R!I;B!T:&4@4%)#+"!T:&4@0V]M<&%N>28C,30V.W,@9&5P;W-I=',@;6%Y
M(&)E(&%T(&$@:&EG:&5R(')I<VL@;V8@;&]S<RX\+W`^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!2
M871E(%)I<VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2UE
M9W@M+3X\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP
M:6X@,&EN(#!P="<^/&(^26YT97)E<W0@4F%T92!2:7-K/"]B/B`F(S$U,#L@
M5&AE($-O;7!A;GD@:7,@97AP;W-E9"!T;R!T:&4@<FES:R!A<FES:6YG(&9R
M;VT@8VAA;F=I;F<@:6YT97)E<W0@<F%T97,L('=H:6-H(&UA>2!A9F9E8W0@
M=&AE(&%B:6QI='D@;V8@<F5P87EM96YT(&]F(&5X:7-T:6YG(&1E8G1S(&%N
M9"!V:6%B:6QI='D@;V8@<V5C=7)I;F<@9G5T=7)E(&1E8G0@:6YS=')U;65N
M=',@=VET:&EN('1H92!04D,N/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C96YT;'D@06YN;W5N8V5D($%C
M8V]U;G1I;F<@4W1A;F1A<F1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\(2TM96=X+2T^/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQB/E)E8V5N=&QY($%N;F]U;F-E9"!!
M8V-O=6YT:6YG(%-T86YD87)D<SPO8CX@)B,Q-3`[(%1H92!&:6YA;F-I86P@
M06-C;W5N=&EN9R!3=&%N9&%R9',@0F]A<F0@*"8C,30W.T9!4T(F(S$T.#LI
M(&ES<W5E9"!!8V-O=6YT:6YG(%-T86YD87)D<R!5<&1A=&4@*"8C,30W.T%3
M528C,30X.RD@,C`Q,2TP-2P@4')E<V5N=&%T:6]N(&]F($-O;7!R96AE;G-I
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M=',N/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)
M3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/B`\<"!S='EL93TS1"=,24Y%+4A%
M24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^05-5(#(P,3$M,#0L
M($9A:7(@5F%L=64@365A<W5R96UE;G0@)B,Q-3`[($%M96YD;65N=',@=&\@
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M=F4@87,@;V8@2F%N=6%R>2`Q+"`R,#$R+B!4:&4@969F96-T<R!O9B!A9&]P
M=&EO;B!W97)E(&YO="!S:6=N:69I8V%N="!T;R!T:&4@86-C;VUP86YY:6YG
M(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<RX\+W`^(#QP('-T
M>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T
M)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@
M34%21TE..C!I;B`P:6X@,'!T)SY!4U4@3F\N(#(P,3(M,#(L(%1E<W1I;F<@
M26YD969I;FET92U,:79E9"!);G1A;F=I8FQE($%S<V5T<R!F;W(@26UP86ER
M;65N="P@<&5R;6ET<RP@8G5T(&1O97,@;F]T(')E<75I<F4L(&%N(&5N=&ET
M>2!T;R!C;VYD=6-T(&%N(&EN:71I86P@<75A;&ET871I=F4@87-S97-S;65N
M="!T;R!D971E<FUI;F4@=VAE=&AE<B!I="!I<R!M;W)E(&QI:V5L>2!T:&%N
M(&YO="!T:&%T(&$@;F]N+6=O;V1W:6QL(&EN9&5F:6YI=&4M;&EV960@87-S
M970@:7,@:6UP86ER960@87,@82!B87-I<R!F;W(@9&5T97)M:6YI;F<@=VAE
M=&AE<B!I="!I<R!N96-E<W-A<GD@=&\@<&5R9F]R;2!T:&4@<75A;G1I=&%T
M:79E(&EM<&%I<FUE;G0@=&5S="!C=7)R96YT;'D@<F5Q=6ER960@*&DN92XL
M(&-O;7!A<FEN9R!T:&4@87-S970G<R!F86ER('9A;'5E('=I=&@@:71S(&-A
M<G)Y:6YG(&%M;W5N="DN(%1H:7,@;F5W('-T86YD87)D('=A<R!A9&]P=&5D
M(&)Y('1H92!#;VUP86YY(&]N(%-E<'1E;6)E<B`S,"P@,C`Q,B!A;F0@:&%D
M(&YO('-I9VYI9FEC86YT(&5F9F5C="!O;B!T:&4@86-C;VUP86YY:6YG(&-O
M;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<RX\+W`^(#QP('-T>6QE
M/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF
M;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%2
M1TE..C!I;B`P:6X@,'!T)SY!4U4@3F\N(#(P,3$M,3$L($1I<V-L;W-U<F5S
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M;VXN(#PO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
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M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%6D8^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0D%325,@3T8@4%)%
M4T5.5$%424].("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D)!4TE3($]&(%!215-%3E1!5$E/3B`H
M5&%B;&5S*3PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F5S96YT871I;VX@;V8@=&AE(&YU;65R871O<G,@86YD(&1E;F]M
M:6YA=&]R<R!U<V5D(&EN('1H92!C86QC=6QA=&EO;B!O9B!B87-I8R!A;F0@
M9&EL=71E9"!E87)N:6YG<R!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CPA+2UE9W@M+3X\<"!S='EL93TS1"=,24Y%+4A%24=(
M5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^1&EL=71E9"!E87)N:6YG
M<R!P97(@<VAA<F4@87)E(&-A;&-U;&%T960@=&\@9VEV92!E9F9E8W0@=&\@
M<&]T96YT:6%L;'D@:7-S=6%B;&4@9&EL=71I=F4@8V]M;6]N('-H87)E<RX\
M+W`^(#QT86)L92!W:61T:#TS1#0Y,R!S='EL93TS1"=-05)'24XZ875T;R!A
M=71O(&%U=&\@+3`N-S5P=#L@5TE$5$@Z,S<P<'0[($)/4D1%4BU#3TQ,05!3
M13IC;VQL87!S92<@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,#X@
M/'1R/B`\=&0@=VED=&@],T0S-#$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M
M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@,C4V<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@
M/'1D('=I9'1H/3-$,34R(&-O;'-P86X],T0S('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$Q-'!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQB
M/D9O<B!T:&4@665A<G,@16YD960\+V(^/"]P/CPO=&0^/"]T<CX@/'1R/B`\
M=&0@=VED=&@],T0S-#$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F
M,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[
M(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!W:61T:#H@,C4V<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B
M;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A
M9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1T;W`^/"]T9#X@/'1D('=I9'1H
M/3-$,34R(&-O;'-P86X],T0S('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I
M;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q,31P=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR
M:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)
M1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E
M<CX\8CY$96-E;6)E<B`S,2P\+V(^/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@
M=VED=&@],T0S-#$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@,C4V<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D
M97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I
M;F<M=&]P.B`P:6X[)R!V86QI9VX],T1T;W`^/"]T9#X@/'1D('=I9'1H/3-$
M-S$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L
M:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#4S+C5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%2
M1TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\8CXR,#$R/"]B/CPO
M<#X\+W1D/B`\=&0@=VED=&@],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#$N.#5P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D
M/B`\=&0@=VED=&@],T0W."!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD
M;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3@N-C5P=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR
M:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)
M1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E
M<CX\8CXR,#$Q/"]B/CPO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$
M,S0Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL
M969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD
M+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED
M=&@Z(#(U-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(
M5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^3F5T(&EN8V]M93PO<#X\
M+W1D/B`\=&0@=VED=&@],T0W,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W
M:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R
M96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3,N-7!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)
M3CHP:6X@,&EN(#!P="<^)FYB<W`[)"`T+#8Q-RPV-3D@/"]P/CPO=&0^(#QT
M9"!W:61T:#TS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@,2XX-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T
M:#TS1#<X('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T
M('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`U."XV-7!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S
M='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P
M="<^)FYB<W`[)"`Q.2PR-CDL-C0R(#PO<#X\+W1D/CPO='(^(#QT<CX@/'1D
M('=I9'1H/3-$,S0Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#(U-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,
M24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^0F%S:6,@
M=V5I9VAT960M879E<F%G92!C;VUM;VX@<VAA<F5S(&]U='-T86YD:6YG/"]P
M/CPO=&0^(#QT9"!W:61T:#TS1#<Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#4S+C5P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H=#L@3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$<FEG:'0^-#,L-3<Y+#4U
M-R`\+W`^/"]T9#X@/'1D('=I9'1H/3-$,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q+C@U<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^
M/"]T9#X@/'1D('=I9'1H/3-$-S@@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M
M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3@N-C5P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H=#L@3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$<FEG:'0^-#,L-#<Y+#@Y
M.2`\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#,T,2!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F
M,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A
M;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`R-39P=#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O
M<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG
M;CTS1'1O<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'
M24XZ,&EN(#!I;B`P<'0G/D5F9F5C="!O9B!D:6QU=&EV92!S96-U<FET:65S
M.CPO<#X\+W1D/B`\=&0@=VED=&@],T0W,2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U,RXU<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1T;W`^/"]T
M9#X@/'1D('=I9'1H/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F
M,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I
M;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('=I9'1H.B`Q+C@U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1T;W`^/"]T9#X@/'1D('=I
M9'1H/3-$-S@@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R
M9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG
M<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!W:61T:#H@-3@N-C5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1'1O<#X\+W1D/CPO='(^(#QT<CX@/'1D
M('=I9'1H/3-$,S0Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#(U-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$=&]P/B`\<"!S='EL93TS1"=,24Y%
M+4A%24=(5#IN;W)M86P[(%1%6%0M24Y$14Y4.C$P<'0[($U!4D=)3CHP:6X@
M,&EN(#!P="<^5V%R<F%N=',\+W`^/"]T9#X@/'1D('=I9'1H/3-$-S$@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3,N
M-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F
M,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@
M=F%L:6=N/3-$=&]P/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[
M($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[("TF;F)S<#LF;F)S<#L@/"]P
M/CPO=&0^(#QT9"!W:61T:#TS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M
M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@,2XX-7!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$=&]P/CPO=&0^(#QT
M9"!W:61T:#TS1#<X('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#4X+C8U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B
M;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A
M9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1T;W`^/"]T9#X\+W1R/B`\='(^
M(#QT9"!W:61T:#TS1#,T,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F
M,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I
M;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('=I9'1H.B`R-39P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1'1O<#X@/'`@<W1Y;&4],T0G
M3$E.12U(14E'2%0Z;F]R;6%L.R!415A4+4E.1$5.5#HQ,'!T.R!-05)'24XZ
M,&EN(#!I;B`P<'0G/D]P=&EO;G,\+W`^/"]T9#X@/'1D('=I9'1H/3-$-S$@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#4S+C5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O
M<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D
M9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1'1O<#X@/'`@<W1Y;&4],T0G3$E.
M12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.R9N
M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P
M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`M
M)FYB<W`[)FYB<W`[(#PO<#X\+W1D/B`\=&0@=VED=&@],T0R('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P
M.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N
M<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$N.#5P=#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O
M<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG
M;CTS1'1O<#X\+W1D/B`\=&0@=VED=&@],T0W."!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3@N
M-C5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1'1O<#X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X\+W1D/CPO='(^(#QT
M<CX@/'1D('=I9'1H/3-$,S0Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F
M,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#(U-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P
M.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL
M93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^
M1&EL=71E9"!W96EG:'1E9"UA=F5R86=E(&-O;6UO;B!S:&%R97,@;W5T<W1A
M;F1I;F<\+W`^/"]T9#X@/'1D('=I9'1H/3-$-S$@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C
M9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R
M.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4S
M+C5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H
M=#L@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L
M:6=N/3-$<FEG:'0^-#,L-3<Y+#4U-R`\+W`^/"]T9#X@/'1D('=I9'1H/3-$
M,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F
M=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC
M;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H
M.B`Q+C@U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-S@@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O
M<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K
M9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=VED=&@Z(#4X+C8U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D
M97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I
M;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ<FEG:'0[($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/C0S+#0W.2PX.3D@/"]P/CPO=&0^
M/"]T<CX@/'1R/B`\=&0@=VED=&@],T0S-#$@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M
M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,C4V<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^
M(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P
M:6X@,'!T)SY"87-I8R!E87)N:6YG<R!P97(@<VAA<F4\+W`^/"]T9#X@/'1D
M('=I9'1H/3-$-S$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O
M='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4S+C5P=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@
M/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I
M;B`P<'0G/B9N8G-P.R0F;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF
M;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@,"XQ,2`\+W`^/"]T9#X@/'1D('=I
M9'1H/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R
M;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`Q+C@U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M
M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M
M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$
M-S@@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L
M:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#4X+C8U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE
M/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF
M;F)S<#LD)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#`N-#0@/"]P/CPO=&0^/"]T
M<CX@/'1R/B`\=&0@=VED=&@],T0S-#$@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,C4V<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP
M('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@
M,'!T)SY$:6QU=&5D(&5A<FYI;F=S('!E<B!S:&%R93PO<#X\+W1D/B`\=&0@
M=VED=&@],T0W,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT
M(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3,N-7!T.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C
M9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\
M<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN
M(#!P="<^)FYB<W`[)"9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N
M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`P+C$Q(#PO<#X\+W1D/B`\=&0@=VED
M=&@],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#$N.#5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT
M;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT
M;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0W
M."!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI
M9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[
M(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!W:61T:#H@-3@N-C5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4]
M,T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N
M8G-P.R0F;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@,"XT-"`\+W`^/"]T9#X\+W1R
M/CPO=&%B;&4^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%2
M1TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)TQ)3D4M
M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0;W1E;G1I86P@8V]M;6]N('-H87)E<R!W97)E(&YO="!I;F-L=61E9"!I
M;B!T:&4@8V]M<'5T871I;VX@;V8@9&EL=71E9"!E87)N:6YG<R!P97(@<VAA
M<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2UE9W@M+3X\
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M>6QE/3-$)TU!4D=)3CIA=71O(&%U=&\@875T;R`M,"XW-7!T.R!724142#HS
M-S!P=#L@0D]21$52+4-/3$Q!4%-%.F-O;&QA<'-E)R!C96QL<&%D9&EN9STS
M1#`@8V5L;'-P86-I;F<],T0P/B`\='(^(#QT9"!W:61T:#TS1#,T,2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`R-39P
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0Q-3(@8V]L<W!A;CTS
M1#,@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M
M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T
M:#H@,3$T<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M8V5N=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P
M="<@86QI9VX],T1C96YT97(^/&(^1F]R('1H92!996%R<R!%;F1E9#PO8CX\
M+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#,T,2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`R-39P=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E
M<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0Q-3(@8V]L<W!A;CTS1#,@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O
M<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K
M9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=VED=&@Z(#$Q-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R
M+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG
M+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4
M+4%,24=..F-E;G1E<CL@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN
M(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQB/D1E8V5M8F5R(#,Q+#PO8CX\
M+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#,T,2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`R-39P=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E
M<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0W,2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3,N
M-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F
M,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E
M<CL@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L
M:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]P/CPO=&0^(#QT9"!W:61T:#TS
M1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M
M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T
M:#H@,2XX-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#<X('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C
M:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('=I9'1H.B`U."XV-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=4
M15A4+4%,24=..F-E;G1E<CL@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ
M,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3$\+V(^/"]P/CPO
M=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0S-#$@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,C4V<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)SY787)R86YT<R!W:71H(&5X97)C:7-E('!R:6-E<R!O9B`D
M,RXP,"!T;R`D,RXX,"!P97(@<VAA<F4\+W`^/"]T9#X@/'1D('=I9'1H/3-$
M-S$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M
M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T
M:#H@-3,N-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(
M5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#$U,"PP,#`@/"]P/CPO=&0^(#QT9"!W
M:61T:#TS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R
M9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG
M<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!W:61T:#H@,2XX-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R
M+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG
M+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS
M1#<X('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL
M969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD
M+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED
M=&@Z(#4X+C8U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#LF;F)S<#LF
M;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@,34P+#`P,"`\
M+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#,T,2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`R-39P=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E
M<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'
M24XZ,&EN(#!I;B`P<'0G/D]P=&EO;G,@=VET:"!A;B!E>&5R8VES92!P<FEC
M92!O9B`D,BXU-"!T;R`D,RXT-R!P97(@<VAA<F4\+W`^/"]T9#X@/'1D('=I
M9'1H/3-$-S$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q
M<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#4S+C5P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@
M<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P
M<'0G/B9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P
M.R9N8G-P.R`U,"PP,#`@/"]P/CPO=&0^(#QT9"!W:61T:#TS1#(@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P
M9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R
M86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,2XX-7!T
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@
M8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#<X('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F
M=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC
M;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H
M.B`U."XV-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(
M5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#,Q,"PP,#`@/"]P
M/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0S-#$@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R
M96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,C4V<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@5$585"U)
M3D1%3E0Z,3!P=#L@34%21TE..C!I;B`P:6X@,'!T)SY4;W1A;#PO<#X\+W1D
M/B`\=&0@=VED=&@],T0W,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD
M;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3,N-7!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I
M9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP
M:6X@,&EN(#!P="<^)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB
M<W`[(#(P,"PP,#`@/"]P/CPO=&0^(#QT9"!W:61T:#TS1#(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,2XX-7!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#<X('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U
M."XV-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[)FYB<W`[)FYB<W`[
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#0V,"PP,#`@/"]P/CPO
M=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?930P9C8S-C!?.#`T95\T-S4Y7V%F,3)?,V)A864S.61C
M,3@V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4T,&8V,S8P7S@P
M-&5?-#<U.5]A9C$R7S-B86%E,SED8S$X-B]7;W)K<VAE971S+U-H965T,C(N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY)3E9%
M3E1/4EDH5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY)3E9%3E1/4ED@*%1A8FQE<RD\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV96YT;W)Y(&-O
M;G-I<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM96=X
M+2T^/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN
M(#!I;B`P<'0G/DEN=F5N=&]R>2!C;VYS:7-T960@;V8@=&AE(&9O;&QO=VEN
M9SH\+W`^(#QT86)L92!W:61T:#TS1#0T-2!S='EL93TS1"=-05)'24XZ875T
M;R!A=71O(&%U=&\@+3`N-S5P=#L@5TE$5$@Z,S,S+C=P=#L@0D]21$52+4-/
M3$Q!4%-%.F-O;&QA<'-E)R!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<]
M,T0P/B`\='(^(#QT9"!W:61T:#TS1#(U,2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q.#AP=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\
M+W1D/B`\=&0@=VED=&@],T0W('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F
M,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@
M=VED=&@],T0X."!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C
M:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('=I9'1H.B`V-2XW<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D
M97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I
M;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H
M/3-$,3$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R
M+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U
M;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W
M:61T:#H@.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#<@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-7!T
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@
M8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@S('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8R<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#(U,2!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F
M,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A
M;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q.#AP=#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O
M<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0Y-"!C;VQS<&%N/3-$,B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`W
M,"XW<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N
M=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@
M86QI9VX],T1C96YT97(^/&(^)FYB<W`[1&5C96UB97(@,S$L(#PO8CX\+W`^
M/"]T9#X@/'1D('=I9'1H/3-$,3$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M
M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P
M.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT
M9"!W:61T:#TS1#@Y(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O
M='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8W<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!,24Y%+4A%24=(5#IN;W)M
M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^/&(^)FYB
M<W`[1&5C96UB97(@,S$L(#PO8CX\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W
M:61T:#TS1#(U,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C
M:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('=I9'1H.B`Q.#AP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@]
M,T0W('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL
M969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD
M+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED
M=&@Z(#5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X."!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R
M9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG
M<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!W:61T:#H@-C4N-W!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R
M+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG
M+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4
M+4%,24=..F-E;G1E<CL@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN
M(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]P/CPO=&0^
M(#QT9"!W:61T:#TS1#$Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#AP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O
M<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D
M9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED
M=&@],T0W('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X,R!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@-C)P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\8CXR,#$Q/"]B/CPO<#X\+W1D
M/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,C4Q('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$X.'!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@
M,&EN(#!P="<^4F%W(&UA=&5R:6%L<SPO<#X\+W1D/B`\=&0@=VED=&@],T0W
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T
M.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O
M;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z
M(#5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X."!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F
M,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A
M;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V-2XW<'0[
M('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B
M;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ<FEG:'0[($Q)
M3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS
M1')I9VAT/B9N8G-P.R0F;F)S<#LF;F)S<#L@,S`L,3DX+#@Q-B`\+W`^/"]T
M9#X@/'1D('=I9'1H/3-$,3$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!W:61T:#H@.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W
M:61T:#TS1#<@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R
M9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG
M<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!W:61T:#H@-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@S
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T
M.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O
M;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z
M(#8R<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ<FEG
M:'0[($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A
M;&EG;CTS1')I9VAT/B9N8G-P.R0F;F)S<#LF;F)S<#L@,C0L.3(P+#@R-2`\
M+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#(U,2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q.#AP=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E
M<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'
M24XZ,&EN(#!I;B`P<'0G/D9I;FES:&5D(&=O;V1S/"]P/CPO=&0^(#QT9"!W
M:61T:#TS1#<@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R
M9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG
M<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!W:61T:#H@-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@X
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('=I9'1H.B`V-2XW<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B
M;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A
M9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ<FEG:'0[($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE.
M.C!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/B9N8G-P.R9N8G-P.R9N8G-P
M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`W+#DS,"PV.#0@/"]P/CPO=&0^
M(#QT9"!W:61T:#TS1#$Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#AP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O
M<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D
M9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED
M=&@],T0W('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X,R!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@-C)P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CIR:6=H=#L@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN
M(#!I;B`P<'0G(&%L:6=N/3-$<FEG:'0^)FYB<W`[)FYB<W`[)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#4L-#4W+#@S,R`\+W`^/"]T9#X\+W1R
M/B`\='(^(#QT9"!W:61T:#TS1#(U,2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q.#AP=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D
M/B`\=&0@=VED=&@],T0W('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O
M<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D
M9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED
M=&@],T0X."!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R
M;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`V-2XW<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M
M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M
M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ<FEG:'0[($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P
M:6X@,'!T)R!A;&EG;CTS1')I9VAT/B9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P
M.R9N8G-P.R`S."PQ,CDL-3`P(#PO<#X\+W1D/B`\=&0@=VED=&@],T0Q,2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`X
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-R!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$.#,@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M
M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C)P=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H=#L@3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$<FEG:'0^)FYB<W`[
M)FYB<W`[("9N8G-P.R9N8G-P.R9N8G-P.S,P+#,W."PV-3@@/"]P/CPO=&0^
M/"]T<CX@/'1R/B`\=&0@=VED=&@],T0R-3$@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M
M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3@X<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^
M(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P
M:6X@,'!T)SY!;&QO=V%N8V4@9F]R(&]B<V]L97-C96YC92`M(')A=R!M871E
M<FEA;',\+W`^/"]T9#X@/'1D('=I9'1H/3-$-R!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^
M/"]T9#X@/'1D('=I9'1H/3-$.#@@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M
M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C4N-W!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S
M='EL93TS1"=415A4+4%,24=..G)I9VAT.R!,24Y%+4A%24=(5#IN;W)M86P[
M($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1R:6=H=#XF;F)S<#LF;F)S
M<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@*#$L-S8Y+#DX-"D\+W`^/"]T
M9#X@/'1D('=I9'1H/3-$,3$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!W:61T:#H@.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W
M:61T:#TS1#<@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R
M9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG
M<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!W:61T:#H@-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@S
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T
M.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O
M;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z
M(#8R<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ<FEG
M:'0[($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A
M;&EG;CTS1')I9VAT/B9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N
M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P
M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`M
M)FYB<W`[)FYB<W`[(#PO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$
M,C4Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL
M969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD
M+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED
M=&@Z(#$X.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(
M5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^/&(^5&]T86P@:6YV96YT
M;W)Y/"]B/CPO<#X\+W1D/B`\=&0@=VED=&@],T0W('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#5P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X\+W1D/B`\=&0@=VED=&@],T0X."!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C4N-W!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@=VEN9&]W=&5X="`Q
M<'0@<V]L:60[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CIR:6=H=#L@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P
M<'0G(&%L:6=N/3-$<FEG:'0^)FYB<W`[)"9N8G-P.R9N8G-P.R`S-BPS-3DL
M-3$V(#PO<#X\+W1D/B`\=&0@=VED=&@],T0Q,2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`X<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^
M/"]T9#X@/'1D('=I9'1H/3-$-R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D
M('=I9'1H/3-$.#,@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O
M='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8R<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B;W)D97(M=&]P.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..G)I9VAT.R!,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1R
M:6=H=#XF;F)S<#LD)FYB<W`[)FYB<W`[(#,P+#,W."PV-3@@/"]P/CPO=&0^
M/"]T<CX\+W1A8FQE/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[
M($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?930P9C8S-C!?.#`T95\T-S4Y
M7V%F,3)?,V)A864S.61C,3@V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V4T,&8V,S8P7S@P-&5?-#<U.5]A9C$R7S-B86%E,SED8S$X-B]7;W)K
M<VAE971S+U-H965T,C,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5:1CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY04D]015)462!!3D0@15%525!-14Y4("A486)L97,I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E!23U!%4E19($%.1"!%455)4$U%3E0@*%1A8FQE<RD\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD(&5Q
M=6EP;65N="!C;VYS:7-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/"$M+65G>"TM/CQP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@
M34%21TE..C!I;B`P:6X@,'!T)SY0<F]P97)T>2!A;F0@97%U:7!M96YT(&-O
M;G-I<W1E9"!O9B!T:&4@9F]L;&]W:6YG.CPO<#X@/'1A8FQE('=I9'1H/3-$
M-#,P('-T>6QE/3-$)TU!4D=)3CIA=71O(&%U=&\@875T;R`M,"XW-7!T.R!7
M24142#HS,C(N-'!T.R!"3U)$15(M0T],3$%04T4Z8V]L;&%P<V4G(&-E;&QP
M861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`^(#QT<CX@/'1D('=I9'1H/3-$
M,C4Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL
M969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD
M+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED
M=&@Z(#$X.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C
M9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R
M.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0W."!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U."XR<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1C
M96YT97(^/&(^)FYB<W`[1&5C96UB97(@,S$L(#PO8CX\+W`^/"]T9#X@/'1D
M('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R
M+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG
M+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS
M1#<X('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL
M969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD
M+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED
M=&@Z(#4X+C)P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@
M,'!T)R!A;&EG;CTS1&-E;G1E<CX\8CXF;F)S<#M$96-E;6)E<B`S,2P@/"]B
M/CPO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,C4Q('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P
M.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N
M<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$X.'!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X\+W1D/B`\=&0@=VED=&@],T0W."!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3@N,G!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.
M12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$
M8V5N=&5R/CQB/C(P,3(\+V(^/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C
M9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R
M.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0W."!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M
M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T
M:#H@-3@N,G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=.
M.F-E;G1E<CL@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P
M<'0G(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3$\+V(^/"]P/CPO=&0^/"]T<CX@
M/'1R/B`\=&0@=VED=&@],T0R-3$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M
M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3@X<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T
M>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T
M)SY097)M:70@;V8@;&%N9"!U<V4\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z
M("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L
M;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@
M.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F
M,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#<X('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P
M.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N
M<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4X+C)P=#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O
M<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H=#L@3$E.
M12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$
M<FEG:'0^)FYB<W`[)"9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`T
M-#<L,#$S(#PO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^/"]T9#X@/'1D('=I9'1H/3-$-S@@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3@N,G!T.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C
M9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\
M<"!S='EL93TS1"=415A4+4%,24=..G)I9VAT.R!,24Y%+4A%24=(5#IN;W)M
M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1R:6=H=#XF;F)S<#LD
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#0T,BPY-S@@/"]P/CPO
M=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0R-3$@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3@X<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)SY"=6EL9&EN9SPO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-S@@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3@N,G!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..G)I9VAT.R!,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1R
M:6=H=#XF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@,BPT,3DL,3(U
M(#PO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T
M9#X@/'1D('=I9'1H/3-$-S@@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!W:61T:#H@-3@N,G!T.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P
M.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL
M93TS1"=415A4+4%,24=..G)I9VAT.R!,24Y%+4A%24=(5#IN;W)M86P[($U!
M4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1R:6=H=#XF;F)S<#LF;F)S<#LF
M;F)S<#LF;F)S<#LF;F)S<#L@,BPS.3<L,C@V(#PO<#X\+W1D/CPO='(^(#QT
M<CX@/'1D('=I9'1H/3-$,C4Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F
M,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#$X.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P
M.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL
M93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^
M4&QA;G0L(&UA8VAI;F5R>2!A;F0@97%U:7!M96YT/"]P/CPO=&0^(#QT9"!W
M:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O
M<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K
M9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT
M;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT
M;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0W
M."!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F
M=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC
M;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H
M.B`U."XR<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M<FEG:'0[($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T
M)R!A;&EG;CTS1')I9VAT/B9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P
M.R`V+#,X,2PR,#D@/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P
M.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N
M<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E
M<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0W."!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U."XR<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ<FEG:'0[($Q)3D4M2$5)1TA4
M.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/B9N
M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`V+#$X-"PR-30@/"]P/CPO
M=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0R-3$@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3@X<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)SY-;W1O<B!V96AI8VQE/"]P/CPO=&0^(#QT9"!W:61T:#TS
M1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL
M969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD
M+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED
M=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0W."!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U."XR
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ<FEG:'0[
M($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG
M;CTS1')I9VAT/B9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P
M.R9N8G-P.R9N8G-P.R`Q-#<L,#@P(#PO<#X\+W1D/B`\=&0@=VED=&@],T0Q
M,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F
M=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC
M;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H
M.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-S@@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P
M9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R
M86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3@N,G!T
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@
M8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..G)I9VAT.R!,
M24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX]
M,T1R:6=H=#XF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF
M;F)S<#LF;F)S<#L@,30U+#,P,"`\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W
M:61T:#TS1#(U,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C
M:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('=I9'1H.B`Q.#AP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.
M12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/D]F9FEC92!E
M<75I<&UE;G0\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R
M96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I
M9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^(#QT9"!W:61T:#TS1#<X('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O
M='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4X+C)P=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H=#L@3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$<FEG:'0^)FYB<W`[
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#(R
M,BPR-S,@/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X\+W1D/B`\=&0@=VED=&@],T0W."!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U."XR<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ<FEG:'0[($Q)3D4M2$5)1TA4.FYO<FUA
M;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/B9N8G-P.R9N
M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`R,#0L
M-34R(#PO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,C4Q('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F
M,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T
M<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$X.'!T
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@
M8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[
M($U!4D=)3CHP:6X@,&EN(#!P="<^0V]N<W1R=6-T:6]N(&EN('!R;V=R97-S
M/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O
M='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D
M/B`\=&0@=VED=&@],T0W."!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD
M;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3@N,G!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I
M9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..G)I9VAT.R!,24Y%+4A%24=(
M5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1R:6=H=#XF
M;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@,RPV.#@L-38W(#PO<#X\
M+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D
M('=I9'1H/3-$-S@@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O
M='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4X+C)P=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@
M/'`@<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H=#L@3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$<FEG:'0^)FYB<W`[
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#,U
M,2PU-S$@/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0R-3$@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3@X
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA
M;#L@5$585"U)3D1%3E0Z,3`N,#5P=#L@34%21TE..C!I;B`P:6X@,'!T)SX\
M8CY4;W1A;#PO8CX\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#<X('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4X+C)P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H=#L@3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$<FEG:'0^)FYB
M<W`[)FYB<W`[)FYB<W`[(#$S+#,P-2PR-C<@/"]P/CPO=&0^(#QT9"!W:61T
M:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0W."!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U
M."XR<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ<FEG
M:'0[($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A
M;&EG;CTS1')I9VAT/B9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`Y
M+#<R-2PY-#$@/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0R-3$@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z
M("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L
M;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@
M,3@X<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO
M<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SY,97-S.B!A8V-U;75L871E9"!D
M97!R96-I871I;VX\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#<X('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4X+C)P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H=#L@3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$<FEG:'0^)FYB
M<W`[)FYB<W`[)FYB<W`[("@T+#(W,RPS-S,I/"]P/CPO=&0^(#QT9"!W:61T
M:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0W."!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U
M."XR<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ<FEG
M:'0[($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A
M;&EG;CTS1')I9VAT/B9N8G-P.R9N8G-P.R9N8G-P.R`H,RPS.3$L,3(T*3PO
M<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,C4Q('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$X.'!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)
M3CHP:6X@,&EN(#!P="<^/&(^4')O<&5R='D@86YD($5Q=6EP;65N="P@;F5T
M/"]B/CPO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^
M/"]T9#X@/'1D('=I9'1H/3-$-S@@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4X+C)P=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@,7!T
M('-O;&ED.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M<FEG:'0[($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T
M)R!A;&EG;CTS1')I9VAT/B9N8G-P.R0F;F)S<#LF;F)S<#L@.2PP,S$L.#DT
M(#PO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T
M9#X@/'1D('=I9'1H/3-$-S@@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN
M9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4X+C)P=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@,7!T('-O
M;&ED.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ<FEG
M:'0[($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A
M;&EG;CTS1')I9VAT/B9N8G-P.R0F;F)S<#LF;F)S<#L@-BPS,S0L.#$W(#PO
M<#X\+W1D/CPO='(^/"]T86)L93X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5S969U
M;"!L:79E<R!O9B!T:&4@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\(2TM96=X+2T^/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/D1E<')E8VEA=&EO;B!I<R!C;VUP
M=71E9"!O;B!A('-T<F%I9VAT+6QI;F4@8F%S:7,@;W9E<B!T:&4@97-T:6UA
M=&5D('5S969U;"!L:79E<R!O9B!T:&4@87-S971S(&%S(&9O;&QO=W,Z/"]P
M/B`\=&%B;&4@=VED=&@],T0S,S<@<W1Y;&4],T0G34%21TE..F%U=&\@875T
M;R!A=71O("TP+C<U<'0[(%=)1%1(.C(U,W!T.R!"3U)$15(M0T],3$%04T4Z
M8V]L;&%P<V4G(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`^(#QT
M<CX@/'1D('=I9'1H/3-$,C4Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I
M;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q.#AP=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR
M:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)
M1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E
M<CY!<W-E=#PO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^/"]T9#X@/'1D('=I9'1H/3-$-S4@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P
M.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N
M<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4V<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1C
M96YT97(^)FYB<W`[3&EF92`M('EE87)S(#PO<#X\+W1D/CPO='(^(#QT<CX@
M/'1D('=I9'1H/3-$,C4Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#$X.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS
M1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^4&5R
M;6ET(&]F(&QA;F0@=7-E/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F
M,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T
M<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O
M<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0W-2!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U-G!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I
M9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.12U(14E'
M2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R
M/C0P("T@-S`\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#(U,2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q
M.#AP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/D)U:6QD:6YG/"]P/CPO=&0^(#QT
M9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@]
M,T0W-2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M
M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N
M9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I
M9'1H.B`U-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=.
M.F-E;G1E<CL@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P
M<'0G(&%L:6=N/3-$8V5N=&5R/C(P("T@,S4\+W`^/"]T9#X\+W1R/B`\='(^
M(#QT9"!W:61T:#TS1#(U,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F
M,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I
M;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('=I9'1H.B`Q.#AP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4]
M,T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/E!L
M86YT+"!M86-H:6YE<GD@86YD(&5Q=6EP;65N=#PO<#X\+W1D/B`\=&0@=VED
M=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R
M;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-S4@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z
M("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L
M;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@
M-39P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIC96YT
M97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A
M;&EG;CTS1&-E;G1E<CXQ,#PO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H
M/3-$,C4Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#$X.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%
M24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^36]T;W(@=F5H:6-L
M93PO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T
M9#X@/'1D('=I9'1H/3-$-S4@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!W:61T:#H@-39P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%2
M1TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CXU("T@,3`\+W`^/"]T
M9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#(U,2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q.#AP=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN
M(#!I;B`P<'0G/D]F9FEC92!E<75I<&UE;G0\+W`^/"]T9#X@/'1D('=I9'1H
M/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R
M+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U
M;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W
M:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#<U('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C
M9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R
M.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4V
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R
M.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI
M9VX],T1C96YT97(^,RTU/"]P/CPO=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?930P9C8S-C!?.#`T
M95\T-S4Y7V%F,3)?,V)A864S.61C,3@V#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V4T,&8V,S8P7S@P-&5?-#<U.5]A9C$R7S-B86%E,SED8S$X
M-B]7;W)K<VAE971S+U-H965T,C0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5:1CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY)3E1!3D=)0DQ%($%34T544R`H5&%B;&5S*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY);G1A;F=I8FQE($%S<V5T<R`H5&%B;&5S*3PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1A;F=I8FQE($%S<V5T<R!-
M961I8V%L($9O<FUU;&%S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\(2TM96=X+2T^/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-
M05)'24XZ,&EN(#!I;B`P<'0G/DEN=&%N9VEB;&4@87-S971S(&-O;G-I<W1E
M9"!S;VQE;'D@;V8@4T9$02!A<'!R;W9E9"!M961I8V%L(&9O<FUU;&%S(&%S
M(&9O;&QO=W,Z/"]P/B`\=&%B;&4@=VED=&@],T0S-3<@<W1Y;&4],T0G34%2
M1TE..F%U=&\@875T;R!A=71O("TP+C<U<'0[(%=)1%1(.C(V-RXT<'0[($)/
M4D1%4BU#3TQ,05!313IC;VQL87!S92<@8V5L;'!A9&1I;F<],T0P(&-E;&QS
M<&%C:6YG/3-$,#X@/'1R/B`\=&0@=VED=&@],T0Q.#<@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R
M96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,30P<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$,38@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M
M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3)P=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\
M+W1D/B`\=&0@=VED=&@],T0W,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`U,RXR<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@
M/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F
M,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[
M(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T
M:#TS1#<Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#4S+C)P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT
M;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT
M;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/CPO='(^(#QT<CX@/'1D
M('=I9'1H/3-$,3@W('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#$T,'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T
M:#TS1#$V('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#$R<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$,34T
M(&-O;'-P86X],T0S('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E
M>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q,34N-'!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQB
M/D1E8V5M8F5R(#,Q+#PO8CX\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T
M:#TS1#$X-R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R
M;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`Q-#!P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT
M;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT
M;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0Q
M-B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F
M=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC
M;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H
M.B`Q,G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#<Q('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R
M;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`U,RXR<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M
M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M
M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ8V5N=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@
M,&EN(#!P="<@86QI9VX],T1C96YT97(^/&(^,C`Q,CPO8CX\+W`^/"]T9#X@
M/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F
M,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[
M(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T
M:#TS1#<Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T
M('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`U,RXR<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[
M($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^/&(^,C`Q,3PO
M8CX\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#$X-R!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F
M,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A
M;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q-#!P=#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O
M<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-
M05)'24XZ,&EN(#!I;B`P<'0G/D=R;W-S(&-A<G)Y:6YG(&%M;W5N=#PO<#X\
M+W1D/B`\=&0@=VED=&@],T0Q-B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`Q,G!T.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P
M.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT
M9"!W:61T:#TS1#<Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#4S+C)P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O
M<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D
M9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G
M3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P
M.R0@-2PS-3<L-3@P(#PO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F
M,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A
M;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-S$@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3,N,G!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I
M9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP
M:6X@,&EN(#!P="<^)FYB<W`[)"`V+#$R-"PT-S4@/"]P/CPO=&0^/"]T<CX@
M/'1R/B`\=&0@=VED=&@],T0Q.#<@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M
M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@,30P<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T
M>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T
M)SY!8V-U;75L871E9"!A;6]R=&EZ871I;VX\+W`^/"]T9#X@/'1D('=I9'1H
M/3-$,38@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R
M+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U
M;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W
M:61T:#H@,3)P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0W,2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U
M,RXR<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO
M<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L@*#(L.30T+#<R-BD\
M+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M(#QT9"!W:61T:#TS1#<Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#4S+C)P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4]
M,T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N
M8G-P.R`H,RPP-#$L.#`T*3PO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H
M/3-$,3@W('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#$T,'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%
M24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^3F5T(&-A<G)Y:6YG
M(&%M;W5N=#PO<#X\+W1D/B`\=&0@=VED=&@],T0Q-B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q,G!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I
M9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^(#QT9"!W:61T:#TS1#<Q('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F
M,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A
M;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U,RXR<'0[
M('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B!W:6YD;W=T97AT
M(#%P="!S;VQI9#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%
M24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[)"`R+#0Q
M,BPX-30@/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X\+W1D/B`\=&0@=VED=&@],T0W,2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3,N,G!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@=VEN9&]W=&5X="`Q
M<'0@<V]L:60[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.R0@,RPP.#(L
M-C<Q(#PO<#X\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&%N9VEB;&4@07-S971S
M($%M;W)T:7IA=&EO;B!%>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\(2TM96=X+2T^/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/E1H92!E<W1I;6%T960@86=G<F5G
M871E(&%N;G5A;"!A;6]R=&EZ871I;VX@97AP96YS92!F;W(@96%C:"!O9B!T
M:&4@;F5X="!F:79E('EE87)S(&%N9"!T:&5R96%F=&5R(&ES(&%S(&9O;&QO
M=W,Z/"]P/B`\=&%B;&4@=VED=&@],T0Q-#0@<W1Y;&4],T0G34%21TE..F%U
M=&\@875T;R!A=71O("TP+C<U<'0[(%=)1%1(.C$N-6EN.R!"3U)$15(M0T],
M3$%04T4Z8V]L;&%P<V4G(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS
M1#`^(#QT<CX@/'1D('=I9'1H/3-$-C,@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P
M.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N
M<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#0W<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1C
M96YT97(^/&(^665A<CPO8CX\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@
M8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#8Y('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F
M=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC
M;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H
M.B`U,G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E
M;G1E<CL@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M(&%L:6=N/3-$8V5N=&5R/CQB/B9N8G-P.T%M;W5N="`\+V(^/"]P/CPO=&0^
M/"]T<CX@/'1R/B`\=&0@=VED=&@],T0V,R!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`T-W!T.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C
M9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\
M<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/C(P,3,\
M+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M(#QT9"!W:61T:#TS1#8Y('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#4R<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B
M;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A
M9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ<FEG:'0[($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE.
M.C!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/B9N8G-P.R0F;F)S<#LF;F)S
M<#LF;F)S<#L@-3(Q+#DX,"`\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T
M:#TS1#8S('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#0W<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ8V5N=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN
M(#!P="<@86QI9VX],T1C96YT97(^,C`Q-#PO<#X\+W1D/B`\=&0@=VED=&@]
M,T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M
M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N
M9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I
M9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-CD@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3)P
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H=#L@
M3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N
M/3-$<FEG:'0^)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[
M(#4P-2PV-3,@/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0V,R!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`T
M-W!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F
M,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E
M<CL@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L
M:6=N/3-$8V5N=&5R/C(P,34\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@
M8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#8Y('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4R<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ<FEG:'0[($Q)3D4M2$5)
M1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT
M/B9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`S-C0L.3<X
M(#PO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$-C,@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-#=P=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E
M<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M
M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E
M;G1E<CXR,#$V/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR
M:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;3X\+W1D/B`\=&0@=VED=&@],T0V.2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U,G!T.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C
M9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\
M<"!S='EL93TS1"=415A4+4%,24=..G)I9VAT.R!,24Y%+4A%24=(5#IN;W)M
M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1R:6=H=#XF;F)S<#LF
M;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@,S$X+#DS.2`\+W`^/"]T
M9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#8S('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#0W<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^
M(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^,C`Q
M-SPO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T
M9#X@/'1D('=I9'1H/3-$-CD@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!W:61T:#H@-3)P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CIR:6=H=#L@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'
M24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$<FEG:'0^)FYB<W`[)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#(W,BPS.#8@/"]P/CPO=&0^/"]T<CX@
M/'1R/B`\=&0@=VED=&@],T0V,R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`T-W!T.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P
M.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL
M93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.12U(14E'2%0Z;F]R;6%L.R!-
M05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/E1H97)E869T97(\
M+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M(#QT9"!W:61T:#TS1#8Y('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#4R<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B
M;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A
M9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ<FEG:'0[($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE.
M.C!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/B9N8G-P.R9N8G-P.R9N8G-P
M.R9N8G-P.R9N8G-P.R9N8G-P.R`T,C@L.3$X(#PO<#X\+W1D/CPO='(^(#QT
M<CX@/'1D('=I9'1H/3-$-C,@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!W:61T:#H@-#=P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%2
M1TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\8CY4;W1A;#PO8CX\
M+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M(#QT9"!W:61T:#TS1#8Y('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U,G!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@=VEN9&]W=&5X="`Q<'0@<V]L:60[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIR:6=H=#L@
M3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N
M/3-$<FEG:'0^)FYB<W`[)"`R+#0Q,BPX-30@/"]P/CPO=&0^/"]T<CX\+W1A
M8FQE/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP
M:6X@,&EN(#!P="<^)FYB<W`[/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?930P9C8S-C!?.#`T95\T-S4Y7V%F,3)?,V)A
M864S.61C,3@V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4T,&8V
M,S8P7S@P-&5?-#<U.5]A9C$R7S-B86%E,SED8S$X-B]7;W)K<VAE971S+U-H
M965T,C4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5704%#/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/DE.0T]-12!405A%4R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY)3D-/344@5$%815,@*%1A
M8FQE<RD\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0W5R<F5N="!487AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/"$M+65G>"TM/CQP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@
M34%21TE..C!I;B`P:6X@,'!T)SY5;F1E<B!C=7)R96YT('1A>"!L87<@:6X@
M=&AE(%!20RP@=&AE($-O;7!A;GD@:7,@86YD('=I;&P@8F4@<W5B:F5C="!T
M;R!T:&4@9F]L;&]W:6YG(&5N=&5R<')I<V4@:6YC;VUE('1A>"!R871E<SH\
M+W`^(#QT86)L92!W:61T:#TS1#(T,"!S='EL93TS1"=-05)'24XZ875T;R!A
M=71O(&%U=&\@+3`N-S5P=#L@5TE$5$@Z,BXU:6X[($)/4D1%4BU#3TQ,05!3
M13IC;VQL87!S92<@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,#X@
M/'1R/B`\=&0@=VED=&@],T0Y-B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`Q:6X[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D
M('=I9'1H/3-$,C4@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@,3EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@]
M,T0Q,3D@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('=I9'1H.B`X.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@<F]W<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M/B`\
M<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQB/D5N
M=&5R<')I<V4@26YC;VUE(%1A>"!2871E/"]B/CPO<#X\+W1D/CPO='(^(#QT
M<CX@/'1D('=I9'1H/3-$.38@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN
M9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#%I;CL@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4
M.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\
M8CY996%R/"]B/CPO<#X\+W1D/B`\=&0@=VED=&@],T0R-2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q.7!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0Y-B!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F
M,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A
M;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q:6X[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1C
M96YT97(^,C`Q,SPO<#X\+W1D/B`\=&0@=VED=&@],T0R-2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q.7!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#$Q.2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`X.7!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/C$U
M)3PO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$.38@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,6EN.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.12U(
M14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N
M=&5R/C(P,30@86YD(&%F=&5R/"]P/CPO=&0^(#QT9"!W:61T:#TS1#(U('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C
M9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R
M.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$Y
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$,3$Y('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P
M.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N
M<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#@Y<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1C
M96YT97(^,C4E/"]P/CPO=&0^/"]T<CX\+W1A8FQE/B`\<"!S='EL93TS1"=,
M24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[
M/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')O=FES:6]N($9O<B!);F-O;64@5&%X97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CPA+2UE9W@M+3X\<"!S='EL93TS1"=,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P
M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@
M,&EN(#!P="<^5&AE('!R;W9I<VEO;B!F;W(@:6YC;VUE('1A>&5S(&-O;G-I
M<W1E9"!O9B!T:&4@9F]L;&]W:6YG.CPO<#X@/'1A8FQE('=I9'1H/3-$-#@S
M('-T>6QE/3-$)TU!4D=)3CIA=71O(&%U=&\@875T;R`M,"XW-7!T.R!72414
M2#HS-C)P=#L@0D]21$52+4-/3$Q!4%-%.F-O;&QA<'-E)R!C96QL<&%D9&EN
M9STS1#`@8V5L;'-P86-I;F<],T0P/B`\='(^(#QT9"!W:61T:#TS1#,P-"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`R
M,CAP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F
M,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A
M;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$,38W(&-O;'-P86X],T0S('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C
M:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('=I9'1H.B`Q,C5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.
M12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQB/EEE87)S
M($5N9&5D($1E8V5M8F5R(#,Q+#PO8CX\+W`^/"]T9#X\+W1R/B`\='(^(#QT
M9"!W:61T:#TS1#,P-"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('=I9'1H.B`R,CAP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O
M<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D
M9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED
M=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R
M;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$.#(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#8Q+C4U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B
M;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A
M9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$
M)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SX\8CXR
M,#$R/"]B/CPO<#X\+W1D/B`\=&0@=VED=&@],T0R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$N.#5P=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR
M:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;3X\+W1D/B`\=&0@=VED=&@],T0X,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P
M9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R
M86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C$N-G!T
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@
M8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[
M($U!4D=)3CHP:6X@,&EN(#!P="<^/&(^,C`Q,3PO8CX\+W`^/"]T9#X\+W1R
M/B`\='(^(#QT9"!W:61T:#TS1#,P-"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`R,CAP=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@
M<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P
M<'0G/D-U<G)E;G0\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8Q+C4U<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)SXD)FYB<W`[)FYB<W`[)FYB<W`[(#$L-#$T+#$W,3PO<#X\
M+W1D/B`\=&0@=VED=&@],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F
M,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#$N.#5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F
M,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\
M=&0@=VED=&@],T0X,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('=I9'1H.B`V,2XV<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B
M;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A
M9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$
M)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXD)FYB
M<W`[)FYB<W`[)FYB<W`[(#,L-#4X+#4V.#PO<#X\+W1D/CPO='(^(#QT<CX@
M/'1D('=I9'1H/3-$,S`T('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#(R.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS
M1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^1&5F
M97)R960\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^(#QT9"!W:61T:#TS1#@R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,2XU-7!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!
M4D=)3CHP:6X@,&EN(#!P="<^*#0S,"PR-3`I/"]P/CPO=&0^(#QT9"!W:61T
M:#TS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R
M+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U
M;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W
M:61T:#H@,2XX-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@R
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('=I9'1H.B`V,2XV<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B
M;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A
M9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$
M)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXH,38L
M,C$S*3PO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,S`T('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F
M,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T
M<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#(R.'!T
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@
M8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[
M($U!4D=)3CHP:6X@,&EN(#!P="<^/&(^5&]T86P@:6YC;VUE('1A>"!E>'!E
M;G-E/"]B/CPO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^/"]T9#X@/'1D('=I9'1H/3-$.#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P
M.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N
M<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8Q+C4U<'0[
M('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B
M;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@
M34%21TE..C!I;B`P:6X@,'!T)SXD)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[
M)FYB<W`[)FYB<W`[(#DX,RPY,C$\+W`^/"]T9#X@/'1D('=I9'1H/3-$,B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q
M+C@U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$.#(@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#8Q+C9P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT
M;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT
M;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(
M14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B0F;F)S<#LF;F)S
M<#LF;F)S<#L@,RPT-#(L,S4U/"]P/CPO=&0^/"]T<CX\+W1A8FQE/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^169F
M96-T:79E($EN8V]M92!487@@4F%T92!296-O;F-I;&EA=&EO;BX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2UE9W@M+3X\<"!S='EL93TS
M1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^1F]L
M;&]W:6YG(&ES(&$@<F5C;VYC:6QI871I;VX@;V8@:6YC;VUE('1A>&5S(&-A
M;&-U;&%T960@870@=&AE(&9E9&5R86P@<W1A='5T;W)Y(')A=&4@=&\@=&AE
M('!R;W9I<VEO;B!F;W(@:6YC;VUE('1A>&5S.CPO<#X@/'1A8FQE('=I9'1H
M/3-$-#DP('-T>6QE/3-$)TU!4D=)3CIA=71O(&%U=&\@875T;R`M,"XW-7!T
M.R!724142#HS-C<N-'!T.R!"3U)$15(M0T],3$%04T4Z8V]L;&%P<V4G(&-E
M;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`^(#QT<CX@/'1D('=I9'1H
M/3-$,S`T('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#(R.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#$R
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T
M.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O
M;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z
M(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X,2!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F
M,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A
M;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,"XW<'0[
M('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B
M;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R
M96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I
M9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@Q('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O
M='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8P+C=P=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\
M+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,S`T('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#(R.'!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I
M9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O
M='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D
M/B`\=&0@=VED=&@],T0Q-S0@8V]L<W!A;CTS1#,@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C
M9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R
M.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$S
M,"XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO
M<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SY996%R<R!%;F1E9"!$96-E;6)E
M<B`S,2P\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#,P-"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`R,CAP
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$.#$@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F
M,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T
M<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8P+C=P
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G/C(P,3(\+W`^/"]T9#X@/'1D('=I9'1H
M/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R
M+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U
M;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W
M:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@Q('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C
M:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('=I9'1H.B`V,"XW<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D
M97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I
M;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)
M3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXR,#$Q/"]P
M/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0S,#0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R
M96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,C(X<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE.
M.C!I;B`P:6X@,'!T)SY487@@870@<W1A='5T;W)Y(')A=&4@;V8@,C4E/"]P
M/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F
M,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\
M=&0@=VED=&@],T0X,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('=I9'1H.B`V,"XW<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B
M;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A
M9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$
M)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXD)FYB
M<W`[)FYB<W`[)FYB<W`[(#$L-#`P+#,Y-3PO<#X\+W1D/B`\=&0@=VED=&@]
M,T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M
M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N
M9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I
M9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$.#$@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C`N
M-W!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F
M,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M
M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)"9N8G-P.R9N8G-P.R9N8G-P.R`U
M+#8W-RPY.3D\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#,P-"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`R
M,CAP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/DYO;BUD961U8W1I8FQE('-T;V-K
M+6)A<V5D(&-O;7!E;G-A=&EO;B!F<F]M/"]P/CPO=&0^(#QT9"!W:61T:#TS
M1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL
M969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD
M+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED
M=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X,2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,"XW
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@Q('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8P+C=P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,S`T('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#(R.'!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)
M3CHP:6X@,&EN(#!P="<^8W5R<F5N="!A;F0@<')I;W(@>65A<G,\+W`^/"]T
M9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W
M:61T:#TS1#@Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O
M<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K
M9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=VED=&@Z(#8P+C=P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.
M12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/C$T.2PV-#0\
M+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M(#QT9"!W:61T:#TS1#@Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#8P+C=P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4]
M,T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/C(V
M,2PQ,C(\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#,P-"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`R,CAP
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G/D5F9F5C="!O9B!T87@@:&]L:61A>3PO
M<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@
M/'1D('=I9'1H/3-$.#$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F
M,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[
M(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!W:61T:#H@-C`N-W!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS
M1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^*#8U
M-2PY-#<I/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X\+W1D/B`\=&0@=VED=&@],T0X,2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,"XW<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP
M('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@
M,'!T)SXH,BPS,S`L-38V*3PO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H
M/3-$,S`T('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#(R.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%
M24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^3W1H97(L('!R:6UA
M<FEL>2!T:&4@969F96-T(&]F(%53('1A>"!R871E<SPO<#X\+W1D/B`\=&0@
M=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C
M:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M
M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M
M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$
M.#$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M
M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T
M:#H@-C`N-W!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(
M5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^*#<P+#0W,2D\+W`^/"]T
M9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W
M:61T:#TS1#@Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O
M<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K
M9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=VED=&@Z(#8P+C=P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.
M12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/BT\+W`^/"]T
M9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#,P-"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`R,CAP=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN
M(#!I;B`P<'0G/D-H86YG92!I;B!V86QU871I;VX@86QL;W=A;F-E/"]P/CPO
M=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F
M,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@
M=VED=&@],T0X,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C
M:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('=I9'1H.B`V,"XW<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D
M97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I
M;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)
M3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXQ-C`L,S`P
M/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O
M='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D
M/B`\=&0@=VED=&@],T0X,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F
M,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I
M;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('=I9'1H.B`V,"XW<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE
M/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXH
M,38V+#(P,"D\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#,P-"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`R
M,CAP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/DEN8V]M92!T87@@97AP96YS93PO
M<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@
M/'1D('=I9'1H/3-$.#$@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W
M=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8P+C=P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z('=I;F1O=W1E>'0@,7!T('-O;&ED
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA
M;#L@34%21TE..C!I;B`P:6X@,'!T)SXD)FYB<W`[)FYB<W`[)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[(#DX,RPY,C$\+W`^/"]T9#X@/'1D('=I9'1H/3-$
M,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M
M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T
M:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@Q('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R
M;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`V,"XW<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M
M=&]P.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S
M='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P
M="<^)"9N8G-P.R9N8G-P.R9N8G-P.R`S+#0T,BPS-34\+W`^/"]T9#X\+W1R
M/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$969E<G)E9"!487@@07-S971S(&%N9"!,:6%B:6QI=&EE
M<RX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2UE9W@M+3X\
M<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN
M(#!P="<^5&AE('1E;7!O<F%R>2!D:69F97)E;F-E<R!W:&EC:"!G:79E(')I
M<V4@=&\@=&AE(&1E9F5R<F5D(&EN8V]M92!T87@@87-S971S(&%N9"!L:6%B
M:6QI='D@87)E(&%S(&9O;&QO=W,Z/"]P/B`\9&EV(&%L:6=N/3-$8V5N=&5R
M/B`\=&%B;&4@=VED=&@],T0T.#,@<W1Y;&4],T0G34%21TE..F%U=&\@875T
M;R!A=71O("TP+C<U<'0[(%=)1%1(.C,V,BXP-7!T.R!"3U)$15(M0T],3$%0
M4T4Z8V]L;&%P<V4G(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`^
M(#QT<CX@/'1D('=I9'1H/3-$,S`T('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#(R.'!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O
M<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D
M9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED
M=&@],T0Q-C<@8V]L<W!A;CTS1#,@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$R-2XP-7!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.
M12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$
M8V5N=&5R/CQB/D1E8V5M8F5R(#,Q+#PO8CX\+W`^/"]T9#X\+W1R/B`\='(^
M(#QT9"!W:61T:#TS1#,P-"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F
M,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I
M;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('=I9'1H.B`R,CAP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@
M=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C
M:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M
M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M
M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$
M.#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L
M:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#8Q+C9P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%2
M1TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\8CXR,#$R/"]B/CPO
M<#X\+W1D/B`\=&0@=VED=&@],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#$N.#5P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D
M/B`\=&0@=VED=&@],T0X,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD
M;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C$N-G!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I
M9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.12U(14E'
M2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R
M/CQB/C(P,3$\+V(^/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0S
M,#0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M
M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T
M:#H@,C(X<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4
M.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SX\8CY$969E<G)E9"!I;F-O
M;64@=&%X(&%S<V5T<SH\+V(^/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C
M9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R
M.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X,B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,2XV<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$,B!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q+C@U<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^/"]T9#X@/'1D('=I9'1H/3-$.#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C$N-G!T.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C
M9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0S,#0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,C(X<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)SY!;&QO=V%N8V4@9F]R(&1O=6)T9G5L('1R861E(')E8V5I
M=F%B;&5S/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X\+W1D/B`\=&0@=VED=&@],T0X,B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,2XV<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP
M('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@
M,'!T)SXF;F)S<#LD)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB
M<W`[(#8V-"PT.3(@/"]P/CPO=&0^(#QT9"!W:61T:#TS1#(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS
M<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,2XX-7!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8Q+C9P=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR
M:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ
M,&EN(#!I;B`P<'0G/B9N8G-P.R0F;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF
M;F)S<#LF;F)S<#L@-3,P+#0V,2`\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W
M:61T:#TS1#,P-"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C
M:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('=I9'1H.B`R,CAP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.
M12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/D%L;&]W86YC
M92!F;W(@9&]U8G1F=6P@;W1H97(@<F5C96EV86)L97,\+W`^/"]T9#X@/'1D
M('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R
M+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG
M+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS
M1#@R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL
M969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD
M+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED
M=&@Z(#8Q+C9P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.R9N8G-P.R9N
M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P
M.R9N8G-P.R9N8G-P.R9N8G-P.R`W+#0X,B`\+W`^/"]T9#X@/'1D('=I9'1H
M/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M
M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N
M9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I
M9'1H.B`Q+C@U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$.#(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z
M("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L
M;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@
M-C$N-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[)FYB<W`[)FYB<W`[
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[(#4L.#,X(#PO<#X\+W1D/CPO='(^(#QT<CX@/'1D
M('=I9'1H/3-$,S`T('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#(R.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,
M24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^26YV96YT
M;W)Y(&]B<V]L97-C96YC92!R97-E<G9E/"]P/CPO=&0^(#QT9"!W:61T:#TS
M1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL
M969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD
M+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED
M=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X,B!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,2XV
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA
M;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@,C8U+#0Y."`\+W`^
M/"]T9#X@/'1D('=I9'1H/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`Q+C@U<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@
M/'1D('=I9'1H/3-$.#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F
M,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[
M(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!W:61T:#H@-C$N-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS
M1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[("TF;F)S<#LF;F)S<#L@/"]P/CPO=&0^/"]T<CX@
M/'1R/B`\=&0@=VED=&@],T0S,#0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M
M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@,C(X<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T
M>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T
M)SY%>'!E;G-E<R!N;W0@9&5D=6-T:6)L92!I;B!C=7)R96YT('EE87(\+W`^
M/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M
M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P
M.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT
M9"!W:61T:#TS1#@R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#8Q+C9P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O
M<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D
M9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G
M3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P
M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N
M8G-P.R9N8G-P.R9N8G-P.R`S,"PR,#`@/"]P/CPO=&0^(#QT9"!W:61T:#TS
M1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M
M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T
M:#H@,2XX-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@R('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C
M9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R
M.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8Q
M+C9P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.R9N8G-P.R9N8G-P.R9N
M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P
M.R`R.2PY,C<@/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0S,#0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z
M("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L
M;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@
M,C(X<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO
M<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SY3:&%R92!B87-E9"!C;VUP96YS
M871I;VX\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^(#QT9"!W:61T:#TS1#@R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#8Q+C9P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@
M<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P
M<'0G/B9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P
M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`T-2PW-S<@/"]P/CPO=&0^(#QT
M9"!W:61T:#TS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@,2XX-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T
M:#TS1#@R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#8Q+C9P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT
M;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT
M;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(
M14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.R9N8G-P
M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`Q
M-S(L.3$Q(#PO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,S`T('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C
M9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R
M.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#(R
M.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F
M,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M
M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^52Y3+B!N970@;W!E<F%T:6YG(&QO
M<W,@8V%R<GD@9F]R=V%R9',\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@
M8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8Q+C9P=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E
M<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'
M24XZ,&EN(#!I;B`P<'0G/B9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P
M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`Y,#4L-C8Y(#PO<#X\+W1D/B`\
M=&0@=VED=&@],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#$N.#5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O
M<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D
M9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED
M=&@],T0X,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R
M;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`V,2XV<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M
M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M
M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M
M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#LF;F)S
M<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@
M-C$X+#(S-B`\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#,P-"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`R
M,CAP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/E1O=&%L(&1E9F5R<F5D(&EN8V]M
M92!T87@@87-S971S/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P
M.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N
M<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E
M<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X,B!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,2XV<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B!W:6YD;W=T97AT(#%P="!S;VQI
M9#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M
M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[)FYB<W`[)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[(#$L.3$Y+#$Q."`\+W`^/"]T9#X@/'1D('=I9'1H
M/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M
M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N
M9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I
M9'1H.B`Q+C@U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$.#(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z
M("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L
M;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@
M-C$N-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@=VEN
M9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D
M9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G
M3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P
M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`Q+#,U-RPS-S,@/"]P
M/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0S,#0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R
M96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,C(X<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE.
M.C!I;B`P:6X@,'!T)SY686QU871I;VX@86QL;W=A;F-E/"]P/CPO=&0^(#QT
M9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@]
M,T0X,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S
M;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!W:61T:#H@-C$N-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P
M.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL
M93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[("@Y
M-3$L-#0W*3PO<#X\+W1D/B`\=&0@=VED=&@],T0R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$N.#5P=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR
M:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;3X\+W1D/B`\=&0@=VED=&@],T0X,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P
M9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R
M86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C$N-G!T
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@
M8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[
M($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[
M)FYB<W`[)FYB<W`[)FYB<W`[("@W.3$L,30W*3PO<#X\+W1D/CPO='(^(#QT
M<CX@/'1D('=I9'1H/3-$,S`T('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F
M,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#(R.'!T.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P
M.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL
M93TS1"=,24Y%+4A%24=(5#IN;W)M86P[(%1%6%0M24Y$14Y4.C$P<'0[($U!
M4D=)3CHP:6X@,&EN(#!P="<^3F5T(&1E9F5R<F5D(&EN8V]M92!T87@@87-S
M970\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M
M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C
M9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^(#QT9"!W:61T:#TS1#@R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I
M;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,2XV<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE.
M.C!I;B`P:6X@,'!T)SXF;F)S<#LD)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[
M)FYB<W`[)FYB<W`[(#DV-RPV-S$@/"]P/CPO=&0^(#QT9"!W:61T:#TS1#(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z
M("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L
M;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@
M,2XX-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R
M;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`V,2XV<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M
M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M
M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M
M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#LD)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#4V-BPR,C8@/"]P
M/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@],T0S,#0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R
M96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,C(X<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE.
M.C!I;B`P:6X@,'!T)SX\8CY$969E<G)E9"!I;F-O;64@=&%X(&QI86)I;&ET
M>3H\+V(^/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X\+W1D/B`\=&0@=VED=&@],T0X,B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,2XV<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T
M9#X@/'1D('=I9'1H/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F
M,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I
M;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('=I9'1H.B`Q+C@U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D
M('=I9'1H/3-$.#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@-C$N-G!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^/"]T<CX@/'1R
M/B`\=&0@=VED=&@],T0S,#0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!W:61T:#H@,C(X<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE
M/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SY)
M;G1A;F=I8FQE(&%S<V5T<SPO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[
M('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B
M;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$.#(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T
M.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O
M;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z
M(#8Q+C9P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIR
M:6=H=#L@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M(&%L:6=N/3-$<FEG:'0^)FYB<W`[)"9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P
M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`Y-2PY-C,@/"]P/CPO=&0^(#QT
M9"!W:61T:#TS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@,2XX-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T
M:#TS1#@R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T
M('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`V,2XV<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ<FEG:'0[($Q)3D4M2$5)1TA4.FYO<FUA;#L@
M34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1')I9VAT/B9N8G-P.R0F;F)S
M<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@,3(X+#DP.2`\+W`^
M/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^(#QP('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-#!F-C,V
M,%\X,#1E7S0W-3E?868Q,E\S8F%A93,Y9&,Q.#8-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO930P9C8S-C!?.#`T95\T-S4Y7V%F,3)?,V)A864S
M.61C,3@V+U=O<FMS:&5E=',O4VAE970R-BYH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D9!25(@5D%,544@345!4U5214U%3E13
M("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D9!25(@5D%,544@345!4U5214U%3E13("A486)L97,I
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%S
M<V5T<R!&86ER(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\(2TM96=X+2T^/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-
M05)'24XZ,&EN(#!I;B`P<'0G/E1H92!#;VUP86YY(&AE;&0@=&AE(&9O;&QO
M=VEN9R!A<W-E=',@86YD(&QI86)I;&ET:65S(')E8V]R9&5D(&%T(&9A:7(@
M=F%L=64@87,@;V8@1&5C96UB97(@,S$L(#(P,3(@86YD(#(P,3$Z(#PO<#X@
M/'1A8FQE('=I9'1H/3-$-#@Y('-T>6QE/3-$)U=)1%1(.C,V-BXV<'0[($)/
M4D1%4BU#3TQ,05!313IC;VQL87!S92<@8V5L;'!A9&1I;F<],T0P(&-E;&QS
M<&%C:6YG/3-$,#X@/'1R/B`\=&0@=VED=&@],T0Q-C$@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R
M96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3(P+C1P=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E
M<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0Q,R!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y+C1P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X\+W1D/B`\=&0@=VED=&@],T0X-2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,RXT<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T
M9#X@/'1D('=I9'1H/3-$,3,@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!W:61T:#H@.2XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D
M('=I9'1H/3-$-C4@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@-#@N-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T
M:#TS1#$S('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#DN-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#8U
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T
M.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O
M;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z
M(#0X+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0Q,R!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y+C1P
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0V-2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`T."XT<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#$V,2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q,C`N
M-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F
M,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#$S('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P
M.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N
M<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#DN-'!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@U('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8S+C1P=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR
M:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;3X\+W1D/B`\=&0@=VED=&@],T0Q,R!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y+C1P=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\
M+W1D/B`\=&0@=VED=&@],T0R,3D@8V]L<W!A;CTS1#4@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R
M96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,38T<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE.
M.C!I;B`P:6X@,'!T)SX\8CY&86ER(%9A;'5E($UE87-U<F5M96YT<R!A=#PO
M8CX\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#$V,2!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F
M,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A
M;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q,C`N-'!T
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@
M8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#$S('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#DN-'!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@U('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8S+C1P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN
M(#!I;B`P<'0G/CQB/D1E8V5M8F5R(#,Q+#PO8CX\+W`^/"]T9#X@/'1D('=I
M9'1H/3-$,3,@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R
M9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG
M<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!W:61T:#H@.2XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M
M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M
M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$
M,C$Y(&-O;'-P86X],T0U('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q-C1P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN
M(#!I;B`P<'0G/CQB/E)E<&]R=&EN9R!$871E(%5S:6YG/"]B/CPO<#X\+W1D
M/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,38Q('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q,C`N
M-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F
M,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M
M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^/&(^1&5S8W)I<'1I;VX\+V(^/"]P
M/CPO=&0^(#QT9"!W:61T:#TS1#$S('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#DN-'!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M(#QT9"!W:61T:#TS1#@U('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O
M=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,RXT<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)SX\8CXR,#$R/"]B/CPO<#X\+W1D/B`\=&0@=VED=&@],T0Q
M,R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F
M=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC
M;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H
M.B`Y+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0V-2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R
M9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG
M<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T
M.R!W:61T:#H@-#@N-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R
M+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG
M+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^/&(^3&5V96P@
M,3PO8CX\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3,@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.2XT<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG
M:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T
M;VT^/"]T9#X@/'1D('=I9'1H/3-$-C4@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P
M.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N
M<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#0X+C1P=#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O
M<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-
M05)'24XZ,&EN(#!I;B`P<'0G/CQB/DQE=F5L(#(\+V(^/"]P/CPO=&0^(#QT
M9"!W:61T:#TS1#$S('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B
M86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#DN-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T
M:#TS1#8U('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T
M('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`T."XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T
M>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T
M)SX\8CY,979E;"`S/"]B/CPO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H
M/3-$,38Q('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#$R,"XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M
M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M
M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M
M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SY"86YK97(G<R!A
M8V-E<'1A;F-E(&YO=&5S/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$S('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F
M,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T
M<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#DN-'!T
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@
M8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@U('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F
M=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC
M;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H
M.B`V,RXT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4
M.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXD)FYB<W`[)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#$P,2PU-S`\+W`^
M/"]T9#X@/'1D('=I9'1H/3-$,3,@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M
M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@.2XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@
M/'1D('=I9'1H/3-$-C4@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W
M=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#0X+C1P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN
M(#!I;B`P<'0G/B0F;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@+3PO<#X\+W1D/B`\
M=&0@=VED=&@],T0Q,R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('=I9'1H.B`Y+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O
M<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D
M9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED
M=&@],T0V-2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P
M="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M
M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@-#@N-'!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S
M='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P
M="<^)"9N8G-P.R`Q,#$L-3<P/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$S('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C
M9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R
M.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#DN
M-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F
M,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#8U('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M
M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N
M9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I
M9'1H.B`T."XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXD)FYB<W`[)FYB<W`[
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[("9N8G-P.R9N8G-P.R9N
M8G-P.R9N8G-P.RT\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#$V
M,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F
M=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC
M;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H
M.B`Q,C`N-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(
M5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^5&]T86P\+W`^/"]T9#X@
M/'1D('=I9'1H/3-$,3,@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F
M,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[
M(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!W:61T:#H@.2XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B
M;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A
M9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I
M9'1H/3-$.#4@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q
M<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O
M;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#8S+C1P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@
M<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P
M<'0G/B0F;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#LF;F)S<#L@,3`Q+#4W,#PO<#X\+W1D/B`\=&0@=VED=&@],T0Q,R!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y+C1P
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0V-2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M
M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T
M:#H@-#@N-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(
M5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)"9N8G-P.R9N8G-P.R9N
M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P
M.R9N8G-P.R`M/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$S('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#DN-'!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#8U('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`T."XT
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA
M;#L@34%21TE..C!I;B`P:6X@,'!T)SXD)FYB<W`[(#$P,2PU-S`\+W`^/"]T
M9#X@/'1D('=I9'1H/3-$,3,@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!W:61T:#H@.2XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D
M('=I9'1H/3-$-C4@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X
M="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O
M='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#0X+C1P=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@
M/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I
M;B`P<'0G/B0F;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF
M;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@+3PO<#X\+W1D/CPO='(^
M/"]T86)L93X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'
M24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G3$E.12U(
M14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X@
M/'1A8FQE('=I9'1H/3-$-#@Y('-T>6QE/3-$)U=)1%1(.C,V-BXV<'0[($)/
M4D1%4BU#3TQ,05!313IC;VQL87!S92<@8V5L;'!A9&1I;F<],T0P(&-E;&QS
M<&%C:6YG/3-$,#X@/'1R/B`\=&0@=VED=&@],T0Q-C$@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R
M96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3(P+C1P=#L@<&%D
M9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E
M<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0Q,R!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y+C1P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X\+W1D/B`\=&0@=VED=&@],T0X-2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,RXT<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F
M,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T
M9#X@/'1D('=I9'1H/3-$,3,@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!W:61T:#H@.2XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D
M('=I9'1H/3-$-C4@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@-#@N-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R
M9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D
M:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T
M:#TS1#$S('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#DN-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#8U
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T
M.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O
M;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z
M(#0X+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0Q,R!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y+C1P
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0V-2!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P
M87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`T."XT<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#$V,2!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q,C`N
M-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F
M,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#$S('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P
M.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N
M<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#DN-'!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@U('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8S+C1P=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR
M:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;3X\+W1D/B`\=&0@=VED=&@],T0Q,R!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y+C1P=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\
M+W1D/B`\=&0@=VED=&@],T0R,3D@8V]L<W!A;CTS1#4@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R
M96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,38T<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!,24Y%+4A%
M24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1C96YT
M97(^/&(^1F%I<B!686QU92!-96%S=7)E;65N=',@870\+V(^/"]P/CPO=&0^
M/"]T<CX@/'1R/B`\=&0@=VED=&@],T0Q-C$@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M
M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3(P+C1P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X\+W1D/B`\=&0@=VED=&@],T0Q,R!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y+C1P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D
M/B`\=&0@=VED=&@],T0X-2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F
M,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I
M;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('=I9'1H.B`V,RXT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[
M('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[($U!
M4D=)3CHP:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^/&(^1&5C96UB97(@
M,S$L/"]B/CPO<#X\+W1D/B`\=&0@=VED=&@],T0Q,R!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y+C1P=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR
M:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;3X\+W1D/B`\=&0@=VED=&@],T0R,3D@8V]L<W!A;CTS1#4@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#$V-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,
M24=..F-E;G1E<CL@3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I
M;B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQB/E)E<&]R=&EN9R!$871E(%5S:6YG
M/"]B/CPO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,38Q('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R
M;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`Q,C`N-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R
M+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG
M+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^/&(^1&5S8W)I
M<'1I;VX\+V(^/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$S('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A
M<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#DN-'!T.R!P861D
M:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#@U('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@
M=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,RXT
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R
M.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI
M9VX],T1C96YT97(^/&(^,C`Q,3PO8CX\+W`^/"]T9#X@/'1D('=I9'1H/3-$
M,3,@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M
M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T
M:#H@.2XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H/3-$-C4@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O
M<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K
M9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=VED=&@Z(#0X+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I
M;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\8CY,979E;"`Q/"]B/CPO<#X\
M+W1D/B`\=&0@=VED=&@],T0Q,R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`Y+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F
M,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\
M=&0@=VED=&@],T0V-2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T
M97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M
M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-#@N-'!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT
M.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M
M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQB
M/DQE=F5L(#(\+V(^/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$S('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P
M.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N
M<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#DN-'!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#8U('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`T
M."XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N
M=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@
M86QI9VX],T1C96YT97(^/&(^3&5V96P@,SPO8CX\+W`^/"]T9#X\+W1R/B`\
M='(^(#QT9"!W:61T:#TS1#$V,2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`Q,C`N-'!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S
M='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P
M="<^0F%N:V5R)W,@86-C97!T86YC92!N;W1E<SPO<#X\+W1D/B`\=&0@=VED
M=&@],T0Q,R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R
M;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`Y+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT
M;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT
M;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@],T0X
M-2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI
M9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[
M(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!W:61T:#H@-C,N-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS
M1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB
M<W`[)"9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P
M.R9N8G-P.R9N8G-P.R9N8G-P.R`X,RPU,3(@/"]P/CPO=&0^(#QT9"!W:61T
M:#TS1#$S('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O
M=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@
M=VED=&@Z(#DN-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT9"!W:61T:#TS1#8U
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@
M-2XT<'0[('=I9'1H.B`T."XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B
M;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A
M9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$
M)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S
M<#LD)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[("TF;F)S<#LF;F)S<#L@/"]P/CPO
M=&0^(#QT9"!W:61T:#TS1#$S('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F
M,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#DN-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P
M.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO=&0^(#QT
M9"!W:61T:#TS1#8U('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E
M>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`T."XT<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^
M(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P
M:6X@,'!T)SXF;F)S<#LD)FYB<W`[)FYB<W`[)FYB<W`[(#@S+#4Q,B`\+W`^
M/"]T9#X@/'1D('=I9'1H/3-$,3,@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M
M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@.2XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@
M/'1D('=I9'1H/3-$-C4@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W
M=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#0X+C1P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN
M(#!I;B`P<'0G/B9N8G-P.R0F;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@+29N8G-P
M.R9N8G-P.R`\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#$V,2!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO
M<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q
M,C`N-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^5&]T86P\+W`^/"]T9#X@/'1D
M('=I9'1H/3-$,3,@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@.2XT<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D
M97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I
M;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^/"]T9#X@/'1D('=I9'1H
M/3-$.#4@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@
M<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#8S+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F
M,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y
M;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G
M/B9N8G-P.R0F;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF
M;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@.#,L-3$R(#PO<#X\+W1D/B`\=&0@
M=VED=&@],T0Q,R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@8F%C
M:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I;F<M;&5F=#H@-2XT
M<'0[('=I9'1H.B`Y+C1P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D/B`\=&0@=VED=&@]
M,T0V-2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S
M;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!W:61T:#H@-#@N-'!T.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P
M.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL
M93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^
M)FYB<W`[)"9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N
M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`M)FYB<W`[)FYB<W`[(#PO
M<#X\+W1D/B`\=&0@=VED=&@],T0Q,R!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y+C1P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X\+W1D
M/B`\=&0@=VED=&@],T0V-2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD
M;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-#@N-'!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I
M9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP
M:6X@,&EN(#!P="<^)FYB<W`[)"9N8G-P.R9N8G-P.R9N8G-P.R`X,RPU,3(@
M/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$S('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O
M='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#DN-'!T.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C
M9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^(#QT9"!W:61T:#TS1#8U('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I
M;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D
M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E
M;G0[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`T."XT<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M
M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE.
M.C!I;B`P:6X@,'!T)SXF;F)S<#LD)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[("TF
M;F)S<#LF;F)S<#L@/"]P/CPO=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?930P9C8S-C!?.#`T95\T
M-S4Y7V%F,3)?,V)A864S.61C,3@V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V4T,&8V,S8P7S@P-&5?-#<U.5]A9C$R7S-B86%E,SED8S$X-B]7
M;W)K<VAE971S+U-H965T,C<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY35$]#2R!/4%1)3TX@04-4259)5%D@*%1A8FQE<RD\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4W1O8VL@;W!T:6]N(&%C=&EV:71Y/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&]P=&EO;B!A8W1I=FET>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+65G>"TM/CQP('-T
M>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T
M)SY!('-U;6UA<GD@;V8@<W1O8VL@;W!T:6]N(&%C=&EV:71Y(&%S(&]F($1E
M8V5M8F5R(#,Q+"`R,#$R+"!A;F0@8VAA;F=E<R!D=7)I;F<@=&AE('EE87(@
M=&AE;B!E;F1E9"!I<R!P<F5S96YT960@8F5L;W<Z/"]P/B`\=&%B;&4@=VED
M=&@],T0U-#(@<W1Y;&4],T0G34%21TE..F%U=&\@875T;R!A=71O("TP+C<U
M<'0[(%=)1%1(.C0P-BXR<'0[($)/4D1%4BU#3TQ,05!313IC;VQL87!S92<@
M8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,#X@/'1R/B`\=&0@=VED
M=&@],T0R,C<@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R
M9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q-S!P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA
M;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^/"]T9#X@/'1D('=I
M9'1H/3-$-C@@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R
M9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`U,"XW<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F
M,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M
M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/CPO=&0^(#QT9"!W
M:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O
M<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=VED
M=&@],T0V-"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#0X<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@
M8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[
M($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/CPO=&0^(#QT9"!W:61T
M:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O
M<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-
M05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=VED=&@]
M,T0X,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M
M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#8Q+C5P=#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B
M;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!,
M24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI9VX]
M,T1C96YT97(^/&(^5V5I9VAT960M/"]B/CPO<#X\+W1D/B`\=&0@=VED=&@]
M,T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M
M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%2
M1TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^/"]T9#X@/'1D('=I9'1H/3-$
M-C4@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE
M9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[('!A9&1I;F<M;&5F
M=#H@-2XT<'0[('=I9'1H.B`T.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E
M<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'
M24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X\+W1D/CPO='(^(#QT<CX@/'1D
M('=I9'1H/3-$,C(W('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3<P<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/CPO=&0^(#QT
M9"!W:61T:#TS1#8X('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3`N-W!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\
M=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO
M<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^/"]T9#X@/'1D
M('=I9'1H/3-$-C0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`T.'!T.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIC96YT
M97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A
M;&EG;CTS1&-E;G1E<CX\8CY796EG:'1E9"T\+V(^/"]P/CPO=&0^(#QT9"!W
M:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O
M<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=VED
M=&@],T0X,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#8Q+C5P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R
M.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI
M9VX],T1C96YT97(^/&(^079E<F%G93PO8CX\+W`^/"]T9#X@/'1D('=I9'1H
M/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R
M+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!
M4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/CPO=&0^(#QT9"!W:61T:#TS
M1#8U('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL
M969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE
M9G0Z(#4N-'!T.R!W:61T:#H@-#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%2
M1TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^/"]T9#X\+W1R/B`\='(^(#QT
M9"!W:61T:#TS1#(R-R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$W,'!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\
M=&0@=VED=&@],T0V."!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4P+C=P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4
M.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^/"]T9#X@
M/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F
M,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/CPO=&0^(#QT
M9"!W:61T:#TS1#8T('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-#AP=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N
M=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@
M86QI9VX],T1C96YT97(^/&(^079E<F%G93PO8CX\+W`^/"]T9#X@/'1D('=I
M9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R
M9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N
M-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@
M8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L
M:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[
M($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/CPO=&0^(#QT9"!W:61T
M:#TS1#@R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C$N-7!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIC96YT97([
M($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG
M;CTS1&-E;G1E<CX\8CY296UA:6YI;F<\+V(^/"]P/CPO=&0^(#QT9"!W:61T
M:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P
M=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O
M<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG
M;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-
M05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=VED=&@]
M,T0V-2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M
M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#0Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.
M12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$
M8V5N=&5R/CQB/D%G9W)E9V%T93PO8CX\+W`^/"]T9#X\+W1R/B`\='(^(#QT
M9"!W:61T:#TS1#(R-R!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$W,'!T.R!P861D:6YG+7)I
M9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F
M,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\
M=&0@=VED=&@],T0V."!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P
M.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@
M<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4P+C=P=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4
M.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^/"]T9#X@
M/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F
M,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/CPO=&0^(#QT
M9"!W:61T:#TS1#8T('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[
M(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P
M861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-#AP=#L@<&%D9&EN9RUR:6=H
M=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C9C!F
M,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[
M)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N
M=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@
M86QI9VX],T1C96YT97(^/&(^17AE<F-I<V4\+V(^/"]P/CPO=&0^(#QT9"!W
M:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O
M<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=VED
M=&@],T0X,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D
M97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@<&%D9&EN
M9RUL969T.B`U+C1P=#L@=VED=&@Z(#8Q+C5P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R
M.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<@86QI
M9VX],T1C96YT97(^/&(^0V]N=')A8W1U86P@/"]B/CPO<#X\+W1D/B`\=&0@
M=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA
M;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^/"]T9#X@/'1D('=I
M9'1H/3-$-C4@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R
M9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`T.7!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G5$585"U!3$E'3CIC96YT97([
M($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)R!A;&EG
M;CTS1&-E;G1E<CX\8CY);G1R:6YS:6,\+V(^/"]P/CPO=&0^/"]T<CX@/'1R
M/B`\=&0@=VED=&@],T0R,C<@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q-S!P=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^/"]T
M9#X@/'1D('=I9'1H/3-$-C@@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@=VEN
M9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@
M-3`N-W!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI
M=&4[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F
M,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y
M;&4],T0G5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@
M34%21TE..C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\8CY3:&%R97,\
M+V(^/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O
M<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D
M9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G
M5$585"U!3$E'3CIC96YT97([($Q)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE.
M.C!I;B`P:6X@,'!T)R!A;&EG;CTS1&-E;G1E<CX\8CXF;F)S<#L\+V(^/"]P
M/CPO=&0^(#QT9"!W:61T:#TS1#8T('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@
M<&%D9&EN9RUB;W1T;VTZ(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED
M=&@Z(#0X<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W
M:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S
M='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQB/E!R:6-E
M/"]B/CPO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B
M;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A
M9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ8V5N=&5R.R!,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)
M3CHP:6X@,&EN(#!P="<@86QI9VX],T1C96YT97(^/&(^)FYB<W`[/"]B/CPO
M<#X\+W1D/B`\=&0@=VED=&@],T0X,B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I
M9'1H.B`V,2XU<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD
M.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C
M9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\
M<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQB/E1E
M<FT@*%EE87)S*3PO8CX\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P
M9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD
M.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C
M9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\
M<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN
M(#!P="<^)FYB<W`[/"]P/CPO=&0^(#QT9"!W:61T:#TS1#8U('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M
M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@<&%D9&EN9RUL
M969T.B`U+C1P=#L@=VED=&@Z(#0Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/B`\<"!S='EL93TS1"=415A4+4%,24=..F-E;G1E<CL@3$E.
M12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$
M8V5N=&5R/CQB/E9A;'5E/"]B/CPO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I
M9'1H/3-$,C(W('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O
M<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@,3<P<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F
M,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M
M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^3W5T<W1A;F1I;F<@870@1&5C96UB
M97(@,S$L(#(P,3$\+W`^/"]T9#X@/'1D('=I9'1H/3-$-C@@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I
M9'1H.B`U,"XW<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD
M.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C
M9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\
M<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN
M(#!P="<^)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#,Q,"PP,#`@/"]P/CPO
M=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F
M,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@
M,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG
M+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z
M("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z
M(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X\+W1D
M/B`\=&0@=VED=&@],T0V-"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F
M,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I
M;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#0X<'0[('!A9&1I;F<M
M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@
M(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(
M5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[)"9N8G-P.R9N
M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`S+C`S(#PO<#X\
M+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C
M9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ
M(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^/"]T
M9#X@/'1D('=I9'1H/3-$.#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P
M9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P
M:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,2XU<'0[('!A9&1I
M;F<M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O
M<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%
M24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^/&(^)FYB<W`[/"]B
M/CPO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D
M97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I
M;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)
M3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\
M+W`^/"]T9#X@/'1D('=I9'1H/3-$-C4@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`T.7!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.
M12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQB/B9N8G-P
M.SPO8CX\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!W:61T:#TS1#(R-R!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=VED=&@Z(#$W,'!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F%C:V=R
M;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H
M=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O
M;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!415A4+4E.1$5.
M5#HQ,'!T.R!-05)'24XZ,&EN(#!I;B`P<'0G/D9O<F9E:71E9#PO<#X\+W1D
M/B`\=&0@=VED=&@],T0V."!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F
M,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I
M;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#4P+C=P=#L@<&%D9&EN
M9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P
M.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#LF;F)S<#LF
M;F)S<#LF;F)S<#LF;F)S<#L@*#4P+#`P,"D\+W`^/"]T9#X@/'1D('=I9'1H
M/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R
M+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T
M.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R
M9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N
M/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!
M4D=)3CHP:6X@,&EN(#!P="<^/&(^)FYB<W`[/"]B/CPO<#X\+W1D/B`\=&0@
M=VED=&@],T0V-"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#0X<'0[('!A9&1I;F<M<FEG:'0Z
M(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F
M,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@
M=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M
M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[)FYB<W`[)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#(N-30@
M/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O
M='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P
M861D:6YG+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E
M<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN
M9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.
M12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO
M<#X\+W1D/B`\=&0@=VED=&@],T0X,B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8Q+C5P=#L@
M<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D
M97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I
M;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)
M3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SX\8CXF;F)S
M<#L\+V(^/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D
M:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@
M.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4]
M,T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N
M8G-P.SPO<#X\+W1D/B`\=&0@=VED=&@],T0V-2!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN
M9RUB;W1T;VTZ(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#0Y
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS
M1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^/&(^
M)FYB<W`[/"]B/CPO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,C(W
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T
M.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!W:61T:#H@,3<P<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B
M86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[(%1%6%0M
M24Y$14Y4.C$P<'0[($U!4D=)3CHP:6X@,&EN(#!P="<^17AP:7)E9#PO<#X\
M+W1D/B`\=&0@=VED=&@],T0V."!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W
M:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H
M.B`U,"XW<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W
M:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S
M='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P
M="<^)FYB<W`[)FYB<W`[)FYB<W`[("@R,S4L,#`P*3PO<#X\+W1D/B`\=&0@
M=VED=&@],T0Q,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B
M;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@<&%D
M9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C9C!F,&8P
M.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA
M;#L@34%21TE..C!I;B`P:6X@,'!T)SX\8CXF;F)S<#L\+V(^/"]P/CPO=&0^
M(#QT9"!W:61T:#TS1#8T('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-#AP=#L@<&%D9&EN9RUR
M:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C
M9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P
M:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4
M.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#LF;F)S<#LF;F)S
M<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@
M,RXQ.2`\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I
M;F<M8F]T=&]M.B`P:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y
M<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS
M1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB
M<W`[/"]P/CPO=&0^(#QT9"!W:61T:#TS1#@R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C$N
M-7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[
M(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@
M<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4]
M,T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQB
M/B9N8G-P.SPO8CX\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[
M('!A9&1I;F<M8F]T=&]M.B`P:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I
M9'1H.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W
M:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F
M,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S
M='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P
M="<^)FYB<W`[/"]P/CPO=&0^(#QT9"!W:61T:#TS1#8U('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P
M861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T
M:#H@-#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H
M:71E.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P
M9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T
M>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T
M)SX\8CXF;F)S<#L\+V(^/"]P/CPO=&0^/"]T<CX@/'1R/B`\=&0@=VED=&@]
M,T0R,C<@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R
M+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[('!A9&1I;F<M
M;&5F=#H@-2XT<'0[('=I9'1H.B`Q-S!P=#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B
M;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@
M34%21TE..C!I;B`P:6X@,'!T)SX\8CY/=71S=&%N9&EN9R!A="!$96-E;6)E
M<B`S,2P@,C`Q,CPO8CX\+W`^/"]T9#X@/'1D('=I9'1H/3-$-C@@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@-3`N-W!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P
M.R9N8G-P.R9N8G-P.R`R-2PP,#`@/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T
M.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F%C
M:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR
M:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O
M='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ
M,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=VED=&@],T0V-"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`T.'!T.R!P861D:6YG+7)I9VAT
M.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F,&8P
M9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R
M;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.R0F;F)S<#LF;F)S<#LF
M;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@,BXU-"`\+W`^/"]T9#X@
M/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F
M,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[
M('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Y<'0[('!A9&1I;F<M<FEG
M:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P
M9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN
M;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[/"]P/CPO=&0^(#QT
M9"!W:61T:#TS1#@R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ('=I;F1O=W1E
M>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB
M;W1T;VTZ(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#8Q+C5P
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B
M;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A
M9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$
M)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S
M<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF
M;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#L@,"XT,"`\+W`^/"]T9#X@/'1D('=I9'1H/3-$,3(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A
M9&1I;F<M8F]T=&]M.B`P:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H
M.B`Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET
M93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P
M.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL
M93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^
M)FYB<W`[/"]P/CPO=&0^(#QT9"!W:61T:#TS1#8U('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@
M(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@<&%D9&EN9RUL969T.B`U
M+C1P=#L@=VED=&@Z(#0Y<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B86-K
M9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I
M9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T
M=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)3CHP
M:6X@,&EN(#!P="<^)FYB<W`[)"9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N
M8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R`F;F)S<#LF;F)S<#LM)FYB
M<W`[)FYB<W`[(#PO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,C(W
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T
M.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z
M(#4N-'!T.R!W:61T:#H@,3<P<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B
M86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R
M+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$
M8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%+4A%24=(5#IN;W)M86P[($U!4D=)
M3CHP:6X@,&EN(#!P="<^/&(^17AE<F-I<V%B;&4@870@1&5C96UB97(@,S$L
M(#(P,3(\+V(^/"]P/CPO=&0^(#QT9"!W:61T:#TS1#8X('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!B;W)D97(M;&5F
M=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#4P+C=P=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[
M(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D
M97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX]
M,T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%2
M1TE..C!I;B`P:6X@,'!T)SXF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S
M<#LF;F)S<#L@,C4L,#`P(#PO<#X\+W1D/B`\=&0@=VED=&@],T0Q,B!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P
M9C!F,#L@<&%D9&EN9RUB;W1T;VTZ(#!I;CL@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=VED=&@Z(#EP=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)A8VMG<F]U
M;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z
M("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^
M(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P
M:6X@,'!T)SXF;F)S<#L\+W`^/"]T9#X@/'1D('=I9'1H/3-$-C0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@=VEN9&]W=&5X="`Q<'0@<V]L:60[(&)O<F1E
M<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D:6YG
M+6QE9G0Z(#4N-'!T.R!W:61T:#H@-#AP=#L@<&%D9&EN9RUR:6=H=#H@-2XT
M<'0[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B`C9C!F,&8P.R!B
M;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M=&]P.B`P:6X[)R!V86QI
M9VX],T1B;W1T;VT^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@
M34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#LD)FYB<W`[)FYB<W`[)FYB<W`[
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#(N-30@/"]P/CPO=&0^(#QT9"!W
M:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O
M<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T.R!P861D:6YG+7)I9VAT.B`U
M+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F,&8P9C`[
M(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A
M;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L
M.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=VED
M=&@],T0X,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!W:6YD;W=T97AT(#%P
M="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M
M.B`P:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`V,2XU<'0[('!A
M9&1I;F<M<FEG:'0Z(#4N-'!T.R!B86-K9W)O=6YD.B!W:&ET93L@8F]R9&5R
M+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG
M+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/B`\<"!S='EL93TS1"=,24Y%
M+4A%24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[)FYB
M<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[
M)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[)FYB<W`[(#`N
M-#`@/"]P/CPO=&0^(#QT9"!W:61T:#TS1#$R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG
M+6)O='1O;3H@,&EN.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@.7!T
M.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O
M<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P9C!F,#L@<&%D
M9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@<W1Y;&4],T0G
M3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P
M.SPO<#X\+W1D/B`\=&0@=VED=&@],T0V-2!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F,&8P
M9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[('!A9&1I;F<M;&5F=#H@-2XT<'0[
M('=I9'1H.B`T.7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F%C:V=R;W5N
M9#H@=VAI=&4[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@
M(V8P9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@
M/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I
M;B`P<'0G/B9N8G-P.R0F;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF
M;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@+29N8G-P.R9N
M8G-P.R`\+W`^/"]T9#X\+W1R/CPO=&%B;&4^(#QP('-T>6QE/3-$)TQ)3D4M
M2$5)1TA4.FYO<FUA;#L@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-#!F
M-C,V,%\X,#1E7S0W-3E?868Q,E\S8F%A93,Y9&,Q.#8-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO930P9C8S-C!?.#`T95\T-S4Y7V%F,3)?,V)A
M864S.61C,3@V+U=O<FMS:&5E=',O4VAE970R."YH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D955%5212!-24Y)355-($-/34U)
M5$U%3E13("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D955%5212!-24Y)355-($-/34U)5$U%3E13
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D95
M5%5212!-24Y)355-($-/34U)5$U%3E13/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\(2TM96=X+2T^/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P<'0G/D9U='5R92!M:6YI;75M(&-O
M;6UI=&UE;G1S('5N9&5R('1H92!A9W)E96UE;G1S(&%R92!A<R!F;VQL;W=S
M.CPO<#X@/'1A8FQE('=I9'1H/3-$,S0Q('-T>6QE/3-$)TU!4D=)3CIA=71O
M(&%U=&\@875T;R`M,"XW-7!T.R!724142#HR-39P=#L@0D]21$52+4-/3$Q!
M4%-%.F-O;&QA<'-E)R!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P
M/B`\='(^(#QT9"!W:61T:#TS1#(U-2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B`C9C!F,&8P.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D9&EN9RUB;W1T
M;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=')A;G-P87)E;G0[('!A9&1I
M;F<M;&5F=#H@-2XT<'0[('=I9'1H.B`Q.3%P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X@/'`@
M<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-05)'24XZ,&EN(#!I;B`P
M<'0G/CQB/D9O<B!T:&4@665A<G,@16YD:6YG($1E8V5M8F5R(#,Q.CPO8CX\
M+W`^/"]T9#X@/'1D('=I9'1H/3-$.#<@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C5P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG/CPO=&0^/"]T<CX@/'1R/B`\=&0@
M=VED=&@],T0R-34@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@(V8P9C!F,#L@
M8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N
M-'!T.R!W:61T:#H@,3DQ<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D
M97(M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I
M;F<M=&]P.B`P:6X[)SX@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L
M.R!415A4+4E.1$5.5#HQ,7!T.R!-05)'24XZ,&EN(#!I;B`P<'0G/C(P,3,\
M+W`^/"]T9#X@/'1D('=I9'1H/3-$.#<@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@(V8P9C!F,#L@8F]R9&5R+6QE9G0Z("-F,&8P9C`[('!A9&1I;F<M8F]T
M=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z('1R86YS<&%R96YT.R!P861D
M:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C5P=#L@<&%D9&EN9RUR:6=H=#H@
M-2XT<'0[(&)O<F1E<BUT;W`Z("-F,&8P9C`[(&)O<F1E<BUR:6=H=#H@(V8P
M9C!F,#L@<&%D9&EN9RUT;W`Z(#!I;CLG/B`\<"!S='EL93TS1"=,24Y%+4A%
M24=(5#IN;W)M86P[($U!4D=)3CHP:6X@,&EN(#!P="<^)FYB<W`[)"`Q,RPQ
M,S,L-#DX(#PO<#X\+W1D/CPO='(^(#QT<CX@/'1D('=I9'1H/3-$,C4U('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O<F1E<BUL969T.B`C
M9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K9W)O=6YD+6-O;&]R
M.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P=#L@=VED=&@Z(#$Y
M,7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@8F]R9&5R+71O<#H@(V8P9C!F
M,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P861D:6YG+71O<#H@,&EN.R<^
M(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO<FUA;#L@5$585"U)3D1%3E0Z
M,3%P=#L@34%21TE..C!I;B`P:6X@,'!T)SXR,#$T/"]P/CPO=&0^(#QT9"!W
M:61T:#TS1#@W('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P9C`[(&)O
M<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN.R!B86-K
M9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#L@=VED=&@Z(#8U<'0[('!A9&1I;F<M<FEG:'0Z(#4N-'!T.R!B;W)D97(M
M=&]P.B`C9C!F,&8P.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M
M=&]P.B`P:6X[)SX@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-
M05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N
M8G-P.R9N8G-P.R9N8G-P.R`Y-C@L.#8P(#PO<#X\+W1D/CPO='(^(#QT<CX@
M/'1D('=I9'1H/3-$,C4U('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ("-F,&8P
M9C`[(&)O<F1E<BUL969T.B`C9C!F,&8P.R!P861D:6YG+6)O='1O;3H@,&EN
M.R!B86-K9W)O=6YD+6-O;&]R.B!T<F%N<W!A<F5N=#L@<&%D9&EN9RUL969T
M.B`U+C1P=#L@=VED=&@Z(#$Y,7!T.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@
M8F]R9&5R+71O<#H@(V8P9C!F,#L@8F]R9&5R+7)I9VAT.B`C9C!F,&8P.R!P
M861D:6YG+71O<#H@,&EN.R<^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.FYO
M<FUA;#L@5$585"U)3D1%3E0Z,3%P=#L@34%21TE..C!I;B`P:6X@,'!T)SY4
M;W1A;#PO<#X\+W1D/B`\=&0@=VED=&@],T0X-R!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@8F]R9&5R+6QE9G0Z("-F
M,&8P9C`[('!A9&1I;F<M8F]T=&]M.B`P:6X[(&)A8VMG<F]U;F0M8V]L;W(Z
M('1R86YS<&%R96YT.R!P861D:6YG+6QE9G0Z(#4N-'!T.R!W:61T:#H@-C5P
M=#L@<&%D9&EN9RUR:6=H=#H@-2XT<'0[(&)O<F1E<BUT;W`Z('=I;F1O=W1E
M>'0@,7!T('-O;&ED.R!B;W)D97(M<FEG:'0Z("-F,&8P9C`[('!A9&1I;F<M
M=&]P.B`P:6X[)SX@/'`@<W1Y;&4],T0G3$E.12U(14E'2%0Z;F]R;6%L.R!-
M05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.R0@,30L,3`R+#,U."`\+W`^/"]T
M9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%]E-#!F-C,V,%\X,#1E7S0W-3E?868Q,E\S8F%A93,Y9&,Q
M.#8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO930P9C8S-C!?.#`T
M95\T-S4Y7V%F,3)?,V)A864S.61C,3@V+U=O<FMS:&5E=',O4VAE970R.2YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14)'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D)!4TE3
M($]&(%!215-%3E1!5$E/3B`H1&5T86EL<RD\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!S
M:&%R92!O=VYE9"!B>2!#:&EN82!0:&%R;6$@2&]L9&EN9W,@26YC(&]F($]N
M;GD@26YV97-T;65N="!,:6UI=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,#`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&]F('-H87)E(&]W;F5D(&)Y
M($-H:6YA(%!H87)M82!(;VQD:6YG<R!);F,@;V8@2&5L<'-O;B!-961I8V%L
M("9A;7`[($)I;W1E8VAN;VQO9WD@0V\N+"!,=&0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$P,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<F-E=&%G92!O9B!A8W%U:7)E
M9"!B>2!/;FYY(&EN($AE;'!S;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$P,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
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M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%64M!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY"05-)
M4R!/1B!04D5314Y4051)3TX@0F%S:6,@86YD($1I;'5T960@16%R;FEN9W,@
M<&5R($-O;6UO;B!3:&%R92`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@:6YC;VUE/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0L-C$W+#8U.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3DL
M,C8Y+#8T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0F%S:6,@=V5I9VAT960M879E<F%G92!C;VUM;VX@<VAA<F5S
M(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M,RPU-SDL-34W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#,L-#<Y+#@Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1I;'5T960@=V5I9VAT960M879E<F%G
M92!C;VUM;VX@<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT,RPU-SDL-34W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#,L-#<Y+#@Y.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:6,@96%R
M;FEN9W,@<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`N,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`N-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1I;'5T960@96%R;FEN9W,@<&5R('-H87)E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,3$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N-#0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V4T,&8V,S8P
M7S@P-&5?-#<U.5]A9C$R7S-B86%E,SED8S$X-@T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]E-#!F-C,V,%\X,#1E7S0W-3E?868Q,E\S8F%A93,Y
M9&,Q.#8O5V]R:W-H965T<R]3:&5E=#,Q+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%6D9!0SX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY"05-)4R!/1B!04D5314Y4051)3TX@
M4$],24-)15,@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@=VET:"!E>&5R8VES
M92!P<FEC97,@;V8@)#,N,#`@=&\@)#,N.#`@<&5R('-H87)E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N
M<R!W:71H(&%N(&5X97)C:7-E('!R:6-E(&]F("0R+C4T('1O("0S+C0W('!E
M<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S$P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5&]T86P@5V%R<F%N=',@06YD($]P=&EO;G,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-C`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-O9VYI
M>F5D(&%N(&EM<&%I<FUE;G0@;&]S<R!O9B!I=',@:6YT86YG:6)L92!A<W-E
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3DS+#`Y-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]M<&%N>2!C;VYT<FEB=71I;VX@=&\@<F5T:7)E;65N="!B96YE9FET
M('!L86YS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(S,RPX
M-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$V-BPP-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
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M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%-$5!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY)3E9%3E1/
M4EDN("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F%W(&UA=&5R:6%L<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S,"PQ.3@L.#$V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R-"PY
M,C`L.#(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y&:6YI<VAE9"!G;V]D<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-RPY,S`L-C@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-2PT-3<L.#,S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E;G1O<GD@1W)O<W,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,X+#$R.2PU,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,"PS
M-S@L-C4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!;&QO=V%N8V4@9F]R(&]B<V]L97-C96YC92`M(')A=R!M871E
M<FEA;',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-S8Y+#DX
M-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1O=&%L($EN=F5N=&]R>2!N970\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,S8L,S4Y+#4Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S`L,S<X+#8U.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?930P9C8S-C!?.#`T95\T
M-S4Y7V%F,3)?,V)A864S.61C,3@V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V4T,&8V,S8P7S@P-&5?-#<U.5]A9C$R7S-B86%E,SED8S$X-B]7
M;W)K<VAE971S+U-H965T,S,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5:34%#/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,3X\<W1R;VYG/E!23U!%4E19($%.1"!%455)4$U%3E0@*$1E=&%I
M;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y097)M:70@;V8@;&%N9"!U<V4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#0W+#`Q,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#0R+#DW.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0G5I
M;&1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-#$Y+#$R
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(L,SDW+#(X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4&QA;G0L(&UA8VAI;F5R>2!A;F0@97%U:7!M96YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#,X,2PR,#D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#$X-"PR
M-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DUO=&]R('9E:&EC;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$T-RPP.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-#4L,S`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/9F9I8V4@97%U:7!M96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,C(L,C<S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`T+#4U,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N<W1R
M=6-T:6]N(&EN('!R;V=R97-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS+#8X."PU-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS-3$L-3<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!0<F]P97)T>2!A;F0@17%U
M:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPS,#4L
M,C8W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.2PW,C4L.30Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y,97-S.B!A8V-U;75L871E9"!D97!R96-I871I;VX@
M9&5T86EL<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PR-S,L
M,S<S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#,L,SDQ+#$R-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0L(&YE=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y+#`S,2PX.30\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8L
M,S,T+#@Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?930P9C8S-C!?.#`T95\T-S4Y7V%F,3)?,V)A864S.61C,3@V#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4T,&8V,S8P7S@P-&5?-#<U.5]A
M9C$R7S-B86%E,SED8S$X-B]7;W)K<VAE971S+U-H965T,S0N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$571T%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/E!23U!%4E19($%.
M1"!%455)4$U%3E0@07-S971S($QI9F4@*$1E=&%I;',I/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<FUI="!O
M9B!L86YD('5S92!M:6YI;75M(&QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y097)M:70@;V8@;&%N9"!U<V4@;6%X:6UU;2!L:69E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0G5I;&1I;F<@
M;6EN:6UU;2!L:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0G5I;&1I;F<@;6%X:6UU;2!L:69E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4&QA;G0L(&UA8VAI;F5R>2!A;F0@97%U:7!M96YT
M(&QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-;W1O
M<B!V96AI8VQE(&UI;FEM=6T@;&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^36]T;W(@=F5H:6-L92!M87AI;75M(&QI9F4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/9F9I8V4@97%U:7!M96YT
M(&UI;FEM=6T@;&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3V9F:6-E(&5Q=6EP;65N="!M87AI;75M(&QI9F4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%2$@^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M05-31513($1E<')E8VEA=&EO;B`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97!R96-I871I
M;VX@17AP96YS92!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#@U,2PP-#<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4U-2PP,S8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T
M:7IA=&EO;B!%>'!E;G-E($EN=&%N9VEB;&4@87-S971S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#8Q,2PW,C0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4Y-BPU,C4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V4T,&8V,S8P7S@P
M-&5?-#<U.5]A9C$R7S-B86%E,SED8S$X-@T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B]E-#!F-C,V,%\X,#1E7S0W-3E?868Q,E\S8F%A93,Y9&,Q
M.#8O5V]R:W-H965T<R]3:&5E=#,V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%64%!13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#$^/'-T<F]N9SY)3E1!3D=)0DQ%($%34T544R!31D1!($%P
M<')O=F5D($UE9&EC86P@1F]R;75L87,@*$1E=&%I;',I("A54T0@)"D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y'<F]S<R!C87)R>6EN9R!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-2PS-3<L-3@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V+#$R-"PT-S4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D
M(&%M;W)T:7IA=&EO;B!);G1A;F=I8FQE(&%S<V5T<R!31D1!($%P<')O=F5D
M($UE9&EC86P@1F]R;75L87,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(L.30T+#<R-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@S+#`T,2PX,#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%R<GEI;F<@86UO=6YT
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#0Q,BPX-30\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#`X
M,BPV-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%N;G5A;"!A;6]R=&EZ871I;VX@,C`Q,SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-3(Q+#DX,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06YN=6%L(&%M;W)T:7IA=&EO
M;B`R,#$T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,#4L-C4S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!;FYU86P@86UO<G1I>F%T:6]N(#(P,34\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,V-"PY-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%N;G5A;"!A;6]R=&EZ871I;VX@,C`Q
M-CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$X+#DS.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06YN
M=6%L(&%M;W)T:7IA=&EO;B`R,#$W/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR-S(L,S@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!;FYU86P@86UO<G1I>F%T:6]N(%1H97)E869T
M97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0R."PY,3@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%N
M;G5A;"!A;6]R=&EZ871I;VX@5&]T86P\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L-#$R+#@U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M<&%N>2!O8FQI9V%T:6]N('1O('!A
M>2!L86)O<F%T;W)I97,@86YD(&]T:&5R<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`V+#0W-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
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M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%,D@^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^4D5,051%1"!005)462!44D%.4T%#5$E/3E,@365M8F5R($]F($)/1"`H
M1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!;6]U;G0@861V86YC960@8GD@365M8F5R(&]F($)/
M1"!T;R!T:&4@0V]M<&%N>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`T.3,L,#`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`U.34L-C<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!R871E(&]N(&%D=F%N
M8V5S(&9R;VT@365M8F5R(&]F($)/1#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?930P9C8S-C!?.#`T95\T-S4Y7V%F,3)?,V)A864S
M.61C,3@V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4T,&8V,S8P
M7S@P-&5?-#<U.5]A9C$R7S-B86%E,SED8S$X-B]7;W)K<VAE971S+U-H965T
M,S@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5!1CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY2
M14Q!5$5$(%!!4E19(%1204Y304-424].4R!/=VEN9W,@*$1E=&%I;',I("A5
M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!9&%V86YC97,@;W=I;F<@=&\@8F]A<F0@;65M8F5R/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,S4T+#4V-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.#8Q
M+#4V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M930P9C8S-C!?.#`T95\T-S4Y7V%F,3)?,V)A864S.61C,3@V#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4T,&8V,S8P7S@P-&5?-#<U.5]A9C$R
M7S-B86%E,SED8S$X-B]7;W)K<VAE971S+U-H965T,SDN:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$540D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/DY/5$53(%!!64%"3$53
M+B`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D]C="X@,C8L(#(P,3$\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F]L=FEN9R!L:6YE(&]F(&-R
M961I="!W:71H(&$@8F%N:R`H(%)-1"`R-2PP,#`L,#`P*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#DW,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%N;G5A;"!I
M;G1E<F5S="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<N-30E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y/=71S=&%N9&EN9R!B86QA;F-E(&1U92!U;F1E<B!R979O
M;'9I;F<@;&EN92!O9B!C<F5D:70@*%)-0B`S,"PP,#`L,#`P*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#<V,2PP-S,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
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M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%24)!0SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#$^/'-T<F]N9SY)3D-/344@5$%815,@56YD:7-T<FEB=71E
M9"!%87)N:6YG<R!!;F0@26YC;VUE(%1A>"!2871E<R`H1&5T86EL<RD@*%53
M1"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y5;F1I<W1R:6)U=&5D(&5A<FYI;F=S(&]F($AE;'!S;VX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3$S+#0P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN
M=F5S=&UE;G0@:6X@2&5L<'-O;BP@82!F;W)E:6=N('-U8G-I9&EA<GD@9F]R
M('1H92!C;VUP86YY/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#(S+#,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5N=&5R<')I<V4@26YC;VUE(%1A>"!2871E<R!F;W(@
M=&AE('EE87(@,C`Q,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,34N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%;G1E<G!R:7-E($EN8V]M92!487@@4F%T97,@9F]R('1H92!Y
M96%R(#(P,3,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+C`P
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^16YT97)P<FES92!);F-O;64@5&%X(%)A=&5S(&9O<B!T:&4@>65A<B`R
M,#$T(&%N9"!A9G1E<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C4N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%]E-#!F-C,V,%\X,#1E7S0W-3E?868Q,E\S8F%A93,Y9&,Q.#8-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO930P9C8S-C!?.#`T95\T-S4Y7V%F
M,3)?,V)A864S.61C,3@V+U=O<FMS:&5E=',O4VAE970T,2YH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14A"04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^24Y#3TU%(%1!6$53
M(%!R;W9I<VEO;B`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT('1A>"!P<F]V:7-I
M;VXN/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-#$T+#$W
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,RPT-3@L-38X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$969E<G)E9"!T87@@<')O=FES:6]N+CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#,P+#(U,"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-BPR,3,I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A
M;"!I;F-O;64@=&%X(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@.3@S+#DR,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,RPT-#(L,S4U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-#!F-C,V,%\X,#1E7S0W-3E?868Q
M,E\S8F%A93,Y9&,Q.#8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M930P9C8S-C!?.#`T95\T-S4Y7V%F,3)?,V)A864S.61C,3@V+U=O<FMS:&5E
M=',O4VAE970T,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P145(04,^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^4F5C;VYC:6QI871I;VX@;V8@:6YC;VUE('1A>&5S("A$971A
M:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1A>"!A="!S=&%T=71O<GD@<F%T92!O9B`R-24\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PT,#`L,SDU/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+#8W-RPY
M.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-U<G)E;G0@86YD('!R:6]R('EE87)S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-#DL-C0T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C8Q+#$R,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^169F96-T(&]F('1A>"!H
M;VQI9&%Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V-34L.30W
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#(L,S,P+#4V-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D]T:&5R+"!P<FEM87)I;'D@=&AE(&5F9F5C="!O9B!5
M4R!T87@@<F%T97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<P
M+#0W,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-H86YG92!I;B!V86QU871I;VX@86QL;W=A;F-E(%)E8V]N8VEL
M:6%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-C`L,S`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,38V+#(P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DEN8V]M92!T87@@97AP96YS92!296-O;F-I;&EA=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y.#,L.3(Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#0T
M,BPS-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
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M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%05!!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#:&%N9V5S(&]F(&1E
M9F5R<F5D(&EN8V]M92!T87@@87-S971S(&%N9"!L:6%B:6QI='D@*$1E=&%I
M;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06QL;W=A;F-E(&9O<B!D;W5B=&9U;"!T<F%D92!R96-E:79A
M8FQE<R!D969E<G)E9"!T87@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-C8T+#0Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-3,P+#0V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06QL;W=A;F-E(&9O<B!D;W5B=&9U
M;"!O=&AE<B!R96-E:79A8FQE<R!D969E<G)E9"!T87@\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<L-#@R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PX,S@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5N=&]R>2!O8G-O
M;&5S8V5N8V4@<F5S97)V93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C8U+#0Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^17AP96YS97,@;F]T(&1E9'5C=&EB;&4@:6X@8W5R<F5N
M="!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,"PR,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M.2PY,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-H87)E(&)A<V5D(&-O;7!E;G-A=&EO;B!D969E<G)E9"!T87@\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0U+#<W-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W,BPY,3$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E4N4RX@;F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y(&9O<G=A<F1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,#4L-C8Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C$X+#(S-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P@9&5F97)R960@:6YC;VUE('1A>"!A<W-E=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L.3$Y+#$Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S4W+#,W,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F%L=6%T:6]N
M(&%L;&]W86YC92!D969E<G)E9"!T87@@87-S971S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Y-3$L-#0W*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<Y,2PQ-#<I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@9&5F97)R
M960@:6YC;VUE('1A>"!A<W-E="X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/CDV-RPV-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU-C8L,C(V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1A;F=I8FQE(&%S<V5T<R!I;F-O
M;64@=&%X(&QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Y-2PY-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$R."PY,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%04%!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N
M9SY$15))5D%4259%(%=!4E)!3E0@3$E!0DE,2519("A$971A:6QS*2`H55-$
M("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA>2`S,"P@,C`P.#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87D@,C<L(#(P,#@\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DES<W5E(&]F('=A<G)A;G1S(&9O<B!P=7)C:&%S92!O9B!C;VUM
M;VX@<W1O8VL@=')E871E9"!A<R!D97)I=F%T:79E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C4P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F%L=64@<&5R
M('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N.3@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#(N.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M930P9C8S-C!?.#`T95\T-S4Y7V%F,3)?,V)A864S.61C,3@V#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4T,&8V,S8P7S@P-&5?-#<U.5]A9C$R
M7S-B86%E,SED8S$X-B]7;W)K<VAE971S+U-H965T-#4N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5)1CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$15))5D%4259%(%=!4E)!
M3E0@1T%)3E,@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5R:79A=&EV92!G86EN<R!R96-O
M9VYI>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#DS
M-"PR-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
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M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%,4M!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY&04E2(%9!3%5%($U%
M05-54D5-14Y44R!!="!297!O<G1I;F<@1&%T92!5<VEN9R`H1&5T86EL<RD@
M*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D)A;FME<G,@86-C97!T86YC92!N;W1E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,#$L-3<P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X,RPU,3(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O
M=&%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#$L-3<P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#,L
M-3$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y"86YK97)S(&%C8V5P=&%N8V4@;F]T97,@3&5V96P@,3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L($QE=F5L(#$\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86YK97)S(&%C8V5P
M=&%N8V4@;F]T97,@3&5V96P@,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3`Q+#4W,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@S+#4Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@3&5V96P@,CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3`Q+#4W,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@S+#4Q,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%N:V5R<R!A
M8V-E<'1A;F-E(&YO=&5S($QE=F5L(#,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4;W1A;"!,979E;"`S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%3D=!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N
M9SY0<F5F97)R960@0V]M;6]N(%-T;V-K($%N9"!787)R86YT<R`H1&5T86EL
M<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VUM;VX@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDU+#`P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E
M9"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@8V]M;6]N('-T;V-K('-H87)E
M<R!T;R!P=7)C:&%S92!B>2!W87)R86YT<R!O=71S=&%N:6YG(&%N9"!E>&5R
M8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5V%R<F%N=',@<W1A<G0@<F%N9V4@97AE<F-I<V4@<')I8V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@96YD(')A
M;F=E(&5X97)C:7-E('!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#,N.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5V%R<F%N=',@=V5I9VAT960@879E<F%G92!E>&5R8VES
M92!P<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+C0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E=A<G)A;G1S('=E:6=H=&5D(&%V97)A9V4@8V]N=')A8W1U86P@;&EF93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XT/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!I;G1R
M:6YS:6,@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?930P
M9C8S-C!?.#`T95\T-S4Y7V%F,3)?,V)A864S.61C,3@V#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V4T,&8V,S8P7S@P-&5?-#<U.5]A9C$R7S-B
M86%E,SED8S$X-B]7;W)K<VAE971S+U-H965T-#@N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4V
M04%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/C(P,3`@4W1O8VL@3W!T:6]N
M(%!L86X@*$1E=&%I;',I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^3F]V+B`Q,BP@,C`Q,#QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(&-O;6UO;B!S:&%R97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#`P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU
M;6)E<B!O9B!C;VUM;VX@<VAA<F5S('!U<F-H87-E9"!B>2!O<'1I;VYS/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C4L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@
M;W!T:6]N<R!G<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?930P9C8S-C!?.#`T95\T-S4Y7V%F,3)?,V)A864S.61C,3@V#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V4T,&8V,S8P7S@P-&5?-#<U
M.5]A9C$R7S-B86%E,SED8S$X-B]7;W)K<VAE971S+U-H965T-#DN:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$4U0D%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/C(P,3`@4W1O
M8VL@3W!T:6]N(%!L86X@1G)A;FL@5V%U;F<@*$1E=&%I;',I("A54T0@)"D\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^07!R
M+B`R."P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5F5S=&5D(&%N9"!U;F5X97)C:7-E9"!O<'1I;VYS/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ.#4L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@9&%Y<R!O
M<'!O<V5D(&%F=&5R('1H92!E;7!L;WEM96YT('1E<FUI;F%T:6]N(&1A=&4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<VAA
M<F5S(&=R86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E)E8V]R9&5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4U+#<W-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!O
M9B`Q.#4P,#`@;W!T:6]N<R!C86YC96QL960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!O9B`Q,#`P,#`@8V]M;6]N
M('-H87)E<R!E>&-H86YG960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-38L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;&]S:6YG(&UA<FME="!P<FEC92!O9B!C;VUM;VX@
M<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XU-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4W1A<G1I;F<@<FES:R!F<F5E(&EN=&5R97-T(')A=&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`N,30E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;&]S:6YG(')I<VL@9G)E92!I
M;G1E<F5S="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M+C$Y)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^17AP96-T960@9&EV:61E;F0@>6EE;&0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!V;VQA=&EL:71Y/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-BXW,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;FEM=6T@
M97AP96-T960@;&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,"XU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y-87AI;75M(&5X<&5C=&5D(&QI9F4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$N,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(&]P=&EO;G,@=&\@<'5R8VAA
M<V4@8V]M;6]N('-T;V-K(&=R86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!E>&5R8VES92!P<FEC93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C4T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O
M8VL@<VAA<F5S(&=R86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%]E-#!F-C,V,%\X,#1E7S0W-3E?868Q,E\S8F%A93,Y9&,Q.#8-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO930P9C8S-C!?.#`T95\T
M-S4Y7V%F,3)?,V)A864S.61C,3@V+U=O<FMS:&5E=',O4VAE970U,"YH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14A(/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;7!E;G-A
M=&EO;B!%>'!E;G-E("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8V]G;FEZ960@8V]M<&5N
M<V%T:6]N(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$T,2PW,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$Y-BPQ.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8V]M92!487@@8F5N969I="!R96-O
M9VYI>F5D(&9R;VT@<W1O8VL@8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,U+#0S,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#DL,#0V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-#!F-C,V,%\X
M,#1E7S0W-3E?868Q,E\S8F%A93,Y9&,Q.#8-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO930P9C8S-C!?.#`T95\T-S4Y7V%F,3)?,V)A864S.61C
M,3@V+U=O<FMS:&5E=',O4VAE970U,2YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14)'/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,3X\<W1R;VYG/E5N<F5C;V=N:7IE9"!#;VUP96YS871I;VX@
M17AP96YS92`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;G)E8V]G;FEZ960@8V]M
M<&5N<V%T:6]N(&5X<&5N<V4@<F5L871E9"!T;R!P97)F;W)M86YC92!B87-E
M9"!S=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$W+#8T-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^56YR96-O9VYI>F5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E
M(')E;&%T960@=&\@9FEX960@<W1O8VL@;W!T:6]N<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@<F5M86EN:6YG('5N<F5C;V=N
M:7IE9"!C;VUP96YS871I;VX@97AP96YS92!R96QA=&5D('1O(')E<W1R:6-T
M:79E('-T;V-K(&=R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%]E-#!F-C,V,%\X,#1E7S0W-3E?868Q,E\S8F%A93,Y9&,Q.#8-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO930P9C8S-C!?.#`T95\T-S4Y7V%F
M,3)?,V)A864S.61C,3@V+U=O<FMS:&5E=',O4VAE970U,BYH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P131"044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^15A%0U54259%($]&
M1DE#15)3(#(P,3`@4W1O8VL@3W!T:6]N(%!L86X@*$1E=&%I;',I("A54T0@
M)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%Y(#(U+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.=6UB97(@;V8@8V]M;6]N('-H87)E<R!I<W-U960@=&\@='=O(&5X
M96-U=&EV92!O9F9I8V5R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3G5M8F5R(&]F(&YO;BUQ=6%L:69I960@<W1O8VL@;W!T
M:6]N<R!T;R!P=7)C:&%S92!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@4')I8V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BXU-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!E>'!I
M<FEN9R!O;B!-87D@,C4L(#(P,3,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3W!T:6]N<R!T;R!V97-T(&]N('1H<F5E(&UO;G1H
M(&%N;FEV97)S87)Y('!E<F9O<FUA;F-E(&)A<V5D('9E<W1I;F<@8W)I=&5R
M:6$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^475A
M;&EF:65D('-T;V-K(&]P=&EO;G,@9W)A;G1E9"!T;R!F;W)M97(@0T9/(&YO
M;B!Q=6%L:69I960@;W!T:6]N<R!T;R!P=7)C:&%S92!C;VUM;VX@<W1O8VL\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I
M<V4@4')I8V4N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N
M-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D]P=&EO;G,@=F5S=&5D(&]N($%P<FEL(#(X+"`R,#$S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@=&\@=F5S
M="!O;B!T:')E92!M;VYT:"!A;FYI=F5R<V%R>2!P97)F;W)M86YC92!B87-E
M9"!V97-T:6YG(&-R:71E<FEA+CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y'<F%N=&5D(&1A=&4@9F%I<B!V86QU92!O9B!T:&4@
M;W!T:6]N<R!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,"XW,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1W)A;G1E9"!D871E(&9A:7(@=F%L=64@;V8@=&AE(&]P
M=&EO;G,@=&]T86P@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-S`L-3@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y'<F%N=&5D(&1A=&4@8VQO<VEN9R!M87)K970@<')I
M8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BXU-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4FES
M:R!F<F5E(&EN=&5R97-T(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`N-30E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$:79I9&5N9"!9:65L9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('9O;&%T86QI='D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<P+C0P)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@
M<&5R:6]D(&]F(&QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V4T
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M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M34M!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY/1D9)0T524R`R,#$P(%-T
M;V-K($]P=&EO;B!0;&%N("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA>2`R-2P@,C`Q,3QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F
M(&-O;6UO;B!S:&%R97,@:7-S=65D('1O(&5X96-U=&EV92!O9F9I8V5R<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(U+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F%L=64@
M;V8@=&AE(&]P=&EO;G,@9W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`S,3<L-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!0<FEC92!F;W(@;W!T:6]N
M<R!G<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N
M-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)E<W1R:6-T960@<W1O8VL@9W)A;G1E9"!T;R!#14\\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<U+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!T;R!V97-T
M(&]N('-I>"!M;VYT:"!A;FYI=F5R<V%R>2!P97)F;W)M86YC92!B87-E9"!V
M97-T:6YG(&-R:71E<FEA/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]P=&EO;G,@=F5S=&5D(&]N($UA>2`R-2P@,C`Q,CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D
M('-T;V-K(&]P=&EO;G,@9W)A;G1E9"!T;R!F;W)M97(@0T9//"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@=F5S=&5D
M(&]N($%P<FEL(#(X+"`R,#$R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D]P=&EO;G,@=&\@=F5S="!O;B!S:7@@;6]N=&@@86YN
M:79E<G-A<GD@<&5R9F]R;6%N8V4@8F%S960@=F5S=&EN9R!C<FET97)I82X\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S
M(&9O<F9E:71E9"!D=64@=&\@;F]N(&%C:&EE=F5M96YT(&]F('!E<F9O<FUA
M;F-E(&-R:71E<FEA/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/G-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!R96QA=&5D('1O('1H
M92!F:7AE9"!S:&%R92!A=V%R9',@=V%S(')E8V]G;FEZ960@;W9E<B!T:&4@
M<&5R:6]D('1H92!S:&%R97,@=F5S=&5D+CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%-D]!13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N
M9SY3=6UM87)Y(&]F('-T;V-K(&]P=&EO;B!A8W1I=FET>2`H1&5T86EL<RD\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3F\N
M($]F('-H87)E<SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y7
M96EG:'1E9"U!=F5R86=E(&5X97)C:7-E('!R:6-E/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E=E:6=H=&5D+4%V97)A9V4@4F5M86EN:6YG
M($-O;G1R86-T=6%L('1E<FT@*%EE87)S*3QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y!9V=R96=A=&4@26YT<FEN<VEC('9A;'5E/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=71S=&%N9&EN9R!O
M<'1I;VYS(&%T($1E8RX@,S$L(#(P,3$\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,Q,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS+C`S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&;W)F96ET960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#4P+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+C4T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!I<F5D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,S4L,#`P*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,N,3D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C
M:7-A8FQE(&%T($1E8V5M8F5R(#,Q+"`R,#$R(&%T($1E8RX@,S$L(#(P,3(\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(N-30\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y/=71S=&%N9&EN9R!O<'1I;VYS+B!A="!$96,N(#,Q+"`R,#$R/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+C4T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XT/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?930P9C8S-C!?
M.#`T95\T-S4Y7V%F,3)?,V)A864S.61C,3@V#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V4T,&8V,S8P7S@P-&5?-#<U.5]A9C$R7S-B86%E,SED
M8S$X-B]7;W)K<VAE971S+U-H965T-34N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$502#X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#$^/'-T<F]N9SY#3TU-251-14Y44R!!3D0@0T].5$E.1T5.
M0TE%4R`H1$5404E,4RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y087EM96YT<R!M861E(&9O<B!#
M;VYS=')U8W1I;VX@:6X@4')O9W)E<W,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,RPQ,3`L,S$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&;W(@=&AE('EE87(@,C`Q,SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,L,3,S+#0Y.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F]R('1H
M92!Y96%R(#(P,30\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDV
M."PX-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1O=&%L($%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q-"PQ,#(L,S4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%]E-#!F-C,V,%\X,#1E7S0W-3E?868Q,E\S8F%A93,Y
M9&,Q.#8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO930P9C8S-C!?
M.#`T95\T-S4Y7V%F,3)?,V)A864S.61C,3@V+U=O<FMS:&5E=',O4VAE970U
M-BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14=$04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M0T].0T5.5%)!5$E/3E,@4V%L97,@06YD(%!U<F-H87-E<R`H1&5T86EL<RD\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R
M8V5N=&%G92!O9B!N;R!C=7-T;VUE<B!A8V-O=6YT960@9F]R(&UO<F4@=&AA
M;B!S86QE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`N-#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3`N,C`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y097)C96YT86=E(&]F(&]N92!C=7-T;VUE<B!A8V-O=6YT960@
M9F]R(&UO<F4@=&AA;B!S86QE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!P=7)C:&%S97,@9G)O
M;2!O;F4@<W5P<&QI97(@;V8@<F%W(&UA=&5R:6%L<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"XX,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<F-E;G1A9V4@;V8@
M;VYE(&-U<W1O;65R(&%C8V]U;G1E9"!F;W(@86-C;W5N=',@<F5C96EV86)L
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V4T,&8V
M,S8P7S@P-&5?-#<U.5]A9C$R7S-B86%E,SED8S$X-@T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B]E-#!F-C,V,%\X,#1E7S0W-3E?868Q,E\S8F%A
M93,Y9&,Q.#8O5V]R:W-H965T<R]3:&5E=#4W+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%048^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0T].0T5.5%)!5$E/3E,@06-C;W5N
M=',@4&%Y86)L92`H1&5T86EL<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&]F(&%C8V]U
M;G1S('!A>6%B;&4@=&\@='=O('-U<'!L:65R<R!F;W(@<'5R8VAA<V4@;V8@
M<F%W(&UA=&5R:6%L<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3(N,3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3`N,S`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%]E-#!F-C,V,%\X,#1E7S0W-3E?868Q,E\S8F%A93,Y9&,Q.#8-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO930P9C8S-C!?.#`T95\T
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M:V)O;VLN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Q+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,BYH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,#,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#`T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-2YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#8N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#`W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970P."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#DN:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$P+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970Q,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,3(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$S+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-"YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,34N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#$V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-RYH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3@N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#$Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970R,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C$N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(R+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970R,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,C0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(U
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-BYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,C<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#(X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R
M.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S`N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,Q+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970S,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,S,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,T+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970S-2YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,S8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#,W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S."YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,SDN:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#0P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970T,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#(N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0S+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970T-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T-#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0V+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T-RYH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T-#@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#0Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970U,"YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-3$N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#4R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970U,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-30N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4U+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970U-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T-3<N:'1M;"(O/@T*/"]X;6P^#0HM+2TM+2T]7TYE>'1087)T7V4T
F,&8V,S8P7S@P-&5?-#<U.5]A9C$R7S-B86%E,SED8S$X-BTM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAPAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Changes of deferred income tax assets and liability (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AllowanceForDoubtfulTradeReceivablesDeferredTax', window );">Allowance for doubtful trade receivables deferred tax</a></td>
        <td class="nump">$ 664,492<span></span></td>
        <td class="nump">$ 530,461<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AllowanceForDoubtfulOtherReceivablesDeferredTax', window );">Allowance for doubtful other receivables deferred tax</a></td>
        <td class="nump">7,482<span></span></td>
        <td class="nump">5,838<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InventoryObsolescenceReserve', window );">Inventory obsolescence reserve</a></td>
        <td class="nump">265,498<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ExpensesNotDeductibleInCurrentYear', window );">Expenses not deductible in current year</a></td>
        <td class="nump">30,200<span></span></td>
        <td class="nump">29,927<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share based compensation deferred tax</a></td>
        <td class="nump">45,777<span></span></td>
        <td class="nump">172,911<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">U.S. net operating loss carry forwards</a></td>
        <td class="nump">905,669<span></span></td>
        <td class="nump">618,236<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalDeferredIncomeTaxAssets', window );">Total deferred income tax assets</a></td>
        <td class="nump">1,919,118<span></span></td>
        <td class="nump">1,357,373<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance deferred tax assets</a></td>
        <td class="num">(951,447)<span></span></td>
        <td class="num">(791,147)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NetDeferredIncomeTaxAsset', window );">Net deferred income tax asset.</a></td>
        <td class="nump">967,671<span></span></td>
        <td class="nump">566,226<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Intangible assets income tax liability</a></td>
        <td class="nump">$ 95,963<span></span></td>
        <td class="nump">$ 128,909<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AllowanceForDoubtfulOtherReceivablesDeferredTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Allowance for doubtful other receivables deferred tax</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AllowanceForDoubtfulOtherReceivablesDeferredTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AllowanceForDoubtfulTradeReceivablesDeferredTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Allowance for doubtful trade receivables deferred tax</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AllowanceForDoubtfulTradeReceivablesDeferredTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ExpensesNotDeductibleInCurrentYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expenses not deductible in current year</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ExpensesNotDeductibleInCurrentYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InventoryObsolescenceReserve">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Inventory obsolescence reserve</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_InventoryObsolescenceReserve</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NetDeferredIncomeTaxAsset">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net deferred income tax asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NetDeferredIncomeTaxAsset</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalDeferredIncomeTaxAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total deferred income tax assets</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_TotalDeferredIncomeTaxAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the tax effects as of the balance sheet date of the amount of excesses of tax deductions over gross income in a year which cannot be used on the tax returns in the current year but can be carried forward to reduce taxable income or income taxes payable in a future year, for which there must be sufficient tax-basis income to utilize a portion or all of the carryforward amount to realize the deferred tax asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6969291&amp;loc=d3e28680-109314<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43, 289<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from equity-based compensation costs, which can only be deducted for tax purposes when actual costs are incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6969291&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 11<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the portions of deferred tax assets as of the balance sheet date for which, based on the weight of available evidence, it is more likely than not will not be realized through future reductions of tax-based income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 17<br><br> -Subparagraph e<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43-49<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsValuationAllowance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of all deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A taxable temporary difference is a difference between the tax basis and the carrying amount of an asset or liability in the financial statements prepared in accordance with generally accepted accounting principles that will result in taxable amounts in one or more future periods.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 42, 43<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31931-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EBG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>BASIS OF PRESENTATION (Details)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercentageOfShareOwned', window );">Percentage of share owned by China Pharma Holdings Inc of Onny Investment Limited</a></td>
        <td class="nump">100.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercentageOfShareOwnedofHelpsonMedicalAmpBiotechnologyCoLtd', window );">Percentage of share owned by China Pharma Holdings Inc of Helpson Medical &amp; Biotechnology Co., Ltd</a></td>
        <td class="nump">100.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercetageOfAcquiredByOnnyInHelpson', window );">Percetage of acquired by Onny in Helpson</a></td>
        <td class="nump">100.00%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercentageOfShareOwned">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of share owned by China Pharma Holdings Inc of Onny Investment Limited</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PercentageOfShareOwned</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercentageOfShareOwnedofHelpsonMedicalAmpBiotechnologyCoLtd">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of share owned by China Pharma Holdings Inc of Helpson Medical &amp;amp; Biotechnology Co., Ltd</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PercentageOfShareOwnedofHelpsonMedicalAmpBiotechnologyCoLtd</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercetageOfAcquiredByOnnyInHelpson">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percetage of acquired by Onny in Helpson</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PercetageOfAcquiredByOnnyInHelpson</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>FUTURE MINIMUM COMMITMENTS (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_Leases1Abstract', window );"><strong>FUTURE MINIMUM COMMITMENTS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock', window );">FUTURE MINIMUM COMMITMENTS</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Future minimum commitments under the agreements are as follows:</p> <table width="341" style="MARGIN:auto auto auto -0.75pt; WIDTH:256pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td width="255" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:191pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>For the Years Ending December 31:</b></p></td> <td width="87" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in"></td></tr> <tr style="HEIGHT:15pt"> <td width="255" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:191pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in"> <p style="LINE-HEIGHT:normal; TEXT-INDENT:11pt; MARGIN:0in 0in 0pt">2013</p></td> <td width="87" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$ 13,133,498 </p></td></tr> <tr style="HEIGHT:15pt"> <td width="255" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:191pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in"> <p style="LINE-HEIGHT:normal; TEXT-INDENT:11pt; MARGIN:0in 0in 0pt">2014</p></td> <td width="87" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 968,860 </p></td></tr> <tr style="HEIGHT:15.75pt"> <td width="255" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:191pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in"> <p style="LINE-HEIGHT:normal; TEXT-INDENT:11pt; MARGIN:0in 0in 0pt">Total</p></td> <td width="87" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$ 14,102,358 </p></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_Leases1Abstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_Leases1Abstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Publisher FASB<br><br> -Number <br><br> -Article <br><br> -Subparagraph (b)<br><br> -Name Accounting Standards Codification<br><br> -Paragraph 1<br><br> -Section 50<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EGDAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONCENTRATIONS Sales And Purchases (Details)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercentageOfNoCustomerAccountedForMoreThanSales', window );">Percentage of no customer accounted for more than sales</a></td>
        <td class="nump">20.40%<span></span></td>
        <td class="nump">10.20%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercentageOfOneCustomerAccountedForMoreThanSales', window );">Percentage of one customer accounted for more than sales</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercentageOfPurchasesFromOneSupplierOfRawMaterials', window );">Percentage of purchases from one supplier of raw materials</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">20.80%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercentageOfOneCustomerAccountedForAccountsReceivables', window );">Percentage of one customer accounted for accounts receivables</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercentageOfNoCustomerAccountedForMoreThanSales">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of no customer accounted for more than sales</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PercentageOfNoCustomerAccountedForMoreThanSales</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercentageOfOneCustomerAccountedForAccountsReceivables">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of one customer accounted for accounts receivables</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PercentageOfOneCustomerAccountedForAccountsReceivables</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercentageOfOneCustomerAccountedForMoreThanSales">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of one customer accounted for more than sales</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PercentageOfOneCustomerAccountedForMoreThanSales</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercentageOfPurchasesFromOneSupplierOfRawMaterials">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of purchases from one supplier of raw materials</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PercentageOfPurchasesFromOneSupplierOfRawMaterials</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAAAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>DERIVATIVE WARRANT LIABILITY (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>May 30, 2008</div>
        </th>
        <th class="th">
          <div>May 27, 2008</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IssueOfWarrantsForPurchaseOfCommonStockTreatedAsDerivatives', window );">Issue of warrants for purchase of common stock treated as derivatives</a></td>
        <td class="nump">300,000<span></span></td>
        <td class="nump">1,250,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ValuePerShare', window );">Value per share</a></td>
        <td class="nump">$ 2.98<span></span></td>
        <td class="nump">$ 2.80<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IssueOfWarrantsForPurchaseOfCommonStockTreatedAsDerivatives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issue of warrants for purchase of common stock treated as derivatives</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_IssueOfWarrantsForPurchaseOfCommonStockTreatedAsDerivatives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value per share</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EYKAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>BASIS OF PRESENTATION Basic and Diluted Earnings per Common Share (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NetIncome', window );">Net income</a></td>
        <td class="nump">$ 4,617,659<span></span></td>
        <td class="nump">$ 19,269,642<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Basic weighted-average common shares outstanding</a></td>
        <td class="nump">43,579,557<span></span></td>
        <td class="nump">43,479,899<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_Warrants', window );">Warrants</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_Options', window );">Options</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common shares outstanding</a></td>
        <td class="nump">43,579,557<span></span></td>
        <td class="nump">43,479,899<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BasicEarningsPerShare', window );">Basic earnings per share</a></td>
        <td class="nump">$ 0.11<span></span></td>
        <td class="nump">$ 0.44<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DilutedEarningsPerShare', window );">Diluted earnings per share</a></td>
        <td class="nump">$ 0.11<span></span></td>
        <td class="nump">$ 0.44<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BasicEarningsPerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_BasicEarningsPerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DilutedEarningsPerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DilutedEarningsPerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NetIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NetIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_Options">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_Options</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_Warrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_Warrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1505-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e2646-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1448-109256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesIssuedBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EZFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>BASIS OF PRESENTATION POLICIES (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_WarrantsWithExercisePrice', window );">Warrants with exercise prices of $3.00 to $3.80 per share</a></td>
        <td class="nump">150,000<span></span></td>
        <td class="nump">150,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OptionsWithAnExercisePrice', window );">Options with an exercise price of $2.54 to $3.47 per share</a></td>
        <td class="nump">50,000<span></span></td>
        <td class="nump">310,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalWarrantsAndOptions', window );">Total Warrants And Options</a></td>
        <td class="nump">200,000<span></span></td>
        <td class="nump">460,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RecognizedAnImpairmentLossOfItsIntangibleAssets', window );">Recognized an impairment loss of its intangible assets</a></td>
        <td class="nump">$ 593,095<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CompanyContributionToRetirementBenefitPlans', window );">Company contribution to retirement benefit plans</a></td>
        <td class="nump">$ 233,846<span></span></td>
        <td class="nump">$ 166,071<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CompanyContributionToRetirementBenefitPlans">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Company contribution to retirement benefit plans</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_CompanyContributionToRetirementBenefitPlans</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OptionsWithAnExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Options with an exercise price of $2.54 to $3.47 per share</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_OptionsWithAnExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RecognizedAnImpairmentLossOfItsIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Recognized an impairment loss of its intangible assets</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_RecognizedAnImpairmentLossOfItsIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalWarrantsAndOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total Warrants And Options</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_TotalWarrantsAndOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_WarrantsWithExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants with exercise prices of $3.00 to $3.80 per share</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_WarrantsWithExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORY.<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORY.</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY.</a></td>
        <td class="text"><!--egx--><p style="MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:"><b>NOTE 2 &#150; INVENTORY.</b></p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Inventory consisted of the following:</p> <table width="445" style="MARGIN:auto auto auto -0.75pt; WIDTH:333.7pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="88" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="11" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="83" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="94" colspan="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:70.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>&nbsp;December 31, </b></p></td> <td width="11" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="89" colspan="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:67pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>&nbsp;December 31, </b></p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="88" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2012</b></p></td> <td width="11" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="83" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2011</b></p></td></tr> <tr style="HEIGHT:15.75pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Raw materials</p></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="88" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;$&nbsp;&nbsp; 30,198,816 </p></td> <td width="11" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="83" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;$&nbsp;&nbsp; 24,920,825 </p></td></tr> <tr style="HEIGHT:15pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Finished goods</p></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="88" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7,930,684 </p></td> <td width="11" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="83" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5,457,833 </p></td></tr> <tr style="HEIGHT:15pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="88" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 38,129,500 </p></td> <td width="11" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="83" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30,378,658 </p></td></tr> <tr style="HEIGHT:15pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Allowance for obsolescence - raw materials</p></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="88" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (1,769,984)</p></td> <td width="11" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="83" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; </p></td></tr> <tr style="HEIGHT:15.75pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Total inventory</b></p></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="88" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;$&nbsp;&nbsp; 36,359,516 </p></td> <td width="11" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="83" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;$&nbsp;&nbsp; 30,378,658 </p></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 3<br><br> -Section A<br><br> -Paragraph 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a, b, c<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E4EAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>INVENTORY. (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
        <td class="nump">$ 30,198,816<span></span></td>
        <td class="nump">$ 24,920,825<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
        <td class="nump">7,930,684<span></span></td>
        <td class="nump">5,457,833<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory Gross</a></td>
        <td class="nump">38,129,500<span></span></td>
        <td class="nump">30,378,658<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AllowanceForObsolescenceRawMaterials', window );">Allowance for obsolescence - raw materials</a></td>
        <td class="num">(1,769,984)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalInventoryNet', window );">Total Inventory net</a></td>
        <td class="nump">$ 36,359,516<span></span></td>
        <td class="nump">$ 30,378,658<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AllowanceForObsolescenceRawMaterials">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Allowance for obsolescence - raw materials</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AllowanceForObsolescenceRawMaterials</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalInventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_TotalInventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryFinishedGoods</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.  Also includes purchased parts that will be used as components of a finished product.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryRawMaterials</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EIBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>INCOME TAXES Undistributed Earnings And Income Tax Rates (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_UndistributedEarningsOfHelpson', window );">Undistributed earnings of Helpson</a></td>
        <td class="nump">$ 113,400,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany', window );">Investment in Helpson, a foreign subsidiary for the company</a></td>
        <td class="nump">$ 23,300,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EnterpriseIncomeTaxRatesForTheYear2012', window );">Enterprise Income Tax Rates for the year 2012</a></td>
        <td class="nump">15.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EnterpriseIncomeTaxRatesForTheYear2013', window );">Enterprise Income Tax Rates for the year 2013</a></td>
        <td class="nump">15.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EnterpriseIncomeTaxRatesForTheYear2014AndAfter', window );">Enterprise Income Tax Rates for the year 2014 and after</a></td>
        <td class="nump">25.00%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EnterpriseIncomeTaxRatesForTheYear2012">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Enterprise Income Tax Rates for the year 2012</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_EnterpriseIncomeTaxRatesForTheYear2012</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EnterpriseIncomeTaxRatesForTheYear2013">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Enterprise Income Tax Rates for the year 2013</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_EnterpriseIncomeTaxRatesForTheYear2013</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EnterpriseIncomeTaxRatesForTheYear2014AndAfter">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Enterprise Income Tax Rates for the year 2014 and after</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_EnterpriseIncomeTaxRatesForTheYear2014AndAfter</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Investment in Helpson, a foreign subsidiary for the company</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_UndistributedEarningsOfHelpson">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Undistributed earnings of Helpson</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_UndistributedEarningsOfHelpson</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EMKAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>OFFICERS 2010 Stock Option Plan (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>May 25, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NumberOfCommonSharesIssuedToExecutiveOfficers', window );">Number of common shares issued to executive officers</a></td>
        <td class="nump">125,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ValueOfTheOptionsGranted', window );">Value of the options granted</a></td>
        <td class="nump">$ 317,500<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ExercisePriceForOptionsGranted', window );">Exercise Price for options granted</a></td>
        <td class="nump">$ 2.54<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RestrictedStockGrantedToCEO', window );">Restricted stock granted to CEO</a></td>
        <td class="nump">75,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria', window );">Options to vest on six month anniversary performance based vesting criteria</a></td>
        <td class="nump">25,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OptionsVestedOnMay252012', window );">Options vested on May 25, 2012</a></td>
        <td class="nump">50,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RestrictedStockOptionsGrantedToFormerCFO', window );">Restricted stock options granted to former CFO</a></td>
        <td class="nump">25,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OptionsVestedOnApril282012', window );">Options vested on April 28, 2012</a></td>
        <td class="nump">25,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria1', window );">Options to vest on six month anniversary performance based vesting criteria.</a></td>
        <td class="nump">25,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SharesForfeitedDueToNonAchievementOfPerformanceCriteria', window );">Shares forfeited due to non achievement of performance criteria</a></td>
        <td class="nump">50,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ShareBasedCompensationRelatedToTheFixedShareAwardsWasRecognizedOverThePeriodTheSharesVested', window );">share-based compensation related to the fixed share awards was recognized over the period the shares vested.</a></td>
        <td class="nump">$ 50,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ExercisePriceForOptionsGranted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise Price for options granted</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ExercisePriceForOptionsGranted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NumberOfCommonSharesIssuedToExecutiveOfficers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of common shares issued to executive officers</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NumberOfCommonSharesIssuedToExecutiveOfficers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Options to vest on six month anniversary performance based vesting criteria</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Options to vest on six month anniversary performance based vesting criteria.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_OptionsToVestOnSixMonthAnniversaryPerformanceBasedVestingCriteria1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OptionsVestedOnApril282012">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Options vested on April 28, 2012</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_OptionsVestedOnApril282012</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OptionsVestedOnMay252012">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Options vested on May 25, 2012</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_OptionsVestedOnMay252012</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RestrictedStockGrantedToCEO">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Restricted stock granted to CEO</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_RestrictedStockGrantedToCEO</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RestrictedStockOptionsGrantedToFormerCFO">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Restricted stock options granted to former CFO</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_RestrictedStockOptionsGrantedToFormerCFO</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ShareBasedCompensationRelatedToTheFixedShareAwardsWasRecognizedOverThePeriodTheSharesVested">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>share-based compensation related to the fixed share awards was recognized over the period the shares vested.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ShareBasedCompensationRelatedToTheFixedShareAwardsWasRecognizedOverThePeriodTheSharesVested</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_SharesForfeitedDueToNonAchievementOfPerformanceCriteria">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Shares forfeited due to non achievement of performance criteria</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_SharesForfeitedDueToNonAchievementOfPerformanceCriteria</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ValueOfTheOptionsGranted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of the options granted</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ValueOfTheOptionsGranted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E4LAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 4,029,708<span></span></td>
        <td class="nump">$ 4,050,854<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Banker's acceptances</a></td>
        <td class="nump">101,570<span></span></td>
        <td class="nump">83,512<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade accounts receivable, less allowance for doubtful accounts of $4,429,945 and $3,536,405, respectively</a></td>
        <td class="nump">66,175,570<span></span></td>
        <td class="nump">69,695,556<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables, less allowance for doubtful accounts of $49,881 and $38,921, respectively</a></td>
        <td class="nump">80,799<span></span></td>
        <td class="nump">55,039<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesToSuppliers', window );">Advances to suppliers</a></td>
        <td class="nump">4,816,354<span></span></td>
        <td class="nump">5,778,841<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory:</a></td>
        <td class="nump">36,359,516<span></span></td>
        <td class="nump">30,378,658<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetCurrent', window );">Deferred tax assets</a></td>
        <td class="nump">967,671<span></span></td>
        <td class="nump">566,226<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
        <td class="nump">112,531,188<span></span></td>
        <td class="nump">110,608,686<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesForPurchasesOfPropertyAndEquipment', window );">Advances for purchases of property and equipment</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">170,323<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesForPurchasesOfIntangibleAssets', window );">Advances for purchases of intangible assets:</a></td>
        <td class="nump">39,263,977<span></span></td>
        <td class="nump">36,194,494<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $4,273,373 and $3,391,124, respectively</a></td>
        <td class="nump">9,031,894<span></span></td>
        <td class="nump">6,334,817<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization of $2,944,726 and $3,041,804, respectively</a></td>
        <td class="nump">2,412,854<span></span></td>
        <td class="nump">3,082,671<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
        <td class="nump">163,239,913<span></span></td>
        <td class="nump">156,390,991<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payable</a></td>
        <td class="nump">2,841,862<span></span></td>
        <td class="nump">3,112,385<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump">202,185<span></span></td>
        <td class="nump">184,017<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Accrued taxes payable</a></td>
        <td class="nump">2,426,826<span></span></td>
        <td class="nump">3,082,353<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other payables</a></td>
        <td class="nump">1,094,886<span></span></td>
        <td class="nump">822,448<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerAdvancesCurrent', window );">Advances from customers</a></td>
        <td class="nump">1,945,984<span></span></td>
        <td class="nump">1,784,474<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Other payables - related parties</a></td>
        <td class="nump">1,354,567<span></span></td>
        <td class="nump">861,563<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Short-term notes payable</a></td>
        <td class="nump">4,761,073<span></span></td>
        <td class="nump">3,931,745<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
        <td class="nump">14,627,383<span></span></td>
        <td class="nump">13,778,985<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Long-term deferred tax liability</a></td>
        <td class="nump">95,963<span></span></td>
        <td class="nump">128,909<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
        <td class="nump">14,723,346<span></span></td>
        <td class="nump">13,907,894<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 95,000,000 shares authorized; 43,579,557 shares and 43,529,557 shares outstanding, respectively</a></td>
        <td class="nump">43,580<span></span></td>
        <td class="nump">43,530<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">23,590,204<span></span></td>
        <td class="nump">23,448,534<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
        <td class="nump">108,904,325<span></span></td>
        <td class="nump">104,286,666<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
        <td class="nump">15,978,458<span></span></td>
        <td class="nump">14,704,367<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
        <td class="nump">148,516,567<span></span></td>
        <td class="nump">142,483,097<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
        <td class="nump">$ 163,239,913<span></span></td>
        <td class="nump">$ 156,390,991<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesForPurchasesOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Advances for purchases of intangible assets</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AdvancesForPurchasesOfIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesForPurchasesOfPropertyAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>AdvancesForPurchasesOfPropertyAndEquipment</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AdvancesForPurchasesOfPropertyAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesToSuppliers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of advances to suppliers.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AdvancesToSuppliers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 3<br><br> -Section A<br><br> -Paragraph 7<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableOtherCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 3<br><br> -Section A<br><br> -Paragraph 7<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableTradeCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e653-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 14, 17, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS115-1/124-1<br><br> -Paragraph 15D<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e637-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e681-108580<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 7<br><br> -Section 03<br><br> -Paragraph 12<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br> -Section S99<br><br> -Name Accounting Standards Codification<br><br> -Publisher FASB<br><br> -Paragraph 1<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br> -Number 6<br><br> -Paragraph 25<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 18<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Section 45<br><br> -SubTopic 10<br><br> -Topic 210<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Paragraph 1<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrestricted cash available for day-to-day operating needs, for an entity that has cash equivalents, but does not aggregate cash equivalents with cash on the balance sheet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Cash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash equivalents may be reported as cash equivalents, while legally restricted equivalents held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular equivalents are not generally reported as part of unrestricted cash equivalents.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerAdvancesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current portion of prepayments received from customers for goods or services to be provided in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CustomerAdvancesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current portion of the aggregate tax effects as of the balance sheet date of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after deducting the allocated valuation allowance, if any, to reduce such amount to net realizable value. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, are classified according to the expected reversal date of the temporary difference. An unrecognized tax benefit that is directly related to a position taken in a tax year that results in a net operating loss carryforward is presented as a reduction of the related deferred tax asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31928-109318<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 41, 42, 43<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31958-109318<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31917-109318<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31931-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the noncurrent portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A noncurrent taxable temporary difference is a difference between the tax basis and the carrying amount of a noncurrent asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise separates deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, are classified according to the expected reversal date of the temporary difference.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31958-109318<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 41, 42<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31917-109318<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907571&amp;loc=d3e31931-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph k<br><br> -Subparagraph 1<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 57<br><br> -Paragraph 2<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DueToRelatedPartiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 42, 45<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph ((a)(1),(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsNetExcludingGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19-26)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 32<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.32)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 7<br><br> -Section 03<br><br> -Paragraph 25<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 21<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of other receivables, net, due within one year of the balance sheet date (or one operating cycle, if longer) from third parties or arising from transactions not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherReceivablesNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 7<br><br> -Section 03<br><br> -Paragraph 8<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -Subparagraph b, c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.3,4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ReceivablesNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A3<br><br> -Appendix A<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TaxesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EIF">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>DERIVATIVE WARRANT GAINS (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DerivativeGainsRecognized', window );">Derivative gains recognized</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 934,260<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DerivativeGainsRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Derivative gains recognized</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DerivativeGainsRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EY4AG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income for the period</a></td>
        <td class="nump">$ 4,617,659<span></span></td>
        <td class="nump">$ 19,269,642<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">1,462,771<span></span></td>
        <td class="nump">1,174,822<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_StockBasedCompensation', window );">Stock based compensation.</a></td>
        <td class="nump">141,720<span></span></td>
        <td class="nump">196,183<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DerivativeGain', window );">Derivative gain.</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(934,260)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BadDebtExpenseBenefit', window );">Bad debt expense (benefit).</a></td>
        <td class="nump">871,613<span></span></td>
        <td class="nump">108,085<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets.</a></td>
        <td class="nump">593,095<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Inventory obsolescence provision</a></td>
        <td class="nump">1,769,984<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
        <td class="num">(430,250)<span></span></td>
        <td class="nump">37,281<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Trade accounts and other receivables.</a></td>
        <td class="num">(1,098,322)<span></span></td>
        <td class="num">(11,392,154)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ChangesInAdvancesToSuppliers', window );">Changes in Advances to suppliers.</a></td>
        <td class="nump">1,014,760<span></span></td>
        <td class="num">(251,171)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory.</a></td>
        <td class="num">(4,702,575)<span></span></td>
        <td class="num">(2,925,143)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Trade accounts payables.</a></td>
        <td class="num">(306,040)<span></span></td>
        <td class="num">(1,928,259)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
        <td class="nump">246,817<span></span></td>
        <td class="nump">758,783<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable', window );">Accrued taxes payable.</a></td>
        <td class="num">(683,357)<span></span></td>
        <td class="nump">591,470<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Other payables.</a></td>
        <td class="nump">744<span></span></td>
        <td class="nump">13,327<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInCustomerAdvances', window );">Advances from customers.</a></td>
        <td class="nump">145,201<span></span></td>
        <td class="nump">518,718<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by Operating Activities</a></td>
        <td class="nump">3,643,820<span></span></td>
        <td class="nump">5,237,324<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NetInvestmentInBankerSAcceptances', window );">Net investment in banker's acceptances</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(82,149)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesForPaymentOfPurchasesOfPropertyAndEquipment', window );">Advances for payment of purchases of property and equipment.</a></td>
        <td class="num">(1,612,670)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesForPaymentOfPurchasesOfIntangibleAssets', window );">Advances for payment of purchases of intangible assets.</a></td>
        <td class="num">(3,218,035)<span></span></td>
        <td class="num">(5,191,385)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(156,878)<span></span></td>
        <td class="num">(352,362)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used in Investing Activities</a></td>
        <td class="num">(4,987,583)<span></span></td>
        <td class="num">(5,625,896)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes payable</a></td>
        <td class="nump">793,223<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Borrowings from related party</a></td>
        <td class="nump">493,004<span></span></td>
        <td class="nump">595,670<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided by Financing Activity</a></td>
        <td class="nump">1,286,227<span></span></td>
        <td class="nump">595,670<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of Exchange Rate Changes on Cash</a></td>
        <td class="nump">36,390<span></span></td>
        <td class="nump">151,670<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net Increase (Decrease) in Cash</a></td>
        <td class="num">(21,146)<span></span></td>
        <td class="nump">358,768<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents at Beginning of Period</a></td>
        <td class="nump">4,050,854<span></span></td>
        <td class="nump">3,692,086<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents at End of Period</a></td>
        <td class="nump">4,029,708<span></span></td>
        <td class="nump">4,050,854<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
        <td class="nump">298,433<span></span></td>
        <td class="nump">248,018<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
        <td class="nump">2,138,853<span></span></td>
        <td class="nump">4,532,592<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Noncash Investing and Financing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AccountsPayableForPurchasesOfPropertyAndEquipment', window );">Accounts payable for purchases of property and equipment</a></td>
        <td class="nump">151,731<span></span></td>
        <td class="nump">143,151<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AccountsReceivableCollectedWithBankerSAcceptances', window );">Accounts receivable collected with banker's acceptances</a></td>
        <td class="nump">4,354,825<span></span></td>
        <td class="nump">6,102,570<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InventoryPurchasedWithBankerSAcceptances', window );">Inventory purchased with banker's acceptances</a></td>
        <td class="nump">2,768,805<span></span></td>
        <td class="nump">6,102,570<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesForPurchasesOfPropertyAndEquipmentPaidWithBankerSAcceptances', window );">Advances for purchases of property and equipment paid with banker's acceptances</a></td>
        <td class="nump">1,540,820<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances', window );">Advances for purchases of intangibles paid with banker's acceptances</a></td>
        <td class="nump">$ 27,909<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AccountsPayableForPurchasesOfPropertyAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accounts receivable collected with banker's acceptances</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AccountsPayableForPurchasesOfPropertyAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AccountsReceivableCollectedWithBankerSAcceptances">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accounts receivable collected with banker's acceptances</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AccountsReceivableCollectedWithBankerSAcceptances</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesForPaymentOfPurchasesOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Advances for payment of purchases of intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AdvancesForPaymentOfPurchasesOfIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesForPaymentOfPurchasesOfPropertyAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Advances for payment of purchases of property and equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AdvancesForPaymentOfPurchasesOfPropertyAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Advances for purchases of intangibles paid with banker's acceptances</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesForPurchasesOfPropertyAndEquipmentPaidWithBankerSAcceptances">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Advances for purchases of property and equipment paid with banker's acceptances</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AdvancesForPurchasesOfPropertyAndEquipmentPaidWithBankerSAcceptances</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BadDebtExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_BadDebtExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ChangesInAdvancesToSuppliers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Changes in Advances to suppliers.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ChangesInAdvancesToSuppliers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DerivativeGain">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DerivativeGain</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InventoryPurchasedWithBankerSAcceptances">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Inventory purchased with banker's acceptances</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_InventoryPurchasedWithBankerSAcceptances</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NetInvestmentInBankerSAcceptances">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for the net investment in bankers acceptances.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NetInvestmentInBankerSAcceptances</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_StockBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_StockBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 45<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 289<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6889476&amp;loc=d3e330036-122817<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredIncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The effect of exchange rate changes on cash balances held in foreign currencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 25<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 46<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16373-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 46<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16373-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOfIntangibleAssetsFinitelived</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 27<br><br> -Subparagraph f<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxesPaidNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableTrade</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedTaxesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInCustomerAdvances">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amount of prepayments by customers for goods or services to be provided at a later date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInCustomerAdvances</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInInventories</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other obligations due by the reporting entity that are payable within one year (or one business cycle), not otherwise defined in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromRelatedPartyDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EHH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>ASSETS Depreciation (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DepreciationExpensePropertyAndEquipment', window );">Depreciation Expense property and equipment</a></td>
        <td class="nump">$ 851,047<span></span></td>
        <td class="nump">$ 555,036<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AmortizationExpenseIntangibleAssets', window );">Amortization Expense Intangible assets</a></td>
        <td class="nump">$ 611,724<span></span></td>
        <td class="nump">$ 596,525<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AmortizationExpenseIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amortization Expense Intangible assets</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AmortizationExpenseIntangibleAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DepreciationExpensePropertyAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Depreciation Expense property and equipment</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DepreciationExpensePropertyAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORY(Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InventoryTablesAbstract', window );"><strong>INVENTORY (Tables)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory consists</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Inventory consisted of the following:</p> <table width="445" style="MARGIN:auto auto auto -0.75pt; WIDTH:333.7pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="88" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="11" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="83" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="94" colspan="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:70.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>&nbsp;December 31, </b></p></td> <td width="11" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="89" colspan="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:67pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>&nbsp;December 31, </b></p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="88" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2012</b></p></td> <td width="11" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="83" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2011</b></p></td></tr> <tr style="HEIGHT:15.75pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Raw materials</p></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="88" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;$&nbsp;&nbsp; 30,198,816 </p></td> <td width="11" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="83" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;$&nbsp;&nbsp; 24,920,825 </p></td></tr> <tr style="HEIGHT:15pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Finished goods</p></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="88" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7,930,684 </p></td> <td width="11" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="83" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5,457,833 </p></td></tr> <tr style="HEIGHT:15pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="88" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 38,129,500 </p></td> <td width="11" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="83" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;30,378,658 </p></td></tr> <tr style="HEIGHT:15pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Allowance for obsolescence - raw materials</p></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="88" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (1,769,984)</p></td> <td width="11" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="83" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; </p></td></tr> <tr style="HEIGHT:15.75pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Total inventory</b></p></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="88" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65.7pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;$&nbsp;&nbsp; 36,359,516 </p></td> <td width="11" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:8pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="7" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:5pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="83" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:62pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;$&nbsp;&nbsp; 30,378,658 </p></td></tr></table> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InventoryTablesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_InventoryTablesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Topic <br><br> -SubTopic <br><br> -Publisher SEC<br><br> -Number 210<br><br> -Article 5<br><br> -Subparagraph a,b,c<br><br> -Name Regulation S-X (SX)<br><br> -Paragraph 6<br><br> -Section 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfInventoryCurrentTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EYAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>INTANGIBLE ASSETS SFDA Approved Medical Formulas (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_GrossCarryingAmount', window );">Gross carrying amount</a></td>
        <td class="nump">$ 5,357,580<span></span></td>
        <td class="nump">$ 6,124,475<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AccumulatedAmortizationIntangibleAssetsSFDAApprovedMedicalFormulas', window );">Accumulated amortization Intangible assets SFDA Approved Medical Formulas</a></td>
        <td class="num">(2,944,726)<span></span></td>
        <td class="num">(3,041,804)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NetCarryingAmount', window );">Net carrying amount</a></td>
        <td class="nump">2,412,854<span></span></td>
        <td class="nump">3,082,671<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AnnualAmortization2013', window );">Annual amortization 2013</a></td>
        <td class="nump">521,980<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AnnualAmortization2014', window );">Annual amortization 2014</a></td>
        <td class="nump">505,653<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AnnualAmortization2015', window );">Annual amortization 2015</a></td>
        <td class="nump">364,978<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AnnualAmortization2016', window );">Annual amortization 2016</a></td>
        <td class="nump">318,939<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AnnualAmortization2017', window );">Annual amortization 2017</a></td>
        <td class="nump">272,386<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AnnualAmortizationThereafter', window );">Annual amortization Thereafter</a></td>
        <td class="nump">428,918<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AnnualAmortizationTotal', window );">Annual amortization Total</a></td>
        <td class="nump">2,412,854<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CompanyObligationToPayLaboratoriesAndOthers', window );">Company obligation to pay laboratories and others</a></td>
        <td class="nump">$ 6,476,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AccumulatedAmortizationIntangibleAssetsSFDAApprovedMedicalFormulas">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated amortization Intangible assets SFDA Approved Medical Formulas</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AccumulatedAmortizationIntangibleAssetsSFDAApprovedMedicalFormulas</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AnnualAmortization2013">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Annual amortization 2013</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AnnualAmortization2013</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AnnualAmortization2014">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Annual amortization 2014</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AnnualAmortization2014</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AnnualAmortization2015">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Annual amortization 2015</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AnnualAmortization2015</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AnnualAmortization2016">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Annual amortization 2016</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AnnualAmortization2016</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AnnualAmortization2017">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Annual amortization 2017</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AnnualAmortization2017</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AnnualAmortizationThereafter">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Annual amortization Thereafter</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AnnualAmortizationThereafter</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AnnualAmortizationTotal">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Annual amortization Total</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AnnualAmortizationTotal</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CompanyObligationToPayLaboratoriesAndOthers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Company obligation to pay laboratories and others</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_CompanyObligationToPayLaboratoriesAndOthers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_GrossCarryingAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross carrying amount</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_GrossCarryingAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NetCarryingAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net carrying amount</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NetCarryingAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EZF">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IntangibleAssetsTablesAbstract', window );"><strong>Intangible Assets (Tables)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IntangibleAssetsMedicalFormulasTablesTextBlock', window );">Intangible Assets Medical Formulas</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Intangible assets consisted solely of SFDA approved medical formulas as follows:</p> <table width="357" style="MARGIN:auto auto auto -0.75pt; WIDTH:267.4pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:12.75pt"> <td width="187" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:140pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="16" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="71" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="71" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:12.75pt"> <td width="187" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:140pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="16" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="154" colspan="3" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:115.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>December 31,</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="187" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:140pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="16" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2012</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2011</b></p></td></tr> <tr style="HEIGHT:17.1pt"> <td width="187" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:140pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Gross carrying amount</p></td> <td width="16" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="71" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$ 5,357,580 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="71" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$ 6,124,475 </p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="187" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:140pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Accumulated amortization</p></td> <td width="16" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="71" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp; (2,944,726)</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="71" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp; (3,041,804)</p></td></tr> <tr style="HEIGHT:0.25in"> <td width="187" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:140pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Net carrying amount</p></td> <td width="16" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$ 2,412,854 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$ 3,082,671 </p></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IntangibleAssetsAmortizationExpense', window );">Intangible Assets Amortization Expense</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">The estimated aggregate annual amortization expense for each of the next five years and thereafter is as follows:</p> <table width="144" style="MARGIN:auto auto auto -0.75pt; WIDTH:1.5in; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:13.9pt"> <td width="63" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Year</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="69" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>&nbsp;Amount </b></p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="63" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">2013</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="69" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;$&nbsp;&nbsp;&nbsp; 521,980 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="63" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">2014</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="69" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 505,653 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="63" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">2015</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="69" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 364,978 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="63" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">2016</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="69" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 318,939 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="63" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">2017</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="69" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 272,386 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="63" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">Thereafter</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="69" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 428,918 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="63" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Total</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="69" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;$ 2,412,854 </p></td></tr></table> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IntangibleAssetsAmortizationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Table text block that refers to Intangible Assets Amortization Expense</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_IntangibleAssetsAmortizationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IntangibleAssetsMedicalFormulasTablesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabluar disclosure of Intangible Assets Medical Formulas</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_IntangibleAssetsMedicalFormulasTablesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IntangibleAssetsTablesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_IntangibleAssetsTablesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</a></td>
        <td class="text"><!--egx--><p style="MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:"><b>NOTE 1 &#150; ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Organization and Nature of Operations</b> &#150; China Pharma Holdings, Inc., a Nevada corporation as of December 31, 2012, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, that in turn owns 100% of Hainan Helpson Medical &amp; Biotechnology Co., Ltd (Helpson), a company organized under the laws of the People's Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.&nbsp; </p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">On December 31, 2012, China Pharma Holdings, Inc consummated a reincorporation merger for the purpose of changing the state of incorporation from Delaware to Nevada pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012.&nbsp; The reincorporation merger was approved by stockholders holding the majority of the outstanding common shares on December 21, 2012.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">The Foreign Investment Industrial Catalogue&nbsp;(the &#147;Catalogue&#148;) jointly issued by the China&#146;s Ministry of Commerce and the National Development and Reform Commission (as the latest version is the year 2012 version, effective January 30, 2012) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the &#147;FIE&#148;) shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case of the Company&#146;s business.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson&#146;s business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson from Helpson&#146;s three former shareholders on May 25, 2005 by entry into an Equity Transfer Agreement with such three parties on May 25, 2005. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">The Company has and continues to acquire well-accepted medical formulas to a diverse portfolio of Western and Chinese medicines.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Consolidation and Basis of Presentation</b> &#150; The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Helpson&#146;s functional currency is the Chinese Renminbi. Helpson&#146;s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson&#146;s financial statements are included in accumulated other comprehensive income, which is a component of stockholders&#146; equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>&nbsp;</b></p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Reclassification </b>- The Company has made certain reclassifications to the consolidated balance sheet at December 31, 2011 to conform to the December 31, 2012 presentation. These reclassifications had no effect on the consolidated statements of operations or cash flows for any periods presented.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Accounting Estimates</b> - The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the management of the Company (&#147;Management&#148;) to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Cash and Cash Equivalents</b> &#150; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker&#146;s acceptances purchased with maturities of three months or less. </p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Trade Accounts Receivable and Allowance for Doubtful Accounts</b> &#150; Trade accounts receivables are carried at original invoiced amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts and an estimation of the overall economic conditions affecting the Company's customer base. The Company reviews a customer's credit history before extending credit. If the financial condition of its customers were to deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable to the extent they are considered unlikely to be collected. It is common practice in the PRC for receivables to extend beyond one year. Customer balances outstanding for more than one year are allowed for at a greater rate when calculating the allowance for doubtful accounts. At December 31, 2012, trade accounts receivables included $30,134,909 from sales that occurred more than one year prior to December 31, 2012, that Management believes are collectable.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Advances to Suppliers and Advances from Customers</b> &#150; Common practice in the PRC is to make advances to suppliers for materials and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances received from customers are applied against trade accounts receivable when finished products are sold.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Inventory </b>&#150; Inventory is stated at the lower of cost or net realizable value, computed on an average cost basis. An allowance for inventory obsolescence is provided when the market value of inventory items is lower than its cost.&nbsp; The Company recognized an inventory obsolescence reserve of $1,769,984 and $0 for the years ended December 31, 2012 and 2011, respectively.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Valuation of Long-Lived Assets</b> &#150; The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash flows estimated to be generated by the asset. The Company evaluated its long-lived assets at December 31, 2012 and determined that the value of certain of its intangible assets were impaired and recognized an impairment loss of $593,095 for the year ended December 31, 2012. No impairment was recognized during the year ended December 31, 2011.&nbsp; See Note 4.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Property and Equipment</b> &#150; Property and equipment are stated at cost. Maintenance and repairs are charged to expense as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Revenue Recognition</b> &#150; Revenue is considered earned when the Company has persuasive evidence of an arrangement with the customer, delivery of the products has occurred, the sales price is fixed or determinable, and collectability is reasonably assured. Delivery does not occur until products have been shipped to the customer, risk of loss has transferred to the customer and customer acceptance has been obtained, customer acceptance provisions have lapsed, or the Company has objective evidence that the criteria specified in the customer acceptance provisions have been satisfied. The sales price is not considered to be fixed or determinable until all contingencies related to the sale have been resolved.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Cost of Revenues</b> &#150; Cost of revenues includes wages, materials, handling charges, and other expenses associated with the manufacture and delivery of products.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Research and Development</b> &#150; Research and development expenditures are recorded as expenses in the period in which they occur. Research and development costs were not material during the years ended December 31, 2012 and 2011.&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>&nbsp;</b></p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Retirement Benefit Plans</b> &#150; The Company is required to make monthly contributions at prescribed rates to various employee retirement benefit plans organized by provincial governments. The governments benefit plans assume the retirement benefit obligations of all existing and future retired employees of the Company. The Company contributed $233,846 and $166,071 to retirement benefit plans for the years ended December 31, 2012 and 2011, respectively. Contributions to these plans are charged to expense as incurred.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Advertising Costs</b> &#150; Advertising costs are expensed when incurred. The Company did not incur any advertising costs for the years ended December 31, 2012 and 2011.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Basic and Diluted Earnings per Common Share</b> - Basic earnings per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per share are calculated to give effect to potentially issuable dilutive common shares.</p> <table width="493" style="MARGIN:auto auto auto -0.75pt; WIDTH:370pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="152" colspan="3" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:114pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>For the Years Ended</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"></td> <td width="152" colspan="3" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:114pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>December 31,</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2012</b></p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2011</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Net income</p></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$ 4,617,659 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$ 19,269,642 </p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Basic weighted-average common shares outstanding</p></td> <td width="71" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">43,579,557 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">43,479,899 </p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Effect of dilutive securities:</p></td> <td width="71" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt">Warrants</p></td> <td width="71" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt">Options</p></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td></tr> <tr style="HEIGHT:19.5pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:19.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Diluted weighted-average common shares outstanding</p></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:19.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">43,579,557 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:19.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:19.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">43,479,899 </p></td></tr> <tr style="HEIGHT:0.25in"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Basic earnings per share</p></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.11 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.44 </p></td></tr> <tr style="HEIGHT:0.25in"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Diluted earnings per share</p></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.11 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.44 </p></td></tr></table> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Potential common shares were not included in the computation of diluted earnings per share as their effect would have been anti-dilutive as follows:</p> <table width="493" style="MARGIN:auto auto auto -0.75pt; WIDTH:370pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="152" colspan="3" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:114pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>For the Years Ended</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="152" colspan="3" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:114pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>December 31,</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2012</b></p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2011</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Warrants with exercise prices of $3.00 to $3.80 per share</p></td> <td width="71" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 150,000 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 150,000 </p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Options with an exercise price of $2.54 to $3.47 per share</p></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50,000 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 310,000 </p></td></tr> <tr style="HEIGHT:13.5pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt">Total</p></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 200,000 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 460,000 </p></td></tr></table> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Credit Risk </b>&#150; The carrying amounts of accounts receivable included in the balance sheet represent the Company's exposure to credit risk in relation to its financial assets. No other financial assets carry a significant exposure to credit risk. The Company performs ongoing credit evaluations of each customer's financial condition. It maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded Management's estimations.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secure due to the state policy on protecting depositors&#146; interests. The PRC promulgated a new Bankruptcy Law in August 2006, effective June&nbsp;1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. In the event that bankruptcy laws are enacted for banks in the PRC, the Company&#146;s deposits may be at a higher risk of loss.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Interest Rate Risk</b> &#150; The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and viability of securing future debt instruments within the PRC.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Recently Announced Accounting Standards</b> &#150; The Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) 2011-05, Presentation of Comprehensive Income, which revises the manner in which comprehensive income is presented in an entity&#146;s financial statements. This update requires the presentation of the components of comprehensive income in either a continuous statement of comprehensive income or in two separate but consecutive financial statements. The option to present comprehensive income in the statement of stockholders&#146; equity has been eliminated. The provisions of this update were effective as of January 1, 2012, and the Company has included a continuous consolidated statement of comprehensive income as part of these consolidated financial statements.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">ASU 2011-04, Fair Value Measurement &#150; Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS, provides converged guidance on how to measure fair value, which is largely consistent with existing U.S. GAAP. This update also requires additional fair value measurement disclosures. The provisions of this update were effective as of January 1, 2012. The effects of adoption were not significant to the accompanying consolidated financial statements.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">ASU No. 2012-02, Testing Indefinite-Lived Intangible Assets for Impairment, permits, but does not require, an entity to conduct an initial qualitative assessment to determine whether it is more likely than not that a non-goodwill indefinite-lived asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test currently required (i.e., comparing the asset's fair value with its carrying amount). This new standard was adopted by the Company on September 30, 2012 and had no significant effect on the accompanying consolidated financial statements.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">ASU No. 2011-11, Disclosures about Offsetting Assets and Liabilities, requires disclosures about assets and liabilities that are offset or have the potential to be offset. This new guidance will be effective for reporting periods beginning January 1, 2013, with retrospective application required. The adoption of this guidance is not expected to have a material impact on the Company&#146;s results of operations or financial position. </p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 720<br><br> -SubTopic 15<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122524<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921930&amp;loc=d3e5614-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6970148&amp;loc=SL6228881-111685<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Name Statement of Position (SOP)<br><br> -Publisher AICPA<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS140-4/FIN46(R)-8<br><br> -Paragraph 8, C1, C7<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Name FASB Interpretation (FIN)<br><br> -Publisher FASB<br><br> -Number 46R<br><br> -Paragraph 4, 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 852<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2209116<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2134480<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 2-6<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122150<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359553&amp;loc=d3e288-107754<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELEAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS PARENTHETICALS (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts on trade accounts receivables</a></td>
        <td class="nump">$ 4,429,945<span></span></td>
        <td class="nump">$ 3,536,405<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AllowanceForDoubtfulAccountsOnOtherReceivables', window );">Allowance for doubtful accounts on other receivables</a></td>
        <td class="nump">49,881<span></span></td>
        <td class="nump">38,921<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation on property and equipment</a></td>
        <td class="nump">4,273,373<span></span></td>
        <td class="nump">3,391,124<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization on intangible assets</a></td>
        <td class="nump">$ 2,944,726<span></span></td>
        <td class="nump">$ 3,041,804<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, par or stated value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized</a></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="nump">5,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par or stated value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized</a></td>
        <td class="nump">95,000,000<span></span></td>
        <td class="nump">95,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued</a></td>
        <td class="nump">43,579,557<span></span></td>
        <td class="nump">43,529,557<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding</a></td>
        <td class="nump">43,579,557<span></span></td>
        <td class="nump">43,529,557<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AllowanceForDoubtfulAccountsOnOtherReceivables">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A valuation allowance for other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AllowanceForDoubtfulAccountsOnOtherReceivables</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6965416&amp;loc=d3e5074-111524<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The accumulated amount of amortization of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 45<br><br> -Subparagraph a(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
        <td class="text"><!--egx--><p style="MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:"><b>NOTE 11 - STOCKHOLDERS' EQUITY</b></p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">On December 31, 2012, the domicile of China Pharma Holdings, Inc. was changed from the State of Delaware to the State of Nevada through a merger of the Delaware corporation with and into its newly set-up Nevada subsidiary, with the Nevada subsidiary being the surviving corporation. Each common share, warrant and stock option outstanding on the merger date was automatically converted into a common share, warrant or stock option of the Nevada corporation. </p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">The Company is authorized to issue 95,000,000 shares of common shares, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Company&#146;s board of directors.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Warrants</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">As of December 31, 2012, the Company had warrants outstanding and exercisable to purchase an aggregate of 150,000 shares of Company's common stock at exercise prices ranging from $3.00 to $3.80 per share, which expire May 16, 2013. At December 31, 2012, the warrants had a weighted-average exercise price of $3.40 per share, a weighted-average remaining contractual life of 0.4 years and a total intrinsic value of $0.&nbsp;&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Employee Stock Options</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">2010 Incentive Plan</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">On November 12, 2010, the Company&#146;s Board of Directors adopted, and on December 22, 2010 its stockholders approved the 2010 Long-Term Incentive Plan (the &#147;2010 Incentive Plan&#148;), which gave the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries. The 2010 Incentive Plan currently allows for equity awards of up to 4,000,000 shares of common stock.&nbsp; Through December 31, 2012, 125,000 shares of common stock and options to purchase an aggregate of 100,000 shares of stock options had been granted under the 2010 Incentive Plan.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">On May 25, 2011 the Company issued two-year options to purchase a total of 100,000 shares of its common stock under the 2010 Incentive Plan to two of its executive officers as follows. The Company&#146;s Chief Executive Officer was granted non-qualified stock options to purchase 50,000 shares of common stock at an exercise price of $2.54 per share, the closing price of the Company&#146;s common stock on the day prior to the day of grant, expiring on May 25, 2013, of which 25,000 shares vested on May 25, 2012 and 25,000 shares were to vest on the three-month anniversary of the achievement of certain performance-based vesting criteria. The Company also granted its former Chief Financial Officer non-qualified stock options to purchase 50,000 shares of common stock at an exercise price of $2.54 per share, expiring on April 28, 2013, of which 25,000 shares vested on April 28, 2012 and 25,000 shares were to vest on the three-month anniversary of the achievement of certain performance-based vesting criteria.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">The grant-date fair value of the options of $0.71 per share, or $70,580 in total, was based on the grant-date closing market price of $2.54 per share and on the following weighted-average assumptions: risk free interest rate of 0.54%, expected dividend yield of 0%, expected volatility of 70.4% and an expected life of 1.0 year. The share-based compensation expense relative to the fixed stock options was recognized over the period the options vested. Share-based compensation relative to the performance-based options will be recognized only if the performance criterion is met. </p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">In addition, on May 25, 2011 the Company granted 125,000 shares of common stock under the 2010 Incentive Plan to two of its executive officers valued at $317,500 based on the closing market price on the date of grant of $2.54 per share. Specifically, the Company granted 75,000 shares of restricted stock to its Chief Executive Officer, of which 50,000 shares vested on May 25, 2012, and 25,000 shares were to vest on the six-month anniversary of the achievement of certain performance-based vesting criteria, and the Company granted 50,000 shares of restricted stock to its former Chief Financial Officer, of which 25,000 shares vested on April 28, 2012 and 25,000 shares were to vest on the six-month anniversary of the achievement of certain performance-based vesting criteria. The performance criterion was not met and the performance-based shares were forfeited during the year ended December 31, 2012. The share-based compensation related to the fixed share awards was recognized over the period the shares vested.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Effective April 28, 2012, the Company and Frank Waung, its former Chief Financial Officer, entered into an Amendment Agreement to Non-Qualified Stock Option Agreements to amend the terms of the equity awards previously granted to Mr. Waung in conjunction with the termination of his employment agreement with the Company effective April 29, 2012.&nbsp;&nbsp;The effect of the amendment was to terminate a total of 185,000 vested but unexercised options immediately on April 28, 2012 as opposed to 90 days after the employment termination date. Effective the same date, the Company awarded 100,000 shares of common stock to Mr. Waung for his previous service to the Company.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Accordingly, the Company recorded a total of $55,775 of stock compensation expense based upon the excess of the fair value of the common stock issued in exchange for the options that were cancelled, i.e., 185,000 options with a fair value of $225 in exchange for 100,000 shares of common stock with a fair value of $56,000 based on the closing market price of the common stock of $0.56 per share on the date awarded. The fair value of the stock options was computed using the Black-Scholes Option Pricing Model, using the following assumptions: risk free interest rate of 0.14% to 0.19%, expected dividend yield of 0%, expected volatility of 66.7% and an expected life of 0.5 to 1.1 years. </p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">On April 27 and 28, 2012 a total of 50,000 options to purchase common stock granted under the 2010 Incentive Plan with an exercise price of $2.54 per share were forfeited due to the failure to achieve the performance-based vesting criteria. </p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">The Company recognized $141,720 and $196,183 of compensation expense during the years ended December 31, 2012 and 2011, respectively, as general and administrative expenses related to the awards of common shares and grants and modifications of stock options. The total income tax benefit recognized from the related stock-based compensation was $35,430 and $49,046 for the years ended December 31, 2012 and 2011, respectively. &nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model using the assumptions noted in the preceding paragraphs. Expected volatility is based on the historical volatility of the Company&#146;s common stock prices. The Company uses historical data to estimate employee termination rates. The expected term of options granted is determined by the simplified method, which is one-half of the original contractual term. The simplified method is used due to the lack of historical share option exercise data to provide a reasonable basis upon which to estimate expected term. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. </p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">A summary of stock option activity as of December 31, 2012, and changes during the year then ended is presented below:</p> <table width="542" style="MARGIN:auto auto auto -0.75pt; WIDTH:406.2pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:12.75pt"> <td width="227" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="68" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="64" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Weighted-</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="227" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="68" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="64" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Weighted-</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Average</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="227" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="68" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="64" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Average</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Remaining</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Aggregate</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="227" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="68" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="64" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Exercise</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Contractual </b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Intrinsic</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="227" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="68" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Shares</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>&nbsp;</b></p></td> <td width="64" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Price</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>&nbsp;</b></p></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Term (Years)</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Value</b></p></td></tr> <tr style="HEIGHT:15pt"> <td width="227" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Outstanding at December 31, 2011</p></td> <td width="68" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp; 310,000 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="64" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.03 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>&nbsp;</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>&nbsp;</b></p></td></tr> <tr style="HEIGHT:15pt"> <td width="227" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt">Forfeited</p></td> <td width="68" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (50,000)</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>&nbsp;</b></p></td> <td width="64" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.54 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>&nbsp;</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>&nbsp;</b></p></td></tr> <tr style="HEIGHT:15pt"> <td width="227" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt">Expired</p></td> <td width="68" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp; (235,000)</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>&nbsp;</b></p></td> <td width="64" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.19 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>&nbsp;</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>&nbsp;</b></p></td></tr> <tr style="HEIGHT:15pt"> <td width="227" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Outstanding at December 31, 2012</b></p></td> <td width="68" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25,000 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="64" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.54 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.40 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; </p></td></tr> <tr style="HEIGHT:15pt"> <td width="227" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Exercisable at December 31, 2012</b></p></td> <td width="68" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25,000 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="64" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.54 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.40 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; </p></td></tr></table> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">At December 31, 2012, there was no remaining unrecognized compensation expense related to the fixed stock options. The unrecognized performance-based compensation expense related to performance-based options was $17,645, but will only be recognized if the performance criterion is met. There was no remaining unrecognized compensation expense related to restrictive stock awards at December 31, 2012.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph d<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 1<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EWIAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 14, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">CHINA PHARMA HOLDINGS, INC.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-K<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Dec. 31,
         2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001106644<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">43,579,557<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, POS AM and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityPublicFloat</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommitmentAndContingenciesAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
        <td class="text"><!--egx--><p style="MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:"><b>NOTE 12 &#150; COMMITMENTS AND CONTINGENCIES</b></p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Economic environment - Substantially all of the Company's operations are conducted in the PRC, and therefore the Company is subject to special considerations and significant risks not typically associated with companies operating in the United States of America. These risks include, among others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The Company's results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely affect the Company&#146;s operations.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">In addition, all of the Company's revenue is denominated in the PRC's currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Contractual Commitments &#150; The Company entered into purchase and construction agreements during the year ended December 31, 2012 in connection with the construction of a new facility and required manufacturing improvements. &nbsp;Under these agreements, the Company made payments in the amount of $3,110,319 during the year ended December 31, 2012. These payments are classified as construction in progress on the accompanying balance sheet at December 31, 2012. Future minimum commitments under the agreements are as follows:</p> <table width="341" style="MARGIN:auto auto auto -0.75pt; WIDTH:256pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:15pt"> <td width="255" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:191pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>For the Years Ending December 31:</b></p></td> <td width="87" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in"></td></tr> <tr style="HEIGHT:15pt"> <td width="255" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:191pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in"> <p style="LINE-HEIGHT:normal; TEXT-INDENT:11pt; MARGIN:0in 0in 0pt">2013</p></td> <td width="87" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$ 13,133,498 </p></td></tr> <tr style="HEIGHT:15pt"> <td width="255" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:191pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in"> <p style="LINE-HEIGHT:normal; TEXT-INDENT:11pt; MARGIN:0in 0in 0pt">2014</p></td> <td width="87" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 968,860 </p></td></tr> <tr style="HEIGHT:15.75pt"> <td width="255" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:191pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in"> <p style="LINE-HEIGHT:normal; TEXT-INDENT:11pt; MARGIN:0in 0in 0pt">Total</p></td> <td width="87" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65pt; PADDING-RIGHT:5.4pt; HEIGHT:15.75pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$ 14,102,358 </p></td></tr> <tr style="HEIGHT:15pt"> <td width="255" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:191pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="87" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:65pt; PADDING-RIGHT:5.4pt; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr></table> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommitmentAndContingenciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_CommitmentAndContingenciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14435-108349<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 14<br><br> -Paragraph 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 9, 10, 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EM4AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
        <td class="nump">$ 54,507,049<span></span></td>
        <td class="nump">$ 81,166,739<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
        <td class="nump">38,660,814<span></span></td>
        <td class="nump">52,178,680<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory obsolescence</a></td>
        <td class="nump">1,769,984<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
        <td class="nump">14,076,251<span></span></td>
        <td class="nump">28,988,059<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling expenses</a></td>
        <td class="nump">3,535,214<span></span></td>
        <td class="nump">3,439,522<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
        <td class="nump">3,313,306<span></span></td>
        <td class="nump">3,716,397<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense</a></td>
        <td class="nump">871,612<span></span></td>
        <td class="nump">108,085<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment of intangible assets</a></td>
        <td class="nump">593,095<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">8,313,227<span></span></td>
        <td class="nump">7,264,004<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_GovernmentSubsidyIncome', window );">Government subsidy income</a></td>
        <td class="nump">141,987<span></span></td>
        <td class="nump">301,672<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
        <td class="nump">5,905,011<span></span></td>
        <td class="nump">22,025,727<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="nump">4,944<span></span></td>
        <td class="nump">7,208<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num">(308,375)<span></span></td>
        <td class="num">(255,198)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfDerivatives', window );">Derivative gain</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">934,260<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Net other income (expense)</a></td>
        <td class="num">(303,431)<span></span></td>
        <td class="nump">686,270<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
        <td class="nump">5,601,580<span></span></td>
        <td class="nump">22,711,997<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
        <td class="num">(983,921)<span></span></td>
        <td class="num">(3,442,355)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
        <td class="nump">4,617,659<span></span></td>
        <td class="nump">19,269,642<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease', window );">Other comprehensive income - foreign currency translation adjustment</a></td>
        <td class="nump">1,274,091<span></span></td>
        <td class="nump">5,080,098<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
        <td class="nump">$ 5,891,750<span></span></td>
        <td class="nump">$ 24,349,740<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per Share:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
        <td class="nump">$ 0.11<span></span></td>
        <td class="nump">$ 0.44<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
        <td class="nump">$ 0.11<span></span></td>
        <td class="nump">$ 0.44<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_GovernmentSubsidyIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of Government subsidy income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_GovernmentSubsidyIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e540-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A5<br><br> -Appendix A<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(3)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 8, 9, 10, 11, 12, 13, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508144<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e557-108580<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 2<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945512&amp;loc=d3e4984-109258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 20<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 7<br><br> -Paragraph 18<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.23)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 36, 37, 38<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1252-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 11, 12, 36<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 20<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1252-109256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 7<br><br> -Paragraph 18<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfDerivatives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.13(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfDerivatives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetImpairment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1,2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GrossProfit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 10<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 45<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cost of borrowed funds accounted for as interest that was charged against earnings during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 34<br><br> -Paragraph 21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher OTS<br><br> -Name Federal Regulation (FR)<br><br> -Number Title 12<br><br> -Chapter V<br><br> -Section 563c.102<br><br> -Paragraph 9<br><br> -Subsection II<br><br> -LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy.  It will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386783&amp;loc=d3e4542-108314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 4<br><br> -Section 7<br><br> -Paragraph 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br> -Number 6<br><br> -Paragraph 86<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryWriteDown</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency of the reporting entity, net of tax.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 20<br><br> -Subparagraph (b),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32211-110900<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920433&amp;loc=d3e998-108581<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 24<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(3)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 14, 17, 19, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 52<br><br> -Paragraph 13, 20, 31<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6922042&amp;loc=SL4591551-111686<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A1, A4, A5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921930&amp;loc=SL4573702-111684<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6922042&amp;loc=SL4591552-111686<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 5<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4569616-111683<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProfitLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.5)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProvisionForDoubtfulAccounts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 1<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expenses recognized in the period that are directly related to the selling and distribution of products or services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SellingExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
        <td class="text"><!--egx--><p style="MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:"><b>NOTE 6 &#150; RELATED PARTY TRANSACTIONS</b></p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">During the years ended December 31, 2012 and December 31, 2011, a member of the Company&#146;s board of directors advanced the Company $493,004 and $595,670, respectively. The advances bear interest at a rate of 1.0% per year.&nbsp; Total interest expense of $9,942 and $7,180 was recognized for the years ended December 31, 2012 and 2011. Total advances owing to the board member were $1,354,567 and $861,563 as of December 31, 2012 and December 31, 2011, respectively, and are recorded as other payables &#150; related parties on the accompanying consolidated balance sheets. </p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 3A<br><br> -Section 04<br><br> -Paragraph b<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 57<br><br> -Paragraph 1-4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph k<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesForPurchasesOfIntangibleAssetsAbstract', window );"><strong>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock', window );">ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.</a></td>
        <td class="text"><!--egx--><p style="MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:"><b>NOTE 5 &#150; ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS. </b></p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">In order to expand the number of medicines manufactured and marketed by the Company, it has entered into contracts with independent laboratories and others for the purchase of medical formulas. Although SFDA approval had not been obtained for these medical formulas at the dates of the contracts, the objective of the contracts is for the Company to obtain SFDA-approved medical formulas once the SFDA approval process is completed. The Company received the title to two patents that relate to medical formulas currently in the SFDA approval process at December 31, 2012. The related patents have not expired. </p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Prior to entering into the contracts, the laboratories typically have completed all required research and development to determine the medical formula for and the method of production of the generic medicine. The application to the SFDA for production approval must be made by the production facility that will produce the related product. As a result, a contract typically provides that the Company buys the medical formula from the laboratory and the laboratory is required to assist the Company in applying for and obtaining the production approval from the SFDA.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">A typical SFDA approval process for the production of a generic medical product involves a number of steps that generally requires three to five years. If the medical formula is purchased at the point when the generic medical product receives the SFDA&#146;s approval for a clinical study, which is very typical for the Company, the clinical study that follows will usually take from one and a half to three years to complete. After the clinical study is completed, the results are submitted to the SFDA and a production approval application is filed with the SFDA. In most cases, it will take between eight to eighteen months to prepare and submit the production approval application and obtain SFDA approval. Upon approving the generic medical product, the SFDA issues a production certificate and the Company can produce and sell the generic medical product. As a result of this process, SFDA approval is expected to be received in approximately two to five years from the dates of the medical formula contracts.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Under the terms of the contracts, the laboratories are required to assist the Company in obtaining production approval for the medical formulas from the SFDA. Management monitors the status of each medical formula on a regular basis in order to assess whether the laboratories are performing adequately under the contracts. If a medical product is not approved by the SFDA, as evidenced by their issuance of a denial letter, or if the laboratory breaches the contract, the laboratory is required under the contract to provide a refund to the Company of the full amount of the payments made to the laboratory for that formula, or the Company can require the application of those payments to another medical formula with the same laboratory. As a result of the refund right, the Company is ultimately purchasing an approved medical product. Accordingly, payments made prior to the issuance of production approval by the SFDA are recorded as advances for purchases of intangible assets. </p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">To date, no formula has failed to receive SFDA production approval nor has the Company been informed or become aware of any formula that may fail to receive such approval. However, there is no assurance that the medical products will receive production approval and if the Company does not receive such approval, it will enforce its contractual rights to receive the refund from the laboratory or have the payments applied to another medical formula with the same laboratory.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">At December 31, 2012, the Company was obligated to pay laboratories and others approximately $6,476,000 upon completion of the various phases of contracts to provide SFDA production approval of medical formulas. </p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesForPurchasesOfIntangibleAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AdvancesForPurchasesOfIntangibleAssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure of advances for purchases of intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EZF">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PropertyAndEquipmentTablesAbstract', window );"><strong>PROPERTY AND EQUIPMENT (Tables)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and equipment consists</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Property and equipment consisted of the following:</p> <table width="430" style="MARGIN:auto auto auto -0.75pt; WIDTH:322.4pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>&nbsp;December 31, </b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>&nbsp;December 31, </b></p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2012</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2011</b></p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Permit of land use</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 447,013 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 442,978 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Building</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2,419,125 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2,397,286 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Plant, machinery and equipment</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6,381,209 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6,184,254 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Motor vehicle</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 147,080 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 145,300 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Office equipment</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 222,273 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 204,552 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Construction in progress</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3,688,567 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 351,571 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; TEXT-INDENT:10.05pt; MARGIN:0in 0in 0pt"><b>Total</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp; 13,305,267 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9,725,941 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Less: accumulated depreciation</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp; (4,273,373)</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp; (3,391,124)</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Property and Equipment, net</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;$&nbsp;&nbsp; 9,031,894 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.2pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;$&nbsp;&nbsp; 6,334,817 </p></td></tr></table> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_UsefulLivesOfTheAssetsTableTextBlock', window );">Useful lives of the assets</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:</p> <table width="337" style="MARGIN:auto auto auto -0.75pt; WIDTH:253pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">Asset</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="75" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:56pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">&nbsp;Life - years </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Permit of land use</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="75" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:56pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">40 - 70</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Building</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="75" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:56pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">20 - 35</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Plant, machinery and equipment</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="75" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:56pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">10</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Motor vehicle</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="75" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:56pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">5 - 10</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="251" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:188pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Office equipment</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="75" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:56pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">3-5</p></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PropertyAndEquipmentTablesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PropertyAndEquipmentTablesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_UsefulLivesOfTheAssetsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of useful lives of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_UsefulLivesOfTheAssetsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONCENTRATIONS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>CONCENTRATIONS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">CONCENTRATIONS</a></td>
        <td class="text"><!--egx--><p style="MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:"><b>NOTE 13 &#150; CONCENTRATIONS</b></p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">For the year ended December 31, 2011, a customer accounted for 20.4% of sales and at December 31, 2011, one customer accounted for 10.2% of accounts receivable. For the year ended December 31, 2011, purchases from a supplier made up 20.8% of raw material purchases. </p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:"><font style="LINE-HEIGHT:115%">For the year ended December 31, 2012, no customer accounted for more than 10% of sales or ending accounts receivable. Two suppliers accounted for 12.1% and 10.3%, respectively, of the raw materials &nbsp;the Company purchased during the year ended December 31, 2012.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 94-6<br><br> -Paragraph 21, 22, 24<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13537-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 15A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6442-108592<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13531-108611<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6327-108592<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RisksAndUncertaintiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>DERIVATIVE WARRANT LIABILITY<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DerivativeInstrumentsAndHedgingActivitiesAbstract', window );"><strong>DERIVATIVE WARRANT LIABILITY</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesAndFairValueTextBlock', window );">DERIVATIVE WARRANT LIABILITY</a></td>
        <td class="text"><!--egx--><p style="MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:"><b>NOTE 9 &#150; DERIVATIVE WARRANT LIABILITY</b></p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">On May 27, 2008 and on May 30, 2008, the Company issued warrants to purchase 1,250,000 shares of common stock at $2.80 per share and warrants to purchase 300,000 shares of common stock at $2.98 per share, respectively, exercisable for a period of three years. These warrants contained certain pricing reset provisions which caused the warrants to be treated as a derivative. These warrants were never exercised and expired on May 27, 2011. Changes to the warrant derivative liability were recognized in the results of operations and resulted in derivative gains of $0 and $934,260 for the years ended December 31, 2012 and 2011, respectively. </p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DerivativeInstrumentsAndHedgingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_DerivativeInstrumentsAndHedgingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesAndFairValueTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for derivatives and fair value of assets and liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativesAndFairValueTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>NOTES PAYABLE<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NotesPayable1Abstract', window );"><strong>NOTES PAYABLE</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NotesPayableTextBlock', window );">NOTES PAYABLE</a></td>
        <td class="text"><!--egx--><p style="MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:"><b>NOTE 7 &#150; NOTES PAYABLE</b></p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">On September 30, 2010, the Company entered into a revolving line of credit with a bank in the amount of RMB 25,000,000 (approximately $3.97 million). Advances on the line of credit were due one year from the date of the advance, with the note payable collateralized by certain land use rights and buildings. On October 26, 2011, the Company renewed the underlying note with the same bank.&nbsp; The note bears interest at a base rate equal to the PRC&#146;s floating six-month to one year rate of 6.56% plus an additional 15% of the base rate, with a resulting rate of 7.54% at December 31, 2011. Advances on the line of credit were due one year from the date of the advance and collateralized by certain land use rights and buildings. The outstanding balance due under the revolving line of credit was RMB 25,000,000 ($3,931,745) at December 31, 2011. This amount was classified as a short-term notes payable in the accompanying consolidated balance sheet at December 31, 2011. On October 18, 2012, the Company fully paid the amount due under this line of credit and on October 26, 2012, it matured and was not renewed. </p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">On October 30, 2012, the Company entered into a new revolving line of credit with another bank in the amount of RMB 30,000,000.&nbsp;The related note payable bears interest at an annual rate of 6.90% (based upon 115% of the PRC government&#146;s current short term rate of 6.00%). Advances on the line of credit are due one year from the date of the advance and are collateralized by certain land use rights, buildings and accounts receivable. The outstanding balance due under the revolving line of credit was RMB30,000,000 ($4,761,073) as of December 31, 2012.&nbsp; The Company has no additional amounts available to it under the line of credit.&nbsp; This amount has been classified as short-term notes payable in the accompanying consolidated balance sheet at December 31, 2012.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Fair Value of Notes Payable &#150; Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts of notes payable outstanding at December 31, 2012 and 2011 approximated their fair value because of the immediate or short-term maturity of these financial instruments or because the underlying instruments bear interest rates that approximated current market rates.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NotesPayable1Abstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NotesPayable1Abstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NotesPayableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure of notes payable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NotesPayableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INCOME TAXES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
        <td class="text"><!--egx--><p style="MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:"><b>NOTE 8 - INCOME TAXES</b></p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax laws or rates is recognized in income in the period that includes the enactment date.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Undistributed earnings of Helpson, the Company&#146;s foreign subsidiary, since its acquisition, amounted to approximately $113.4 million at December 31, 2012. Those earnings, as well as the investment in Helpson of approximately $23.3 million, are considered to be indefinitely reinvested and, accordingly, no U.S. federal or state income taxes have been provided thereon. Upon distribution of those earnings in the form of dividends or otherwise, the Company would be subject to U.S. federal and state income taxes (net of an adjustment for foreign tax credits) and withholding taxes payable to the PRC. Determination of the amount of unrecognized deferred U.S. income tax liability is not practical because of the complexities associated with its hypothetical calculation; however, unrecognized foreign tax credits may be available to reduce a portion of the U.S. tax liability.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Liabilities are established for uncertain tax positions expected to be taken in income tax returns when such positions are judged to meet the &#147;more-likely-than-not&#148; threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax penalties are included as a component of other expenses. Through December 31, 2012, the Company has not identified any uncertain tax positions that it had taken. U.S. income tax returns for the years ended December 31, 2009 through December 31, 2012 and the Chinese income tax return for the year ended December 31, 2012 are open for possible examination. </p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">On March 16, 2007, the National People&#146;s Congress of China passed the new Enterprise Income Tax Law (EIT Law) and on December 6, 2007, the State Council of China issued the Implementation Regulations for the EIT Law which took effect on January&nbsp;1, 2008. The EIT Law and Implementation Regulations impose a unified EIT of 25% on all domestic-invested enterprises and Foreign Invested Entities, or FIEs, unless they qualify under certain limited exceptions.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">The Company is located in a special region, which had a 15% corporate income tax rate before the new EIT Law. The new EIT Law abolished the preferential corporate income tax rate in the special region. The Company has transitioned to the new 25% tax rate over a five year period which began on January 1, 2008. During 2010, the Company applied for and received a favorable tax rate of 15% for fiscal 2011 through 2013 due to its status in the PRC as a high technology enterprise. Under current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:</p> <table width="240" style="MARGIN:auto auto auto -0.75pt; WIDTH:2.5in; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:12.75pt"> <td width="96" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1in; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="25" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:19pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="119" style="BORDER-BOTTOM:black 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:89pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" rowspan="2" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Enterprise Income Tax Rate</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="96" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1in; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Year</b></p></td> <td width="25" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:19pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:12.75pt"> <td width="96" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1in; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">2013</p></td> <td width="25" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:19pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="119" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:89pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">15%</p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="96" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1in; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">2014 and after</p></td> <td width="25" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:19pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="119" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:89pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">25%</p></td></tr></table> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">The provision for income taxes consisted of the following:</p> <table width="483" style="MARGIN:auto auto auto -0.75pt; WIDTH:362pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="167" colspan="3" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:125pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Years Ended December 31,</b></p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.55pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>2012</b></p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>2011</b></p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Current</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.55pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp; 1,414,171</p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp; 3,458,568</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Deferred</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.55pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">(430,250)</p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">(16,213)</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Total income tax expense</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.55pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 983,921</p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp; 3,442,355</p></td></tr></table> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Following is a reconciliation of income taxes calculated at the federal statutory rate to the provision for income taxes:</p> <table width="490" style="MARGIN:auto auto auto -0.75pt; WIDTH:367.4pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:18.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:18.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:18.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:18.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:18.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:18.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="174" colspan="3" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:130.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Years Ended December 31,</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">2012</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">2011</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Tax at statutory rate of 25%</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp; 1,400,395</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp; 5,677,999</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Non-deductible stock-based compensation from</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">current and prior years</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">149,644</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">261,122</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Effect of tax holiday</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">(655,947)</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">(2,330,566)</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Other, primarily the effect of US tax rates</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">(70,471)</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">-</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Change in valuation allowance</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">160,300</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">(166,200)</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Income tax expense</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 983,921</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="81" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:60.7pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp; 3,442,355</p></td></tr></table> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">The effect of the tax holiday amounted to savings of $655,947 and $2,330,566 for the years ended December 31, 2012 and 2011, which was equivalent to basic and diluted earnings per share of $0.02 and $0.05 per share for the years ended December 31, 2012 and 2011, respectively. The temporary differences which give rise to the deferred income tax assets and liability are as follows:</p> <div align="center"> <table width="483" style="MARGIN:auto auto auto -0.75pt; WIDTH:362.05pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="167" colspan="3" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:125.05pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>December 31,</b></p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2012</b></p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2011</b></p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Deferred income tax assets:</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Allowance for doubtful trade receivables</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 664,492 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 530,461 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Allowance for doubtful other receivables</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7,482 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5,838 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Inventory obsolescence reserve</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 265,498 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Expenses not deductible in current year</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30,200 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 29,927 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Share based compensation</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 45,777 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 172,911 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">U.S. net operating loss carry forwards</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 905,669 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 618,236 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Total deferred income tax assets</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,919,118 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,357,373 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Valuation allowance</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (951,447)</p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (791,147)</p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt">Net deferred income tax asset</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 967,671 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 566,226 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Deferred income tax liability:</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:13.9pt"> <td width="304" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:228pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Intangible assets</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 95,963 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:61.6pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 128,909 </p></td></tr></table></div> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">As of December 31, 2012, the Company has net operating losses from continuing operations for United States federal income tax purposes of $2,663,731 which are available to offset future taxable income, if any, and expire, if not used, from 2029 through 2032.&nbsp; In assessing the realizability of deferred tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.&nbsp; The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized.&nbsp; Management considers projected future taxable income and tax planning strategies in making this assessment.&nbsp; Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, Management believes it is not likely the Company will realize all of the benefits of the deferred tax assets as of December 31, 2012 and 2011.&nbsp; Therefore, the Company has provided for a valuation allowance against its deferred tax assets of $951,447 and $791,147 as of December 31, 2012 and 2011, respectively.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">The Company has also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.&nbsp; During 2012 and 2011, the Company received an incentive payment from the tax authority of the Hainan provincial government in the PRC totaling $141,987 and $301,672, respectively, which has been recorded as government subsidy income on the accompanying statements of operations and comprehensive income for the years ended December 31, 2012 and 2011.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 136, 172<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43, 44, 45, 46, 47, 48, 49<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
        <td class="text"><!--egx--><p style="MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:"><b>NOTE 10 &#150; FAIR VALUE MEASUREMENTS</b></p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 &#150; Quoted prices in active markets for identical assets or liabilities. Level 2 &#150; Observable inputs other than Level 1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable market data. Level 3 &#150; Unobservable inputs supported by little or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. </p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">The Company uses fair value to measure the derivative warrant liability on a recurring basis because fair value is the primary measure for accounting. The Company also uses fair value to measure the value of the banker&#146;s acceptance notes it holds.&nbsp;&nbsp;The Company values its derivative warrants using a valuation method explained above.&nbsp;&nbsp;The banker&#146;s acceptance notes are recorded at cost which approximates fair value.&nbsp;&nbsp;The Company held the following assets and liabilities recorded at fair value as of December 31, 2012 and 2011: </p> <table width="489" style="WIDTH:366.6pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:12.75pt"> <td width="161" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:12.75pt"> <td width="161" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="219" colspan="5" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:164pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Fair Value Measurements at</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="161" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>December 31,</b></p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="219" colspan="5" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:164pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Reporting Date Using</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="161" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Description</b></p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>2012</b></p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Level 1</b></p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Level 2</b></p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Level 3</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="161" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Banker's acceptance notes</p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 101,570</p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -</p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp; 101,570</p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -</p></td></tr> <tr style="HEIGHT:13.5pt"> <td width="161" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Total</p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 101,570</p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -</p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp; 101,570</p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -</p></td></tr></table> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <table width="489" style="WIDTH:366.6pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:12.75pt"> <td width="161" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:12.75pt"> <td width="161" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="219" colspan="5" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:164pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Fair Value Measurements at</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="161" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>December 31,</b></p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="219" colspan="5" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:164pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Reporting Date Using</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="161" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Description</b></p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2011</b></p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Level 1</b></p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Level 2</b></p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Level 3</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="161" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Banker's acceptance notes</p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 83,512 </p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; </p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp; 83,512 </p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; </p></td></tr> <tr style="HEIGHT:13.5pt"> <td width="161" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Total</p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 83,512 </p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; </p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp; 83,512 </p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; </p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="161" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the fair value measurement of assets and liabilities which includes [financial] instruments measured at fair value that are classified in stockholders' equity. Such assets and liabilities may be measured on a recurring or nonrecurring basis. The disclosures which may be required or desired include: (1) for assets and liabilities measured on a recurring basis, disclosure may include: (a) the fair value measurements at the reporting date; (b) the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3); (c) for fair value measurements using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (i) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (ii) purchases, sales, issuances, and settlements (net); (iii) transfers in and transfers out of Level 3 (for example,  transfers due to changes in the observability of significant inputs); (d) the amount of the total gains or losses for the period in subparagraph (c) (i) above included in earnings (or changes in net assets) that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date and a description of where those unrealized gains or losses are reported in the statement of income (or activities); (e) the valuation technique(s) used to measure fair value and a discussion of changes in valuation techniques, if any, during the period and (2) for assets and liabilities that are measured at fair value on a nonrecurring basis (for example,  impaired assets) disclosure may include, in addition to (a) above: (a) the reasons for the fair value measurements recorded; (b) the same as (b) above; (c) for fair value measurements using significant unobservable inputs (Level 3), a description of the inputs and the information used to develop the inputs; and (d) the valuation technique(s) used to measure fair value and a discussion of changes, if any, in the valuation technique(s) used to measure similar assets and/or liabilities in prior periods.  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19279-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 32<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 33<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19296-110258<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19207-110258<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 157<br><br> -Paragraph 6<br><br> -Footnote 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6925170&amp;loc=d3e19190-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementInputsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EWGAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT Assets Life (Details)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PermitOfLandUseMinimumLife', window );">Permit of land use minimum life</a></td>
        <td class="nump">40<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PermitOfLandUseMaximumLife', window );">Permit of land use maximum life</a></td>
        <td class="nump">70<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BuildingMinimumLife', window );">Building minimum life</a></td>
        <td class="nump">20<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BuildingMaximumLife', window );">Building maximum life</a></td>
        <td class="nump">35<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PlantMachineryAndEquipmentLife', window );">Plant, machinery and equipment life</a></td>
        <td class="nump">10<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MotorVehicleMinimumLife', window );">Motor vehicle minimum life</a></td>
        <td class="nump">5<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MotorVehicleMaximumLife', window );">Motor vehicle maximum life</a></td>
        <td class="nump">10<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OfficeEquipmentMinimumLife', window );">Office equipment minimum life</a></td>
        <td class="nump">3<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OfficeEquipmentMaximumLife', window );">Office equipment maximum life</a></td>
        <td class="nump">5<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BuildingMaximumLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_BuildingMaximumLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BuildingMinimumLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_BuildingMinimumLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MotorVehicleMaximumLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_MotorVehicleMaximumLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MotorVehicleMinimumLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_MotorVehicleMinimumLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OfficeEquipmentMaximumLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_OfficeEquipmentMaximumLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OfficeEquipmentMinimumLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_OfficeEquipmentMinimumLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PermitOfLandUseMaximumLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PermitOfLandUseMaximumLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PermitOfLandUseMinimumLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PermitOfLandUseMinimumLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PlantMachineryAndEquipmentLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Plant, machinery and equipment life</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PlantMachineryAndEquipmentLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EBG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Unrecognized Compensation Expense (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_UnrecognizedCompensationExpenseRelatedToPerformanceBasedStockOptions', window );">Unrecognized compensation expense related to performance based stock options</a></td>
        <td class="nump">$ 17,645<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_UnrecognizedCompensationExpenseRelatedToFixedStockOptions', window );">Unrecognized compensation expense related to fixed stock options</a></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalRemainingUnrecognizedCompensationExpenseRelatedToRestrictiveStockGrants', window );">Total remaining unrecognized compensation expense related to restrictive stock grants</a></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalRemainingUnrecognizedCompensationExpenseRelatedToRestrictiveStockGrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Intrinsic value of outstanding stock options</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_TotalRemainingUnrecognizedCompensationExpenseRelatedToRestrictiveStockGrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_UnrecognizedCompensationExpenseRelatedToFixedStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized compensation expense related to fixed stock options</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_UnrecognizedCompensationExpenseRelatedToFixedStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_UnrecognizedCompensationExpenseRelatedToPerformanceBasedStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized compensation expense related to performance based stock options</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_UnrecognizedCompensationExpenseRelatedToPerformanceBasedStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EZF">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>BASIS OF PRESENTATION (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BasisOfPresentationTablesAbstract', window );"><strong>BASIS OF PRESENTATION (Tables)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Presentation of the numerators and denominators used in the calculation of basic and diluted earnings per share</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Diluted earnings per share are calculated to give effect to potentially issuable dilutive common shares.</p> <table width="493" style="MARGIN:auto auto auto -0.75pt; WIDTH:370pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="152" colspan="3" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:114pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>For the Years Ended</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"></td> <td width="152" colspan="3" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:114pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>December 31,</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2012</b></p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2011</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Net income</p></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$ 4,617,659 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$ 19,269,642 </p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Basic weighted-average common shares outstanding</p></td> <td width="71" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">43,579,557 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">43,479,899 </p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Effect of dilutive securities:</p></td> <td width="71" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt">Warrants</p></td> <td width="71" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt">Options</p></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td></tr> <tr style="HEIGHT:19.5pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:19.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Diluted weighted-average common shares outstanding</p></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:19.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">43,579,557 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:19.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:19.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">43,479,899 </p></td></tr> <tr style="HEIGHT:0.25in"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Basic earnings per share</p></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.11 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.44 </p></td></tr> <tr style="HEIGHT:0.25in"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Diluted earnings per share</p></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.11 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.44 </p></td></tr></table> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PotentialCommonSharesWereNotIncludedInTheComputationOfDilutedEarningsPerShareTableTextBlock', window );">Potential common shares were not included in the computation of diluted earnings per share</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Potential common shares were not included in the computation of diluted earnings per share as their effect would have been anti-dilutive as follows:</p> <table width="493" style="MARGIN:auto auto auto -0.75pt; WIDTH:370pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="152" colspan="3" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:114pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>For the Years Ended</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="152" colspan="3" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:114pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>December 31,</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2012</b></p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2011</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Warrants with exercise prices of $3.00 to $3.80 per share</p></td> <td width="71" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 150,000 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 150,000 </p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Options with an exercise price of $2.54 to $3.47 per share</p></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50,000 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 310,000 </p></td></tr> <tr style="HEIGHT:13.5pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt">Total</p></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 200,000 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 460,000 </p></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BasisOfPresentationTablesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_BasisOfPresentationTablesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PotentialCommonSharesWereNotIncludedInTheComputationOfDilutedEarningsPerShareTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of common shares not included in earnings per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_PotentialCommonSharesWereNotIncludedInTheComputationOfDilutedEarningsPerShareTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of an entity's basic and diluted earnings per share calculations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueMeasurementsTablesAbstract', window );"><strong>FAIR VALUE MEASUREMENTS (Tables)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AssetsFairValuesTablETextBlock', window );">Assets Fair Value</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">The Company held the following assets and liabilities recorded at fair value as of December 31, 2012 and 2011: </p> <table width="489" style="WIDTH:366.6pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:12.75pt"> <td width="161" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:12.75pt"> <td width="161" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="219" colspan="5" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:164pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Fair Value Measurements at</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="161" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>December 31,</b></p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="219" colspan="5" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:164pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Reporting Date Using</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="161" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Description</b></p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>2012</b></p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Level 1</b></p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Level 2</b></p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Level 3</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="161" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Banker's acceptance notes</p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 101,570</p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -</p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp; 101,570</p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;-</p></td></tr> <tr style="HEIGHT:13.5pt"> <td width="161" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Total</p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 101,570</p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -</p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp; 101,570</p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -</p></td></tr></table> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <table width="489" style="WIDTH:366.6pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:12.75pt"> <td width="161" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:12.75pt"> <td width="161" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="219" colspan="5" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:164pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Fair Value Measurements at</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="161" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>December 31,</b></p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="219" colspan="5" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:164pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Reporting Date Using</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="161" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Description</b></p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2011</b></p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Level 1</b></p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Level 2</b></p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Level 3</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="161" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Banker's acceptance notes</p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 83,512 </p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; </p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp; 83,512 </p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; </p></td></tr> <tr style="HEIGHT:13.5pt"> <td width="161" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:120.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Total</p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="85" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:63.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 83,512 </p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; </p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp; 83,512 </p></td> <td width="13" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:48.4pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; </p></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AssetsFairValuesTablETextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of assets vair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AssetsFairValuesTablETextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueMeasurementsTablesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FairValueMeasurementsTablesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E5BAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>2010 Stock Option Plan Frank Waung (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Apr. 28, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_VestedAndUnexercisedOptions', window );">Vested and unexercised options</a></td>
        <td class="nump">185,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NumberOfDaysOpposedAfterTheEmploymentTerminationDate', window );">Number of days opposed after the employment termination date</a></td>
        <td class="nump">90<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommonSharesGranted', window );">Common shares granted</a></td>
        <td class="nump">100,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RecordedCompensationExpense', window );">Recorded compensation expense</a></td>
        <td class="nump">$ 55,775<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueOf185000OptionsCancelled', window );">Fair value of 185000 options cancelled</a></td>
        <td class="nump">225<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueOf100000CommonSharesExchanged', window );">Fair value of 100000 common shares exchanged</a></td>
        <td class="nump">$ 56,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ClosingMarketPriceOfCommonStock', window );">Closing market price of common stock</a></td>
        <td class="nump">$ 0.56<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_StartingRiskFreeInterestRate', window );">Starting risk free interest rate</a></td>
        <td class="nump">0.14%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ClosingRiskFreeInterestRate', window );">Closing risk free interest rate</a></td>
        <td class="nump">0.19%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ExpectedDividendYield', window );">Expected dividend yield</a></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ExpectedVolatility', window );">Expected volatility</a></td>
        <td class="nump">66.70%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MinimumExpectedLife', window );">Minimum expected life</a></td>
        <td class="nump">0.5<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MaximumExpectedLife', window );">Maximum expected life</a></td>
        <td class="nump">1.1<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NumberOfOptionsToPurchaseCommonStockGranted', window );">Number of options to purchase common stock granted</a></td>
        <td class="nump">50,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OptionsExercisePrice', window );">Options exercise price</a></td>
        <td class="nump">$ 2.54<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommonStockSharesGranted', window );">Common stock shares granted</a></td>
        <td class="nump">$ 50,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ClosingMarketPriceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Closing market price of common stock</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ClosingMarketPriceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ClosingRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Closing risk free interest rate</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ClosingRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommonSharesGranted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common shares granted</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_CommonSharesGranted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommonStockSharesGranted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock shares granted</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_CommonStockSharesGranted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ExpectedDividendYield">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected dividend yield</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ExpectedDividendYield</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ExpectedVolatility">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected volatility</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ExpectedVolatility</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueOf100000CommonSharesExchanged">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of 100000 common shares exchanged</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FairValueOf100000CommonSharesExchanged</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueOf185000OptionsCancelled">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of 185000 options cancelled</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_FairValueOf185000OptionsCancelled</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MaximumExpectedLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum expected life</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_MaximumExpectedLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MinimumExpectedLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum expected life</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_MinimumExpectedLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NumberOfDaysOpposedAfterTheEmploymentTerminationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of days opposed after the employment termination date</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NumberOfDaysOpposedAfterTheEmploymentTerminationDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:pureItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NumberOfOptionsToPurchaseCommonStockGranted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options to purchase common stock granted</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NumberOfOptionsToPurchaseCommonStockGranted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OptionsExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Options exercise price</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_OptionsExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RecordedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Recorded compensation expense</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_RecordedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_StartingRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Starting risk free interest rate</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_StartingRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_VestedAndUnexercisedOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Vested and unexercised options</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_VestedAndUnexercisedOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EHBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INCOME TAXES Provision (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current tax provision.</a></td>
        <td class="nump">$ 1,414,171<span></span></td>
        <td class="nump">$ 3,458,568<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred tax provision.</a></td>
        <td class="num">(430,250)<span></span></td>
        <td class="num">(16,213)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalIncomeTaxExpense', window );">Total income tax expense</a></td>
        <td class="nump">$ 983,921<span></span></td>
        <td class="nump">$ 3,442,355<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalIncomeTaxExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_TotalIncomeTaxExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The component of income tax expense for the period representing amounts of income taxes paid or payable (or refundable) for the period for all income tax obligations as determined by applying the provisions of relevant enacted tax laws to relevant amounts of taxable Income or Loss from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 289<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 45<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6889476&amp;loc=d3e330036-122817<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CurrentIncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The component of total income tax expense for the period comprised of the increase (decrease) during the period in the entity's domestic deferred tax assets and liabilities attributable to continuing operations as determined by applying the provisions of the federally enacted tax law.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 45<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 8, 16, 17, 289<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6889476&amp;loc=d3e330036-122817<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredFederalIncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E5YAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Common Stock Shares</div>
        </th>
        <th class="th">
          <div>Common Stock Amount</div>
        </th>
        <th class="th">
          <div>Additional Paid-in Capital</div>
        </th>
        <th class="th">
          <div>Retained Earnings</div>
        </th>
        <th class="th">
          <div>Accumulated Other Comprehensive Income</div>
        </th>
        <th class="th">
          <div>Total Stockholders' Equity</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at Dec. 31, 2010</a></td>
        <td class="nump">43,404,557<span></span></td>
        <td class="nump">43,405<span></span></td>
        <td class="nump">23,252,476<span></span></td>
        <td class="nump">85,017,024<span></span></td>
        <td class="nump">9,624,269<span></span></td>
        <td class="nump">117,937,174<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of options as compensation</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">76,991<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">76,991<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IssuanceOfStockAsCompensation', window );">Issuance of stock as compensation</a></td>
        <td class="nump">125,000<span></span></td>
        <td class="nump">125<span></span></td>
        <td class="nump">119,067<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">119,192<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NetIncomeForTheYear2011', window );">Net income for the year 2011</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 19,269,642<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 19,269,642<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ForeignCurrencyTranslationAdjustment', window );">Foreign currency translation adjustment</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">5,080,098<span></span></td>
        <td class="nump">5,080,098<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at Dec. 31, 2011</a></td>
        <td class="nump">43,529,557<span></span></td>
        <td class="nump">43,530<span></span></td>
        <td class="nump">23,448,534<span></span></td>
        <td class="nump">104,286,666<span></span></td>
        <td class="nump">14,704,367<span></span></td>
        <td class="nump">142,483,097<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
        <td class="nump">100,000<span></span></td>
        <td class="nump">100<span></span></td>
        <td class="nump">141,620<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">141,720<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ForfeitureOfContingentlyVestingShares', window );">Forfeiture of contingently vesting shares</a></td>
        <td class="num">(50,000)<span></span></td>
        <td class="num">(50)<span></span></td>
        <td class="nump">50<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NetIncomeForTheYear2012', window );">Net income for the year 2012</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">4,617,659<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">4,617,659<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ForeignCurrencyTranslationAdjustment1', window );">Foreign currency translation adjustment.</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 1,274,091<span></span></td>
        <td class="nump">$ 1,274,091<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at Dec. 31, 2012</a></td>
        <td class="nump">43,579,557<span></span></td>
        <td class="nump">43,580<span></span></td>
        <td class="nump">23,590,204<span></span></td>
        <td class="nump">108,904,325<span></span></td>
        <td class="nump">15,978,458<span></span></td>
        <td class="nump">148,516,567<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ForeignCurrencyTranslationAdjustment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency of the reporting entity, net of tax.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ForeignCurrencyTranslationAdjustment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ForeignCurrencyTranslationAdjustment1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency of the reporting entity, net of tax.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ForeignCurrencyTranslationAdjustment1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ForfeitureOfContingentlyVestingShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Forfeiture of contingently vesting shares</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_ForfeitureOfContingentlyVestingShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IssuanceOfStockAsCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_IssuanceOfStockAsCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NetIncomeForTheYear2011">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NetIncomeForTheYear2011</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NetIncomeForTheYear2012">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_NetIncomeForTheYear2012</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued and outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>INTANGIBLE ASSETS</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
        <td class="text"><!--egx--><p style="MARGIN:0in 0in 10pt; TEXT-AUTOSPACE:"><b>NOTE 4 - INTANGIBLE ASSETS</b></p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Intangible assets represent the cost of medical formulas approved for production by the State Food and Drug Administration (the &#147;SFDA&#148;) in China. The Company did not obtain SFDA production approval for any medical formula during the year ended December 31, 2011 and no costs were reclassified from advances to intangible assets in 2011. During the year ended December 31, 2012, the Company received production approval from the SFDA for one medical formula and reclassified $507,174 from advances to intangible assets. The new medical formula is being amortized from the date SFDA approval was received over its estimated useful life of thirteen years and is not expected to have a residual value at the end of its useful life.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Approved medical formulas are amortized from the date SFDA approval is obtained over their individually identifiable estimated useful life, which are from ten to thirteen years.&nbsp; It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets was $611,724 and $596,525 for the years ended December 31, 2012 and 2011, respectively, and was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of their amortization period. </p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">The Company evaluates each approved medical formula for impairment at the date of SFDA approval, when indications of impairment are present and at the date of each financial statement. The Company&#146;s evaluation is based on an estimated undiscounted net cash flow model, considering currently available market data for the related drug and the Company&#146;s estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. As a result of the evaluations, the Company determined that it is not likely that the carrying value of two medical formulas will be realized from future cash flows due to the failure to meet certain improved technical criteria for one formula and from pricing pressures on the other one. As a result, impairment losses relating to those intangible assets were $593,095 for the year ended December 31, 2012. No impairment losses were recognized during the year ended December 31, 2011.&nbsp; </p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Intangible assets consisted solely of SFDA approved medical formulas as follows:</p> <table width="357" style="MARGIN:auto auto auto -0.75pt; WIDTH:267.4pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:12.75pt"> <td width="187" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:140pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="16" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="71" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="71" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td></tr> <tr style="HEIGHT:12.75pt"> <td width="187" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:140pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="16" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="154" colspan="3" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:115.4pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>December 31,</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="187" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:140pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="16" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2012</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2011</b></p></td></tr> <tr style="HEIGHT:17.1pt"> <td width="187" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:140pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Gross carrying amount</p></td> <td width="16" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="71" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$ 5,357,580 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="71" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:17.1pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$ 6,124,475 </p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="187" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:140pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Accumulated amortization</p></td> <td width="16" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="71" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp; (2,944,726)</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="71" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp; (3,041,804)</p></td></tr> <tr style="HEIGHT:0.25in"> <td width="187" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:140pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Net carrying amount</p></td> <td width="16" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$ 2,412,854 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.2pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$ 3,082,671 </p></td></tr></table> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">The estimated aggregate annual amortization expense for each of the next five years and thereafter is as follows:</p> <table width="144" style="MARGIN:auto auto auto -0.75pt; WIDTH:1.5in; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:13.9pt"> <td width="63" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Year</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="69" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>&nbsp;Amount </b></p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="63" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">2013</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="69" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;$&nbsp;&nbsp;&nbsp; 521,980 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="63" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">2014</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="69" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 505,653 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="63" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">2015</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="69" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 364,978 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="63" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">2016</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="69" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 318,939 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="63" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">2017</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="69" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 272,386 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="63" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center">Thereafter</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="69" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 428,918 </p></td></tr> <tr style="HEIGHT:13.9pt"> <td width="63" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:47pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Total</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="69" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:52pt; PADDING-RIGHT:5.4pt; HEIGHT:13.9pt; BORDER-TOP:windowtext 1pt solid; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">&nbsp;$ 2,412,854 </p></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all or part of the information related to intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16373-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 44, 45, 46<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16265-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IntangibleAssetsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCK OPTION ACTIVITY (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CompensationRelatedCostsShareBasedPaymentsAbstract', window );"><strong>Stock option activity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock option activity</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">A summary of stock option activity as of December 31, 2012, and changes during the year then ended is presented below:</p> <table width="542" style="MARGIN:auto auto auto -0.75pt; WIDTH:406.2pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:12.75pt"> <td width="227" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="68" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="64" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Weighted-</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="227" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="68" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="64" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Weighted-</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Average</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="227" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="68" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="64" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Average</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Remaining</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Aggregate</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="227" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="68" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="64" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Exercise</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Contractual </b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Intrinsic</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="227" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="68" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Shares</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>&nbsp;</b></p></td> <td width="64" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Price</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>&nbsp;</b></p></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Term (Years)</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>Value</b></p></td></tr> <tr style="HEIGHT:15pt"> <td width="227" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Outstanding at December 31, 2011</p></td> <td width="68" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp; 310,000 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="64" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.03 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>&nbsp;</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>&nbsp;</b></p></td></tr> <tr style="HEIGHT:15pt"> <td width="227" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt">Forfeited</p></td> <td width="68" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (50,000)</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>&nbsp;</b></p></td> <td width="64" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.54 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>&nbsp;</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>&nbsp;</b></p></td></tr> <tr style="HEIGHT:15pt"> <td width="227" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt">Expired</p></td> <td width="68" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp; (235,000)</p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>&nbsp;</b></p></td> <td width="64" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.19 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="82" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>&nbsp;</b></p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="65" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>&nbsp;</b></p></td></tr> <tr style="HEIGHT:15pt"> <td width="227" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Outstanding at December 31, 2012</b></p></td> <td width="68" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25,000 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="64" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.54 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.40 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;-&nbsp;&nbsp; </p></td></tr> <tr style="HEIGHT:15pt"> <td width="227" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:170pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Exercisable at December 31, 2012</b></p></td> <td width="68" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:50.7pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25,000 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="64" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:48pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.54 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="82" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:61.5pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.40 </p></td> <td width="12" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:9pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="65" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; PADDING-LEFT:5.4pt; WIDTH:49pt; PADDING-RIGHT:5.4pt; BACKGROUND:white; HEIGHT:15pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; </p></td></tr></table> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CompensationRelatedCostsShareBasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_CompensationRelatedCostsShareBasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Publisher FASB<br><br> -Number <br><br> -Article <br><br> -Subparagraph (c)(1)<br><br> -Name Accounting Standards Codification<br><br> -Paragraph 2<br><br> -Section 50<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>50</ContextCount>
  <ElementCount>333</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>10</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000020 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000030 - Statement - CONSOLIDATED BALANCE SHEETS PARENTHETICALS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS PARENTHETICALS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000050 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000070 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000080 - Disclosure - INVENTORY.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINVENTORY</Role>
      <ShortName>INVENTORY.</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000090 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DisclosurePROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000100 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINTANGIBLEASSETS</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000110 - Disclosure - ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS</Role>
      <ShortName>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000120 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureRELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000130 - Disclosure - NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureNOTESPAYABLE</Role>
      <ShortName>NOTES PAYABLE</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000140 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000150 - Disclosure - DERIVATIVE WARRANT LIABILITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureDERIVATIVEWARRANTLIABILITY</Role>
      <ShortName>DERIVATIVE WARRANT LIABILITY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000160 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureFAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000170 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureSTOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000180 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000190 - Disclosure - CONCENTRATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureCONCENTRATIONS</Role>
      <ShortName>CONCENTRATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000200 - Disclosure - Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureAccountingPoliciesPolicies</Role>
      <ShortName>Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000210 - Disclosure - BASIS OF PRESENTATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureBASISOFPRESENTATIONTables</Role>
      <ShortName>BASIS OF PRESENTATION (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000220 - Disclosure - INVENTORY(Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINVENTORYTables</Role>
      <ShortName>INVENTORY(Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000230 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DisclosurePROPERTYANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000240 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINTANGIBLEASSETSTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000250 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureINCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000260 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureFAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>000270 - Disclosure - STOCK OPTION ACTIVITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureSTOCKOPTIONACTIVITYTables</Role>
      <ShortName>STOCK OPTION ACTIVITY (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>000280 - Disclosure - FUTURE MINIMUM COMMITMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DisclosureFUTUREMINIMUMCOMMITMENTSTables</Role>
      <ShortName>FUTURE MINIMUM COMMITMENTS (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>000290 - Statement - BASIS OF PRESENTATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_BASISOFPRESENTATIONDetails</Role>
      <ShortName>BASIS OF PRESENTATION (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>000300 - Statement - BASIS OF PRESENTATION Basic and Diluted Earnings per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_BASISOFPRESENTATIONBasicAndDilutedEarningsPerCommonShareDetails</Role>
      <ShortName>BASIS OF PRESENTATION Basic and Diluted Earnings per Common Share (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>000310 - Statement - BASIS OF PRESENTATION POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_BASISOFPRESENTATIONPOLICIESDetails</Role>
      <ShortName>BASIS OF PRESENTATION POLICIES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>000320 - Statement - INVENTORY. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_INVENTORYDetails</Role>
      <ShortName>INVENTORY. (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>000330 - Statement - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_PROPERTYANDEQUIPMENTDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>000340 - Statement - PROPERTY AND EQUIPMENT Assets Life (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_PROPERTYANDEQUIPMENTAssetsLifeDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT Assets Life (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>000350 - Statement - ASSETS Depreciation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_ASSETSDepreciationDetails</Role>
      <ShortName>ASSETS Depreciation (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>000360 - Statement - INTANGIBLE ASSETS SFDA Approved Medical Formulas (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_INTANGIBLEASSETSSFDAApprovedMedicalFormulasDetails</Role>
      <ShortName>INTANGIBLE ASSETS SFDA Approved Medical Formulas (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>000370 - Statement - RELATED PARTY TRANSACTIONS Member Of BOD (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_RELATEDPARTYTRANSACTIONSMemberOfBODDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS Member Of BOD (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>000380 - Statement - RELATED PARTY TRANSACTIONS Owings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_RELATEDPARTYTRANSACTIONSOwingsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS Owings (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>000390 - Statement - NOTES PAYABLES. (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_NOTESPAYABLESDetails</Role>
      <ShortName>NOTES PAYABLES. (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>000400 - Statement - INCOME TAXES Undistributed Earnings And Income Tax Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_INCOMETAXESUndistributedEarningsAndIncomeTaxRatesDetails</Role>
      <ShortName>INCOME TAXES Undistributed Earnings And Income Tax Rates (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>000410 - Statement - INCOME TAXES Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_INCOMETAXESProvisionDetails</Role>
      <ShortName>INCOME TAXES Provision (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>000420 - Statement - Reconciliation of income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_ReconciliationOfIncomeTaxesDetails</Role>
      <ShortName>Reconciliation of income taxes (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>000430 - Statement - Changes of deferred income tax assets and liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_ChangesOfDeferredIncomeTaxAssetsAndLiabilityDetails</Role>
      <ShortName>Changes of deferred income tax assets and liability (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>000435 - Statement - DERIVATIVE WARRANT LIABILITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DERIVATIVEWARRANTLIABILITYDetails</Role>
      <ShortName>DERIVATIVE WARRANT LIABILITY (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>000440 - Statement - DERIVATIVE WARRANT GAINS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_DERIVATIVEWARRANTGAINSDetails</Role>
      <ShortName>DERIVATIVE WARRANT GAINS (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>000450 - Statement - FAIR VALUE MEASUREMENTS At Reporting Date Using (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_FAIRVALUEMEASUREMENTSAtReportingDateUsingDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS At Reporting Date Using (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>000460 - Statement - Preferred Common Stock And Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_PreferredCommonStockAndWarrantsDetails</Role>
      <ShortName>Preferred Common Stock And Warrants (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>000470 - Statement - 2010 Stock Option Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_StockOptionPlanDetails</Role>
      <ShortName>2010 Stock Option Plan (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>000480 - Statement - 2010 Stock Option Plan Frank Waung (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_StockOptionPlanFrankWaungDetails</Role>
      <ShortName>2010 Stock Option Plan Frank Waung (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>000490 - Statement - Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_CompensationExpenseDetails</Role>
      <ShortName>Compensation Expense (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>000500 - Statement - Unrecognized Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_UnrecognizedCompensationExpenseDetails</Role>
      <ShortName>Unrecognized Compensation Expense (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>000510 - Statement - EXECUTIVE OFFICERS 2010 Stock Option Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_EXECUTIVEOFFICERS2010StockOptionPlanDetails</Role>
      <ShortName>EXECUTIVE OFFICERS 2010 Stock Option Plan (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>000520 - Statement - OFFICERS 2010 Stock Option Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_OFFICERS2010StockOptionPlanDetails</Role>
      <ShortName>OFFICERS 2010 Stock Option Plan (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>000530 - Statement - Summary of stock option activity (Details) {Stockholders Equity}</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_SummaryOfStockOptionActivityDetailsStockholdersEquity</Role>
      <ShortName>Summary of stock option activity (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>000540 - Statement - COMMITMENTS AND CONTINGENCIES (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_COMMITMENTSANDCONTINGENCIESDETAILS</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (DETAILS)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>000550 - Statement - CONCENTRATIONS Sales And Purchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_CONCENTRATIONSSalesAndPurchasesDetails</Role>
      <ShortName>CONCENTRATIONS Sales And Purchases (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>000560 - Statement - CONCENTRATIONS Accounts Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20121231/role/idr_CONCENTRATIONSAccountsPayableDetails</Role>
      <ShortName>CONCENTRATIONS Accounts Payable (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 000020 - Statement - CONSOLIDATED BALANCE SHEETS</Log>
    <Log type="Info">Process Flow-Through: 000030 - Statement - CONSOLIDATED BALANCE SHEETS PARENTHETICALS</Log>
    <Log type="Info">Process Flow-Through: 000040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME</Log>
    <Log type="Info">Process Flow-Through: 000060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</Log>
    <Log type="Info">Process Flow-Through: 000290 - Statement - BASIS OF PRESENTATION (Details)</Log>
    <Log type="Info">Process Flow-Through: 000300 - Statement - BASIS OF PRESENTATION Basic and Diluted Earnings per Common Share (Details)</Log>
    <Log type="Info">Process Flow-Through: 000310 - Statement - BASIS OF PRESENTATION POLICIES (Details)</Log>
    <Log type="Info">Process Flow-Through: 000320 - Statement - INVENTORY. (Details)</Log>
    <Log type="Info">Process Flow-Through: 000330 - Statement - PROPERTY AND EQUIPMENT (Details)</Log>
    <Log type="Info">Process Flow-Through: 000340 - Statement - PROPERTY AND EQUIPMENT Assets Life (Details)</Log>
    <Log type="Info">Process Flow-Through: 000350 - Statement - ASSETS Depreciation (Details)</Log>
    <Log type="Info">Process Flow-Through: 000360 - Statement - INTANGIBLE ASSETS SFDA Approved Medical Formulas (Details)</Log>
    <Log type="Info">Process Flow-Through: 000370 - Statement - RELATED PARTY TRANSACTIONS Member Of BOD (Details)</Log>
    <Log type="Info">Process Flow-Through: 000380 - Statement - RELATED PARTY TRANSACTIONS Owings (Details)</Log>
    <Log type="Info">Process Flow-Through: 000390 - Statement - NOTES PAYABLES. (Details)</Log>
    <Log type="Info">Process Flow-Through: 000400 - Statement - INCOME TAXES Undistributed Earnings And Income Tax Rates (Details)</Log>
    <Log type="Info">Process Flow-Through: 000410 - Statement - INCOME TAXES Provision (Details)</Log>
    <Log type="Info">Process Flow-Through: 000420 - Statement - Reconciliation of income taxes (Details)</Log>
    <Log type="Info">Process Flow-Through: 000430 - Statement - Changes of deferred income tax assets and liability (Details)</Log>
    <Log type="Info">Process Flow-Through: 000435 - Statement - DERIVATIVE WARRANT LIABILITY (Details)</Log>
    <Log type="Info">Process Flow-Through: 000440 - Statement - DERIVATIVE WARRANT GAINS (Details)</Log>
    <Log type="Info">Process Flow-Through: 000450 - Statement - FAIR VALUE MEASUREMENTS At Reporting Date Using (Details)</Log>
    <Log type="Info">Process Flow-Through: 000460 - Statement - Preferred Common Stock And Warrants (Details)</Log>
    <Log type="Info">Process Flow-Through: 000470 - Statement - 2010 Stock Option Plan (Details)</Log>
    <Log type="Info">Process Flow-Through: 000480 - Statement - 2010 Stock Option Plan Frank Waung (Details)</Log>
    <Log type="Info">Process Flow-Through: 000490 - Statement - Compensation Expense (Details)</Log>
    <Log type="Info">Process Flow-Through: 000500 - Statement - Unrecognized Compensation Expense (Details)</Log>
    <Log type="Info">Process Flow-Through: 000510 - Statement - EXECUTIVE OFFICERS 2010 Stock Option Plan (Details)</Log>
    <Log type="Info">Process Flow-Through: 000520 - Statement - OFFICERS 2010 Stock Option Plan (Details)</Log>
    <Log type="Info">Process Flow-Through: 000540 - Statement - COMMITMENTS AND CONTINGENCIES (DETAILS)</Log>
    <Log type="Info">Process Flow-Through: 000550 - Statement - CONCENTRATIONS Sales And Purchases (Details)</Log>
    <Log type="Info">Process Flow-Through: 000560 - Statement - CONCENTRATIONS Accounts Payable (Details)</Log>
  </Logs>
  <InputFiles>
    <File>cphi-20121231.xml</File>
    <File>cphi-20121231.xsd</File>
    <File>cphi-20121231_cal.xml</File>
    <File>cphi-20121231_def.xml</File>
    <File>cphi-20121231_lab.xml</File>
    <File>cphi-20121231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAF">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS Owings (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdavanceOwingToBoardmember', window );">Adavances owing to board member</a></td>
        <td class="nump">$ 1,354,567<span></span></td>
        <td class="nump">$ 861,563<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdavanceOwingToBoardmember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Adavance owing to boardmember</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AdavanceOwingToBoardmember</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EJGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AccountingPoliciesPoliciesAbstract', window );"><strong>Accounting Policies (Policies)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Nature of Operations</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Organization and Nature of Operations</b> &#150; China Pharma Holdings, Inc., a Nevada corporation as of December 31, 2012, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, that in turn owns 100% of Hainan Helpson Medical &amp; Biotechnology Co., Ltd (Helpson), a company organized under the laws of the People's Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.&nbsp; </p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">On December 31, 2012, China Pharma Holdings, Inc consummated a reincorporation merger for the purpose of changing the state of incorporation from Delaware to Nevada pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012.&nbsp; The reincorporation merger was approved by stockholders holding the majority of the outstanding common shares on December 21, 2012.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">The Foreign Investment Industrial Catalogue&nbsp;(the &#147;Catalogue&#148;) jointly issued by the China&#146;s Ministry of Commerce and the National Development and Reform Commission (as the latest version is the year 2012 version, effective January 30, 2012) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the &#147;FIE&#148;) shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case of the Company&#146;s business.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson&#146;s business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson from Helpson&#146;s three former shareholders on May 25, 2005 by entry into an Equity Transfer Agreement with such three parties on May 25, 2005. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">The Company has and continues to acquire well-accepted medical formulas to a diverse portfolio of Western and Chinese medicines.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation and Basis of Presentation</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Consolidation and Basis of Presentation</b> &#150; The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Helpson&#146;s functional currency is the Chinese Renminbi. Helpson&#146;s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson&#146;s financial statements are included in accumulated other comprehensive income, which is a component of stockholders&#146; equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Reclassifications', window );">Reclassification</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Reclassification </b>- The Company has made certain reclassifications to the consolidated balance sheet at December 31, 2011 to conform to the December 31, 2012 presentation. These reclassifications had no effect on the consolidated statements of operations or cash flows for any periods presented.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Accounting Estimates</b> - The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the management of the Company (&#147;Management&#148;) to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents Policy</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Cash and Cash Equivalents</b> &#150; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker&#146;s acceptances purchased with maturities of three months or less. </p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Trade Accounts Receivable and Allowance for Doubtful Accounts</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Trade Accounts Receivable and Allowance for Doubtful Accounts</b> &#150; Trade accounts receivables are carried at original invoiced amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts and an estimation of the overall economic conditions affecting the Company's customer base. The Company reviews a customer's credit history before extending credit. If the financial condition of its customers were to deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable to the extent they are considered unlikely to be collected. It is common practice in the PRC for receivables to extend beyond one year. Customer balances outstanding for more than one year are allowed for at a greater rate when calculating the allowance for doubtful accounts. At December 31, 2012, trade accounts receivables included $30,134,909 from sales that occurred more than one year prior to December 31, 2012, that Management believes are collectable.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock', window );">Advances to Suppliers and Advances from Customers</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Advances to Suppliers and Advances from Customers</b> &#150; Common practice in the PRC is to make advances to suppliers for materials and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances received from customers are applied against trade accounts receivable when finished products are sold.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory.Policy</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Inventory </b>&#150; Inventory is stated at the lower of cost or net realizable value, computed on an average cost basis. An allowance for inventory obsolescence is provided when the market value of inventory items is lower than its cost.&nbsp; The Company recognized an inventory obsolescence reserve of $1,769,984 and $0 for the years ended December 31, 2012 and 2011, respectively.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Valuation of Long-Lived Assets</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Valuation of Long-Lived Assets</b> &#150; The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash flows estimated to be generated by the asset. The Company evaluated its long-lived assets at December 31, 2012 and determined that the value of certain of its intangible assets were impaired and recognized an impairment loss of $593,095 for the year ended December 31, 2012. No impairment was recognized during the year ended December 31, 2011.&nbsp; See Note 4.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment Policy</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Property and Equipment</b> &#150; Property and equipment are stated at cost. Maintenance and repairs are charged to expense as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Revenue Recognition</b> &#150; Revenue is considered earned when the Company has persuasive evidence of an arrangement with the customer, delivery of the products has occurred, the sales price is fixed or determinable, and collectability is reasonably assured. Delivery does not occur until products have been shipped to the customer, risk of loss has transferred to the customer and customer acceptance has been obtained, customer acceptance provisions have lapsed, or the Company has objective evidence that the criteria specified in the customer acceptance provisions have been satisfied. The sales price is not considered to be fixed or determinable until all contingencies related to the sale have been resolved.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Revenues</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Cost of Revenues</b> &#150; Cost of revenues includes wages, materials, handling charges, and other expenses associated with the manufacture and delivery of products.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development.</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Research and Development</b> &#150; Research and development expenditures are recorded as expenses in the period in which they occur. Research and development costs were not material during the years ended December 31, 2012 and 2011.&nbsp;</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Retirement Benefit Plans</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Retirement Benefit Plans</b> &#150; The Company is required to make monthly contributions at prescribed rates to various employee retirement benefit plans organized by provincial governments. The governments benefit plans assume the retirement benefit obligations of all existing and future retired employees of the Company. The Company contributed $233,846 and $166,071 to retirement benefit plans for the years ended December 31, 2012 and 2011, respectively. Contributions to these plans are charged to expense as incurred.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Advertising Costs</b> &#150; Advertising costs are expensed when incurred. The Company did not incur any advertising costs for the years ended December 31, 2012 and 2011.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Earnings per Common Share</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Basic and Diluted Earnings per Common Share</b> - Basic earnings per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per share are calculated to give effect to potentially issuable dilutive common shares.</p> <table width="493" style="MARGIN:auto auto auto -0.75pt; WIDTH:370pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="152" colspan="3" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:114pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>For the Years Ended</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"></td> <td width="152" colspan="3" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:114pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>December 31,</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2012</b></p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2011</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Net income</p></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$ 4,617,659 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$ 19,269,642 </p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Basic weighted-average common shares outstanding</p></td> <td width="71" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">43,579,557 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">43,479,899 </p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Effect of dilutive securities:</p></td> <td width="71" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt">Warrants</p></td> <td width="71" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt">Options</p></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p></td></tr> <tr style="HEIGHT:19.5pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:19.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Diluted weighted-average common shares outstanding</p></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:19.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">43,579,557 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:19.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:19.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:right; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="right">43,479,899 </p></td></tr> <tr style="HEIGHT:0.25in"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Basic earnings per share</p></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.11 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.44 </p></td></tr> <tr style="HEIGHT:0.25in"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Diluted earnings per share</p></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.11 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:0.25in; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.44 </p></td></tr></table> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Potential common shares were not included in the computation of diluted earnings per share as their effect would have been anti-dilutive as follows:</p> <table width="493" style="MARGIN:auto auto auto -0.75pt; WIDTH:370pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="152" colspan="3" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:114pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>For the Years Ended</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="152" colspan="3" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:114pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>December 31,</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2012</b></p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:normal; MARGIN:0in 0in 0pt" align="center"><b>2011</b></p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Warrants with exercise prices of $3.00 to $3.80 per share</p></td> <td width="71" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 150,000 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 150,000 </p></td></tr> <tr style="HEIGHT:12.75pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">Options with an exercise price of $2.54 to $3.47 per share</p></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50,000 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:12.75pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 310,000 </p></td></tr> <tr style="HEIGHT:13.5pt"> <td width="341" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:256pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; TEXT-INDENT:10pt; MARGIN:0in 0in 0pt">Total</p></td> <td width="71" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:53.5pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 200,000 </p></td> <td width="2" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:1.85pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"></td> <td width="78" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:58.65pt; PADDING-RIGHT:5.4pt; HEIGHT:13.5pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 460,000 </p></td></tr></table> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCreditLossesRelatedToFinancingReceivablesCurrentAndNoncurrentTableTextBlock', window );">Credit Risk</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Credit Risk </b>&#150; The carrying amounts of accounts receivable included in the balance sheet represent the Company's exposure to credit risk in relation to its financial assets. No other financial assets carry a significant exposure to credit risk. The Company performs ongoing credit evaluations of each customer's financial condition. It maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded Management's estimations.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secure due to the state policy on protecting depositors&#146; interests. The PRC promulgated a new Bankruptcy Law in August 2006, effective June&nbsp;1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. In the event that bankruptcy laws are enacted for banks in the PRC, the Company&#146;s deposits may be at a higher risk of loss.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock', window );">Interest Rate Risk</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Interest Rate Risk</b> &#150; The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and viability of securing future debt instruments within the PRC.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recently Announced Accounting Standards</a></td>
        <td class="text"><!--egx--><p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt"><b>Recently Announced Accounting Standards</b> &#150; The Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) 2011-05, Presentation of Comprehensive Income, which revises the manner in which comprehensive income is presented in an entity&#146;s financial statements. This update requires the presentation of the components of comprehensive income in either a continuous statement of comprehensive income or in two separate but consecutive financial statements. The option to present comprehensive income in the statement of stockholders&#146; equity has been eliminated. The provisions of this update were effective as of January 1, 2012, and the Company has included a continuous consolidated statement of comprehensive income as part of these consolidated financial statements.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">ASU 2011-04, Fair Value Measurement &#150; Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS, provides converged guidance on how to measure fair value, which is largely consistent with existing U.S. GAAP. This update also requires additional fair value measurement disclosures. The provisions of this update were effective as of January 1, 2012. The effects of adoption were not significant to the accompanying consolidated financial statements.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">ASU No. 2012-02, Testing Indefinite-Lived Intangible Assets for Impairment, permits, but does not require, an entity to conduct an initial qualitative assessment to determine whether it is more likely than not that a non-goodwill indefinite-lived asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test currently required (i.e., comparing the asset's fair value with its carrying amount). This new standard was adopted by the Company on September 30, 2012 and had no significant effect on the accompanying consolidated financial statements.</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt">ASU No. 2011-11, Disclosures about Offsetting Assets and Liabilities, requires disclosures about assets and liabilities that are offset or have the potential to be offset. This new guidance will be effective for reporting periods beginning January 1, 2013, with retrospective application required. The adoption of this guidance is not expected to have a material impact on the Company&#146;s results of operations or financial position. </p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AccountingPoliciesPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>fil_AccountingPoliciesPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>fil_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for advertising costs. For those costs that cannot be capitalized, discloses whether such costs are expensed as incurred or the first period in which the advertising takes place. For direct response advertising costs that are capitalized, describes those assets and the accounting policy used, including a description of the qualifying activity, the types of costs capitalized and the related amortization period. An entity also may disclose its accounting policy for cooperative advertising arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6387522&amp;loc=d3e8384-108330<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6387501&amp;loc=d3e8275-108329<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 93-7<br><br> -Paragraph 49<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 20<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2127066<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 02-16<br><br> -Paragraph 6<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdvertisingCostsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 8, 9, 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Technical Practice Aid (TPA)<br><br> -Number 2110<br><br> -Paragraph 6<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122427<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5, 6, 7, 9, 11, 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Publisher FASB<br><br> -Number 123R<br><br> -Paragraph 4, 9-15, A240<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CompensationRelatedCostsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 2-6<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 3A<br><br> -Section 02, 03<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 18<br><br> -Paragraph 20<br><br> -Subparagraph a(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 97-2<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 96-16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 46R<br><br> -Paragraph 4<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 46R<br><br> -Paragraph 4<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.3A-02)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959686&amp;loc=d3e355033-122828<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 46R<br><br> -Paragraph 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph k<br><br> -Article 1<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 325<br><br> -SubTopic 20<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197087<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 860<br><br> -SubTopic 40<br><br> -Section 45<br><br> -URI http://asc.fasb.org/section&amp;trid=2197723<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2196966<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 18<br><br> -Paragraph 5, 6, 16-19<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 140<br><br> -Paragraph 46<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382870&amp;loc=d3e33801-111570<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921930&amp;loc=d3e5614-111684<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConsolidationPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 50<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197414<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 50<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6408645&amp;loc=d3e63676-111659<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 2<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfSalesPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 6, 8-16, 60<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of financing receivables by credit quality indicator. The credit quality indicator is a statistic about the credit quality of financing receivables. Examples include, but not limited to, consumer credit risk scores, credit-rating-agency ratings, an entity's internal credit risk grades, loan-to-value ratios, collateral, collection experience and other internal metrics.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 29<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6965416&amp;loc=SL6953659-111524<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6951925&amp;loc=SL6953803-111525<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 7-15, 26, 30-37<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386783&amp;loc=d3e4556-108314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 3<br><br> -Section A<br><br> -Paragraph 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386783&amp;loc=d3e4492-108314<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 81-1<br><br> -Paragraph 69-75<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2126999<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 4<br><br> -Paragraph 3, 5-10, 15, 16, 17<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 206<br><br> -Chapter 2<br><br> -Paragraph b<br><br> -Subparagraph i, ii<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Name Statement of Position (SOP)<br><br> -Publisher AICPA<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NatureOfOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for property, plant and equipment which may include the basis of such assets, depreciation methods used and estimated useful lives, the entity's capitalization policy, including its accounting treatment for costs incurred for repairs and maintenance activities, whether such asset balances include capitalized interest and the method by which such is calculated, how disposals of such assets are accounted for and how impairment of such assets is assessed and recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 7<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 9<br><br> -Section C<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 34<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3-5<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 114<br><br> -Paragraph 20<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2196772<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 92-5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 01-6<br><br> -Paragraph 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 20<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2196816<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ReceivablesPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Reclassifications">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 2<br><br> -Section A<br><br> -Paragraph 2<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Reclassifications</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2127266<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 8, 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 6<br><br> -Paragraph 5, 6, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 42<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpensePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8, 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCreditLossesRelatedToFinancingReceivablesCurrentAndNoncurrentTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the activity in the total allowance for credit losses related to financing receivables (such as loans or lease receivables) for entities that have an unclassified balance sheet, including the balance in the allowance at the beginning and end of each period, additions charged to operations, direct write-downs charged against the allowance, and recoveries of amounts previously charged off.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Publisher FASB<br><br> -Number <br><br> -Article <br><br> -Subparagraph (c)<br><br> -Name Accounting Standards Codification<br><br> -Paragraph 11B<br><br> -Section 50<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6965416&amp;loc=SL6953423-111524<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfCreditLossesRelatedToFinancingReceivablesCurrentAndNoncurrentTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e765-108305<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Accounting Change<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6503790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 250<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6801783&amp;loc=d3e22583-107794<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 28<br><br> -Paragraph 23, 24<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.10-01.(b)(6))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6958853&amp;loc=d3e46468-122699<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e725-108305<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 01<br><br> -Paragraph b<br><br> -Subparagraph 6<br><br> -Article 10<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Direct Effects of a Change in Accounting Principle<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510796<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 154<br><br> -Paragraph 2, 17, 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Change in Accounting Principle<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507316<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Retrospective Application<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523989<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 250<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6801783&amp;loc=d3e22580-107794<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 250<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6801783&amp;loc=d3e22499-107794<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Indirect Effects of a Change in Accounting Principle<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515603<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for arrangements in which the entity has agreed to expend funds to procure goods or service from one or more suppliers, or to commit resources to supply goods or services to one or more customers.  May include identification of the goods or services to be purchased, the goods or services to be furnished, identity of the buyer or seller, pricing, effects on pricing (such as penalties) of failing to reach minimum quantities required to be purchased, effects on pricing (such as penalties) of failing to deliver minimum quantities required to be furnished, cancellation rights, and termination provisions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 25<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 17<br><br> -Article 9<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 7<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantPurchaseAndSupplyCommitmentExcludingLongtermCommitmentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 94-6<br><br> -Paragraph 11, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
